UNIVERSITY^{OF} BIRMINGHAM University of Birmingham Research at Birmingham

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications:

Mullish, Benjamin; Quraishi, Mohammed Nabil; Segal, Jonathan; McCune, Victoria; Baxter, Melissa; Marsden, Gemma L.; Moore, David; Colville, Alaric; Bhala, Neeraj; Iqbal, Tariq H.; Settle, Christopher; Kontkowski, Graziella; Hart, Ailsa L.; Hawkey, Peter; Goldenberg, Simon D.; Williams, Horace R. T.

DOI:

10.1016/j.jhin.2018.07.037

License: Other (please specify with Rights Statement)

Document Version Peer reviewed version

Citation for published version (Harvard):

Mullish, B, Quraishi, MN, Segal, J, McCune, V, Baxter, M, Marsden, GL, Moore, D, Colville, A, Bhala, N, Iqbal, TH, Settle, C, Kontkowski, G, Hart, AL, Hawkey, P, Goldenberg, SD & Williams, HRT 2018, 'The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines', *Gut.* https://doi.org/10.1016/j.jhin.2018.07.037

Link to publication on Research at Birmingham portal

Publisher Rights Statement:

Checked for eligibility 18/07/2018

Mullish BH, Quraishi MN, Segal JP, et al The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines Gut Published Online First: 28 August 2018. doi: 10.1136/gutjnl-2018-316818

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Gut

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.

Journal:	Gut
Manuscript ID	gutjnl-2018-316818.R2
Article Type:	Guidelines
Date Submitted by the Author:	27-Jun-2018
Complete List of Authors:	Mullish, Benjamin; Imperial College London, Division of Integrative Systems Medicine and Digestive Disease, Department of Surgery and Cancer; Imperial College Healthcare NHS Trust, Department of Gastroenterology and Hepatology, St Mary's Hospital Quraishi, Mohammed; Queen Elizabeth Hospital Birmingham, Department of Gastroenterology Segal, Jonathan; Imperial College London, Division of Digestive Diseases/ Liver Unit; Imperial College Faculty of Medicine - Northwick Park and Saint Marks Campus, Inflammatory Bowel Disease Unit McCune, Victoria; Public Health Laboratory Birmingham, Public Health England; University of Birmingham, Institute of Microbiology and Infection Baxter, Melissa; Royal Devon and Exeter NHS Foundation Trust, Department of Microbiology Marsden, Gemma; Healthcare Infection Society Moore, David; University of Birmingham, School of Health and Population Sciences Colville, Alaric ; Royal Devon and Exeter NHS Foundation Trust, Department of Microbiology Bhala, Neeraj; University Hospital Birmingham NHS Foundation Trust, Gastroenterology; University of Birmingham, Institute of Translational Medicine Iqbal, Tariq; University Hospital Birmingham NHS Frust, Gastroenterology; University of Birmingham, Institute of Translational Medicine Settle, Christopher; City Hospitals Sunderland NHS Foundation Trust, Department of Microbiology Kontkowski, Graziella; C diff Support Hart, Ailsa; Imperial College Faculty of Medicine - Northwick Park and Saint Marks Campus, Inflammatory Bowel Disease Unit; Imperial College London, Division of Integrative Systems Medicine and Digestive Disease, Department of Surgery and Cancer Hawkey, Peter; University of Birmingham, Institute of Microbiology and Infection Goldenberg, Simon; King's College London, Centre for Clinical Infection and Diagnostics Research; Guy's and St Thomas' NHS Foundation Trust,

Department of Microbiology Williams, Horace; Imperial College London, Division of Integrative Systems Medicine and Digestive Disease, Department of Surgery and Cancer; Imperial College Healthcare NHS Trust, Department of Gastroenterology and Hepatology, St Mary's Hospital
Keywords: ENTERIC BACTERIAL MICROFLORA, INTESTINAL MICROBIOLOGY, COLONIC MICROFLORA, INFECTIVE COLITIS, INFLAMMATORY BOWEL DISEASE
SCHOLARONE [™] Manuscripts
SCHOLARONE [™] Manuscripts
https://mc.manuscriptcentral.com/gut




Figure 1: Proposed summary pathway for donor screening for centres preparing frozen FMT from recurring donors.

60x88mm (300 x 300 DPI)

https://mc.manuscriptcentral.com/gut

 Gut

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Benjamin H Mullish^{*1,2}, Mohammed Nabil Quraishi^{*3}, Jonathan Segal^{*1,4}, Victoria L McCune^{5,6}, Melissa Baxter⁷, Gemma L Marsden⁸, David Moore⁹, Alaric Colville⁷, Neeraj Bhala^{3,9,10}, Tarig H Igbal^{3,10}, Christopher Settle¹¹, Graziella Kontkowski¹², Ailsa L Hart^{1,4}, Peter M Hawkey⁶, Simon D Goldenberg^{O13,14}, Horace RT Williams^{$O\Box1,2$}. 1. Division of Integrative Systems Medicine and Digestive Disease, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK. 2. Departments of Gastroenterology and Hepatology, St Mary's Hospital, Imperial College Healthcare NHS Trust, Paddington, London, UK. 3. Department of Gastroenterology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. 4. Inflammatory Bowel Disease Unit, St Mark's Hospital, Harrow, London, UK. 5. Public Health England, Public Health Laboratory Birmingham, Birmingham, UK. 6. Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK. 7. Department of Microbiology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK. 8. Healthcare Infection Society, London, UK. 9. Institute of Applied Health Research, University of Birmingham, Birmingham, UK. 10. Institute of Translational Medicine, University of Birmingham, Edgbaston, Birmingham, UK. 11. Department of Microbiology, City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK. 12. C diff Support, UK. 13. Centre for Clinical Infection and Diagnostics Research, King's College London, London, UK. 14. Department of Microbiology, Guy's and St Thomas' NHS Foundation Trust, London UK. *Joint first authors. ^oJoint senior authors. [□]Corresponding author.

Gut

	32	Contact via:	Dr Hora	ace Williams
	33		Depart	ment of Gastroenterology
	34		3 rd Floo	or, Salton House
)	35		St Mary	y's Hospital, Imperial College Healthcare NHS Trust
 <u>2</u>	36		London	n, W2 1NY
3 1	37		United	Kingdom
5	38		Email: I	n.williams@imperial.ac.uk
3	39			
<i>)</i>)	40	Keywords:	microb	iota; faecal transplant; <i>Clostridium difficile;</i> inflammatory bowel disease
1 <u>2</u> 8	41			
5 1 5	42	Word count:	16301	
5 7	43			
3	44	Abbreviations:	FMT	faecal microbiota transplant
)	45		CDI	Clostridium difficile infection
<u>/</u> 3 1	46		EBV	Epstein-Barr virus
5	47		CMV	cytomegalovirus
3	48		BMI	body mass index
))	49		GI	gastrointestinal
 <u>2</u>	50		RCT	-
3 1 -	51		NAAT	nucleic acid amplification test
5 7	52		GDH	randomised controlled trial nucleic acid amplification test glutamate dehydrogenase
3	53		EIA	enzymes immunoassay
)	54		PCR	polymerase chain reaction
<u>2</u> 3	55		IBD	inflammatory bowel disease
1 5	55		IBS	irritable bowel syndrome
) 7	50		כטו	
)				

https://mc.manuscriptcentral.com/gut

Gut

HIS/ BSG FMT Guideline:	Main Document, Gut version.
-------------------------	-----------------------------

	H	IS/ BSG FMT Guideline: Main Document, Gut version.
1		
2 3	57	HIV human immunodeficiency virus
4	37	inv indianinanoucheckey virus
5	58	AIDS acquired immune deficiency syndrome
6		
7	59	CPE carbapenemase-producing Enterobacteriaceae
8		
9	60	ESBL extended-spectrum beta-lactamase
10		
11 12	61	VRE vancomycin-resistant <i>Enterococci</i>
12		
14	62	MRSA methicillin-resistant Staphylococcus aureus
15		
16	63	PPI proton pump inhibitor
17		
18	64	UC ulcerative colitis
19		
20	65	HE hepatic encephalopathy
21 22		
22	66	MELD Model for End-Stage Liver Disease
24		
25	67	
26		
27	68	
28		
29	69	
30		
31 32	70	
33		
34	71	
35		
36	72	
37		
38	73	
39 40		
40	74	
42		
43	75	
44		
45	76	
46		
47 48	77	
48 49	70	
50	78	
51	79	
52	79	
53	80	
54	00	
55	81	
56 57	01	
57 58		
59		
60		https://mc.manuscriptcentral.com/gut

82 1. Abstract:

Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory Clostridium difficile infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the United Kingdom (UK) have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. Whilst the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.

96 2. Executive summary:

97 2.1. <u>Overview:</u>

98 The remit of the British Society of Gastroenterology (BSG)/ Healthcare Infection Society (HIS) 99 working group was to provide recommendations as to best practice in the provision of a faecal 100 microbiota transplant (FMT) service. This guideline considers the use of FMT for the treatment of 101 *Clostridium difficile* infection (CDI) – as well as for potential non-CDI indications – in adults. The 102 working group have primarily targeted their report at clinicians involved in the use and provision of 103 FMT services, but have also aimed it to be of interest to patients and their relatives.

105 2.2. Summary of recommendations:

2.2.1. <u>Which patients with Clostridium difficile infection should be considered for faecal</u> microbiota transplant, and how should they be followed up after treatment?

2.2.1.1. Prior to faecal microbiota transplant. Patient selection:

2.2.1.1.1. Recurrent *Clostridium difficile* infection:

110 We recommend that FMT should be offered to patients with recurrent CDI who have had at 111 least two recurrences, or those who have had one recurrence and have risk factors for 112 further episodes, including severe and severe-complicated CDI (*GRADE of evidence: high;* 113 strength of recommendation: strong).

https://mc.manuscriptcentral.com/gut

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1					
2 3	114				
4 5	115	2.2.1.1.2. Refractory Clostridium difficile infection:			
6 7	116	We recommend that FMT should be considered in cases of refractory CDI (GRADE of			
8 9	117	evidence: moderate; strength of recommendation: strong).			
10 11	110				
12	118				
13 14	119	2.2.1.1.3. FMT as initial therapy for <i>Clostridium difficile</i> infection:			
15 16	120	We recommend that FMT should not be administered as initial treatment for CDI (GRADE of			
17	121	evidence: low; strength of recommendation: strong).			
18 19 20	122				
21 22	123	2.2.1.1.4. Antimicrobial/ antitoxin therapy prior to considering FMT for patients with CDI:			
23	124	<i>i.</i> We recommend that FMT for recurrent CDI should only be considered after			
24 25	125	recurrence of symptoms following resolution of an episode of CDI that was treated			
26 27	126	with appropriate antimicrobials for at least 10 days (GRADE of evidence: low;			
28 29	127	strength of recommendation: strong).			
30	128	<i>ii.</i> We recommend consideration of treatment with extended/ pulsed vancomycin			
31 32	129	and/or fidaxomicin before considering FMT as treatment for recurrent CDI (GRADE			
33 34	130	of evidence: low; strength of recommendation: strong).			
35 36	131	iii. For those with severe or complicated CDI, which appears to be associated with			
37	132	reduced cure rates, we recommend that consideration should be given to offering			
38 39	133	patients treatment with medications which are associated with reduced risk of			
40 41	134	recurrence (e.g. fidaxomicin and bezlotoxumab), before offering FMT (GRADE of			
42	135	evidence: low; strength of recommendation: strong).			
43 44	136				
45 46	137	2.2.1.2. Post-FMT follow-up, outcomes and adverse events:			
47 48	138	2.2.1.2.1. Management of FMT failure:			
49	139	We recommend that FMT should be offered after initial FMT failure (GRADE of evidence:			
50 51	140	high; strength of recommendation: strong).			
52 53	141				
54 55					
56	142	2.2.1.2.2. General approach to follow-up post-FMT:			
57 58					
59 60		https://mc.manuscfiptcentral.com/gut			

Page 8 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

We recommend that all FMT recipients should routinely receive follow-up. Clinicians should

follow-up FMT recipients for long enough to fully establish efficacy/adverse events, and for

at least eight weeks in total (GRADE of evidence: low; strength of recommendation: strong).

2.2.1.2.3. Management of the FMT recipient:

- i. We recommend that immediate management after endoscopic administration of FMT should be as per endoscopy unit protocol (GRADE of evidence: very low: strength of recommendation: strong).
- ii. We recommend that patients should be warned about short term adverse events, in particular the possibility of self-limiting GI symptoms. They should be advised that serious adverse events are rare (GRADE of evidence: very low; strength of recommendation: strong).
- After enteral tube administration, we recommend that patients may have the tube iii. removed and oral water given from 30 minutes post-administration (GRADE of evidence: very low; strength of recommendation: strong).
- - 2.2.1.2.4. Definition of cure post-FMT for CDI:

We recommend that a decision regarding cure/remission from CDI should be recorded during follow-up. However, this has no uniformly-agreed definition, and should be decided on a case-by-case basis (GRADE of evidence: very low; strength of recommendation: strong).

2.2.1.2.5. Definition of treatment failure post-FMT for CDI:

We recommend that treatment failure/recurrence should be defined on a case-by-case basis. Routine testing for C. difficile toxin after FMT is not recommended, but it is appropriate to consider in the case of persistent CDI symptoms/suspected relapse (GRADE of evidence: low; strength of recommendation: strong).

- 2.2.2. What recipient factors influence the outcome of faecal microbiota transplant when treating people with *Clostridium difficile* infection?
- 2.2.2.1. General approach to co-morbidities and FMT:

https://mc.manuscriptcentral.com/gut

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1 2	
3	173
4 5	174
6 7	175
8 9	176
10	177
11 12	178
13 14	179
15	180
16 17	181
18 19	182
20 21	183
22	184
23 24	185
25 26	186
27 28	187
29 30	188
31 32	189
33	190
34 35	191
36 37	192
38 39	193
40	194
41 42	195
43 44	196
45	197
46 47	198
48 49	199
50 51	200
52 53	201
54 55	202
56 57	203

58 59

60

i. We recommend that FMT should be avoided in those with anaphylactic food allergy *(GRADE of evidence: very low; strength of recommendation: strong).*

ii. We suggest that FMT should be offered with caution to patients with CDI and
 decompensated chronic liver disease (*GRADE of evidence: very low; strength of recommendation: weak*).

- Immunosuppression and FMT:
- *i.* We recommend that FMT should be offered with caution to immunosuppressed
 patients, in whom FMT appears efficacious without significant additional adverse
 effects (*GRADE of evidence: moderate; strength of recommendation: strong*).
- *ii.* We recommend that immunosuppressed FMT recipients at risk of severe infection if
 exposed to EBV or CMV should only receive FMT from donors negative for EBV and
 CMV (GRADE of evidence: very low; strength of recommendation: strong).
- 187 **2.2.2.3.** Other comorbidities and FMT:

2.2.2.2.

i. We recommend that FMT should be offered to those with recurrent CDI and inflammatory bowel disease, but patients should be counselled about a small but recognised risk of exacerbation of IBD (*GRADE of evidence: moderate; strength of recommendation: strong*).

192 *ii.* We recommend that FMT should be considered for appropriate patients with
193 recurrent CDI regardless of other comorbidities (*GRADE of evidence: moderate;*194 strength of recommendation: strong).

2.2.3. What donor factors influence the outcome of faecal microbiota transplant when treating people with *Clostridium difficile* infection?

98 **2.2.3.1.** General approach to donor selection:

- 199 We recommend that related or unrelated donors should both be considered acceptable.
- 200 However, where possible, FMT is best sourced from a centralised stool bank, from a healthy
- 201 unrelated donor (*GRADE of evidence: low; strength of recommendation: strong*).
 - 203 **2.2.3.2.** Age and BMI restrictions for potential donors:

https://mc.manuscriptcentral.com/gut

204 We suggest that people should only be considered as potential FMT donors if they are \geq 18

and ≤ 60 years old, and have a BMI of ≥ 18 and ≤ 30 kg/m² (*GRADE of evidence: low; strength* of recommendation: weak).

2.2.3.3. General approach to the donor screening assessment:

It is mandatory to screen potential donors by questionnaire and personal interview, to
establish risk factors for transmissible diseases and factors influencing the gut microbiota
(Table 1) (GRADE of evidence: low; strength of recommendation: strong).

2.2.3.4. Laboratory screening of potential donors:

Blood and stool screening of donors is mandatory (Tables 2 and 3) (GRADE of evidence: low;

- 215 strength of recommendation: strong).

2.2.3.5. Repeat donor checks, and donation pathway:

i. In centres using frozen FMT, before FMT may be used clinically, we recommend that
 donors should have successfully completed a donor health questionnaire and laboratory
 screening assays both before and after the period of stool donation. This is the
 preferred means of donor screening (GRADE of evidence: low; strength of
 recommendation: strong).

ii. In centres using fresh FMT, we recommend that a repeat health questionnaire should be
 assessed at the time of each stool donation. To ensure ongoing suitability for inclusion
 as a donor, the donor health questionnaire and laboratory screening should be repeated
 regularly (*GRADE of evidence: low; strength of recommendation: strong*).

228 2.2.4. What factors related to the preparation of the transplant influence the outcome of 229 faecal microbiota transplant when treating people with *Clostridium difficile* 230 infection?

2.2.4.1. General principles of FMT preparation:

 Gut

	HIS/ I	3SG FMT Guideline: Main Document, Gut version.
232	i.	We recommend that stool collection should follow a standard protocol (GRADE of

ii. We recommend that donor stool should be processed within 6 hours of defaecation
235 (*GRADE of evidence: low; strength of recommendation: strong*).

evidence: low; strength of recommendation: strong).

- iii. We recommend that both aerobically and anaerobically prepared FMT treatments
 should be considered suitable when preparing FMT for the treatment of recurrent
 CDI (GRADE of evidence: moderate; strength of recommendation: strong).
- *iv.*We recommend that sterile 0.9% saline should be considered as an appropriate1617240diluent for FMT production, and cryoprotectant such as glycerol should be added for18241frozen FMT (GRADE of evidence: moderate: strength of recommendation: strong).
 - v. We recommend using ≥50g of stool in each FMT preparation (GRADE of evidence:
 moderate: strength of recommendation: strong).
 - 244 vi. We suggest that stool should be mixed 1:5 with diluent to make the initial faecal
 245 emulsion (GRADE of evidence: low; strength of recommendation: weak).
 - vii. We suggest that homogenisation and filtration of FMT should be undertaken in a
 closed disposable system (GRADE of evidence: low; strength of recommendation:
 weak).

2.2.4.2. Fresh vs frozen FMT:

We recommend that the use of banked frozen FMT material should be considered preferable to fresh preparations for CDI (*GRADE of evidence: high; strength of recommendation: strong*).

2.2.4.3. Use of frozen FMT:

i. We recommend that FMT material stored frozen at -80°C should be regarded as having a
 maximum shelf life of six months from preparation (*GRADE of evidence: low; strength of recommendation: strong*).

ii. We suggest consideration of thawing frozen FMT at ambient temperature, and using
within six hours of thawing (GRADE of evidence: low; strength of recommendation:
weak).

- *iii.* We suggest not thawing FMT in warm water baths, due to the risks of cross
 263 contamination with *Pseudomonas* (and other contaminants) and reduced bacterial
 264 viability (*GRADE of evidence: very low; strength of recommendation: weak*).

- 266 2.2.5. What factors related to administration of the transplant influence the outcome of
 267 faecal microbiota transplant when treating people with *Clostridium difficile* 268 infection?
- **2.2.5.1.** Use of specific medications in the period around FMT administration:
- **2.2.5.1.1. General principles of FMT administration:**
- *i.* We recommended that bowel lavage should be administered prior to FMT via the
 lower GI route, and that bowel lavage should be considered prior to FMT via the
 upper GI route; polyethylene glycol preparation is preferred (*GRADE of evidence: low; strength of recommendation: strong*).
- *ii.* For upper GI FMT administration, we suggest that a proton pump inhibitor should be
 276 considered, e.g. the evening before and morning of delivery (*GRADE of evidence:*277 *low; strength of recommendation: weak*).
- *iii.* We suggest that a single dose of loperamide (or other anti-motility drugs) should be
 279 considered following lower GI FMT delivery (*GRADE of evidence: low; strength of recommendation: weak*).
- iv. We suggest that prokinetics (such as metoclopramide) should be considered prior to
 FMT via the upper GI route (GRADE of evidence: low; strength of recommendation:
 weak).
 - v. We recommend that best practice for prevention of further transmission of CDI
 should be applied throughout when administering FMT to patients with CDI (nursing
 with enteric precautions, sporicidal treatment of endoscope, etc) (GRADE of *evidence: high; strength of recommendation: strong).*

2.2.5.1.2. Additional antibiotics pre-FMT:

- 290 We recommend the administration of further antimicrobial treatment for CDI for at least 72
- 291 hours prior to FMT (GRADE of evidence: low; strength of recommendation: strong).

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

2		
3	293	2.2.5.1.3. Washout period between antibiotic use and FMT:
4 5	294	i. To minimise any deleterious effect of antimicrobials on the FMT material, we
6 7	295	recommend that there should be a minimum washout period of 24 hours between the
8 9	296	last dose of antibiotic and treatment with FMT (GRADE of evidence: low; strength of
10	297	recommendation: strong).
11 12	298	ii. We suggest considering consultation with infectious disease specialists or medical
13 14	299	microbiologists for advice whenever FMT recipients also have an indication for long-
15	300	term antibiotics, or have an indication for non-CDI antibiotics within eight weeks of FMT
16 17	301	(GRADE of evidence: very low; strength of recommendation: weak).
18 19	302	
20 21	303	2.2.5.2. Route of FMT delivery:
22	304	2.2.5.2.1. Upper gastrointestinal tract administration of FMT:
23 24	305	<i>i.</i> We recommend that upper GI administration of FMT as treatment for recurrent or
25 26	306	refractory CDI should be used where clinically appropriate (GRADE of evidence: high;
27	307	strength of recommendation: strong).
28 29	308	<i>ii.</i> Where upper GI administration is considered most appropriate, we recommend that
30 31		
32	309	FMT administration should be via nasogastric, nasoduodenal, or nasojejunal tube, or
33 34	310	alternatively via upper GI endoscopy. Administration via a permanent feeding tube
35	311	is also appropriate (GRADE of evidence: high; strength of recommendation: strong).
36 37	312	<i>iii.</i> We recommend that no more than 100ml of FMT is administered to the upper GI
38 39	313	tract (GRADE of evidence: low; strength of recommendation: strong).
40	314	<i>iv.</i> We recommend that upper GI administration of FMT should be used with caution in
41 42	315	those at risk of regurgitation and/ or those with swallowing disorders (GRADE of
43 44	316	evidence: low; strength of recommendation: strong).
45	317	
46 47	318	2.2.5.2.2. Lower gastrointestinal tract administration of FMT:
48		
49 50	319	<i>i.</i> We recommend that colonoscopic administration of FMT as treatment for recurrent
51 52	320	or refractory CDI should be used where appropriate (GRADE of evidence: high;
53	321	strength of recommendation: strong).
54 55		
56 57		
58		
59 60		https://mc.manuscriptcentral.com/gut

Page 14 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

- *ii.* Where colonoscopic administration is used, we suggest considering preferential
 323 delivery to the caecum or terminal ileum, as this appears to give the highest efficacy
 324 rate (GRADE of evidence: low; strength of recommendation: weak).
 - *iii.* We recommend that FMT via enema should be used as a lower GI option when 326 delivery using colonoscopy or flexible sigmoidoscopy is not possible (*GRADE of evidence: high; strength of recommendation: strong*).

2.2.5.2.3. Capsulised FMT:

Capsulised FMT holds promise as a treatment option for recurrent CDI and we recommend that this should be offered to patients as a potential treatment modality where available. Capsule preparations should follow a standard protocol. Further evidence regarding optimal dosing and formulation is required (*GRADE of evidence: high; strength of recommendation: strong*).

336 2.2.6. What is the clinical effectiveness of FMT in treating conditions other than 337 Clostridium difficile infection?

We do not currently recommended FMT as treatment for inflammatory bowel disease. Apart from CDI, there is insufficient evidence to recommend FMT for any other gastrointestinal or non-gastrointestinal disease (*GRADE of evidence: moderate; strength of recommendation: strong*).

2.2.7. Basic requirements for implementing a FMT service:

2.2.7.1. General considerations:

- *i.* The development of FMT centres should be encouraged (*GRADE of evidence: very*346 *low; strength of recommendation: strong*).
 - *ii.* We suggest that FMT centres should work to raise awareness about FMT as a
 348 treatment option amongst clinicians caring for patients with CDI, and provide
 349 training to relevant healthcare professionals on the practicalities of delivering an
 350 FMT service (*GRADE of evidence: very low; strength of recommendation: weak*).

https://mc.manuscriptcentral.com/gut

 Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

352	2.2.7.2.	Legal aspects and clinical governance:
-----	----------	--

In the UK, FMT must be manufactured in accordance with MHRA guidance for human medicines regulation. When FMT is supplied on a named patient basis, within a single organisation, a pharmacy exemption may be used, subject to ensuring proper governance and traceability. All centres that are processing and distributing FMT should seek guidance from the MHRA and where necessary obtain appropriate licenses prior to establishing an FMT service. This is a legal requirement. In countries other than the UK, FMT should only be manufactured following appropriate approval from the national authority of that country (GRADE of evidence: very low; strength of recommendation: strong).

2.2.7.3. Multidisciplinary teams:

363 We recommend that a multidisciplinary team should be formed to deliver FMT services 364 (*GRADE of evidence: very low; strength of recommendation: strong*).

2.2.7.4. Infrastructure:

We recommend utilisation of suitable laboratory facilities and infrastructure for FMT
production (*GRADE of evidence: very low; strength of recommendation: strong*).

2.2.7.5. FMT manufacturing:

We recommend ensuring the traceability of supply (GRADE of evidence: very low; strength
of recommendation: strong).

2.2.7.6. FMT production quality control:

We recommend monitoring, notification and investigation of all adverse events and
reactions related to FMT (*GRADE of evidence: very low; strength of recommendation:*strong).

2.2.7.7. Donor screening governance:

380 We recommend ensuring the clinical governance of donor screening (GRADE of evidence:

381 very low; strength of recommendation: strong).

https://mc.manuscriptcentral.com/gut

383 3. Introduction:

The aim of the BSG/ HIS FMT working group was to establish a guideline that defined best practice in all aspects of a FMT service, by providing evidence-based recommendations wherever possible, and consensus multi-disciplinary expert opinion where specific published evidence is currently lacking. This included the evaluation of the use of FMT in the treatment of *Clostridium difficile* infection (CDI; also referred to as *Clostridioides difficile*¹), and also in potential non-CDI indications. Relevant guidance published to date includes the interventional procedure guidance from the National Institute for Health and Care Excellence (NICE)², UK, European and US microbiological guidelines on the treatment of *Clostridium difficile* infection (CDI)³⁻⁵, and recent expert consensus documents on FMT in clinical practice^{6,7}. Furthermore, there have also been national recommendations regarding FMT produced by working groups in several different countries^{8–10}. Principally as a result of randomised studies that have been published in recent years^{11–18}, FMT has become an accepted treatment for recurrent/refractory CDI.

Gut

397 The unique remit and objectives of this guideline when commissioned by the BSG and HIS was:

i. To review the rapidly-growing body of randomised trial evidence for the efficacy of FMT in the treatment of adults (\geq 18 years), both in CDI and in other clinical conditions, much of which has been published after the publication of current CDI treatment algorithms^{3,4}.

401 ii. To provide specific guidance about best practice for an FMT service within the context of the
 402 regulatory framework for the intervention as it currently exists in the UK^{19,20}.

The elucidation of the mechanisms underlying the efficacy of FMT in treating CDI remains an active area of global research, with the aim of rationalising FMT from its current crude form to a more targeted, refined therapeutic modality²¹. Previous research has demonstrated that commensal bacteria cultured from the stool of healthy donors²², sterile faecal filtrate²³, and/ or spores of *Firmicutes* derived from ethanol-treated stool from healthy donors²⁴, may have similar efficacy to conventional FMT in treating CDI, although results of the latter approach produced disappointing outcome data when extended to a Phase II clinical trial²⁵. For the purposes of this guideline, the BSG/HIS working group considered only studies that used the administration of manipulated whole stool (including encapsulated faeces). They deemed studies using cultured microorganisms (or their

 HIS/ BSG FMT Guideline: Main Document, Gut version.

proteins, metabolites or other components), or microbiota suspensions, to be in the pre-clinicalresearch stage, without firm evidence.

FMT has been shown to be very acceptable to patients, both in the setting of CDI^{11,26} and in non-CDI settings, e.g. ulcerative colitis²⁷. However, the absence of appropriate protocols^{28–31} specifically taking into account UK clinical practice and regulation of FMT has been perceived as a barrier to the use of FMT in the UK and Ireland; these guidelines seek to rectify this problem.

421 4. Guideline development:

422 4.1. Guideline development team

BSG and HIS commissioned the authors to undertake the Working Party Report. The authors represent the membership of both societies. The working group included gastroenterologists, infectious diseases/microbiology clinicians, a clinical scientist, a systematic reviewer, and patient representatives. The views expressed in this publication are those of the authors, and have been endorsed by BSG and HIS following consultation.

429 4.2. Scope of the guidelines

The main scope of the guidelines is to provide guidance for the optimal provision of an effective and safe FMT service, principally for recurrent or refractory CDI, but non-CDI indications are also considered. These guidelines only apply to adult patients (≥18 years); the working party did not consider the role of FMT in the treatment of either CDI or non-CDI indications in children or young people. The guidelines were written with a focus upon UK practice, but also with consideration of more global practice as it applied. The diagnosis and management of *Clostridium difficile* infection in general are outside the remit of these guidelines.

4.3. Evidence appraisal

Questions for review were derived from the Working Party Group, which included patient
 representatives in accordance with the PICO process³². To prepare these recommendations, the
 working group collectively reviewed relevant peer-reviewed research.

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

4.4. Data sources and search strategy

A systematic literature search was undertaken using MEDLINE, EMBASE databases and Cochrane Library for relevant articles published from 1st January 1980 to 1st January 2018. The MEDLINE and EMBASE strategy are shown in **Supplementary Material 1, Appendix 2ii**. Free text and MESH/ index terms for faecal microbial transplant and *Clostridium difficile* or other diseases of interest were In addition, conference proceedings from microbiology, infectious disease, and combined. gastroenterology conferences were also searched to identify additional studies.

4.5. Study eligibility and selection criteria

The members of the guideline group determined criteria for study inclusion. Two reviewers (BHM, MNQ) screened the titles and abstracts of each article for relevance independently; any disagreements were resolved by discussion with a third reviewer (JPS). Copies of relevant articles were obtained and assessed for inclusion as evidence in the guideline by all three reviewers. The reason for not selecting studies was recorded. Only articles published in English and human clinical studies were included. For evidence on FMT for CDI, both randomised studies (including randomised controlled trials (RCTs)) and case series with at least 10 patients were selected. Only randomised trials were included as evidence for FMT for non-CDI indications. Conference abstracts were only included for CDI and non-CDI indications if they reported a randomised trial; where abstracts were available reporting data from a randomised trial that was subsequently published, only the published paper was reviewed. 4.

4.6. Data extraction and quality assessment

The initial search identified 2658 publications, and of these, 802 duplicates were excluded. 1856 studies were subsequently screened, from which 78 studies were assessed by reviewing the full text for eligibility (see Supplementary Material 1, Appendix 2iii and Supplementary Material 2, Additional Appendix D). Of these 78 studies, 58 studies were included as the basis of evidence for writing this guideline. In total, 39 were case studies in CDI including at least 10 patients (see Supplementary Material 2, Additional Appendix C.1), and ten were randomised studies in CDI (see Supplementary Material 2, Additional Appendix C.2). Nine were randomised trials for non-CDI indications (see Supplementary Material 2, Additional Appendix C.3). Data were extracted for patient demographics, disease characteristics, donor screening characteristics, stool preparation and administration, clinical outcomes and adverse events. The quality of randomised studies was

Page 19 of 454

 HIS/ BSG FMT Guideline: Main Document, Gut version.

assessed with the Cochrane Collaboration's risk of bias tool. Case series were assessed using theCentre for Reviews and Dissemination guidance.

4.7. Rating of evidence and recommendations

The BSG version of these guidelines was prepared in keeping with the BSG Clinical Services & Standards Committee (CSSC) advice document on the writing of clinical guidelines³³. Evidence tables were presented and discussed by the working group, and guidelines were prepared according to the nature and applicability of the evidence regarding efficacy and patient preference and acceptability. For the BSG version of this guideline, the GRADE system (Grades of Recommendation Assessment, Development and Evaluation)³⁴ was used to assess the strength of evidence (high/ moderate/ low/ very low) and strength of recommendation (strong/ weak) (Table 4). The section entitled 'Basic requirements for implementing an FMT service' (Supplementary Material 3) was based on expert opinion, since this was a key area of the working party's remit but not one amenable to evaluation by the PICO process. Face-to-face meetings and group teleconferences were held to agree on recommendations. Any disagreements on recommendations or the strength of recommendation were resolved by discussion and, where necessary, voting by the members of the working group, with consensus achieved when >80% were in agreement.

4.8. Consultation process

Feedback on draft guidelines was received from the Scientific Development Committee (SDC) of HIS, and changes made. These guidelines were then opened to consultation with relevant stakeholders (see **Supplementary Material 1, Appendix 3** of this document). The draft report was available on the HIS website for one month. Views were invited on format, content, local applicability, patient acceptability, and recommendations. The working group reviewed stakeholder comments, and collectively agreed revisions. Final changes were made after repeat reviews from HIS (Chair of the SDC and HIS Council) and BSG (BSG CSSC and BSG Council), and after further external peer review.

502 4.9. Guideline accreditation and scheduled review

503 The guidelines will be reviewed at least every four years and updated if change(s) in the evidence are504 sufficient to require a change in practice.

https://mc.manuscriptcentral.com/gut

Gut

Page 20 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

506 4.0. Additional information:

507 Additional information related to this guideline (including a lay summary, background on the 508 working party report, and information on the implementation of these guidelines) is contained 509 within **Supplementary Material 1, Section 1**.

5. <u>Rationale for recommendations:</u>

512 5.1. Which patients with *Clostridium difficile* infection should be considered for faecal 513 microbiota transplant, and how should they be followed up after treatment?

5.1.1. Prior to faecal microbiota transplant. Patient selection:

5.1.1.1. Recurrent *Clostridium difficile* infection:

As already described, there is widespread consensus that FMT is an efficacious treatment for recurrent CDI. In defining recurrent CDI, some studies have relied on a minimum threshold of return of clinical symptoms (e.g. at least three unformed bowel movements within 24 hours, for at least two consecutive days)^{12,18} following previous successful CDI treatment; most studies have also included a requirement for a positive microbiological test^{12,14,18,35-45}. Other studies explicitly state that a positive test was not required⁴⁶. Recommendations for CDI testing are beyond the scope of this guideline, and there are already well-established evidence-based guidelines⁴⁷. These recommend testing with either a nucleic acid amplification test (NAAT) or GDH assay, followed by detection of free toxin (either by toxin A/B enzyme immunoassay (EIA) or cytotoxin neutralisation assay), which allows differentiation of patients with active disease as well as those who are likely colonised⁴⁷. However, the working group discussed the importance of the accurate diagnosis of true recurrent CDI prior to consideration of FMT; in particular, they noted a study which observed that of 117 patients with presumed recurrent CDI referred for work-up for FMT, 25% (n=29/117) were determined to have a non-CDI diagnosis, with irritable bowel syndrome (n=18) and inflammatory bowel disease (n=3) being the most common alternative diagnoses, and younger patients more likely to be misdiagnosed⁴⁸.

All of the reviewed studies have included patients with recurrent CDI, however some studies offered FMT to patients at the first recurrence (second episode)^{12,15,16,18,35,37,42,43,46,49}, whereas others offered FMT after the second recurrence (third episode)^{13,14,39,41,44,45,50,51}. Some protocols offered FMT after three or more recurrences⁵², whilst others did not define the point at which it was adminstered^{40,53}.

https://mc.manuscriptcentral.com/gut

Page 21 of 454

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

The severity of infection has been used as a parameter to decide at which stage FMT is offered. Youngster *et al.* offered FMT to patients with at least three episodes of mild to moderate CDI, or at least two episodes of severe CDI resulting in hospitalisation and associated with significant morbidity¹⁷. Another study selected patients for FMT using four categories of severity, which also accounted for prior anti-CDI therapy and requirement for hospitalisation⁵⁴.

None of the studies directly compared the efficacy of FMT according to the stage at which it was offered (i.e. first recurrence vs. \geq two recurrences). A small number of studies^{55–57} included patients with severe CDI (defined as hypoalbuminaemia with increased peripheral white cell count and/or abdominal tenderness) or complicated CDI (defined as admission to Intensive Care, altered mental status, hypotension, fever, ileus, white blood cell count $> 30 \times 10^9$ /l, lactate > 2.2mmol/l, or evidence of end organ damage). A single study described an apparent lower rate of treatment success when FMT was used to treat patients with recurrent CDI with disease caused by ribotype 027^{43} , but this is the case for all anti-CDI treatment modalities for this ribotype in comparison to others. The working group agreed that there was insufficient evidence to suggest that C. difficile ribotype should influence whether or not FMT is offered.

A lower primary cure rate was reported for complicated CDI (66%) compared with recurrent CDI (82%) and severe CDI (91%) in one study⁵⁵; in a case series of 17 patients who all had severe and/or complicated CDI, a primary cure rate of 88% was described⁵⁷. A cohort of 328 patients was analysed to determine which factors were associated with failure of FMT⁵⁸. Higher early (one month) failure rates were found in patients with severe (72%, n=19/25) or severe-complicated (52.9%, n=9/17) CDI than for recurrent CDI (11.9%, n=34/286). This study also identified that patients who were treated with FMT as an inpatient were nearly four times more likely to fail as those who had FMT as an outpatient; however, the working group noted that the authors of this study themselves identified that inpatient status is likely a proxy of severity of CDI and/or co-morbidities. A further similar study, including 64 patients treated with FMT as treatment for recurrent CDI, also identified severe CDI as the strongest independent risk factor for FMT failure on multivariate analysis⁵⁹.

567 The working group discussed their experience of treating patients with CDI whose disease fitted an 568 intermediate pattern to the typical descriptions given of recurrent or refractory CDI, e.g. patients 569 with CDI who have some (but incomplete) symptomatic improvement with anti-CDI antibiotics and 570 worsening of disease when these are stopped. The experience of the working group was that such

https://mc.manuscriptcentral.com/gut

571 patients experienced excellent responses to FMT, and that these patients should be considered for572 FMT.

Gut

As FMT is currently an unlicensed medicine with poorly-studied long term sequelae, the working group considered that it should generally be reserved for patients who have had three or more episodes of infection. There are no studies directly comparing its effectiveness with some of the newer agents such as fidaxomicin or bezlotoxumab, hence this recommendation is made on the basis of safety. However, the working group agreed that it may be reasonable in certain patient groups with ongoing risk factors for further recurrence to offer FMT after the second episode.

Recommendation:

We recommend that FMT should be offered to patients with recurrent CDI who have had at least two recurrences, or those who have had one recurrence and have risk factors for further episodes, including severe and severe-complicated CDI (GRADE of evidence: high; strength of recommendation: strong).

5.1.1.2. Refractory *Clostridium difficile* infection:

Two randomised trials allowed the recruitment of patients with refractory CDI. The first defined this as at least three weeks of ongoing severe symptoms despite standard antimicrobial therapy for CDI¹⁷. The second required persistent or worsening diarrhoea and one of the following: ongoing abdominal pain, fever > 38°C, or white blood cell count > 15x 10⁹/l despite oral vancomycin at a dose of 500mg four times daily for at least five days¹⁶. Both studies included only small numbers of patients with refractory CDI (n=4/20 (20%) and n=15/219 (6.8%), respectively). There did not appear to be any significant difference in primary outcome measure (clinical cure) in patients with recurrent or refractory CDI, although neither study was designed to assess this difference. There are also a number of case series in which FMT was given to patients with refractory CDI; however, outcome measures were not reported for these groups individually in these studies^{37,38,54,60}.

599 Overall, the working group concluded that there is little consensus on the definition of refractory 600 CDI, with some studies using the terms 'refractory' and 'recurrent' interchangeably (as well as other 601 terms, e.g. 'salvage therapy'). Consequently, the quality of evidence for the utility of FMT in

 Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

refractory cases of CDI is lower than for recurrent CDI. The standardisation of definitions will allowmore robust comparison between patient cohorts.

Recommendation:

606 We recommend that FMT should be considered in cases of refractory CDI (GRADE of 607 evidence: moderate; strength of recommendation: strong).

5.1.1.3. FMT as initial therapy for *Clostridium difficile* infection:

Experience of the use of FMT as initial therapy for CDI is very limited. In a case series of patients with CDI with ribotype 027, use of anti-CDI antibiotics together with nasogastric FMT within a week of diagnosis during an initial episode of CDI was associated with reduced mortality when compared to using FMT only after the failure of three courses of antibiotics (mortality of 18.75% (n=3/16patients) vs 64.4% $(n=29/45 \text{ patients})^{61}$. However, 37.5% (n=6/16) of the patients treated with FMT within a week of CDI diagnosis required further antibiotics and a second FMT within one month of the first FMT because of relapse⁶¹. In a small pilot randomised trial, patients were randomised to either vancomycin or multi-donor FMT (administered either via upper or lower GI routes) as initial therapy for CDI; CDI resolution occurred in 88.9% (n=8/9) patients with vancomycin, compared to 57.1% of patients (n=4/7) patients with one FMT, and 71.4% of patients (n=5/7) after two FMTs 62 . Given the small size of these studies and equivocal results, the working group concluded that the reviewed studies did not support FMT as initial therapy for CDI.

Recommendation:

624 We recommend that FMT should not be administered as initial treatment for CDI (GRADE

- 625 of evidence: low; strength of recommendation: strong).

6275.1.1.4.Antimicrobial/ antitoxin therapy prior to considering FMT for patients with628CDI:

There are now at least two licensed agents (fidaxomicin and bezlotoxumab) which have been shown
 to significantly reduce the risk of recurrence compared with vancomycin^{63,64}. There is also some
 evidence that pulsed/tapered dosing of vancomycin and fidaxomicin (including pulsed fidaxomicin⁶⁵)
 results in fewer recurrences than with standard dosing of these agents^{66,67} (although this finding has

https://mc.manuscriptcentral.com/gut

633 not been replicated in all studies⁶⁸). Pre-planned subgroup analysis of patients with severe CDI in a 634 randomised trial demonstrated a significantly lower recurrence rate when treated with fidaxomicin 635 (13.0%, n=12/92) than when treated with vancomycin (26.6%, n=29/209)⁶³; this finding was 636 replicated in another randomised controlled trial, with 8.3% (n=4/48) and 32.6% (n=14/43) 637 experiencing a recurrence respectively⁶⁹. In a further randomised trial, bezlotoxumab (together with 638 standard of care antibiotics) was shown to reduce recurrence of severe CDI compared to standard of 639 care antibiotics alone (10.9% (n=6/55) vs 20% (n=13/65) respectively)⁶⁴.

As discussed above, the working group noted that there are no studies comparing FMT to fidaxomicin or bezlotoxumab, and only one study comparing a vancomycin taper to FMT¹². The working group agreed that in the absence of this evidence, on the balance of safety and potential risks, consideration should be given to using antimicrobial/antitoxin therapy associated with reduced CDI recurrence prior to considering the use of FMT.

Several studies specify that patients should be treated with anti-*C. difficile* antibiotics for a minimum
 period of 10 days before diagnosing recurrent CDI and offering FMT^{12,15,16,18}.

Recommendations:

- i. We recommend that FMT for recurrent CDI should only be considered after
 recurrence of symptoms following resolution of an episode of CDI that was treated
 with appropriate antimicrobials for at least 10 days (GRADE of evidence: low;
 strength of recommendation: strong).
- 655 ii. We recommend consideration of treatment with extended/ pulsed vancomycin
 656 and/or fidaxomicin before considering FMT as treatment for recurrent CDI (GRADE
 657 of evidence: low; strength of recommendation: strong).
- iii. For those with severe or complicated CDI, which appears to be associated with
 reduced cure rates, we recommend that consideration should be given to offering
 patients treatment with medications which are associated with reduced risk of
 recurrence (e.g. fidaxomicin and bezlotoxumab), before offering FMT (GRADE of
 evidence: low; strength of recommendation: strong).

5.1.2. Post-FMT follow-up, outcomes and adverse events:

5.1.2.1. Management of FMT failure:

Page 25 of 454

 Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

Where patients were deemed not to have responded to an initial FMT, many studies have offered repeat FMT and success rates have been excellent even in patients with modest response to a first FMT^{14,15,17,18,35,43,46,51,54,70,71}. The success of a second FMT appears to be high whether treatment failure represents non-response to the first FMT, or a late failure (i.e. further relapse of CDI after an initial response); however, these terms have been defined variably between different studies (also see Section 5.1.2.5). Second FMTs have been offered as soon as 24-72 hours after an initial FMT for presumed non-response^{37,72,73}. For FMT failure in patients with pseudomembranous colitis, repeat FMT every three days until resolution of pseudomembranes has been a successful approach¹⁸. Good outcomes in pseudomembranous disease have also been achieved through a protocol that routinely restarted five days of vancomycin if FMT failed, before offering another FMT⁷³. Other studies have demonstrated potential success in treating initial FMT failure with further antibiotics, including repeat FMT with vancomycin between procedures⁴², or anti-CDI antibiotics alone^{35,42,43,45,51,70,71}. Patients unresponsive to two FMTs have been offered further FMT or antibiotic therapy¹⁶, or even the administration of intravenous immunoglobulin³⁵. Whilst the working group collectively agreed that there was strong evidence to recommend repeat FMT after initial FMT failure, they were not able to recommend a specific protocol for administering repeat FMT and/ or maximum number of FMTs, given the wide heterogeneity of approach described within the reviewed literature.

Recommendation:

- We recommend that FMT should be offered after initial FMT failure (GRADE of evidence:
- high; strength of recommendation: strong).

5.1.2.2. General approach to follow-up post-FMT:

Follow-up post-FMT (in terms of duration, modality and regimen for follow-up) varies considerably between studies, and is largely dependent upon study design. Follow-up regimens vary not only between studies but within them too, reflecting the retrospective nature of many early FMT studies in CDI, where follow-up mostly reflected pragmatic routine clinical care.

review^{14,43,58,71,74–76} included Modalities of follow-up have outpatient telephone interview^{17,39,43,46,58,71,74} and case note/ database review^{35,39,70,71,74,40,42,43,45,46,49,51,54}. Follow-up duration has varied from 60 days⁴⁵ to 8 years³⁶, with very different durations used in each study. Once again, however, this variability in follow-up largely reflects the retrospective analysis of case

https://mc.manuscriptcentral.com/gut

series rather than being justified by any specific methodology. The working group decided by
consensus that at least eight weeks of follow-up was appropriate post-FMT to fully assess efficacy
and potential adverse events; this figure was also influenced by discussions regarding the timepoint
after FMT at which a decision could be made regarding cure/ remission of CDI (see Section 5.1.2.4).

Recommendation:

We recommend that all FMT recipients should routinely receive follow-up. Clinicians should follow-up FMT recipients for long enough to fully establish efficacy/adverse events, and for at least eight weeks in total (GRADE of evidence: low; strength of recommendation: strong).

5.1.2.3. Management of the FMT recipient:

Procedural adverse events during administration of FMT have predominantly occurred with colonoscopic administration of FMT. These have included mild nausea and vomiting attributed to sedation for the colonoscopy, minor mucosal tears during colonoscopy^{49,60}, and microperforation following biopsy of an area of presumed ischaemic small bowel injury in a patient with chronically dilated small bowel (which resolved with conservative management⁴⁶). One death occurred due to witnessed aspiration at the time of colonoscopy⁶⁰. Faecal regurgitation and vomiting with temporal association to upper GI FMT administration has also been described (discussed further in Section **5.5.2.2**)⁷⁷.

The predominant short term adverse events post-FMT for CDI are mild: self-limiting GI symptoms have been the most frequently reported adverse events. These may be related to the route of administration and include belching¹⁵, nausea^{15,16,49,60}, abdominal cramps/ discomfort/ bloating/ pain^{15,18,49,60,72}, and diarrhoea^{15,16,18,60}. One patient with a history of autonomic dysfunction experienced dizziness with diarrhoea after FMT¹⁵. These symptoms are typically short-lived, resolving in hours to days^{15,16,18,49,72}. Minor subsequent adverse events have included a range of GI discomfort^{14,17,57,76}, abdominal nausea^{14,49,70}. side effects including self-limiting flatulence^{14,16,17,41,42,49,57}, self-limiting irregular bowel movements⁴¹, *C. difficile*-toxin negative diarrhoea^{52,55}, constipation^{14,15,42,55,70} and constitutional symptoms/ temperature disturbance^{14,17}.

https://mc.manuscriptcentral.com/gut

 Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

As such, immediately post-endoscopic administration of FMT, most FMT centres typically manage patients using standard protocols for an endoscopic procedure^{41,49}, without any specific adaptations (apart from to reiterate advice about the possibility of self-limiting GI side effects, and the use of departmental infection control protocols). There is often a relatively short period of post-procedural observation^{15,18}. Most studies allow patients to leave the administration site after the period of observation, although overnight observation was the protocol used for a cohort of very elderly patients with multiple comorbidities⁵¹. Where enteral tube administration is used, post-procedure management has ranged between removal of the tube after 30 minutes (following nasoenteral administration of 500ml of FMT¹⁵) to prompt post-procedure removal and oral water administration (after nasogastric administration of 90ml of FMT⁷²), with no direct adverse outcomes in either case. The working group felt that removal of the tube at 30 minutes, with administration of water at this point, was a pragmatic approach.

The definition of post-FMT serious adverse events has varied between studies, but has included significant morbidity necessitating hospital admission and death in the follow up period. Many of these events are described as not directly caused by the FMT, including the scenario of post-FMT severe CDI recurrences⁷² and probable or certain CDI-related deaths^{16,60,70} occurring in the context of FMT failure, or deaths related to patient comorbidities^{17,55}. One patient was admitted to hospital with self-limiting abdominal pain post-FMT⁶⁰, and four patients with flares of inflammatory bowel disease⁶⁰. Three patients underwent colectomy during the post-FMT follow-up period, with all related to ulcerative colitis and not believed to be due to CDI⁶⁰. Other reported serious adverse events include recurrent urinary tract infection¹⁵, fever during haemodialysis¹⁵ and upper gastrointestinal haemorrhage after nasogastric FMT (in a patient taking NSAIDs⁵¹), none of which were thought to be strongly linked to FMT. There have also been a number of new onset autoimmune, inflammatory and metabolic conditions described post-FMT, although these have been described from single centres only, with these findings not replicated elsewhere. Such conditions include microscopic colitis, Sjögren's syndrome, follicular lymphoma, peripheral neuropathy, immune thrombocytopenia and rheumatoid arthritis^{53,55}.

758 Significant adverse events are therefore rare but well-described. Furthermore, the procedure is 759 relatively novel, and longer-term follow-up data regarding safety are required. Therefore, the 760 working group opined that formal follow-up post-FMT to assess outcome and possible adverse 761 events is essential.

2
3
-
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
20
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
40 47
48
49
50
51
52
53
54
55
56

762 763 The use of questionnaires to compare symptoms pre- and post-FMT is common. Specifically, data collected have included clinical response to symptom severity⁵⁵, stool frequency^{15,17,46,55,57,72}, stool 764 consistency^{14,15,72}, abdominal pain or tenderness^{55,57}, rating of gastrointestinal symptoms⁷², general 765 well-being^{55,72}, days to improvement post-FMT⁵⁷, weight change⁷², functional status⁵⁵, and changes 766 in medication/use of antibiotics^{57,72}. Additionally, certain patients have been given specific advice 767 post-FMT to contact their clinical team if there is recurrence of diarrhoea or symptoms^{14,35,41,43}. 768 769 Where patients underwent outpatient clinical evaluation, this was generally undertaken relatively early post-FMT^{39,52,76}. In one study, patients were additionally given instructions for cleaning and 770 disinfection at home, with the aim of reducing the possibility of *C. difficile* reinfection⁴³, and 771 counselling on the risk of recurrent CDI with future antibiotic courses⁷⁶. 772

773

774 *Recommendations:*

- 775 i. We recommend that immediate management after endoscopic administration of
 776 FMT should be as per endoscopy unit protocol (GRADE of evidence: very low:
 777 strength of recommendation: strong).
- We recommend that patients should be warned about short term adverse events,
 in particular the possibility of self-limiting GI symptoms. They should be advised
 that serious adverse events are rare (GRADE of evidence: very low; strength of
 recommendation: strong).
- 782 iii. After enteral tube administration, we recommend that patients may have the tube
 783 removed and oral water given from 30 minutes post-administration (GRADE of
 784 evidence: very low; strength of recommendation: strong).

57 58 59

60

785

786 **5.1.2.4. Definition of cure post-FMT for CDI:**

1787 It is recognised that symptoms of CDI resolve relatively promptly post-successful FMT, although this 1788 has been variably described (within hours in some studies⁵², at an average of 4-5 days in others^{57,71}). 1789 Treatment success post-FMT for CDI has no uniformly-agreed definition, with the time point at 1790 which cure/ remission is defined on clinical grounds varying between 3-5 days³⁶ up to six months⁴². 1791 A consensus document from the USA recommends 'resolution of symptoms as a primary end point; 1792 absence within eight weeks of FMT as a secondary end point'⁷⁸. The working group recommended 1793 that this definition should be made on a case-by-case basis; however, they agreed that an

https://mc.manuscriptcentral.com/gut

Page 29 of 454

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

assessment for cure/ remission of CDI within eight weeks post-FMT was reasonable in most cases,
and therefore that this was also a reasonable minimum length of time to undertake follow-up postFMT (see Section 5.1.2.2).

Recommendation:

We recommend that a decision regarding cure/remission from CDI should be recorded during follow-up. However, this has no uniformly-agreed definition, and should be decided on a case-by-case basis (GRADE of evidence: very low; strength of recommendation: strong).

5.1.2.5. Definition of treatment failure post-FMT for CDI:

There is no uniformly-agreed definition of treatment failure/recurrence post-FMT for CDI, with varied definitions used in studies. The use of C. difficile toxin as a marker of treatment success or failure is variable, with some studies opting not to test for CDT unless symptoms consistent with CDI recurred^{49,52–54,60,72,74}. Some studies have routinely performed CDT testing without specifying any action taken after a positive result^{14,15,18,36,39,41}, whilst others have tested for *C. difficile* PCR but relied on clinical criteria (even if PCR was positive) post-FMT for evaluating FMT efficacy¹⁴. A recent prospective study from the USA identified that only 3% (3/129) of patients who were asymptomatic at four weeks post-FMT for recurrent CDI had positive C. difficile PCR, again emphasising that symptoms rather than laboratory assays are more useful contributors to establishing FMT success⁷⁹.

Recommendation:

816 We recommend that treatment failure/recurrence should be defined on a case-by-case 817 basis. Routine testing for C. difficile toxin after FMT is not recommended, but it is 818 appropriate to consider in the case of persistent CDI symptoms/suspected relapse (GRADE 819 of evidence: low; strength of recommendation: strong).

5.2. What recipient factors influence the outcome of faecal microbiota transplant when treating people with *Clostridium difficile* infection?

5.2.1. General approach to co-morbidities and FMT:

824 Most published studies had a core set of general recipient exclusions which included: significant/ 825 anaphylactic food allergy^{14,17}, pregnancy^{12–15,17,18}, breastfeeding¹⁴, admission to Intensive Care or the

https://mc.manuscriptcentral.com/gut

Page 30 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

requirement for vasopressors^{12,15,18}, chronic diarrhoea or other infectious cause of diarrhoea^{12,14,18,50},
 inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)^{14,36}, immunodeficiency due to
 recent chemotherapy and/ or neutropenia^{12,14–18,50}, HIV/AIDS^{14,17,18}, prolonged use of
 corticosteroids^{15,17,18}, graft versus host disease¹², and decompensated cirrhosis^{14,15,17,18}.

The working group discussed the reported practice of several centres of treating patients with recurrent CDI and food allergies through the use of FMT prepared from a patient-directed donor instructed to avoid trigger foods before stool donation. They agreed that this seemed reasonable for patients with true adverse immunological reactions to defined food groups (e.g. gluten-free diet donor for a recipient with coeliac disease). However, the working group noted that food allergies are often poorly-defined clinically, and also expressed concerns that there was no means to verify how closely a donor had followed an exclusion diet; as such, they felt unable to make any specific recommendation about FMT in patients with food allergies in general. In contrast, whilst the working group were unaware of any reports in the literature of anaphylaxis attributable to FMT, they felt that the theoretical risk of a serious adverse outcome in patients with anaphylactic food allergy merited a specific recommendation that such individuals should not be offered FMT. Similarly, the working group expressed concern about the theoretical risk of adverse outcomes when administering FMT to patients with advanced decompensated chronic liver disease (including translocation of microbial material from the intestinal tract into the portal and systemic circulations, and theoretical risk of sepsis), and felt that FMT should be used with caution in this patient group.

Recommendations:

i. We recommend that FMT should be avoided in those with anaphylactic food allergy
 (GRADE of evidence: very low; strength of recommendation: strong).

ii. We suggest that FMT should be offered with caution to patients with CDI and
decompensated chronic liver disease (GRADE of evidence: very low; strength of
recommendation: weak).

5.2.2. Immunosuppression and FMT:

855 One randomised study¹⁶ included patients with immunodeficiency (treatment with 856 immunosuppressive therapy (azathioprine, ciclosporin, infliximab, methotrexate alone, or in 857 combination with corticosteroids) (n=18), renal transplant (n=5), chronic haemodialysis (n=5), solid 858 organ tumours (n=3) and haematological malignancy (n=4)) at the time of FMT. Clinical resolution Page 31 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

rates after up to two FMTs were high: 27/29 (93%) for immunocompromised individuals, 5/6 (83%)
for patients with IBD.

There are also limited data from case series and single case reports describing the use of FMT in patients with immunocompromise. Agrawal and colleagues⁵⁵ included 46/146 (32%) patients with a history of cancer, and an additional 15/146 (10%) patients with non-cancer-related immunologic dysfunction, although primary outcome measures were not specifically reported for these groups. Overall cure at 12 weeks in a case series of 80 patients with immunocompromise was reported in 71 (89%) of patients⁶⁰. Adverse events occurred in 12 (15%) immunocompromised patients; this included two deaths (one due to respiratory failure and another due to pneumonia resulting from aspiration at the time of FMT administration)⁶⁰; however, such adverse events have also been reported in non-immunocompromised patient populations⁸⁰. Hefazi and coauthors described high efficacy rates in a case series of FMT for recurrent CDI and a range of haematological or solid organ malignancies (remission after one FMT in 11/12 with haematological patients, and 8/10 in solid organ malignancy patients). No significant FMT-related complications were reported⁸¹. A further case series⁴⁵ reported FMT treatment for 75 patients with recurrent CDI and found no significant difference in primary cure rates for patients with diabetes mellitus, malignancy, or steroid use in the preceding three months.

The working group discussed the potential impact of donor EBV and CMV status for the immunocompromised FMT recipient at risk of severe infection if exposed to these viruses. Their opinion was that such recipients should only receive FMT from donors with negative EBV and CMV status.

Recommendations:

- We recommend that FMT should be offered with caution to immunosuppressed
 patients, in whom FMT appears efficacious without significant additional adverse
 effects (GRADE of evidence: moderate; strength of recommendation: strong).
- We recommend that immunocompromised FMT recipients at risk of severe infection if
 exposed to EBV or CMV should only receive FMT from donors negative for EBV and
 CMV (GRADE of evidence: very low; strength of recommendation: strong).

5.2.3. Other comorbidities and FMT:

Only a limited number of cited studies included specific detail about the presence of comorbidities in patients receiving FMT. However, several studies reported median Charlson comorbidity scores^{12,14,15,18,50}. One randomised study reported the presence of IBD in 10/17 (59%) FMT recipients¹⁶, and there did not appear to be any significant difference in primary outcome measures in this group. Another randomised trial included 14/72 (33%) patients with IBD and reported clinical cure of CDI in 12/14 (86%) of these patients¹³. This study also included 64/72 (89%) patients with cardiac, respiratory, renal, central nervous system or multi-organ system comorbidities¹³; however outcomes were not stratified according to co-morbidity. Kelly and coauthors⁶⁰ reported an overall cure rate of 94% in a subset of CDI patients with IBD. A meta-analysis of studies in which patients with IBD received FMT (either primarily as treatment for concurrent recurrent CDI, or with the aim of treating IBD) noted a small risk of exacerbation of IBD in association with the use of FMT⁸². The working group noted the complexity of the relationship between IBD and CDI, given that IBD is itself a risk factor for CDI.

906 Other exclusions have been more directly related to the mode of administration. For upper 907 gastrointestinal delivery, exclusion criteria have included delayed gastric emptying, chronic 908 aspiration, 'swallow dysfunction', and dysphagia^{17,50}. Exclusions for lower GI administration have 909 included colostomy/ileostomy^{16,50}, significant bleeding disorders¹², untreated colorectal cancer^{14,36,54}, 910 and ileus/small bowel obstruction⁵⁰.

912 In summary, the working group noted that co-morbidities amongst patients with recurrent CDI are 913 common. Most studies did not analyse primary outcome measures according to co-morbidity; 914 however, a small number of studies have analysed primary outcome measures (clinical cure) for 915 patients with IBD receiving FMT for recurrent CDI and have found no significant difference compared 916 to those without IBD, along with no overall significant worsening of IBD activity.

Recommendations:

919 i. We recommend that FMT should be offered to those with recurrent CDI and
 920 inflammatory bowel disease, but patients should be counselled about a small but
 921 recognised risk of exacerbation of IBD (GRADE of evidence: moderate; strength of
 922 recommendation: strong).

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

923 ii. We recommend that FMT should be considered for appropriate patients with
 924 recurrent CDI regardless of other comorbidities (GRADE of evidence: moderate;
 925 strength of recommendation: strong).

5.3. What donor factors influence the outcome of faecal microbiota transplant when treating people with *Clostridium difficile* infection?

5.3.1. General approach to donor selection:

Excellent efficacy has been shown in treating recurrent CDI using FMT derived from both related^{14,36,54,57,59,61,83,38,40,41,43,45,46,49,53} and unrelated^{14,15,57,59,61,72,74,83–87,16,17,35,37,38,41,43,53} donors. To date, there have been no randomised studies comparing differences in efficacy. Case series have tended to rely more on donation of stool from healthy family members. In randomised studies using FMT, all donors were healthy unrelated individuals^{12–18,88}. Three case series used donor stool from healthcare professionals^{39,61,85}; no randomised studies have used stool from this cohort. However, the working group noted that there were clear advantages to using FMT from a screened anonymous donor, in particular with regards to monitoring and traceability, as discussed further later.

Recommendation:

We recommend that related or unrelated donors should both be considered acceptable.
However, where possible, FMT is best sourced from a centralised stool bank, from a
healthy unrelated donor (GRADE of evidence: low; strength of recommendation: strong).

5.3.2. Age and BMI restrictions for potential donors:

There are no well-defined age restrictions on donors. Randomised studies have used donors of $\geq 18^{12,72}$ and ≤ 60 years old^{15,17,18} with satisfactory outcomes. Two of the case series defined age limitations for donors as ≥ 18 and ≤ 50 years^{72,89}. A recent study demonstrated that *Bacteroides: Firmicutes* ratio and microbial diversity was similar for donors above and below 60 years, and their stool donations had similar clinical efficacy as FMT; however, there were loss of the phylum *Actinobacteria* and family *Bifidobactericeae* from donors older than 60 years⁹⁰. On balance, the working group agreed that an age range of 18 – 60 years was appropriate for donors.

https://mc.manuscriptcentral.com/gut

A widely-reported case study noted apparent weight gain in a recipient of FMT for treatment of CDI when an overweight donor was used⁹¹, but any association between a donor with a raised BMI and weight gain post-FMT has not been replicated elsewhere in the literature⁹². Whereas most randomised studies did not report donor-specific BMIs, some have excluded those without a 'normal' BMI^{13,17}. The working group considered an acceptable BMI for donors as between \geq 18 to \leq 30 kg/m².

 Recommendation:

962 We suggest that people should only be considered as potential FMT donors if they are \geq 18 963 and \leq 60 years old, and have a BMI of \geq 18 and \leq 30 kg/m² (GRADE of evidence: low; 964 strength of recommendation: weak).

5.3.3. General approach to the donor screening assessment:

There is a clear theoretical risk of the transmission of infection by FMT; furthermore, given the large number of conditions in which perturbation of the gut microbiota has been described⁹³, there is a concern regarding a risk of transmission of microbiota associated with vulnerability to disease. Whilst FMT is efficacious for recurrent CDI, adverse events may be associated with its use (discussed further later), and long-term safety follow-up is lacking. The aim of a donor screening questionnaire and interview is to minimise post-FMT adverse events by excluding potential donors from whom FMT may be associated with risk to recipients. Randomised studies performed to date used various pre-screening questionnaires, including self-screening questionnaires which focused on high risk behaviours for blood-borne infections^{12–16}, guestionnaires that focused on previous potential transferable medical conditions¹⁸, and adaptations from the American Association of Blood Banks Donor Questionnaire^{14,17}. One randomised study used the OpenBiome questionnaire as a screening questionnaire⁹⁴. Some studies have suggested excluding potential donors who have recently travelled to defined regions (typically tropical areas), varying between 3-6 months prior to donation^{38,39,49,52,55,59,74,87}; this is also the protocol employed in randomised studies^{14,16,18}. Another important point for assessment is recent use of medications by potential donors. In particular, given the profound effects of antimicrobials on the gut microbiota^{95–98} (along with the theoretical concern that recent antimicrobials might precipitate gut colonisation with antimicrobial-resistant bacteria that could be transferred during FMT), studies advocate either a three month^{14,46,53–55,57,61,74} or six month^{16–18,35,38,39,43,49,85,99,100} period without antimicrobial use prior to FMT donation.

Page 35 of 454

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

The working group agreed that, given the growing evidence for the contribution of the gut microbiota to the aetiopathogenesis of colorectal carcinoma, patients with a significant personal or family history of (or risk factors for) this condition should be excluded as donors (**Table 1**). However, the working group noted an added complexity, in that their recommendation was that potential donors may be up to 60 years of age, but bowel scope screening for colorectal carcinoma currently begins within the UK at 55 years of age, and formal NHS bowel cancer screening starts at the age of 60 years¹⁰¹. The working group agreed that potential donors living in countries with bowel cancer screening programmes that start before the age of 60 years should have therefore completed appropriate screening with negative/ normal tests before they are considered further as donors.

997 The working group was of the opinion that a screening process is mandatory; any positive responses 998 should usually result in exclusion from donation, although this will depend upon the particular 999 circumstances/ answers given. A donor screening questionnaire should be performed both prior to 1000 considering a person as a donor, and also at a further point in time (discussed further in **Section 5.3.5**).

Recommendation:

1004It is mandatory to screen potential donors by questionnaire and personal interview, to1005establish risk factors for transmissible diseases and factors influencing the gut microbiota

1006 (Table 1) (GRADE of evidence: low; strength of recommendation: strong).

5.3.4. Laboratory screening of potential donors:

Currently, there are no known confirmed cases of blood-borne pathogens being transmitted by FMT, but strict preventative measures are important, as the potential risk of transmission is unknown. Many of the suggestions are extended from established blood screening guidelines¹⁰². Case series almost universally screen for HIV, hepatitis B and hepatitis C as a minimum^{35,36,52-} ^{55,59,61,72,74,84,86,37,87,103,39–43,46,49}; other studies (including the randomised trials) have a more thorough blood screening process^{14–18}. Many studies have also included a 'metabolic/general blood screen', to select out donors with hitherto undiagnosed chronic illness. Table 2 shows the suggested blood screening protocol of the BSG/HIS working group.

Page 36 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

The working group specifically discussed the role of screening donors for their EBV and CMV status; the importance of the rationale for this is discussed in **Section 5.2.2.** They agreed that EBV and CMV testing was only required where there is the potential that the FMT prepared from that donor would be administered to immunosuppressed patients at risk of severe infection if exposed to CMV and EBV. The primary aim of stool screening of potential donors is to minimise the risk of transmission of pathogens; again, the relative novelty of FMT for CDI means that these risks are not currently well-defined. Stool screening protocols are universal amongst published studies, though widely-variable protocols have been used. Table 3 displays the suggested stool screening protocol of the working group. The working group discussed stool screening for multi-drug resistant bacteria carriage, and agreed that carbapenemase-producing Enterobacteriaceae (CPE) should be screened for. Although these bacteria are carried only by a minority of the UK population, transfer into debilitated patients with CDI is clearly undesirable given that CPE are potentially so difficult to treat. They also agreed that extended-spectrum beta-lactamase (ESBL)-producing organisms could also potentially cause severe disease (with limited antimicrobial options) if transplanted into patients with CDI, and so should also be screened for. Whilst vancomycin-resistant Enterococci (VRE) carriage is relatively common in the community (probably related to food consumption)¹⁰⁴, community strains of VRE are genetically distinct from (and generally of much lower pathogenicity than) those found nosocomially¹⁰⁵; as such, the working group thought that routine screening was not justified. The working group also noted that methicillin-resistant Staphylococcus aureus (MRSA) carriage is very rare in healthy adults in non-healthcare settings (with significant intestinal carriage even rarer), so did not justify routine screening. However, the working group acknowledged that the potential infection risk from VRE and MRSA would vary regionally dependent upon local prevalence and pathogenicity, and as such recommended that a risk assessment is performed to assess whether screening for these organisms should be considered. A donor laboratory screening should be performed both prior to considering a person as a donor, and also at a further point in time (discussed further in Section 5.3.5). **Recommendation:**

https://mc.manuscriptcentral.com/gut

Gut

Page 37 of 454

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

Blood and stool screening of donors is mandatory (Tables 2 and 3) (GRADE of evidence:
low; strength of recommendation: strong).

5.3.5. Repeat donor checks, and donation pathway:

Almost all reviewed studies have repeated at least some elements of the initial donor screening process either at the time of donation of each stool sample used to prepare FMT, or at the end of a period of donation to assess ongoing suitability for inclusion. However, protocols have differed widely between studies.

The opinion of the working group was that when a donor had met criteria for donation (both with an acceptable health questionnaire and satisfactory laboratory tests), they were suitable to begin donation of stool that may be prepared into FMT. Repeat donor screening was also deemed necessary. In centres where frozen FMT is being prepared, stool may be collected and processed immediately after the first donor screen is successfully completed, but should be stored in 'quarantine' pending further donor screening, rather than used immediately for clinical use. At the end of the locally-defined period of donation, potential donors should undergo repeat testing, with a further health questionnaire and laboratory screening. If the donor's health questionnaire remains acceptable and repeat laboratory screening is negative at this point, then the frozen FMT may be released from 'quarantine', and used. The working group thought that donor screening both before and after donation was the safest route possible, and that this represented the preferred scenario. A proposed summary pathway for donor screening in this scenario is provided in Figure 1.

1071 In centres using fresh FMT, the working group agreed that a repeat health questionnaire should be 1072 completed at the time of donation of each stool sample used to prepare FMT. Formal repetition of 1073 both the personal interview/ health questionnaire and laboratory screening tests should occur at 1074 regular intervals to ensure ongoing suitability for inclusion as a donor. The working group's opinion 1075 was that this repetition of the screening process should occur at least once every four months.

Recommendations:

1078i. In centres using frozen FMT, before FMT may be used clinically, we recommend that1079donors should have successfully completed a donor health questionnaire and

1080 laboratory screening assays both before and after the period of stool donation. This is
 1081 the preferred means of donor screening (GRADE of evidence: low; strength of
 1082 recommendation: strong).

ii. In centres using fresh FMT, we recommend that a repeat health questionnaire should
 be assessed at the time of each stool donation. To ensure ongoing suitability for
 inclusion as a donor, the donor health questionnaire and laboratory screening should
 be repeated regularly (GRADE of evidence: low; strength of recommendation: strong).

10885.4.What factors related to the preparation of the transplant influence the outcome of1089faecal microbiota transplant when treating people with Clostridium difficile1090infection?

5.4.1. General principles of FMT preparation:

There is very little evidence or guidance on the collection of donor stool. Critical steps during this process centre on the reduction of environmental cross-contamination risk, so the use of clean collection devices and clean collection procedures is advocated. To promote standardised practice and a safe and effective product, clear instructions should be provided to the donor for stool collection (**Table 5**).

1098 Regardless of the methods used to prepare FMT, stool donations should be processed within six 1099 hours of defaecation. The period of six hours has been generally applied across many successful 1100 studies of FMT treatment in CDI^{14,18,35,39,43,52}, although no formal comparative study has been 1101 undertaken. This strategy aims to minimise sample degradation and alteration over time, which may 1102 occur due to the complex metabolic and environmental requirements of the faecal microbiota.

There are no comparative trials of anaerobically versus aerobically prepared FMT in the treatment of recurrent CDI. With the exception of small observational studies^{41,74}, the vast majority of FMT preparation has been undertaken aerobically for the treatment of CDI and has proved highly efficacious. There appears to be no clear need to process anaerobically, a method which introduces complexity and cost for the treatment of CDI.

 Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

The reviewed randomised studies reported variable amounts of stool used in the preparation of each FMT aliquot, and the lack of comparative data means that it is not possible to link stool mass to outcome from these studies. However, a previous systematic review of case series using FMT as treatment for recurrent CDI reported similar rates of treatment efficacy, but an approximate fourfold increase in recurrence rates, if <50g of stool was used compared to \geq 50g¹⁰⁶. Similarly, the initial volume of diluent used to create the faecal emulsion is variable between studies, although the most common practice appears to be creation of a stool: diluent ratio of approximately 1:5. The overwhelming majority of the reviewed studies used stool from only a single donor per FMT (rather than stool pooled from a mixture of donors), and there are no comparative studies of outcomes of CDI from single donor vs pooled donor FMT; as such, the working group found no justification to recommend donor stool pooling for FMT for CDI.

 The majority of studies have used preservative-free sterile 0.9% saline as the diluent for FMT production, although there have been a handful of reports of other diluents including potable water^{16,35,43}. There have been no comparative studies of FMT diluent. In cases where frozen FMT is prepared, an appropriate cryoprotective substance should be added prior to freezing. Most studies use glycerol at a final concentration of $\sim 10\%^{16,41}$. It has been demonstrated that storing stool at -80°C for up to six months in saline without glycerol decreases viable aerobic and anaerobic bacterial counts; the reduction was statistically significant in all bacterial groups with the exception of E. coli and total anaerobes. When stored with glycerol, no significant reduction in viable counts was observed⁷⁴.

A variety of homogenisation and open filtration systems have been used, with no apparent major variation in efficacy. Open filtration systems such as gauze^{16,37,40,55}, filter paper³⁹ and strainers/ sieves^{17,41} are unpleasant to use and pose a risk of external contamination. In order to best comply with GMP standards, a sterile, single-use closed homogenisation and filtration system is recommended. An example of such a system includes the use of sterile filter bags inside a laboratory paddle homogeniser.

Recommendations:

i. We recommend that donor stool collection should follow a standard protocol (GRADE of evidence: low; strength of recommendation: strong).

Page 40 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

Gut

2		
3 4	1142	<i>ii.</i> We recommend that donor stool should be processed within 6 hours of defaecation
5	1143	(GRADE of evidence: low; strength of recommendation: strong).
6 7	1144	<i>iii.</i> We recommend that both aerobically and anaerobically prepared FMT treatments
8	1145	should be considered suitable when preparing FMT for the treatment of recurrent
9 10	1146	CDI (GRADE of evidence: moderate; strength of recommendation: strong).
11 12	1147	iv. We recommend that sterile 0.9% saline should be considered as an appropriate
13	1148	diluent for FMT production, and cryoprotectant such as glycerol should be added
14 15	1149	for frozen FMT (GRADE of evidence: moderate: strength of recommendation:
16 17	1150	strong).
18 19	1151	v. We recommend using ≥50g of stool in each FMT preparation (GRADE of evidence:
20	1152	moderate: strength of recommendation: strong).
21 22	1153	vi. We suggest that stool should be mixed 1:5 with diluent to make the initial faecal
23 24	1154	emulsion (GRADE of evidence: low; strength of recommendation: weak).
25	1155	vii. We suggest that homogenisation and filtration of FMT should be undertaken in a
26 27	1156	closed disposable system (GRADE of evidence: low; strength of recommendation:
28 29	1157	weak).
30	1158	
21	2200	
31 32		5.4.2 Fresh vs frozen EMT:
32 33	1159	5.4.2. Fresh vs frozen FMT:
32 33 34 35		5.4.2. Fresh vs frozen FMT: Two randomised studies have examined this area. One double-blind randomised study concluded
32 33 34 35 36	1159	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT ($n=91$) was non-inferior for clinical resolution of diarrhoea to fresh FMT
32 33 34 35 36 37 38	1159 1160	Two randomised studies have examined this area. One double-blind randomised study concluded
32 33 34 35 36 37	1159 1160 1161	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT ($n=91$) was non-inferior for clinical resolution of diarrhoea to fresh FMT
32 33 34 35 36 37 38 39 40 41	1159 1160 1161 1162	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT ($n=91$) was non-inferior for clinical resolution of diarrhoea to fresh FMT ($n=87$) for the treatment of recurrent or refractory CDI ¹⁶ (with frozen FMT in this study stored at -
32 33 34 35 36 37 38 39 40 41 42 43	1159 1160 1161 1162 1163	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT ($n=91$) was non-inferior for clinical resolution of diarrhoea to fresh FMT ($n=87$) for the treatment of recurrent or refractory CDI ¹⁶ (with frozen FMT in this study stored at - 20°C for up to 30 days). A further randomised study demonstrated statistically comparable
32 33 34 35 36 37 38 39 40 41 42 43 44	1159 1160 1161 1162 1163 1164	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT ($n=91$) was non-inferior for clinical resolution of diarrhoea to fresh FMT ($n=87$) for the treatment of recurrent or refractory CDI ¹⁶ (with frozen FMT in this study stored at - 20°C for up to 30 days). A further randomised study demonstrated statistically comparable remission rates for recurrent CDI with fresh or frozen FMT delivered colonoscopically ($n=25/25$ vs
32 33 34 35 36 37 38 39 40 41 42 43	1159 1160 1161 1162 1163 1164 1165	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT (n =91) was non-inferior for clinical resolution of diarrhoea to fresh FMT (n =87) for the treatment of recurrent or refractory CDI ¹⁶ (with frozen FMT in this study stored at - 20°C for up to 30 days). A further randomised study demonstrated statistically comparable remission rates for recurrent CDI with fresh or frozen FMT delivered colonoscopically (n =25/25 vs 20/24 respectively, p =0.233) (using frozen FMT stored at -80°C for up to six months) ¹³ . These data
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47	1159 1160 1161 1162 1163 1164 1165 1166	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT (n =91) was non-inferior for clinical resolution of diarrhoea to fresh FMT (n =87) for the treatment of recurrent or refractory CDI ¹⁶ (with frozen FMT in this study stored at - 20°C for up to 30 days). A further randomised study demonstrated statistically comparable remission rates for recurrent CDI with fresh or frozen FMT delivered colonoscopically (n =25/25 vs 20/24 respectively, p =0.233) (using frozen FMT stored at -80°C for up to six months) ¹³ . These data support the findings of earlier small observational studies ^{35,41} . Frozen FMT is preferable to fresh FMT
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	1159 1160 1161 1162 1163 1164 1165 1166 1167	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT ($n=91$) was non-inferior for clinical resolution of diarrhoea to fresh FMT ($n=87$) for the treatment of recurrent or refractory CDI ¹⁶ (with frozen FMT in this study stored at - 20°C for up to 30 days). A further randomised study demonstrated statistically comparable remission rates for recurrent CDI with fresh or frozen FMT delivered colonoscopically ($n=25/25$ vs 20/24 respectively, $p=0.233$) (using frozen FMT stored at -80°C for up to six months) ¹³ . These data support the findings of earlier small observational studies ^{35,41} . Frozen FMT is preferable to fresh FMT on logistical and cost grounds ¹⁶ . Banked frozen FMT also enables the window period for donor
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	1159 1160 1161 1162 1163 1164 1165 1166 1167 1168	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT (n =91) was non-inferior for clinical resolution of diarrhoea to fresh FMT (n =87) for the treatment of recurrent or refractory CDI ¹⁶ (with frozen FMT in this study stored at - 20°C for up to 30 days). A further randomised study demonstrated statistically comparable remission rates for recurrent CDI with fresh or frozen FMT delivered colonoscopically (n =25/25 vs 20/24 respectively, p =0.233) (using frozen FMT stored at -80°C for up to six months) ¹³ . These data support the findings of earlier small observational studies ^{35,41} . Frozen FMT is preferable to fresh FMT on logistical and cost grounds ¹⁶ . Banked frozen FMT also enables the window period for donor screening to be minimised, allowing centres to more closely to meet regulatory requirements (also
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52	1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT (n =91) was non-inferior for clinical resolution of diarrhoea to fresh FMT (n =87) for the treatment of recurrent or refractory CDI ¹⁶ (with frozen FMT in this study stored at - 20°C for up to 30 days). A further randomised study demonstrated statistically comparable remission rates for recurrent CDI with fresh or frozen FMT delivered colonoscopically (n =25/25 vs 20/24 respectively, p =0.233) (using frozen FMT stored at -80°C for up to six months) ¹³ . These data support the findings of earlier small observational studies ^{35,41} . Frozen FMT is preferable to fresh FMT on logistical and cost grounds ¹⁶ . Banked frozen FMT also enables the window period for donor screening to be minimised, allowing centres to more closely to meet regulatory requirements (also
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51	1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT (n =91) was non-inferior for clinical resolution of diarrhoea to fresh FMT (n =87) for the treatment of recurrent or refractory CDI ¹⁶ (with frozen FMT in this study stored at - 20°C for up to 30 days). A further randomised study demonstrated statistically comparable remission rates for recurrent CDI with fresh or frozen FMT delivered colonoscopically (n =25/25 vs 20/24 respectively, p =0.233) (using frozen FMT stored at -80°C for up to six months) ¹³ . These data support the findings of earlier small observational studies ^{35,41} . Frozen FMT is preferable to fresh FMT on logistical and cost grounds ¹⁶ . Banked frozen FMT also enables the window period for donor screening to be minimised, allowing centres to more closely to meet regulatory requirements (also
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT ($n=91$) was non-inferior for clinical resolution of diarrhoea to fresh FMT ($n=87$) for the treatment of recurrent or refractory CDI ¹⁶ (with frozen FMT in this study stored at - 20°C for up to 30 days). A further randomised study demonstrated statistically comparable remission rates for recurrent CDI with fresh or frozen FMT delivered colonoscopically ($n=25/25$ vs 20/24 respectively, $p=0.233$) (using frozen FMT stored at -80°C for up to six months) ¹³ . These data support the findings of earlier small observational studies ^{35,41} . Frozen FMT is preferable to fresh FMT on logistical and cost grounds ¹⁶ . Banked frozen FMT also enables the window period for donor screening to be minimised, allowing centres to more closely to meet regulatory requirements (also see Section 5.3.5).
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56	1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT ($n=91$) was non-inferior for clinical resolution of diarrhoea to fresh FMT ($n=87$) for the treatment of recurrent or refractory CDI ¹⁶ (with frozen FMT in this study stored at - 20°C for up to 30 days). A further randomised study demonstrated statistically comparable remission rates for recurrent CDI with fresh or frozen FMT delivered colonoscopically ($n=25/25$ vs 20/24 respectively, $p=0.233$) (using frozen FMT stored at -80°C for up to six months) ¹³ . These data support the findings of earlier small observational studies ^{35,41} . Frozen FMT is preferable to fresh FMT on logistical and cost grounds ¹⁶ . Banked frozen FMT also enables the window period for donor screening to be minimised, allowing centres to more closely to meet regulatory requirements (also see Section 5.3.5).
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170	Two randomised studies have examined this area. One double-blind randomised study concluded that enema frozen FMT ($n=91$) was non-inferior for clinical resolution of diarrhoea to fresh FMT ($n=87$) for the treatment of recurrent or refractory CDI ¹⁶ (with frozen FMT in this study stored at - 20°C for up to 30 days). A further randomised study demonstrated statistically comparable remission rates for recurrent CDI with fresh or frozen FMT delivered colonoscopically ($n=25/25$ vs 20/24 respectively, $p=0.233$) (using frozen FMT stored at -80°C for up to six months) ¹³ . These data support the findings of earlier small observational studies ^{35,41} . Frozen FMT is preferable to fresh FMT on logistical and cost grounds ¹⁶ . Banked frozen FMT also enables the window period for donor screening to be minimised, allowing centres to more closely to meet regulatory requirements (also see Section 5.3.5).

https://mc.manuscriptcentral.com/gut

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1172 We recommend that the use of banked frozen FMT material should be considered 1173 preferable to fresh preparations for CDI (GRADE of evidence: high; strength of 1174 recommendation: strong).

5.4.3. Use of frozen FMT:

1177 Frozen FMT has been used up to six months after storage at -80°C^{17,41,74}, with high efficacy rates 1178 (>70%) observed in the cases treated. However, there have been no comparative trials investigating 1179 storage durations. A trend towards decrease in the viability of certain gut microbiota taxa was noted 1180 when faecal aliquots were frozen in 10% glycerol for six months⁷⁴, and as such, the working group 1181 agreed that six months was the acceptable limit for freezing of an FMT in glycerol. Storage at -80°C 1182 is recommended rather than -20°C to minimise sample degradation.

1184 Warm water baths have been recommended to speed thawing⁶; however, the working group 1185 thought that this should be strongly discouraged, as this may introduce risks of cross contamination 1186 by *Pseudomonas* species (and other contaminants) from the water bath^{107,108}, and may reduce 1187 bacterial viability in the FMT. Repetitive freeze thawing of FMT samples should be avoided as 1188 bacterial numbers will be reduced during this process¹⁰⁹.

Recommendations:

- i. We recommend that FMT material stored frozen at -80°C should be regarded as
 having a maximum shelf life of six months from preparation (GRADE of evidence:
 low; strength of recommendation: strong).
- 421194ii.We suggest consideration of thawing frozen FMT at ambient temperature, and431195using within six hours of thawing (GRADE of evidence: low; strength of451196recommendation: weak).
- 47
48
491197iii.We suggest not thawing FMT in warm water baths, due to the risks of cross
contamination with Pseudomonas (and other contaminants) and reduced bacterial
so
5150
511199viability (GRADE of evidence: very low; strength of recommendation: weak).

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

12015.5.What factors related to administration of the transplant influence the outcome of1202faecal microbiota transplant when treating people with Clostridium difficile1203infection?

5.5.1. Use of specific medications in the period around FMT administration:

5.5.1.1. General principles of FMT administration:

Bowel purgatives have been proposed pre-FMT as a means of removing residual antibiotics that may affect engraftment of transplanted microorganisms, and as a means of removing any residual C. *difficile* toxin, spores and vegetative cells^{110–114}. Furthermore, bowel purgatives pre-colonoscopic FMT delivery facilitate safe endoscopy. Various bowel purgatives have been used in colonoscopic FMT studies, including polyethylene glycol (PEG) (often 4 litres)^{14,17,115–117,35,41,43,46,54–56,100}. MoviPrep^{®35,41}, and macrogol^{13,15,18,59}. In those studies that used an upper GI route for FMT, PEG^{54,55,84} and Klean-Prep^{®15,61} were used. FMT without bowel preparation has also been used as treatment for recurrent CDI without any apparent reduction in efficacy, including in randomised studies¹⁶.

The rationale for the use of proton pump inhibitors (PPI) prior to upper GI FMT is to minimise acidity
which may impair engraftment of transplanted microorganisms; however, PPIs have been shown to
alter the gut microbiota^{118,119}, and have also been associated with primary and recurrent CDI^{120,121}.
Some studies advocate the use of PPI prior to receiving FMT via the upper GI route^{37,39,45,84,85,122,123},
but there appears to be comparable efficacy data in studies where it has not been used. Certain
studies have also given recipients PPI prior to receiving colonoscopic FMT^{17,87}.

1223 The use of prokinetics (such as metoclopramide) has been described prior to FMT delivery via the 1224 upper GI tract route, but only in a very small number of studies⁸⁵. Given the potential risk of 1225 regurgitation/aspiration associated with upper GI administration of FMT, the working group felt that 1226 its use should be considered where appropriate.

A single dose/ short course of loperamide has been used following FMT (predominantly for lower GI administration) in an attempt to prolong the exposure of the FMT to the mucosa, and to aid retention of the FMT within the GI tract^{13,46,49,55,84,123}. One study utilised diphenoxylate with atropine⁵⁴ instead. However, no studies have compared FMT with and without anti-motility drugs. Page 43 of 454

1

60

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

2		
3	1232	
4		
5 6	1233	The working group also discussed infection control aspects as they apply to FMT administration.
7	1234	Specifically, they agreed that recipients should ideally be cared for in a single room with en-suite
8 9	1235	bathroom facilities and, where appropriate, be placed at the end of an endoscopy list, to facilitate
10	1236	enhanced environmental decontamination and prevention of transmission of C. difficile spores.
11 12	1237	Protocols for decontamination of endoscopes should follow national guidance ^{124,125} , using a
13	1238	sporicidal agent. Best practice for prevention of transmission of healthcare-associated infections, as
14 15	1239	described in national guidelines ¹²⁶ , should also be applied throughout.
16 17	1240	
18	1241	Recommendations:
19 20		
20 21	1242	i. We recommend that bowel lavage should be administered prior to FMT via the
22 23	1243	lower GI route, and bowel lavage should be considered prior to FMT via the upper
24	1244	GI route; polyethylene glycol preparation is preferred (GRADE of evidence: low;
25 26	1245	strength of recommendation: strong).
27	1246	ii. For upper GI FMT administration, we suggest that a proton pump inhibitor should
28 29	1247	be considered, e.g. the evening before and morning of delivery (GRADE of
30 31	1248	evidence: low; strength of recommendation: weak).
32	1249	iii. We suggest that a single dose of loperamide (or other anti-motility drugs) should
33 34	1250	be considered following lower GI FMT delivery (GRADE of evidence: low; strength
35 36	1251	of recommendation: weak).
37 38	1252	iv. We suggest that prokinetics (such as metoclopramide) should be considered prior
39	1253	to FMT via the upper GI route (GRADE of evidence: low; strength of
40 41	1254	recommendation: weak).
42 43	1255	v. We recommend that best practice for prevention of further transmission of CDI
44	1256	should be applied throughout when administering FMT to patients with CDI
45 46	1257	(nursing with enteric precautions, sporicidal treatment of endoscope, etc) (GRADE
47 48	1258	of evidence: high; strength of recommendation: strong).
49	1259	
50 51		
52	1260	5.5.1.2. Additional antibiotics pre-FMT:
53	1261	Many studies have given further courses of conventional antimicrobial C. difficile treatment prior to
54 55	1262	FMT. Regimens have included vancomycin alone ^{12,14,18,35,39,55,59,86,117} , metronidazole or
56	1202	
57		
58 50		
59 60		https://mc.manuscriptcentral.com/gut

vancomycin^{40,41,43,122}, or alternatively vancomycin, fidaxomicin or metronidazole⁵⁶, with one study
using a range of regimens which included rifaximin¹²³. The length of treatment was also variable,
ranging from 24 hours⁵⁴ up to four days prior to receiving FMT^{39,45}; however, comparative studies
have not been undertaken.

Recommendation:

1269 We recommend the administration of further antimicrobial treatment for CDI for at least **72** hours prior to FMT (GRADE of evidence: low; strength of recommendation: strong).

5.5.1.3. Washout period between antibiotic use and FMT:

Nearly all studies specified a washout period after completing anti-CDI antibiotics and before
administration of FMT. However, this time period appeared to be arbitrarily selected and varied
from as little as four⁴⁶ or 12 hours⁵¹, up to 72 hours³⁶. The majority of studies specified either 24
hours^{15,37,39,40,45,54,127} or 48 hours^{41,42,49,60}, however some allowed a range from 1-3 days^{16,44,52,53,55}.
One study appeared to allow co-administration of vancomycin with bowel preparation, without a
washout period¹⁸.

The working group discussed the challenging scenario of providing FMT to patients with recurrent CDI, but who also had a strong indication for long-term non-anti-CDI antibiotics (e.g. splenectomy, osteomyelitis, or infective endocarditis), or patients who develop an indication for antibiotics for a reason other than CDI shortly after receiving FMT. The concern in this instance is that the use of antibiotics may limit engraftment of microbial communities derived from the FMT, and therefore reduce its effectiveness. The working group discussed a recent retrospective study demonstrating that exposure to non-anti-CDI antimicrobials within eight weeks of FMT is associated with an approximate threefold risk of FMT failure (n=8/29 failures with antibiotic exposure vs 36/320 failures without antibiotic exposure)¹²⁸. Similarly, the experience of the large pan-Netherlands stool bank¹²⁹ was that ~50% of their failures of FMT in the treatment of recurrent CDI occurred in patients who had received antibiotics within one month of their FMT. For patients requiring long-term antibiotics, the working group's expert opinion was that such patients should still be eligible for FMT, but that the regimen for the use of non-anti-CDI antibiotics should be decided on a case-by-case basis, based on factors including response to FMT and/or strength of indication of antibiotics. Both in this scenario, and the scenario in which antibiotics are required shortly after receiving FMT, the working

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

party agreed that infectious diseases specialists/medical microbiologists should be involved inmaking decisions regarding the choice of agents used.

Recommendations:

iii. To minimise any deleterious effect of antimicrobials on the FMT material, we
 recommend that there should be a minimum washout period of 24 hours between the
 last dose of antibiotic and treatment with FMT (GRADE of evidence: low; strength of
 recommendation: strong).

iv. We suggest considering consultation with infectious disease specialists or medical
 microbiologists for advice whenever FMT recipients also have an indication for long term antibiotics, or have an indication for non-CDI antibiotics within eight weeks of
 FMT (GRADE of evidence: very low; strength of recommendation: weak).

5.5.2. Route of FMT delivery:

5.5.2.1. Introduction:

FMT can be delivered via the lower GI route (retention enema, colonoscopy), upper GI route (endoscopically, or via nasogastric tube, nasoduodenal or nasojejenal tube), or via capsules (containing either frozen FMT or lyophilised faecal material). Systematic reviews with meta-analysis suggest that FMT for recurrent CDI via colonoscopy may have slightly higher efficacy compared to upper GI administration^{127,130–132} with similar safety profiles, but also note the trend towards using larger amounts of stool or 'higher concentration' FMT in lower GI administration. One systematic review (reviewing principally case series, and including only one randomised study) compared remission rates for CDI using FMT delivered to different areas of the GI tract, and reported that for FMT infused into the stomach, duodenum/jejunum, caecum/ascending colon, and rectum the rates of cure rate were 81%, 86%, 93%, and 84%, respectively 131 .

1321 In the only randomised study that directly compared upper and lower GI administration, there was 1322 no significant difference in overall cure rate (p = 0.53)¹⁷.

5.5.2.2. Upper gastrointestinal tract administration of FMT:

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

FMT has been shown to be safe and efficacious in the treatment of C. difficile when administered via nasogastric tube^{37,39,45,61,83,123}, nasoduodenal tube^{15,84,85}, enteroscopy^{122,123}, or via the infusion channel on a gastroscope^{40,45}. In a randomised trial, nasoduodenal donor FMT has been shown to be more efficacious than vancomycin in treating recurrent CDI¹⁵. Furthermore, it has been shown that FMT can also be safely and effectively delivered via a percutaneous endoscopic gastrectomy tube^{45,83}. The working group noted that upper GI administration of FMT may be particularly suitable for certain patient groups, such as those in whom there are contraindications or who would find it difficult to tolerate lower GI endoscopy, and/ or patients unlikely to be unable to retain enemas.

Typically, smaller volumes of faecal suspension are administered to the upper GI tract compared to lower GI administration, with quoted volumes ranging from 25ml³⁹ up to 150ml⁸⁴- 250ml^{37,85}. Up to 500ml of suspension has been given safely and effectively via the upper GI route^{15,77}. However, the working group expressed concerns regarding the risk of regurgitation and aspiration if large volumes of FMT are administered to the upper GI tract, and also discussed cases in which this has been described with adverse outcomes⁸⁰. This included a reported death from aspiration, after 100-150ml of FMT was delivered by enteroscope into the distal duodenum under general anaesthetic as attempted treatment for recurrent CDI¹³³. A further reported case described a case of fatal aspiration pneumonitis likely related to a 500ml FMT via nasoduodenal tube; this patient had a swallowing disorder following oropharyngeal radiation after surgical removal of a maxillary carcinoma two years previously⁷⁷. Based on their expert opinion, the working group recommended that upper GI FMT should be used with caution in those at risk of regurgitation (e.g. known large hiatus hernia, severe gastro-oesophageal reflux disease, etc) and/ or with swallowing disorders (although administration via a gastrostomy tube would be acceptable). They also recommended that no more than 100ml of FMT should be administered to the upper GI tract to minimise these risks.

Recommendations:

- i. We recommend that upper GI administration of FMT as treatment for recurrent or
 refractory CDI should be used where clinically appropriate (GRADE of evidence:
 high; strength of recommendation: strong).
- 1355ii.Where upper GI administration is considered most appropriate, we recommend1356that FMT administration should be via nasogastric, nasoduodenal, or nasojejunal

Gut

in those at risk of regurgitation and/ or those with swallowing disorders (GRADE of

HIS/ BSG FMT Guideline: Main Document, Gut version.

2			
3	1357		tube, or alternatively via upper GI endoscopy. Administration via a permanent
4 5	1358		feeding tube is also appropriate (GRADE of evidence: high; strength of
6 7	1359		recommendation: strong).
8 9	1360	v .	We recommend that no more than 100ml of FMT is administered to the upper GI
10	1361		tract (GRADE of evidence: low; strength of recommendation: strong).
11 12	1362	vi.	We recommend that upper GI administration of FMT should be used with caution
13	1363		in those at risk of regurgitation and/ or those with swallowing disorders (GRADE of

5.5.2.3. Lower gastrointestinal tract administration of FMT:

evidence: low; strength of recommendation: strong).

Successful treatment of C. difficile with FMT enema has been FMT via enema: demonstrated^{16,38,42,53,55,83,86} but enema appears to have a lower efficacy than other routes of FMT administration. Specifically, in a randomised study primarily comparing the efficacy of fresh and frozen FMT in the treatment of recurrent CDI, only 52.8% of patients in the 'frozen' arm and 50.5% of patients in the 'fresh' arm of the study (n=57/108 and 56/111 respectively) experienced resolution of symptoms after a single enema, by modified intention to treat analysis¹⁶. However, resolution rates in both arms only reached >80% after at least three enemas¹⁶. A recent randomised study demonstrated similar rates of recurrence of CDI in patients with recurrent CDI treated with either a single FMT enema or a six week vancomycin taper (n=9/16) patients with recurrence vs 5/12respectively)¹². Notwithstanding this, enemas do have specific advantages, such as being a treatment option where full colonoscopy is contraindicated. It is also possible to give multiple infusions relatively easily and outside a hospital setting.

FMT via colonoscopy: Randomised study evidence has demonstrated that colonoscopic FMT has higher efficacy in treating recurrent CDI than vancomycin¹⁸. Efficacy is similar whether FMT is fresh or frozen, but modestly reduced when using a lyophilised FMT product¹³. Colonoscopic delivery of donor FMT into the ileum or caecum was associated with a 91% cure rate for recurrent CDI¹⁴. Observational studies highlighted similar success, describing cure rates of 88% $(n=14/16)^{74}$ and $91\%^{46}$ (n=21/23) in response to infusion of donor FMT into the caecum or terminal ileum. A further advantage of using colonoscopy to administer FMT has been to allow assessment for the presence of pseudomembranes; in certain reviewed studies, the presence or absence of pseudomembranes has influenced the FMT regimen used^{18,73}. However, the working group noted that that many patients

https://mc.manuscriptcentral.com/gut

Page 48 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

with CDI are frail and elderly, and as such it will not always be safe or feasible to undertake
colonoscopy in this particular group of patients. Flexible sigmoidoscopy appears to be an feasible
option where full colonoscopy cannot be performed e.g. unable to tolerate colonoscopy, severity of
colitis^{56,60}.

The amount of faecal suspension via enema has varied between 150-500mls^{16,38,42,55,86}. The amount of faecal suspension delivered via colonoscopy has been similarly variable, with some studies suggesting as little as 100ml can be used with success rates of 94%⁴³. 250ml-400ml had a success rate of 100%³⁶, whereas infusions of up to 500-700ml were associated with cure rates of 92%⁴⁶. However, the working group noted that it is difficult to compare 'concentration' of FMT in different studies as different protocols used varied starting amounts of faecal material. Currently, there are no randomised studies that compare concentration/ volume of colonoscopic or enema FMT. As such, no recommendation was made to this regard.

Recommendations:

We recommend that colonoscopic administration of FMT as treatment for
 recurrent or refractory CDI should be used where appropriate (GRADE of evidence:
 high; strength of recommendation: strong).

1407ii.Where colonoscopic administration is used, we suggest considering preferential1408delivery to the caecum or terminal ileum, as this appears to give the highest1409efficacy rate (GRADE of evidence: low; strength of recommendation: weak).

1410iii.We recommend that FMT via enema should be used as a lower GI option when1411delivery using colonoscopy or flexible sigmoidoscopy is not possible (GRADE of1412evidence: high; strength of recommendation: strong).

5.5.2.4. Capsulised FMT:

1415 Capsulised FMT aims to remove some of the concerns regarding conventional FMT, such as the 1416 invasive means of administration and palatability. The largest case series describing the use of 1417 capsules as treatment for recurrent $\text{CDI}^{72,89}$ noted clinical resolution at eight weeks off antibiotics for 1418 CDI in 82% of cases (*n*=147/180) after one course of capsules, and 91% (*n*=164/180) after two 1419 courses. The capsules contained frozen FMT prepared in a diluent of saline with 10% glycerol; 15

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

capsules were administered each day for two consecutive days (equating to a mean 48g of original
crude stool). Other smaller case series have demonstrated comparable results^{87,123,134}, including
when lyophilised stool is used instead of frozen whole FMT¹³⁴.

The working group reviewed two randomised studies which have examined the efficacy of capsulised FMT in treating recurrent CDI. In one study, published in abstract form⁹⁴, a 'high dose' regimen of frozen FMT capsules (30 capsules each day for two days) was compared to 'low dose' (30 capsules in one day). CDI resolution was comparably high in both arms with one treatment course (77% (n=7/9)) in the 'high dose' arm vs 70% (n=7/10) in the 'low dose arm'). 4/5 initial nonresponders entered remission after a second capsule course with the 'high dose' regimen⁹⁴. In a recent large randomised trial, patients with recurrent CDI were randomised to receive either thawed frozen FMT either via colonoscopy or via capsules (one treatment of 40 capsules)¹¹. On per protocol analysis, remission at 12 weeks after a single treatment occurred in 96% in both arms (n=51/53 by capsule, *n*=50/52 by colonoscopy).

The working group discussed certain unresolved issues regarding capsules. Specifically, capsules are often large, and swallowing 30 capsules in a single day may be a significant undertaking for patients with CDI, such as the frail elderly with an existing high pill burden. They also noted that follow-up data post-capsule administration is relatively short compared to other modalities of FMT.

Recommendation:

1441 Capsulised FMT holds promise as a treatment option for recurrent CDI and we recommend 1442 that this should be offered to patients as a potential treatment modality where available. 1443 Capsule preparations should follow a standard protocol. Further evidence regarding 1444 optimal dosing and formulation is required (GRADE of evidence: high; strength of 1445 recommendation: strong).

14475.6.What is the clinical effectiveness of FMT in treating conditions other than1448Clostridium difficile infection?

5.6.1. Introduction:

In current clinical practice, FMT is used predominantly in the treatment of recurrent CDI. Its success has led to exploration of its efficacy in other GI diseases, primarily ulcerative colitis (UC), where perturbation of the gut microbiota has been observed and implicated in disease pathogenesis¹³⁵. Due to variability of the quality, methodology and cohorts of patients recruited in trials of FMT for non-CDI indications, and in order to control for significant confounding factors, the working group only included randomised trials involving patients with well-defined conditions and in which there was a primary clinical outcome. To date, there have been a total of 71 such studies investigating the role of FMT in IBD; of these, only four are prospective randomised controlled trials, limited to patients with ulcerative colitis^{136–139}. Five other reviewed randomised studies investigated the use of FMT in irritable bowel syndrome¹⁴⁰, slow transit constipation¹⁴¹, hepatic encephalopathy¹⁴² and metabolic syndrome^{143,144}

1462 5.6.2. Use of FMT for ulcerative colitis:

5.6.2.1. Efficacy:

All four RCTs, with a total of 277 subjects, included patients with mild to moderate UC (Mayo score 3-11 and endoscopic sub-score of at least 1). Participants were aged between 27 and 56 years and largely included patients on stable immunosuppressive therapy (only one study excluded patients using biologic treatments and methotrexate within the preceding two months)¹³⁶. Three studies included patients on oral corticosteroids at the time of FMT, however only two required a mandatory wean of these to meet eligibility. Studies generally included patients with all disease distributions found in UC. Time to evaluation of response to FMT in these studies varied between seven and twelve weeks. Two studies used autologous FMT as placebo^{136,139}. Three of the four studies demonstrated that patients receiving donor FMT were significantly more likely to achieve clinical and endoscopic remission compared to placebo^{137–139}. The pooled rate of combined clinical and endoscopic remission was 27.9% for donor FMT and 9.5% for placebo. A pooled risk ratio for failure of FMT to achieve these combined outcomes was 0.8 (95% CI: 0.7-0.9). Deep remission (histological) was only reported in one RCT: 18.4% of patients receiving FMT achieved this outcome compared to 2.7% of those receiving placebo¹³⁷.

5.6.2.2. Characteristics of FMT preparation and delivery:

The four RCTs varied in their FMT preparation and delivery methodology. Two RCTs delivered frozen
FMT, one fresh FMT, and one used a combination. Three RCTs with a positive outcome delivered the
FMT via the lower GI route; these studies used a high intensity protocol ranging from a total of three

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

infusions in one week to 40 FMTs over an eight week period^{137–139}. The other RCT (that failed to show efficacy of FMT for UC) had adopted a low intensity protocol of two nasoduodenal infusions given three weeks apart¹³⁶. Interestingly, the only RCT that prepared stool in anaerobic conditions demonstrated the highest rate of steroid-free clinical remission and steroid-free clinical response with donor FMT¹³⁹. A further interesting observation in one study was a trend towards higher rates of remission with one particular donor¹³⁷.

5.6.2.3. Adverse events:

Short-lived GI symptoms such as abdominal bloating, cramps, diarrhoea and fever were reported in patients receiving FMT for UC. There were no significant differences in serious adverse events between patients receiving FMT compared to placebo (10 vs 7 respectively). Most of the serious adverse events were a consequence of worsening colitis: one patient who received FMT required a colectomy¹³⁶. In addition, one patient developed concurrent CDI¹³⁷. No deaths were reported in any of the studies.

5.6.3. Use of FMT in functional bowel disorders:

Two RCTs have investigated the role of FMT in functional bowel disorders. In a double-blind placebo controlled RCT that recruited 90 patients with IBS with diarrhoea or with diarrhoea and constipation¹⁴⁰, the primary endpoint only just reached statistical significance in inducing symptom relief (as assessed by 75 point reduction in IBS-severity scoring system at three months following a single infusion FMT by colonoscopy) (p=0.049). The second RCT randomised 60 patients with slow transit constipation to either six consecutive days of nasogastric-delivered FMT or conventional treatment¹⁴¹. This demonstrated that a significant proportion of patients achieved the primary endpoint of a mean of at least three complete spontaneous bowel movements per week (53.3% vs. 20.0%, p=0.009) along with improvement in stool consistency score and colonic transit time. However, the intervention group had more treatment-related adverse events than did the control group (total of 50 vs 4 cases).

5.6.4. Use of FMT in hepatic encephalopathy:

One small study has investigated the role of FMT in the management of hepatic encephalopathy (HE)¹⁴². This RCT randomised 20 male patients with cirrhosis with refractory HE to receive either five days of broad-spectrum antibiotic pre-treatment followed by a single FMT enema or standard of

Page 52 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

1515 care. Patients in the FMT arm had a significantly lower incidence of serious adverse events and
1516 improved cognition. The Model for End-Stage Liver Disease (MELD) score, however, transiently
1517 worsened post-antibiotics in the FMT arm. The study was potentially confounded as patients in the
1518 FMT arm continued to receive lactulose and/or rifaximin for treatment of their HE.

Gut

5.6.5. Use of FMT for metabolic syndrome:

Two randomised studies^{143,144}, with a combined total of 56 patients, demonstrated an improvement in peripheral (but not hepatic) insulin sensitivity in Caucasian male obese patients with metabolic syndrome following one or two infusions via nasoduodenal tube of FMT obtained from lean donors. This improvement was observed at six weeks post-FMT, but was no longer present by 18 weeks. No improvement in insulin sensitivity was identified in patients transplanted with autologous FMT (i.e. patients transplanted with their own collected faeces). The improvement in peripheral insulin sensitivity in the lean donor FMT group was accompanied by a small but significant improvement in HbA1c at six weeks¹⁴⁴, but no improvements in other metabolic parameters, such as weight. Whilst these data are of interest, the working group felt that the limited, transient nature of the benefits seen and small size of the studies meant that FMT could not be recommended as treatment for metabolic syndrome.

5.6.6. Future directions for randomised trials of FMT for non-CDI indications:

1534 Currently there are a large number of randomised trials (including RCTs) being undertaken globally, 1535 to evaluate the potential role of FMT as treatment for a wide range of conditions. The working 1536 group concluded that until there are more reliable data to inform decision-making, the best practice 1537 principles described in this document for the governance of an FMT service for recurrent CDI should 1538 also be applied to FMT clinical trials for other conditions. However, specific adaptations may be 1539 considered depending on the condition being studied, e.g. consideration of using anaerobic 1540 conditions for the preparation of FMT in trials for the treatment of UC, as described above.

1542 In conclusion, FMT has the potential to be an effective treatment option for mild to moderate 1543 ulcerative colitis, and appears to be safe despite the use of immunosuppressive therapy. FMT may 1544 also have a potential role in the treatment of functional bowel disorders. However, 1545 recommendations for clinical use for both these indications cannot be made until there is clearer 1546 evidence of the most appropriate patient characteristics, preparation methodology, route of delivery

 Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

and intensity of administration of FMT. The evidence for the use of FMT in hepatic encephalopathy and metabolic syndrome is currently limited, and further well-designed RCTs are needed to evaluate its potential role here.

Recommendation:

We do not currently recommended FMT as treatment for inflammatory bowel disease. Apart from CDI, there is insufficient evidence to recommend FMT for any other gastrointestinal or non-gastrointestinal disease (GRADE of evidence: moderate; strength of recommendation: strong).

6. Basic requirements for implementing a FMT service:

As discussed above, there is an absence of published studies to support the recommendations in this section (although the experience of setting up a nationwide stool bank has recently been reported from the Netherlands¹²⁹). This section is therefore based on the working group's expert opinion and experience of developing FMT services. The working group considered best practice in this area as it applied to legal and clinical governance aspects, the relevant professionals required to establish an FMT service, the infrastructure of a service, and appropriate practices for FMT manufacturing and quality control monitoring where relevant. The full text of this section is in Supplementary Material 3. CLIC

7. Key performance indicators:

- All donors to have completed initial screening questionnaires and blood and stool screening results, as well as final health check prior to each stool donation processed to FMT. Results from each subsequent serial round of screening also to be documented.
- All FMT recipients to have clear documentation of details of their disease course and preparation prior to FMT, including whether recurrent or refractory disease, previous antimicrobial courses, and use of bowel purgatives/other preparatory medications pre-FMT.
- All FMT recipients to have sufficient documentation to allow clear traceability of the exact FMT • aliquot transfused. Records should include identification of the donor, as well as a frozen FMT aliquot (and original faecal sample) - as well as serum - from that donor (see Supplementary Material 3).

Page 54 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

All FMT recipients for recurrent or refractory CDI to have documentation during follow-up of
 treatment success or failure (and subsequent treatment plan if failure), together with clear
 documentation of any adverse events that may be attributable to FMT.

Gut

1582 8. Further research:

As described within this guideline, many aspects of the terminology of CDI are used variably
 between studies, and end-points in FMT trials are inconsistent. The working group noted the
 need to standardise this terminology to allow more robust comparisons between studies.

Given the relative novelty of FMT as a procedure, any potential long-term adverse events associated with its use are poorly-defined. The establishment of formal FMT registries should be considered. Whilst this would primarily act as an important tool for defining the safety and efficacy of FMT, it would also be a valuable database for researchers within the field. Standardisation of other key documentation related to FMT administration (e.g. establishment of a proforma for assessing eligibility for FMT and/or follow-up after FMT) would also be advantageous for the same reasons.

The working group noted the lack of consistency in definitions related to the severity of CDI disease and to response or failure to FMT. This limited interpretation of the published studies. As such, the working group thought that standardisation of these definitions would allow more accurate delineation of the factors influencing the efficacy of FMT for CDI. The working group also noted that only one reviewed study had reported the relationship between C difficile ribotype and FMT outcome, and that recording of this information should be encouraged better to evaluate its influence.

Further well-designed clinical trials (in particular, RCTs) are required to identify the optimal
 means of administration of FMT as treatment for recurrent and/or refractory CDI.

The working group noted that even capsulised FMT may be associated with potential drawbacks. They also noted that there are many patients with recurrent CDI for whom FMT (or any form of 'bacteriotherapy') may be inappropriate, including those with very marked immunosuppression, and/or multi-organ disease. Despite high levels of efficacy, there is a small but appreciable FMT failure rate and it is not currently understood whether this is due to underlying donor or recipient factors. Therefore, a research priority should be in basic and translational studies better to define the mechanisms underlying the efficacy of FMT in CDI. This includes comparing the structure and function of the microbiota of donors to patients pre-FMT and post-FMT, via techniques including next-generation microbial sequencing, metabolic profiling, and

 Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

immunological assays. This would allow the refinement of FMT from its current state to a more targeted therapy, removing the concerns associated with FMT.

The working group identified a need for further well-designed RCTs to investigate the potential role of FMT for non-CDI indications.

9. Conclusions:

FMT has become an accepted, efficacious treatment for recurrent and/or refractory CDI. In developing this guideline, the evidence for the technique has been reviewed in the context of other available treatments. Specific guidance for best practice for an FMT service is provided.

10.Funding:

There was no external funding for this work. BHM is the recipient of a Medical Research Council Clinical Research Training Fellowship (grant reference: MR/R000875/1). BHM and HRTW receive support from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust and Imperial College London.

11.Competing interests:

- THI: Acted as consultant, advisor or speaker for Pharmacosmos and Shield Therapeutics.
- ALH: Acted as consultant, advisory board member or speaker for AbbVie, Atlantic, Bristol-Myers Squibb, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda. ALH also serves on the Global Steering Committee for Genentech.
- SDG: Received consultancy fees, speaker fees and research grant support from Astellas between • 2015-2017; received consultancy fees and speaker fees from MSD between 2015-2017; and received consultancy fees in 2017 from Pfizer.
- All other authors declared no conflict of interest.

12. Provenance and peer review:

Commissioned. Peer review through stakeholder consultation, HIS (SDC and Council), BSG (CSSC and Council) and externally.

13.<u>Acknowledgements:</u>

1642 The authors would like to acknowledge the support of the Gut Microbiota for Health Expert Panel of 1643 the British Society of Gastroenterology, along with that of the Healthcare Infection Society. They 1644 would also like to thank Ian Rees from the MHRA for contributions regarding the legal aspects and 1645 clinical governance of FMT within the UK and beyond.

14. <u>R</u>	eferences:
1.	Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of Clostridium difficile as
	Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938. Anaerobe. 2016;40:95-99.
	doi:10.1016/j.anaerobe.2016.06.008.
2.	Faecal microbiota transplant for recurrent Clostridium difficile infection Guidance and
	guidelines NICE. https://www.nice.org.uk/guidance/ipg485. Accessed October 2, 2017.
	1.

Gut

1		HIS/	BSG FMT Guideline: Main Document, Gut version.
2 3	1665	3.	Health England P. Updated guidance on the management and treatment of Clostridium
4 5	1666		difficile infection. 2013. http://www.gov.uk/phe. Accessed March 20, 2017.
6	1667	4.	Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious
7 8	1668		Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection. <i>Clin</i>
9	1669		<i>Microbiol Infect</i> . 2014;20(s2):1-26. doi:10.1111/1469-0691.12418.
10 11	1005		Where bold inject. 2014,20(32).1 20. doi:10.1111/1405 0051.12410.
12	1670	5.	McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium
13 14	1671		difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of
15	1672		America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis.
16 17 18	1673		February 2018. doi:10.1093/cid/cix1085.
19	1674	6.	Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota
20 21	1675		transplantation in clinical practice. Gut. 2017;66(4):569-580. doi:10.1136/gutjnl-2016-
22	1676		313017.
23 24	1677	7.	König J, Siebenhaar A, Högenauer C, et al. Consensus report: faecal microbiota transfer -
25 26	1678	7.	clinical applications and procedures. <i>Aliment Pharmacol Ther</i> . 2017;45(2):222-239.
27	1679		doi:10.1111/apt.13868.
28 29	1079		doi.10.1111/apt.13606.
30	1680	8.	Treating Clostridium difficile Infection With Fecal Microbiota Transplantation. Clin
31 32	1681		Gastroenterol Hepatol. 2011;9(12):1044-1049. doi:10.1016/J.CGH.2011.08.014.
33 34	1682	9.	Kump P, Krause R, Steininger C, et al. Empfehlungen zur Anwendung der fäkalen
35	1683		Mikrobiotatransplantation "Stuhltransplantation": Konsensus der Österreichischen
36 37	1684		Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH) in Zusammenarbeit mit der
38	1685		Österreichischen Gesellschaft für Infektiologie und. Z Gastroenterol. 2014;52(12):1485-1492.
39 40	1686		doi:10.1055/s-0034-1385562.
41 42	1687	10.	Faecal microbiota transplantation in recurrent Clostridium difficile infection:
43	1688		Recommendations from the French Group of Faecal microbiota Transplantation. Dig Liver Dis.
44 45	1689		2016;48(3):242-247. doi:10.1016/J.DLD.2015.08.017.
46 47	1600	11	Kao D. Roach R. Silva M. et al. Effect of Oral Capsula, vs. Colonossony, Delivered Escal
48	1690	11.	Kao D, Roach B, Silva M, et al. Effect of Oral Capsule– vs Colonoscopy-Delivered Fecal
49 50	1691		Microbiota Transplantation on Recurrent <i>Clostridium difficile</i> Infection. <i>JAMA</i> .
51	1692		2017;318(20):1985. doi:10.1001/jama.2017.17077.
52 53	1693	12.	Hota SS, Sales V, Tomlinson G, et al. Oral Vancomycin Followed by Fecal Transplantation
54	1694		Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An
55 56	1695		Open-Label, Randomized Controlled Trial. Clin Infect Dis. 2017;64(3):265-271.
57			
58 59			
<u> </u>			https://mc.manuscontreal.com/gut

1		HIS/	BSG FMT Guideline: Main Document, Gut version.
1 2			
3 4	1696		doi:10.1093/cid/ciw731.
5	1697	13.	Jiang ZD, Ajami NJ, Petrosino JF, et al. Randomised clinical trial: faecal microbiota
6 7	1698		transplantation for recurrent Clostridum difficile infection – fresh, or frozen, or lyophilised
8 9	1699		microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol
10	1700		Ther. 2017;45(7):899-908. doi:10.1111/apt.13969.
11 12	1701	14.	Kelly CR, Khoruts A, Staley C, et al. Effect of Fecal Microbiota Transplantation on Recurrence
13 14	1702		in Multiply Recurrent Clostridium difficile Infection. Ann Intern Med. 2016;165(9):609.
15 16	1703		doi:10.7326/M16-0271.
17 18	1704	15.	van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal Infusion of Donor Feces for Recurrent
19	1705		Clostridium difficile. <i>N Engl J Med</i> . 2013;368(5):407-415. doi:10.1056/NEJMoa1205037.
20 21	1706	16.	Lee CH, Steiner T, Petrof EO, et al. Frozen vs Fresh Fecal Microbiota Transplantation and
22 23	1707		Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection.
24 25	1708		JAMA. 2016;315(2):142. doi:10.1001/jama.2015.18098.
26 27	1709	17.	Youngster I, Sauk J, Pindar C, et al. Fecal Microbiota Transplant for Relapsing Clostridium
28	1710		difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-
29 30	1711		Label, Controlled Pilot Study. Clin Infect Dis. 2014;58(11):1515-1522. doi:10.1093/cid/ciu135.
31 32	1712	18.	Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota
33 34	1713		transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium
35 36	1714		difficile infection. Aliment Pharmacol Ther. 2015;41(9):835-843. doi:10.1111/apt.13144.
37 38	1715	19.	Faecal Microbiota Transplantation (FMT) MHRA's position.
39	1716		http://www.bsg.org.uk/images/stories/docs/clinical/guidance/fmt_mhra_position_june2015.
40 41	1717		pdf. Accessed October 3, 2017.
42 43	1718	20.	Thomas A. HTA Policy on the Regulation of Faecal Microbiota Transplant. 2015.
44 45	1719		http://www.bsg.org.uk/images/stories/docs/clinical/guidance/hta_pol_030_policy_regulatio
46 47	1720		n_of_fmt.pdf. Accessed October 3, 2017.
48	1721	21.	Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota
49 50	1722		transplantation. Nat Rev Gastroenterol Hepatol. 2016;13(9):508-516.
51 52	1723		doi:10.1038/nrgastro.2016.98.
53 54	1724	22.	Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication
55	1725		of Clostridium difficile infection: 'RePOOPulating' the gut. <i>Microbiome</i> . 2013;1(1):3.
56 57	1726		doi:10.1186/2049-2618-1-3.
58 59			56
60			https://mc.manuscriptcentral.com/gut

Gut

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1		HIS/	BSG FMT Guideline: Main Document, Gut version.
2 3	1727	23.	Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating
4	1728		Patients With Clostridium difficile Infection. <i>Gastroenterology</i> . 2017;152(4):799-811.e7.
5 6 7	1729		doi:10.1053/j.gastro.2016.11.010.
8	1730	24.	Khanna S, Pardi DS, Kelly CR, et al. A Novel Microbiome Therapeutic Increases Gut Microbial
9 10	1731		Diversity and Prevents Recurrent Clostridium difficile Infection. J Infect Dis. 2016;214(2):173-
11 12	1732		181. doi:10.1093/infdis/jiv766.
13 14	1733	25.	Martin J, Wilcox M. New and emerging therapies for Clostridium difficile infection. Curr Opin
15 16	1734		Infect Dis. 2016;29(6):546-554. doi:10.1097/QCO.000000000000320.
17 18	1735	26.	Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient Attitudes Toward the
19 20	1736		Use of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium difficile
20 21	1737		Infection. <i>Clin Infect Dis</i> . 2012;55(12):1652-1658. doi:10.1093/cid/cis809.
22 23	1738	27.	Kahn SA, Vachon A, Rodriquez D, et al. Patient perceptions of fecal microbiota
24 25	1739		transplantation for ulcerative colitis. Inflamm Bowel Dis. 2013;19(7):1506-1513.
26 27	1740		doi:10.1097/MIB.0b013e318281f520.
28	1741	28.	Quraishi MN, Segal J, Mullish B, et al. National survey of practice of faecal microbiota
29 30	1742		transplantation for Clostridium difficile infection in the UK. J Hosp Infect. 2016.
31 32	1743		doi:10.1016/j.jhin.2016.10.023.
33 34	1744	29.	Porter RJ, Fogg C. Faecal microbiota transplantation for Clostridium difficile infection in the
35 36	1745		United Kingdom. Clin Microbiol Infect. 2015;21(6):578-582. doi:10.1016/j.cmi.2015.01.020.
37 38	1746	30.	Ding NS, Mullish BH, McLaughlin J, Hart A, Marchesi JR. Meeting update: faecal microbiota
39	1747		transplantation—bench, bedside, courtroom? Frontline Gastroenterol. November
40 41	1748		2016:flgastro-2016-100752. doi:10.1136/flgastro-2016-100752.
42 43	1749	31.	Prior AR, Kevans D, McDowell L, Cudmore S, Fitzpatrick F. Treatment of Clostridium difficile
44 45	1750		infection: a national survey of clinician recommendations and the use of faecal microbiota
45 46 47	1751		transplantation. <i>J Hosp Infect</i> . 2017;95(4):438-441. doi:10.1016/j.jhin.2016.10.004.
48	1752	32.	1995 - The well-built clinical question: a key to evidence-based decisions (Editorial) 1995
49 50	1753		Nov-Dec : Volume 123, Number 3, Page A12 ACP Journal Club Archives.
51 52	1754		https://acpjc.acponline.org/Content/123/3/issue/ACPJC-1995-123-3-A12.htm. Accessed
53 54	1755		October 18, 2017.
55	1756	33.	British Society of Gastroenterology CS and SC. Guideline Development Within the BSG Clinical
56 57	1757		Services and Standards Committee Policies. https://www.bsg.org.uk/resource/guideline-
58 59 60			https://mc.manuscriptcentral.com/gut

1

2			
3	1758		development-within-the-bsg-clinical-services-and-standards-committee-policies.html.
4 5	1759		Accessed April 25, 2018.
6 7	1760	34.	Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of
8 9	1761		evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
9 10 11	1762		doi:10.1136/bmj.39489.470347.AD.
12	1763	35.	Satokari R, Mattila E, Kainulainen V, Arkkila PET. Simple faecal preparation and efficacy of
13 14	1764		frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile
15 16	1765		infection - an observational cohort study. Aliment Pharmacol Ther. 2015;41(1):46-53.
17 18	1766		doi:10.1111/apt.13009.
19	1767	36.	Yoon SS, Brandt LJ. Treatment of Refractory/Recurrent C. difficile-associated Disease by
20 21	1768		Donated Stool Transplanted Via Colonoscopy. J Clin Gastroenterol. 2010;44(8):562-566.
22 23	1769		doi:10.1097/MCG.0b013e3181dac035.
24 25	1770	37.	Zainah H, Hassan M, Shiekh-Sroujieh L, Hassan S, Alangaden G, Ramesh M. Intestinal
26	1771		microbiota transplantation, a simple and effective treatment for severe and refractory
27 28	1772		Clostridium difficile infection. <i>Dig Dis Sci</i> . 2014;60(1):181-185. doi:10.1007/s10620-014-3296-
29 30	1773		у.
31 32	1774	38.	Kassam Z. Fecal Transplant via Retention Enema for Refractory or Recurrent <emph< td=""></emph<>
32 33	1775		type="ital">Clostridium difficile Infection. Arch Intern Med.
34 35	1776		2012;172(2):191. doi:10.1001/archinte.172.2.191.
36 37	1777	39.	Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile Colitis: Case Series Involving 18
38	1778		Patients Treated with Donor Stool Administered via a Nasogastric Tube. Clin Infect Dis.
39 40 41	1779		2003;36(5):580-585. doi:10.1086/367657.
42	1780	40.	Garborg K, Waagsbø B, Stallemo A, Matre J, Sundøy A. Results of faecal donor instillation
43 44	1781		therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis.
45	1782		2010;42(11-12):857-861. doi:10.3109/00365548.2010.499541.
46 47 48	1783	41.	Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized Frozen Preparation for
48 49	1784		Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection. Am J
50 51	1785		Gastroenterol. 2012;107(5):761-767. doi:10.1038/ajg.2011.482.
52 53	1786	42.	Lee CH, Belanger JE, Kassam Z, et al. The outcome and long-term follow-up of 94 patients
54	1787		with recurrent and refractory Clostridium difficile infection using single to multiple fecal
55 56 57	1788		microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis.
58 59 60			https://mc.manuscriptcentral.com/gut

Gut

Gut

1		HIS/	BSG FMT Guideline: Main Document, Gut version.
2 3	1789		2014;33(8):1425-1428. doi:10.1007/s10096-014-2088-9.
4 5	1790	43.	Mattila E, Uusitalo-Seppälä R, Wuorela M, et al. Fecal transplantation, through colonoscopy,
6 7	1791		is effective therapy for recurrent Clostridium difficile infection. Gastroenterology.
8 9	1792		2012;142(3):490-496. doi:10.1053/j.gastro.2011.11.037.
10 11	1793	44.	Rohlke F, Surawicz CM, Stollman N. Fecal Flora Reconstitution for Recurrent Clostridium
12	1794		difficile Infection: Results and Methodology. J Clin Gastroenterol. 2010;44(8):567-570.
13 14 15	1795		doi:10.1097/MCG.0b013e3181dadb10.
16	1796	45.	Rubin TA, Gessert CE, Aas J, Bakken JS. Fecal microbiome transplantation for recurrent
17	1797		Clostridium difficile infection: Report on a case series. Anaerobe. 2013;19:22-26.
18 19 20	1798		doi:10.1016/j.anaerobe.2012.11.004.
21	1799	46.	Patel NC, Griesbach CL, DiBaise JK, Orenstein R. Fecal Microbiota Transplant for Recurrent
22 23	1800		Clostridium difficile Infection: Mayo Clinic in Arizona Experience. Mayo Clin Proc.
24 25	1801		2013;88(8):799-805. doi:10.1016/j.mayocp.2013.04.022.
26 27	1802	47.	Crobach MJT, Planche T, Eckert C, et al. European Society of Clinical Microbiology and
28	1803		Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile
29 30	1804		infection. <i>Clin Microbiol Infect</i> . 2016;22 Suppl 4:S63-81. doi:10.1016/j.cmi.2016.03.010.
31 32	1805	48.	Jackson M, Olefson S, Machan JT, Kelly CR. A High Rate of Alternative Diagnoses in Patients
33	1806		Referred for Presumed Clostridium difficile Infection. J Clin Gastroenterol. 2016;50(9):742-
34 35 36	1807		746. doi:10.1097/MCG.00000000000447.
37	1808	49.	Ray A, Smith R, Breaux J. Fecal Microbiota Transplantation for Clostridium difficile Infection:
38 39	1809		The Ochsner Experience. <i>Ochsner J</i> . 2014;14(4):538-544.
40 41	1810		http://www.ncbi.nlm.nih.gov/pubmed/25598718. Accessed October 9, 2017.
42 43	1811	50.	Kao, D., Roach B., Hotte, N., Silva, M., Madsen, K., Beck, P., Louie T, Canadian Association for
44	1812		the Study of the Liver. A Prospective, Dual Center, Randomized Trial Comparing Colonoscopy
45 46	1813		versus Capsule Delivered Fecal Microbiota Transplantation (FMT) in the Management of
47	1814		Recurrent Clostridium Difficile Infection (RCDI). In: Canadian Journal of Gastroenterology and
48 49 50	1815		Hepatology. Vol 2016. Hindawi; 2016:1-204. doi:10.1155/2016/4792898.
51	1816	51.	MacConnachie AA, Fox R, Kennedy DR, Seaton RA. Faecal transplant for recurrent Clostridium
52 53	1817		difficile-associated diarrhoea: a UK case series. QJM. 2009;102(11):781-784.
53 54 55	1818		doi:10.1093/qjmed/hcp118.
56 57	1819	52.	Kelly CR, de Leon L, Jasutkar N. Fecal Microbiota Transplantation for Relapsing Clostridium
58 59 60			https://mc.manus <mark>519</mark> ptcentral.com/gut

Gut

1		HIS/ I	BSG FMT Guideline: Main Document, Gut version.
2	4020		
3 4	1820		difficile Infection in 26 Patients. J Clin Gastroenterol. 2012;46(2):145-149.
5	1821		doi:10.1097/MCG.0b013e318234570b.
6 7	1822	53.	Brandt LJ, Aroniadis OC, Mellow M, et al. Long-Term Follow-Up of Colonoscopic Fecal
8	1823		Microbiota Transplant for Recurrent Clostridium difficile Infection. Am J Gastroenterol.
9 10	1824		2012;107(7):1079-1087. doi:10.1038/ajg.2012.60.
11 12	1825	54.	Pathak R, Enuh HA, Patel A, Wickremesinghe P. Treatment of relapsing Clostridium difficile
13 14	1826		infection using fecal microbiota transplantation. <i>Clin Exp Gastroenterol</i> . 2013;7:1-6.
15 16	1827		doi:10.2147/CEG.S53410.
17 18	1828	55.	Agrawal M, Aroniadis OC, Brandt LJ, et al. The Long-term Efficacy and Safety of Fecal
19	1829		Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection
20 21	1830		in 146 Elderly Individuals. J Clin Gastroenterol. 2015;50(5):1.
22 23	1831		doi:10.1097/MCG.000000000000410.
24	1832	56.	Fischer M, Kao D, Kelly C, et al. Fecal Microbiota Transplantation is Safe and Efficacious for
25 26	1833		Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel
27 28	1834		Disease. Inflamm Bowel Dis. 2016;22(10):2402-2409. doi:10.1097/MIB.0000000000000908.
29 30	1835	57.	Aroniadis OC, Brandt LJ, Greenberg A, et al. Long-term Follow-up Study of Fecal Microbiota
31 32	1836		Transplantation for Severe and/or Complicated Clostridium difficile Infection. J Clin
32 33 34	1837		Gastroenterol. 2015;50(5):1. doi:10.1097/MCG.00000000000374.
35	1838	58.	Fischer M, Kao D, Mehta SR, et al. Predictors of Early Failure After Fecal Microbiota
36 37	1839		Transplantation for the Therapy of Clostridium Difficile Infection: A Multicenter Study. Am J
38 39	1840		Gastroenterol. 2016;111(7):1024-1031. doi:10.1038/ajg.2016.180.
40 41	1841	59.	Ianiro G, Valerio L, Masucci L, et al. Predictors of failure after single faecal microbiota
42	1842		transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year,
43 44	1843		single-centre cohort study. <i>Clin Microbiol Infect</i> . 2017;23(5):337.e1-337.e3.
45 46	1844		doi:10.1016/j.cmi.2016.12.025.
47 48	1845	60.	Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium
49	1846		difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109(7):1065-
50 51	1847		1071. doi:10.1038/ajg.2014.133.
52 53	1848	61.	Lagier J-C, Delord M, Million M, et al. Dramatic reduction in Clostridium difficile ribotype 027-
54 55	1849		associated mortality with early fecal transplantation by the nasogastric route: a preliminary
56 57	1850		report. Eur J Clin Microbiol Infect Dis. 2015;34(8):1597-1601. doi:10.1007/s10096-015-2394-x.
58			
59 60			https://mc.manuscriptcentral.com/gut

Gut

Page 63 d	of 454		Gut
1		HIS/	BSG FMT Guideline: Main Document, Gut version.
1 2	4054	60	
3 4	1851	62.	Camacho-Ortiz A, Gutiérrez-Delgado EM, Garcia-Mazcorro JF, et al. Randomized clinical trial
5	1852		to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in
6 7	1853		intestinal microbiome. Green J, ed. <i>PLoS One</i> . 2017;12(12):e0189768.
8	1854		doi:10.1371/journal.pone.0189768.
9 10	1855	63.	Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus Vancomycin for Clostridium
11 12	1856		difficile Infection. N Engl J Med. 2011;364(5):422-431. doi:10.1056/NEJMoa0910812.
13 14	1857	64.	Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for Prevention of Recurrent
15	1858		Clostridium difficile Infection. N Engl J Med. 2017;376(4):305-317.
16 17	1859		doi:10.1056/NEJMoa1602615.
18 19	1860	65.	Guery B, Menichetti F, Anttila V-J, et al. Extended-pulsed fidaxomicin versus vancomycin for
20 21	1861		Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised,
22	1862		controlled, open-label, phase 3b/4 trial. <i>Lancet Infect Dis</i> . December 2017.
23 24 25	1863		doi:10.1016/S1473-3099(17)30751-X.
25 26	1864	66.	McFarland L V., Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163
27 28	1865		cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97(7):1769-1775.
29 30	1866		doi:10.1111/j.1572-0241.2002.05839.x.
31 32	1867	67.	Sirbu BD, Soriano MM, Manzo C, Lum J, Gerding DN, Johnson S. Vancomycin Taper and Pulse
33	1868		Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection.
34 35	1869		Clin Infect Dis. 2017;65(8):1396-1399. doi:10.1093/cid/cix529.
36 37	1870	68.	Gentry CA, Giancola SE, Thind S, Kurdgelashvili G, Skrepnek GH, Williams RJ. A Propensity-
38 39	1871		Matched Analysis Between Standard Versus Tapered Oral Vancomycin Courses for the
40	1872		Management of Recurrent Clostridium difficile Infection. Open Forum Infect Dis.
41 42	1873		2017;4(4):ofx235. doi:10.1093/ofid/ofx235.
43 44	1874	69.	Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with
45	1875		Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority,
46 47	1876		randomised controlled trial. Lancet Infect Dis. 2012;12(4):281-289. doi:10.1016/S1473-
48 49	1877		3099(11)70374-7.
50 51	1878	70.	Tauxe WM, Haydek JP, Rebolledo PA, et al. Fecal microbiota transplant for Clostridium
52	1879		difficile infection in older adults. Therap Adv Gastroenterol. 2016;9(3):273-281.
53 54	1880		doi:10.1177/1756283X15622600.
55 56 57 58	1881	71.	Khan MA, Sofi AA, Ahmad U, et al. Efficacy and safety of, and patient satisfaction with,
59 60			https://mc.manusenptcentral.com/gut

1

Gut

1		
2 3 1882		colonoscopic-administered fecal microbiota transplantation in relapsing and refractory
4 1883 5		community- and hospital-acquired Clostridium difficile infection. Can J Gastroenterol Hepatol.
6 1884		2014;28(8):434-438. http://www.ncbi.nlm.nih.gov/pubmed/25014180. Accessed October 9,
7 8 1885 9		2017.
10 1886	72.	Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, Capsulized, Frozen
11 1887 12		Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection. JAMA.
13 1888 14		2014;312(17):1772. doi:10.1001/jama.2014.13875.
15 1889	73.	Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of
16 17 1890		vancomycin for severe-complicated Clostridium difficile infection: description of a protocol
18 1891 19		with high success rate. Aliment Pharmacol Ther. 2015;42(4):470-476. doi:10.1111/apt.13290.
20 21 1892	74.	Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota
22 1893		transplant for recurrent Clostridium difficile infection using long-term frozen stool is
23 24 1894		effective: Clinical efficacy and bacterial viability data. Aliment Pharmacol Ther.
25 1895 26		2015;42(8):1011-1018. doi:10.1111/apt.13366.
27 28 1896	75.	Hui J, Kench JG, Chitturi S, et al. Long-Term outcomes of cirrhosis in nonalcoholic
29 1897		steatohepatitis compared with hepatitis C. <i>Hepatology</i> . 2003;38(2):420-427.
30 31 1898 32		doi:10.1053/jhep.2003.50320.
33 1899	76.	Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for
34 1900 35		recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154.
36 37 1901	77.	van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications,
38 1902		effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for
39 40 1903		treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.
41 1904 42		2017;5(6):868-879. doi:10.1177/2050640616678099.
43 44 1905	78.	Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal
45 1906		Microbiota Transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049.
46 47 1907 48		doi:10.1016/j.cgh.2011.08.014.
48 49 1908	79.	Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium
50 1909 51		difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool
52 1910 53		assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.
54 1911	80.	Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the
55 56 1912 57 58		literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024.
59 60		https://mc.manuscriptcentral.com/gut

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1		HIS/	BSG FMT Guideline: Main Document, Gut version.
1 2			
3	1913	81.	Hefazi M, Patnaik MM, Hogan WJ, Litzow MR, Pardi DS, Khanna S. Safety and Efficacy of Fecal
4 5	1914		Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer
6	1915		Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. Mayo
7 8	1916		<i>Clin Proc</i> . 2017;92(11):1617-1624. doi:10.1016/j.mayocp.2017.08.016.
9 10	1917	82.	Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti JR. The risk of inflammatory
11 12	1918		bowel disease flares after fecal microbiota transplantation: Systematic review and meta-
13	1919		analysis. Gut Microbes. July 2017:1-15. doi:10.1080/19490976.2017.1353848.
14 15	1920	83.	Meighani A, Hart BR, Mittal C, Miller N, John A, Ramesh M. Predictors of fecal transplant
16 17	1921		failure. Eur J Gastroenterol Hepatol. 28:826-830. doi:10.1097/MEG.0000000000000614.
18 19	1922	84.	Alrabaa S, Jariwala R, Zeitler K, Montero J. Fecal microbiota transplantation outcomes in
20 21	1923		immunocompetent and immunocompromised patients: A single-center experience. Transpl
22	1924		Infect Dis. 2017;19(4):e12726. doi:10.1111/tid.12726.
23 24	1925	85.	Cohen NA, Livovsky DM, Yaakobovitch S, et al. A Retrospective Comparison of Fecal Microbial
25		65.	
26 27	1926		Transplantation Methods for Recurrent Clostridium Difficile Infection. <i>Isr Med Assoc J.</i>
28 29	1927		2016;18(10):594-599.
30	1928	86.	Orenstein R, Dubberke E, Hardi R, et al. Safety and Durability of RBX2660 (Microbiota
31 32	1929		Suspension) for Recurrent <i>Clostridium difficile</i> Infection: Results of the PUNCH CD Study. <i>Clin</i>
33	1930		Infect Dis. 2016;62(5):596-602. doi:10.1093/cid/civ938.
34 35	1931	87.	Hirsch BE, Saraiya N, Poeth K, Schwartz RM, Epstein ME, Honig G. Effectiveness of fecal-
36	1932		derived microbiota transfer using orally administered capsules for recurrent Clostridium
37 38	1933		difficile infection. BMC Infect Dis. 2015;15(1):191. doi:10.1186/s12879-015-0930-z.
39 40			
41	1934	88.	Kao D, Roach B, Beck P, Hotte N, Madsen K, Louie T. A dual center, randomized trial
42 43	1935		comparing colonoscopy and oral capsule delivered fecal microbiota transplantation in the
44	1936		treatment of recurrent clostridium difficile infection: Preliminary results. Am J Gastroenterol.
45 46	1937		2015;110:S553. doi:http://dx.doi.org/10.1038/ajg.2015.294.
47	1938	89.	Youngster I, Mahabamunuge J, Systrom HK, et al. Oral, frozen fecal microbiota transplant
48 49	1939		(FMT) capsules for recurrent Clostridium difficile infection. BMC Med. 2016;14(1):134.
50 51	1940		doi:10.1186/s12916-016-0680-9.
52 53	1941	90.	Anand R, Song Y, Garg S, et al. Effect of Aging on the Composition of Fecal Microbiota in
54	1942		Donors for FMT and Its Impact on Clinical Outcomes. <i>Dig Dis Sci</i> . 2017;62(4):1002-1008.
55 56	1943		doi:10.1007/s10620-017-4449-6.
57			
58 59			63
60			https://mc.manuscriptcentral.com/gut

1

Gut

2			
3	1944	91.	Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open forum Infect Dis.
4 5	1945		2015;2(1):ofv004. doi:10.1093/ofid/ofv004.
6 7	1946	92.	Fischer M, Kao D, Kassam Z, et al. Stool Donor Body Mass Index Does Not Affect Recipient
8	1947		Weight After a Single Fecal Microbiota Transplantation for C. difficile Infection. Clin
9 10 11	1948		Gastroenterol Hepatol. December 2017. doi:10.1016/J.CGH.2017.12.007.
12	1949	93.	Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical
13 14 15	1950		frontier. <i>Gut</i> . 2016;65(2):330-339. doi:10.1136/gutjnl-2015-309990.
16	1951	94.	Allegretti JR, Fischer M, Papa E, et al. Su1738 Fecal Microbiota Transplantation Delivered via
17 18	1952		Oral Capsules Achieves Microbial Engraftment Similar to Traditional Delivery Modalities:
19	1953		Safety, Efficacy and Engraftment Results From a Multi-Center Cluster Randomized Dose-
20 21	1954		Finding Study. Gastroenterology. 2016;150(4):S540. doi:10.1016/S0016-5085(16)31855-8.
22 23	1955	95.	Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout
24	1956		development and alternative approaches for therapeutic modulation. Genome Med.
25 26 27	1957		2016;8(1):39. doi:10.1186/s13073-016-0294-z.
28	1958	96.	Lange K, Buerger M, Stallmach A, Bruns T. Effects of Antibiotics on Gut Microbiota. Dig Dis.
29 30 31	1959		2016;34(3):260-268. doi:10.1159/000443360.
32	1960	97.	Becattini S, Taur Y, Pamer EG. Antibiotic-Induced Changes in the Intestinal Microbiota and
33 34	1961		Disease. Trends Mol Med. 2016;22(6):458-478. doi:10.1016/j.molmed.2016.04.003.
35 36	1962	98.	Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between
37 38	1963		good and evil. <i>Gut</i> . 2016;65(11):1906-1915. doi:10.1136/gutjnl-2016-312297.
39 40	1964	99.	Boostrom SY, Mathis KL, Pendlimari R, et al. Burden of Clostridium difficile on the healthcare
41 42	1965		system. Inflamm Bowel Dis. 2012;18(1):994-1002. doi:10.1126/science.1241214.
43 44	1966	100.	J.R. A, J.R. K, M.J. H. Intestinal microbiome restoration for recurrent clostridium difficile
44 45	1967		infection in patients with concurrent inflammatory bowel disease. Gastroenterology.
46 47	1968		2015;148(4 SUPPL. 1):S869.
48 49	1969	101.	National Health Service. Population screening programmes: NHS bowel cancer screening
50	1970		(BCSP) programme - GOV.UK. https://www.gov.uk/topic/population-screening-
51 52 53	1971		programmes/bowel. Accessed June 10, 2018.
54	1972	102.	London: TSO Guidelines for the Blood Transfusion Services in the United Kingdom 7 th Edition
55 56 57	1973		2005 TSO Accredited Agents Web Access.
58 59			
60			https://mc.manuscriptcentral.com/gut

Page 67 of 454			Gut
		HIS/ E	BSG FMT Guideline: Main Document, Gut version.
1 2 3	1974	103.	Emanuelsson F, Claesson BEB, Ljungström L, Tvede M, Ung K-A. Faecal microbiota
4		105.	
5	1975		transplantation and bacteriotherapy for recurrent Clostridium difficile infection: A
6 7	1976		retrospective evaluation of 31 patients. <i>Scand J Infect Dis</i> . 2014;46(2):89-97.
8 9	1977		doi:10.3109/00365548.2013.858181.
10	1978	104.	Endtz HP, van den Braak N, van Belkum A, et al. Fecal carriage of vancomycin-resistant
11 12	1979		enterococci in hospitalized patients and those living in the community in The Netherlands. J
12	1980		Clin Microbiol. 1997;35(12):3026-3031. http://www.ncbi.nlm.nih.gov/pubmed/9399488.
14 15	1981		Accessed February 15, 2018.
16			
17 18	1982	105.	Willems RJL, Top J, van Santen M, et al. Global spread of vancomycin-resistant Enterococcus
18 19	1983		faecium from distinct nosocomial genetic complex. <i>Emerg Infect Dis</i> . 2005;11(6):821-828.
20 21	1984		doi:10.3201/eid1106.041204.
22	1985	106.	Gough E, Shaikh H, Manges AR. Systematic Review of Intestinal Microbiota Transplantation
23 24	1986		(Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection. Clin Infect Dis.
25 26	1987		2011;53(10):994-1002. doi:10.1093/cid/cir632.
27	1988	107.	Casewell MW, Slater NGP, Cooper JE. Operating theatre water-baths as a cause of
28 29	1989		pseudomonas septicaemia. J Hosp Infect. 1981;2:237-240. doi:10.1016/0195-6701(81)90043-
30 31	1990		8.
32			
33 34	1991	108.	Muyldermans G, de Smet F, Pierard D, et al. Neonatal infections with Pseudomonas
35	1992		aeruginosa associated with a water-bath used to thaw fresh frozen plasma. J Hosp Infect.
36 37	1993		1998;39(4):309-314. http://www.ncbi.nlm.nih.gov/pubmed/9749402. Accessed June 11,
38	1994		2018.
39 40	1995	109.	Sleight SC, Wigginton NS, Lenski RE. Increased susceptibility to repeated freeze-thaw cycles in
41	1996		Escherichia coli following long-term evolution in a benign environment. BMC Evol Biol.
42 43 44	1997		2006;6(1):104. doi:10.1186/1471-2148-6-104.
44 45	1998	110.	O'Brien CL, Allison GE, Grimpen F, Pavli P. Impact of colonoscopy bowel preparation on
46	1999		intestinal microbiota. <i>PLoS One</i> . 2013;8(5):e62815. doi:10.1371/journal.pone.0062815.
47 48	1999		
49	2000	111.	Mai V, Stine OC. Bowel preparation for colonoscopy: relevant for the gut's microbiota? Gut.
50 51	2001		2015;64(10):1504-1505. doi:10.1136/gutjnl-2014-308937.
52 53	2002	112.	Jalanka J, Salonen A, Salojärvi J, et al. Effects of bowel cleansing on the intestinal microbiota.
54	2003		<i>Gut</i> . 2015;64(10):1562-1568. doi:10.1136/gutjnl-2014-307240.
55 56 57	2004	113.	Mai V, Greenwald B, Glenn Morris J, Raufman J-P, Stine OC. Effect of bowel preparation and

1

2			
3	2005		colonoscopy on post-procedure intestinal microbiota composition. Gut. 2006;55(12):1822-
4 5	2006		1823. doi:10.1136/gut.2006.108266.
6 7	2007	114.	Harrell L, Wang Y, Antonopoulos D, et al. Standard Colonic Lavage Alters the Natural State of
8 9	2008		Mucosal-Associated Microbiota in the Human Colon. Singh SR, ed. PLoS One.
10	2009		2012;7(2):e32545. doi:10.1371/journal.pone.0032545.
11 12	2010	115.	Chin SM, Sauk J, Mahabamunuge J, Kaplan JL, Hohmann EL, Khalili H. Fecal Microbiota
13 14	2011		Transplantation for Recurrent Clostridium difficile Infection in Patients With Inflammatory
15	2012		Bowel Disease: A Single-Center Experience. Clin Gastroenterol Hepatol. 2017;15(4):597-599.
16 17 18	2013		doi:10.1016/j.cgh.2016.11.028.
19	2014	116.	Wang S, Xu M, Wang W, et al. Systematic Review: Adverse Events of Fecal Microbiota
20 21	2015		Transplantation. <i>PLoS One</i> . 2016;11(8):e0161174. doi:10.1371/journal.pone.0161174.
22 23	2016	117.	Khoruts A, Rank KM, Newman KM, et al. Inflammatory Bowel Disease Affects the Outcome of
24	2017		Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Clin
25 26 27	2018		Gastroenterol Hepatol. 2016;14(10):1433-1438. doi:10.1016/j.cgh.2016.02.018.
28	2019	118.	de Jager CPC, Wever PC, Gemen EFA, et al. Proton pump inhibitor therapy predisposes to
29 30	2020		community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther.
31 32	2021		2012;36(10):941-949. doi:10.1111/apt.12069.
32 33 34	2022	119.	Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome.
35 36	2023		<i>Gut</i> . 2016;65(5):740-748. doi:10.1136/gutjnl-2015-310376.
37 38	2024	120.	McDonald EG, Milligan J, Frenette C, Lee TC. Continuous Proton Pump Inhibitor Therapy and
38 39	2025		the Associated Risk of Recurrent Clostridium difficile Infection. JAMA Intern Med.
40 41	2026		2015;175(5):784. doi:10.1001/jamainternmed.2015.42.
42 43	2027	121.	Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-Associated Diarrhea and
44 45	2028		Proton Pump Inhibitor Therapy: A Meta-Analysis. Am J Gastroenterol. 2012;107(7):1001-
45 46 47	2029		1010. doi:10.1038/ajg.2012.179.
48	2030	122.	Girotra M, Garg S, Anand R, Song Y, Dutta SK. Fecal Microbiota Transplantation for Recurrent
49 50	2031		Clostridium difficile Infection in the Elderly: Long-Term Outcomes and Microbiota Changes.
50 51 52	2032		<i>Dig Dis Sci</i> . 2016;61(10):3007-3015. doi:10.1007/s10620-016-4229-8.
53 54	2033	123.	Hagel S, Fischer A, Ehlermann P, et al. Fecal Microbiota Transplant in Patients With Recurrent
55	2034		Clostridium Difficile Infection. Dtsch Arztebl Int. 2016;113(35-36):583-589.
56 57	2035		doi:10.3238/arztebl.2016.0583.
58			
59 60			https://mc.manuscriptcentral.com/gut

Gut

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1		1113/1	sourier ourdenne. Man Document, our version.
2 3	2036	124.	Department of Health (UK). Management and decontamination of flexible endoscopes (HTM
4	2037		01-06) - GOV.UK. https://www.gov.uk/government/publications/management-and-
5 6	2038		decontamination-of-flexible-endoscopes. Accessed December 19, 2017.
7 8			
9	2039	125.	British Society of Gastroenterology. Guidance on Decontamination of Equipment for
10 11	2040		Gastrointestinal Endoscopy: 2017 Edition. https://www.bsg.org.uk/resource/guidance-on-
12	2041		decontamination-of-equipment-for-gastrointestinal-endoscopy-2017-edition.html. Accessed
13 14	2042		December 19, 2017.
15 16	2043	126.	Loveday HP, Wilson JA, Pratt RJ, et al. epic3: National Evidence-Based Guidelines for
17	2044		Preventing Healthcare-Associated Infections in NHS Hospitals in England. J Hosp Infect.
18 19	2045		2014;86(1):S1-S70. doi:10.1016/S0195-6701(13)60012-2.
20 21	2046	127.	Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal Microbiota Transplantation for Clostridium difficile
22	2047		Infection: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2013;108(4):500-508.
23 24 25	2048		doi:10.1038/ajg.2013.59.
26	2049	128.	Allegretti JR, Kao D, Sitko J, Fischer M, Kassam Z. Early antibiotic use post-fecal microbiota
27 28	2050		transplantation increases the risk of treatment failure. Clin Infect Dis. August 2017.
28 29 30	2051		doi:10.1093/cid/cix684.
31	2052	129.	Terveer EM, van Beurden YH, Goorhuis A, et al. How to: Establish and run a stool bank. Clin
32 33	2053		Microbiol Infect. 2017;23(12):924-930. doi:10.1016/j.cmi.2017.05.015.
34 35	2054	130.	Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of
36 37	2055		faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium
38 39	2056		difficile infection. Aliment Pharmacol Ther. 2017;46(5):479-493. doi:10.1111/apt.14201.
40 41	2057	131.	Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of
42	2058		Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48(8):693-702.
43 44	2059		doi:10.1097/MCG.000000000000046.
45 46	2060	132.	D. D, J. R, S. G, et al. Fecal microbiota transplantation for clostridium difficile infection a
47 48	2061		systematic review. Ann Intern Med. 2015;162(9):630-638.
49 50	2062	133.	Baxter M, Ahmad T, Colville A, Sheridan R. Fatal Aspiration Pneumonia as a Complication of
51 52	2063		Fecal Microbiota Transplant. Clin Infect Dis. 2015;61(1):136-137. doi:10.1093/cid/civ247.
53 54	2064	134.	Hecker MT, Obrenovich ME, Cadnum JL, et al. Fecal Microbiota Transplantation by Freeze-
55	2065		Dried Oral Capsules for Recurrent Clostridium difficile Infection. Open forum Infect Dis.
56 57	2066		2016;3(2):ofw091. doi:10.1093/ofid/ofw091.
58 59 60			https://mc.manuscriptcentral.com/gut

1

Gut

2	2007	405	
3 4	2067	135.	Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? <i>Nat</i>
5	2068		Rev Gastroenterol Hepatol. 2017;14(10):573-584. doi:10.1038/nrgastro.2017.88.
6 7	2069	136.	Rossen NG, Fuentes S, van der Spek MJ, et al. Findings From a Randomized Controlled Trial of
8 9	2070		Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. 2015;149(1):110-
10 11	2071		118.e4. doi:10.1053/j.gastro.2015.03.045.
12	2072	137.	Moayyedi P, Surette MG, Kim PT, et al. Fecal Microbiota Transplantation Induces Remission in
13 14	2073		Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology.
15 16	2074		2015;149(1):102-109.e6. doi:10.1053/j.gastro.2015.04.001.
17 18	2075	138.	Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota
19	2076		transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet
20 21	2077		(London, England). 2017;389(10075):1218-1228. doi:10.1016/S0140-6736(17)30182-4.
22 23	2078	139.	Costello S, Waters O, Bryant R. Short Duration, Low Intensity, Pooled Fecal Microbiota
24	2079		Transplantation Induces Remission in Patients with Mild-Moderately Active Ulcerative Colitis:
25 26 27	2080		A Randomised Controlled Trial. (Abstract). Gastroenterology. 152(5):S198-S199.
28	2081	140.	Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo
29 30	2082		for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-
31	2083		controlled, parallel-group, single-centre trial. <i>lancet Gastroenterol Hepatol</i> . 2018;3(1):17-24.
32 33	2084		doi:10.1016/S2468-1253(17)30338-2.
34 35	2085	141.	Tian H, Ge X, Nie Y, et al. Fecal microbiota transplantation in patients with slow-transit
36 37	2086		constipation: A randomized, clinical trial. Green J, ed. PLoS One. 2017;12(2):e0171308.
38 39	2087		doi:10.1371/journal.pone.0171308.
40 41	2088	142.	Bajaj JS, Kassam Z, Fagan A, et al. Fecal Microbiota Transplant from a Rational Stool Donor
41 42	2089		Improves Hepatic Encephalopathy: A Randomized Clinical Trial. Hepatology. June 2017.
43 44	2090		doi:10.1002/hep.29306.
45 46	2091	143.	Vrieze A, Van Nood E, Holleman F, et al. Transfer of Intestinal Microbiota From Lean Donors
47 48	2092		Increases Insulin Sensitivity in Individuals With Metabolic Syndrome. Gastroenterology.
49 50	2093		2012;143(4):913-916.e7. doi:10.1053/j.gastro.2012.06.031.
51	2094	144.	Kootte RS, Levin E, Salojärvi J, et al. Improvement of Insulin Sensitivity after Lean Donor Feces
52 53	2095		in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab.
54 55	2096		2017;26(4):611-619.e6. doi:10.1016/j.cmet.2017.09.008.
56 57	2097		
58 59			
60			https://mc.manuscriptcentral.com/gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

s 107 108 • rening for centres preparing f stitve resr 101 Table 1: Recommended donor history/ questionnaire: A positive response to any of these questions would usually result in exclusion from further consideration as a donor, although this would depend upon the particular circumstances/ answers given.

1

60

1 2		
3	2125	1. Receipt of antimicrobials within the past three months.
4 5	2126	2. Known prior exposure to HIV and/ or viral hepatitis, and known previous or latent
6	2127	tuberculosis.
7 8	2128	3. Risk factors for blood-borne viruses - including high risk sexual behaviours, use of illicit
9	2129	drugs, any tattoo/ body piercing/ needlestick injury/ blood transfusion/ acupuncture, all
10 11	2130	within the previous six months.
12 13	2131	4. Receipt of a live attenuated virus within the past six months.
14	2132	5. Underlying gastrointestinal conditions/ symptoms (e.g. history of IBD, IBS, chronic diarrhoea,
15 16	2133	chronic constipation, coeliac disease, bowel resection or bariatric surgery) - also including
17	2134	acute diarrhoea/ gastrointestinal symptoms within the past two weeks.
18 19	2135	6. Family history of any significant gastrointestinal conditions (e.g. family history of IBD, or
20 21	2136	colorectal cancer).
21	2137	7. History of atopy (e.g. asthma, eosinophilic disorders).
23 24	2138	8. Any systemic autoimmune conditions.
25	2139	9. Any metabolic conditions, including diabetes and obesity.
26 27	2140	10. Any neurological or psychiatric conditions, or known risk of prion disease.
28	2141	11. History of chronic pain syndromes, including chronic fatigue syndrome and fibromyalgia.
29 30	2142	12. History of any malignancy.
31 32	2143	13. Taking particular regular medications, or such medications within the past three months, i.e.
33	2144	antimicrobials, proton pump inhibitors, immunosuppression, chemotherapy
34 35	2145	14. History of receiving growth hormone, insulin from cows, or clotting factor concentrates.
36	2146	15. History of receiving an experimental medicine or vaccine within the past six months.
37 38	2147	16. History of travel to tropical countries within the past six months.
39		
40 41	2148	
42 43	2149	
44 45	2150	Table 2: Recommended blood screening for stool donors: *EBV and CMV testing is only
46 47	2151	recommended where there is the potential that the FMT prepared from that donor will be
48	2152	administered to immunosuppressed patients at risk of severe infection if exposed to CMV and EBV.
49 50		
51		
52 53		
54		
55 56		
57		
58 59		
59		https://mc.manuscriptcentral.com/gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

Gut

Pathogen screening: Hepatitis A IgM Hepatitis B (HBsAg and HBcAb) Hepatitis C antibody . Hepatitis E IgM . HIV -1 and -2 antibodies HTLV-1 and -2 antibodies Treponema pallidum antibodies (TPHA, VDRL) Epstein-Barr virus IgM and IgG* Cytomegalovirus IgM and IgG* • Strongyloides stercoralis IgG . Entamoeba histolytica serology *General/ metabolic screening:* Full blood count with differential. Creatinine and electrolytes Liver enzymes (including albumin, bilirubin, aminotransferases, gamma-glutamyltransferase and alkaline phosphatase). C-reactive protein Table 3: Recommended stool screening for stool donors: *Whilst CPE and ESBL are the only multi-drug resistant bacteria that are recommended to be screened for universally, consider testing for other resistant organisms (including vancomycin-resistant Enterococci (VRE) and/ or methicillin-resistant Staphylococcus aureus (MRSA)) based upon risk assessment and local prevalence.

Gut

GRA	DE - strength of evidence:	GRADE - strength of recommendatio
2179	Table 4: A summary of the GRADE system:	
2178		
2177		
2176		
2175		
2174		
2173		
2172		
2171		
2170		
2169		
2168		
2167		
2166		
2165		
2164		
	Norovirus, Rotavirus PCR.	
	 Acid fast stain for <i>Cyclospora</i> and <i>Isosp</i> <i>Helicobacter pylori</i> faecal antigen. 	uru.
	Faecal antigen for <i>Cryptosporidium</i> and	
	 Stool ova, cysts and parasite analysis, in 	
	(CPE) and extended-spectrum beta-lact	tamases (ESBL)*.
		st carbapenemase-producing Enterobacteria
	Shiga toxin-producing Escherichia coli b	
	Clostridium difficile PCR Campylobacter, Salmonella, and Shiael	<i>la</i> by standard stool culture and/ or PCR

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

	HIS/ BSG FMT Guideline: Main Document, <i>Gut</i> version.	
High	quality: Further research is very unlikely to change our	The trade-offs: Taking into accoun
confi	idence in the estimate of effect.	estimate size of the effect for main out
		the confidence limits around those est
		and the relative value placed on each out
Mod	lerate quality: Further research is likely to have an	The quality of the evidence.
impo	ortant impact on our confidence in the estimate of effect	
and r	may change the estimate.	
Low	quality: Further research is very likely to have an	Translation of the evidence into practic
impc	ortant impact on our confidence in the estimate of effect	particular setting: Taking into conside
and i	is likely to change the estimate.	important factors that could be expect
		modify the size of expected effects.
Very	low quality: Any estimate of effect is very uncertain.	Uncertainty about the baseline risk fo
		population of interest.
2180		
2181		
24.02		
2182		
2183		
2184		
2185		
2186		
2187		
2188		
2189		
2190		
2130		
2191		
	Table 5: Criteria for stool collection:	

Clear instructions should be given to donors regarding hand hygiene. Collect stool donations in a sealable clean container. A number of specifically designed devices are available commercially.

 etty into th

 it ansferred to thi.

 uere, if a short period of storage.

 Stool should ideally be passed directly into the clean container for collection; alternatively, it may be collected in clean tissue and transferred to the clean container. Stool should be transported to the FMT production site as soon as possible post defaecation (and within six hours); however, if a short period of storage is necessary, this should be at 4°C.

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Benjamin H Mullish^{*1,2}, Mohammed Nabil Quraishi^{*3}, Jonathan Segal^{*1,4}, Victoria L McCune^{5,6}, Melissa Baxter⁷, Gemma L Marsden⁸, David Moore⁹, Alaric Colville⁷, Neeraj Bhala^{3,9,10}, Tarig H Igbal^{3,10}, Christopher Settle¹¹, Graziella Kontkowski¹², Ailsa L Hart^{1,4}, Peter M Hawkey⁶, Simon D Goldenberg^{O13,14}, Horace RT Williams^{$O\Box1,2$}. 1. Division of Integrative Systems Medicine and Digestive Disease, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK. 2. Departments of Gastroenterology and Hepatology, St Mary's Hospital, Imperial College Healthcare NHS Trust, Paddington, London, UK. 3. Department of Gastroenterology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. 4. Inflammatory Bowel Disease Unit, St Mark's Hospital, Harrow, London, UK. 5. Public Health England, Public Health Laboratory Birmingham, Birmingham, UK. 6. Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK. 7. Department of Microbiology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK. 8. Healthcare Infection Society, London, UK. 9. Institute of Applied Health Research, University of Birmingham, Birmingham, UK. 10. Institute of Translational Medicine, University of Birmingham, Edgbaston, Birmingham, UK. 11. Department of Microbiology, City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK. 12. C diff Support, UK. 13. Centre for Clinical Infection and Diagnostics Research, King's College London, London, UK. 14. Department of Microbiology, Guy's and St Thomas' NHS Foundation Trust, London UK. *Joint first authors. ^oJoint senior authors. [□]Corresponding author.

	32	Contact via:	Dr Hora	ace Williams
	33		Depart	ment of Gastroenterology
	34		3 rd Floo	or, Salton House
0	35		St Mary	y's Hospital, Imperial College Healthcare NHS Trust
1 2	36		London	n, W2 1NY
2 3 4 5 5 7	37		United	Kingdom
5 6	38		Email: I	n.williams@imperial.ac.uk
7 8 9	39			
9 D	40	Keywords:	microh	iota; faecal transplant; <i>Clostridium difficile;</i> inflammatory bowel disease
1 2		Reywords.	merob	
3 4	41			
2 3 4 5 6 7	42	Word count:	16301	
	43			
8 9 0	44	Abbreviations:	FMT	faecal microbiota transplant
1	45		CDI	Clostridium difficile infection
3 4	46		EBV	Epstein-Barr virus
2 3 4 5 6 7	47		CMV	cytomegalovirus
8	48		BMI	body mass index
9) 1	49		GI	gastrointestinal
2	50		RCT	randomised controlled trial
2 3 4 5 6 7	51		NAAT	nucleic acid amplification test
	52		GDH	randomised controlled trial nucleic acid amplification test glutamate dehydrogenase
8 9 0	53		EIA	enzymes immunoassay
1	54		PCR	polymerase chain reaction
2 3 4 5 5 7	55		IBD	inflammatory bowel disease
5	56		IBS	irritable bowel syndrome
7 3				

58 59

60

Gut

	HIS/ BSG FMT Guideline	e: Main Document, Gut version.
57	HIV	human immunodeficiency virus

1			
2 3	57	HIV	human immunodeficiency virus
3 4	57	IIIV	numan minunouenciency virus
5	58	AIDS	acquired immune deficiency syndrome
6	38	AIDS	acquired initiale deficiency syndrome
7	59	CDE	carbananamaca producing Enterphysicariacana
8	29	CPE	carbapenemase-producing Enterobacteriaceae
9	60	FCDI	a ta dada a satu na bata ta da satu
10	60	ESBL	extended-spectrum beta-lactamase
11			
12	61	VRE	vancomycin-resistant Enterococci
13			
14	62	MRSA	methicillin-resistant Staphylococcus aureus
15			
16	63	PPI	proton pump inhibitor
17			
18	64	UC 🕓	ulcerative colitis
19 20			
20	65	HE	hepatic encephalopathy
21 22			
22	66	MELD	Model for End-Stage Liver Disease
23 24			J
25	67		
26			
27	68		
28	00		
29	69		
30	05		
31	70		
32	70		
33	71		
34	/1		
35	72		
36 37	12		
37 38	70		
39	73		
40			
41	74		
42			
43	75		
44			
45	76		
46			
47	77		
48			
49	78		
50			
51 52	79		
52 53			
53 54	80		
54 55			
56	81		
57			
58			

1. Abstract:

Interest in the therapeutic potential of faecal microbiota transplant (FMT) has been increasing globally in recent years, particularly as a result of randomised studies in which it has been used as an intervention. The main focus of these studies has been the treatment of recurrent or refractory Clostridium difficile infection (CDI), but there is also an emerging evidence base regarding potential applications in non-CDI settings. The key clinical stakeholders for the provision and governance of FMT services in the United Kingdom (UK) have tended to be in two major specialty areas: gastroenterology and microbiology/infectious diseases. Whilst the National Institute for Health and Care Excellence (NICE) guidance (2014) for use of FMT for recurrent or refractory CDI has become accepted in the UK, clear evidence-based UK guidelines for FMT have been lacking. This resulted in discussions between the British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS), and a joint BSG/HIS FMT working group was established. This guideline document is the culmination of that joint dialogue.

Gut

96 2. Executive summary:

97 2.1. Overview:

98 The remit of the British Society of Gastroenterology (BSG)/ Healthcare Infection Society (HIS) 99 working group was to provide recommendations as to best practice in the provision of a faecal 100 microbiota transplant (FMT) service. This guideline considers the use of FMT for the treatment of 101 *Clostridium difficile* infection (CDI) – as well as for potential non-CDI indications – in adults. The 102 working group have primarily targeted their report at clinicians involved in the use and provision of 103 <u>FMT services, but have also aimed it to be of interest to patients and their relatives.</u>

105 2.2. Summary of recommendations:

2.2.1. <u>Which patients with Clostridium difficile infection should be considered for faecal</u> microbiota transplant, and how should they be followed up after treatment?

2.2.1.1. Prior to faecal microbiota transplant. Patient selection:

2.2.1.1.1. Recurrent *Clostridium difficile* infection:

110 <u>We recommend that FMT should be offered</u> to patients with recurrent CDI who have had at 111 least two recurrences, or those who have had one recurrence and have risk factors for 112 further episodes, including severe and severe-complicated CDI (*GRADE of evidence: high;*

113 strength of recommendation: strong).

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1		,
2	111	
3 4	114	
5	115	2.2.1.1.2. Refractory Clostridium difficile infection:
7 8	116	We recommend that FMT should be considered in cases of refractory CDI (GRADE of
9	117	evidence: moderate; strength of recommendation: strong).
10 11 12	118	
13 14	119	2.2.1.1.3. FMT as initial therapy for Clostridium difficile infection:
15 16	120	We recommend that FMT should not be administered as initial treatment for CDI (GRADE of
17	121	evidence: low; strength of recommendation: strong).
18 19 20	122	
21 22	123	2.2.1.1.4. Antimicrobial/ antitoxin therapy prior to considering FMT for patients with CDI:
23 24	124	<i>i.</i> <u>We recommend that</u> FMT for recurrent CDI should only be considered after
25 26	125	recurrence of symptoms following resolution of an episode of CDI that was treated
27	126	with appropriate antimicrobials for at least 10 days (GRADE of evidence: low;
28 29	127	strength of recommendation: strong).
30 31	128	<i>ii.</i> <u>We recommend consideration of</u> treatment with extended/ pulsed vancomycin
32 33	129	and/or fidaxomicin before considering FMT as treatment for recurrent CDI (GRADE
34	130	of evidence: low; strength of recommendation: strong).
35 36	131	<i>iii.</i> For those with severe or complicated CDI, which appears to be associated with
37 38	132	reduced cure rates, we recommend that consideration should be given to offering
39 40	133	patients treatment with medications which are associated with reduced risk of
41	134	recurrence (e.g. fidaxomicin and bezlotoxumab), before offering FMT (GRADE of
42 43	135	evidence: low; strength of recommendation: strong).
44 45	136	
46	137	2.2.1.2. Post-FMT follow-up, outcomes and adverse events:
47 48	138	2.2.1.2.1. Management of FMT failure:
49 50	139	We recommend that FMT should be offered after initial FMT failure (GRADE of evidence:
51 52	140	high; strength of recommendation: strong).
53 54	141	
55 56 57 58	142	2.2.1.2.2. General approach to follow-up post-FMT:
59 60		https://mc.manuscfiptcentral.com/gut

Page 82 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

- 144 follow-up FMT recipients for long enough to fully establish efficacy/adverse events, and for
- 145 at least eight weeks in total (GRADE of evidence: low; strength of recommendation: strong).

2.2.1.2.3. Management of the FMT recipient:

- *i.* <u>We recommend that immediate management after endoscopic administration of</u>
 FMT should be as per endoscopy unit protocol (*GRADE of evidence: very low:* strength of recommendation: strong).
- *ii.* <u>We recommend that patients</u> should be warned about short term adverse events, in
 particular the possibility of self-limiting GI symptoms. They should be advised that
 serious adverse events are rare (*GRADE of evidence: very low; strength of recommendation: strong*).
- *iii.* After enteral tube administration, <u>we recommend that</u> patients may have the tube
 156 removed and oral water given from 30 minutes post-administration (*GRADE of*157 *evidence: very low; strength of recommendation: strong*).
- - **2.2.1.2.4. Definition of cure post-FMT for CDI**:

160 <u>We recommend that a</u> decision regarding cure/remission from CDI should be recorded 161 during follow-up. However, this has no uniformly-agreed definition, and should be decided 162 on a case-by-case basis (*GRADE of evidence: very low; strength of recommendation: strong*).

2.2.1.2.5. Definition of treatment failure post-FMT for CDI:

165 <u>We recommend that treatment</u> failure/recurrence should be defined on a case-by-case 166 basis. Routine testing for *C. difficile* toxin after FMT is not recommended, but it is 167 appropriate to consider in the case of persistent CDI symptoms/suspected relapse (*GRADE* 168 of evidence: low; strength of recommendation: strong).

- 170 2.2.2. What recipient factors influence the outcome of faecal microbiota transplant when
 171 treating people with *Clostridium difficile* infection?
- **2.2.2.1.** General approach to co-morbidities and FMT:

Page 83 of 454

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

We recommend that FMT should be avoided in those with anaphylactic food allergy i. (GRADE of evidence: very low; strength of recommendation: strong). We suggest that FMT should be offered with caution to patients with CDI and ii. decompensated chronic liver disease (GRADE of evidence: very low; strength of recommendation: weak). 2.2.2.2. Immunosuppression and FMT: We recommend that FMT should be offered with caution to immunosuppressed i. patients, in whom FMT appears efficacious without significant additional adverse effects (GRADE of evidence: moderate; strength of recommendation: strong). We recommend that immunosuppressed FMT recipients at risk of severe infection if ii. exposed to EBV or CMV should only receive FMT from donors negative for EBV and CMV (GRADE of evidence: very low; strength of recommendation: strong). 2.2.2.3. Other comorbidities and FMT: We recommend that FMT should be offered to those with recurrent CDI and i. inflammatory bowel disease, but patients should be counselled about a small but recognised risk of exacerbation of IBD (GRADE of evidence: moderate; strength of recommendation: strong). We recommend that FMT should be considered for appropriate patients with ii. recurrent CDI regardless of other comorbidities (GRADE of evidence: moderate; strength of recommendation: strong). 2.2.3. What donor factors influence the outcome of faecal microbiota transplant when treating people with *Clostridium difficile* infection? 2.2.3.1. General approach to donor selection: We recommend that related or unrelated donors should both be considered acceptable. However, where possible, FMT is best sourced from a centralised stool bank, from a healthy unrelated donor (GRADE of evidence: low; strength of recommendation: strong). Age and BMI restrictions for potential donors: 2.2.3.2.

204 <u>We suggest that people</u> should only be considered as potential FMT donors if they are \geq 18 205 and \leq 60 years old, and have a BMI of \geq 18 and \leq 30 kg/m² (*GRADE of evidence: low; strength* 206 of recommendation: weak).

2.2.3.3. General approach to the donor screening assessment:

It is mandatory to screen potential donors by questionnaire and personal interview, to
establish risk factors for transmissible diseases and factors influencing the gut microbiota
(Table 1) (GRADE of evidence: low; strength of recommendation: strong).

2.2.3.4. Laboratory screening of potential donors:

Blood and stool screening of donors is mandatory (Tables 2 and 3) (GRADE of evidence: low;

- 215 strength of recommendation: strong).

2.2.3.5. Repeat donor checks, and donation pathway:

i. In centres using frozen FMT, before FMT may be used clinically, we recommend that
 donors should have successfully completed a donor health questionnaire and laboratory
 screening assays both before and after the period of stool donation. This is the
 preferred means of donor screening (GRADE of evidence: low; strength of
 recommendation: strong).

ii. In centres using fresh FMT, we recommend that a repeat health questionnaire should be
 assessed at the time of each stool donation. To ensure ongoing suitability for inclusion
 as a donor, the donor health questionnaire and laboratory screening should be repeated
 regularly (GRADE of evidence: low; strength of recommendation: strong).

- - 228 2.2.4. What factors related to the preparation of the transplant influence the outcome of
 faecal microbiota transplant when treating people with *Clostridium difficile* 230 infection?
- **2.2.4.1.** General principles of FMT preparation:

454		Gut
	HIS/ BS	SG FMT Guideline: Main Document, Gut version.
232	i.	We recommend that stool collection should follow a standard protocol (GRADE of
233		evidence: low; strength of recommendation: strong).
234	ii.	We recommend that donor stool should be processed within 6 hours of defaecation
235		(GRADE of evidence: low; strength of recommendation: strong).
236	iii.	We recommend that both aerobically and anaerobically prepared FMT treatments
237		should be considered suitable when preparing FMT for the treatment of recurrent
238		CDI (GRADE of evidence: moderate; strength of recommendation: strong).
239	iv.	We recommend that sterile 0.9% saline should be considered as an appropriate
240		diluent for FMT production, and cryoprotectant such as glycerol should be added for
241		frozen FMT (GRADE of evidence: moderate: strength of recommendation: strong).
242	v.	We recommend using \geq 50g of stool in each FMT preparation (GRADE of evidence:
243		moderate: strength of recommendation: strong).
244	vi.	We suggest that stool should be mixed 1:5 with diluent to make the initial faecal
245		emulsion (GRADE of evidence: low; strength of recommendation: weak).
246	vii.	We suggest that homogenisation and filtration of FMT should be undertaken in a
247		closed disposable system (GRADE of evidence: low; strength of recommendation:
248		weak).
249		
250	2.2.4.	2. Fresh vs frozen FMT:
251	We r	ecommend that the use of banked frozen FMT material should be considered
252	prefer	rable to fresh preparations for CDI (GRADE of evidence: high; strength of
253	recom	nmendation: strong).

2.2.4.3. **Use of frozen FMT:**

We recommend that FMT material stored frozen at -80°C should be regarded as having a i. maximum shelf life of six months from preparation (GRADE of evidence: low; strength of recommendation: strong).

ii. We suggest consideration of thawing frozen FMT at ambient temperature, and using within six hours of thawing (GRADE of evidence: low; strength of recommendation: weak).

- *iii.* We suggest not thawing FMT in warm water baths, due to the risks of cross
 263 contamination with *Pseudomonas* (and other contaminants) and reduced bacterial
 264 viability (*GRADE of evidence: very low; strength of recommendation: weak*).
 265
 - 266 2.2.5. What factors related to administration of the transplant influence the outcome of
 267 faecal microbiota transplant when treating people with *Clostridium difficile* 268 infection?
 - **2.2.5.1.** Use of specific medications in the period around FMT administration:
 - **2.2.5.1.1. General principles of FMT administration:**
- *i.* <u>We recommended that bowel</u> lavage should be administered prior to FMT via the
 lower GI route, and <u>that</u> bowel lavage should be considered prior to FMT via the
 upper GI route; polyethylene glycol preparation is preferred (*GRADE of evidence: low; strength of recommendation: strong*).
- *ii.* For upper GI FMT administration, <u>we suggest that</u> a proton pump inhibitor should be
 276 considered, e.g. the evening before and morning of delivery (*GRADE of evidence:*277 *low; strength of recommendation: weak*).
- iii. <u>We suggest that a</u> single dose of loperamide (or other anti-motility drugs) should be
 considered following lower GI FMT delivery (*GRADE of evidence: low; strength of recommendation: weak*).
- 36
37281*iv.*We suggest that prokinetics (such as metoclopramide) should be considered prior to37
38
40282FMT via the upper GI route (GRADE of evidence: low; strength of recommendation:
weak).
 - v. <u>We recommend that best</u> practice for prevention of further transmission of CDI
 should be applied throughout when administering FMT to patients with CDI (nursing
 with enteric precautions, sporicidal treatment of endoscope, etc) (*GRADE of evidence: high; strength of recommendation: strong*).

2.2.5.1.2. Additional antibiotics pre-FMT:

- 290 <u>We recommend the administration of</u> further antimicrobial treatment for CDI for at least 72
- 291 hours prior to FMT (GRADE of evidence: low; strength of recommendation: strong).

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1		HIS/ BSG FMT Guideline: Main Document, Gut version.
2 3	293	2.2.5.1.3. Washout period between antibiotic use and FMT:
4	294	<i>i.</i> To minimise any deleterious effect of antimicrobials on the FMT material, we
5 6	295	recommend that there should be a minimum washout period of 24 hours between the
7		
8 9	296	last dose of antibiotic and treatment with FMT (GRADE of evidence: low; strength of
10 11	297	recommendation: strong).
12	298	<i>ii.</i> <u>We suggest considering</u> consultation with infectious disease specialists or medical
13 14	299	microbiologists for advice whenever FMT recipients also have an indication for long-
15	300	term antibiotics, or have an indication for non-CDI antibiotics within eight weeks of FMT
16 17	301	(GRADE of evidence: very low; strength of recommendation: weak).
18 19	302	
20	303	2.2.5.2. Route of FMT delivery:
21 22		
23 24	304	2.2.5.2.1. Upper gastrointestinal tract administration of FMT:
25	305	<i>i.</i> <u>We recommend that upper</u> GI administration of FMT as treatment for recurrent or
26 27	306	refractory CDI should be used where clinically appropriate (GRADE of evidence: high;
28	307	strength of recommendation: strong).
29 30	308	<i>ii.</i> Where upper GI administration is considered most appropriate, <u>we recommend that</u>
31 32	309	FMT administration should be via nasogastric, nasoduodenal, or nasojejunal tube, or
33	310	alternatively via upper GI endoscopy. Administration via a permanent feeding tube
34 35	311	is also appropriate (GRADE of evidence: high; strength of recommendation: strong).
36 37	312	<i>iii.</i> <u>We recommend</u> that no more than 100ml of FMT is administered to the upper GI
38	313	tract (GRADE of evidence: low; strength of recommendation: strong).
39 40	314	<i>iv.</i> We recommend that upper GI administration of FMT should be used with caution in
41 42	315	those at risk of regurgitation and/ or those with swallowing disorders (GRADE of
43	316	evidence: low; strength of recommendation: strong).
44 45	317	
46		
47 48	318	2.2.5.2.2. Lower gastrointestinal tract administration of FMT:
49 50	319	<i>i.</i> <u>We recommend that colonoscopic</u> administration of FMT as treatment for recurrent
51	320	or refractory CDI should be used where appropriate (GRADE of evidence: high;
52 53	321	strength of recommendation: strong).
54 55		
56		
57 58		
59		https://mc.manus11.ptcontrol.com/gut

Page 88 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

- ii. Where colonoscopic administration is used, we suggest considering preferential delivery to the caecum or terminal ileum, as this appears to give the highest efficacy rate (GRADE of evidence: low; strength of recommendation: weak).
 - iii. We recommend that FMT via enema should be used as a lower GI option when delivery using colonoscopy or flexible sigmoidoscopy is not possible (GRADE of evidence: high; strength of recommendation: strong).

2.2.5.2.3. Capsulised FMT:

Capsulised FMT holds promise as a treatment option for recurrent CDI and we recommend that this should be offered to patients as a potential treatment modality where available. Capsule preparations should follow a standard protocol. Further evidence regarding optimal dosing and formulation is required (GRADE of evidence: high; strength of recommendation: strong).

2.2.6. What is the clinical effectiveness of FMT in treating conditions other than **Clostridium difficile infection?**

We do not currently recommended FMT as treatment for inflammatory bowel disease. Apart from CDI, there is insufficient evidence to recommend FMT for any other gastrointestinal or non-gastrointestinal disease (GRADE of evidence: moderate; strength of recommendation: strong).

2.2.7. <u>Basic requirements for implementing a FMT service:</u>

2.2.7.1. **General considerations:**

- The development of FMT centres should be encouraged (GRADE of evidence: very i. low; strength of recommendation: strong).
 - ii. We suggest that FMT centres should work to raise awareness about FMT as a treatment option amongst clinicians caring for patients with CDI, and provide training to relevant healthcare professionals on the practicalities of delivering an FMT service (GRADE of evidence: very low; strength of recommendation: weak).

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1		his bot full dudeline. Main bocument, du version.
2	. –	
3 4	352	2.2.7.2. Legal aspects and clinical governance:
5	353	In the UK, FMT must be manufactured in accordance with MHRA guidance for human
6 7	354	medicines regulation. When FMT is supplied on a named patient basis, within a single
8	355	organisation, a pharmacy exemption may be used, subject to ensuring proper governance
9 10	356	and traceability. All centres that are processing and distributing FMT should seek guidance
11 12	357	from the MHRA and where necessary obtain appropriate licenses prior to establishing an
13	358	FMT service. This is a legal requirement. In countries other than the UK, FMT should only
14 15	359	be manufactured following appropriate approval from the national authority of that country
16 17	360	(GRADE of evidence: very low; strength of recommendation: strong).
18	361	
19 20		
21	362	2.2.7.3. Multidisciplinary teams:
22 23	363	We recommend that a multidisciplinary team should be formed to deliver FMT services
24 25	364	(GRADE of evidence: very low; strength of recommendation: strong).
26	365	
27 28	366	2.2.7.4. Infrastructure:
29 30		
31	367	<u>We recommend utilisation of</u> suitable laboratory facilities and infrastructure for FMT
32 33	368	production (GRADE of evidence: very low; strength of recommendation: strong).
34	369	
35 36	370	2.2.7.5. FMT manufacturing:
37	371	We recommend ensuring the traceability of supply (GRADE of evidence: very low; strength
38 39	372	of recommendation: strong).
40 41	373	
42	274	2.2.7.6. FMT production quality control:
43 44	374	
45	375	We recommend monitoring, notification and investigation of all adverse events and
46 47	376	reactions related to FMT (GRADE of evidence: very low; strength of recommendation:
48 49	377	strong).
50	378	
51 52	379	2.2.7.7. Donor screening governance:
53	380	<u>We recommend ensuring the clinical governance of donor screening (GRADE of evidence:</u>
54 55		
56	381	very low; strength of recommendation: strong).
57 58		
59		https://mc.manuscriptcentral.com/gut

383 3. Introduction:

The aim of the BSG/ HIS FMT working group was to establish a guideline that defined best practice in all aspects of a FMT service, by providing evidence-based recommendations wherever possible, and consensus multi-disciplinary expert opinion where specific published evidence is currently lacking. This included the evaluation of the use of FMT in the treatment of *Clostridium difficile* infection (CDI; also referred to as *Clostridioides difficile*¹), and also in potential non-CDI indications. Relevant guidance published to date includes the interventional procedure guidance from the National Institute for Health and Care Excellence (NICE)², UK, European and US microbiological guidelines on the treatment of *Clostridium difficile* infection (CDI)³⁻⁵, and recent expert consensus documents on FMT in clinical practice^{6,7}. Furthermore, there have also been national recommendations regarding FMT produced by working groups in several different countries^{8–10}. Principally as a result of randomised studies that have been published in recent years^{11–18}, FMT has become an accepted treatment for recurrent/refractory CDI.

397 The unique remit and objectives of this guideline when commissioned by the BSG and HIS was:

i. To review the rapidly-growing body of randomised trial evidence for the efficacy of FMT in the treatment of adults (\geq 18 years), both in CDI and in other clinical conditions, much of which has been published after the publication of current CDI treatment algorithms^{3,4}.

401 ii. To provide specific guidance about best practice for an FMT service within the context of the
 402 regulatory framework for the intervention as it currently exists in the UK^{19,20}.

The elucidation of the mechanisms underlying the efficacy of FMT in treating CDI remains an active area of global research, with the aim of rationalising FMT from its current crude form to a more targeted, refined therapeutic modality²¹. Previous research has demonstrated that commensal bacteria cultured from the stool of healthy donors²², sterile faecal filtrate²³, and/ or spores of *Firmicutes* derived from ethanol-treated stool from healthy donors²⁴, may have similar efficacy to conventional FMT in treating CDI, although results of the latter approach produced disappointing outcome data when extended to a Phase II clinical trial²⁵. For the purposes of this guideline, the BSG/HIS working group considered only studies that used the administration of manipulated whole stool (including encapsulated faeces). They deemed studies using cultured microorganisms (or their

https://mc.manuscriptcentral.com/gut

 HIS/ BSG FMT Guideline: Main Document, Gut version.

proteins, metabolites or other components), or microbiota suspensions, to be in the pre-clinicalresearch stage, without firm evidence.

FMT has been shown to be very acceptable to patients, both in the setting of CDI^{11,26} and in non-CDI settings, e.g. ulcerative colitis²⁷. However, the absence of appropriate protocols^{28–31} specifically taking into account UK clinical practice and regulation of FMT has been perceived as a barrier to the use of FMT in the UK and Ireland; these guidelines seek to rectify this problem.

421 4. Guideline development:

422 4.1. Guideline development team

BSG and HIS commissioned the authors to undertake the Working Party Report. The authors represent the membership of both societies. The working group included gastroenterologists, infectious diseases/microbiology clinicians, a clinical scientist, a systematic reviewer, and patient representatives. The views expressed in this publication are those of the authors, and have been endorsed by BSG and HIS following consultation.

429 4.2. Scope of the guidelines

The main scope of the guidelines is to provide guidance for the optimal provision of an effective and safe FMT service, principally for recurrent or refractory CDI, but non-CDI indications are also considered. These guidelines only apply to adult patients (≥18 years); the working party did not consider the role of FMT in the treatment of either CDI or non-CDI indications in children or young people. The guidelines were written with a focus upon UK practice, but also with consideration of more global practice as it applied. The diagnosis and management of *Clostridium difficile* infection in general are outside the remit of these guidelines.

4.3. Evidence appraisal

Questions for review were derived from the Working Party Group, which included patient
representatives in accordance with the PICO process³². To prepare these recommendations, the
working group collectively reviewed relevant peer-reviewed research.

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

4.4. Data sources and search strategy

A systematic literature search was undertaken using MEDLINE, EMBASE databases and Cochrane Library for relevant articles published from 1st January 1980 to 1st January 2018. The MEDLINE and EMBASE strategy are shown in **Supplementary Material 1, Appendix 2ii**. Free text and MESH/ index terms for faecal microbial transplant and *Clostridium difficile* or other diseases of interest were In addition, conference proceedings from microbiology, infectious disease, and combined. gastroenterology conferences were also searched to identify additional studies.

4.5. Study eligibility and selection criteria

The members of the guideline group determined criteria for study inclusion. Two reviewers (BHM, MNQ) screened the titles and abstracts of each article for relevance independently; any disagreements were resolved by discussion with a third reviewer (JPS). Copies of relevant articles were obtained and assessed for inclusion as evidence in the guideline by all three reviewers. The reason for not selecting studies was recorded. Only articles published in English and human clinical studies were included. For evidence on FMT for CDI, both randomised studies (including randomised controlled trials (RCTs)) and case series with at least 10 patients were selected. Only randomised trials were included as evidence for FMT for non-CDI indications. Conference abstracts were only included for CDI and non-CDI indications if they reported a randomised trial; where abstracts were available reporting data from a randomised trial that was subsequently published, only the published paper was reviewed. 4.

4.6. Data extraction and quality assessment

The initial search identified 2658 publications, and of these, 802 duplicates were excluded. 1856 studies were subsequently screened, from which 78 studies were assessed by reviewing the full text for eligibility (see Supplementary Material 1, Appendix 2iii and Supplementary Material 2, Additional Appendix D). Of these 78 studies, 58 studies were included as the basis of evidence for writing this guideline. In total, 39 were case studies in CDI including at least 10 patients (see Supplementary Material 2, Additional Appendix C.1), and ten were randomised studies in CDI (see Supplementary Material 2, Additional Appendix C.2). Nine were randomised trials for non-CDI indications (see Supplementary Material 2, Additional Appendix C.3). Data were extracted for patient demographics, disease characteristics, donor screening characteristics, stool preparation and administration, clinical outcomes and adverse events. The quality of randomised studies was

Page 93 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

Gut

assessed with the Cochrane Collaboration's risk of bias tool. Case series were assessed using theCentre for Reviews and Dissemination guidance.

4.7. Rating of evidence and recommendations

The BSG version of these guidelines was prepared in keeping with the BSG Clinical Services & Standards Committee (CSSC) advice document on the writing of clinical guidelines³³. Evidence tables were presented and discussed by the working group, and guidelines were prepared according to the nature and applicability of the evidence regarding efficacy and patient preference and acceptability. For the BSG version of this guideline, the GRADE system (Grades of Recommendation Assessment, Development and Evaluation)³⁴ was used to assess the strength of evidence (high/ moderate/ low/ very low) and strength of recommendation (strong/ weak) (Table 4). The section entitled 'Basic requirements for implementing an FMT service' (Supplementary Material 3) was based on expert opinion, since this was a key area of the working party's remit but not one amenable to evaluation by the PICO process. Face-to-face meetings and group teleconferences were held to agree on recommendations. Any disagreements on recommendations or the strength of recommendation were resolved by discussion and, where necessary, voting by the members of the working group, with consensus achieved when >80% were in agreement.

4.8. Consultation process

Feedback on draft guidelines was received from the Scientific Development Committee (SDC) of HIS, and changes made. These guidelines were then opened to consultation with relevant stakeholders (see **Supplementary Material 1, Appendix 3** of this document). The draft report was available on the HIS website for one month. Views were invited on format, content, local applicability, patient acceptability, and recommendations. The working group reviewed stakeholder comments, and collectively agreed revisions. Final changes were made after repeat reviews from HIS (Chair of the SDC and HIS Council) and BSG (BSG CSSC and BSG Council), and after further external peer review.

4.9. Guideline accreditation and scheduled review

503 The guidelines will be reviewed at least every four years and updated if change(s) in the evidence are 504 sufficient to require a change in practice.

Page 94 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

506 4.0. Additional information:

507 Additional information related to this guideline (including a lay summary, background on the 508 working party report, and information on the implementation of these guidelines) is contained 509 within **Supplementary Material 1, Section 1**.

5. <u>Rationale for recommendations:</u>

512 5.1. Which patients with *Clostridium difficile* infection should be considered for faecal 513 microbiota transplant, and how should they be followed up after treatment?

5.1.1. Prior to faecal microbiota transplant. Patient selection:

5.1.1.1. Recurrent *Clostridium difficile* infection:

As already described, there is widespread consensus that FMT is an efficacious treatment for recurrent CDI. In defining recurrent CDI, some studies have relied on a minimum threshold of return of clinical symptoms (e.g. at least three unformed bowel movements within 24 hours, for at least two consecutive days)^{12,18} following previous successful CDI treatment; most studies have also included a requirement for a positive microbiological test^{12,14,18,35-45}. Other studies explicitly state that a positive test was not required⁴⁶. Recommendations for CDI testing are beyond the scope of this guideline, and there are already well-established evidence-based guidelines⁴⁷. These recommend testing with either a nucleic acid amplification test (NAAT) or GDH assay, followed by detection of free toxin (either by toxin A/B enzyme immunoassay (EIA) or cytotoxin neutralisation assay), which allows differentiation of patients with active disease as well as those who are likely colonised⁴⁷. However, the working group discussed the importance of the accurate diagnosis of true recurrent CDI prior to consideration of FMT; in particular, they noted a study which observed that of 117 patients with presumed recurrent CDI referred for work-up for FMT, 25% (n=29/117) were determined to have a non-CDI diagnosis, with irritable bowel syndrome (n=18) and inflammatory bowel disease (n=3) being the most common alternative diagnoses, and younger patients more likely to be misdiagnosed⁴⁸.

All of the reviewed studies have included patients with recurrent CDI, however some studies offered FMT to patients at the first recurrence (second episode)^{12,15,16,18,35,37,42,43,46,49}, whereas others offered FMT after the second recurrence (third episode)^{13,14,39,41,44,45,50,51}. Some protocols offered FMT after three or more recurrences⁵², whilst others did not define the point at which it was adminstered^{40,53}.

Page 95 of 454

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

The severity of infection has been used as a parameter to decide at which stage FMT is offered. Youngster *et al.* offered FMT to patients with at least three episodes of mild to moderate CDI, or at least two episodes of severe CDI resulting in hospitalisation and associated with significant morbidity¹⁷. Another study selected patients for FMT using four categories of severity, which also accounted for prior anti-CDI therapy and requirement for hospitalisation⁵⁴.

None of the studies directly compared the efficacy of FMT according to the stage at which it was offered (i.e. first recurrence vs. \geq two recurrences). A small number of studies^{55–57} included patients with severe CDI (defined as hypoalbuminaemia with increased peripheral white cell count and/or abdominal tenderness) or complicated CDI (defined as admission to Intensive Care, altered mental status, hypotension, fever, ileus, white blood cell count $> 30 \times 10^9$ /l, lactate > 2.2mmol/l, or evidence of end organ damage). A single study described an apparent lower rate of treatment success when FMT was used to treat patients with recurrent CDI with disease caused by ribotype 027^{43} , but this is the case for all anti-CDI treatment modalities for this ribotype in comparison to others. The working group agreed that there was insufficient evidence to suggest that C. difficile ribotype should influence whether or not FMT is offered.

A lower primary cure rate was reported for complicated CDI (66%) compared with recurrent CDI (82%) and severe CDI (91%) in one study⁵⁵; in a case series of 17 patients who all had severe and/or complicated CDI, a primary cure rate of 88% was described⁵⁷. A cohort of 328 patients was analysed to determine which factors were associated with failure of FMT⁵⁸. Higher early (one month) failure rates were found in patients with severe (72%, n=19/25) or severe-complicated (52.9%, n=9/17) CDI than for recurrent CDI (11.9%, n=34/286). This study also identified that patients who were treated with FMT as an inpatient were nearly four times more likely to fail as those who had FMT as an outpatient; however, the working group noted that the authors of this study themselves identified that inpatient status is likely a proxy of severity of CDI and/or co-morbidities. A further similar study, including 64 patients treated with FMT as treatment for recurrent CDI, also identified severe CDI as the strongest independent risk factor for FMT failure on multivariate analysis⁵⁹.

567 The working group discussed their experience of treating patients with CDI whose disease fitted an 568 intermediate pattern to the typical descriptions given of recurrent or refractory CDI, e.g. patients 569 with CDI who have some (but incomplete) symptomatic improvement with anti-CDI antibiotics and 570 worsening of disease when these are stopped. The experience of the working group was that such

https://mc.manuscriptcentral.com/gut

571 patients experienced excellent responses to FMT, and that these patients should be considered for572 FMT.

As FMT is currently an unlicensed medicine with poorly-studied long term sequelae, the working group considered that it should generally be reserved for patients who have had three or more episodes of infection. There are no studies directly comparing its effectiveness with some of the newer agents such as fidaxomicin or bezlotoxumab, hence this recommendation is made on the basis of safety. However, the working group agreed that it may be reasonable in certain patient groups with ongoing risk factors for further recurrence to offer FMT after the second episode.

Recommendation:

582 <u>We recommend that</u> FMT should be offered to patients with recurrent CDI who have had 583 at least two recurrences, or those who have had one recurrence and have risk factors for 584 further episodes, including severe and severe-complicated CDI (GRADE of evidence: high; 585 strength of recommendation: strong).

5.1.1.2. Refractory *Clostridium difficile* infection:

Two randomised trials allowed the recruitment of patients with refractory CDI. The first defined this as at least three weeks of ongoing severe symptoms despite standard antimicrobial therapy for CDI¹⁷. The second required persistent or worsening diarrhoea and one of the following: ongoing abdominal pain, fever > 38°C, or white blood cell count > 15x 10⁹/l despite oral vancomycin at a dose of 500mg four times daily for at least five days¹⁶. Both studies included only small numbers of patients with refractory CDI (n=4/20 (20%) and n=15/219 (6.8%), respectively). There did not appear to be any significant difference in primary outcome measure (clinical cure) in patients with recurrent or refractory CDI, although neither study was designed to assess this difference. There are also a number of case series in which FMT was given to patients with refractory CDI; however, outcome measures were not reported for these groups individually in these studies^{37,38,54,60}.

599 Overall, the working group concluded that there is little consensus on the definition of refractory 600 CDI, with some studies using the terms 'refractory' and 'recurrent' interchangeably (as well as other 601 terms, e.g. 'salvage therapy'). Consequently, the quality of evidence for the utility of FMT in

 Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

refractory cases of CDI is lower than for recurrent CDI. The standardisation of definitions will allowmore robust comparison between patient cohorts.

Recommendation:

606 <u>We recommend that</u> FMT should be considered in cases of refractory CDI (GRADE of 607 evidence: moderate; strength of recommendation: strong).

5.1.1.3. FMT as initial therapy for *Clostridium difficile* infection:

Experience of the use of FMT as initial therapy for CDI is very limited. In a case series of patients with CDI with ribotype 027, use of anti-CDI antibiotics together with nasogastric FMT within a week of diagnosis during an initial episode of CDI was associated with reduced mortality when compared to using FMT only after the failure of three courses of antibiotics (mortality of 18.75% (n=3/16patients) vs 64.4% $(n=29/45 \text{ patients})^{61}$. However, 37.5% (n=6/16) of the patients treated with FMT within a week of CDI diagnosis required further antibiotics and a second FMT within one month of the first FMT because of relapse⁶¹. In a small pilot randomised trial, patients were randomised to either vancomycin or multi-donor FMT (administered either via upper or lower GI routes) as initial therapy for CDI; CDI resolution occurred in 88.9% (n=8/9) patients with vancomycin, compared to 57.1% of patients (n=4/7) patients with one FMT, and 71.4% of patients (n=5/7) after two FMTs 62 . Given the small size of these studies and equivocal results, the working group concluded that the reviewed studies did not support FMT as initial therapy for CDI.

Recommendation:

624 <u>We recommend that</u> FMT should not be administered as initial treatment for CDI (GRADE 625 of evidence: low; strength of recommendation: strong).

6275.1.1.4.Antimicrobial/ antitoxin therapy prior to considering FMT for patients with628CDI:

There are now at least two licensed agents (fidaxomicin and bezlotoxumab) which have been shown
 to significantly reduce the risk of recurrence compared with vancomycin^{63,64}. There is also some
 evidence that pulsed/tapered dosing of vancomycin and fidaxomicin (including pulsed fidaxomicin⁶⁵)
 results in fewer recurrences than with standard dosing of these agents^{66,67} (although this finding has

https://mc.manuscriptcentral.com/gut

633 not been replicated in all studies⁶⁸). Pre-planned subgroup analysis of patients with severe CDI in a 634 randomised trial demonstrated a significantly lower recurrence rate when treated with fidaxomicin 635 (13.0%, n=12/92) than when treated with vancomycin (26.6%, n=29/209)⁶³; this finding was 636 replicated in another randomised controlled trial, with 8.3% (n=4/48) and 32.6% (n=14/43) 637 experiencing a recurrence respectively⁶⁹. In a further randomised trial, bezlotoxumab (together with 638 standard of care antibiotics) was shown to reduce recurrence of severe CDI compared to standard of 639 care antibiotics alone (10.9% (n=6/55) vs 20% (n=13/65) respectively)⁶⁴.

As discussed above, the working group noted that there are no studies comparing FMT to fidaxomicin or bezlotoxumab, and only one study comparing a vancomycin taper to FMT¹². The working group agreed that in the absence of this evidence, on the balance of safety and potential risks, consideration should be given to using antimicrobial/antitoxin therapy associated with reduced CDI recurrence prior to considering the use of FMT.

Several studies specify that patients should be treated with anti-*C. difficile* antibiotics for a minimum
 period of 10 days before diagnosing recurrent CDI and offering FMT^{12,15,16,18}.

Recommendations:

- *i.* <u>We recommend that</u> FMT for recurrent CDI should only be considered after
 recurrence of symptoms following resolution of an episode of CDI that was treated with appropriate antimicrobials for at least 10 days (GRADE of evidence: low; strength of recommendation: strong).
- 655 ii. <u>We recommend consideration of</u> treatment with extended/ pulsed vancomycin
 656 and/or fidaxomicin before considering FMT as treatment for recurrent CDI (GRADE
 657 of evidence: low; strength of recommendation: strong).
- For those with severe or complicated CDI, which appears to be associated with
 reduced cure rates, <u>we recommend that</u> consideration should be given to offering
 patients treatment with medications which are associated with reduced risk of
 recurrence (e.g. fidaxomicin and bezlotoxumab), before offering FMT (GRADE of
 evidence: low; strength of recommendation: strong).

5.1.2. Post-FMT follow-up, outcomes and adverse events:

5.1.2.1. Management of FMT failure:

Page 99 of 454

 Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

Where patients were deemed not to have responded to an initial FMT, many studies have offered repeat FMT and success rates have been excellent even in patients with modest response to a first FMT^{14,15,17,18,35,43,46,51,54,70,71}. The success of a second FMT appears to be high whether treatment failure represents non-response to the first FMT, or a late failure (i.e. further relapse of CDI after an initial response); however, these terms have been defined variably between different studies (also see Section 5.1.2.5). Second FMTs have been offered as soon as 24-72 hours after an initial FMT for presumed non-response^{37,72,73}. For FMT failure in patients with pseudomembranous colitis, repeat FMT every three days until resolution of pseudomembranes has been a successful approach¹⁸. Good outcomes in pseudomembranous disease have also been achieved through a protocol that routinely restarted five days of vancomycin if FMT failed, before offering another FMT⁷³. Other studies have demonstrated potential success in treating initial FMT failure with further antibiotics, including repeat FMT with vancomycin between procedures⁴², or anti-CDI antibiotics alone^{35,42,43,45,51,70,71}. Patients unresponsive to two FMTs have been offered further FMT or antibiotic therapy¹⁶, or even the administration of intravenous immunoglobulin³⁵. Whilst the working group collectively agreed that there was strong evidence to recommend repeat FMT after initial FMT failure, they were not able to recommend a specific protocol for administering repeat FMT and/ or maximum number of FMTs, given the wide heterogeneity of approach described within the reviewed literature.

Recommendation:

- We recommend that FMT should be offered after initial FMT failure (GRADE of evidence:
- high; strength of recommendation: strong).

5.1.2.2. General approach to follow-up post-FMT:

Follow-up post-FMT (in terms of duration, modality and regimen for follow-up) varies considerably between studies, and is largely dependent upon study design. Follow-up regimens vary not only between studies but within them too, reflecting the retrospective nature of many early FMT studies in CDI, where follow-up mostly reflected pragmatic routine clinical care.

review^{14,43,58,71,74–76} included Modalities of follow-up have outpatient telephone interview^{17,39,43,46,58,71,74} and case note/ database review^{35,39,70,71,74,40,42,43,45,46,49,51,54}. Follow-up duration has varied from 60 days⁴⁵ to 8 years³⁶, with very different durations used in each study. Once again, however, this variability in follow-up largely reflects the retrospective analysis of case

https://mc.manuscriptcentral.com/gut

series rather than being justified by any specific methodology. The working group decided by
consensus that at least eight weeks of follow-up was appropriate post-FMT to fully assess efficacy
and potential adverse events; this figure was also influenced by discussions regarding the timepoint
after FMT at which a decision could be made regarding cure/ remission of CDI (see Section 5.1.2.4).

Recommendation:

704 <u>We recommend that all</u> FMT recipients should routinely receive follow-up. Clinicians 705 should follow-up FMT recipients for long enough to fully establish efficacy/adverse events, 706 and for at least eight weeks in total (GRADE of evidence: low; strength of 707 recommendation: strong).

5.1.2.3. Management of the FMT recipient:

Procedural adverse events during administration of FMT have predominantly occurred with colonoscopic administration of FMT. These have included mild nausea and vomiting attributed to sedation for the colonoscopy, minor mucosal tears during colonoscopy^{49,60}, and microperforation following biopsy of an area of presumed ischaemic small bowel injury in a patient with chronically dilated small bowel (which resolved with conservative management⁴⁶). One death occurred due to witnessed aspiration at the time of colonoscopy⁶⁰. Faecal regurgitation and vomiting with temporal association to upper GI FMT administration has also been described (discussed further in Section **5.5.2.2**)⁷⁷.

The predominant short term adverse events post-FMT for CDI are mild: self-limiting GI symptoms have been the most frequently reported adverse events. These may be related to the route of administration and include belching¹⁵, nausea^{15,16,49,60}, abdominal cramps/ discomfort/ bloating/ pain^{15,18,49,60,72}, and diarrhoea^{15,16,18,60}. One patient with a history of autonomic dysfunction experienced dizziness with diarrhoea after FMT¹⁵. These symptoms are typically short-lived, resolving in hours to days^{15,16,18,49,72}. Minor subsequent adverse events have included a range of GI abdominal discomfort^{14,17,57,76}, nausea^{14,49,70}. side effects including self-limiting flatulence^{14,16,17,41,42,49,57}, self-limiting irregular bowel movements⁴¹, *C. difficile*-toxin negative diarrhoea^{52,55}, constipation^{14,15,42,55,70} and constitutional symptoms/ temperature disturbance^{14,17}.

https://mc.manuscriptcentral.com/gut

 Gut

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

As such, immediately post-endoscopic administration of FMT, most FMT centres typically manage patients using standard protocols for an endoscopic procedure^{41,49}, without any specific adaptations (apart from to reiterate advice about the possibility of self-limiting GI side effects, and the use of departmental infection control protocols). There is often a relatively short period of post-procedural observation^{15,18}. Most studies allow patients to leave the administration site after the period of observation, although overnight observation was the protocol used for a cohort of very elderly patients with multiple comorbidities⁵¹. Where enteral tube administration is used, post-procedure management has ranged between removal of the tube after 30 minutes (following nasoenteral administration of 500ml of FMT¹⁵) to prompt post-procedure removal and oral water administration (after nasogastric administration of 90ml of FMT⁷²), with no direct adverse outcomes in either case. The working group felt that removal of the tube at 30 minutes, with administration of water at this point, was a pragmatic approach.

The definition of post-FMT serious adverse events has varied between studies, but has included significant morbidity necessitating hospital admission and death in the follow up period. Many of these events are described as not directly caused by the FMT, including the scenario of post-FMT severe CDI recurrences⁷² and probable or certain CDI-related deaths^{16,60,70} occurring in the context of FMT failure, or deaths related to patient comorbidities^{17,55}. One patient was admitted to hospital with self-limiting abdominal pain post-FMT⁶⁰, and four patients with flares of inflammatory bowel disease⁶⁰. Three patients underwent colectomy during the post-FMT follow-up period, with all related to ulcerative colitis and not believed to be due to CDI⁶⁰. Other reported serious adverse events include recurrent urinary tract infection¹⁵, fever during haemodialysis¹⁵ and upper gastrointestinal haemorrhage after nasogastric FMT (in a patient taking NSAIDs⁵¹), none of which were thought to be strongly linked to FMT. There have also been a number of new onset autoimmune, inflammatory and metabolic conditions described post-FMT, although these have been described from single centres only, with these findings not replicated elsewhere. Such conditions include microscopic colitis, Sjögren's syndrome, follicular lymphoma, peripheral neuropathy, immune thrombocytopenia and rheumatoid arthritis^{53,55}.

758 Significant adverse events are therefore rare but well-described. Furthermore, the procedure is 759 relatively novel, and longer-term follow-up data regarding safety are required. Therefore, the 760 working group opined that formal follow-up post-FMT to assess outcome and possible adverse 761 events is essential.

2
2
3
4
5
6
7
/
8
9
10
11
11
12
13
14
15
16
17
17
18
19
20
21
21
2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 7 8 9 10 11 2 3 4 5 7 8 9 10 11 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
23
24
25
26
27
2/
28
29
30
31
27
52
33
31 32 33 34 35 36 37 38
35
36
27
3/
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
J∠ 52
53
54
55
56

762

1

763 The use of questionnaires to compare symptoms pre- and post-FMT is common. Specifically, data collected have included clinical response to symptom severity⁵⁵, stool frequency^{15,17,46,55,57,72}, stool 764 consistency^{14,15,72}, abdominal pain or tenderness^{55,57}, rating of gastrointestinal symptoms⁷², general 765 well-being^{55,72}, days to improvement post-FMT⁵⁷, weight change⁷², functional status⁵⁵, and changes 766 in medication/use of antibiotics^{57,72}. Additionally, certain patients have been given specific advice 767 post-FMT to contact their clinical team if there is recurrence of diarrhoea or symptoms^{14,35,41,43}. 768 769 Where patients underwent outpatient clinical evaluation, this was generally undertaken relatively early post-FMT^{39,52,76}. In one study, patients were additionally given instructions for cleaning and 770 disinfection at home, with the aim of reducing the possibility of *C. difficile* reinfection⁴³, and 771 counselling on the risk of recurrent CDI with future antibiotic courses⁷⁶. 772

Gut

773

774 *Recommendations:*

- 775 i. <u>We recommend that immediate</u> management after endoscopic administration of
 776 FMT should be as per endoscopy unit protocol (GRADE of evidence: very low:
 777 strength of recommendation: strong).
- ii. <u>We recommend that patients</u> should be warned about short term adverse events,
 in particular the possibility of self-limiting GI symptoms. They should be advised
 that serious adverse events are rare (GRADE of evidence: very low; strength of
 recommendation: strong).
- 782 iii. After enteral tube administration, <u>we recommend that</u> patients may have the tube
 783 removed and oral water given from 30 minutes post-administration (GRADE of
 784 evidence: very low; strength of recommendation: strong).

57 58 59

60

785

786 **5.1.2.4. Definition of cure post-FMT for CDI**:

1787 It is recognised that symptoms of CDI resolve relatively promptly post-successful FMT, although this
has been variably described (within hours in some studies⁵², at an average of 4-5 days in others^{57,71}).
Treatment success post-FMT for CDI has no uniformly-agreed definition, with the time point at
which cure/ remission is defined on clinical grounds varying between 3-5 days³⁶ up to six months⁴².
A consensus document from the USA recommends 'resolution of symptoms as a primary end point;
absence within eight weeks of FMT as a secondary end point'⁷⁸. The working group recommended
that this definition should be made on a case-by-case basis; however, they agreed that an

Page 103 of 454

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

assessment for cure/ remission of CDI within eight weeks post-FMT was reasonable in most cases,
and therefore that this was also a reasonable minimum length of time to undertake follow-up postFMT (see Section 5.1.2.2).

Recommendation:

799 <u>We recommend that a</u> decision regarding cure/remission from CDI should be recorded 800 during follow-up. However, this has no uniformly-agreed definition, and should be 801 decided on a case-by-case basis (GRADE of evidence: very low; strength of 802 recommendation: strong).

5.1.2.5. Definition of treatment failure post-FMT for CDI:

There is no uniformly-agreed definition of treatment failure/recurrence post-FMT for CDI, with varied definitions used in studies. The use of C. difficile toxin as a marker of treatment success or failure is variable, with some studies opting not to test for CDT unless symptoms consistent with CDI recurred^{49,52–54,60,72,74}. Some studies have routinely performed CDT testing without specifying any action taken after a positive result^{14,15,18,36,39,41}, whilst others have tested for *C. difficile* PCR but relied on clinical criteria (even if PCR was positive) post-FMT for evaluating FMT efficacy¹⁴. A recent prospective study from the USA identified that only 3% (3/129) of patients who were asymptomatic at four weeks post-FMT for recurrent CDI had positive C. difficile PCR, again emphasising that symptoms rather than laboratory assays are more useful contributors to establishing FMT success⁷⁹.

Recommendation:

816 <u>We recommend that treatment</u> failure/recurrence should be defined on a case-by-case 817 basis. Routine testing for C. difficile toxin after FMT is not recommended, but it is 818 appropriate to consider in the case of persistent CDI symptoms/suspected relapse (GRADE 819 of evidence: low; strength of recommendation: strong).

5.2. What recipient factors influence the outcome of faecal microbiota transplant when treating people with *Clostridium difficile* infection?

5.2.1. General approach to co-morbidities and FMT:

824 Most published studies had a core set of general recipient exclusions which included: significant/ 825 anaphylactic food allergy^{14,17}, pregnancy^{12–15,17,18}, breastfeeding¹⁴, admission to Intensive Care or the

https://mc.manuscriptcentral.com/gut

Page 104 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

requirement for vasopressors^{12,15,18}, chronic diarrhoea or other infectious cause of diarrhoea^{12,14,18,50},
 inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)^{14,36}, immunodeficiency due to
 recent chemotherapy and/ or neutropenia^{12,14–18,50}, HIV/AIDS^{14,17,18}, prolonged use of
 corticosteroids^{15,17,18}, graft versus host disease¹², and decompensated cirrhosis^{14,15,17,18}.

The working group discussed the reported practice of several centres of treating patients with recurrent CDI and food allergies through the use of FMT prepared from a patient-directed donor instructed to avoid trigger foods before stool donation. They agreed that this seemed reasonable for patients with true adverse immunological reactions to defined food groups (e.g. gluten-free diet donor for a recipient with coeliac disease). However, the working group noted that food allergies are often poorly-defined clinically, and also expressed concerns that there was no means to verify how closely a donor had followed an exclusion diet; as such, they felt unable to make any specific recommendation about FMT in patients with food allergies in general. In contrast, whilst the working group were unaware of any reports in the literature of anaphylaxis attributable to FMT, they felt that the theoretical risk of a serious adverse outcome in patients with anaphylactic food allergy merited a specific recommendation that such individuals should not be offered FMT. Similarly, the working group expressed concern about the theoretical risk of adverse outcomes when administering FMT to patients with advanced decompensated chronic liver disease (including translocation of microbial material from the intestinal tract into the portal and systemic circulations, and theoretical risk of sepsis), and felt that FMT should be used with caution in this patient group.

Recommendations:

i. <u>We recommend that</u> FMT should be avoided in those with anaphylactic food allergy
 (GRADE of evidence: very low; strength of recommendation: strong).

ii. <u>We suggest that</u> FMT should be offered with caution to patients with CDI and decompensated chronic liver disease (GRADE of evidence: very low; strength of recommendation: weak).

5.2.2. Immunosuppression and FMT:

855 One randomised study¹⁶ included patients with immunodeficiency (treatment with 856 immunosuppressive therapy (azathioprine, ciclosporin, infliximab, methotrexate alone, or in 857 combination with corticosteroids) (n=18), renal transplant (n=5), chronic haemodialysis (n=5), solid 858 organ tumours (n=3) and haematological malignancy (n=4)) at the time of FMT. Clinical resolution Page 105 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

rates after up to two FMTs were high: 27/29 (93%) for immunocompromised individuals, 5/6 (83%)
for patients with IBD.

Gut

There are also limited data from case series and single case reports describing the use of FMT in patients with immunocompromise. Agrawal and colleagues⁵⁵ included 46/146 (32%) patients with a history of cancer, and an additional 15/146 (10%) patients with non-cancer-related immunologic dysfunction, although primary outcome measures were not specifically reported for these groups. Overall cure at 12 weeks in a case series of 80 patients with immunocompromise was reported in 71 (89%) of patients⁶⁰. Adverse events occurred in 12 (15%) immunocompromised patients; this included two deaths (one due to respiratory failure and another due to pneumonia resulting from aspiration at the time of FMT administration)⁶⁰; however, such adverse events have also been reported in non-immunocompromised patient populations⁸⁰. Hefazi and coauthors described high efficacy rates in a case series of FMT for recurrent CDI and a range of haematological or solid organ malignancies (remission after one FMT in 11/12 with haematological patients, and 8/10 in solid organ malignancy patients). No significant FMT-related complications were reported⁸¹. A further case series⁴⁵ reported FMT treatment for 75 patients with recurrent CDI and found no significant difference in primary cure rates for patients with diabetes mellitus, malignancy, or steroid use in the preceding three months.

The working group discussed the potential impact of donor EBV and CMV status for the immunocompromised FMT recipient at risk of severe infection if exposed to these viruses. Their opinion was that such recipients should only receive FMT from donors with negative EBV and CMV status.

Recommendations:

- i. <u>We recommend that</u> FMT should be offered with caution to immunosuppressed
 patients, in whom FMT appears efficacious without significant additional adverse
 effects (GRADE of evidence: moderate; strength of recommendation: strong).
- ii. <u>We recommend that immunocompromised</u> FMT recipients at risk of severe infection if
 exposed to EBV or CMV should only receive FMT from donors negative for EBV and
 CMV (GRADE of evidence: very low; strength of recommendation: strong).

5.2.3. Other comorbidities and FMT:

Only a limited number of cited studies included specific detail about the presence of comorbidities in patients receiving FMT. However, several studies reported median Charlson comorbidity scores^{12,14,15,18,50}. One randomised study reported the presence of IBD in 10/17 (59%) FMT recipients¹⁶, and there did not appear to be any significant difference in primary outcome measures in this group. Another randomised trial included 14/72 (33%) patients with IBD and reported clinical cure of CDI in 12/14 (86%) of these patients¹³. This study also included 64/72 (89%) patients with cardiac, respiratory, renal, central nervous system or multi-organ system comorbidities¹³; however outcomes were not stratified according to co-morbidity. Kelly and coauthors⁶⁰ reported an overall cure rate of 94% in a subset of CDI patients with IBD. A meta-analysis of studies in which patients with IBD received FMT (either primarily as treatment for concurrent recurrent CDI, or with the aim of treating IBD) noted a small risk of exacerbation of IBD in association with the use of FMT⁸². The working group noted the complexity of the relationship between IBD and CDI, given that IBD is itself a risk factor for CDI.

Gut

906 Other exclusions have been more directly related to the mode of administration. For upper 907 gastrointestinal delivery, exclusion criteria have included delayed gastric emptying, chronic 908 aspiration, 'swallow dysfunction', and dysphagia^{17,50}. Exclusions for lower GI administration have 909 included colostomy/ileostomy^{16,50}, significant bleeding disorders¹², untreated colorectal cancer^{14,36,54}, 910 and ileus/small bowel obstruction⁵⁰.

912 In summary, the working group noted that co-morbidities amongst patients with recurrent CDI are 913 common. Most studies did not analyse primary outcome measures according to co-morbidity; 914 however, a small number of studies have analysed primary outcome measures (clinical cure) for 915 patients with IBD receiving FMT for recurrent CDI and have found no significant difference compared 916 to those without IBD, along with no overall significant worsening of IBD activity.

Recommendations:

919i.We recommend thatFMT should be offered to those with recurrent CDI and920inflammatory bowel disease, but patients should be counselled about a small but921recognised risk of exacerbation of IBD (GRADE of evidence: moderate; strength of922recommendation: strong).

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

923ii.We recommend thatFMT should be considered for appropriate patients with924recurrent CDI regardless of other comorbidities (GRADE of evidence: moderate;925strength of recommendation: strong).

927 5.3. What donor factors influence the outcome of faecal microbiota transplant when 928 treating people with *Clostridium difficile* infection?

5.3.1. General approach to donor selection:

Excellent efficacy has been shown in treating recurrent CDI using FMT derived from both related^{14,36,54,57,59,61,83,38,40,41,43,45,46,49,53} and unrelated^{14,15,57,59,61,72,74,83–87,16,17,35,37,38,41,43,53} donors. To date, there have been no randomised studies comparing differences in efficacy. Case series have tended to rely more on donation of stool from healthy family members. In randomised studies using FMT, all donors were healthy unrelated individuals^{12–18,88}. Three case series used donor stool from healthcare professionals^{39,61,85}; no randomised studies have used stool from this cohort. However, the working group noted that there were clear advantages to using FMT from a screened anonymous donor, in particular with regards to monitoring and traceability, as discussed further later.

Recommendation:

941 <u>We recommend that related</u> or unrelated donors should both be considered acceptable. 942 However, where possible, FMT is best sourced from a centralised stool bank, from a 943 healthy unrelated donor (GRADE of evidence: low; strength of recommendation: strong).

5.3.2. Age and BMI restrictions for potential donors:

There are no well-defined age restrictions on donors. Randomised studies have used donors of $\geq 18^{12,72}$ and ≤ 60 years old^{15,17,18} with satisfactory outcomes. Two of the case series defined age limitations for donors as ≥ 18 and ≤ 50 years^{72,89}. A recent study demonstrated that *Bacteroides: Firmicutes* ratio and microbial diversity was similar for donors above and below 60 years, and their stool donations had similar clinical efficacy as FMT; however, there were loss of the phylum *Actinobacteria* and family *Bifidobactericeae* from donors older than 60 years⁹⁰. On balance, the working group agreed that an age range of 18 - 60 years was appropriate for donors.

A widely-reported case study noted apparent weight gain in a recipient of FMT for treatment of CDI when an overweight donor was used⁹¹, but any association between a donor with a raised BMI and weight gain post-FMT has not been replicated elsewhere in the literature⁹². Whereas most randomised studies did not report donor-specific BMIs, some have excluded those without a 'normal' BMI^{13,17}. The working group considered an acceptable BMI for donors as between \geq 18 to \leq 30 kg/m².

Gut

Recommendation:

962 <u>We suggest that people</u> should only be considered as potential FMT donors if they are \geq 18 963 and \leq 60 years old, and have a BMI of \geq 18 and \leq 30 kg/m² (GRADE of evidence: low; 964 strength of recommendation: weak).

5.3.3. General approach to the donor screening assessment:

There is a clear theoretical risk of the transmission of infection by FMT; furthermore, given the large number of conditions in which perturbation of the gut microbiota has been described⁹³, there is a concern regarding a risk of transmission of microbiota associated with vulnerability to disease. Whilst FMT is efficacious for recurrent CDI, adverse events may be associated with its use (discussed further later), and long-term safety follow-up is lacking. The aim of a donor screening questionnaire and interview is to minimise post-FMT adverse events by excluding potential donors from whom FMT may be associated with risk to recipients. Randomised studies performed to date used various pre-screening questionnaires, including self-screening questionnaires which focused on high risk behaviours for blood-borne infections^{12–16}, guestionnaires that focused on previous potential transferable medical conditions¹⁸, and adaptations from the American Association of Blood Banks Donor Questionnaire^{14,17}. One randomised study used the OpenBiome questionnaire as a screening questionnaire⁹⁴. Some studies have suggested excluding potential donors who have recently travelled to defined regions (typically tropical areas), varying between 3-6 months prior to donation^{38,39,49,52,55,59,74,87}; this is also the protocol employed in randomised studies^{14,16,18}. Another important point for assessment is recent use of medications by potential donors. In particular, given the profound effects of antimicrobials on the gut microbiota^{95–98} (along with the theoretical concern that recent antimicrobials might precipitate gut colonisation with antimicrobial-resistant bacteria that could be transferred during FMT), studies advocate either a three month^{14,46,53–55,57,61,74} or six month^{16–18,35,38,39,43,49,85,99,100} period without antimicrobial use prior to FMT donation.

Page 109 of 454

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

The working group agreed that, given the growing evidence for the contribution of the gut microbiota to the aetiopathogenesis of colorectal carcinoma, patients with a significant personal or family history of (or risk factors for) this condition should be excluded as donors (**Table 1**). However, the working group noted an added complexity, in that their recommendation was that potential donors may be up to 60 years of age, but bowel scope screening for colorectal carcinoma currently begins within the UK at 55 years of age, and formal NHS bowel cancer screening starts at the age of 60 years¹⁰¹. The working group agreed that potential donors living in countries with bowel cancer screening programmes that start before the age of 60 years should have therefore completed appropriate screening with negative/ normal tests before they are considered further as donors.

997 The working group was of the opinion that a screening process is mandatory; any positive responses 998 should usually result in exclusion from donation, although this will depend upon the particular 999 circumstances/ answers given. A donor screening questionnaire should be performed both prior to 1000 considering a person as a donor, and also at a further point in time (discussed further in **Section 5.3.5**).

Recommendation:

1004It is mandatory to screen potential donors by questionnaire and personal interview, to1005establish risk factors for transmissible diseases and factors influencing the gut microbiota

1006 (Table 1) (GRADE of evidence: low; strength of recommendation: strong).

5.3.4. Laboratory screening of potential donors:

Currently, there are no known confirmed cases of blood-borne pathogens being transmitted by FMT, but strict preventative measures are important, as the potential risk of transmission is unknown. Many of the suggestions are extended from established blood screening guidelines¹⁰². Case series almost universally screen for HIV, hepatitis B and hepatitis C as a minimum^{35,36,52-} ^{55,59,61,72,74,84,86,37,87,103,39–43,46,49}; other studies (including the randomised trials) have a more thorough blood screening process^{14–18}. Many studies have also included a 'metabolic/general blood screen', to select out donors with hitherto undiagnosed chronic illness. Table 2 shows the suggested blood screening protocol of the BSG/HIS working group.

https://mc.manuscriptcentral.com/gut

Page 110 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

2		
3 4	1017	
5	1018	The working group specifically discussed the role of screening donors for their EBV and CMV status;
6 7	1019	the importance of the rationale for this is discussed in Section 5.2.2. They agreed that EBV and CMV
8	1020	testing was only required where there is the potential that the FMT prepared from that donor would
9 10	1021	be administered to immunosuppressed patients at risk of severe infection if exposed to CMV and
11 12	1022	EBV.
12	1023	
14 15	1023	
16	1024	The primary aim of stool screening of potential donors is to minimise the risk of transmission of
17 18	1025	pathogens; again, the relative novelty of FMT for CDI means that these risks are not currently well-
19	1026	defined. Stool screening protocols are universal amongst published studies, though widely-variable
20 21	1027	protocols have been used. Table 3 displays the suggested stool screening protocol of the working
22 23	1028	group. The working group discussed stool screening for multi-drug resistant bacteria carriage, and
24	1029	agreed that carbapenemase-producing Enterobacteriaceae (CPE) should be screened for. Although
25 26	1030	these bacteria are carried only by a minority of the UK population, transfer into debilitated patients
27	1031	with CDI is clearly undesirable given that CPE are potentially so difficult to treat. They also agreed
28 29	1032	that extended-spectrum beta-lactamase (ESBL)-producing organisms could also potentially cause
30	1033	severe disease (with limited antimicrobial options) if transplanted into patients with CDI, and so
31 32	1034	should also be screened for. Whilst vancomycin-resistant Enterococci (VRE) carriage is relatively
33 34	1035	common in the community (probably related to food consumption) ¹⁰⁴ , community strains of VRE are
35	1036	genetically distinct from (and generally of much lower pathogenicity than) those found
36 37	1037	nosocomially ¹⁰⁵ ; as such, the working group thought that routine screening was not justified. The
38	1038	working group also noted that methicillin-resistant Staphylococcus aureus (MRSA) carriage is very
39 40	1039	rare in healthy adults in non-healthcare settings (with significant intestinal carriage even rarer), so
41	1040	did not justify routine screening. However, the working group acknowledged that the potential
42 43	1041	infection risk from VRE and MRSA would vary regionally dependent upon local prevalence and
44 45	1042	pathogenicity, and as such recommended that a risk assessment is performed to assess whether
46	1043	screening for these organisms should be considered.
47 48	1044	
49		
50 51	1045	A donor laboratory screening should be performed both prior to considering a person as a donor,
52	1046	and also at a further point in time (discussed further in Section 5.3.5).
53 54	1047	
55 56		
57	1048	Recommendation:
58 59		
60		https://mc.manuscriptcentral.com/gut

60

1

https://mc.manuscriptcentral.com/gut

Page 111 of 454

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1049 Blood and stool screening of donors is mandatory (Tables 2 and 3) (GRADE of evidence: 1050 low; strength of recommendation: strong).

5.3.5. Repeat donor checks, and donation pathway:

Almost all reviewed studies have repeated at least some elements of the initial donor screening process either at the time of donation of each stool sample used to prepare FMT, or at the end of a period of donation to assess ongoing suitability for inclusion. However, protocols have differed widely between studies.

The opinion of the working group was that when a donor had met criteria for donation (both with an acceptable health questionnaire and satisfactory laboratory tests), they were suitable to begin donation of stool that may be prepared into FMT. Repeat donor screening was also deemed necessary. In centres where frozen FMT is being prepared, stool may be collected and processed immediately after the first donor screen is successfully completed, but should be stored in 'quarantine' pending further donor screening, rather than used immediately for clinical use. At the end of the locally-defined period of donation, potential donors should undergo repeat testing, with a further health questionnaire and laboratory screening. If the donor's health questionnaire remains acceptable and repeat laboratory screening is negative at this point, then the frozen FMT may be released from 'quarantine', and used. The working group thought that donor screening both before and after donation was the safest route possible, and that this represented the preferred scenario. A proposed summary pathway for donor screening in this scenario is provided in Figure 1.

1071 In centres using fresh FMT, the working group agreed that a repeat health questionnaire should be 1072 completed at the time of donation of each stool sample used to prepare FMT. Formal repetition of 1073 both the personal interview/ health questionnaire and laboratory screening tests should occur at 1074 regular intervals to ensure ongoing suitability for inclusion as a donor. The working group's opinion 1075 was that this repetition of the screening process should occur at least once every four months.

Recommendations:

1078i. In centres using frozen FMT, before FMT may be used clinically, we recommend that1079donors should have successfully completed a donor health questionnaire and

1080Iaboratory screening assays both before and after the period of stool donation. This is1081the preferred means of donor screening (GRADE of evidence: low; strength of1082recommendation: strong).

ii. In centres using fresh FMT, we recommend that a repeat health questionnaire should
 be assessed at the time of each stool donation. To ensure ongoing suitability for
 inclusion as a donor, the donor health questionnaire and laboratory screening should
 be repeated regularly (GRADE of evidence: low; strength of recommendation: strong).

10885.4.What factors related to the preparation of the transplant influence the outcome of1089faecal microbiota transplant when treating people with Clostridium difficile1090infection?

5.4.1. General principles of FMT preparation:

There is very little evidence or guidance on the collection of donor stool. Critical steps during this process centre on the reduction of environmental cross-contamination risk, so the use of clean collection devices and clean collection procedures is advocated. To promote standardised practice and a safe and effective product, clear instructions should be provided to the donor for stool collection (**Table 5**).

1098 Regardless of the methods used to prepare FMT, stool donations should be processed within six 1099 hours of defaecation. The period of six hours has been generally applied across many successful 1100 studies of FMT treatment in CDI^{14,18,35,39,43,52}, although no formal comparative study has been 1101 undertaken. This strategy aims to minimise sample degradation and alteration over time, which may 1102 occur due to the complex metabolic and environmental requirements of the faecal microbiota.

1104 There are no comparative trials of anaerobically versus aerobically prepared FMT in the treatment of 1105 recurrent CDI. With the exception of small observational studies^{41,74}, the vast majority of FMT 1106 preparation has been undertaken aerobically for the treatment of CDI and has proved highly 1107 efficacious. There appears to be no clear need to process anaerobically, a method which introduces 1108 complexity and cost for the treatment of CDI.

 Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

The reviewed randomised studies reported variable amounts of stool used in the preparation of each FMT aliquot, and the lack of comparative data means that it is not possible to link stool mass to outcome from these studies. However, a previous systematic review of case series using FMT as treatment for recurrent CDI reported similar rates of treatment efficacy, but an approximate fourfold increase in recurrence rates, if <50g of stool was used compared to \geq 50g¹⁰⁶. Similarly, the initial volume of diluent used to create the faecal emulsion is variable between studies, although the most common practice appears to be creation of a stool: diluent ratio of approximately 1:5. The overwhelming majority of the reviewed studies used stool from only a single donor per FMT (rather than stool pooled from a mixture of donors), and there are no comparative studies of outcomes of CDI from single donor vs pooled donor FMT; as such, the working group found no justification to recommend donor stool pooling for FMT for CDI.

The majority of studies have used preservative-free sterile 0.9% saline as the diluent for FMT production, although there have been a handful of reports of other diluents including potable water^{16,35,43}. There have been no comparative studies of FMT diluent. In cases where frozen FMT is prepared, an appropriate cryoprotective substance should be added prior to freezing. Most studies use glycerol at a final concentration of $\sim 10\%^{16,41}$. It has been demonstrated that storing stool at -80°C for up to six months in saline without glycerol decreases viable aerobic and anaerobic bacterial counts; the reduction was statistically significant in all bacterial groups with the exception of E. coli and total anaerobes. When stored with glycerol, no significant reduction in viable counts was observed⁷⁴.

A variety of homogenisation and open filtration systems have been used, with no apparent major variation in efficacy. Open filtration systems such as gauze^{16,37,40,55}, filter paper³⁹ and strainers/ sieves^{17,41} are unpleasant to use and pose a risk of external contamination. In order to best comply with GMP standards, a sterile, single-use closed homogenisation and filtration system is recommended. An example of such a system includes the use of sterile filter bags inside a laboratory paddle homogeniser.

Recommendations:

i. We recommend that donor stool collection should follow a standard protocol (GRADE of evidence: low; strength of recommendation: strong).

Page 114 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

Gut

1		HIS/ BSG FMT Guideline: Main Document, Gut version.
2		
3 4	1142	<i>We recommend that donor stool should be processed within 6 hours of defaecation</i>
5	1143	(GRADE of evidence: low; strength of recommendation: strong).
6 7	1144	<i>iii.</i> <u>We recommend that both</u> aerobically and anaerobically prepared FMT treatments
8 9	1145	should be considered suitable when preparing FMT for the treatment of recurrent
9 10	1146	CDI (GRADE of evidence: moderate; strength of recommendation: strong).
11 12	1147	iv. <u>We recommend that sterile</u> 0.9% saline should be considered as an appropriate
13 14	1148	diluent for FMT production, and cryoprotectant such as glycerol should be added
15	1149	for frozen FMT (GRADE of evidence: moderate: strength of recommendation:
16 17	1150	strong).
18 19	1151	v. <u>We recommend using ≥50g of stool in each</u> FMT preparation (GRADE of evidence:
20	1152	moderate: strength of recommendation: strong).
21 22	1153	vi. <u>We suggest that stool</u> should be mixed 1:5 with diluent to make the initial faecal
23 24	1154	emulsion (GRADE of evidence: low; strength of recommendation: weak).
25 26	1155	vii. <u>We suggest that homogenisation</u> and filtration of FMT should be undertaken in a
27	1156	closed disposable system (GRADE of evidence: low; strength of recommendation:
28 29	1157	weak).
30 31	1158	
32 33	1159	5.4.2. Fresh vs frozen FMT:
34 35	1160	Two randomised studies have examined this area. One double-blind randomised study concluded
36 37	1161	that enema frozen FMT ($n=91$) was non-inferior for clinical resolution of diarrhoea to fresh FMT
38	1162	($n=87$) for the treatment of recurrent or refractory CDI ¹⁶ (with frozen FMT in this study stored at -
39 40	1163	20°C for up to 30 days). A further randomised study demonstrated statistically comparable
41 42	1164	remission rates for recurrent CDI with fresh or frozen FMT delivered colonoscopically ($n=25/25$ vs
43	1165	20/24 respectively, $p=0.233$) (using frozen FMT stored at -80°C for up to six months) ¹³ . These data
44 45	1166	support the findings of earlier small observational studies ^{35,41} . Frozen FMT is preferable to fresh FMT
46	1167	on logistical and cost grounds ¹⁶ . Banked frozen FMT also enables the window period for donor
47 48	1168	screening to be minimised, allowing centres to more closely to meet regulatory requirements (also
49 50	1169	see Section 5.3.5).
51	1170	
52		
53 54 55	1171	Recommendation:
54 55 56	1171	Recommendation:
54 55 56 57	1171	Recommendation:
54 55 56	1171	Recommendation: https://mc.manus28

Page 115 of 454

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

We recommend that the use of banked frozen FMT material should be considered preferable to fresh preparations for CDI (GRADE of evidence: high; strength of recommendation: strong). 5.4.3. Use of frozen FMT: Frozen FMT has been used up to six months after storage at -80°C^{17,41,74}, with high efficacy rates (>70%) observed in the cases treated. However, there have been no comparative trials investigating storage durations. A trend towards decrease in the viability of certain gut microbiota taxa was noted when faecal aliquots were frozen in 10% glycerol for six months⁷⁴, and as such, the working group agreed that six months was the acceptable limit for freezing of an FMT in glycerol. Storage at -80°C is recommended rather than -20°C to minimise sample degradation. Warm water baths have been recommended to speed thawing⁶; however, the working group thought that this should be strongly discouraged, as this may introduce risks of cross contamination by Pseudomonas species (and other contaminants) from the water bath^{107,108}, and may reduce bacterial viability in the FMT. Repetitive freeze thawing of FMT samples should be avoided as bacterial numbers will be reduced during this process¹⁰⁹. **Recommendations:** We recommend that FMT material stored frozen at -80°C should be regarded as i. having a maximum shelf life of six months from preparation (GRADE of evidence: low; strength of recommendation: strong). ii. We suggest consideration of thawing frozen FMT at ambient temperature, and using within six hours of thawing (GRADE of evidence: low; strength of recommendation: weak). iii. We suggest not thawing FMT in warm water baths, due to the risks of cross contamination with Pseudomonas (and other contaminants) and reduced bacterial viability (GRADE of evidence: very low; strength of recommendation: weak).

Page 116 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

12015.5.What factors related to administration of the transplant influence the outcome of1202faecal microbiota transplant when treating people with Clostridium difficile1203infection?

5.5.1. Use of specific medications in the period around FMT administration:

5.5.1.1. General principles of FMT administration:

Bowel purgatives have been proposed pre-FMT as a means of removing residual antibiotics that may affect engraftment of transplanted microorganisms, and as a means of removing any residual C. *difficile* toxin, spores and vegetative cells^{110–114}. Furthermore, bowel purgatives pre-colonoscopic FMT delivery facilitate safe endoscopy. Various bowel purgatives have been used in colonoscopic FMT studies, including polyethylene glycol (PEG) (often 4 litres)^{14,17,115–117,35,41,43,46,54–56,100}. MoviPrep^{®35,41}, and macrogol^{13,15,18,59}. In those studies that used an upper GI route for FMT, PEG^{54,55,84} and Klean-Prep^{®15,61} were used. FMT without bowel preparation has also been used as treatment for recurrent CDI without any apparent reduction in efficacy, including in randomised studies¹⁶.

The rationale for the use of proton pump inhibitors (PPI) prior to upper GI FMT is to minimise acidity
which may impair engraftment of transplanted microorganisms; however, PPIs have been shown to
alter the gut microbiota^{118,119}, and have also been associated with primary and recurrent CDI^{120,121}.
Some studies advocate the use of PPI prior to receiving FMT via the upper GI route^{37,39,45,84,85,122,123},
but there appears to be comparable efficacy data in studies where it has not been used. Certain
studies have also given recipients PPI prior to receiving colonoscopic FMT^{17,87}.

1223 The use of prokinetics (such as metoclopramide) has been described prior to FMT delivery via the 1224 upper GI tract route, but only in a very small number of studies⁸⁵. Given the potential risk of 1225 regurgitation/aspiration associated with upper GI administration of FMT, the working group felt that 1226 its use should be considered where appropriate.

A single dose/ short course of loperamide has been used following FMT (predominantly for lower GI administration) in an attempt to prolong the exposure of the FMT to the mucosa, and to aid retention of the FMT within the GI tract^{13,46,49,55,84,123}. One study utilised diphenoxylate with atropine⁵⁴ instead. However, no studies have compared FMT with and without anti-motility drugs. Page 117 of 454

1

60

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

2	1232	
4		
5	1233	The working group also discussed infection control aspects as they apply to FMT administration.
6 7	1234	Specifically, they agreed that recipients should ideally be cared for in a single room with en-suite
8 9	1235	bathroom facilities and, where appropriate, be placed at the end of an endoscopy list, to facilitate
9 10	1236	enhanced environmental decontamination and prevention of transmission of C. difficile spores.
11 12	1237	Protocols for decontamination of endoscopes should follow national guidance ^{124,125} , using a
13	1238	sporicidal agent. Best practice for prevention of transmission of healthcare-associated infections, as
14 15	1239	described in national guidelines ¹²⁶ , should also be applied throughout.
16 17	1240	
18 19	1241	Recommendations:
20	1242	<i>i. <u>We recommend that bowel</u> lavage should be administered prior to FMT via the</i>
21 22	1243	lower GI route, and bowel lavage should be considered prior to FMT via the upper
23		
24 25	1244	GI route; polyethylene glycol preparation is preferred (GRADE of evidence: low;
26	1245	strength of recommendation: strong).
27 28	1246	ii. For upper GI FMT administration, <u>we suggest that a</u> proton pump inhibitor should
29	1247	be considered, e.g. the evening before and morning of delivery (GRADE of
30 31	1248	evidence: low; strength of recommendation: weak).
32 33	1249	iii. <u>We suggest that a</u> single dose of loperamide (or other anti-motility drugs) should
34	1250	be considered following lower GI FMT delivery (GRADE of evidence: low; strength
35 36	1251	of recommendation: weak).
37 38	1252	iv. <u>We suggest that prokinetics</u> (such as metoclopramide) should be considered prior
39	1253	to FMT via the upper GI route (GRADE of evidence: low; strength of
40 41	1254	recommendation: weak).
42 43	1255	v. <u>We recommend that best</u> practice for prevention of further transmission of CDI
44	1256	should be applied throughout when administering FMT to patients with CDI
45 46	1257	(nursing with enteric precautions, sporicidal treatment of endoscope, etc) (GRADE
47 48	1258	of evidence: high; strength of recommendation: strong).
49	1259	
50 51		
52	1260	5.5.1.2. Additional antibiotics pre-FMT:
53 54	1261	Many studies have given further courses of conventional antimicrobial C. difficile treatment prior to
55	1262	FMT. Regimens have included vancomycin alone ^{12,14,18,35,39,55,59,86,117} , metronidazole or
56 57		
58		
59 60		https://mc.manuscriptcentral.com/gut

https://mc.manuscriptcentral.com/gut

vancomycin^{40,41,43,122}, or alternatively vancomycin, fidaxomicin or metronidazole⁵⁶, with one study
using a range of regimens which included rifaximin¹²³. The length of treatment was also variable,
ranging from 24 hours⁵⁴ up to four days prior to receiving FMT^{39,45}; however, comparative studies
have not been undertaken.

Recommendation:

1269 <u>We recommend the administration of</u> further antimicrobial treatment for CDI for at least
 1270 72 hours prior to FMT (GRADE of evidence: low; strength of recommendation: strong).

5.5.1.3. Washout period between antibiotic use and FMT:

1273 Nearly all studies specified a washout period after completing anti-CDI antibiotics and before 1274 administration of FMT. However, this time period appeared to be arbitrarily selected and varied 1275 from as little as four⁴⁶ or 12 hours⁵¹, up to 72 hours³⁶. The majority of studies specified either 24 1276 hours^{15,37,39,40,45,54,127} or 48 hours^{41,42,49,60}, however some allowed a range from 1-3 days^{16,44,52,53,55}. 1277 One study appeared to allow co-administration of vancomycin with bowel preparation, without a 1278 washout period¹⁸.

The working group discussed the challenging scenario of providing FMT to patients with recurrent CDI, but who also had a strong indication for long-term non-anti-CDI antibiotics (e.g. splenectomy, osteomyelitis, or infective endocarditis), or patients who develop an indication for antibiotics for a reason other than CDI shortly after receiving FMT. The concern in this instance is that the use of antibiotics may limit engraftment of microbial communities derived from the FMT, and therefore reduce its effectiveness. The working group discussed a recent retrospective study demonstrating that exposure to non-anti-CDI antimicrobials within eight weeks of FMT is associated with an approximate threefold risk of FMT failure (n=8/29 failures with antibiotic exposure vs 36/320 failures without antibiotic exposure)¹²⁸. Similarly, the experience of the large pan-Netherlands stool bank¹²⁹ was that ~50% of their failures of FMT in the treatment of recurrent CDI occurred in patients who had received antibiotics within one month of their FMT. For patients requiring long-term antibiotics, the working group's expert opinion was that such patients should still be eligible for FMT, but that the regimen for the use of non-anti-CDI antibiotics should be decided on a case-by-case basis, based on factors including response to FMT and/or strength of indication of antibiotics. Both in this scenario, and the scenario in which antibiotics are required shortly after receiving FMT, the working

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

party agreed that infectious diseases specialists/medical microbiologists should be involved inmaking decisions regarding the choice of agents used.

Recommendations:

iii. To minimise any deleterious effect of antimicrobials on the FMT material, we
 recommend that there should be a minimum washout period of 24 hours between the
 last dose of antibiotic and treatment with FMT (GRADE of evidence: low; strength of
 recommendation: strong).

iv. <u>We suggest considering</u> consultation with infectious disease specialists or medical
 microbiologists for advice whenever FMT recipients also have an indication for long term antibiotics, or have an indication for non-CDI antibiotics within eight weeks of
 FMT (GRADE of evidence: very low; strength of recommendation: weak).

5.5.2. Route of FMT delivery:

5.5.2.1. Introduction:

FMT can be delivered via the lower GI route (retention enema, colonoscopy), upper GI route (endoscopically, or via nasogastric tube, nasoduodenal or nasojejenal tube), or via capsules (containing either frozen FMT or lyophilised faecal material). Systematic reviews with meta-analysis suggest that FMT for recurrent CDI via colonoscopy may have slightly higher efficacy compared to upper GI administration^{127,130–132} with similar safety profiles, but also note the trend towards using larger amounts of stool or 'higher concentration' FMT in lower GI administration. One systematic review (reviewing principally case series, and including only one randomised study) compared remission rates for CDI using FMT delivered to different areas of the GI tract, and reported that for FMT infused into the stomach, duodenum/jejunum, caecum/ascending colon, and rectum the rates of cure rate were 81%, 86%, 93%, and 84%, respectively 131 .

1321 In the only randomised study that directly compared upper and lower GI administration, there was 1322 no significant difference in overall cure rate (p = 0.53)¹⁷.

5.5.2.2. Upper gastrointestinal tract administration of FMT:

Page 120 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

FMT has been shown to be safe and efficacious in the treatment of C. difficile when administered via nasogastric tube^{37,39,45,61,83,123}, nasoduodenal tube^{15,84,85}, enteroscopy^{122,123}, or via the infusion channel on a gastroscope^{40,45}. In a randomised trial, nasoduodenal donor FMT has been shown to be more efficacious than vancomycin in treating recurrent CDI¹⁵. Furthermore, it has been shown that FMT can also be safely and effectively delivered via a percutaneous endoscopic gastrectomy tube^{45,83}. The working group noted that upper GI administration of FMT may be particularly suitable for certain patient groups, such as those in whom there are contraindications or who would find it difficult to tolerate lower GI endoscopy, and/ or patients unlikely to be unable to retain enemas.

Typically, smaller volumes of faecal suspension are administered to the upper GI tract compared to lower GI administration, with quoted volumes ranging from 25ml³⁹ up to 150ml⁸⁴- 250ml^{37,85}. Up to 500ml of suspension has been given safely and effectively via the upper GI route^{15,77}. However, the working group expressed concerns regarding the risk of regurgitation and aspiration if large volumes of FMT are administered to the upper GI tract, and also discussed cases in which this has been described with adverse outcomes⁸⁰. This included a reported death from aspiration, after 100-150ml of FMT was delivered by enteroscope into the distal duodenum under general anaesthetic as attempted treatment for recurrent CDI¹³³. A further reported case described a case of fatal aspiration pneumonitis likely related to a 500ml FMT via nasoduodenal tube; this patient had a swallowing disorder following oropharyngeal radiation after surgical removal of a maxillary carcinoma two years previously⁷⁷. Based on their expert opinion, the working group recommended that upper GI FMT should be used with caution in those at risk of regurgitation (e.g. known large hiatus hernia, severe gastro-oesophageal reflux disease, etc) and/ or with swallowing disorders (although administration via a gastrostomy tube would be acceptable). They also recommended that no more than 100ml of FMT should be administered to the upper GI tract to minimise these risks.

Recommendations:

- 1352i.We recommend that upper GI administration of FMT as treatment for recurrent or1353refractory CDI should be used where clinically appropriate (GRADE of evidence:1354high; strength of recommendation: strong).
- 1355ii.Where upper GI administration is considered most appropriate, we recommend1356that FMT administration should be via nasogastric, nasoduodenal, or nasojejunal

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

2		
3	1357	tube, or alternatively via upper GI endoscopy. Administration via a permanent
4 5	1358	feeding tube is also appropriate (GRADE of evidence: high; strength of
6 7	1359	recommendation: strong).
8	1360	v. <u>We recommend</u> that no more than 100ml of FMT is administered to the upper GI
9 10	1361	tract (GRADE of evidence: low; strength of recommendation: strong).
11 12	1362	vi. <u>We recommend that upper</u> GI administration of FMT should be used with caution
13	1363	in those at risk of regurgitation and/ or those with swallowing disorders (GRADE of
14 15	1364	evidence: low; strength of recommendation: strong).
16 17	1365	
18		
19	1366	5.5.2.3. Lower gastrointestinal tract administration of FMT:
20 21	1367	FMT via enema: Successful treatment of C. difficile with FMT enema has been
22	1368	demonstrated ^{16,38,42,53,55,83,86} but enema appears to have a lower efficacy than other routes of FMT
23		

wer efficacy than other routes of FMT administration. Specifically, in a randomised study primarily comparing the efficacy of fresh and frozen FMT in the treatment of recurrent CDI, only 52.8% of patients in the 'frozen' arm and 50.5% of patients in the 'fresh' arm of the study (n=57/108 and 56/111 respectively) experienced resolution of symptoms after a single enema, by modified intention to treat analysis¹⁶. However, resolution rates in both arms only reached >80% after at least three enemas¹⁶. A recent randomised study demonstrated similar rates of recurrence of CDI in patients with recurrent CDI treated with either a single FMT enema or a six week vancomycin taper (n=9/16) patients with recurrence vs 5/12respectively)¹². Notwithstanding this, enemas do have specific advantages, such as being a treatment option where full colonoscopy is contraindicated. It is also possible to give multiple infusions relatively easily and outside a hospital setting.

FMT via colonoscopy: Randomised study evidence has demonstrated that colonoscopic FMT has higher efficacy in treating recurrent CDI than vancomycin¹⁸. Efficacy is similar whether FMT is fresh or frozen, but modestly reduced when using a lyophilised FMT product¹³. Colonoscopic delivery of donor FMT into the ileum or caecum was associated with a 91% cure rate for recurrent CDI¹⁴. Observational studies highlighted similar success, describing cure rates of 88% $(n=14/16)^{74}$ and $91\%^{46}$ (n=21/23) in response to infusion of donor FMT into the caecum or terminal ileum. A further advantage of using colonoscopy to administer FMT has been to allow assessment for the presence of pseudomembranes; in certain reviewed studies, the presence or absence of pseudomembranes has influenced the FMT regimen used^{18,73}. However, the working group noted that that many patients

https://mc.manuscriptcentral.com/gut

Page 122 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

with CDI are frail and elderly, and as such it will not always be safe or feasible to undertake
colonoscopy in this particular group of patients. Flexible sigmoidoscopy appears to be an feasible
option where full colonoscopy cannot be performed e.g. unable to tolerate colonoscopy, severity of
colitis^{56,60}.

The amount of faecal suspension via enema has varied between 150-500mls^{16,38,42,55,86}. The amount of faecal suspension delivered via colonoscopy has been similarly variable, with some studies suggesting as little as 100ml can be used with success rates of 94%⁴³. 250ml-400ml had a success rate of 100%³⁶, whereas infusions of up to 500-700ml were associated with cure rates of 92%⁴⁶. However, the working group noted that it is difficult to compare 'concentration' of FMT in different studies as different protocols used varied starting amounts of faecal material. Currently, there are no randomised studies that compare concentration/ volume of colonoscopic or enema FMT. As such, no recommendation was made to this regard.

Recommendations:

- 1404i.We recommend that colonoscopicadministration of FMT as treatment for1405recurrent or refractory CDI should be used where appropriate (GRADE of evidence:1406high; strength of recommendation: strong).
- 1407ii.Where colonoscopic administration is used, we suggest considering preferential1408delivery to the caecum or terminal ileum, as this appears to give the highest1409efficacy rate (GRADE of evidence: low; strength of recommendation: weak).
- 1410iii.We recommend that FMT via enema should be used as a lower GI option when1411delivery using colonoscopy or flexible sigmoidoscopy is not possible (GRADE of1412evidence: high; strength of recommendation: strong).

5.5.2.4. Capsulised FMT:

1415 Capsulised FMT aims to remove some of the concerns regarding conventional FMT, such as the 1416 invasive means of administration and palatability. The largest case series describing the use of 1417 capsules as treatment for recurrent $\text{CDI}^{72,89}$ noted clinical resolution at eight weeks off antibiotics for 1418 CDI in 82% of cases (*n*=147/180) after one course of capsules, and 91% (*n*=164/180) after two 1419 courses. The capsules contained frozen FMT prepared in a diluent of saline with 10% glycerol; 15

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1420 capsules were administered each day for two consecutive days (equating to a mean 48g of original
1421 crude stool). Other smaller case series have demonstrated comparable results^{87,123,134}, including
1422 when lyophilised stool is used instead of frozen whole FMT¹³⁴.

The working group reviewed two randomised studies which have examined the efficacy of capsulised FMT in treating recurrent CDI. In one study, published in abstract form⁹⁴, a 'high dose' regimen of frozen FMT capsules (30 capsules each day for two days) was compared to 'low dose' (30 capsules in one day). CDI resolution was comparably high in both arms with one treatment course (77% (n=7/9)) in the 'high dose' arm vs 70% (n=7/10) in the 'low dose arm'). 4/5 initial nonresponders entered remission after a second capsule course with the 'high dose' regimen⁹⁴. In a recent large randomised trial, patients with recurrent CDI were randomised to receive either thawed frozen FMT either via colonoscopy or via capsules (one treatment of 40 capsules)¹¹. On per protocol analysis, remission at 12 weeks after a single treatment occurred in 96% in both arms (n=51/53 by capsule, *n*=50/52 by colonoscopy).

The working group discussed certain unresolved issues regarding capsules. Specifically, capsules are often large, and swallowing 30 capsules in a single day may be a significant undertaking for patients with CDI, such as the frail elderly with an existing high pill burden. They also noted that follow-up data post-capsule administration is relatively short compared to other modalities of FMT.

Recommendation:

1441 Capsulised FMT holds promise as a treatment option for recurrent CDI and <u>we recommend</u> 1442 <u>that this</u> should be offered to patients as a potential treatment modality where available. 1443 Capsule preparations should follow a standard protocol. Further evidence regarding 1444 optimal dosing and formulation is required (GRADE of evidence: high; strength of 1445 recommendation: strong).

14475.6.What is the clinical effectiveness of FMT in treating conditions other than1448Clostridium difficile infection?

5.6.1. Introduction:

In current clinical practice, FMT is used predominantly in the treatment of recurrent CDI. Its success has led to exploration of its efficacy in other GI diseases, primarily ulcerative colitis (UC), where perturbation of the gut microbiota has been observed and implicated in disease pathogenesis¹³⁵. Due to variability of the quality, methodology and cohorts of patients recruited in trials of FMT for non-CDI indications, and in order to control for significant confounding factors, the working group only included randomised trials involving patients with well-defined conditions and in which there was a primary clinical outcome. To date, there have been a total of 71 such studies investigating the role of FMT in IBD; of these, only four are prospective randomised controlled trials, limited to patients with ulcerative colitis^{136–139}. Five other reviewed randomised studies investigated the use of FMT in irritable bowel syndrome¹⁴⁰, slow transit constipation¹⁴¹, hepatic encephalopathy¹⁴² and metabolic syndrome^{143,144}

5.6.2. Use of FMT for ulcerative colitis:

5.6.2.1. Efficacy:

All four RCTs, with a total of 277 subjects, included patients with mild to moderate UC (Mayo score 3-11 and endoscopic sub-score of at least 1). Participants were aged between 27 and 56 years and largely included patients on stable immunosuppressive therapy (only one study excluded patients using biologic treatments and methotrexate within the preceding two months)¹³⁶. Three studies included patients on oral corticosteroids at the time of FMT, however only two required a mandatory wean of these to meet eligibility. Studies generally included patients with all disease distributions found in UC. Time to evaluation of response to FMT in these studies varied between seven and twelve weeks. Two studies used autologous FMT as placebo^{136,139}. Three of the four studies demonstrated that patients receiving donor FMT were significantly more likely to achieve clinical and endoscopic remission compared to placebo^{137–139}. The pooled rate of combined clinical and endoscopic remission was 27.9% for donor FMT and 9.5% for placebo. A pooled risk ratio for failure of FMT to achieve these combined outcomes was 0.8 (95% CI: 0.7-0.9). Deep remission (histological) was only reported in one RCT: 18.4% of patients receiving FMT achieved this outcome compared to 2.7% of those receiving placebo¹³⁷.

5.6.2.2. Characteristics of FMT preparation and delivery:

The four RCTs varied in their FMT preparation and delivery methodology. Two RCTs delivered frozen
FMT, one fresh FMT, and one used a combination. Three RCTs with a positive outcome delivered the
FMT via the lower GI route; these studies used a high intensity protocol ranging from a total of three

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

infusions in one week to 40 FMTs over an eight week period^{137–139}. The other RCT (that failed to show efficacy of FMT for UC) had adopted a low intensity protocol of two nasoduodenal infusions given three weeks apart¹³⁶. Interestingly, the only RCT that prepared stool in anaerobic conditions demonstrated the highest rate of steroid-free clinical remission and steroid-free clinical response with donor FMT¹³⁹. A further interesting observation in one study was a trend towards higher rates of remission with one particular donor¹³⁷.

5.6.2.3. Adverse events:

Short-lived GI symptoms such as abdominal bloating, cramps, diarrhoea and fever were reported in patients receiving FMT for UC. There were no significant differences in serious adverse events between patients receiving FMT compared to placebo (10 vs 7 respectively). Most of the serious adverse events were a consequence of worsening colitis: one patient who received FMT required a colectomy¹³⁶. In addition, one patient developed concurrent CDI¹³⁷. No deaths were reported in any of the studies.

5.6.3. Use of FMT in functional bowel disorders:

Two RCTs have investigated the role of FMT in functional bowel disorders. In a double-blind placebo controlled RCT that recruited 90 patients with IBS with diarrhoea or with diarrhoea and constipation¹⁴⁰, the primary endpoint only just reached statistical significance in inducing symptom relief (as assessed by 75 point reduction in IBS-severity scoring system at three months following a single infusion FMT by colonoscopy) (p=0.049). The second RCT randomised 60 patients with slow transit constipation to either six consecutive days of nasogastric-delivered FMT or conventional treatment¹⁴¹. This demonstrated that a significant proportion of patients achieved the primary endpoint of a mean of at least three complete spontaneous bowel movements per week (53.3% vs. 20.0%, p=0.009) along with improvement in stool consistency score and colonic transit time. However, the intervention group had more treatment-related adverse events than did the control group (total of 50 vs 4 cases).

5.6.4. Use of FMT in hepatic encephalopathy:

One small study has investigated the role of FMT in the management of hepatic encephalopathy (HE)¹⁴². This RCT randomised 20 male patients with cirrhosis with refractory HE to receive either five days of broad-spectrum antibiotic pre-treatment followed by a single FMT enema or standard of

https://mc.manuscriptcentral.com/gut

Page 126 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

care. Patients in the FMT arm had a significantly lower incidence of serious adverse events and
improved cognition. The Model for End-Stage Liver Disease (MELD) score, however, transiently
worsened post-antibiotics in the FMT arm. The study was potentially confounded as patients in the
FMT arm continued to receive lactulose and/or rifaximin for treatment of their HE.

5.6.5. Use of FMT for metabolic syndrome:

Two randomised studies^{143,144}, with a combined total of 56 patients, demonstrated an improvement in peripheral (but not hepatic) insulin sensitivity in Caucasian male obese patients with metabolic syndrome following one or two infusions via nasoduodenal tube of FMT obtained from lean donors. This improvement was observed at six weeks post-FMT, but was no longer present by 18 weeks. No improvement in insulin sensitivity was identified in patients transplanted with autologous FMT (i.e. patients transplanted with their own collected faeces). The improvement in peripheral insulin sensitivity in the lean donor FMT group was accompanied by a small but significant improvement in HbA1c at six weeks¹⁴⁴, but no improvements in other metabolic parameters, such as weight. Whilst these data are of interest, the working group felt that the limited, transient nature of the benefits seen and small size of the studies meant that FMT could not be recommended as treatment for metabolic syndrome.

5.6.6. Future directions for randomised trials of FMT for non-CDI indications:

1534 Currently there are a large number of randomised trials (including RCTs) being undertaken globally, 1535 to evaluate the potential role of FMT as treatment for a wide range of conditions. The working 1536 group concluded that until there are more reliable data to inform decision-making, the best practice 1537 principles described in this document for the governance of an FMT service for recurrent CDI should 1538 also be applied to FMT clinical trials for other conditions. However, specific adaptations may be 1539 considered depending on the condition being studied, e.g. consideration of using anaerobic 1540 conditions for the preparation of FMT in trials for the treatment of UC, as described above.

1542 In conclusion, FMT has the potential to be an effective treatment option for mild to moderate 1543 ulcerative colitis, and appears to be safe despite the use of immunosuppressive therapy. FMT may 1544 also have a potential role in the treatment of functional bowel disorders. However, 1545 recommendations for clinical use for both these indications cannot be made until there is clearer 1546 evidence of the most appropriate patient characteristics, preparation methodology, route of delivery

 Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

and intensity of administration of FMT. The evidence for the use of FMT in hepatic encephalopathy and metabolic syndrome is currently limited, and further well-designed RCTs are needed to evaluate its potential role here.

Recommendation:

We do not currently recommended FMT as treatment for inflammatory bowel disease. Apart from CDI, there is insufficient evidence to recommend FMT for any other gastrointestinal or non-gastrointestinal disease (GRADE of evidence: moderate; strength of recommendation: strong).

6. Basic requirements for implementing a FMT service:

As discussed above, there is an absence of published studies to support the recommendations in this section (although the experience of setting up a nationwide stool bank has recently been reported from the Netherlands¹²⁹). This section is therefore based on the working group's expert opinion and experience of developing FMT services. The working group considered best practice in this area as it applied to legal and clinical governance aspects, the relevant professionals required to establish an FMT service, the infrastructure of a service, and appropriate practices for FMT manufacturing and quality control monitoring where relevant. The full text of this section is in Supplementary Material 3. CLIC

7. Key performance indicators:

All donors to have completed initial screening questionnaires and blood and stool screening results, as well as final health check prior to each stool donation processed to FMT. Results from each subsequent serial round of screening also to be documented.

All FMT recipients to have clear documentation of details of their disease course and preparation prior to FMT, including whether recurrent or refractory disease, previous antimicrobial courses, and use of bowel purgatives/other preparatory medications pre-FMT.

All FMT recipients to have sufficient documentation to allow clear traceability of the exact FMT • aliquot transfused. Records should include identification of the donor, as well as a frozen FMT aliquot (and original faecal sample) - as well as serum - from that donor (see Supplementary Material 3).

All FMT recipients for recurrent or refractory CDI to have documentation during follow-up of
 treatment success or failure (and subsequent treatment plan if failure), together with clear
 documentation of any adverse events that may be attributable to FMT.

1582 8. Further research:

As described within this guideline, many aspects of the terminology of CDI are used variably
 between studies, and end-points in FMT trials are inconsistent. The working group noted the
 need to standardise this terminology to allow more robust comparisons between studies.

Given the relative novelty of FMT as a procedure, any potential long-term adverse events associated with its use are poorly-defined. The establishment of formal FMT registries should be considered. Whilst this would primarily act as an important tool for defining the safety and efficacy of FMT, it would also be a valuable database for researchers within the field. Standardisation of other key documentation related to FMT administration (e.g. establishment of a proforma for assessing eligibility for FMT and/or follow-up after FMT) would also be advantageous for the same reasons.

The working group noted the lack of consistency in definitions related to the severity of CDI disease and to response or failure to FMT. This limited interpretation of the published studies. As such, the working group thought that standardisation of these definitions would allow more accurate delineation of the factors influencing the efficacy of FMT for CDI. The working group also noted that only one reviewed study had reported the relationship between C difficile ribotype and FMT outcome, and that recording of this information should be encouraged better to evaluate its influence.

Further well-designed clinical trials (in particular, RCTs) are required to identify the optimal
 means of administration of FMT as treatment for recurrent and/or refractory CDI.

The working group noted that even capsulised FMT may be associated with potential drawbacks. They also noted that there are many patients with recurrent CDI for whom FMT (or any form of 'bacteriotherapy') may be inappropriate, including those with very marked immunosuppression, and/or multi-organ disease. Despite high levels of efficacy, there is a small but appreciable FMT failure rate and it is not currently understood whether this is due to underlying donor or recipient factors. Therefore, a research priority should be in basic and translational studies better to define the mechanisms underlying the efficacy of FMT in CDI. This includes comparing the structure and function of the microbiota of donors to patients pre-FMT and post-FMT, via techniques including next-generation microbial sequencing, metabolic profiling, and

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

immunological assays. This would allow the refinement of FMT from its current state to a more targeted therapy, removing the concerns associated with FMT.

The working group identified a need for further well-designed RCTs to investigate the potential role of FMT for non-CDI indications.

9. Conclusions:

FMT has become an accepted, efficacious treatment for recurrent and/or refractory CDI. In developing this guideline, the evidence for the technique has been reviewed in the context of other available treatments. Specific guidance for best practice for an FMT service is provided.

10.Funding:

There was no external funding for this work. BHM is the recipient of a Medical Research Council Clinical Research Training Fellowship (grant reference: MR/R000875/1). BHM and HRTW receive support from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust and Imperial College London.

11.Competing interests:

- THI: Acted as consultant, advisor or speaker for Pharmacosmos and Shield Therapeutics.
- ALH: Acted as consultant, advisory board member or speaker for AbbVie, Atlantic, Bristol-Myers Squibb, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda. ALH also serves on the Global Steering Committee for Genentech.
- SDG: Received consultancy fees, speaker fees and research grant support from Astellas between • 2015-2017; received consultancy fees and speaker fees from MSD between 2015-2017; and received consultancy fees in 2017 from Pfizer.
- All other authors declared no conflict of interest.

12. Provenance and peer review:

Commissioned. Peer review through stakeholder consultation, HIS (SDC and Council), BSG (CSSC and Council) and externally.

13.Acknowledgements:

The authors would like to acknowledge the support of the Gut Microbiota for Health Expert Panel of the British Society of Gastroenterology, along with that of the Healthcare Infection Society. They would also like to thank Ian Rees from the MHRA for contributions regarding the legal aspects and

doi:10.1016/j.anaerobe.2016.06.008. 2. Faecal microbiota transplant for recurrent Clostridium difficile infection | Guidance and

guidelines | NICE. https://www.nice.org.uk/guidance/ipg485. Accessed October 2, 2017. Gut

1		HIS/I	BSG FMT Guideline: Main Document, Gut version.
2 3	1665	3.	Health England P. Updated guidance on the management and treatment of Clostridium
4	1666	5.	difficile infection. 2013. http://www.gov.uk/phe. Accessed March 20, 2017.
5 6	1000		
7	1667	4.	Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious
8 9	1668		Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection. Clin
10	1669		Microbiol Infect. 2014;20(s2):1-26. doi:10.1111/1469-0691.12418.
11 12	1670	5.	McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium
13 14	1671		difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of
15	1672		America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis.
16 17 18	1673		February 2018. doi:10.1093/cid/cix1085.
19	1674	6.	Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota
20 21	1675		transplantation in clinical practice. Gut. 2017;66(4):569-580. doi:10.1136/gutjnl-2016-
22 23	1676		313017.
24	1677	7.	König J, Siebenhaar A, Högenauer C, et al. Consensus report: faecal microbiota transfer -
25 26	1678		clinical applications and procedures. Aliment Pharmacol Ther. 2017;45(2):222-239.
27 28	1679		doi:10.1111/apt.13868.
29 30	1680	8.	Treating Clostridium difficile Infection With Fecal Microbiota Transplantation. Clin
31 32	1681		Gastroenterol Hepatol. 2011;9(12):1044-1049. doi:10.1016/J.CGH.2011.08.014.
33 34	1682	9.	Kump P, Krause R, Steininger C, et al. Empfehlungen zur Anwendung der fäkalen
35	1683		Mikrobiotatransplantation "Stuhltransplantation": Konsensus der Österreichischen
36 37	1684		Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH) in Zusammenarbeit mit der
38 39	1685		Österreichischen Gesellschaft für Infektiologie und. Z Gastroenterol. 2014;52(12):1485-1492.
40	1686		doi:10.1055/s-0034-1385562.
41 42	1687	10.	Faecal microbiota transplantation in recurrent Clostridium difficile infection:
43	1688		Recommendations from the French Group of Faecal microbiota Transplantation. <i>Dig Liver Dis</i> .
44 45	1689		2016;48(3):242-247. doi:10.1016/J.DLD.2015.08.017.
46 47			
48	1690	11.	Kao D, Roach B, Silva M, et al. Effect of Oral Capsule– vs Colonoscopy-Delivered Fecal
49 50	1691		Microbiota Transplantation on Recurrent <i>Clostridium difficile</i> Infection. JAMA.
51	1692		2017;318(20):1985. doi:10.1001/jama.2017.17077.
52 53	1693	12.	Hota SS, Sales V, Tomlinson G, et al. Oral Vancomycin Followed by Fecal Transplantation
54 55	1694		Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An
56	1695		Open-Label, Randomized Controlled Trial. Clin Infect Dis. 2017;64(3):265-271.
57 58			
59 60			https://mc.manuscriptcentral.com/gut

1		HIS/	BSG FMT Guideline: Main Document, Gut version.
1 2			
3 4	1696		doi:10.1093/cid/ciw731.
5	1697	13.	Jiang ZD, Ajami NJ, Petrosino JF, et al. Randomised clinical trial: faecal microbiota
6 7	1698		transplantation for recurrent Clostridum difficile infection – fresh, or frozen, or lyophilised
8 9	1699		microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol
10	1700		Ther. 2017;45(7):899-908. doi:10.1111/apt.13969.
11 12	1701	14.	Kelly CR, Khoruts A, Staley C, et al. Effect of Fecal Microbiota Transplantation on Recurrence
13 14	1702		in Multiply Recurrent Clostridium difficile Infection. Ann Intern Med. 2016;165(9):609.
15 16	1703		doi:10.7326/M16-0271.
17	1704	15.	van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal Infusion of Donor Feces for Recurrent
18 19	1705		Clostridium difficile. N Engl J Med. 2013;368(5):407-415. doi:10.1056/NEJMoa1205037.
20 21	1706	16.	Lee CH, Steiner T, Petrof EO, et al. Frozen vs Fresh Fecal Microbiota Transplantation and
22 23	1707		Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection.
24 25	1708		JAMA. 2016;315(2):142. doi:10.1001/jama.2015.18098.
26 27	1709	17.	Youngster I, Sauk J, Pindar C, et al. Fecal Microbiota Transplant for Relapsing Clostridium
28	1710		difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-
29 30	1711		Label, Controlled Pilot Study. <i>Clin Infect Dis</i> . 2014;58(11):1515-1522. doi:10.1093/cid/ciu135.
31 32	1712	18.	Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota
33	1713		transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium
34 35	1714		difficile infection. Aliment Pharmacol Ther. 2015;41(9):835-843. doi:10.1111/apt.13144.
36 37	1715	19.	Faecal Microbiota Transplantation (FMT) MHRA's position.
38 39	1716		http://www.bsg.org.uk/images/stories/docs/clinical/guidance/fmt_mhra_position_june2015.
40 41	1717		pdf. Accessed October 3, 2017.
42	1718	20.	Thomas A. HTA Policy on the Regulation of Faecal Microbiota Transplant. 2015.
43 44	1719	20.	http://www.bsg.org.uk/images/stories/docs/clinical/guidance/hta_pol_030_policy_regulatio
45 46	1720		n_of_fmt.pdf. Accessed October 3, 2017.
47 48	1721	21.	Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota
49	1721	21.	transplantation. Nat Rev Gastroenterol Hepatol. 2016;13(9):508-516.
50 51	1723		doi:10.1038/nrgastro.2016.98.
52 53	1724	22.	Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication
54 55	1724	22.	of Clostridium difficile infection: 'RePOOPulating' the gut. <i>Microbiome</i> . 2013;1(1):3.
56	1726		doi:10.1186/2049-2618-1-3.
57 58	1720		
59			https://mc.manuscriptcentral.com/gut
60			https://ne.manuscipicential.com/gut

Gut

Page 13	3 of 454		Gut
1		HIS/	BSG FMT Guideline: Main Document, Gut version.
1 2			
3 4	1727	23.	Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating
5	1728		Patients With Clostridium difficile Infection. <i>Gastroenterology</i> . 2017;152(4):799-811.e7.
6 7	1729		doi:10.1053/j.gastro.2016.11.010.
8 9	1730	24.	Khanna S, Pardi DS, Kelly CR, et al. A Novel Microbiome Therapeutic Increases Gut Microbial
10	1731		Diversity and Prevents Recurrent Clostridium difficile Infection. J Infect Dis. 2016;214(2):173-
11 12	1732		181. doi:10.1093/infdis/jiv766.
13 14	1733	25.	Martin J, Wilcox M. New and emerging therapies for Clostridium difficile infection. Curr Opin
15 16	1734		Infect Dis. 2016;29(6):546-554. doi:10.1097/QCO.0000000000000320.
17 18	1735	26.	Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient Attitudes Toward the
19	1736		Use of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium difficile
20 21	1737		Infection. <i>Clin Infect Dis</i> . 2012;55(12):1652-1658. doi:10.1093/cid/cis809.
22 23	1738	27.	Kahn SA, Vachon A, Rodriquez D, et al. Patient perceptions of fecal microbiota
24 25	1739		transplantation for ulcerative colitis. Inflamm Bowel Dis. 2013;19(7):1506-1513.
23 26 27	1740		doi:10.1097/MIB.0b013e318281f520.
28	1741	28.	Quraishi MN, Segal J, Mullish B, et al. National survey of practice of faecal microbiota
29 30	1742		transplantation for Clostridium difficile infection in the UK. J Hosp Infect. 2016.
31 32	1743		doi:10.1016/j.jhin.2016.10.023.
33 34	1744	29.	Porter RJ, Fogg C. Faecal microbiota transplantation for Clostridium difficile infection in the
35 36	1745		United Kingdom. Clin Microbiol Infect. 2015;21(6):578-582. doi:10.1016/j.cmi.2015.01.020.
37	1746	30.	Ding NS, Mullish BH, McLaughlin J, Hart A, Marchesi JR. Meeting update: faecal microbiota
38 39	1747		transplantation—bench, bedside, courtroom? Frontline Gastroenterol. November
40 41	1748		2016:flgastro-2016-100752. doi:10.1136/flgastro-2016-100752.
42 43	1749	31.	Prior AR, Kevans D, McDowell L, Cudmore S, Fitzpatrick F. Treatment of Clostridium difficile
44 45	1750		infection: a national survey of clinician recommendations and the use of faecal microbiota
45 46 47	1751		transplantation. <i>J Hosp Infect</i> . 2017;95(4):438-441. doi:10.1016/j.jhin.2016.10.004.
48	1752	32.	1995 - The well-built clinical question: a key to evidence-based decisions (Editorial) 1995
49 50	1753		Nov-Dec : Volume 123, Number 3, Page A12 ACP Journal Club Archives.
51 52	1754		https://acpjc.acponline.org/Content/123/3/issue/ACPJC-1995-123-3-A12.htm. Accessed
52 53	1755		October 18, 2017.
54 55 56	1756	33.	British Society of Gastroenterology CS and SC. Guideline Development Within the BSG Clinical
50 57 58	1757		Services and Standards Committee Policies. https://www.bsg.org.uk/resource/guideline-
59			https://mc.manuscriptcentral.com/gut
60			TILLDS.//TILL.ITIdTUSCTIDICETILIdI.COTT/QUL

https://mc.manuscriptcentral.com/gut

1

2	1750		development within the bag aliginal convices and standards comparities policies by
3 4	1758		development-within-the-bsg-clinical-services-and-standards-committee-policies.html.
5	1759		Accessed April 25, 2018.
6 7	1760	34.	Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of
8 9	1761		evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
9 10 11	1762		doi:10.1136/bmj.39489.470347.AD.
12	1763	35.	Satokari R, Mattila E, Kainulainen V, Arkkila PET. Simple faecal preparation and efficacy of
13 14	1764		frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile
15	1765		infection - an observational cohort study. Aliment Pharmacol Ther. 2015;41(1):46-53.
16 17 18	1766		doi:10.1111/apt.13009.
19	1767	36.	Yoon SS, Brandt LJ. Treatment of Refractory/Recurrent C. difficile-associated Disease by
20 21	1768		Donated Stool Transplanted Via Colonoscopy. J Clin Gastroenterol. 2010;44(8):562-566.
22 23	1769		doi:10.1097/MCG.0b013e3181dac035.
24 25	1770	37.	Zainah H, Hassan M, Shiekh-Sroujieh L, Hassan S, Alangaden G, Ramesh M. Intestinal
25 26	1771		microbiota transplantation, a simple and effective treatment for severe and refractory
27 28	1772		Clostridium difficile infection. <i>Dig Dis Sci</i> . 2014;60(1):181-185. doi:10.1007/s10620-014-3296-
29 30	1773		у.
31	1774	38.	Kassam Z. Fecal Transplant via Retention Enema for Refractory or Recurrent <emph< td=""></emph<>
32 33	1775		type="ital">Clostridium difficile Infection. Arch Intern Med.
34 35	1776		2012;172(2):191. doi:10.1001/archinte.172.2.191.
36 37	1777	39.	Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile Colitis: Case Series Involving 18
38	1778		Patients Treated with Donor Stool Administered via a Nasogastric Tube. Clin Infect Dis.
39 40 41	1779		2003;36(5):580-585. doi:10.1086/367657.
42	1780	40.	Garborg K, Waagsbø B, Stallemo A, Matre J, Sundøy A. Results of faecal donor instillation
43 44	1781		therapy for recurrent Clostridium difficile-associated diarrhoea. <i>Scand J Infect Dis</i> .
45	1782		2010;42(11-12):857-861. doi:10.3109/00365548.2010.499541.
46 47	1783	41.	Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized Frozen Preparation for
48 49	1784		Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection. Am J
50 51	1785		Gastroenterol. 2012;107(5):761-767. doi:10.1038/ajg.2011.482.
52 53	1786	42.	Lee CH, Belanger JE, Kassam Z, et al. The outcome and long-term follow-up of 94 patients
54	1787		with recurrent and refractory Clostridium difficile infection using single to multiple fecal
55 56 57	1788		microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis.
58 59 60			https://mc.manuscriptcentral.com/gut

1		HIS/I	BSG FMT Guideline: Main Document, Gut version.
2 3 4	1789		2014;33(8):1425-1428. doi:10.1007/s10096-014-2088-9.
5	1790	43.	Mattila E, Uusitalo-Seppälä R, Wuorela M, et al. Fecal transplantation, through colonoscopy,
6 7	1791		is effective therapy for recurrent Clostridium difficile infection. Gastroenterology.
8 9	1792		2012;142(3):490-496. doi:10.1053/j.gastro.2011.11.037.
10 11	1793	44.	Rohlke F, Surawicz CM, Stollman N. Fecal Flora Reconstitution for Recurrent Clostridium
12	1794		difficile Infection: Results and Methodology. J Clin Gastroenterol. 2010;44(8):567-570.
13 14	1795		doi:10.1097/MCG.0b013e3181dadb10.
15 16	1796	45.	Rubin TA, Gessert CE, Aas J, Bakken JS. Fecal microbiome transplantation for recurrent
17 18	1797		Clostridium difficile infection: Report on a case series. Anaerobe. 2013;19:22-26.
19 20	1798		doi:10.1016/j.anaerobe.2012.11.004.
21	1799	46.	Patel NC, Griesbach CL, DiBaise JK, Orenstein R. Fecal Microbiota Transplant for Recurrent
22 23	1800		Clostridium difficile Infection: Mayo Clinic in Arizona Experience. Mayo Clin Proc.
24 25	1801		2013;88(8):799-805. doi:10.1016/j.mayocp.2013.04.022.
26	1802	47.	Crobach MJT, Planche T, Eckert C, et al. European Society of Clinical Microbiology and
27 28	1803		Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile
29 30	1804		infection. <i>Clin Microbiol Infect</i> . 2016;22 Suppl 4:S63-81. doi:10.1016/j.cmi.2016.03.010.
31	4005	40	
32 33	1805	48.	Jackson M, Olefson S, Machan JT, Kelly CR. A High Rate of Alternative Diagnoses in Patients
34	1806		Referred for Presumed Clostridium difficile Infection. J Clin Gastroenterol. 2016;50(9):742-
35 36	1807		746. doi:10.1097/MCG.00000000000447.
37 38	1808	49.	Ray A, Smith R, Breaux J. Fecal Microbiota Transplantation for Clostridium difficile Infection:
39	1809		The Ochsner Experience. Ochsner J. 2014;14(4):538-544.
40 41	1810		http://www.ncbi.nlm.nih.gov/pubmed/25598718. Accessed October 9, 2017.
42 43	1811	50.	Kao, D., Roach B., Hotte, N., Silva, M., Madsen, K., Beck, P., Louie T, Canadian Association for
44 45	1812		the Study of the Liver. A Prospective, Dual Center, Randomized Trial Comparing Colonoscopy
43 46	1813		versus Capsule Delivered Fecal Microbiota Transplantation (FMT) in the Management of
47	1814		Recurrent Clostridium Difficile Infection (RCDI). In: Canadian Journal of Gastroenterology and
48 49 50	1815		Hepatology. Vol 2016. Hindawi; 2016:1-204. doi:10.1155/2016/4792898.
51	1816	51.	MacConnachie AA, Fox R, Kennedy DR, Seaton RA. Faecal transplant for recurrent Clostridium
52 53	1817		difficile-associated diarrhoea: a UK case series. QJM. 2009;102(11):781-784.
53 54 55	1818		doi:10.1093/qjmed/hcp118.
56 57	1819	52.	Kelly CR, de Leon L, Jasutkar N. Fecal Microbiota Transplantation for Relapsing Clostridium
58			
59 60			https://mc.manuscriptcentral.com/gut

Gut

1		HIS/	BSG FMT Guideline: Main Document, Gut version.
1 2			
3	1820		difficile Infection in 26 Patients. J Clin Gastroenterol. 2012;46(2):145-149.
4 5	1821		doi:10.1097/MCG.0b013e318234570b.
6 7	1822	53.	Brandt ⊔, Aroniadis OC, Mellow M, et al. Long-Term Follow-Up of Colonoscopic Fecal
8 9	1823		Microbiota Transplant for Recurrent Clostridium difficile Infection. Am J Gastroenterol.
10 11	1824		2012;107(7):1079-1087. doi:10.1038/ajg.2012.60.
12	1825	54.	Pathak R, Enuh HA, Patel A, Wickremesinghe P. Treatment of relapsing Clostridium difficile
13 14	1826		infection using fecal microbiota transplantation. Clin Exp Gastroenterol. 2013;7:1-6.
15 16	1827		doi:10.2147/CEG.S53410.
17 18	1828	55.	Agrawal M, Aroniadis OC, Brandt LJ, et al. The Long-term Efficacy and Safety of Fecal
19	1829		Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection
20 21	1830		in 146 Elderly Individuals. J Clin Gastroenterol. 2015;50(5):1.
22 23	1831		doi:10.1097/MCG.000000000000410.
24 25	1832	56.	Fischer M, Kao D, Kelly C, et al. Fecal Microbiota Transplantation is Safe and Efficacious for
26	1833		Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel
27 28 29	1834		Disease. Inflamm Bowel Dis. 2016;22(10):2402-2409. doi:10.1097/MIB.0000000000000908.
30	1835	57.	Aroniadis OC, Brandt LJ, Greenberg A, et al. Long-term Follow-up Study of Fecal Microbiota
31 32	1836		Transplantation for Severe and/or Complicated Clostridium difficile Infection. J Clin
33 34	1837		Gastroenterol. 2015;50(5):1. doi:10.1097/MCG.000000000000374.
35	1838	58.	Fischer M, Kao D, Mehta SR, et al. Predictors of Early Failure After Fecal Microbiota
36 37	1839		Transplantation for the Therapy of Clostridium Difficile Infection: A Multicenter Study. Am J
38 39	1840		Gastroenterol. 2016;111(7):1024-1031. doi:10.1038/ajg.2016.180.
40 41	1841	59.	Ianiro G, Valerio L, Masucci L, et al. Predictors of failure after single faecal microbiota
42	1842		transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year,
43 44	1843		single-centre cohort study. <i>Clin Microbiol Infect</i> . 2017;23(5):337.e1-337.e3.
45 46	1844		doi:10.1016/j.cmi.2016.12.025.
47 48	1845	60.	Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium
49	1846		difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109(7):1065-
50 51	1847		1071. doi:10.1038/ajg.2014.133.
52 53	1848	61.	Lagier J-C, Delord M, Million M, et al. Dramatic reduction in Clostridium difficile ribotype 027-
54 55	1849		associated mortality with early fecal transplantation by the nasogastric route: a preliminary
56	1850		report. Eur J Clin Microbiol Infect Dis. 2015;34(8):1597-1601. doi:10.1007/s10096-015-2394-x.
57 58			
59			https://mc.manuscriptcentral.com/gut
60			nttps://mc.manuscriptcentral.com/gut

Gut

1		HIS/	BSG FMT Guideline: Main Document, Gut version.
2	1851	62.	Camacho-Ortiz A, Gutiérrez-Delgado EM, Garcia-Mazcorro JF, et al. Randomized clinical trial
4	1852		to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in
5 6	1853		intestinal microbiome. Green J, ed. <i>PLoS One</i> . 2017;12(12):e0189768.
7 8	1854		doi:10.1371/journal.pone.0189768.
9	1855	63.	Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus Vancomycin for Clostridium
10 11	1855	05.	difficile Infection. N Engl J Med. 2011;364(5):422-431. doi:10.1056/NEJMoa0910812.
12 13	1030		aljjicie intection. N engrj Mea. 2011,304(3).422-431. uol.10.1030/NEJM080910812.
14	1857	64.	Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for Prevention of Recurrent
15 16	1858		Clostridium difficile Infection. N Engl J Med. 2017;376(4):305-317.
17	1859		doi:10.1056/NEJMoa1602615.
18 19	1860	65.	Guery B, Menichetti F, Anttila V-J, et al. Extended-pulsed fidaxomicin versus vancomycin for
20 21	1861		Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised,
22	1862		controlled, open-label, phase 3b/4 trial. <i>Lancet Infect Dis</i> . December 2017.
23 24	1863		doi:10.1016/S1473-3099(17)30751-X.
25 26	1864	66.	McFarland L V., Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163
27	1865		cases of recurrent Clostridium difficile disease. <i>Am J Gastroenterol</i> . 2002;97(7):1769-1775.
28 29	1866		doi:10.1111/j.1572-0241.2002.05839.x.
30			
31 32	1867	67.	Sirbu BD, Soriano MM, Manzo C, Lum J, Gerding DN, Johnson S. Vancomycin Taper and Pulse
33	1868		Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection.
34 35	1869		Clin Infect Dis. 2017;65(8):1396-1399. doi:10.1093/cid/cix529.
36 37	1870	68.	Gentry CA, Giancola SE, Thind S, Kurdgelashvili G, Skrepnek GH, Williams RJ. A Propensity-
38	1871		Matched Analysis Between Standard Versus Tapered Oral Vancomycin Courses for the
39 40	1872		Management of Recurrent Clostridium difficile Infection. Open Forum Infect Dis.
41	1873		2017;4(4):ofx235. doi:10.1093/ofid/ofx235.
42 43	107/	60	Corpoly OA Crook DW/ Especito B at al Eidayomicin versus vancemucin for infection with
44 45	1874	69.	Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with
46	1875		Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority,
47 48	1876		randomised controlled trial. Lancet Infect Dis. 2012;12(4):281-289. doi:10.1016/S1473-
49	1877		3099(11)70374-7.
50 51	1878	70.	Tauxe WM, Haydek JP, Rebolledo PA, et al. Fecal microbiota transplant for Clostridium
52	1879		difficile infection in older adults. Therap Adv Gastroenterol. 2016;9(3):273-281.
53 54	1880		doi:10.1177/1756283X15622600.
55 56 57	1881	71.	Khan MA, Sofi AA, Ahmad U, et al. Efficacy and safety of, and patient satisfaction with,
58 59 60			https://mc.manus <mark>61</mark> ptcentral.com/gut

1

1883 community- and hospital-acquired Clostridium difficile infection. Can J Gastroenterol Hepatol. 1884 2014;28(8):434-438. http://www.ncbi.nlm.nih.gov/pubmed/25014180. Accessed October 9, 1885 2017. 1886 72. 1887 Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection. JAMA. 1888 2014;312(17):1772. doi:10.1001/jama.2014.13875. 1889 73. 1889 73. 1890 Vancomycin for severe complicated Clostridium difficile Infection: description of a protocol 1891 with high success rate. Aliment Pharmacol Ther. 2015;42(4):470-476. doi:10.1111/apt.13290. 1892 74. Costello SP, Conion MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota 1893 effective: Clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 1894 effective: Clinical efficacy and bacterial viability data. Aliment Pharmocol Ther. 1895 2015;42(8):1011-1018. doi:10.1111/apt.13366. 1896 75. Hui J, Kench JG, Chitturi S, et al. Long-Term Outcomes of cirrhosis in nonalcoholic 1897 steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420-427. 1908 76. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent	2 3	1882		colonoscopic-administered fecal microbiota transplantation in relapsing and refractory
 1884 2014;28(8):434-438. http://www.ncbi.nlm.nih.gov/pubmed/25014180. Accessed October 9, 2017. 1885 2017. 72. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, Capsulized, Frozen Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection. JAMA. 2014;312(17):1772. doi:10.1001/jama.2014.13875. 73. Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated <i>Clostridium difficile</i> infection: description of a protocol with high success rate. <i>Aliment Pharmacol Ther.</i> 2015;42(4):470-476. doi:10.1111/apt.13290. 74. Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: Clinical efficacy and bacterial viability data. <i>Aliment Pharmacol Ther.</i> 2015;42(8):1011-1018. doi:10.1111/apt.13366. 75. Hui J, Kench JG, Chituri S, et al. Long-Term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. <i>Hepatology</i>. 2003;38(2):420-427. doi:10.1033/jhep.2003.50320. 76. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154. 77. van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transplantation via colonoscopy for treatment of recurrent Clostridium difficile infection. United Eur Gostroenterol J. 2017;5(6):868-879. doi:10.1117/2050640616678099. 78. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection Mith Fecal Microbiota Transplantation. <i>Clin Gastroenterol Hepatol</i>. 2011;9(12):1044-1049. doi:10.1016/j.cph.2011.08.014. 79. Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clost				
 1885 2017. 1886 72. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, Capsulized, Frozen Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection. <i>JAMA</i>. 2014;312(17):1772. doi:10.1001/jama.2014.13875. 1889 73. Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancowycin for severe -complicated <i>Clostridium difficile</i> infection: description of a protocol with high success rate. <i>Aliment Pharmacol Ther</i>. 2015;42(4):470-476. doi:10.1111/apt.13290. 74. Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: Clinical efficacy and bacterial viability data. <i>Aliment Pharmacol Ther</i>. 2015;42(8):1011-1018. doi:10.1111/apt.13366. 75. Hui J, Kench JG, Chitturi S, et al. Long-Term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. <i>Hepatology</i>. 2003;38(2):420-427. doi:10.1033/jhep.2003.50320. 76. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. <i>J Vis Exp</i>. 2014;(94). doi:10.3791/52154. 77. van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transplantation Via colonoscopy for treatment of recurrent Clostridium difficile infection. <i>United Eur Gastroenterol J</i>. 2017;5(6):868-879. doi:10.11177/2050640616678099. 78. Bakken JS, Borody T, Brant LJ, et al. Treating Clostridium difficile Infection With Fecal Microbiota Transplantatic Clostridium difficile carriage rate post fecal microbiota transplant is low: a prospective clinical and stool assessment. <i>Clin Microbiol Infect</i>. November 2017. doi:10.1016/j.CMI.2017.10.022. 79. Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium difficile ca				
 Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, Capsulized, Frozen Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection. JAMA. 2014;312(17):1772. doi:10.1001/jama.2014.13875. Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated <i>Clostridium difficile</i> infection: description of a protocol with high success rate. <i>Aliment Pharmacol Ther.</i> 2015;42(4):470-476. doi:10.1111/apt.13290. Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: Clinical efficacy and bacterial viability data. <i>Aliment Pharmacol Ther.</i> 2015;42(8):1011-1018. doi:10.1111/apt.13366. Hui J, Kench JG, Chitturi S, et al. Long-Term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. <i>Hepatology</i>. 2003;38(2):420-427. doi:10.1053/jhep.2003.50320. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. <i>J Vis Exp.</i> 2014;(94). doi:10.3791/52154. van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transplantation via colonoscopy for treatment of recurrent Clostridium difficile infection. <i>United Eur Gastroenterol J</i>. 2017;5(6):868-879. doi:10.1177/2050640616678099. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal Microbiota Transplantation. <i>Clin Gastroenterol Hepatol</i>. 2011;9(12):1044-1049. doi:10.1016/j.cgh.2011.08.014. Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment. <i>Clin Microbiol Infect</i>. November 2017. doi				
1886 72. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, Capsulized, Frozen 187 Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection. JAMA. 188 2014;312(17):1772. doi:10.1001/jama.2014.13875. 1889 73. Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of 1890 vancomycin for severe-complicated Clostridium difficile infection: description of a protocol 1891 with high success rate. Aliment Pharmacol Ther. 2015;42(4):470-476. doi:10.1111/apt.13290. 1892 74. Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota 1893 transplant for recurrent Clostridium difficile infection using long-term frozen stool is 1894 effective: Clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 1895 2015;42(8):1011-1018. doi:10.1111/apt.13366. 1896 75. Hui J, Kench JG, Chitturi S, et al. Long-Term outcomes of cirrhosis in nonalcoholic 1897 steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420-427. 1900 recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154. 1901 77. van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transplen		1885		2017.
187 Pecka microbiolog transplantation for Nealpsing Closif hubble infection. JAMA. 188 2014;312(17):1772. doi:10.1001/jama.2014.13875. 189 73. Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42(4):470-476. doi:10.1111/apt.13290. 189 74. Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: Clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 189 2015;42(8):1011-1018. doi:10.1111/apt.13366. 1896 75. Hui J, Kench JG, Chitturi S, et al. Long-Term outcomes of cirrhosis in nonalcoholic 1897 steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420-427. 1898 doi:10.1053/jhep.2003.50320. 1899 76. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3731/52154. 1901 77. van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transplantation via colonoscopy for treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J. 1901 77. van Beurden	10	1886	72.	Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, Capsulized, Frozen
1888 2014;312(17):1772. doi:10.1001/jama.2014.13875. 1899 73. Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe complicated <i>Clostridium difficile</i> infection: description of a protocol 1891 with high success rate. <i>Aliment Phormacol Ther.</i> 2015;42(4):470-476. doi:10.1111/apt.13290. 1892 74. Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota 1893 transplant for recurrent Clostridium difficile infection using long-term frozen stool is 1894 effective: Clinical efficacy and bacterial viability data. <i>Aliment Phormacol Ther.</i> 1895 2015;42(8):1011-1018. doi:10.1111/apt.13366. 178 Hui J, Kench JG, Chitturi S, et al. Long-Term outcomes of cirrhosis in nonalcoholic 1897 steatohepatitis compared with hepatitis <i>C. Hepatology.</i> 2003;38(2):420-427. 1898 doi:10.1053/jhep.2003.50320. 1899 76. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. <i>J Vis Exp.</i> 2014;(94). doi:10.3791/52154. 1901 77. van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transplantation via clostridium difficile infection. <i>United Eur Gastroenterol J</i> . 1902 effectiveness, and long term fol		1887		Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection. JAMA.
1890 vancomycin for severe-complicated Clostridium difficile infection: description of a protocol 1891 with high success rate. Aliment Pharmacol Ther. 2015;42(4):470-476. doi:10.1111/apt.13290. 1892 74. Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota 1893 transplant for recurrent Clostridium difficile infection using long-term frozen stool is 1894 effective: Clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 1895 2015;42(8):1011-1018. doi:10.1111/apt.13366. 1896 75. Hui J, Kench JG, Chitturi S, et al. Long-Term outcomes of cirrhosis in nonalcoholic 1897 steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420-427. 1898 doi:10.1053/jhep.2003.50320. 1899 76. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154. 1901 77. van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J. 2017;5(6):868-879. doi:10.1177/2050640616678099. 1905 78. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal Microbiota Transplantation. Clin G	13	1888		2014;312(17):1772. doi:10.1001/jama.2014.13875.
1890 vancomycin for severe-complicated Clostridium difficile infection: description of a protocol 1891 with high success rate. Aliment Pharmacol Ther. 2015;42(4):470-476. doi:10.1111/apt.13290. 1892 74. Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota 1893 transplant for recurrent Clostridium difficile infection using long-term frozen stool is 1894 effective: Clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 1895 2015;42(8):1011-1018. doi:10.1111/apt.13366. 1896 75. Hui J, Kench JG, Chitturi S, et al. Long-Term outcomes of cirrhosis in nonalcoholic 1897 steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420-427. 1898 doi:10.1053/jhep.2003.50320. 1899 76. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for 1900 recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154. 1901 77. van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, 1901 902 effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for 1903 transplantation. Clin Gastroenterol J. 2011;9(12):1044-1049. 1904 2017;5(6):868-879. doi:10.1177/2050640616678099.		1889	73.	Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of
1891 with high success rate. Aliment Pharmacol Ther. 2015;42(4):470-476. doi:10.1111/apt.13290. 1892 74. Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota 1893 transplant for recurrent Clostridium difficile infection using long-term frozen stool is 1894 effective: Clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 1895 2015;42(8):1011-1018. doi:10.1111/apt.13366. 1896 75. Hui J, Kench JG, Chitturi S, et al. Long-Term outcomes of cirrhosis in nonalcoholic 1897 steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420-427. 1898 doi:10.1053/jhep.2003.50320. 1899 76. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for 1900 recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154. 1901 77. van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, 1902 effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for 1903 treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J. 1904 2017;5(6):868-879. doi:10.1177/2050640616678099. 1905 78. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infect		1890		vancomycin for severe-complicated Clostridium difficile infection: description of a protocol
1892 74. Costello SP, Conton MA, Yuaran MS, Roberts- Inomson IC, Andrews JM. Faccal microbiota 1893 transplant for recurrent Clostridium difficile infection using long-term frozen stool is 1894 effective: Clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 1895 2015;42(8):1011-1018. doi:10.1111/apt.13366. 1896 75. Hui J, Kench JG, Chitturi S, et al. Long-Term outcomes of cirrhosis in nonalcoholic 1897 steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420-427. 1898 doi:10.1053/jhep.2003.50320. 1899 76. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for 1900 recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154. 1901 77. van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, 1902 effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for 1903 treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J. 1904 2017;5(6):868-879. doi:10.1177/2050640616678099. 1905 78. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal 1906 Microbiota Transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-104	18	1891		with high success rate. Aliment Pharmacol Ther. 2015;42(4):470-476. doi:10.1111/apt.13290.
1893transplant for recurrent Clostridium difficile infection using long-term frozen stool is1894effective: Clinical efficacy and bacterial viability data. Aliment Pharmacol Ther.18952015;42(8):1011-1018. doi:10.1111/apt.13366.189675.Hui J, Kench JG, Chitturi S, et al. Long-Term outcomes of cirrhosis in nonalcoholic1897steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420-427.1898doi:10.1053/jhep.2003.50320.189976.Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for1900recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154.190177.van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications,1902effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for1903treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.19042017;5(6):868-879. doi:10.1177/2050640616678099.190578.Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal1906Microbiota Transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049.1907doi:10.1016/j.cgh.2011.08.014.190879.Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium1909difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool1910assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.191180.Baxter M, Colville A. Adverse events in fa		1892	74.	Costello SP, Conlon MA, Vuaran MS, Roberts-Thomson IC, Andrews JM. Faecal microbiota
1894effective: Clinical efficacy and bacterial viability data. Aliment Pharmacol Ther.18952015;42(8):1011-1018. doi:10.1111/apt.13366.189675.1897steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420-427.1898doi:10.1053/jhep.2003.50320.189976.189976.1900recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154.190177.1902effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for1903treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.19042017;5(6):868-879. doi:10.1177/2050640616678099.190578.Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal19041907doi:10.1016/j.cgh.2011.08.014.190879.Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium1909difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool1909assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.191080.Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the1912literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024.	22	1893		transplant for recurrent Clostridium difficile infection using long-term frozen stool is
2518952015;42(8):1011-1018. doi:10.1111/apt.13366.75.Hui J, Kench JG, Chitturi S, et al. Long-Term outcomes of cirrhosis in nonalcoholic1897steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420-427.1898doi:10.1053/jhep.2003.50320.189976.Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154.1900recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154.190177.van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.1902effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.19042017;5(6):868-879. doi:10.1177/2050640616678099.190578.Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal Microbiota Transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049. doi:10.1016/j.cgh.2011.08.014.190879.Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.1910Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhi		1894		effective: Clinical efficacy and bacterial viability data. Aliment Pharmacol Ther.
 Hui J, Kench JG, Chitturi S, et al. Long-Term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. <i>Hepatology</i>. 2003;38(2):420-427. doi:10.1053/jhep.2003.50320. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. <i>J Vis Exp</i>. 2014;(94). doi:10.3791/52154. 77. van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection. <i>United Eur Gostroenterol J</i>. 2017;5(6):868-879. doi:10.1177/2050640616678099. 78. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal Microbiota Transplantation. <i>Clin Gastroenterol Hepatol</i>. 2011;9(12):1044-1049. doi:10.1016/j.gh.2011.08.014. 79. Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment. <i>Clin Microbiol Infect</i>. November 2017. doi:10.1016/J.CMI.2017.10.022. 80. Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. <i>J Hosp Infect</i>. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024. 	25	1895		2015;42(8):1011-1018. doi:10.1111/apt.13366.
1896 75. Hui J, Kehch JG, Chitturi S, et al. Long-Term Outcomes of chrnosis in hohalcoholic 1897 steatohepatitis compared with hepatitis C. Hepatology. 2003;38(2):420-427. 1898 doi:10.1053/jhep.2003.50320. 1899 76. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for 1900 recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154. 1901 77. van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, 1902 effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for 1903 treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J. 1904 2017;5(6):868-879. doi:10.1177/2050640616678099. 1905 78. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal 1906 Microbiota Transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049. 1907 doi:10.1016/j.cgh.2011.08.014. 1908 79. Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium 1909 difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool 1910 assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.				
301898doi:10.1053/jhep.2003.50320.31189976.Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154.331900recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154.34190177.van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.401903treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.4119042017;5(6):868-879. doi:10.1177/2050640616678099.43190578.Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal Microbiota Transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049. doi:10.1016/j.cgh.2011.08.014.44190879.Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool 	28		75.	
311898doi:10.1053/jhep.2003.50320.33189976.Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154.361900recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154.37190177.van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.401903treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.4119042017;5(6):868-879. doi:10.1177/2050640616678099.43190578.Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal Microbiota Transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049. doi:10.1016/j.cgh.2011.08.014.441907doi:10.1016/j.cgh.2011.08.014.45190879.Allegretti JS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.54191180.Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024.		1897		steatohepatitis compared with hepatitis C. <i>Hepatology</i> . 2003;38(2):420-427.
33189976.Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for341900recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154.36190177.van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications,381902effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for391903treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.4119042017;5(6):868-879. doi:10.1177/2050640616678099.43190578.Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal451906Microbiota Transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049.461907doi:10.1016/j.cgh.2011.08.014.48190879.Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium501909difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool531910assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.54191180.Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the551912literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024.	31	1898		doi:10.1053/jhep.2003.50320.
341900recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154.36190177.van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for381902effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for401903treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.4119042017;5(6):868-879. doi:10.1177/2050640616678099.43190578.Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal441906Microbiota Transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049.451906doi:10.1016/j.cgh.2011.08.014.48190879.Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium501909difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool511909assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.53191180.Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the551912literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024.		1899	76.	Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for
37190177.van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications,381902effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for391903treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.4119042017;5(6):868-879. doi:10.1177/2050640616678099.43190578.Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal44190578.Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal451906Microbiota Transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049.46471907471907doi:10.1016/j.cgh.2011.08.014.48190879.49190879.411909assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.541910assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.541912Ilterature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024.551912Ilterature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024.	34	1900		recurrent C. difficile Infection. J Vis Exp. 2014;(94). doi:10.3791/52154.
381902effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for391903treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.4119042017;5(6):868-879. doi:10.1177/2050640616678099.42190578.Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal451906Microbiota Transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049.46doi:10.1016/j.cgh.2011.08.014.471907doi:10.1016/j.cgh.2011.08.014.48190879.Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium501909difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool521910assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.53191180.Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the561912literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024.		1901	77.	van Beurden YH, de Groot PF, van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications,
401903treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.4119042017;5(6):868-879. doi:10.1177/2050640616678099.43190578.Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal44190578.Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal451906Microbiota Transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049.46471907471907doi:10.1016/j.cgh.2011.08.014.4849190879.49190879.40Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium501909difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool521910assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.53191180.Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the551912literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024.57585914000000000000000000000000000000000000	38	1902		effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for
 1904 2017,5(0).808-879. doi:10.1177/2030040010078059. 1905 78. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal 1906 Microbiota Transplantation. <i>Clin Gastroenterol Hepatol</i>. 2011;9(12):1044-1049. 1907 doi:10.1016/j.cgh.2011.08.014. 1908 79. Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium 1909 difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool 1910 assessment. <i>Clin Microbiol Infect</i>. November 2017. doi:10.1016/J.CMI.2017.10.022. 1911 80. Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the 1912 literature. <i>J Hosp Infect</i>. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024. 		1903		treatment of recurrent Clostridium difficile infection. United Eur Gastroenterol J.
43 44190578.Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile Infection With Fecal45 46 471906Microbiota Transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-1049. doi:10.1016/j.cgh.2011.08.014.48 49190879.Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.54 55 561911 191280.Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024.		1904		2017;5(6):868-879. doi:10.1177/2050640616678099.
 Microbiota Transplantation. <i>Clin Gastroenterol Hepatol</i>. 2011;9(12):1044-1049. Horobiota Transplantation. <i>Clin Microbiol Infect</i>. November 2017. doi:10.1016/J.CMI.2017.10.022. Horobiota Transplantation. <i>Clin Microbiol Infect</i>. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024. Horobiota Transplantation. <i>Clin Gastroenterol</i>. Horobiota Transplantation. <i>Clin Hepatol</i>. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024. 	43	1905	78.	Bakken JS. Borody T. Brandt LJ. et al. Treating Clostridium difficile Infection With Fecal
 46 47 49 49 49 50 50 51 54 54 55 54 55 56 56 57 56 57 58 59 				
 Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool assessment. <i>Clin Microbiol Infect</i>. November 2017. doi:10.1016/J.CMI.2017.10.022. Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. <i>J Hosp Infect</i>. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024. 	46			
501909difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool511910assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.5354191180.54191180.Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the551912literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024.57585962				
511909difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool521910assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.5354191180.54191180.Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the551912literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024.57585959		1908	79.	Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium
521910assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.5354191180.Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the55561912literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024.575859621000000000000000000000000000000000000		1909		difficile carriage rate post-fecal microbiota transplant is low: a prospective clinical and stool
54 1911 80. Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the 55 1912 literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024. 57 58 59 62	52	1910		assessment. Clin Microbiol Infect. November 2017. doi:10.1016/J.CMI.2017.10.022.
 55 56 1912 literature. J Hosp Infect. 2016;92(2):117-127. doi:10.1016/j.jhin.2015.10.024. 57 58 59 	54	1911	80.	Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the
57 58 59 62				
59 62	57			
$\mathbf{D}_{\mathbf{A}}$				
-	60			https://mc.manuscriptcentral.com/gut

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1		HIS/	BSG FMT Guideline: Main Document, <i>Gut</i> version.
1 2			
3	1913	81.	Hefazi M, Patnaik MM, Hogan WJ, Litzow MR, Pardi DS, Khanna S. Safety and Efficacy of Fecal
4 5	1914		Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer
6	1915		Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. Mayo
7 8	1916		<i>Clin Proc</i> . 2017;92(11):1617-1624. doi:10.1016/j.mayocp.2017.08.016.
9	1917	82.	Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti JR. The risk of inflammatory
10 11		02.	bowel disease flares after fecal microbiota transplantation: Systematic review and meta-
12	1918		
13 14	1919		analysis. Gut Microbes. July 2017:1-15. doi:10.1080/19490976.2017.1353848.
15	1920	83.	Meighani A, Hart BR, Mittal C, Miller N, John A, Ramesh M. Predictors of fecal transplant
16 17	1921		failure. Eur J Gastroenterol Hepatol. 28:826-830. doi:10.1097/MEG.0000000000000614.
18 19	1922	84.	Alrabaa S, Jariwala R, Zeitler K, Montero J. Fecal microbiota transplantation outcomes in
20 21	1923		immunocompetent and immunocompromised patients: A single-center experience. <i>Transpl</i>
21	1924		Infect Dis. 2017;19(4):e12726. doi:10.1111/tid.12726.
23 24			
25	1925	85.	Cohen NA, Livovsky DM, Yaakobovitch S, et al. A Retrospective Comparison of Fecal Microbial
26 27	1926		Transplantation Methods for Recurrent Clostridium Difficile Infection. <i>Isr Med Assoc J</i> .
28	1927		2016;18(10):594-599.
29 30	1928	86.	Orenstein R, Dubberke E, Hardi R, et al. Safety and Durability of RBX2660 (Microbiota
31	1929		Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. Clin
32 33	1930		Infect Dis. 2016;62(5):596-602. doi:10.1093/cid/civ938.
34 35	1021	07	Linch DE Caraine N. Daath K. Caburata DM. Eastain NE Ularia C. Effectiveness of food
36	1931	87.	Hirsch BE, Saraiya N, Poeth K, Schwartz RM, Epstein ME, Honig G. Effectiveness of fecal-
37 38	1932		derived microbiota transfer using orally administered capsules for recurrent Clostridium
39	1933		difficile infection. BMC Infect Dis. 2015;15(1):191. doi:10.1186/s12879-015-0930-z.
40 41	1934	88.	Kao D, Roach B, Beck P, Hotte N, Madsen K, Louie T. A dual center, randomized trial
42	1935		comparing colonoscopy and oral capsule delivered fecal microbiota transplantation in the
43 44	1936		treatment of recurrent clostridium difficile infection: Preliminary results. Am J Gastroenterol.
45	1937		2015;110:S553. doi:http://dx.doi.org/10.1038/ajg.2015.294.
46 47	1938	89.	Youngster I, Mahabamunuge J, Systrom HK, et al. Oral, frozen fecal microbiota transplant
48	1939	05.	(FMT) capsules for recurrent Clostridium difficile infection. <i>BMC Med</i> . 2016;14(1):134.
49 50	1939		doi:10.1186/s12916-016-0680-9.
51 52	1940		001.10.1180/512910-010-0080-9.
53	1941	90.	Anand R, Song Y, Garg S, et al. Effect of Aging on the Composition of Fecal Microbiota in
54 55	1942		Donors for FMT and Its Impact on Clinical Outcomes. <i>Dig Dis Sci</i> . 2017;62(4):1002-1008.
56	1943		doi:10.1007/s10620-017-4449-6.
57 58			
59			https://mc.manus <mark>63</mark> ptcentral.com/gut
60			nups://mc.manuscriptcentral.com/gut

1

1944	91.	Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open forum Infect Dis.
1945		2015;2(1):ofv004. doi:10.1093/ofid/ofv004.
1946	92.	Fischer M, Kao D, Kassam Z, et al. Stool Donor Body Mass Index Does Not Affect Recipient
1947		Weight After a Single Fecal Microbiota Transplantation for C. difficile Infection. Clin
1948		Gastroenterol Hepatol. December 2017. doi:10.1016/J.CGH.2017.12.007.
1949	93.	Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical
1950		frontier. <i>Gut</i> . 2016;65(2):330-339. doi:10.1136/gutjnl-2015-309990.
1951	94.	Allegretti JR, Fischer M, Papa E, et al. Su1738 Fecal Microbiota Transplantation Delivered via
1952		Oral Capsules Achieves Microbial Engraftment Similar to Traditional Delivery Modalities:
1953		Safety, Efficacy and Engraftment Results From a Multi-Center Cluster Randomized Dose-
1954		Finding Study. Gastroenterology. 2016;150(4):S540. doi:10.1016/S0016-5085(16)31855-8.
1955	95.	Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout
1956		development and alternative approaches for therapeutic modulation. Genome Med.
1957		2016;8(1):39. doi:10.1186/s13073-016-0294-z.
1958	96.	Lange K, Buerger M, Stallmach A, Bruns T. Effects of Antibiotics on Gut Microbiota. Dig Dis.
1959		2016;34(3):260-268. doi:10.1159/000443360.
1960	97.	Becattini S, Taur Y, Pamer EG. Antibiotic-Induced Changes in the Intestinal Microbiota and
1961		Disease. Trends Mol Med. 2016;22(6):458-478. doi:10.1016/j.molmed.2016.04.003.
1962	98.	Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between
1963		good and evil. Gut. 2016;65(11):1906-1915. doi:10.1136/gutjnl-2016-312297.
1964	99.	Boostrom SY, Mathis KL, Pendlimari R, et al. Burden of Clostridium difficile on the healthcare
1965		system. Inflamm Bowel Dis. 2012;18(1):994-1002. doi:10.1126/science.1241214.
1966	100.	J.R. A, J.R. K, M.J. H. Intestinal microbiome restoration for recurrent clostridium difficile
1967		infection in patients with concurrent inflammatory bowel disease. Gastroenterology.
1968		2015;148(4 SUPPL. 1):S869.
1969	101.	National Health Service. Population screening programmes: NHS bowel cancer screening
1970		(BCSP) programme - GOV.UK. https://www.gov.uk/topic/population-screening-
1971		programmes/bowel. Accessed June 10, 2018.
1972	102.	London: TSO Guidelines for the Blood Transfusion Services in the United Kingdom 7 th Edition
1973		2005 TSO Accredited Agents Web Access.
		https://mc.manuscriptcentral.com/gut
	 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1965 1964 1965 1965 1964 1965 <li< td=""><td>1945194692.194793.194893.195094.195194.195294.195395.195495.195595.195697.195896.195993.195495.195595.195610.195795.195896.195910.196197.196298.1963100.196499.1965100.1965100.1967101.1970101.1971102.</td></li<>	1945194692.194793.194893.195094.195194.195294.195395.195495.195595.195697.195896.195993.195495.195595.195610.195795.195896.195910.196197.196298.1963100.196499.1965100.1965100.1967101.1970101.1971102.

Gut

Page 141	l of 454		Gut
1		HIS/ E	3SG FMT Guideline: Main Document, Gut version.
2	1974	103.	Emanuelsson F, Claesson BEB, Ljungström L, Tvede M, Ung K-A. Faecal microbiota
3 4	1974	105.	transplantation and bacteriotherapy for recurrent Clostridium difficile infection: A
5 6	1975		retrospective evaluation of 31 patients. <i>Scand J Infect Dis.</i> 2014;46(2):89-97.
7	1976		doi:10.3109/00365548.2013.858181.
8 9	1977		001.10.5109/00505546.2015.656161.
10	1978	104.	Endtz HP, van den Braak N, van Belkum A, et al. Fecal carriage of vancomycin-resistant
11 12	1979		enterococci in hospitalized patients and those living in the community in The Netherlands. J
13	1980		<i>Clin Microbiol</i> . 1997;35(12):3026-3031. http://www.ncbi.nlm.nih.gov/pubmed/9399488.
14 15	1981		Accessed February 15, 2018.
16 17	1982	105.	Willems RJL, Top J, van Santen M, et al. Global spread of vancomycin-resistant Enterococcus
18 19	1983		faecium from distinct nosocomial genetic complex. Emerg Infect Dis. 2005;11(6):821-828.
20 21	1984		doi:10.3201/eid1106.041204.
21 22 23	1985	106.	Gough E, Shaikh H, Manges AR. Systematic Review of Intestinal Microbiota Transplantation
24	1986		(Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection. Clin Infect Dis.
25 26	1987		2011;53(10):994-1002. doi:10.1093/cid/cir632.
27 28	1988	107.	Casewell MW, Slater NGP, Cooper JE. Operating theatre water-baths as a cause of
29	1989		pseudomonas septicaemia. <i>J Hosp Infect</i> . 1981;2:237-240. doi:10.1016/0195-6701(81)90043-
30 31	1990		8.
32 33	1991	108.	Muyldermans G, de Smet F, Pierard D, et al. Neonatal infections with Pseudomonas
34 35	1992		aeruginosa associated with a water-bath used to thaw fresh frozen plasma. J Hosp Infect.
36	1993		1998;39(4):309-314. http://www.ncbi.nlm.nih.gov/pubmed/9749402. Accessed June 11,
37 38	1994		2018.
39 40	1995	109.	Sleight SC, Wigginton NS, Lenski RE. Increased susceptibility to repeated freeze-thaw cycles in
41 42	1996		Escherichia coli following long-term evolution in a benign environment. BMC Evol Biol.
42 43 44	1997		2006;6(1):104. doi:10.1186/1471-2148-6-104.
45	1998	110.	O'Brien CL, Allison GE, Grimpen F, Pavli P. Impact of colonoscopy bowel preparation on
46 47	1999		intestinal microbiota. PLoS One. 2013;8(5):e62815. doi:10.1371/journal.pone.0062815.
48 49	2000	111.	Mai V, Stine OC. Bowel preparation for colonoscopy: relevant for the gut's microbiota? <i>Gut</i> .
50 51	2001		2015;64(10):1504-1505. doi:10.1136/gutjnl-2014-308937.
52	2002	112.	Jalanka J, Salonen A, Salojärvi J, et al. Effects of bowel cleansing on the intestinal microbiota.
53 54	2002	114.	<i>Gut.</i> 2015;64(10):1562-1568. doi:10.1136/gutjnl-2014-307240.
55	2005		Gat. 2013,04(10).1302 1300. doi:10.1130/gatjii-2014-30/240.
56 57	2004	113.	Mai V, Greenwald B, Glenn Morris J, Raufman J-P, Stine OC. Effect of bowel preparation and
58 59			
60			https://mc.manuscriptcentral.com/gut

https://mc.manuscriptcentral.com/gut

1

2			
3	2005		colonoscopy on post-procedure intestinal microbiota composition. Gut. 2006;55(12):1822-
4 5	2006		1823. doi:10.1136/gut.2006.108266.
6 7	2007	114.	Harrell L, Wang Y, Antonopoulos D, et al. Standard Colonic Lavage Alters the Natural State of
8	2008		Mucosal-Associated Microbiota in the Human Colon. Singh SR, ed. PLoS One.
9 10	2009		2012;7(2):e32545. doi:10.1371/journal.pone.0032545.
11 12	2010	115.	Chin SM, Sauk J, Mahabamunuge J, Kaplan JL, Hohmann EL, Khalili H. Fecal Microbiota
13 14	2011		Transplantation for Recurrent Clostridium difficile Infection in Patients With Inflammatory
15	2012		Bowel Disease: A Single-Center Experience. Clin Gastroenterol Hepatol. 2017;15(4):597-599.
16 17 18	2013		doi:10.1016/j.cgh.2016.11.028.
19	2014	116.	Wang S, Xu M, Wang W, et al. Systematic Review: Adverse Events of Fecal Microbiota
20 21	2015		Transplantation. PLoS One. 2016;11(8):e0161174. doi:10.1371/journal.pone.0161174.
22 23	2016	117.	Khoruts A, Rank KM, Newman KM, et al. Inflammatory Bowel Disease Affects the Outcome of
24	2017		Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Clin
25 26 27	2018		Gastroenterol Hepatol. 2016;14(10):1433-1438. doi:10.1016/j.cgh.2016.02.018.
28	2019	118.	de Jager CPC, Wever PC, Gemen EFA, et al. Proton pump inhibitor therapy predisposes to
29 30	2020		community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther.
31 32	2021		2012;36(10):941-949. doi:10.1111/apt.12069.
33 34	2022	119.	Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome.
35 36	2023		<i>Gut</i> . 2016;65(5):740-748. doi:10.1136/gutjnl-2015-310376.
37 38	2024	120.	McDonald EG, Milligan J, Frenette C, Lee TC. Continuous Proton Pump Inhibitor Therapy and
39	2025		the Associated Risk of Recurrent Clostridium difficile Infection. JAMA Intern Med.
40 41	2026		2015;175(5):784. doi:10.1001/jamainternmed.2015.42.
42 43	2027	121.	Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-Associated Diarrhea and
44	2028		Proton Pump Inhibitor Therapy: A Meta-Analysis. Am J Gastroenterol. 2012;107(7):1001-
45 46 47	2029		1010. doi:10.1038/ajg.2012.179.
48	2030	122.	Girotra M, Garg S, Anand R, Song Y, Dutta SK. Fecal Microbiota Transplantation for Recurrent
49 50	2031		Clostridium difficile Infection in the Elderly: Long-Term Outcomes and Microbiota Changes.
50 51 52	2032		<i>Dig Dis Sci</i> . 2016;61(10):3007-3015. doi:10.1007/s10620-016-4229-8.
53 54	2033	123.	Hagel S, Fischer A, Ehlermann P, et al. Fecal Microbiota Transplant in Patients With Recurrent
55	2034		Clostridium Difficile Infection. Dtsch Arztebl Int. 2016;113(35-36):583-589.
56 57	2035		doi:10.3238/arztebl.2016.0583.
58			
59 60			https://mc.manuscriptcentral.com/gut

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1		HIS/ E	3SG FMT Guideline: Main Document, Gut version.
1 2			
3	2036	124.	Department of Health (UK). Management and decontamination of flexible endoscopes (HTM
4 5	2037		01-06) - GOV.UK. https://www.gov.uk/government/publications/management-and-
6 7	2038		decontamination-of-flexible-endoscopes. Accessed December 19, 2017.
8	2039	125.	British Society of Gastroenterology. Guidance on Decontamination of Equipment for
9 10	2040		Gastrointestinal Endoscopy: 2017 Edition. https://www.bsg.org.uk/resource/guidance-on-
11 12	2041		decontamination-of-equipment-for-gastrointestinal-endoscopy-2017-edition.html. Accessed
12 13 14	2042		December 19, 2017.
15	2043	126.	Loveday HP, Wilson JA, Pratt RJ, et al. epic3: National Evidence-Based Guidelines for
16 17	2044		Preventing Healthcare-Associated Infections in NHS Hospitals in England. J Hosp Infect.
18 19	2045		2014;86(1):S1-S70. doi:10.1016/S0195-6701(13)60012-2.
20 21	2046	127.	Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal Microbiota Transplantation for Clostridium difficile
22	2047		Infection: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2013;108(4):500-508.
23 24	2048		doi:10.1038/ajg.2013.59.
25 26	2049	128.	Allegretti JR, Kao D, Sitko J, Fischer M, Kassam Z. Early antibiotic use post-fecal microbiota
27	2050		transplantation increases the risk of treatment failure. <i>Clin Infect Dis</i> . August 2017.
28 29	2051		doi:10.1093/cid/cix684.
30	2002		
31 32	2052	129.	Terveer EM, van Beurden YH, Goorhuis A, et al. How to: Establish and run a stool bank. <i>Clin</i>
33	2053		<i>Microbiol Infect</i> . 2017;23(12):924-930. doi:10.1016/j.cmi.2017.05.015.
34 35 26	2054	130.	Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of
36 37	2055		faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium
38	2056		difficile infection. Aliment Pharmacol Ther. 2017;46(5):479-493. doi:10.1111/apt.14201.
39 40 41	2057	131.	Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of
42	2058		Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48(8):693-702.
43 44	2059		doi:10.1097/MCG.000000000000046.
45	2000	122	D. D. L. D. C. et al. Food migraphieto transplantation for electricity of difficile infections
46 47	2060	132.	D. D, J. R, S. G, et al. Fecal microbiota transplantation for clostridium difficile infection a
48	2061		systematic review. Ann Intern Med. 2015;162(9):630-638.
49 50	2062	133.	Baxter M, Ahmad T, Colville A, Sheridan R. Fatal Aspiration Pneumonia as a Complication of
51	2063		Fecal Microbiota Transplant. Clin Infect Dis. 2015;61(1):136-137. doi:10.1093/cid/civ247.
52 53	2064	134.	Hecker MT, Obrenovich ME, Cadnum JL, et al. Fecal Microbiota Transplantation by Freeze-
54 55	2065		Dried Oral Capsules for Recurrent Clostridium difficile Infection. Open forum Infect Dis.
56	2066		2016;3(2):ofw091. doi:10.1093/ofid/ofw091.
57 58			
59			https://mc.manuscriptcentral.com/gut
60			https://meinanaschpteentral.com/gut

Page 144 of 454

HIS/ BSG FMT Guideline: Main Document, Gut version.

1

Gut

2			
3	2067	135.	Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? <i>Nat</i>
4 5	2068		Rev Gastroenterol Hepatol. 2017;14(10):573-584. doi:10.1038/nrgastro.2017.88.
6 7	2069	136.	Rossen NG, Fuentes S, van der Spek MJ, et al. Findings From a Randomized Controlled Trial of
8	2070		Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. 2015;149(1):110-
9 10 11	2071		118.e4. doi:10.1053/j.gastro.2015.03.045.
12	2072	137.	Moayyedi P, Surette MG, Kim PT, et al. Fecal Microbiota Transplantation Induces Remission in
13 14	2073		Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology.
15 16	2074		2015;149(1):102-109.e6. doi:10.1053/j.gastro.2015.04.001.
17 18	2075	138.	Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota
19	2076		transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet
20 21 22	2077		(London, England). 2017;389(10075):1218-1228. doi:10.1016/S0140-6736(17)30182-4.
22	2078	139.	Costello S, Waters O, Bryant R. Short Duration, Low Intensity, Pooled Fecal Microbiota
24 25	2079		Transplantation Induces Remission in Patients with Mild-Moderately Active Ulcerative Colitis:
25 26 27	2080		A Randomised Controlled Trial. (Abstract). Gastroenterology. 152(5):S198-S199.
28	2081	140.	Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo
29 30	2082		for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-
31	2083		controlled, parallel-group, single-centre trial. <i>lancet Gastroenterol Hepatol</i> . 2018;3(1):17-24.
32 33 34	2084		doi:10.1016/S2468-1253(17)30338-2.
35	2085	141.	Tian H, Ge X, Nie Y, et al. Fecal microbiota transplantation in patients with slow-transit
36 37	2086		constipation: A randomized, clinical trial. Green J, ed. <i>PLoS One</i> . 2017;12(2):e0171308.
38 39	2087		doi:10.1371/journal.pone.0171308.
40	2088	142.	Bajaj JS, Kassam Z, Fagan A, et al. Fecal Microbiota Transplant from a Rational Stool Donor
41 42	2089		Improves Hepatic Encephalopathy: A Randomized Clinical Trial. <i>Hepatology</i> . June 2017.
43 44	2090		doi:10.1002/hep.29306.
45 46	2091	143.	Vrieze A, Van Nood E, Holleman F, et al. Transfer of Intestinal Microbiota From Lean Donors
47 48	2092		Increases Insulin Sensitivity in Individuals With Metabolic Syndrome. Gastroenterology.
48 49 50	2093		2012;143(4):913-916.e7. doi:10.1053/j.gastro.2012.06.031.
51	2094	144.	Kootte RS, Levin E, Salojärvi J, et al. Improvement of Insulin Sensitivity after Lean Donor Feces
52 53	2095		in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab.
54 55	2096		2017;26(4):611-619.e6. doi:10.1016/j.cmet.2017.09.008.
56 57	2097		
58 59 60			https://mc.manuscriptcentral.com/gut

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

2 3	2098	
4 5	2099	
6 7 8	2100	
9 10	2101	
11 12	2102	
13 14	2103	
15 16 17	2104	
17 18 19	2105	
20 21	2106	
22 23	2107	
24 25 26	2108	
26 27 28	2109	
29 30	2110	
31 32	2111	
33 34 35	2112	
36 37	2113	
38 39	2114	
40	2115	
41 42	2116	
43	2117	
44 45 46	2118	15. Figure legends and tables:
47 48	2119	Figure 1: Proposed summary pathway for donor screening for centres preparing frozen FMT from
49	2120	recurring donors.
50 51	2121	
52 53		
53 54	2122	Table 1: Recommended donor history/ questionnaire: A positive response to any of these
55	2123	questions would usually result in exclusion from further consideration as a donor, although this
56 57 58	2124	would depend upon the particular circumstances/ answers given.
59		https://mc.manuscriptcentral.com/gut
60		https://ficinaliuscipteential.com/gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

1 2		HIS/ BSG FMT Guideline: Main Document, Gut version.
2 3	2125	1. Receipt of antimicrobials within the past three months.
4 5	2126	2. Known prior exposure to HIV and/ or viral hepatitis, and known previous or latent
6	2127	tuberculosis.
7 8	2128	3. Risk factors for blood-borne viruses - including high risk sexual behaviours, use of illicit
9 10	2129	drugs, any tattoo/ body piercing/ needlestick injury/ blood transfusion/ acupuncture, all
10 11	2130	within the previous six months.
12 13	2131	4. Receipt of a live attenuated virus within the past six months.
14	2132	5. Underlying gastrointestinal conditions/ symptoms (e.g. history of IBD, IBS, chronic diarrhoea,
15 16	2133	chronic constipation, coeliac disease, bowel resection or bariatric surgery) - also including
17	2134	acute diarrhoea/ gastrointestinal symptoms within the past two weeks.
18 19	2135	6. Family history of any significant gastrointestinal conditions (e.g. family history of IBD, or
20 21	2136	colorectal cancer).
22	2137	7. History of atopy (e.g. asthma, eosinophilic disorders).
23 24	2138	8. Any systemic autoimmune conditions.
25	2139	9. Any metabolic conditions, including diabetes and obesity.
26 27	2140	10. Any neurological or psychiatric conditions, or known risk of prion disease.
28 29	2141	11. History of chronic pain syndromes, including chronic fatigue syndrome and fibromyalgia.
30	2142	12. History of any malignancy.
31 32	2143	13. Taking particular regular medications, or such medications within the past three months, i.e.
33	2144	antimicrobials, proton pump inhibitors, immunosuppression, chemotherapy
34 35	2145	14. History of receiving growth hormone, insulin from cows, or clotting factor concentrates.
36 27	2146	15. History of receiving an experimental medicine or vaccine within the past six months.
37 38	2147	16. History of travel to tropical countries within the past six months.
39 40		
41	2148	
42 43	2149	
44 45	2150	Table 2: Recommended blood screening for stool donors: *EBV and CMV testing is only
45 46	2150	recommended where there is the potential that the FMT prepared from that donor will be
47 48	2151	administered to immunosuppressed patients at risk of severe infection if exposed to CMV and EBV.
49	2152	
50 51		
52		
53 54		
55		
56 57		
58		
59 60		https://mc.manuscriptcentral.com/gut

https://mc.manuscriptcentral.com/gut

60

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

Gut

Pathogen screening: Hepatitis A IgM Hepatitis B (HBsAg and HBcAb) Hepatitis C antibody . Hepatitis E IgM . HIV -1 and -2 antibodies HTLV-1 and -2 antibodies Treponema pallidum antibodies (TPHA, VDRL) Epstein-Barr virus IgM and IgG* Cytomegalovirus IgM and IgG* • Strongyloides stercoralis IgG . Entamoeba histolytica serology *General/ metabolic screening:* Full blood count with differential. Creatinine and electrolytes Liver enzymes (including albumin, bilirubin, aminotransferases, gamma-glutamyltransferase and alkaline phosphatase). C-reactive protein Table 3: Recommended stool screening for stool donors: *Whilst CPE and ESBL are the only multi-drug resistant bacteria that are recommended to be screened for universally, consider testing for other resistant organisms (including vancomycin-resistant Enterococci (VRE) and/ or methicillin-resistant Staphylococcus aureus (MRSA)) based upon risk assessment and local prevalence.

https://mc.manuscriptcentral.com/gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

GRA	DE - strength of evidence:	GRADE - strength of recommendation:
2179	Table 4: A summary of the GRADE system:	
2178		
2177		
2176		
2175		
2174		
2173		
2172		
2171		
2170		
2169		
2168		
2167		
2166		
2165		
2164		
2465	• Norovirus, Rotavirus PCR.	
	Helicobacter pylori faecal antigen.	
	Acid fast stain for <i>Cyclospora</i> and <i>Isospor</i>	
	 Stool ova, cysts and parasite analysis, inc Faecal antigen for <i>Cryptosporidium</i> and <i>C</i> 	
	(CPE) and extended-spectrum beta-lacta	
		carbapenemase-producing <i>Enterobacteriace</i>
	Shiga toxin-producing <i>Escherichia coli</i> by	
	Campylobacter, Salmonella, and Shigella	by standard stool culture and/ or PCR
	Clostridium difficile PCR	

Gut

HIS/ BSG FMT Guideline: Main Document, Gut version.

High quality: Further research is very unlikely to change our	The trade-offs: Taking into account the
confidence in the estimate of effect.	estimate size of the effect for main outcome
	the confidence limits around those estimat
	and the relative value placed on each outcome
Moderate quality: Further research is likely to have an	The quality of the evidence.
important impact on our confidence in the estimate of effect	
and may change the estimate.	
Low quality: Further research is very likely to have an	Translation of the evidence into practice in
important impact on our confidence in the estimate of effect	particular setting: Taking into considerati
and is likely to change the estimate.	important factors that could be expected
	modify the size of expected effects.
Very low quality: Any estimate of effect is very uncertain.	Uncertainty about the baseline risk for t
	population of interest.
2183 2184 2185 2186	
2187	
2187 2188	
2188	
2188 2189	
2188 2189 2190	

HIS/ BSG FMT Guideline: Main Document, Gut version.

Clear instructions should be given to donors regarding hand hygiene. Collect stool donations in a sealable clean container. A number of specifically designed devices are available commercially.

 etty into th.

 utansferred to th.

 uetrer, if a short period of storage to

 Stool should ideally be passed directly into the clean container for collection; alternatively, it may be collected in clean tissue and transferred to the clean container. Stool should be transported to the FMT production site as soon as possible post defaecation (and within six hours); however, if a short period of storage is necessary, this should be at 4°C.

The use of faecal microbiota transplant as treatment for recurrent or refractory *Clostridium difficile* infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.

Supplementary Material 1: General additional information:

1. Additional information:

1.1. Lay summary:

Faecal microbiota transplant (FMT) involves the transfer of a sample of faeces from a healthy donor to a recipient. There are several different ways to administer the transplant, including via endoscopy, rectally as an enema, via nasogastric/ nasoenteral tube (tube passed through the nose into the stomach/ upper part of the small intestine), or via oral ingestion of capsules that contain faecal material. The transplant may either be administered fresh (i.e. immediately after preparation), or may be prepared in advance, stored in a freezer and thawed when required. FMT is an accepted and effective treatment for recurrent infection by *Clostridium difficile*, a bacterium which can cause severe illness with diarrhoea, most commonly in frail elderly populations as a complication of antibiotic use. Despite adequate treatment, *Clostridium difficile* infection recurs in about 25% of patients, and some may suffer multiple recurrences.

This guideline reviews the evidence for FMT as a treatment for *Clostridium difficile* infection (CDI) and other conditions. Recommendations are made for: which patients are most likely to benefit, how donors should be selected and screened, how FMT should be prepared and administered, how patients should be followed up, and how FMT services should be configured.

1.2. Working Party Report

1.2.1. What is the Working Party Report?

The report is a set of recommendations covering key aspects of safe and efficacious delivery of a FMT service for recurrent/ refractory *Clostridium difficile* infection (CDI). The guidelines also review the evidence for the use of FMT for non-CDI indications.

1.2.2. Why do we need a Working Party Report for this topic?

There is widespread and growing interest in the use of FMT as a treatment for recurrent CDI. The previous absence of randomised trials and lack of evidence-based guidelines describing best practice related to its use has led to uncertainty as to how to establish an FMT service. Existing services may be providing suboptimal clinical care. There is now a developing portfolio of randomised study evidence (including randomised controlled trial data) regarding the use of FMT in CDI and non-CDI indications, providing the opportunity to develop an evidence-based guideline for its use. There have also been recent changes to the UK regulatory framework for FMT (see **Supplementary Material 3**), which are not well-understood by clinicians.

1.2.3. What is the purpose of the Working Party Report's recommendations?

The main purpose is to inform clinicians about the use of FMT (and about the establishment of this service) for the treatment of recurrent and refractory CDI, and other possible future indications. The recommendations provide an evidence-based approach to a high quality clinical service, with appropriate governance structures. This document also serves to illustrate areas in which there are current gaps in knowledge, which will help to direct future areas of research.

1.2.4. Who are these guidelines for?

Any healthcare practitioner may use these guidelines and adapt them for their use. It is anticipated that users will include clinical staff, as well as healthcare infection prevention and control teams. It is expected that these guidelines will raise awareness of FMT amongst clinicians who care for patients with recurrent or refractory CDI, but who may be unaware that it is a feasible and accessible treatment option. The guidelines are also designed to be read by patients with CDI, helping them to understand whether FMT may be an appropriate treatment option for them.

1.2.5. How are the guidelines structured?

Each section comprises an introduction, a summary of the evidence base with levels, and a recommendation graded according to the available evidence.

1.2.6. Aim

The primary aim of this report was to assess the current evidence for all aspects relating to provision of an FMT service as treatment for recurrent or refractory CDI. A secondary aim was to review the current evidence for the efficacy of FMT in treating non-CDI conditions.

1.3. Implementation of these guidelines:

1.3.1. How can these guidelines be used to improve clinical effectiveness?

Primarily, these guidelines will inform the development of local FMT services and appropriate local operational protocols, and will guide clinical decision-making. They also provide a framework for clinical audit, a tool for improving clinical effectiveness. In addition, the future research priorities identified by the working group will allow researchers to refine applications to funding bodies.

1.3.2. How much will it cost to implement these guidelines?

Where FMT is being provided under a MHRA license according to Good Manufacturing Practice (GMP) standards, there are significant costs associated with initial setup and maintenance of the service. These include the cost of obtaining the relevant license, laboratory design and equipment to enable quality assurance, storage facilities for samples, etc. However, there is counterbalance to this, as the expectation of the working group is that the publication of this guideline may encourage provision of FMT as treatment for recurrent or refractory CDI. This has consistently been shown to be cost effective in comparison with anti-*C. difficile* antimicrobial therapy^{1–4}, so overall costs associated with treating the condition may actually decrease. Furthermore, there may be changes to the practice of clinicians already offering the service. For example, encouraging the use of healthy unrelated donors (who can provide multiple stool donations after one screening) reduces the cost of screening when compared to the use of an FMT recipient's relative as donor, who is likely to provide one donation only.

1.3.3. E-learning tools:

Continuing Professional Development questions and their answers are provided for self-assessment in **Appendix 4** of this document.

2. Appendices

Appendix 1: Glossary

Clostridium difficile infection (CDI) - Symptomatic infection caused by the spore-forming, toxinsecreting bacterium, *Clostridium difficile*. It is the most common cause of antibiotic-associated diarrhoea, and symptoms include watery stools, fever, nausea, and abdominal pain.

Refractory CDI – Failure of an episode of CDI to respond to metronidazole and oral vancomycin, although no uniform definition.

Recurrent CDI – Defined in ESMID guidelines as 'when CDI re-occurs within 8 weeks after the onset of a previous episode, provided the symptoms from the previous episode resolved after completion of initial treatment'⁴; however, defined more variably within the reviewed literature within this guideline.

Faecal microbiota transplant – A procedure in which faecal matter (stool) is collected from a healthy screened donor, homogenised, strained, and introduced into the gastrointestinal tract of a patient.

Donor – In the context of FMT, this is a healthy screened individual that provides stool for the use in preparation of FMT.

Nasogastric – A means of reaching/ supplying the stomach via the nose for the purpose of treatment or investigation. This is usually achieved by the insertion of a tube.

Enema – A procedure in which liquid (or gas) is infused into the rectum as means for treatment or investigation.

Gut microbiota - Population of microorganisms that live in the gastrointestinal tract including bacteria, viruses and fungi.

Inflammatory bowel disease – Describes a group of chronic disorders (ulcerative colitis and Crohn's diseases) in which the gastrointestinal tract becomes inflamed. The exact cause is unknown but it is thought to result from a combination of factors that trigger the body's immune system to produce an inflammatory reaction in the gastrointestinal tract.

Medicines and Healthcare Products Regulatory Agency - An executive agency of the Department of Health in the United Kingdom which is responsible for ensuring that medicines and medical devices are efficacious and are acceptably safe.

Appendix 2: Guideline Development

Introduction

The need for a guideline within this area was agreed at a HIS guideline scoping day, and a BSG Gut Microbiota for Health (GMfH) panel teaching/ meeting day, both in September 2015, and further meetings between both bodies confirmed the establishment of a working group. Members were chosen to reflect the range of stakeholders, but were not limited to members of BSG or HIS. Feedback from the HIS guideline scoping day (including patient representatives) was used to establish a basis for PICO questions, with the final structure of PICO questions agreed collectively by teleconference in July 2017. No payment was made to anyone involved in this guideline.

Conflict of interest

Conflict of interest was registered from all working group members and underwent ongoing review up until the point of completion. In the event of a potential conflict being identified, the working group agreed that the member should not contribute to the section affected.

Search Strategy & Results

i. Literature search strategy: PICO Review Questions:

Review Question 1: Which patients with *Clostridium difficile* infection should be considered for faecal microbiota transplant, and how should they be followed up after treatment?

Populations: Adults (18 years and over) with *Clostridium difficile* infection

Intervention: Faecal microbiota transplant

Comparison: Placebo

Vancomycin

Metronidazole

Fidaxomicin Intravenous immunoglobulin Bezlotoxumab Probiotics Cessation of antibiotics for alternative indication **Outcomes:** Critical: Cessation of diarrhoea and other symptoms/ relapse Quality of life Serious adverse events Important: Negative tests for Clostridium difficile infection Adverse events Study design: Randomised trials If no randomised trials identified – prospective cohort studies and retrospective case series Review Question 2: What recipient factors influence the outcome of faecal microbiota transplant when treating people with *Clostridium difficile* infection? Populations: Adults (18 years and over) with Clostridium difficile infection Faecal microbiota transplant Intervention: Comparison: **Preparation of patient:** Use of bowel purgatives vs no bowel purgatives For upper GI administration - use of PPI/ acid suppression prior to procedure vs no acid suppression Use of agents affecting GI motility (e.g. metoclopramide for upper GI/ loperamide for lower GI) vs no use Time before procedure that anti-CDI antibiotics are used and stopped (comparing time courses)

Supplementary Material 1 for Gut

	Comorbidities	
	Severe CDI/ to	xic megacolon vs non-severe disease
	Co-existing inf	lammatory bowel disease (IBD) vs no IBD
	Immunosuppre	ession vs no immunosuppression
	Chronic liver d	lisease/ cirrhosis vs no chronic liver disease
Outcomes:	Critical:	Cessation of diarrhoea and other symptoms/ relapse
		Quality of life
		Serious adverse events
	Important:	Negative tests for Clostridium difficile infection
		Adverse events
Study design:	Randomised tr	rials
	If no randomi	sed trials identified – prospective cohort studies, retrospective case
	series	
Review Quest	ion 3: What de	onor factors influence the outcome of faecal microbiota transplant
when treating	people with <i>Clo</i>	ostridium difficile infection?
Populations:	Adults (18 yea	rs and over) with Clostridium difficile infection
Intervention:	Faecal microbi	iota transplant
Comparison:	Related vs unr	related donor
	Donor working	g in healthcare setting vs donor not from healthcare setting
	BMI (comparir	ng cut-offs used)
	Age (comparin	ig ages)
	Length of time	e since donor had antibiotics (comparing cut-offs used)
Outcomes:	Critical :	Cessation of diarrhoea and other symptoms/ relapse

https://mc.manuscriptcentral.com/gut

Page 158 of 454

Supplementary Material 1 for Gut

		Quality of life					
		Serious adverse events					
	Important:	Negative tests for Clostridium difficile infection					
		Adverse events					
Study design:	Randomised t	rials					
	If no randomi	sed trials identified – prospective cohort studies and retrospective case					
	series						
Review Questi	ion 4: What fact	tors related to the preparation of the transplant influence the outcome					
of faecal micro	obiota transplar	nt when treating people with <i>Clostridium difficile</i> infection?					
Populations:	Adults (18 yea	ars and over) with <i>Clostridium difficile</i> infection					
Intervention:	Faecal microb	iota transplant					
Comparison:	Time after del	Time after delivery when transplant is prepared (comparing time points)					
	Anaerobic pre	Anaerobic preparation vs preparation in ambient air					
	Manual prepa	ration vs use of blender/ homogeniser					
	Diluent used	(comparing normal saline, phosphate-buffered saline, water, milk/					
	yoghurt and o	thers)					
	Amount of sto	ool/ transplant administered (comparing amounts)					
	Fresh prepara	tion vs frozen preparation:					
	-comparing gl	ycerol vs other cryopreservative					
	-comparing co	oncentration of cryopreservative used					
	-comparing le	ngth of time that frozen for before use					
Outcomes:	Critical:	Cessation of diarrhoea and other symptoms/ relapse					
		Quality of life					
		Serious adverse events					
	Important:	Negative tests for Clostridium difficile infection					

Gut

https://mc.manuscriptcentral.com/gut

Gut

Supplementary Material 1 for Gut			
		Adverse events	
Study design:	Randomised t	rials	
	If no randomis	sed trials identified – prospective cohort studies and retrospective case	
	series		
Review Quest	ion 5: What fact	tors related to administration of the transplant influence the outcome	
of faecal micro	obiota transplar	nt when treating people with <i>Clostridium difficile</i> infection?	
Populations:	Adults (18 yea	rs and over) with Clostridium difficile infection	
Intervention:	Faecal microb	iota transplant	
Comparison:	Upper GI adm	inistration (nasogastric, nasoduodenal or nasojejunal tube; upper GI	
	endoscopy) <i>vs</i>	lower GI administration (enema, rectal catheter, colonoscopy)	
	Encapsulated	vs full transplant	
Outcomes:	Critical:	Cessation of diarrhoea and other symptoms/ relapse	
		Quality of life	
		Serious adverse events	
	Important:	Negative tests for Clostridium difficile infection	
		Adverse events	
Study design:	Randomised t	rials	
	If no randomis	sed trials identified – prospective cohort studies, and retrospective case	
	series		
Review Quest	ion 6: What is	the clinical effectiveness of faecal microbiota transplant in treating	
		lium difficile infection?	
Populations:	Adults (18 y	ears and over) with conditions of interest (e.g. inflammatory bowel	
	disease)		
Intervention:	Faecal microb	iota transplant	

Comparison: Standard care for the condition of interest

Autologous faecal microbiota transplant

Outcomes: Critical: **Clinical improvement**

Improvement in laboratory/ radiological/ endoscopic tests

Quality of life

Serious adverse events

Important: Adverse events

Study design: Randomised trials

ii. Literature search terms:

Review Questions 1 – 5:

EMBASE

1. exp Clostridium difficile infection/ or exp Clostridium difficile toxin B/ or exp Clostridium difficile review toxin A/

2. clostridium difficile.ti,ab.

3. c diff*.ti,ab.

4. (CDAD or RCDI or CDI).ti,ab.

5. pseudomembranous.ti,ab.

- 6. exp pseudomembranous colitis/
- 7. (antibiotic* adj2 (diarrhea or diarrhoea or colitis)).ti,ab.

8. (FMT or HPI).ti,ab.

9. ((fecal or faecal or feces or faeces or stool or microbiota) adj2 (transplant* or infus* or transfus* or implant* or instil* or donat* or donor* or reconstitut* or therap* or bacteriotherapy or encapsulated* or capsul*)).ti,ab.

10. (fecal or faecal or feces or faeces or stool or microbiota).ti,ab.

11. transplant*.ti,ab.

Supplementary Material 1 for Gut

13. 8 or 9

14. 10 and (11 or 12)

15. 13 or 14

16. or/1-7

17. 15 and 16

MEDLINE

- 1. Clostridium difficile/
- 2. clostridium difficile.ti,ab.
- 3. c diff\$.ti,ab.
- 4. Enterocolitis, Pseudomembranous/
- 5. (antibiotic\$ adj2 (diarrhoea or colitis)).ti,ab.
- 6. (antibiotic\$ adj2 (diarrhea or colitis)).ti,ab.
- 7. pseudomembranous.ti,ab.

8. (CDAD or CDI).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

9. RCDI.ti,ab.

10. Clostridium Infections/

11. FMT.mp. or HPI.ti,ab. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

12. ((fecal or faecal or feces or faeces or stool or microbiota) adj2 (transplant\$ or infus\$ or transfus\$ or implant\$ or instil\$ or donat\$ or donor or reconstitut\$ or therap\$ or bacteriotherapy or encapsulated\$ or capsul\$)).ti,ab.

13. (fecal or faecal or feces or faeces or stool or microbiota).ti,ab.

14. (transplant\$ or infus\$ or transfus\$ or implant\$ or instil\$ or donat\$ or donor or reconstitut\$ or

therap\$ or bacteriotherapy or encapsulated\$ or capsul\$).ti,ab.

15. Transplantation/

- 16. Transplants/
- 17. 11 or 12
- 18. 14 or 15 or 16
- 19. 13 and 18
- 20. 17 or 19
- 21. or/1-10
- 22. 20 and 21

Limits:

- 1. After 1980.
- 2. Studies in English only.
- 3. Human studies only.
- 4. Exclude case reports.
- 5. Exclude case series with less than 10 patients.

Review Question 6:

EMBASE

- 1. (FMT or HPI).ti,ab.
- 2. ((fecal or faecal or feces or faeces or stool or microbiota) adj2 (transplant* or infus* or transfus* or implant* or instil* or donat* or donor* or reconstitut* or therap* or bacteriotherapy)).ti,ab.
- 3. (fecal or faecal or feces or faeces or stool or microbiota).ti,ab.
- 4. transplant*.ti,ab.
- 5. exp transplantation/
- 6. 1 or 2

Gut

Supplementary Material 1 for Gut

7.3 and (4 or 5)

8.6 or 7

9. (clostridium difficile or CDAD or RCDI or CDI).ti.

10. 8 not 9

11. limit 10 to (clinical trial or randomized controlled trial or controlled clinical trial)

MEDLINE

- 1. FMT.mp. or HPI.ti,ab. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
- 2. ((fecal or faecal or feces or faeces or stool or microbiota) adj2 (transplant\$ or infus\$ or transfus\$ or implant\$ or instil\$ or donor or reconstitut\$ or therap\$ or bacteriotherapy)).ti,ab.

, Review

- 3. (fecal or faecal or feces or faeces or stool or microbiota).ti,ab.
- 4. Transplantation/
- 5. Transplants/
- 6. transplant\$.ti,ab.
- 7. Fecal Microbiota Transplantation/
- 8.4 or 5 or 6
- 9. 3 and 8
- 10.1 or 2 or 7 or 9
- 11. (clostridium difficile or cdiff or CDAD or RCDI or CDI or pseudomembranous).ti.
- 12. 10 not 11
- 13. limit 12 to (clinical trial or randomized controlled trial or controlled clinical trial)


Limits:

- 1. After 1980.
- 2. Studies in English only.

- 3. Human studies only.
- 4. Randomised trials only.

 Supplementary Material 1 for Gut

iii. Summary of the data extraction and literature review process (includes Q1-6):



Appendix 3: Consultation Stakeholders:

Individuals or organisation who were invited to and/ or attended the scoping day for these guidelines (as well as to provide feedback in stakeholder consultation) included:

- HRPA (Ireland) (Dr Eadaoin Griffin attended)
- Human Tissue Authority (Dr Robert Watson attended)
- NHS Wales
- NHS Scotland
- ECDC
- Royal College of Pathologists
- Royal College of General Practitioners
- Infection Prevention Society



- Public Health England
- Royal College of Physicians
- Royal College of Nursing
- Royal College of Surgeons
- ESCMID
- MRSA Action
- HSCNI
- Institute of Microbiology and Infection, University of Birmingham (Prof Peter Hawkey and Dr Victoria McCune attended)
- Microbiology, Royal Devon and Exeter NHS Foundation Trust (Dr Ray Sheridan, Dr Alaric Colville, Dr Robert Porter and Dr Melissa Baxter attended)
- C diff support (Ms Graziella Kontkowski attended)
- OpenBiome (Dr Majdi Osman and Dr Carolyn Edelstein attended)
- Dr Sally Cudmore (University College Cork) attended
- Dr Ngozi Elumogo attended (Microbiology, Norfolk & Norwich University NHS Trust)
- Dr Vanya Gant (University College London Hospitals)
- Dr Simon Goldenberg attended (Guy's and St Thomas' NHS Foundation Trust)
- Dr Bram Goorguis attended (Academic Medical Centre, Amsterdam)
- Dr Geraldine Moloney attended (Microbiology, Trinity College Dublin)
- Dr Benjamin Mullish attended (Imperial College Healthcare NHS Trust)
- Dr Laura Prtak attended (Sheffield Teaching Hospitals NHS Trust)
- Mr Glenn Taylor attended (Taymount Clinic)
- Dr Mark Wilks attended (Microbiology, Barts and The London NHS Trust)

Appendix 4. Continuing Professional Development material

- 1) In which of the following settings would you **most strongly** avoid giving a patient FMT?
 - a) Immunocompromised patients
 - b) Decompensated liver disease
 - c) Heart failure
 - d) History of anaphylactic food allergy
 - e) A previous failed FMT

Supplementary Material 1 for Gut

Answer: d

- 2) Where is FMT best sourced, if available?
 - a) Related healthy donor
 - b) Health care professional
 - c) Centralised stool bank
 - d) Pooled from multiple donors
 - e) Any of above

Answer: c

- 3) What is the maximum recommended length of time between stool donation and stool processing?
 - a) 6 hours
 - b) 7 hours
 - c) 8 hours
 - d) 9 hours
 - e) 10 hours

Answer: a

- 4) For which non-CDI condition is FMT currently recommended?
 - a) Irritable bowel syndrome
 - b) Obesity and metabolic syndrome
 - c) Parkinson's disease
 - d) Ulcerative colitis
 - e) None of the above

```
Answer: e
```

- 5) When considering setting up an FMT service in the UK, which organisation should be contacted to seek guidance in establishing the service?
 - a) Medicines and Healthcare Products and Regulatory Agency
 - b) Medicines and Healthcare Products Regulatory Authority
 - c) Medical Drugs and Healthcare Products and Regulatory Agency

Gut

- d) Medical Drugs and Healthcare Products Regulatory Authority
- e) None of the above

Answer: b

3. <u>References:</u>

 Varier RU, Biltaji E, Smith KJ, et al. Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. *Infect Control Hosp Epidemiol*. 2015;36(4):438-444. doi:10.1017/ice.2014.80.

Gut

- Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. *Clin Infect Dis.* 2014;58(11):1507-1514. doi:10.1093/cid/ciu128.
- Baro E, Galperine T, Denies F, et al. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France. Green J, ed. *PLoS One*. 2017;12(1):e0170258. doi:10.1371/journal.pone.0170258.
- Lapointe-Shaw L, Tran KL, Coyte PC, et al. Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection. Deshpande A, ed. *PLoS One*. 2016;11(2):e0149521. doi:10.1371/journal.pone.0149521.

 Supplementary Material 2 for Gut

The use of faecal microbiota transplant as treatment for recurrent or refractory *Clostridium difficile* infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.

Gut

Supplementary Material 2: Additional Appendices

Appendix A. Scope

1. Guideline title

The use of faecal microbiota transplant as treatment for recurrent or refractory *Clostridium difficile* infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.

1.1. Short title

The use of faecal microbiota transplant

2. The remit

i. To review the evidence (include randomised trial evidence) for the efficacy of faecal microbiota transplant (FMT) in the treatment of adults (≥18 years), both in *Clostridium difficile* infection (CDI) and in other clinical conditions, and use this to make recommendations about optimal recipient selection and management, donor assessment, material preparation and administration, and other key elements of FMT delivery.

ii. To provide specific guidance about best practice for an FMT service within the context of the regulatory framework for the intervention as it currently exists in the UK and beyond.

Whilst this is not a guideline specifically addressing the management of *Clostridium difficile* infection (CDI), the working group will include consideration of where FMT should be considered within the conventional treatment algorithm of patients with CDI (specifically, in which patients it should be considered, and at which point in their care).

The working group agreed that for the purposes of this guideline, faecal microbiota transplant would be defined as treatment that involves the administration of manipulated whole stool.

There is a growing literature of the use of 'bacteriotherapy' originally deriving from healthy donor stool as a potential alternative to FMT (including commensal bacteria, spores, bacteriophages and/ or bacterial proteins or metabolites). However, the working group considered this to still be at the research stage, and would not be considered further.

Gut

2.1. Population

2.1.1. Groups that will be covered

Adults (\geq 18 years) in whom: i. FMT has been used as treatment for CDI.

ii. FMT has been used as treatment for a non-CDI indication.

Given the variability in the means used to diagnose CDI within different studies, the working group agreed to consider the suitability of the definition used on a study-by-study basis.

2.1.2. Groups that will not be covered

Children and young people (<18 years).

2.2. Healthcare setting

All settings in which National Health Service care is received, and/ or clinical trials are undertaken.

2.3. Clinical management

2.3.1. Key clinical issues that will be covered

- a) Appropriate selection of patients with CDI for FMT, and best practice in their management post-FMT.
- b) Optimal selection of donors of faecal material, and maintenance of a donor pool.
- c) Identification of the preferred means of preparation and administration of FMT to recipients.
- d) Evaluation of the safety and efficacy of FMT in treating non-CDI indications.
- e) Best practice in the development and delivery of an FMT service.

2.3.2. Clinical issues that will not be covered

a) General management of CDI.

Gut

Supplementary Material 2 for Gut

b) General management of non-CDI conditions in which FMT may have a role in therapy.

2.4. Main outcomes

Recommendations for practice

- a) Patient/ recipient selection, and peri-FMT management
- b) Donor selection
- c) Preparation and administration of FMT
- d) Efficacy and safety of FMT for non-CDI indications
- e) Provision of an FMT service

2.5. Economic aspects

Where FMT is being provided under a MHRA license according to Good Manufacturing Practice (GMP) standards, there are significant costs associated with initial setup and maintenance of the service. These include the cost of obtaining the relevant license, laboratory design and equipment to enable quality assurance, storage facilities for samples, etc. However, there is counterbalance to this, as the expectation of the working group is that the publication of this guideline may encourage provision of FMT as treatment for recurrent or refractory CDI. This has consistently been shown to be cost effective in comparison with anti-*C. difficile* antimicrobial therapy^{31–34}, so overall costs associated with treating the condition may actually decrease. Furthermore, there may be changes to the practice of clinicians already offering the service. For example, encouraging the use of healthy unrelated donors (who can provide multiple stool donations after one screening) reduces the cost of screening when compared to the use of an FMT recipient's relative as donor, who is likely to provide one donation only.

2.6. Status

2.6.1. Scope

This is the final scope.

2.6.2. Timing

The development of the guideline recommendation will begin in July 2017.

3. Related NICE guidance

National Institute for Health and Care Excellence. *Faecal microbiota transplant for recurrent Clostridium difficile infection*. NICE Interventional Procedures Guidance IPG485. London: NICE; 2014. Available at:

Gut

https://www.nice.org.uk/guidance/ipg485 [last accessed 19th December 2017].

4. Further information

Guideline development process

Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developer's handbook. w rcare In J December 20. Revised edition. Edinburgh: Healthcare Improvement Scotland; 2014. Available at: http://www.sign.ac.uk [last accessed December 2017].

Gut

Appendix B. Declarations of interest

B.1. Introduction

All members of the Working Group were required to make formal declarations of interest at the outset, and these were updated throughout the development process. No interests were declared that required any actions.

B.2. Tariq Iqbal

First meeting 19/07/17: no declarations of interest; second meeting 04/10/17: no change.

Third meeting 19/10/17: consultant, advisor or speaker for: Pharmacosmos and Shield Therapeutics.

B.3. Simon Goldenberg (co-chair)

First meeting 19/07/17

Advisory board and/ or consultancy and/ or speaker fees: Astellas, MSD, Pfizer.

Second meeting 04/10/17; third meeting 19/10/17: no change.

No action required.

B.4. Ailsa Hart

First meeting 19/07/17

Advisory board and/ or consultancy and/ or speaker fees: AbbVie, Atlantic, Bristol-Myers Squibb, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda. Global steering committee for Genentech.

Second meeting 04/10/17; third meeting 19/10/17: no change.

No action required.

No declared conflict of interests for the other participants.

Appendix C. Clinical evidence tables

C.1. Reviewed case series of FMT for recurrent or refractory CDI

Gut

Page 175 of 454

Supplementary Material 2 for Gut

1 2	
3 4	
4 5	
6 7	
7 8	
o 9	
10	
11	
12 13	
14	
15	
16 17	
18	
19	
20	
20 21 22	
23	
24	
25 26	
26 27	
າດ	
20 29 30	
31	
32	
33	
34 35	
36	
37	
38	
39 40	
41	
42	
43 44	
44 45	
46	

Paper	Study and patient characteristics	Donor characteristics	FMT characteristics	Outcomes	Adverse events	CRD
Aas et al, Clinical Infectious Diseases, 2003	Case series. Number of patients: 18. Female: male 13:5. Age (mean): 73+/-9 (range 53-88) years. Comorbidities: x1 patient with Crohn's colitis, x1 with leukaemia. CDI features: Recurrent (at least 2 x laboratory- confirmed CDI after initial antibiotic treatment). CDI diagnosis confirmation: Cytotoxin A and B positivity. Pre-FMT antibiotics: Metronidazole +/- vancomycin (not defined).	Donors were 15 family members, and 3 clinical volunteers. Working in healthcare: Yes - for 3 donors. Donor demographics: Not defined. Donor screening: Questionnaire not explicitly stated. Travel and antibiotic exclusion period: No antibiotics for 6 months prior; nil stated regarding travel. Screening blood tests: Hepatitis A, B and C, HIV-1/-2, syphilis. Screening stool tests: C.difficile, enteric pathogens, ova, cysts and parasites.	 Amount of stool per transplant / administered to patients: 30g stool in 50-70ml normal saline; only 25ml of total administered to patient. Diluent used to prepare: Normal saline. Diluent used to store if frozen: N/A – fresh. Preparation methods: Homogenised in domestic blender, then coffee filter. Time from preparation to transplant (fresh): 6 hours. Time period for storage (frozen): N/A. Route administered: Upper GI: all nasogatric (18); lower GI: nil; capsules: nil. Number of infusions: Single infusion for all patients. Bowel purgative: Not described. PPI: 20mg omeprazole on day prior to FMT and day of FMT. Antimotility: Not described. Prokinetics: Not described. 	Overall cure within stated follow up period: 83.3% (n=15/18). Cure with one infusion alone: 83.3% (n=15/18). Total follow-up period: 90 days.	Minor GI adverse events: Nil stated. Minor non-GI adverse events: Nil stated. Serious adverse events: Nil stated. Deaths: x2 - one related to ESRF, one related to COPD.	Selection/ eligibili reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: No - 89%.

Supplementary Material 2 for Gut

Agrawal et al, Journal of Clinical Gastroenterology, 2016Case series.Number of patients: 146 Female: male: 100: 46. Age(mean): 78.6 (range 65-97) years.Comorbidities: Immunosupression in 15 patients (x3 Crohn's, x2 UC, x1 renal transplant)CDI features: 89 with recurrent CDI.CDI diagnosis confirmation: As per ACG guidelines.Pre-FMT antibiotics: All had prior metronidazole, vancomycin and/ or fidaxomicin.	 Donors were identified by the patient or - if not available - provided by the physician. Working in healthcare: Not stated. Donor demographics: No antibiotics for last three months. Excluded if significant GI disease, metabolic syndrome, chronic illness, immunocompromise, recent travel, and/ or high risk lifestyle in last three months. Donor screening: Questionnaire - excluded if significant GI disease, metabolic syndrome, chronic illness, immunocompromise, recent travel, high risk lifestyle in last three months. Donor screening: Questionnaire - excluded if significant GI disease, metabolic syndrome, chronic illness, immunocompromise, recent travel, high risk lifestyle in last three months. Travel and antibiotic exclusion period: Exclusion if travel to an area of high incidence of infectious diarrhoea, and/ or antibiotics within past three months. Screening blood tests: Hepatitis A, B and C, HIV-1/-2, syphilis. Screening stool tests: <i>C difficile</i>, enteric pathogens, ova, cysts 	 Amount of stool per transplant / administered to patients: 60-100g of fresh stool. Diluent used to prepare: Normal saline, upper GI: 75-200ml; lower GI: 250- 400ml; enema: 150-200ml. Diluent used to store if frozen: N/A – fresh. Preparation methods: Handstirred and blender, sifted through gauze. Time from preparation to transplant (fresh): Not stated. Time period for storage (frozen): N/A. Route administered: upper GI (16); lower GI (130); capsules: nil. Number of infusions: 1 routinely; 2nd infusion given with vancomycin so data unable to be extracted. Bowel purgative: PEG on day prior to FMT. PPI: Not stated. Antimotility: Loperamide on day of FMT. Prokinetics: Not stated. 	Overall cure within stated follow-up period: 83% (n=121/146) . Cure with one infusion alone: 83% (n=121/146) . Total follow up period: mean follow up was 12.3 months (range 1-48 months).	Minor GI adverse events: Nil stated. Minor non-GI adverse events: Nil stated. Serious adverse events: x2 microscopic colitis, x1 Sjögren's, x1 scalp follicular lymphoma, x1 contact dermatitis and idiopathic Bence-Jones gammaglobulinaem ia. In addition, x1 SCC, x1 ileus (died two weeks after ileus), x1 colonic perforation secondary to CMV colitis and subsequent death after 1 year. Patients developing cancers had underlying risk factors. Deaths: x10 (x4 decompensated CCF, x3 malignancies, x1 dementia, x1	Selection/ eligibility reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: No. At least 90% followed up: No.
---	--	--	---	---	--

Son	and parasites, <i>Giardia</i> , <i>Cryptosporidium</i> , <i>Isospora</i> , <i>H.</i> <i>pylori</i> , Rotavirus.	Time before CDI treatment was stopped before FMT: Between 3 days prior to FMT and one day prior to FMT.	stroke, x1 pneumonia); deaths between 19 days to 7 months post-FMT.	
		For Revieu		

Alrabaa et al, Transplant Infectious Diseases, 2017 CC CC CC CC CC CC CC CC CC CC CC CC CC	Case series. Number of patients: 13. Female: male: 8:5. Age (median): 69 (range 59-74) years. Comorbidities: Yes - x4 DLT, x1 kidney/ liver ransplant, x1 lung ransplant, x1 HIV+ with CD4 count of 453. x1 mmunocompromised batients with IBS; no IBD batients with IBS; no IBD batients. CDI features: Not clear if recurrent or refractory. Mean of 4 previous episodes of CDI prior to FMT. CDI diagnosis confirmation: PCR. Pre-FMT antibiotics: All batients had previously had oral vancomycin, x7 prev metronidazole either with or without vancomycin). x5 received fidaxomicin	Donors were unrelated. Working in healthcare: Nox Donor demographics: As per OpenBiome protocolx Donor screening: Questionnaire - as per OpenBiome protocolx Travel and antibiotic exclusion period: As per OpenBiome protocolx Screening bloods: FBC, hepatitis A, B and C, LFTs, HIV, HTLV-1/- 2, syphilis. Screening stools: C.difficile toxin, MC&S, ova, cysts and parasites, <i>H.pyl</i> ori stool antigen.	Amount of stool per transplant / administered to patients: 12.5g of stool in 28.5g of product. Diluent used to prepare: normal saline - diluted to approx 100-150ml to administer. Diluent used to store if frozen: Not clear. Preparation methods: As per OpenBiome protocol. Time from preparation to transplant (fresh): N/A. Time period for storage (frozen): As per OpenBiome protocol - not described in paper. Route administered: Upper GI (nasoduodenal): 13; lower GI: 0; capsules: nil. Number of infusions: One routinely, but retreated if relapsed after primary outcome. However - one renal transplant patient received 2 doses of FMT on consecutive days (with successful outcome). Bowel purgative: Bowel preparation used - GoLytely (PEG). PPI: 40mg pantoprazole night before and morning of procedure.	Overall cure within stated follow up period: 84.6% (n=11/13) at eight weeks post-FMT. Cure with one infusion alone: 100% (n=13/13) at 5 days. Total follow up period: Follow up up to 8 weeks described.	Minor GI adverse events: Several patients transient cramps and/ or diarrhoea. Minor non-GI adverse events: Nil noted. Serious adverse events: x1 patient had episode of CMV reactivation at the time of FMT - thought unrelated. X1 patient had episode of mild transplant rejection two months after FMT - thought unrelated. Deaths: None.	Selection/ eligibility reported: Yes. Consecutively recruited: Not clearly described. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes.
--	---	---	--	--	--	---

with or after oral				
vancomycin.		Antimotility: Loperamide 4mg 1 hour		
		post FMT.		
		Prokinetics: Not described.		
		FIORINETICS. NOT DESCRIDED.		
		Time hofers CDI treatment was stored		
		Time before CDI treatment was stopped		
		before FMT: See last box.		
	YO.			
	ridenti-			
	•			
		10.		
	(3)			

Brandt et al, American Journal of Gastroenterology, 2012	Case series. Number of patients: 77. Female: male: 56: 21. Age (mean): 65+/-17 range 22-87) years. Comorbidities: Not stated. CDI features: All recurrent/ refractory. CDI diagnosis confirmation: Not clear. Pre-FMT antibiotics: 62 patients had had prior netronidazole, 76 vancomycin (25 tapered vancomycin), 17 ifaximin.	Donors were 45 spouses/ partners; 21 relatives; 1 unknown person. Working in healthcare: No. Donor demographics: No antibiotics within past 3 months. Donor screening: Questionnaire - not stated. Travel and antibiotic exclusion period: Excluded if travel to area of high incidence of infectious diarrhoea, or if antibiotics within past three months. Screening blood tests: HIV-1, HIV-2, hepatitis A, B and C, Syphillis. Screening stool tests: <i>Clostridium difficile toxin</i> (if unavailable then EIA), MC&S, <i>Giardia, Cryptosporidium</i> , ova, cysts and parasites, <i>H.pylori</i> , Acid Fast stain for <i>Cyclospora</i> , <i>Isospora</i> .	 Amount of stool per transplant / administered to patients: 6 tablespoons of stool up to entire donation; 300- 700ml of transplant administered. Diluent used to prepare: Normal saline. Diluent used to store if frozen: N/A – fresh. Preparation methods: Hand blender used to prep. Time from preparation to transplant (fresh): Within 8 hours. Time period for storage (frozen): N/A. Route administered: Upper GI: 0; lower GI: all 77 colonoscopic. Number of infusions: 77 patients had one (patients that had second not included because given with concurrent vancomycin). Bowel purgative: All patients given prep but no details. PPI: Not described. Antimotility: Not described. Prokinetics: Not described. 	Overall cure within stated follow up period: N/A. Cure with one infusion alone: 90.9% (<i>n</i> =70/77). Total follow up period: not clear, but some patients followed-up to 3 years.	Minor GI adverse events: Not stated. Minor non-GI adverse events: Not stated. Serious adverse events: Nil. Deaths: x7 deaths (cause unknown in one case, x1 metastatic colorectal cancer (present from pre- FMT), x1 metastatic ovarian cancer, x1 pneumonia (non- enteric organism), x1 MI, x1 stroke, x1 sepsis five months after FMT.	Selection/ eligib reported: Yes. Consecutively recruited: Not clear. Prospectively recruited: No. Loss to follow u explained: Reported but no explained. At least 90% followed up: No only 77%.
--	---	---	---	--	---	--

		Time before CDI treatment was stopped before FMT: 3 days.		
00	Fi .			
	"OPTI-			
		Revie		
LI		.61		
	https://mo	14 manuscriptcentral.com/gut		

Brumbaugh et al, Journal of Pediatrics, 2017	Case series. Number of patients: 42. Female: male: 23: 19. Age (median): 9 (range 1 -18) years. Comorbidities: 31% had IBD (x4 Crohn's, x9 UC); 29% 'medically complex', including oncological, metabolic, cardiopulmonary or neurological diagnoses. CDI features: All children had had at least one course of vancomycin. Previously recurrent - at least 2 episodes. CDI diagnosis: Diarrhoea, haematochezia and/ or crampy abdominal pain in combination with positive <i>C. difficile</i> PCR. Pre-FMT antibiotics: Not stated.	Donor: OpenBiome-supplied FMT. Working in healthcare: No. Donor demographics: Not stated. Donor screening: Questionnaire: As per OpenBiome protocol. Travel and antibiotic exclusion period: As per OpenBiome protocol. Screening bloods: As per OpenBiome protocol. Screening stools: As per OpenBiome protocol.	Amount of stool per transplant / administered to patients: 30ml OpenBiome aliquot/ capsule, although not defined re stool quantity.Diluent used to prepare: As per OpenBiome protocolDiluent used to store if frozen: As per OpenBiome protocolPreparation methods: As per OpenBiome protocolTime from preparation to transplant (fresh): None given freshTime period for storage (frozen): N/ARoute administered: Upper GI: 41, nasogastric administration (some children used pre-existing gastrostomy); lower GI: 0; capsules: 1 (1 x 30 capsules).Number of infusions: 1 routinelyBowel purgative: Not statedPPI: Rantidine for 24hrs prior to FMT Antimotility: N/AProkinetics: N/ATime before CDI treatment was stopped	Overall cure within stated follow up period: 71% (n=30/42). Cure with one infusion alone: 71% (n=30/42) - remission in 94% (n =16/17) otherwise healthy children, 54% (n =7/13) (54%) with IBD, 75% (n=9/12) medically complex. Success in 71% of children when via NGT, and 67% via gastrostomy (non- significant). Total follow up period: 5 patients with initial failure opted for 2nd and 2 cured, so total success of 76% (n=32/42).	Minor GI adverse events: 6/47 FMT administrations accompanied by vomiting within 24hrs; self- resolved. Minor non-GI adverse events: Nil reported. Serious adverse events: Nil reported. Deaths: Nil reported.	Selection/ eligibil reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes.
--	---	---	--	---	--	---

		before FMT: 48 hours, after minimum of 5 days of vancomycin.		
Con	<i>F</i> :			
	ridentia,			
	9	For Rev.		
			V Op	
		16 nc.manuscriptcentral.com/gut		
	https://n	nc.manusc̄rĭptcentral.com/gut		

Chin et al, Clinical Gastroenterology & Hepatology, 2016 CD at 1 CD at 1 CD con sta	ase series. umber of patients: 35. emale: male: 16: 19. ge (mean): 43 (range 8 3) years. omorbidities: IBD in all, on corticosteroids, 3 n Immunomodulators, 1 on biologics. DI features: Recurrent - : least 2 episodes. DI diagnosis onfirmation: Not sated. re-FMT antibiotics: Not sated.	Donors were age 18 - 50, no medications, BMI 18.5 – 25. Working in healthcare: Not stated. Donor demographics: Not stated. Donor screening: Questionnaire - adapted from US blood bank. Travel and antibiotic exclusion period: Excluded if antibiotic within past six months. Screening blood tests: FBC, U&E, LFTs, CRP, ANA, hepatitis A, B and C, HBV, HIV-1/-2, syphilis. Screening stool tests: Faecal occult blood, rotavirus, bacterial pathogens, ova, cysts and parasites, Acid fast stain for <i>Giardia</i> and <i>Cryptosporidium, C</i> <i>difficile, H. pylori.</i>	Amount of stool per transplant / administered to patients: 41g of stool on average. Diluent used to prepare: Normal saline. Diluent used to store if frozen: Frozen in 10% glycerol. Preparation methods: Ambient air. Time from preparation to transplant (fresh): N/A; given fresh. Time period for storage (frozen): Up to 156 days. Route administered: Upper GI: 5 via nasogastric tube; lower GI: 3 via colonoscopy; capsule: 27 patients. Number of infusions: Not stated. Bowel purgative: Not routinely - just for colonoscopy (4 litres of PEG). PPI: 7 on PPI not as premedications. Antimotility: Not described. Prokinetics: Not described. Time before CDI treatment was stopped before FMT: 2 days prior to FMT.	Overall cure within stated follow up period: N/A. Cure with one infusion alone: Not stated. Total follow up period: At least 2 months (range 2 to 6 months).	Minor GI adverse events: Not specified. Minor non-GI adverse events: Not specified. Serious adverse events: two required surgery (diverting colostomy and total proctectomy), two developed perianal disease with no prior history of it. Deaths: Ni.	Selection/ eligibilit reported: No. Consecutively recruited: No. Prospectively recruited: No. Loss to follow up explained: No. At least 90% followed up: No.
---	--	--	--	---	--	---

Cohen et al, Israel Medical Association Journal, 2016	Case series. Number of patients: 22. Female: male: 9: 13. Age (median): Median 71.5 (range 16-92) years. Comorbidities: x1 IBD (colonoscopic group), x2 patients on chemotherapy, unclear why. CDI features: Recurrent or refractory. CDI diagnosis confirmation: Diarrhoea and toxin testing. Pre-FMT antibiotics: 19 patients given previous metronidazole, 9 vancomycin (with 13 both together).	Donors were 13 unrelated, 9 related. Working in healthcare: Yes - for unrelated. Donor demographics: No details - just says screening similar to blood donors. Donor screening: Questionnaire - no details. Travel and antibiotic exclusion period: Excluded if antibiotics within past six months. Screening bloods: No details. Screening stools: No details.	Amount of stool per transplant / administered to patients: 60g stool average (35-75g), 250ml total once mixed with saline (100 - 300ml range).Diluent used to prepare: Normal saline.Diluent used to store if frozen: Not stated.Preparation methods: Some fresh, some frozen.Time from preparation to transplant (fresh): Not stated.Time period for storage (frozen): No details.Route administered: Upper GI: nasoduodenal in 10; lower GI: colonoscopic in 12.Number of infusions: 1 FMT.Bowel purgative: 3I of PEG if colonoscopic administration.PPI: PPI if upper GI administration.Antimotility: Not described.Prokinetics: Metoclopramide just prior to upper GI administration.	Overall cure within stated follow up period: 72.7% (<i>n</i> =16/22) at 2 months. Cure with one infusion alone: 72.7% (<i>n</i> =16/22) (5/10 upper GI (out of 7 analysed), 91.7% (<i>n</i> =11/12) for lower GI (out of 11 analysed)). Total follow up period: Results reported at two months, but followed up to six months (7 months in the upper GI arm and 5 in the lower GI arm followed up to 6 months).	Minor GI adverse events: x5 transient constipation/ abdominal discomfort. Minor non-GI adverse events: Not stated. Serious adverse events: See deaths. Deaths: x7 (x1 due to CDI, x1 chronic resp disease, x1 related to dialysis, x2 pneumonia, x1 sepsis at ten days post-FMT (aspiration of stool; had been gastroscopic administration), x1 died at home ?cause).	Selection/ eligibility reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes.
--	--	--	--	--	---	--

Page 187 of 454

C		Time before CDI treatment was stopped before FMT: 12-24hrs.		
		For Revie		
		ierier	¹ 0.	
	https://u	19 nc.manuscriptcentral.com/gut		

			Amount of stool per transplant /			
			administered to patients: 50g in 500mls.			
	Case series.	Donors were spouses or close relative.	Diluent used to prepare: Normal saline.			
	Number of patients: 23.	Donor working in healthcare:	Diluent used to store if frozen: N/A - fresh.			
	Female: male: 14: 9.	No.	Preparation methods: Anaerobically			
Emanuelsson et al, Scandanavian Journal of Infectious Diseases, 2014	Age (median): 66 years (range 25-99) years (including 8 additional patients treated with 'bacteriotherapy'). Comorbidities: 3 with diabetes mellitus, 1 with microscopic colitis. CDI features: All recurrent. CDI diagnosis confirmation: Culture and/or toxin EIA. Pre-FMT antibiotics: Metronidazole and/or vancomycin used in all patients beforehand.	Donor demographics: Not stated. Donor screening: Questionnaire – asked regarding current and previous GI diagnoses/ symptoms. Travel and antibiotic exclusion period: Definitely an antibiotic use restriction but not clearly stated. Screening blood tests: HIV-1 and -2, hepatitis C virus, and hepatitis B surface antigen. Screening stool tests: Salmonella, Shigella, Campylobacter, enterohemolytic Escherichia coli, and Clostridium difficile.	prepared. Time from preparation to transplant (fresh): Not stated. Time period for storage (frozen): N/A. Route administered: Upper GI: nil; ower GI: 23 (enema/ rectal catheter); capsules: nil. Number of infusions: 22 patients eceived 1 FMT, 1 patient received 2 FMTs. Bowel purgative: Not stated. PPI: Not stated. Antimotility: Not stated. Prokinetics: Not stated.	Overall cure within stated follow up period: 65% (<i>n</i> =15/23). Cure with one infusion alone: 65% (<i>n</i> =15/23). Total follow up period: Median follow up of 18 months (range 0- 201 months).	Minor GI adverse events: None. Minor non-GI adverse events: None. Serious adverse events: None. Deaths: None.	Selection/eligibilit reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes.
			Time before CDI treatment was stopped before FMT: Not stated.			
			Defore FIVIT. Not Stated.			

Gut

2					
3 4 5 6 7 8 9 10 11 12 13 14	6	100000	Antimotility: Loperamide optional for lower GI administration. Prokinetics: Not stated. Time before CDI treatment was stopped before FMT: 24-48 hrs.		
15 16 17 18 19 20 21 22 23 24 25 26 27 22			Prokinetics: Not stated. Time before CDI treatment was stopped before FMT: 24-48 hrs.		
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44			.manuscriptcentral.com/gut	v nj	
45					

	Case series.		Amount of stool per transplant /			
			administered to patients: Not specified.			
	Number of patients: 328.					
			Diluent used to prepare: Not specified.			
	Female: male: 241: 87.					
			Diluent used to store if frozen: Both			
	Age (mean/ standard	Donors were 130 (40%) patient-	fresh and frozen, but specific details not			
	deviation): 61.4 (+/-19.3)	directed donors, and 198	given.			
	years.	universal (60%).				
			Preparation methods: Dependent upon			
	Comorbidities: 77	Donor working in healthcare:	individual centre.			
	immunocompromised	Not stated.			Minor GI adverse	Selection/ eligibility
	(x3 CVID, x3 selective IgA	~//×.	Time from preparation to transplant	Overall cure within	events: Not	reported: Yes.
	deficiency, x71	Donor demographics: Not	(fresh): Dependent upon individual	stated follow up	specified.	
	immunosupressants (20	stated.	centre.	period: 1 month		Consecutively
Fischer <i>et al,</i>	for solid organ	4		81.4% (<i>n</i> =267/328).	Minor non-GI	recruited: No.
American Journal	transplant, 29 for IBD, 6	Donor screening: Questionnaire	Time period for storage (frozen):		adverse events: Not	
of	for rheumatoid arthritis,	 depended upon individual 	Dependent upon individual centre.	Cure with one	specified.	Prospectively
Gastroenterology,	2 for SLE, 1 for	centre.	Uk .	infusion alone: Not		recruited: No.
2016	pemphigoid, 1 for		Route administered: Not specified	specified.	Serious adverse	
2010	chronic obstructive	Travel and antibiotic exclusion	('predominantly colonoscopy').		events: Not	Loss to follow up
	airway disease, 1 for	period: Depended upon		Total follow up	specified.	explained: N/A.
	psoriasis)), x11	individual centre.	Number of infusions: Dependent upon	period: Not		
	chemotherapy for		individual centre.	specified.	Deaths: Not	At least 90%
	malignancy, x63 IBD (25	Screening blood tests:			specified.	followed up: N/A.
	UC, 33 Crohn's), x118	Depended upon individual	Bowel purgative: Not specified. 💦 💋			
	diverticulosis.	centre.	•			
			PPI: Not specified.			
	CDI features: Recurrent	Screening stool test: Depended		Un/		
	disease in 87.2% and	upon individual centre.	Antimotility: Not specified.			
	severe or severe-					
	complicated in 12.8%.		Prokinetics: Not specified.			
	CDI diagnosis		Time before CDI treatment was stopped			
	confirmation: Postive		before FMT: Dependent upon each			
	stool C difficile toxin or		centre.			

Gut

Page 193 of 454

46

PCR.
Pre-FMT antibiotics: vancomycin.
Periodo de la companya de la company
25 https://mc.manuscriptcentral.com/gut

Fischer et al, Gut Microbes, 2017	Case series. Number of patients: 57. Female: male: 34: 23. Age (median): Median 72 (range 25-99) years. Comorbidities: x7 toxic megacolon, x12 acute kidney injury (x3 needing dialysis), x10 with hypovolaemic/ septic shock, x7 mental status changes, x4 on mechanical ventilation. x10 patients had inflammatory bowel disease (x5 with Crohn's and x5 with ulcerative colitis) and x10 patients were on immunosuppressive medications. CDI features: Severe, recurrent and severe- complicated. CDI diagnosis confirmation: Positive stool <i>C.difficle</i> PCR.	Donors were screened patient- selected donors for first 29 patients, whilst next 28 from OpenBiome stool bank. Donors working in healthcare: Not specified. Donor demographics: Not specified. Donor screening: Questionnaire – for patient-selected donors, this was as for Bakken <i>et al, Clin</i> <i>Gastoenterol Hepatol,</i> 2011; for OpenBiome, as per OpenBiome protocol. Travel and antibiotic exclusion period: For patient-selected donors, this was as for Bakken <i>et al, Clin Gastoenterol Hepatol,</i> 2011; for OpenBiome, as per OpenBiome protocol. Screening blood tests: For patient-selected donors, this was as for Bakken <i>et al, Clin</i> <i>Gastoenterol Hepatol,</i> 2011; for OpenBiome, as per OpenBiome protocol. Screening blood tests: For patient-selected donors, this was as for Bakken <i>et al, Clin</i> <i>Gastoenterol Hepatol,</i> 2011; for OpenBiome, as per OpenBiome protocol. Screening stool tests: Ffor patient-selected donors, this	Amount of stool per transplant / administered to patients: As per Fischer <i>et al, Alim Pharm Ther,</i> 2015 or OpenBiome. Diluent used to prepare: As per Fischer <i>et al, Alim Pharm Ther,</i> 2015 or OpenBiome. Diluent used to store if frozen: As per Fischer <i>et al, Alim Pharm Ther,</i> 2015 or OpenBiome . Preparation methods: As per Fischer <i>et al, Alim Pharm Ther,</i> 2015 or OpenBiome. Time from preparation to transplant (fresh): 6 hours. Time period for storage (frozen): As per OpenBiome protocols. Route administered Upper GI: nil; lower GI: 57 via colonoscopy or sigmoidoscopy. Number of infusions: 32 patients: x1, 20 patients x2, 5 patients x3, 1 patient x4,1 patient x5. Pre-planned protocol for serial FMTs +/- vancomycin, as described in Fischer <i>et al, Alim Pharm Ther,</i> 2015.	Overall cure within stated follow up period: 91% (<i>n</i> =52/57), i.e. 100% severe CDI (<i>n</i> =19/19), and 87% (<i>n</i> =33/38). Cure with one infusion alone: 52.6% (<i>n</i> = 30/57). Total follow up period: Up to 6 months.	Minor GI adverse events: Not stated. Minor non-GI adverse events: Not stated. Serious adverse events: Not stated. Deaths: x7 unrelated deaths, x4 CDI-related deaths.	Selection/ eligibility reported: Yes. Consecutively recruited: Yes. Prospectively recruited: Yes. Loss to follow up explained: Yes. At least 90% followed up: Yes.
	Pre-FMT antibiotics: Included vancomycin,	-	Bowel purgative: Not stated.			

Page 195 of 454

fidaxomicin, rectal	for OpenBiome, as per	PPI: Not stated.		
vancomycin, intravenous	OpenBiome protocol.			
metronidazole.		Antimotility: Not stated.		
		Prokinetics: Not stated.		
06		Time before CDI treatment was stopped		
		before FIMT. Not stated.		
	YO,	Prokinetics: Not stated. Time before CDI treatment was stopped before FMT: Not stated.		
	∇x .			
	6			
		10.		
			v Onj	
		27		
	https://mo	c.manuscriptcentral.com/gut		

	Case series.		Amount of stool per transplant /			
			administered to patients: 50-200g of			
	Number of patients: 29.		stool.			
		Donors were either patient			Minor GI adverse	
	Female: male: 17: 12.	selected-donor, or universal donors. If patient-directed,	Diluent used to prepare: 300ml of saline.		events: Not stated.	
	Age (mean/ standard	same donor used for	Diluent used to store if frozen: N/A – all		Minor non-Gl	
	deviation): Overall,	subsequent FMTs if required.	fresh.		adverse events: Not	
	mean 65.2 (+/-17.9)	44 FMTs in all - patient-selected			stated.	
	years (range 25-92	for 16 FMTs, universal donor for	Preparation methods: No additional	Overall cure within		
	years); mean 60.8 (range	28 FMTs.	details.	stated follow up	Serious adverse	
	26-87) years in severe;			period: By 3	events: Nil.	Selection/ eligibil
	67.6 (range 60-78) years	Donors working in healthcare:	Time from preparation to transplant	months, 62%		reported: Yes.
	in severe-complicated.	Not described.	(fresh): Six hours.	Deaths: x2 deaths		
		101		remission.	death from sepsis within 24 hours of FMT); death	Consecutively
Fischer <i>et al,</i>	Comorbidities: x3	Donor demographics: Not clear.	Time period for storage (frozen): N/A.			recruited: Yes.
Alimentary	Crohn's, x2 UC, x1	•		Cure with one		
Pharmacology	hypogammaglobulinaem	Donor screening:	Route administered: Upper GI: nil; lower	infusion alone: 70%		Prospectively
and Therapeutics,	ia, x1 ESKD, x1 ESLD, x1	Questionnaire: As per Bakken	GI: flexible sigmoidoscopy or	(n=7/10) in severe	following	recruited: Yes.
2015	renal transplant, x1 liver	et al, Clin Gastroenterol	colonoscopy either proximal or distal to	arm; 47% (<i>n</i> =9/19)	o/19) collectomy after 3x	
	transplant, x4 on	Hepatol, 2011.	the splenic flexure at the discretion of	in severe- complicated arm.		Loss to follow up
	immunosuppressive		the endoscopist. In practice – proximal		•	explained: Yes.
	meds. 12/19 of pts	Travel and antibiotic exclusion	to the splenic flexure in 18 FMTs, distal			
	treated in ITU at the	Gastroenterol Hepatol, 2011.	By 3 months – x2	At least 90%		
	time with following					followed up: Yes
	complications: x5	Corponing blood tasts. As nor	months	CDI recurrence, x1 death from cirhosis,		
	patients with toxic megacolon (caecal diam	Screening blood tests: As per Bakken <i>et al, Clin Gastroenterol</i>	protocol until end point. 16 x 1 FMT (7 severe, 9 complicated), 11 x 2nd FMT (3		x1 death from	
	>12cm or rectosigmoid>	Hepatol, 2011.	severe, 8 compl), 2 x 3rd FMT (0 severe,	heart failure, x1 death from respiratory failure,		
	6.5cm diameter); x7 AKI		2 complicated).			
	and hypovolaemic/	Screening stool tests: As per				
	septic shock, x4 of which	Bakken <i>et al, Clin Gastroenterol</i>	N.B. Oral vancomycin (125 mg every		x1 death from	
	required vasopressors,	Hepatol, 2011.	6 hours) was resumed 24–48 hours after		aspiration.	
	x3 with change in mental		FMT for a minimum of 5 days if there			
	status, x2 patients		were pseudomembranes present at			
	ventilated. x22 with		colonoscopy. For patients who did not			

Gut

Time before CDI treatment was stopped before FMT: 12-24hr prior to FMT.
--

			Amount of stool per transplant / administered to patients: 50-100g.			
	Case series. Number of patients: 40.		Diluent used to prepare: 250ml sterile normal saline.		Minor GI adverse events: Not stated.	
	Female: male: 21: 19.		Diluent used to store if frozen: All fresh.		Minor non-Gl adverse events: Not	
	Age (mean): Mean age	Donors working in healthcare:	Preparation methods: Stool placed on		stated.	
	75 (range 53-94) years. Comorbidities: x1	No. Donor demographics: Not	gauze pad and strained; flushed with saline; drawn up into syringes ready for administration.	Overall cure within stated follow up	Serious adverse events: Not stated.	Selection/ eligibilit reported: Yes.
	Wegener's, x1 AML.	stated.		period: 835	Deaths: x5 deaths	reported. res.
Garborg <i>et al,</i>	Repeated courses of antibiotics, not formally	Donor screening: Questionnaire (Time from preparation to transplant (fresh): Same day.	(n=33/40).	within 3 weeks - 2 months post-FMT but none attributable to	Consecutively recruited: Yes.
Scandanavian Iournal of	described.	- "Symptoms of GI disease or history of chronic infectious	Time period for storage (frozen): N/A.	Cure with one infusion alone: 73%		Prospectively
Infectious	CDI features: Not described.	disease".	Route administered: Upper GI: OGD with	(<i>n</i> =29/ 40) (28 in duodenum, 1 in	FMT. x2 deaths	recruited: No.
Diseases, 2010	CDI diagnosis	Travel and antibiotic exclusion period: Not stated.	delivery in distal duodenum; 38; lower GI: Colonoscopy; 2.	colon).	attributed to 'frailty', x1 advanced Wegener's, x1 AML/ antibiotics, one patients with	Loss to follow up explained: Yes.
	confirmation: Diarrhoea			Total follow up		
	and + <i>C difficile</i> toxin (testing for A and B).	Screening bloods: Hepatitis A, B and C, HIV.	Number of infusions: One at baseline; follow up if 'did not respond' although not specifically defined.	period: Up to 80 days.		At least 90% followed up: Yes.
	Pre-FMT antibiotics: All	Screening stools: MC&S,		1.	advanced cardiovascular	
	patients had had at least two courses of oral	Yersinia. No routine paraiste screening ("low prevalence in	Bowel purgative: Not mentioned, even for colonoscopy.	Ó.	disease who had fulminant colitis, underwent colectomy, but	
	metronidazole (500mg three times daily) or	Norway").	PPI: Not stated.	γ		
	vancomycin (125mg po four times daily).		Antimotility: Not stated.		died.	
			Prokinetics: Not stated.			

Page 199 of 454

46

	Time before CDI treatment was stopped before FMT: Evening prior to FMT.		
	tial. For Pevio		
	Revie	10001	
	31 https://mc.manuscriptcentral.com/gut		

Girotra et al, Digestive Diseases and Sciences, 2016	Case series. Number of patients: 29. Female: male: 6: 23. Age (mean/ standard deviation): 80.1 (+/-6.49) years (13 patients 70-79, 14 patients 80-89, 2 patients > 90 years). Comorbidities: x8 patients with diabetes mellitus. CDI features: No specific details - purely symptoms > 6 months, failed at least 3 antibiotic regimens. CDI diagnosis confirmation: At least three unformed stools in 24 hour and positive stool <i>C difficile</i> test by toxin (by ELISA) or toxin gene B (by PCR). All patients here defined RCDI by symptoms >6 months and at least x3 failed antibiotics. Pre-FMT antibiotics: Not indicated.	Donors were patient-selected family or friends. Donors working in healthcare: No. Donor demographics: Not stated. Donor screening: Questionnaire – peptic ulcer disease/GORD, IBS, IBD, polyps, malignancy, antibiotic use/ hospitalisation within past 3 months. Travel and antibiotic exclusion period: Excluded as donor if antibiotic use within the past three months. Screening bloods: HIV, HTLV-I/-II, syphilis enzyme immunoassay, hepatitis A immunoglobulin M, hepatitis B surface antigen, hepatitis C antibody, and <i>Helicobacter</i> <i>pylori</i> antibody. Screening stools: MC&S/ ova, cysts and parasites x3, <i>Cryptosporidium, Microspora, C</i> <i>difficile</i> toxin.	Amount of stool per transplant / administered to patients: 450cc - 270cc via colonoscopy AND 180cc into jejunum via enteroscopy. Diluent used to prepare: Saline - whole stool sample (>30g) mixed with 50-70ml of sterile saline, made up to 5 x 90cc aliquots. Diluent used to store if frozen: Fresh. Preparation methods: Stool mixed with saline, homogenised in blender for <4 minutes, filtered x2 with coffee filter paper. Time from preparation to transplant (fresh): Within 6 hours. Time period for storage (frozen): N/A. Route administered: Enteroscopy into jejunum AND colonoscopy in all 29 patients. Number of infusions: 1 FMT per patient (combined upper and lower GI administration). Bowel purgative: Not described. PPI: 20mg omeprazole evening before/ morning of procedure. Antimotility: Not described.	Overall cure within stated follow up period: 100% (n=29/29). Cure with one infusion alone: 100% (n=29/29). Total follow-up period: Reported 25.37 +/- 12.8 months follow-up (range 8-50 months). In addition - researchers report 60% weight gain, 40% stable weight, 75% improved 'failure to thrive' (defined as decrease of weight >10% from baseline, with no improvement despite medical treatment of CDI and nutritional treatment).	Minor GI adverse events: Bloating 10% (<i>n</i> =3/29). Minor non-GI adverse events: Fever 7% (<i>n</i> =2/29) (transient for one day). Serious adverse events: None. Deaths: None.	Selection/ eligibilit reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: N/A. At least 90% followed up: Yes.
---	---	--	--	---	---	---

Gut

2					
3 4 5 6			Prokinetics: Not described.		
7			Time before CDI treatment was stopped		
8			before FMT: >12 hours.		
9					
10					
11					
12					
13					
14		40.			
15					
16					
17			x		
18					
19					
20		•			
21					
22					
23					
24			10		
25					
26 27			before FMT: >12 hours.		
27					
29 30 31 32 33 34 35				r Onj	
36					
37					
38					
39					
40					
41					
42			22		
43		https://mc			
44			-		
45					

	Case series.		Amount of stool per transplant /		Minor GI adverse	
	Case series.		administered to patients: Not stated.		events: x5 nausea,	
	Number of retionter 122				x3 abdominal pain,	
	Number of patients: 133.		Diluent used to prepare: Not stated.		2 belching, x2	
					vomiting, x2 'food	
I	Female: male: 86: 47.		Diluent used to store if frozen: Yes, in		intolerance', x1 IBS.	
I			some cases - no details given.			
	Age (median): Median	<u></u>		Overall cure within	Minor non-Gl	
	75 (IQR 59.5 - 81.5)		Preparation methods: Not stated.	stated follow up	adverse events: x3	
	years.	Donors working in healthcare:		period:	fever, x2 throat	
		not stated	Time from preparation to transplant	Primary cure on	discomfort.	
	Comorbidities: x3		(fresh): Not stated.	day 30 and 90 was		Selection/eligibility
1	chemotherapy, x19	Donor demographics: Not		achieved in 84.2%	Serious adverse	reported: Yes.
1	immunosuppressants, x5	stated.	Time period for storage (frozen): Not	(<i>n</i> =101/120) and	events: x1	
I	solid organ transplant,		stated.	78.3% (<i>n</i> =72/92).	aspiration	Consecutively
L	x1 allogeneic stem cell	Donor screening: Questionnaire			pneumonia, x1	recruited: Not
Hagel <i>et al,</i>	transplant, x43 GI	- not stated.	Route administered: Upper GI: 4 OGD,	Cure with one	haemorrhage	clear.
Deutsches	comorbidities (no		40 enteroscopy, 19 nasoenteric tube;	infusion alone: No	(during endoscopy -	
Arzteblatt	details).	Travel and antibiotic exclusion	lower GI: 55 'endoscopic' (no further	diarrhoea at 30	no details), x1 loss	Prospectively
International,		period: Not stated.	details); capsule: 13. x2 combination of	days in 84.2%	of tooth, x1	recruited: No.
2016	CDI features: Median of		jejunal and colonoscopic FMT.	, (<i>n</i> =101/120); no	polyneuropathy, x1	
1	3 recurrences (IQR 1-4);	Screening blood tests.: Rapid		diarrhoea at 90	weight gain > 10kg	Loss to follow up
I	no specific details re	plasma reagin and fluorescent	Number of infusions: 1 FMT.	days in 78.3%	in 12 months post-	explained: No.
1	recurrent vs refractory	Treponemal antibody-absorbed.		(n=72/92).	FMT.	
I	confirmation.		Bowel purgative: Yes - 117 (no details	· · ·		At least 90%
I		Screening stool tests: Not	given).	Total follow up	Deaths: x7 died	followed up: Yes.
I	Pre-FMT antibiotics: x4	stated.		period: Median	during follow up, x2	
I	metronidazole only, x13		PPI: Yes - 31 (no details given).	follow up 141 days	within 90 days of	
I	vancomycin only, x2			(IQR 50-353 days).	FMT. In x6 cases,	
l I	fidaxomicin only, x61		Antimotility: Yes - 31 (no details given).		definitely not	
1	metronidazole/		, , , , , , , , , , , , , , , , , , , ,		related to CDI (in	
l I	vancomycin, x8		Prokinetics: Not stated.		one patient,	
l I	vancomycin/				recurrence of CDI	
	fidaxomicin, x34		Time before CDI treatment was stopped		one week after	
	metronidazole/		before FMT: Not stated.		FMT contributed to	
1	vancomycin/				her death (but	

Page 203 of 454

1	
2	
2	
3 4 5 6 7 8 9 10	
4	
5	
6	
7	
8	
9	
10	
11	
12	
12	
13	
14	
15	
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	
17	
18	
19	
20	
21	
22	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
30 37	
38	
39	
40	
41	
42	
43	
44	
45	
46	

<u>()</u>				
fidaxomicin, x11			stroke described as	
unknown.			primary cause of	
			death).	
	"Chtia			
	•			
		UK .		
		Orp		
	•			

Hamilton et al, American Journal of Gastroenterology, 2012	Case series. Number of patients: 43. Female: male: 31: 12. Age (mean/ standard deviation): Mean 59 (+/- 21) years. Comorbidities: x14 IBD patients. CDI features: Recurrent. CDI diagnosis confirmation: Toxin positive with at least two subsequent recurrences. Pre-FMT antibiotics: All had vancomycin, 17 patients had addition of vancomycin and 2 weeks of rifaximin (one of these 17 had 4 weeks of rifaximin); 3 patients took 2-4 weeks of nitazoxanide.	Donors were standard donors for 33 FMTs, and individual donors for 10 FMTs. Donors working in healthcare: Not stated. Donor demographics: Not stated. Donor screening: Questionnaire - before recruitment, the donors were required to submit available medical records and have a separate medical history interview away from the recipient patient. The history included assessment of infectious risk, including identification of known risk factors for HIV and hepatitis, current communicable diseases, and recent travel to areas of the world with a higher prevalence of diarrheal illnesses. Travel and antibiotic exclusion period: Excluded as donors if recent travel to areas where high prevelence of diarrheal illness (not specified), and/ or antibiotic use within the past six months.	Amount of stool per transplant / administered to patients: 50g. Diluent used to prepare: 250ml sterile, non-bacteriostatic normal saline. Diluent used to store if frozen: 10% glycerol. Preparation methods: Stool from individual donors was passed through stainless steel tea strainers; stool from universal donors was transported on ice to the lab, and processed within 2 hours. Material was weighed and homogenised in commercial blender under nitrogen gas. Slurry then passed through 2.0, 1.0, 0.5 and 0.25mm stainless steel lab sieves. The resulting material was then cetrifuged at 6000 x g for 15 minutes and resuspended to one-half the original volume in normal saline. Time from preparation to transplant (fresh): 1-2 hours. Time period for storage (frozen): 1-8 weeks. Route administered: Upper GI: nil; lower GI: colonoscopy (with majority into terminal ileum or caecum, with a small proportion into other colonic areas) in all 43; capsules: nil. Number of infusions: 1x FMT in 37	Overall cure within stated follow up period: 95% (<i>n</i> =41/43) within 2 months follow-up. Cure with one infusion alone: 86% (<i>n</i> =37/43). Total follow up period: 2 months following FMT.	Minor GI adverse events: ~1/3 of patients reported flatulance and excessive bowel movements within fortnight following procedure. Minor non-GI adverse events: None. Serious adverse events: None. Deaths: None.	Selection/ eligibility reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: No. At least 90% followed up: Yes.

	Screening blood tests: HIV,	patients, 2x FMT in 6 patients.			
1	hepatitis B/C, RPR, LFTs.				
1		Bowel purgative: Yes - GoLYTELY or			
	Screening stool tests: <i>Clostridium difficile</i> toxin B PCR,	Moviprep.			
	MC&S, ova, cysts and parasites,	PPI: Not described.			
	Giardia, Cryptosporidium, H				
	<i>pylori</i> antigen.	Antimotility: Not described.			
· · · · · · · · · · · · · · · · · · ·					
ר		Prokinetics: Not described.			
		The baffing CDI treatment was standed			
		Time before CDI treatment was stopped before FMT: 2 days.			
		Delore Fivil. 2 days.			
		 			
	`●'				
	1				
	1				
	1				
	1	For Revie			
	1				
	1				
I	,J			<u> </u>	
			^v onj		

	Case series.			Overall cure within		[]
	Case series.		Amount of stool nor transmisst /		Minor Cleatures	
	Number of notionts, 22		Amount of stool per transplant /	stated follow up	Minor GI adverse	
	Number of patients: 23.		administered to patients: ~50g.	period: 92%	events: x3 chronic	
				(<i>n</i> =11/12)	diarrhoea for at	
	Female: male: 13: 10.		Diluent used to prepare: 250ml normal	of haematological	least six months	
			saline.	malignancy	(despite negative C	
	Age (median): 66 (range	Donors: Fresh stool from		patients (other	difficile laboratory	
	23-88) years.	family/ friends in 10 patients,	Diluent used to store if frozen: Not	patient died), and	tests), x8 transient	
		frozen stool from standard	stated.	805 (<i>n</i> =8/10) solid	diarrhoea, x3	
	Comorbidities: x13	donors in 13 patients.		malignancy	abdominal cramps,	
	patients had	40	Preparation methods: As per Patel et al,	patients.	x2 faecal urgency,	
	haematological	Donor working in healthcare:	Mayo Clin Proc, 2013.		x2 constipation, x1	Selection/ eligibility
	malignancy (x4 diffuse	Not stated.		Cure with one	nausea.	reported: Yes.
	large B cell lymphoma,		Time from preparation to transplant	infusion alone: 86%		
	x2 Hodgkin's lymphoma,	Donor demographics: Not	(fresh): Not stated.	(<i>n</i> =19/22) by	Minor non-Gl	Consecutively
	x1 chronic myeloid	stated.		primary outcome	adverse events:	recruited: Yes.
Hefazi <i>et al, Mayo</i>	leukaemia, x1 follicular	•	Time period for storage (frozen): Not	criteria.	None.	
Clinic Proceedings,	lymphoma, x1 stage IV	Donor screening: As per Patel et	stated.			Prospectively
2017	cutaneous T cell	al, Mayo Clin Proc, 2013.	Uh .	Total follow up	Serious adverse	recruited: No.
2017	lymphoma, x1 B cell		Route administered: Upper GI: nil; lower	period: x1 CLL	events: None.	
	acute lymphocytic	Travel and antibiotic exclusion	GI: All 23 patients received FMT via	patient recurred at		Loss to follow up
	leukaemia, x1 hairy cell	period: As per Patel <i>et al, Mayo</i>	colonoscopy into caecum.	22 months post-	Deaths: x1 death	explained: Yes.
	leukaemia, x1 chronic	Clin Proc, 2013.		FMT in context of	after cardiac arrest	
	lymphocytic leukaemia,		Number of infusions: 1 FMT.	ibrutinib and	of Hodgkin's	At least 90%
	x1 severe aplastic	Screening blood tests: As per		coamoxiclav;	lymphoma patient	followed up: Yes.
	anaemia); x1 with active	Patel et al, Mayo Clin Proc,	Bowel purgative: Not stated.	successfully treated	at day 5 (multiple	
	disease at time of FMT,	2013.		with 10 days of	medical	
	x2 with recent		PPI: Not stated.	metronidazole. x1	comorbidities	
	chemotherapy use, x2	Screening stools: As per Patel et		tonsillar cancer	thought likely	
	with neutropenia within	al, Mayo Clin Proc, 2013.	Antimotility: Not stated.	patient had CDI	cause, not FMT); x2	
	12 weeks prior to FMT.	. ,,	,	recurrence at 14	deaths at > 60 days	
	x10 patients with solid		Prokinetics: Not stated.	months after	related to the	
	organ malignancy (x4			exposure to	underlying	
	breast, x2 anal, x1 colon,		Time before CDI treatment was stopped	cefalexin;	malignancy	
	x1 pancreatic, x1		before FMT: 24 hours.	successfully treated	progressing.	
	tonsillar, x1 non-small			with 10 days of	F 0. 0000.	
	tonsmar, At non-small			with to days of		

Gut

cell lung. x5 with metastasis at time of FMT, x3 recent chemotherapy use, x1 with recent neutropenia. Other comorbidities include x1 COPD, x1 ESKD on haemodialysis, x1 graft versus host disease (on immunosuppression), x1	vancomycin then 10 days of fidaxomicin. N.B. In all - x10 more chemotherapy courses and x8 more antibiotic courses after FMT.
granulomatosis with polyangiitis (Wegener's) on immunosuppression, x1 hypogammaglobulinaem ia on intravenous immunoglobulin, x1 inflammatory arthritis on corticosteroids.	Courses and x8 more antibiotic courses after FMT.
CDI features: All recurrent. CDI diagnosis confirmation: Not explicitly defined, but definitions of recurrent, severe and complicated	CLien Op
CDI as per American College of Gastroenterology. Pre-FMT antibiotics: All given additional vancomycin until 24hrs	


2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	prior to FMT. Median of 2.5 standard treatment courses per patient (defined as at least 10 days of metronidazole, vancomycin or fidaxomicin), x1 previous vancomycin taper, and x4 total treatment courses for CDI).	For Review		
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45		.manuscriptcentral.com/gut		

			Amount of stool per transplant / administered to patients: 2.3g.			
	Case series.	Donors were 3 unrelated participants.	Diluent used to prepare: 350ml in 0.9% normal saline.			
Hirsch et al, BMC Infectious Diseases, 2015	 Number of patients: 19. Female: male: 13: 6. Age (mean): 61 (range 26-92) years. Comorbidities: x3 IBS, x2 diabetes mellitus, x1 diverticulitis, x1 lymphoma, x1 acute myeloid leukaemia, x1 renal cancer, x1 chronic renal failure. CDI features: Refractory and recurrent (2 or more episodes). CDI diagnosis confirmation: Not stated. Pre-FMT antibiotics: metronidazole, vancomycin +/or fidaxomicin. 	 Donors working in healthcare: Not stated. Donor demographics: Excluded if BMI>25, diabetes mellitus, psychiatric history, IBD, or IBS. Donor screening: Questionnaire - standard questionnaire, with details as above. Travel and antibiotic exclusion period: Excluded if travel outside the USA within 30 days prior to donation, and/ or use of antibiotics within the past 6 months. Screening blood tests: HIV, hepatitis A, B,C, <i>Treponema</i>/ syphilis, and HTLV-1. Screening stool tests: <i>Clostridium difficile</i> toxin B, <i>Salmonella, Shigella, Campylobacter, E. coli, Yersinia,</i> <i>Vibrio, Aeromonas,</i> <i>Plesiomonas.</i> 	normal saline. Diluent used to store if frozen: 15% glycerol. Preparation methods: Strict environmental contol <6 hours after defaecation. All sterile, wet weight of stool was homogenised in 350ml 0.9% normal saline and aliquoted; samples were then centrifudged at 200 x g for 10 mins. Supernatent was decanted and centrifuged at 4600 x g for 15 minutes. supernatant removed and pellet re- suspended in 0.9% normal saline with glycerol. The typical concentration was 0.5g/ml. The resulting FMT slurry was put in 5-10ml syringes and frozen at - 80°C. Time from preparation to transplant (fresh): N/A. Time period for storage (frozen): 1-3 weeks at -80°C; prior to use, syringes were transferred to -20°C and used within six weeks. Route administered: Nil upper or lower Gl; all capsules. Aliquots of 0.4 mL of FMT slurry were dispensed into Size 1 acid-resistant hypromellose capsules,	Overall cure within stated follow up period: 68% (n=13/19). Cure with one infusion alone: 68% (n=13/19) at 90 days. Total follow up period: Primary outcome assessed at 90 days, whilst secondary outcome assessed at 6 weeks after this.	Minor GI adverse events: x5 abdominal pain 5 (x4 self-resolved; x1 required opiates and was hospitalised). Minor non-GI adverse events: None. Serious adverse events: None. Deaths: x1 died from respiratory failure after failing FMT treatment.	Selection/ eligibili reported: Yes. Consecutively recruited: Not clear. Prospectively recruited: No. Loss to follow up explained: No. At least 90% followed up: Yes.

		subsequently placed within Size 0 acid-		
		resistant hypromellose capsules and		
		then nested within Size 00 gelatin Caps.		
		Capsules were administered		
		Number of infusions: One course was 8-		
	Fidentia	12 capsules (one only took 6).		
		Bowel purgative: Not described.		
	40			
	· CA	PPI: Yes - evening and morning of		
	1/2.	procedure.		
		Antimotility: Not described.		
	•	Prokinetics: Yes - encouraged to drink 4		
		ounces of Kefir fermented milk product		
		twice a day, and also given a list of		
		prebiotics to consume for 3 days.		
		Time before CDI treatment was stopped		
		before FMT: On day prior to FMT.		
	1			

1	Supplemer
2	
3	
4 5	
5	
6 7	
8	
9	
10	
11	
12	
13 14	
15	
16	
17	
18	
19 20	laniro <i>et al,</i>
20 21	Clinical
21	Microbiology and
23	Infection, 2017
24	
25	
26	
27 28	
29	
30	
31	
32	
33	
34 35	
36	
37	
38	
39	
40	
41 42	
42 43	
44	
45	
46	

			Amount of stool per transplant /			
			administered to patients: not reported.			
			Diluent used to prepare: 500ml of 0.9%			
			saline.			
	Case series.					
		Donors were unrelated for 36	Diluent used to store if frozen: N/A –			
	Number of patients: 64.	FMTs, and related for 28 FMTs	fresh.			
	Female:male: 39: 25.	Donor working in healthcare:	Preparation methods: After dilution, the			
		No.	solution was blended and supernatant			
	Age (mean): Mean 74		strained and poured into sterile		Minor GI adverse	Selection/ eligibility
	years.	Donor demographics: Not	container.	Overall cure within	events: Not	reported: Yes.
	Comorbidities: Not	specified.	Time from preparation to transplant	stated follow up period: 975	specified.	Consecutively
	reported.	Donor screening: As per	(fresh): 6 hours.	(<i>n</i> =62/64) at 8	Minor non-Gl	recruited: Yes.
aniro <i>et al,</i>		Cammarota <i>et al, Alim Pharm</i>	(ireally, o hours.	weeks.	adverse events: Not	recruited. res.
linical	CDI features: Recurrent	Ther, 2015.	Time period for storage (frozen): Not	weeks.	specified.	Prospectively
licrobiology and	CDI - all patients had 3	-,	specified.	Cure with one	-1	recruited: No.
fection, 2017	recurrences on average	Travel and antibiotic exclusion		infusion alone: 69%	Serious adverse	
	range (range 2-6).	period: As per Cammarota et al,	Route administered: Upper GI: nil: lower	(<i>n</i> =44/64).	events: Not	Loss to follow up
		Alim Pharm Ther, 2015.	GI: all 64 given FMT via colonoscopy;		specified.	explained: Yes.
	CDI diagnosis		capsules: nil.	Total follow up		
	confirmation: Defined	Screening blood tests: As per		period: 8 weeks.	Deaths: Not	At least 90%
	using ESCMID guidelines.	Cammarota <i>et al, Alim Pharm</i> <i>Ther,</i> 2015.	Number of infusions: 44 patients had x1 FMT, 20 patients had >1 FMT	1	specified.	followed up: Yes.
	Pre-FMT antibiotics: All	Ther, 2015.	(undefined).			
	patients had had prior	Screening stool tests: As per	(undefined).			
	metronidazole,	Cammarota <i>et al</i> , <i>Alim Pharm</i>	Bowel purgative: 4I macrogol on last 1-2			
	vancomycin and/ or	Ther, 2015.	days of antibiotcs treatment.			
	fidaxomicin.					
			PPI: Not specified.			
			Antimotility: Not specified.			
			Prokinetics: Not specified.			



Case series.Number of patieFemale: male 13Age (mean): 69.26-87) years.Comorbidities: I specified.CDI features: Re and refractory.CDI features: Re and refractory.CDI diagnosis confirmation: (1) Laboratory-cond difficile toxin us with no other ca diarrhea; (2) ref CDI (defined as diarrhea despite antimicrobial tra or recurrent CD as symptom res for at least 2 day discontinuation treatment with recurrence of diPre-FMT antibic had at least price metronidazole; subsequent van monotherapy. 8	 3: 14. A (range Not bonors working in healthcare: Not specified. Donor demographics: Not specified. Donor screening: Questionnaire - not specified. Donor screening: Questionnaire - not specified. Travel and antibiotic exclusion period: Excluded if used antibiotics within last 6 months. Screening blood tests: Hepatitis B surface antigen, hepatitis C antibody, <i>Helicobacter pylori</i> and syphilis serologic markers, HIV types -1 and -2, and HTLV types -1 and -1I. Screening stool tests: Stool was processed for enteric bacterial pathogens, <i>C difficile</i> toxin, and ova and parasites. 	Amount of stool per transplant / administered to patients: 150g of stool. Diluent used to prepare: 300mls sterile water. Diluent used to store if frozen: N/A. Preparation methods: Not specified. Time from preparation to transplant (fresh): Not specified. Time period for storage (frozen): N/A – fresh. Route administered: Upper GI: nil; lower GI: 27 via retention enema. Number of infusions: 1 enema in 22 patients, 2 enemas in 5 patients. Bowel purgative: Not specified. PPI: Not specified. PPI: Not specified. Antimotility: Not specified. Prokinetics: Not specified. Time before CDI treatment was stopped before FMT: At least 24 hours before.	Overall cure within stated follow up period: 81% (n=22/27). Cure with one infusion alone: 81% (n=22/27). Total follow up period: Mean follow-up of 427.3 days after transplant.	Minor GI adverse events: Not specified. Minor non-GI adverse events: Not specified. Serious adverse events: Not specified. Deaths: Not specified.	Selection/ eligibility reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes.
---	---	--	--	---	--

Gut

Kelly et al, Journal of Clinical Gastroenterology, 2012	Case series. Number of patients: 26. Female: male: 24:2. Age (mean): 59 years. Comorbidities: Not stated. CDI features: Recurrent. Mean duration of diagnosis of CDI prior to FMT of 12.6 (range 4 to 84) months. CDI diagnosis confirmation: Not stated. Pre-FMT antibiotics: All had previous treatment with metronidazole, and repeated tapering courses of vancomycin. 19 had failed at least one course of rifaximin. Some patients had prior <i>Saccharomyces boulardii</i> or <i>Lactobacillus</i> GG. Pre- FMT, all had 2 weeks of metronidazole or vancomycin, discontinued 2-3 days before FMT.	Donors were family members in 25 cases, and friend in 1 case. Donor working in healthcare: No. Donor demographics: Not specified. Donor screening: Questionnaire – asked regarding known exposure to HIV within 12 months, high-risk sexual behaviours, use of ilicit drugs, tattoo within 6 months, incarceration within 12 months, risk factors for Creutzfleldt- Jakob disease, GI co- morbidities, recent ingestion of allergen, systemic autoimmunity, chronic pain syndromes. Travel and antibiotic exclusion period: No antibiotics for preceeding 90 days. Screening blood tests: blood for hepatitis A, B and C, HIV-1&- 2, <i>Trepenoma pallidum</i> . Screening stool tests: Stool for culture for bacteria, stain for ova and parasites, <i>C difficile</i> toxin A and B.	Amount of stool per transplant / administered to patients: "6:8 tablespoons of donor stool". Diluent used to prepare: 1 litre of sterile water passed through gauze. Aliquoted in 60ml syringes. Diluent used to store if frozen: N/A – fresh. Preparation methods: As above. Time from preparation to transplant (fresh): 6 hours prior to transplant. Time period for storage (frozen): N/A. Route administered: Upper GI: nil; lower GI: all 26 via colonoscopy; capsules: nil. Number of infusions: not explicitly stated but imples single infusion for all patients. Bowel purgative: PEG bowel prep night before transplant. PPI: Not stated. Antimotility: Not stated. Prokinetics: Not stated. Time before CDI treatment was stopped	Overall cure within stated follow up period: 92.3% (<i>n</i> =24/26). Cure with one infusion alone: 92.3% (<i>n</i> =24/26). Total follow up period: follow up of mean 10.7 months (ranged from 2-30 months).	Minor GI adverse events: Mild diarrhoea post-FMT in x3 patients. Minor non-GI adverse events: No. Serious adverse events: No. Deaths: No.	Selection/ eligibility reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes
--	---	--	---	--	---	---

		before FMT: 2-3 days.		
~0n	×C•			
	hx.			
		For Peri		
	9/			
		\sim		
		10.		
			Vo	

Kelly et al, American Journal of Gastroenterology, 2014	Case series. Number of patients: 80. Female: male: 42: 38. Age (mean): N.B. 75 adults, and 5 children. Mean age of adults: 53 (range 20-88) years; mean age of paediatric patients: 10.9 (range 6.5–16) years. Comorbidities: x36 IBD, x19 solid organ transplant, x3 HIV/AIDS, x7 cancer, x4 rheumatoid arthritis, x1 adrenal insufficiency, x6 cirrhosis, x1 ESKD, x1 panhypopituatarism, x1 end-stage COPD, x1 ESKD with allograft failure, x1 Sjögrens. CDI features: Both refractory and recurrent patients included as well as severe/ complicated disease. CDI diagnosis: Not clearly specified. Pre-FMT antibiotics:	Donors working in healthcare: Not specified. Donor demographics: Not specified. Donor screening: Questionnaire: Varied by centre. Travel and antibiotic exclusion period: Varied by centre. Screening blood tests: Varied by centre. Screening stool tests: Varied by centre.	Amount of stool per transplant / administered to patients: Varied by centre. Diluent used to prepare: Varied by centre. Diluent used to store if frozen: Varied by centre. Preparation methods: Varied by centre. Time from preparation to transplant (fresh): Varied by centre. Time period for storage (frozen): Varied by centre. Route administered: Not specified. Number of infusions: 85% (<i>n</i> =68/80) had single FMT, 15% (<i>n</i> =12/80) had > 1 FMT. Bowel purgative: Varied by centre. PPI: Varied by centre. PPI: Varied by centre. Antimotility: Varied by centre. Time before CDI treatment was stopped before FMT: Varied by centre.	Overall cure within stated follow up period: 89% (<i>n</i> =71/80) within a minimum of 12 weeks. Cure with one infusion alone: 78% (<i>n</i> =62/80). Total follow up period: 12 weeks post-FMT.	Minor GI adverse events: x3 self limiting diarrhoea, x3 bloating and abdominal discomfort, x1 Crohn's flare, x1 nausea, x1 minor mucosal tear at colonoscopy. Minor non-GI adverse events: x1 fever, x1 hip pain, x1 pertussis. Serious adverse events: x10 hospitalization (x1 for fever, encephalopathy and pancytopenia; x1 abdo pain post FMT, x3 IBD flares (x2 Crohn's, x1 UC), x1 stroke, x1 colectomy, x1 fall and sustained hip fracture, x1 influenza B and diarrhoea, x1 catheter infection. Deaths: x2 deaths (x1 pneumonia and x1 aspiration after	Selection/ eligibility reported: Yes. Consecutively recruited: No. Prospectively recruited: No. Loss to follow up explained: No. At least 90% followed up: Yes.
---	--	---	--	---	---	--

Vancomycin 67 (84%),				sedation for	
fidaxomicin 23 (29%),				colonoscopic FMT).	
rifaximin 13 (16%),					
metronidazole 55 (69%).					
	.62				
	17.				
	10-				
	Gential.				
	•				
		P			
		ev:			
			1		

Case series.Number of patients: 272.Female: male: 189: 83.Age (mean/ median/ standard deviation): Mean 57.2 (+/- 19.2) years; median 59.0 (range 16-100) years.Comorbidities: x10 dialysis, x22 established Crohn's, x21 established UC, x15 lymphocytic colitis, x5 diagnosed with Crohn's during colonoscopy for FMT, x1 diagnosed UC during colonoscopy for FMT, x14 newly-diagnosed lymphocytic colitis. x13 reclassified in terms of IBD. x8 solid organ recipients, x30 patients without IBD were taking biologics (anti-TNF, rituximab), immunomodulators (methotrexate, purine analogues), and/ or corticosteroids.CDI features: All patients had at least two	 Donors working in healthcare: As per Hamilton <i>et al, Am J</i> <i>Gastroenterol,</i> 2012. Donor demographics: As per Hamilton <i>et al, Am J</i> <i>Gastroenterol,</i> 2012. Donor screening: Questionnaire - as per Hamilton <i>et al, Am J</i> <i>Gastroenterol,</i> 2012. Travel and antibiotic exclusion period: As per Hamilton <i>et al,</i> <i>Am J Gastroenterol,</i> 2012. Screening blood tests: As per Hamilton <i>et al, Am J</i> <i>Gastroenterol,</i> 2012. Screening stools: As per Hamilton <i>et al, Am J</i> <i>Gastroenterol,</i> 2012. 	 Amount of stool per transplant / administered to patients: As per Hamilton <i>et al, Am J Gastroenterol,</i> 2012. Diluent used to prepare: As per Hamilton <i>et al, Am J Gastroenterol,</i> 2012. Diluent used to store if frozen: As per Hamilton <i>et al, Am J Gastroenterol,</i> 2012. Preparation methods: As per Hamilton <i>et al, Am J Gastroenterol,</i> 2012. Time from preparation to transplant (fresh): As per Hamilton <i>et al, Am J Gastroenterol,</i> 2012. Time period for storage (frozen): As per Hamilton <i>et al, Am J Gastroenterol,</i> 2012. Route administered: Upper GI: nil; lower GI: colonoscopy (272); capsule: nil. Number of infusions: One routinely, more than one if required - specific criteria not defined. Bowel purgative: Yes - all had purgative on day prior to procedure (as per Hamilton <i>et al, Am J Gastroenterol,</i> 2012). 	Overall cure within stated follow up period: 74% (<i>n</i> = 32/43) in IBD patients and 92.2% (<i>n</i> =211/229) in non-IBD patients. Cure with one infusion alone: 74% (<i>n</i> = 32/43) in IBD patients and 92.2% (<i>n</i> =211/229) in non IBD patients. Total follow up period: Up to 6 years.	Minor GI adverse events: Not specified. Minor non-GI adverse events: Not specified. Serious adverse events: 25.6% (<i>n</i> =11/43) of IBD patients diagnosed with FMT-related flare. x2 patients hospitalised with IBD flare within two months of FMT. Clearance of CDI by FMT generally associated with improved control of IBD over the long term. x6 patients struggled with IBD despite optimisation of immunosuppressiv e treatment, x3 of whom underwent colectomies. Deaths: Nil.	Selection/ eligibility reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes.
---	--	--	--	--	--

spontaneous relapses of CDI following initial		PPI: Not described.		ŢŢ	
episode, defined as recurrence within three		Antimotility: Not described.			1
months of discontinuation of anti-		Prokinetics: Not described.			1
CDI antibiotics treatment					1
in conjunction with diarrheal symptoms.		Time before CDI treatment was stopped before FMT: 2 days.			
CDI diagnosis					1
confirmation: Positive					1
stool testing within two months of FMT - not					1
clearly defined.	61	1			
Pre-FMT antibiotics:					1
x206 patients had had	I				1
prior metronidazole, x270 vancomycin, x69	I				1
fidaxomicin, x71	I	· R			1
rifaximin, x104	I				1
probiotics.		Via			
]	·····	<u>_</u>	<u> </u> I	<u>.</u>

	Case series.		Amount of stool per transplant /			
			administered to patients: >30g.			
	Number of patients: 61.			Overall cure within		
		Donors were preferentially	Diluent used to prepare: Whole stool	stated follow up		
	Female: male: 40:21.	healthy family members, but	mixed with 400ml normal saline,	period: Global		
		also used healthy volunteer	homogenised for 10 minutes.	death rate of 19%		
	Age (mean): 84 (range	students and residents.		(<i>n</i> =3/16) in early	Minor GI adverse	
	66-101) years.	×··	Diluent used to store if frozen: N/A –	transplant arm (day	events: x24	
		Donor working in healthcare:	fresh.	20, day 37, day	diarrhoea (resolved	
	Comorbidities: Not	Yes - some residents.		166),	day 1 after FMT), x1	
	Specified.	YO.	Preparation methods: 10 minutes of		nausea.	Selection/ eligibility
		Donor demographics: BMI<30,	homogenisation in blender, filtered, put	67% (<i>n</i> =2/3) died in		reported: Yes.
	CDI features: Some	exclude active cancer,	into a syringe at room temperature.	arm of those	Minor non-GI	
	patients refractory/	diarrhoea, current		treated by tardive	adverse events: Not	Consecutively
	recurrent; some during	immunosuppressive drugs,	Time from preparation to transplant	transplant (day 28,	specified.	recruited: No - not
Lagier <i>et al,</i>	first CDI.	antibiotics within past three	(fresh): <6 hours.	day 54).		stated.
European Journal	CDI diagraphia	months.	Time a prized for storage (frequen): N(A	None of these	Serious adverse	
of Clinical Microbiology and	CDI diagnosis confirmation:PCR that	Donor screening:	Time period for storage (frozen): N/A.	patients died with	events: x1 acute heart failure - no	Prospectively
Infectious	detects toxin and B	Questionnaire: As above.	Route administered: Upper GI: Via	evidence of CDI.	details.	recruited: No.
Diseases, 2015	genes, and toxin C gene	Questionnaire. As above.	nasogastric tube in 61 patients; nil lower	evidence of CDI.	uetalis.	
201300303, 2013	deletion that	Travel and antibiotic exclusion	GI or capsules.	Cure with one	Deaths: 3/16 in	Loss to follow up
	characterises 027.	period: Excluded as donor if		infusion alone: 33%	early transplant	explained: Yes.
		antibiotic use within past three	Number of infusions: In early FMT arm -	(n=1/3) treated by	arm (vs 29/45	
	Pre-FMT antibiotics:	months.	one FMT routine; but offered 2nd FMT if	tardive FMT dead	treated by abx only	At least 90%
	Patients divided into		relapse.	at day 31; 4.2%	or tardive	followed up: Yes.
	'tardive transplant' (i.e.	Screening blood tests: HIV,		(n=1/16) treated by	transplant). No	
	only after x3 antibiotic	hepatitis A, B,C, E, active CMV,	Bowel purgative: 4l Klean Prep/ two	early FMT dead at	sign of CDI at time	
	failures) or 'early	active EBV, Treponema	glasses of Fast Prep day before FMT.	day 31.	of death (days 20,	
	transplant' (during first	pallidum, HTLV.			37, 166).	
	week of infection during		PPI: No - but used 200ml 1.4%	Total follow up		
	first treatment,	Screening stool tests: MC&S,	bicarbonate 15 minutes before FMT.	period: No details		
	accompanied by	parasites, toxigenic C difficile.'		on absolute length		
	antibiotics). Antibiotics		Antimotility: Not specified.	of follow-up.		
	were for non-severe					
	disease: metronidazole		Prokinetics: Not specified.			

orally three times a day		Time before CDI treatment was stopped		
for 14 days, then		before FMT: Not specified.		
vancomycin 125mg four				
times a day for 14 days,				
then fidaxomicin 200mg				
twice a day for 10 days;				
for severe disease				
(defined as AKI, paralytic	ו			
ileus, or peritoneal fluid),				
used vancomycin and				
metronidazole for				
primary infection, then				
fidaxomicin if relapse/ failure.				
failure.		7		
		10.		
		For Revio		
			ν _O .	

Case series.Number of patients: 94Female: male: 53: 41.Age (mean): Mean 71.8 (range 24-95) years.Comorbidities: x3 IBD, x3 post-renal transplant.CDI features: Some patients refractory (defined as ongoing diarrhea depsite treatment with at least 5 days of oral vancomycin, 125mg four times daily), or recurrent (symptom Diseases, 2014Diseases, 2014CDI diagnosis confirmation: Toxin positive by enzyme immunoassay or polymerase chain reaction.Pre-FMT antibiotics: Average of 2.1 previous anti-CDI antibiotic	 Donors were volunteers. Donor working in healthcare: Not specified Donor demographics: Not specified. Donor screening: Questionnaire - describes use of questionnaire but no details given - "similar to the Full Length Donor History Questionnaire documents (US Food and Drug administration, DHQ version 1.3, May 2008" Travel and antibiotic exclusion period: Not specified. Screening blood testss: HIV-1/- 2, HTLV-1 and -2. Hepatitis A IgG/M, hepatitis B surface antigen, hepatitis C antibody, <i>Treponema pallidum.</i> Screening stools: Ova, cysts and parasites, MC&S, <i>C difficile</i> toxin, norovirus, adenovirus, rotavirus. 	 Amount of stool per transplant / administered to patients: Not specified. Diluent used to prepare: 300ml water. Diluent used to store if frozen: N/A – fresh. Preparation methods: Homogenisation of stool in water using a disposable spatula. Time from preparation to transplant (fresh): Not specified. Time period for storage (frozen): N/A. Route administered: Upper GI: nil; lower GI: retention enema in all 94 patients; nil capsules. Number of infusions: No fixed number - as many as required to achieve remission. No clear definition of non- response. Bowel purgative: Not specified. PPI: Not specified. Prokinetics: Not specified. Prokinetics: Not specified. Time before CDI treatment was stopped before FMT: Not specified. 	Overall cure within stated follow up period: At 6 months – 87% (<i>n</i> =81/94) in remission after FMT. Cure with one infusion alone: 47.9% (<i>n</i> =45/94) with single FMT in remission at 6 months. Total follow up period: 24 months.	Minor GI adverse events: "10% experienced transient constipation and excess flatulence post-FMT". Minor non-GI adverse events: None described. Serious adverse events: None described. Deaths: 75% (<i>n</i> =6/8) patients not responding to FMT died (not clear when). All "over 70 years of age", with multiple underlying significant comorbidities and passed away due to critical illnesses; none had deaths attributable to FMT or directly due to CDI.	Selection/ eligibility reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes.
--	---	---	--	--	--

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	courses (range 1-4), specifically: x74 metronidazole courses (79.3%), x71 vancomycin (75%), x14 vancomycin taper (15.2%), x3 probiotic monotreatment (0.03%), x16 concomitant metronidazole/ vancomycin (17.4%).	Kor Review		
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45		:.manuscriptcentral.com/gut	v Onj	

MacConnachie et al, QJM, 2009 MacConnachie et al, Participation Pre-lhad metrivano conf spection pre-lhad metrivano conf spection conf spectio	e (median): 81.5 nge 68-95) years. morbidities: no ematological or IBD. features: Relapsing ined as recurrence of se stool following cessful antibiotic atment in a patient h previous toxin sitive CDI. diagnosis nfirmation: Not ecified. -FMT antibiotics: All I had previous	Donors were healthy related volunteers. Working in healthcare: Yes – in three cases where relatives could not be identified. Donor demographics: Not specified. Donor screening: HIV-1/-2, HTLV- 1 and -2, hepatitis A IgG/M, hepatitis B surface antigen, hepatitis C antibody, <i>Treponema pallidum</i> . Questionnaire: Yes, but not specified. Travel and antibiotic exclusion period: Not specified. Screening stools: Ova, cysts and parasites, MC&S, <i>C difficile</i> toxin.	Amount of stool per transplant administered to patients: 30g. Diluent used to prepare: 0.9% normal saline. Diluent used to store if frozen: N/A – fresh. Preparation methods: Stool sample prepared in less than 6 hours; add 50- 70ml of normal saline, homogenise with handheld stool blender,gradually advance speed, continue for 2-4 mins until smooth, filter suspension in coffee filter paper. Time from preparation to transplant (fresh): 6 hours. Time period for storage (frozen): Not applicable. Route administered: Upper GI: All 15 patients received FMT via nasogastric tube; lower GI and capsules: nil. Number of infusions: 1 FMT per patient routinely, repeat if required. Bowel purgative: Not given. PPI: Omeprazole 20mg eve before and on morning. Antimotility: Not given.	Overall cure within stated follow up period: 84% (<i>n</i> =15/18) "resolution". Cure with one infusion alone: 884% (<i>n</i> =15/18) "resolution". Total follow-up period: 90 days.	Minor GI adverse events: x1 diarrhoea. Minor non-GI adverse events: Nil. Serious adverse events: Nil. Deaths: x2 (not felt related to FMT).	Selection/ eligibili reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes.
---	---	--	---	--	---	--

3 4 5 6 7 8 9 10 11 12 13 14 15 16	6	ridenx:	Prokinetics: Not given. Time before CDI treatment was stopped before FMT: Stopped on the evening before FMT.		
17 18 19 20 21 22 23 24 25 26 27 28 29		3.	For Revie	1.	
29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44			c.manuscriptcentral.com/gut		

InterformDescriptionInterformCase series.Donors: 61 donors were close relatives/ other household members; in 9 cases, healthy volunteers.InterformNumber of patients: 70. Female: male: 42: 28. Age (mean): Mean 73 (range 22-90) years.Donor sworking in healthcare: Not specified.InterformAge (mean): Mean 73 (range 22-90) years.Donor demographics: Not specified.Comorbidities: No IBD, one adenocarcinoma of colon diagnosed during colonoscopy for FMT.Donor screening: Questionnair - "No antibiotics and no intestinal symptoms within 6 months".CDI features: Recurrent, mean of 3.5 previous episodes of CDI pre-FMT (range 1-12).Travel and antibiotic exclusion period: Excluded as donor if ar antibiotic use within past six months; no details of travel restrictions.CDI diagnosis confirmation: Positive culture and toxin.Screening blood tests: Hepatiti B surface antigen, Hepatitis C antibody, HIV-1/-2, Treponem pallidum plasma reagin test; total blood count, C-reactive protein, creatine, liver enzymes.Screening stool tests: C difficilic culture/ tox A/ B; MC&S, ova cysts and parasites.	 Time from preparation to transplant (fresh): 6 hours. Time period for storage (frozen): N/A. Route administered: Upper GI: nil; lower GI: colonoscopy (70); capsules: nil. Number of infusions: 1 FMT. Bowel purgative: 4I PEG (Colonsteril). PPI: Not specified. Antimotility: Not specified. Prokinetics: Not specified. 	Overall cure within stated follow up period: 94% (n=66/70) (100% (n=34/34) of those with non-027, 89% (n=32/36) with 027) within 12 weeks. Cure with one infusion alone: 94% (n=66/70) (100% (n=34/34) of those with non-027, 89% (n=32/36) with 027) within 12 weeks. Total follow up period: One year.	Minor GI adverse events: Not specified. Minor non-GI adverse events: Not specified. Serious adverse events: Not specified. Deaths: x4 patients infected with 027 did not respond to FMT and died within 3 months. 10 other patients died of 'unrelated illnesses' during one year of follow- up.	Selection/ eligibility reported: Yes. Consecutively recruited: Not clear. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes.
---	---	--	--	---

Page 229 of 454

2				
3		Time before CDI treatment was stopped		
4		before FMT: 24 hour - not specifically		
5		stated as anti-CDI treatment.		
6				
7				
8				
9				
10				
11				
12				
13				
14				
15		κ.		
16				
17				
18				
19 20				
20 21				
21		Oh .		
23				
24		No.		
25				
26				
27				
28	I	ia. For Revie		
29				
30				
31				
32				
33 24				
34 35				
35 36				
30				
38				
39				
40				
41				
42				
43		61 https://mc.manuscriptcentral.com/gut		
44		https://mc.manuscriptcentral.com/gut		
45				

			Amount of stool per transplant /			
	Case series.		administered to patients: Not defined.			
			administered to patients. Not defined.	Overall cure within		
	Number of patients: 201.		Diluent used to prepare: Not defined.	stated follow up		
				period: As per		
	Female: male: 124: 77.		Diluent used to store if frozen: Not	primary outcome -		
		Donors were typically family	defined.	difficult to give		
	Age (mean/ standard	members, but small number of		more specific		
	deviation): Mean 68.79	unrelated universal donors.	Preparation methods: Not defined.	information than		
	(+/-16.78) years for x181	Amongst IBD cohort - 6 patients		already given.		
	non-IBD patients, mean	had family members as donor,	Time from preparation to transplant			
	46.9 (+/-19.97) for the	universal donor in other 14.	(fresh): Not defined.	Cure with one		Selection/eligibilit
	x20 IBD patients.	~//ו		infusion alone:	Minor GI adverse	reported: Yes.
	Comorbidities: 13/20 IBD	Donor working in healthcare:	Time period for storage (frozen): Not	87.3% (<i>n</i> =158/181)	events: None.	
	patients were	Not defined.	defined.	in non-IBD, 75%	events. None.	Consecutively
	immunosuppressed (no	9		(15/20) in IBD; but	Minor non-Gl	recruited: Yes.
Meighani <i>et al,</i>	further details); no	Donor demographics: Not	Route administered: Upper GI: 5	17.15 (<i>n</i> =31/181)	adverse events:	
Digestive Diseases	further specific details	defined.	nasogastric (IBD patients only; not	non-IBD relapse	None.	Prospectively
and Sciences,	about		described re non-IBD patients) lower GI:	within 90 days/	None.	recruited: No.
2017	immunosuppression).	Donor screening: Questionnaire	13 colonoscopy (IBD patients only; not	13.9% (<i>n</i> =25/180)	Serious adverse	
		- not defined.	described in non-IBD patients); 2	beyond 90 days,	events: None.	Loss to follow up
	CDI features: Recurrent		retention enema (IBD patients only; not	and 25% (<i>n</i> =5/20)		explained: Yes.
	CDI in 13/20 of IBD	Travel and antibiotic exclusion	described re non-IBD patients) (15).	IBD relapse within	Deaths: None.	
	patients, primary	period: Not defined.		90 days/ 20%		At least 90%
	refractory in 7/20. 1.90		Number of infusions: Any relapse	(<i>n</i> =4/20) beyond 90		followed up: Yes.
	(+/- 1.02) CDI infections	Screening blood tests: Not	beyond 90 days was defined as 'new	days. 3/5 failures in		
	in past three months for	defined.	infection'. However, not made clear if	IBD arm had newly-		
	IBD patients, 1.79	Care anima start testa. Not	patients given more than one FMT.	diagnosed IBD, other had severe		
	(+/1.17) CDI infections in	Screening stool tests: Not defined.	Bowel purgative: Not described.	active disease.		
	past three months for	defined.	Bowei purgative: Not described.	active disease.		
	non-IBD patients.		PPI: Not described.	Total follow up		
				period: At least 90		
	CDI diagnosis		Antimotility: Not described.	days.		
	confirmation: GDH first,		Antimotility. Not described.	uays.		
	then toxin A and B; PCR		Prokinetics: Not described.			

Page 231 of 454

Supplementary Material 2 for Gut

used if	f discordance.		Time before CDI treatment was stopped before FMT: No specific deails.		
	/IT antibiotics: Not				
	d for non-IBD; for				
	5 vancomycin				
	5 vancomycin and etronidazole.				
Utatility					
		40.			
		101			
		4	•		
		•			
			No.		
			181.		
			For Revie		

	Case series.					
	Case series.	Donors were healthy family/	Amount of stool per transplant /			
	Number of patients: 31.	contacts of recipients - 14 spouses, 9 children, 5 siblings, 3	administered to patients: Whole stool - median transplanted weight of 115g			
	Female: male: 17: 14.	parents, 1 niece, 1 friend.	(range 18-397g).		Minor GI adverse	
Patel <i>et al, Mayo</i> <i>Clinic Proceedings,</i> 2013	Age (mean/ standard deviation): Mean 61.26 (+/- 19.34) years. Comorbidities: x5 diverticulosis, x5 IBS, x3 UC, x1 Crohn's, x1 gastroparesis, x1 coloanal fistula, x3 prev sigmoid surgery for diverticulitis, x2 subtotal colectomy with ileosigmoid anastomosis, x1 left hemicolectomy with colostomy, x3 long term corticosteroids, x2 hypogammaglobulinaem ia, x1 OLT, x1 renal transplant, x1 long term methotrexate. CDI features: Recurrent -	 Working in healthcare: Not stated. Donor demographics: No stated age/ BMI limits. Donor screening: Questionnaire - exclude if: chronic GI disease, active peptic ulcer disease, GORD requiring daily PPI, IBS, IBD, history of colon polyps/cancer, antibiotics or hospitalisation in past three months. Travel and antibiotic exclusion period: No stated travel restrictions; excluded as donor if antibiotic use within past 3 months. Screening blood tests: hepatitis 	 Diluent used to prepare: Normal saline - "added in 100ml increments until mixture suitable for instillation through working channel of colonoscope". Median volume of FMT 360 (range 180- 900) ml. Diluent used to store if frozen: N/A – fresh. Preparation methods: Blender/ pitcher. Time from preparation to transplant (fresh): Six hours; kept at room temperature until processing. Time period for storage (frozen): N/A. Route administered: Upper GI: nil; lower GI: colonoscopy (31); capsule: nil. Number of infusions: One initially. 	Overall cure within stated follow up period: At 3 months – 91.3% (<i>n</i> =21/23) said diarrhoea no longer present; at 1 year, 100% (<i>n</i> =6/6) reported maintained improvement or resolution. Cure with one infusion alone: Of 29 with diarrhoea – 24.1% (<i>n</i> =7/29) reported improvement and 75.9% (<i>n</i> =22/29) resolution of diarrhoea by median time of three days.	events: Not described. Minor non-GI adverse events: Not described. Serious adverse events: Microperforation - caused by biopsy of an area of presumed ischaemic small bowel injury during the FMT procedure; managed conservatively. Deaths: x1 death at three months - directly related to	Selection/ eligibilit reported: Yes. Consecutively recruited: Yes, implied that were. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes - at least as far as primary outcome.
	A IgM, HBsAg, HBc IgG/M, hepatitis C antibody, HIV-1/-2 antibody, HTLV-1/-2 antibody, RPR/ syphilis EIA.	Bowel purgative: Yes - PEG day before FMT.	Total follow up period: One year.	' nancreatic cancer		
	(i aiioc 2 // cpisoacs.		PPI: Not described.			
	CDI diagnosis confirmation: At least 3x unformed stools/ day, at	Screening stool tests: MC&S, ova, cysts and parasites, <i>Cryptosporidium</i> antigen,	Antimotility: 4mg loperamide either pre- or immediately after colonoscopy.			

Page 233 of 454

least 2 x toxin positive	Microsporidia smear, C difficile	1		
episodes previously to	toxin (PCR or EIA).	Prokinetics: Not described.		
participate.				
		Time before CDI treatment was stopped		
Pre-FMT antibiotics: All 31 previous		before FMT: Antibiotics continued until 4 hours before prep (i.e. stopped day		
methotrexate, all 31		prior to FMT).		
previous vancomycin, 6				
previous fidaxomicin, 10	CI_			
previous rifaximin, 23				
prior probiotic.	YOL			
	∇x .			
		Ok .		
		For Review		
		65		

	Case series. Number of patients: 12. Female: male: 8: 4. Age (mean): Mean 71.9 (range 37 – 90) years. Comorbidities: x1 UC, 1 renal transplant, x1 left	Donors were preferrably family/ first degree relatives; family used in all cases here. Working in healthcare: Not specifically addressed. Donor demographics: Not given. Donor screening: Questionnaire - exposure to HIV, hepatitis,	Amount of stool per transplant / administered to patients: About 6-8 tablespoons. Diluent used to prepare: 1l of tap water. Diluent used to store if frozen: N/A - all fresh. Preparation methods: No specific details. Time from preparation to transplant	Overall cure within stated follow-up	Minor GI adverse events: Not stated. Minor non-GI adverse events: Not stated. Serious adverse events: Not stated. Deaths: x1 death. Patient with perforated appendix	Selection/eligibility reported: Yes.
Pathak et al, Clinical & Experimental Gastroenterology, 2013	 colon adenocarcinoma and diverticulitis; x1 ruptured appendix; x2 ventilator-dependent. CDI features: Recurrent; full details not given. Two of the patients had had recurrent CDI treated with FMT 'many years ago'. CDI diagnosis confirmation: Not specifically defined. Pre-FMT antibiotics: All vancomycin, 8 patients fidaxomicin, 4 patients methotrexate. 	STDs; high risk sexual behaviour; drug use, tattoos/ piercings, imprisonment, other high risk behaviour; known current communicable disease; GI morbidities including IBD or GI malignancy; antibiotic use within 90 days. Travel and antibiotic exclusion period: Excluded as donor if antibiotic use within last 90 days. Screening blood tests: HIV-1/-2, hepatitis A/B/C, STDs. Screening stool tests: MC&S, ova, cysts and parasites, <i>C</i> <i>difficile</i> toxin A and B.	 (fresh): 6 hours. Time period for storage (frozen): N/A. Route administered: Upper GI: nasoduodenal tube (1; as a second FMT); lower GI: colonoscopy (12). Number of infusions: 1 FMT initially. Bowel purgative: PEG the night before FMT. PPI: Not described. Antimotility: 2 tablets diphenoxylate/ atropine post-FMT. Prokinetics: Not described. Time before CDI treatment was stopped before FMT: 24 hours. 	period: 91.7% (<i>n</i> =11/12). Cure with one infusion alone: 91.7% (<i>n</i> =11/12). Total follow up period: 2-26 months.	developed rCDI; didn't respond to six months of anti- CDI treatment, went to ITU. Donor was husband - no screening, and no response to colonoscopic FMT. For 2 nd FMT, used healthy volunteer donor FMT via nasoduodenal tube - responded. Urinary tract infection at nursing home few months later – antibiotic treatment precipitated further CDI. Further sepsis, returned to ITU -	Consecutively recruited: Yes, implied that were. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes.

Page 235 of 454

2 3 4 5 6 7 8 9 10 11	6				declined treatment, then died, four months after initial FMT.	
12 13 14 15 16 17 18 19 20 21 22 23 24 25		oential.	For Review			
26 27 28 29 30 31 32 33 34 35 36 37 38 39				² 07J		
40 41 42 43 44 45 46		https://mc	.manuscriptcentral.com/gut			

Rohlke et al, Journal of Clinical Gastroenterology, 2010	Case series. Number of patients: 19. Female: male: 17: 2. Age (mean): Mean age 49 years. Comorbidities: Not described. CDI features: Recurrent CDI. CDI diagnosis confirmation: Positive <i>C</i> <i>difficile</i> toxin and consistently recurring symptoms over a span of six months. Pre-FMT antibiotics: Not given in detail - all at least three courses of conventional anti-CDI antibiotics, including pulsed and tapered vancomycin.	Donors were 4 family members, 14 partners, and 1 housemate. Donors working in healthcare: Excluded. Donor demographics: Donor screening: Questionnaire – included current or recent diarrhoeal illness, sexual behaviour. Travel and antibiotic exclusion period: Excluded if 'recent antibiotic use'; not further defined. Screening blood tests.: HIV, hepatitis A, B and C, and <i>Trepenoma</i> serology. Screening stool tests: <i>C difficile</i> , bacterial culture, ova, cysts and parasites, <i>Giardia</i> , <i>Cryptosporidium</i> .	 Amount of stool per transplant / administered to patients: 350mls. Diluent used to prepare: Normal saline. Diluent used to store if frozen: N/A - fresh. Preparation methods: Fresh preparation, with manual shaking of stool and saline in large suction canister, followed by filtering. Time from preparation to transplant (fresh): Not stated. Time period for storage (frozen): N/A. Route administered: Upper GI: nil; lower GI: all given via colonoscopy. Number of infusions: One routinely, with one patient having a second FMT. Bowel purgative: PEG. PPI: Not described. Antimotility: Loperamide post-FMT. Prokinetics: Not described. Time before CDI treatment was stopped before FMT: 1-3 days. 	Overall cure within stated follow up period: 100% (<i>n</i> =20/20). Cure with one infusion alone: 95% (<i>n</i> =19/20). Total follow-up period: 6 months to 5 years.	Minor GI adverse events: Nil reported. Minor non-GI adverse events: Nil reported. Serious adverse events: Nil reported. Deaths: Nil reported.	Selection/ eligibilit reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: Yes – variable follow-up. At least 90% followed up: Yes.
---	---	---	---	---	---	---

Rubin et al, Anaerobe, 2013Case series.Rubin et al, Anaerobe, 2013Comorbidities: x10 diabetes mellitus, x8 malignancy, x7 corticosteroids in prior three months.CDI features: Not stated.CDI diagnosis confirmation:Not described.Pre-FMT antibiotics: Oral metronidazole or vancomycin alone or in combination for initial FMT in all cases; not clear exact breakdown/ use for recurrences.	patients: 75.Donors were healthy people from the same household as the patient.ale: 49: 26.Donors were healthy people from the same household as the patient.an): Median i-94) years.Donors working in healthcare: Not stated.ies: x10 ellitus, x8 y, x7 oids in prior ths.Donor demographics: Not described.Donor screening: Questionnair – as per Aas et al, Clin Infect Di 2003. Travel and antibiotic exclusion period: As per Aas et al, Clin Infect Dis, 2003.sis on:NotScreening blood tests: As per Aas et al, Clin Infect Dis, 2003.Screening stool tests: As per Aas et al, Clin Infect Dis, 2003.	Time from preparation to transplant (fresh): As per Aas <i>et al</i> , <i>Clin Infect Dis</i> , 2003. Time period for storage (frozen): N/A – fresh.	Overall cure within stated follow up period: 78.7% (<i>n</i> =59/75). Cure with one infusion alone: 78.7% (<i>n</i> =59/75). Total follow up period: Up to 60 days.	Minor GI adverse events: Nil. Minor non-GI adverse events: Nil. Serious adverse events: Nil. Deaths: No - up to 60 days.	Selection/ eligibili reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes.
---	---	--	--	---	--

			Time before CDI treatment was stopped before FMT: Stopped on the day prior to procedure.						
	07	Fid.							
		ichtia/							
			or Rev						
			Revie						
	70								
70 https://mc.manuscriptcentral.com/gut									

CDI diagnosis confirmation:"Positive culture and toxin".Screening bloods: Total blood count, CRP, creatinine, LFTs, hepatitis B and C, HIV-1/-1, Treponema.Number of infusions: One FMT routinely.One yead with further antibioitcs – x1 died of recurrent CDI, x1 died of arterial thrombosis.Pre-FMT antibiotics: Describes using vancomycin with all, but no specific details.Screening stools: C difficile culture and toxin A/B test, MC&S, ova, cysts and parasites.Number of infusions: One FMT routinely. MoviPrep.Number of infusions: One FMT routinely. Bowel purgative: 4l Colonsteril PEG/ 2l MoviPrep.PPI: Not described.PPI: Not described.Antimotility: Not described.

Yoon et al, Journal of Clinical Gastroenterology, 2010	Case series. Number of patients: 12. Female: male: 9: 3. Age (mean)*: Mean 66 (range 30 - 86) years. Comorbidities: 9 with diverticulosis (with 2 of these having diverticulitis as index infection). CDI features: 1 patient with first CDI, 2 with 2nd, 5 with 3rd, 1 with 4th, 1 with 5th, 1 with 6th, 1 with 8 th . CDI diagnosis confirmation: Toxin testing for either toxin A or B, or assessment of both via EIA. Pre-FMT antibiotics: 12 had oral metronidazole, 3 had intravenous metronidazole, 12 had oral vancomycin, 4 x	Donors were spouses/ partners in 8 patients; for other 4 patients, donors were one son, two daughters, and one granddaughter. Donors working in healthcare: No. Donor demographics: No details. Donor screening: Questionnaire - no details. Travel and antibiotic exclusion period: No details given Screening bloods: Hepatitis B and C, HIV. Screening stools: <i>C difficile</i> toxin, enteric pathogens, ova, cysts and parasites - at treating clinician's discretion.	Amount of stool per transplant / administered to patients: Stool (unclear how much) mixed with 11 normal saline; approx 250-450cc of FMT administered in total. Diluent used to prepare: Normal saline. Diluent used to store if frozen: N/A. Preparation methods: Manually shaken then filtered through gauze. Time from preparation to transplant (fresh): No details. Time period for storage (frozen): N/A. Route administered: Upper GI: (N/A) Lower GI: 10-20cc of FMT administered every 5-10cm of withdrawal distance in all 12 patients. Number of infusions: Single. Bowel purgative: All colonoscopic, but no specific details given. PPI: Not described. Antimotility: Not described.	Overall cure within stated follow up period: 100% (<i>n</i> =12/12). Total follow up period: 3 weeks to 8 years - no details on relation to individual patients.	Minor GI adverse events: Nil described. Minor non-Gl adverse events: Nil described. Serious adverse events: Nil described. Deaths: Nil described.	Selection/ eligibility reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: No. At least 90% followed up: Yes.
---	---	---	---	---	---	---

		Time CDI treatment was stopped before FMT: 3 days.		
C				
-07	R.			
	10/00			
	This !			
	47.	2		
		97P		
		.61	Vo	
	https://mc	74 manuscriptcentral.com/gut		

Youngster <i>et al,</i> JAMA, 2014	 Prospective case series. Number of patients: 20. Female: male: 9: 11. Age (median): Median 64.5 (range 11-89) years. Comorbidities: Specific comorbidities not described. CDI features: Included patients with both recurrent or refractory CDI. CDI diagnosis confirmation:Toxin and ELISA, PCR if toxin negative but ELISA is positive or indeterminate. Pre-FMT antibiotics: Failed vancomycin taper and/ or fidaxomicin. 	Donors were unrelated adult volunteers. Donor working in healthcare: Not stated. Donor demographics: Age range 18-50 years, BMI 18.5 - 25. Donor screening: Questionnaire - American Association of Blood Banks donor questionnaire. Travel and antibiotic exclusion period: Excluded as potential donors if used antibiotics within preceeding 6 months. Screening blood tests: Antibodies to hepatitis A, B, and C; HIV; and <i>Treponema</i> <i>pallidum</i> within 2 weeks of donations. Screening stool tests: " Enteric pathogens".	Amount of stool per transplant / administered to patients: 30 capsules (single treatment) - total 48g of stool. Diluent used to prepare: saline in 1/10th volume of stool. Diluent used to store if frozen: 10% glycerol. Preparation methods: Faecal matter solution was pipetted into size 0 capsules (650 μL), which were closed and then secondarily sealed in size 00 capsules. Capsules were stored frozen at -80°C until use. Time from preparation to transplant (fresh): N/A. Time period for storage (frozen): Mean 113 days (30-252 days). Route administered: All courses were 30 oral capsules. Number of treatments: 1 course (given as 15 capsules on 2 consecutive days). If failed, retreated at a mean of 7 days. Bowel purgative: Not described. PPI: Not described. PPI: Not described.	Overall cure within stated follow up period: 90% (<i>n</i> =18/20). Cure with one infusion alone: 70% (<i>n</i> =14/20). Total follow up period: 8 weeks.	Minor GI adverse events: Transient abdominal cramping and bloating in 6 patients (30%) that resolved in 72 hours. Minor non-GI adverse events: Not described. Serious adverse events: x1 hospitalised with a documented relapse of severe CDI after taking 15 capsules, but had successful treatment after receiving the remaining 15 capsules. No other severe adverse events (grade 2 or above). Deaths: none.	Selection/ eligib reported: Yes. Consecutively recruited: Yes. Prospectively recruited: Yes. Loss to follow up explained: Yes. At least 90% followed up: Yes
---------------------------------------	---	--	---	---	--	---

Page 244 of 454	

Gut

Prokinetics: Not described.

Youngster et al, BMC Medicine, 2016	Case series. Number of patients: 180. Female: male: Not stated. Age (median): Median 64 (range 7–95) years. Comorbidities: Not described. CDI features: Three or more mild-to-moderate episodes of CDI or two episodes requiring hospitalisation. CDI diagnosis confirmation: Not specifically described. Pre-FMT antibiotics: Not described.	Donors were healthy volunteers. Donors working in healthcare: Not mentioned. Donor demographics: 18-50 years of age, on no medications, with a 'normal body mass index'. Donor screening: Questionnaire - initial screening using the American Association of Blood Banks donor questionaire for exposure to infectious agents. Travel and antibiotic exclusion period: Excluded as donor if antibiotic use within 6 months. Screening bloods: Blood was screened for antibodies to hepatitis A, B, and C; HIV; and <i>Treponema pallidum</i> within 2 weeks of donations. Screening stool test: Donor faeces were screened for enteric bacterial pathogens including rotavirus, <i>Listeria monocytogenes, Vibrio cholerae, Escherichia coli</i> O157, ova and parasites (including general microscopy, acid-fast staining, and/or antigen testing	Amount of stool per transplant / administered to patients: 30 capsules derived from a mean of 48g of faeces. Diluent used to prepare: Normal saline. Diluent used to store if frozen: 10% glycerol. Preparation methods: Homogenised using a commercial blender then passed through sieves in ambient air. Time from preparation to transplant (fresh): N/A. Time period for storage (frozen): Study of capsulised FMT. Faecal slurry was double-encapsulated in hypromellose capsules (Capsugel, Cambridge, MA) and stored at -80 °C for up to 6 months pending use. Route administered: All received 30 capsules as a 'dose'. Number of infusions: 1 course of capsules in 147 patients, 2 courses in 26 patients and 3 course in 4 patients. Bowel purgative: not mentioned. PPI: not mentioned.	Overall cure within stated follow up period: 91% (<i>n</i> =164/180) Cure with one infusion alone: 82% (<i>n</i> =147/180) Total follow up period: 8 weeks for primary response.	Minor GI adverse events: x5 vomiting, x112 diarrhoea, x45 nausea/ bloating, x40 abdominal pain. Minor non-GI adverse events: x3 fever, x54 fatigue, malaise, and headache, x12 other complaints. Serious adverse events: Related serious (x1 fever, x2 new UC, x6 hospitalisations for CDI/ diarrhoea). Unrelated serious adverse events: x26 hospitalisations, x14 deaths. Deaths: x14 (unrelated).	Selection/eligibilit reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes.
---	--	--	--	---	--	--

	for Giardia, Cryptosporidium,			
	Isospora, and Microsporidia), C.	Prokinetics: not mentioned.		
	difficile, and Helicobacter pylori			
	antigen.	Time before CDI treatment was stopped		
		before FMT: 24–48 hours prior.		
	×.			
	YO.			
	· O /			
	•			
		10.		
			•	
			V O	

Zainah et al, Digestive Diseases and Sciences, 2014	Case series. Number of patients: 14. Female: male: 9:5. Age (mean +/-range)*: 73.4 (+/-11.9) years. Comorbidities: x4 patients with cancer, x1 OLT patient. CDI features: 8 patients had had prev CDI episodes (2-5 episodes prior). CDI diagnosis: Diarrhoea (at least 3 unformed stool/d for 2 consecutive days) + positive <i>C difficile</i> EIA and/or PCR. All patients here severe by definition - defined here as age >60 years, albumin <2.5mg/dl, temp at least 38.3°C, WBC > 15 within 48 hour of CDI diagnosis; or at least one of the following: pseudomembranes, treatment in intensive care.	Donors: 12 patients received FMT from related donor (7 spouse, 5 children); the other two used unrelated donors. Donors working in healthcare: Not stated. Donor demographics: Not stated. Donor screening: Questionnaire - not described. Travel and antibiotic exclusion period: No details. Screening blood tests: HIV-1/-2, hepatitis A IgM, hepatitis B serology, hepatitis C antibody, syphilis (RPR and FTA-ABS). Screening stools: <i>C difficile</i> toxin by PCR, stool ova, cysts and parasites.	Amount of stool per transplant / administered to patients: 30-50g. Diluent used to prepare: Warm tap water. Diluent used to store if frozen: N/A. Preparation methods: Homogenised mixture, then filtered through gauze; 120-180ml of suspension if through nasogastric tube, 300-500ml if through colonoscopy. Time from preparation to transplant (fresh): "Same day". Time period for storage (frozen): N/A. Route administered: Upper GI: Nasogastric administration in all but one patient (13 patients); lower GI: colonoscopic administration in one patient (1 patient). Number of infusions: One routinely; repeated if no response at 48-72hr. Bowel purgative: No details. PPI: Yes, pre nasogastric administration - no details given. Antimotility: Not described.	Overall cure within stated follow up period: 79% (<i>n</i> =11/14) by seven days. Cure with one infusion alone: 71% (<i>n</i> =10/14). Total follow up period: Up to 100 days .	Minor GI adverse events: Not described. Minor non-GI adverse events: Not described. Serious adverse events: Not described. Deaths: x1 within 7 days of FMT - but died of their malignancy.	Selection/ eligibility reported: Yes. Consecutively recruited: Yes. Prospectively recruited: No. Loss to follow up explained: Yes. At least 90% followed up: Yes.
--	---	---	--	---	--	--

Pre-FMT antibiotics: 14

patients prior

Gut

Prokinetics: Not described.

Time before CDI treatment was stopped

- 5/

Supplementary Material 2 for Gut

Reviewed randomised studies of FMT for recurrent or refractory CDI C.2. Confidential: For Review Only

> https://mc.manuscriptcentral.com/gut

Paper	Study and patient characteristics	Donor characteristics	FMT characteristics	Outcomes	Adverse even
	Intervention: FMT (pooled from		Amount of stool per transplant:		
	three donors).		45ml of pooled donor stool (from		
	Number of patients: 9.	Donors working in healthcare:	three donors), at ~0.19g/ml.		
	Female: male: 3: 4 (data only	Not stated.			
	presented for 7 patients).		Diluent used to prepare: 0.9%		
	Age: Mean of 39.7 (+/- 24.8)	Donor demographics: >18 years,	saline.		
	years.	non-pregnant, BMI 20-25kg/m ²			
			Diluent used to store if frozen: 15%		
	Comparator: Vancomycin (250mg	Donor screening: On	v/v glycerol.		
	every 6 hours for 10-14 days).	questionnaire, rejected potential			
	Number of patients: 10.	donors who in the past three	Preparation methods: Stool from		
	Female: Male: 3: 6 (data only	months had had use of PPI, use of	donors pooled, mixed,	Treatment arm: FMT	
	presented for 9 patients).	antibiotics, use of	resuspended in saline, filtered to	Overall cure rate: 71.4%	
	Age (mean/median): Mean of 46.7	immunosuppressives,	remove particles > 330µm	(<i>n</i> =5/7) (after 2 x FMT)	Minor GI advers
	(+/- 15.8) years.	hospitalisation and/ or diarrhoea.		Cure with one infusion alone: 57.1% (<i>n</i> =4/7).	events: Nil stated.
		Also excluded if high risk sexual	Time from preparation to		
	Comorbidities: In FMT arm – x1 abdominal abscess, x1 Child B	behaviour, first degree relative	transplant (fresh): N/A.		Minor non-GI
amacho-Ortiz et		with diabetes mellitus, abdominal		Treatment arm:	adverse events: Ni
I, PLoS ONE,	cirrhotic, x1 pulmonary TB; in	surgery, and any GI disease/	Time period for storage (frozen):	Vancomycin	stated.
017	vancomycin arm – x2	cancer.	Not stated.	Overall cure rate: 88.9%	
	haemodialysis patients, x1			(<i>n</i> =8/9) (not clear if	Serious adverse
	meningeal TB, x1 'abscessed	Travel and antibiotic exclusion	Route administered: Upper GI: 14	failed patient received	events: Nil state
	squamous cell carcinoma'.	period: Excluded if antibiotics	by OGD; 1 by nasojejunal tube.	FMT subsequently, as is	
		within the past 3 months.	Lower GI: colonic (1; patient with	described in protocol).	Deaths: Nil.
	CDI features: All first episode of CDI, occurring at least 48hrs after admission.		anatomical abnormality due to	acconnect in proceeding.	
		Screening blood tests: Normal full	head and neck neoplasia). Capsule:		
		blood count and liver enzymes	nil.		
		essential for inclusion. Also			
	CDI diagnosis confirmation: >3	screened for HAV, HBV, HCV, HIV,	Number of infusions: routinely 1;		
	bowel movements during the	CMV, EBV, Trypanosoma,	patients not resolving after first		
	previous 24 hours, Bristol scale >	Brucella, Treponema pallidum.	FMT received 2 nd FMT (as did		
	5, positive <i>C. difficile</i> EIA or PCR.		patients not improving with		
		Screening stool tests: Included	vancomycin).		
	Pre-FMT antibiotics: no antibiotics	parasites, enteropathogenic			
	within FMT arm; patients in	bacteria, rotavirus.	Bowel purgative: Not stated.		
	vancomycin arm received 250mg				

Gut

1 2 3	every 6hrs for 10-14 days.	PPI: Not stated.
4 5 7 3	Total follow up period: up to one year. Cochrane Collaboration risk of bias assessment: uncertain risk of	Antimotility: Not stated. Prokinetics: Not stated. Time before CDI treatment was
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27	bias.	Prokinetics: Not stated. Time before CDI treatment was stopped before FMT: Nil given.
8 9 0 1 2 3 4		Chronie
35 36 37 38 39 40 41 42 43		83 https://mc.manuscriptcentral.com/gut
14 15 16		

Cammarota et al, Alimentary Pharmacology and Therapeutics, 2015	Intervention: FMT. Number of patients: 20. Female: Male: 12: 8. Age (mean/median): Mean 71 (range 29-89) years. Comparator: Vancomycin (125mg four times daily for 10 days, follow by a pulse regimen (125- 500mg/day every 2-3 days, for at least three weeks). Number of patients: 19. Female: Male: 11: 8. Age (mean/median): Mean 75 (range 49-93) years. Comorbidities: No significant difference of Charlson comorbidity index between groups. CDI features: All recurrent. 7/20 in FMT arm with pseudomembranous colitis. CDI diagnosis confirmation: Diarrhoea and CDT positive within 10 weeks of previous antibiotic treatment. Pre-FMT antibiotics: All had had vancomycin or metronidazole. 19/20 of FMT arm and 16/20 of vancomycin taper. Total follow up period: 10 weeks.	Donors working in healthcare: no. Donor demographics: Less than 50 years of age, no antibiotics within past 6 months. Donor screening: Questionnaire - no antibiotics for last 6/12. Excluded if significant Gl disease, metabolic syndrome, chronic illness, immunocompromise, recent travel, high risk lifestyle in last three months. Travel and antibiotic exclusion period: 3 month travel exclusion period, 6 month antibiotic exclusion period. Screening blood tests: Hepatitis A, B, and C, HIV, EBV, syphilis, <i>Stongyloides, Entomoeba</i> <i>histolytica</i> , FBC, LFTs, creatinine, CRP. Screening stool tests: <i>C. difficile</i> cult and toxin, enteric bacteria, ova, cysts and parasites, VRE, MRSA, Gram negative multi-drug resistant bacteria.	Amount of stool per transplant / administered to patients: Not specified. Diluent used to prepare: Normal saline 500mls. Diluent used to store if frozen: N/A – fresh. Preparation methods: Blended and strained. Time from preparation to transplant (fresh): 6 hours. Time period for storage (frozen): N/A. Route administered: Upper GI: nil; lower GI: colonic (20); capsule: nil. Number of infusions: 14 had 1 infusion, 4 had 2 infusions, 1 had 3 infusions and 1 had 4 infusions. Initial protocol was that if non- response to first FMT, then second FMT after one week; however, after first two patients, changed to all patients with pseudomembranous colitis receiving repeat FMT every 3 days until resolution of CDI. Bowel purgative: Macrogol. PPI: No.	Treatment arm: FMT Overall cure rate: 90% (n=18/20). Cure with one infusion alone: 65% (n=13/20); none of these were patients with pseudomembranous colitis. The 7 patients not cured with first FMT all had pseudomembranous colitis; of these, 5/7 cured with protocol of recurrent FMTs. Treatment arm: Vancomycin: Overall cure rate: Cure with one infusion alone: 26% (n=5/19).	Minor GI adverse events: x19 diarrhoea, x12 bloating (all resolved at 12 hours). Minor non-GI adverse events: None. Serious adverse events: None. Deaths: x2 from <i>C</i> <i>difficile</i> -related complications.
--	--	---	---	--	--

1 2 3 4	Cochrane Collaboration risk of bias assessment: uncertain risk of		Antimotility: No.		
0	bias.		Prokinetics: No. Time before CDI treatment was stopped before FMT: Between five and two days prior to FMT.		
1 2 3 4 5 6 7	bias.				
8 9 0 1 2 3		· 9/. F			
4 5 6 7 8 9 0			Terien		
5 2 3 4 5 6				N/	
7 3 9 0 1		8	5		
2 3 4 5 6		8: https://mc.manuscr			

Allegretti et al, Gastroenterology (abstract), 2016	Intervention: Low dose FMT capsules (30 pills once). Number of patients: 10. Female: male: Not stated. Age (mean/median): Not stated. Comparator: High dose FMT. capsules (30 pills daily on two consecutive days). Number of patients: 9. Female: male: Not stated. Age (mean/median): Not stated. Comorbidities: Not stated. CDI features:Not stated. CDI features:Not stated. CDI diagnosis confirmation: Not stated. Pre-FMT antibiotics: Not stated. Total follow up period: 8 weeks. Cochrane Collaboration risk of bias assessment: uncertain risk of bias.	Donors were unrelated donors from universal stool bank (OpenBiome). Donors working in healthcare: No. Donor demographics: mean age 26, mean BMI 22.2. Donor screening: Questionnaire - as per OpenBiome protocol. Travel and antibiotic exclusion period: As per OpenBiome protocol. Screening bloods: As per OpenBiome protocol. Screening stools: As per OpenBiome protocol.	Amount of stool per transplant / administered to patients: 30 pills a day for one day. Diluent used to prepare: Not stated. Diluent used to store if frozen: Stored at -80°C prior to use. Preparation methods: Capsules physically stable for 30 days at 25°C using an emulsion-based production protocol. Time from preparation to transplant (fresh): Not stated. Time period for storage (frozen): Not stated. Route administered: All capsule – as described above. Number of infusions: 30 tablets (over one day). Bowel purgative: Not stated. PPI: Not stated. PPI: Not stated. Antimotility: Not stated. Prokinetics: Not stated. Time before CDI treatment was stopped before FMT: Not stated.	Treatment arm: Low dose FMT capsules (30 pills once). Overall cure rate: 70% (<i>n</i> =7/10). Treatment arm: High dose FMT capsules (30 pills daily on two consecutive days). Overall cure rate: 77.8% (<i>n</i> =7/9).	Minor GI adverse events: None. Minor non-GI adverse events: None. Serious adverse events: None. Deaths: None.
--	--	---	---	--	--

2 3 4 5 5 7	Intervention: FMT. Number of patients: 16. Female: male: 11: 5. Age (mean/ standard deviation): Mean 75.7 +/- 14.5 years.		Amount of stool per transplant / administered to patients: 50g. Diluent used to prepare: 500mls normal saline.		
8 9 9 10 10 11 12 13 13 14 15 16 16 17 18 Hota et al, 19 Clinical Infectious 20 Diseases, 21 2016 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37	Comparator: 6 week vancomycin taper. Number of patients: 12. Female: male: 8: 4. Age (mean/ standard deviation): Mean 69.6 +/- 14.2 years. Comorbidities: Not stated, but similar Charlson comorbidity index score between groups. CDI features: All recurrent. CDI diagnosis confirmation: Symptoms and toxin or PCR detection. Pre-FMT antibiotics: At least 1 course of vancomycin for a minimum of 10 days. The majority of patients in both arms had had prior vancomycin tapers. Total follow up period: 120 days. Cochrane Collaboration risk of bias assessment: uncertain risk of bias.	Donors working in healthcare: Not stated. Donor demographics: ≥18yrs. Donor screening: Questionnaire - self-screening questionnaire of behaviours associated with risk for blood-borne pathogens. Travel and antibiotic exclusion period: Antibiotic use for at least two days in the preceding three months. Screening blood tests: Extensive screening comparable with previous studies. Screening stool tests: Extensive screening comparable with previous studies.	 Diluent used to store if frozen: N/A – fresh. Preparation methods: Stomacher laboratory blender. Time from preparation to transplant (fresh): 48 hours. Time period for storage (frozen): N/A. Route administered: Upper GI: nil; lower GI: 16; capsule: nil. Number of infusions: All had 1 infusion. Bowel purgative: None. PPI: None. Antimotility: None. Prokinetics: None. Time before CDI treatment was stopped before FMT: Day prior to FMT. 	Treatment arm: FMT: Overall cure rate: 43.8% (<i>n</i> =7/16). Cure with one infusion alone: 43.8% (<i>n</i> =7/16). Treatment arm: 6 week vancomycin taper. Overall cure rate: 58.3% (<i>n</i> =7/12).	Minor GI adverse events: abdominal pain, tenderness and bloating, equal in both groups. Minor non-GI adverse events: Nil. Serious adverse events: x1 developed anasarca from liver disease, x1 had perforated bowel from diverticulitis at 35 days post-FMT. Deaths: None.

Gut

			Amount of stool per transplant / administered to patients: 50g.		
	Intervention: Fresh FMT.		Diluent used to prepare: Normal		
	Number of patients: 25.		saline.		
	Female: male: 21:4.				
	Age (mean): Mean 75 (range 19-		Diluent used to store if frozen:		
	97) years.		Implied use of glycerol for frozen		
			product but not clearly stated.	Treatment arm: Fresh:	Minor GI adverse
	Comparator: Lyophilised FMT.	Donors working in healthcare:		Overall cure rate: 100%	events: no
	Number of patients: 23.	Not stated.	Preparation methods: mix stool	(<i>n</i> =25/25).	differences in the
	Female: Male: 13: 10.		with normal saline (1:10), aerobic		three groups. Mild
	Age (mean): Mean 63 (range 20-	Donor demographics: "Normal	conditions, use Stomacher to	Cure with one infusion	transient abdominal
	87) years.	BMI".	homogenise.	alone: 100% (<i>n</i> =25/25).	pain and diarrhoea i
					86% of patients. x6
Jiang <i>et al,</i>	Comparator: Frozen FMT.	Donor screening: Questionnaire -	Time from preparation to	Treatment arm: Frozen:	experienced fatigue
Alimentary	Number of patients: 24	as per van Nood <i>et al, NEJM,</i>	transplant (fresh): Within 2 hours	Overall cure rate: 83%	and x4 had a
Pharmacology	Female: Male: 18: 6.	2013.	of preparation.	(<i>n</i> =20/24).	headache. x2 gained
and	Age (mean): Mean 62.5 (range 33-				weight.
Therapeutics,	88) years.	Travel and antibiotic exclusion	Time period for storage (frozen):	Cure with one infusion	
2017		period: As per van Nood <i>et al,</i>	Not specified.	alone: 83% (<i>n</i> =20/24).	Minor non-Gl
	CDI features: All recurrent.	<i>NEJM,</i> 2013.			adverse events: Nor
			Route administered: All	Treatment arm:	stated.
	CDI diagnosis confirmation:Not	Screening blood tests: As per van	colonoscopic.	Lyophilised:	
	explicitly stated, but includes CDI	Nood <i>et al, NEJM,</i> 2013.	Number of infections of	Overall cure rate: 78%	Serious adverse
	toxin.		Number of infusions: 1	(n=20/23). Cure with one infusion	events: None.
	Pre-FMT antibiotics: Not stated.	Screening stool tests: As per van Nood <i>et al, NEJM,</i> 2013.	Bowel purgative: PEG on night		Deaths: None.
	Pre-Fivit antibiotics. Not stated.	NOOU <i>et ul, Nejivi,</i> 2013.	before FMT.	alone: 78% (<i>n</i> =20/23).	Deaths: None.
	Total follow up period: 2 months.				
	Total follow up period. 2 months.		PPI: No.		
	Cochrane Collaboration risk of		FFI. NO.		
	bias assessment: high risk of bias.		Antimotility: 4mg loperamide 3		
			hours before.		
			Prokinetics: No.		

 https://mc.manuscriptcentral.com/gut

Time before CDI treatment was stopped before FMT: Not specified.
Confidential: For Review
89 https://mc.manuscriptcentral.com/gut

Page 258 of 454

	Comparitor: Oral FMT capsules. Number of patients: 57. Female: male: 43: 14. Age (median/standard deviation): 58.7 (+/-18.5) years. Comparitor: Colonoscopic FMT. Number of patients: 59. Female: male: 36: 13. Age (median/standard deviation):	Donors were unrelated	Amount of stool per transplant / administered to patients: 80-100g. Diluent used to prepare: Normal saline. Diluent used to store if frozen: 100% glycerol.		Minor GI adverse events: Capsule group: x3 nausea, x2 vomiting, x1 abdominal pain. Colonoscopy group: x1 nausea, x1 vomiting, x1 fever, x abdominal pain.
	57.4 (+/-19.1) years. CDI features: All recurrent.	volunteers. Working in healthcare: Not stated.	Preparation methods: Mix stool with 200ml of normal saline, and filtered using a Stomacher to homogenise 180ml of faecal slurry.	Treatment arm: Oral FMT capsules: 96.2% (n=51/53) absence of	Minor non-GI adverse events: .1 developed confusio in the colonoscopy
Kao <i>et al, JAMA,</i>	CDI diagnosis: Recurrence of diarrhea (>3 unformed bowel movements every 24 hours) within 8 weeks of completing a prior course of treatment, with	Donor demographics: Not stated. Donor screening: Questionnaire: As per Kelly <i>et al,</i> <i>Gastroenterology,</i> 2015.	Time from preparation to transplant (fresh): up to 2 months frozen, collected fresh within 12 hours.	CDI at 12 weeks. Cure with one treatment alone: 96.2% (<i>n</i> =51/53).	group between tim of screening and delivery of FMT. Th was not communicated to
2017	either a positive <i>C difficile</i> toxin by glutamate dehydrogenase and <i>C</i> <i>difficile</i> toxins A/B (<i>C diff</i> QuikChek Complete; Techlab) or by detection of glutamate	Travel and antibiotic exclusion period: As per Kelly <i>et al, Gastroenterology,</i> 2015.	Time period for storage (frozen): up to 2 months. Route administered: lower GI: 59	Treatment arm: FMT via colonoscopy: 96.2% (<i>n</i> =50/52).	team, and despite a uneventful FMT she died three days late from heart failure.
	dehydrogenase and <i>C</i> difficile cytotoxin B gene (Cepheid), plus resolution of	Screening blood tests: As per Kelly <i>et al, Gastroenterology,</i> 2015.	(colonoscopy); capsule: 57. Number of infusions: x1 of	Cure with one infusion alone: 96.2% (<i>n</i> =50/52).	Serious adverse events: None.
	diarrhea for the current episode. Pre-FMT antibiotics: Oral	Screening stool tests: As per Kelly et al, Gastroenterology, 2015.	colonoscopy, or x40 capsules as one-off.	$O_{\rm A}$	Deaths: x1 in each group from cardiopulmonary
	vancomycin (125mg twice daily) up to 24hrs before FMT.		Bowel purgative: PEG on the night before.	1/2	disease (see above for colonoscopy). T other patient
	Total follow-up period: 12 weeks.		PPI: No. Antimotility: Not stated.		developed Staphylococcus
			Prokinetics: Not stated.		epidermis bacteraemia 10 weeks after capsule

https://mc.manuscriptcentral.com/gut

Gut

1 2 3 4 5 6		Time before CDI treatment was stopped before FMT: 24 hours.	treatment and died from sepsis.
7 8 9 10 11 12	Conrie		
13 14 15 16 17 18 19	Confidential.		
20 21 22 23 24 25		A PR	
26 27 28 29 30		ey.	
31 32 33 34 35			
36 37 38 39 40			
41 42 43 44 45 46	https://mc.r	91 nanuscriptcentral.com/gut	

AComparator: Autologous FMT. Number of patients: 24. Female: male: 19: 5. Age (mean/ standard deviation): Mean age 55 (+/-14) years.a modified AABB full-length donor history questionnaire, and those with risk factors for infectious agents were excluded.Stool in 500m7Age (mean/ standard deviation): Mean age 55 (+/-14) years.a modified AABB full-length donor history questionnaire, and those with risk factors for infectious agents were excluded.Diluent used7Age (mean/ standard deviation): Mean age 55 (+/-14) years.Travel and antibiotic exclusion period: Excluded as donor if antibiotics within preceeding 90 days.Time from pi transplant (fi screening bloods: Testing for HIV- 1 and HIV-2 was performed within 2 weeks before donation for FMT. Other serologic testing was performed within 1 month before FMT and included testing for hepatitis A, B, and C viruses; also, testing for Treponema positive stool test result for C difficile or pseudomembranes on colonoscopy.Screening stool tests: polymerase chain reaction (PCR) testing for detection of C difficile toxin; culture for enteric pathogens (Escherichia coli, Salmonella, Shigella, Yersinia, Campylobac- ter, Listeria monocytogenes, Vibrio parahaemolyticus, and V cholerae]; testing for fecal Giardia and Cryptosporidium antigens; acid-fast stain forPrime before	Not described.
---	----------------

1 2 3 4 5 6 7		<i>Isospora</i> ; ova and parasite testing; and enzyme immunoassay for detection of Rotavirus.	therapy until 2 to 3 days before the procedure.	
7 8 9 10 11 12 13 14	Conrie			
15 16 17 18 19 20 21	Conne			
22 23 24 25 26 27			r Revi	
28 29 30 31 32 33 34			er; eh	
35 36 37 38 39 40 41				
42 43 44 45 46			93 criptcentral.com/gut	

Lee <i>et al,</i> JAMA, 2016	Intervention: Frozen FMT. Number of patients: 108. Female: male: 72: 36. Age (mean/ standard deviation): Mean age 73.0 (+/- 16.4) years. Comparator: Fresh FMT. Number of patients: 111. Female: Male: 74: 37. Age (mean/ standard deviation): Mean age 72.5 (+/- 16.2) years. Comorbidities: Not described. CDI features: All recurrent disease. CDI diagnosis confirmation: Toxin and PCR. Pre-FMT antibiotics: All had had prior metronidazole, vancomycin, or both in combination. Almost all patients had had prior vancomycin taper. Total follow up period: 13 weeks. Cochrane Collaboration risk of bias assessment: low risk of bias.	Donors were unrelated volunteers. Donors working in healthcare: Not specifically described. Donor demographics: Not defined. Donor screening: questionnaire – comparable to blood donor screening questionnaire. Travel and antibiotic exclusion period: Excluded as donor if travel (within the last 6 months) to areas of the world where diarrheal illnesses are endemic or risk of traveler's diarrhea is high; also excluded if antibiotics within the preceeding 3 months. Screening blood tests: HIV-1 and -2, hepatitis A IgM, HBsAg, anti-HBc (both IgG and IgM), and anti-HBs, hepatitis C antibody, RPR and FTA-ABS. Screening stool tests: <i>Clostridium difficile</i> toxin B by PCR; if unavailable, then evaluation for toxins A and B by EIA; routine bacterial culture for enteric pathogens; faecal <i>Cryptosporidium</i> antigen; Acid- fast stain for <i>Cyclospora</i> ,	Amount of stool per transplant / administered to patients: 100g of stool. Diluent used to prepare: 300mls of water. Diluent used to store if frozen: no solvents used for storage. Preparation methods: 100g of stool homogensied and mixed in 300mls of water. Time from preparation to transplant (fresh): If fresh, administered within 24hrs. Time period for storage (frozen): If frozen, kept for 30 days at -20°C. Route administered: Upper GI: nil; lower GI: enema FMT for all patients in both groups; capsule: nil. Number of infusions in frozen arm: 57 patients had 1 infusion; 24 patients had 2 infusions; rest had >2 infusions; in fresh arm: 56 patients had 1 infusion; 22 patients had 2 infusion; rest had >2 infusions. Bowel purgative: Not described. PPI: Nil.	Treatment arm: Frozen: Overall cure rate: 90.7% ($n=98/109$). Cure with one infusion alone: 52.8% ($n=57/108$). Treatment arm: Fresh: Overall cure rate: 85.6% ($n=95/111$). Cure with one infusion alone: 50.5% ($n=56/111$).	Minor GI adverse events: Transient diarrhoea (70%), abdominal cramps (10%), nausea (5%) in 24 hours post-FMT; constipation (20%) and flatulence (25%) in follow-up period. No difference between the two groups. Minor non-GI adverse events: None described. Serious adverse events: x12 patients required hospitalization because of ilnesses unrelated to FMT. Deaths: x6 deaths in frozen and x13 deaths in fresh arm (all unrelated to FMT).
------------------------------------	---	---	--	---	--

1 2 3 4 5	<i>Isospora</i> and, if antigen testing unavailable, <i>Cryptosporidium;</i> ova, cysts and parasites.	Antimotility: Not described. Prokinetics: Not described.		
6 7 8 9 10 11 12 13 14 15	19 ₀ ,	Time before CDI treatment was stopped before FMT: Discontinued 24 - 48 hours prior to FMT.		
16 17 18 19 20 21 22 23 24 25 26	6.	Time before CDI treatment was stopped before FMT: Discontinued 24 - 48 hours prior to FMT.		
27 28 29 30 31 32 33 34 35 36			h Onj	
37 38 39 40 41 42 43 44 45 46	https://mc.n	95 nanuscriptcentral.com/gut		

van Nood et al, New England Journal of Medicine, 2013	 Number of patients: 16. Female: male: 8: 8. Age (mean/ standard deviation): 73 (+/- 13) years. Comparator: Vancomycin (500mg orally four times daily for 14 days). Number of patients: 13. Female: male: 7: 6. Age (mean/ standard deviation): 66 (+/-14) years. Comparator: Vancomycin (500mg orally four times daily for 14 days) + bowel lavage. Number of patients: 13. Female: Male: 3: 10. Age (mean/ standard deviation): 69 (+/-16) years. Comorbidities: No significant difference in median Charlson comorbidity index between groups. CDI features: All recurrent. CDI diagnosis confirmation: Toxin and PCR. Pre-FMT antibiotics: At least one 	volunteers. Donors working in healthcare: No. Donor demographics: <60 years of age. Donor screening: questionnaire: questionnaire addressed risk factors for potentially transmissible diseases. Travel and antibiotic exclusion period: Excluded as donor if travel to tropical area within past 3 months, or antibiotic use within the past two months. Screening blood tests: Blood was screened for HIV; human T-cell lymphotropic virus types 1 and 2; hepatitis A,B, and C; cytomegalovirus; Epstein- Barr virus; <i>Treponema</i> <i>pallidum; Strongyloides</i> <i>stercoralis;</i> and <i>Entamoeba</i> <i>histolytica</i> .	administered to patients: A mean (+/-standard deviation) of 141+/- 71g of faeces was infused. Diluent used to prepare: Faeces were diluted with 500mls of sterile saline, 0.9%. Diluent used to store if frozen: N/A. Preparation methods: The solution was stirred, and the supernatant strained and poured in a sterile bottle. Time from preparation to transplant (fresh): Mean time from defecation to infusion was 3.1+/- 1.9 hours. Time period for storage (frozen): N/A. Route administered: Upper GI: 16 (via nasoduodenal tube); lower GI: nil; capsule: nil. Number of infusions: 16 patients had 1 infusion; 3 who did not respond in this group had 2nd infusion.	Treatment arm: FMT + bowel lavage Overall cure rate: 94% (n=15/16). Cure with one infusion alone: 81% (n=13/16). Treatment arm: Vancomycin: Overall cure rate: 315 (n=4/13) patients at 10 weeks. Treatment arm: Vancomycin + bowel lavage: Overall cure rate: 23% (n=3/13) patients at 10 weeks.	Minor GI adverse events: 94% immediate diarrhoea, 31% abdominal pain with cramping, 19% belching - resolved within 3 hours. During follow-up, x3 patient had constipation (19%). Minor non-GI adverse events: Nil. Serious adverse events: Nil described. Deaths: None.
	course of adequate antibiotic therapy (≥10 days of vancomycin at a dose of ≥125mg four times a day or ≥10 days of metronidazole	Screening stool tests: Donor feces were screened for parasites, including Blastocystis hominis and Dientamoeba fragilis; C	Bowel purgative: 4 litres of macrogol solution (Klean-Prep) on the last day of antibiotic treatment. PPI: Not stated.		

1					
2 3 4	at a dose of 500mg three times per day).	<i>difficile,</i> and enteropathogenic bacteria.	Antimotility: Not stated.		
5 6	Total follow up period: After first infusion at 10 weeks; follow-up		Prokinetics: Not stated.		
7 8 9	was extended to 10 weeks after the second infusion.		Time before CDI treatment was stopped before FMT: 24 hours.		
10 11 12	Cochrane Collaboration risk of bias assessment: low risk of bias.				
13 14 15 16		Chx:	For Revie		
17 18 19 20		2/.			
21 22 23			10r		
24 25 26 27			Ter:		
28 29 30 31				20n/	
32 33 34 35					
36 37 38					
39 40					
41 42 43			97		
44 45 46		nttps://mc.n	nanuscriptcentral.com/gut		

Youngster et al, Clinical infectious diseases, 2014	Intervention: Colonoscopic FMT. Number of patients: 10. Female: male: 6:4. Age (mean/ standard deviation): Mean 50.4 (+/- 28.8) years. Intervention: Nasogastric FMT. Number of patients: 10. Female: male: 5: 5. Age (mean/ standard deviatoin): Mean 58.6(+/-19.6) years. Comorbidities: Not defined. CDI features: Relapsing or recurring (having at least 3 episodes of mild-to-moderate <i>CDI</i> or at least 2 episodes of severe CDI resulting in hospitalization and associated with significant morbidity. CDI diagnosis confirmation: Toxin; initial GDH enzyme-linked immunosorbent assay, followed by PCR only if the GDH test is positive or indeterminate. Pre-FMT antibiotics: Treatment failures of a 6- to 8-week taper with vancomycin (95% of patients) with or without an alternative antibiotic, including fidaxomicin (70% of participants). Total follow up period: 8 weeks follow-up for primary response.	Donors were healthy volunteer non-pregnant adults. Donors working in healthcare: No. Donor demographics: 18-50 years of age, on no medications, with a normal body mass index. Donor screening: questionnaire - initial screening using the American Association of Blood Banks donor questionnaire for exposure to infectious agents. Travel and antibiotic exclusion period: Excluded if antibiotic use within 6 months. Screening blood tests: Blood was screened for antibodies to hepatitis A, B, and C; HIV; and <i>Treponema</i> <i>pallidum</i> within 2 weeks of donations. Screening stool tests: Donor faeces were screened for enteric bacterial pathogens including rotavirus, <i>Listeria</i> <i>monocytogenes, Vibrio</i>	Amount of stool per transplant / administered to patients: 90mls of thawed FMT (41g). Diluent used to prepare: Normal saline. Diluent used to store if frozen: 10% glycerol. Preparation methods: Homogenised using a commercial blender then passed through sieves. Time from preparation to transplant (fresh): N/A. Time period for storage (frozen): Inocula were stored frozen for up to 156 days, range, 29-156 days. Route administered: Upper GI (nasogastric) 10; lower GI (colonoscopy): 10; capsule: nil. Number of infusions: Colonoscopy: 8 patients - 1 infusion, 2 patients – 2 infusions; NG: 7 patients – 1 infusion; 3 patients – 2 infusions. Bowel purgative: For colonic route - 4 liters of PEG solution. PPI: 20mg of omeprazole orally for 48 hours prior to FMT.	Treatment arm: Overall Overall cure rate: 90% (n =18/20). Cure with one infusion alone: 70% (n =14/20). Treatment arm: Colonoscopy: Overall cure rate: 100% (n =10/10). Cure with one infusion alone: 80% (n =8/10). Treatment arm: Nasogastric: Overall cure rate: 80% (n =8/10). Cure with one infusion alone: 60% (n =6/10).	Minor GI adverse events: Mild abdominal discomfort and bloating in x4 patients (20%). X1 child treated colonoscopically had a transient fever of 38.8°C on day 2 that resolved spontaneously. Minor non-GI adverse events: Nil described. Serious adverse events: x1 new diagnosis of malignand x1 hospitalisation for Fournier gangrene (unrelate to FMT). Deaths: x2 deaths (unrelate to FMT).
--	---	---	---	---	--

	Cochrane Collaboration risk of bias assessment: uncertain risk of bias.	cholerae, Escherichia coli O157, ova and parasites (including general microscopy, acid-fast staining, and/or antigen testing for Giardia, Cryptosporidium, Isospora, and Microsporidia), C difficile, and Helicobacter pylori antigen.	Antimotility: single dose of oral loperamide prior to procedure. Prokinetics: Nil. Time before CDI treatment was stopped before FMT: Patients were required to discontinue all antibiotics at least 48 hours prior to the procedure.		
27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46			99 hanuscriptcentral.com/gut	n Onj	

C.3. Reviewed randomised studies of FMT for non-CDI indications

Gut

Paper	Study and patient characteristics	Donor characteristics	FMT characteristics	Outcomes	Adverse eve
Moayyedi et al, Gastroenterology, 2015	Intervention: FMT. Number of patients: 38. Female: male 20: 18. Age (mean +/-range)*: 42.2+/-15.0 years. Comparator: Water enema. Number of patients: 37. Female: male: 11: 26. Age (mean +/-range)*: 35.8 +/- 12.1 years. Primary outcome: Remission at week 7, defined as full Mayo score < 3 and complete healing of mucosa at flexible sigmoidoscopy (endoscopic Mayo score: 0). Secondary outcome: Clinical response (at least 3 point reduction in Mayo score), change in Mayo, IBD Questionnaire scores, EQ-5D scores. Inclusion criteria: >18 years with UC - Mayo at least 4 with endoscopic subscore at least 1 (included patients with severe disease). Exclusions - antibiotics/ probiotics in past 30 days, concomitant <i>C</i> <i>difficile/</i> other enteric pathogens, disease severity requiring hospitalisation, pregnancy, unable	Donors were unrelated volunteers - six donors used. Plus - one patient in active treatment arm had spouse as donor (treatment failure). Working in healthcare: Not specifically stated. Donor demographics: 18-60 years. Donor screening: Questionnaire – yes. Travel and antibiotic exclusion period: Retesting of stool whenever donor travelled outside North America. Excluded as donor if antibiotics within past 3 months. Screening repeated regardless every 6 months. Screening blood tests: HIV, hepatitis A IgM, HBsAg, hepatitis C antibody, syphilis, HTLV-1/-2. Screening stool tests: MC&S, ova, cysts and parasites, <i>C difficile</i> toxin, VRE, MRSA.	Amount of stool per transplant / administered to patients: 8.3g of stool per enema Diluent used to prepare: 50g of stool mixed with 300ml of commercial bottled drinking water, then 50ml of mixture administered as enema. Diluent used to store if frozen: No glycerol. FMT administered either fresh, or stored at -20 degrees. 21 received frozen, 15 received fresh, 1 mixture of fresh and frozen. Preparation methods: Not anaerobic. Single donor per FMT. Time from preparation to transplant (fresh): Processing within 5hr of collection. Time period for storage (frozen): Not stated. Route administered and frequency: Upper GI: nil; lower GI: enema - weekly for 6 weeks. Aimed to retain for at least 20 mins (38); capsule: nil. Bowel purgative: No PEG. PPI: Not described.	FMT arm: Remission rates: 24% (n=9/38). Clincial response rates: 40% (n=15/38) had reduction in full Mayo score of at least 3 points. Quality of Life Assessment: Yes - IBDQ and EQ-5D not significantly different between groups. Water enema arm: Remission rates: 5% (n=2/37) $(p=0.03)Clincial response rates: 24%(n=9/37)$ had reduction in full Mayo score of at least 3 points $(p=0.16)$.	FMT arm: Minor GI adverse e Two patients devel patchy inflam in the colon and also rect abscess formation resolved with antib Minor non-GI adve events: None. Serious adverse events x2 patients had dia changed to Crohn's colitis, one was <i>C d</i> toxin positive at end therapy. Deaths: None. Water enema arm: Minor GI adverse events X1 patient developed patchy inflammation the colon and also abscess formation resolved with antib Minor non-GI adverse events: None. Serious adverse events: None. Serious adverse events: None. Serious adverse events: None.

https://mc.manuscriptcentral.com/gut

12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35	Total follow-up period: Up to 12 months. Cochrane Collaboration risk of bias assessment: low risk of bias.	ential: Fo	Relien		
32 33				54	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Rossen et al, Gastroenterology, 2015 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40	Intervention: Donor faeces. Number of patients: 23. Female: male: 12: 11. Age (median, (range)): 40 (33-56) years. Comparator: Autologous faeces. Number of patients: 25. Female: male: 14:11. Age (median, (range)): 41 (30 – 48) years. Primary outcome: Clinical remission (defined as a SCCAI score ≤2) in combination with 1-point improvement on the combined Mayo endoscopic score of the sigmoid and rectum, as compared with baseline sigmoidoscopy, 12 weeks after the first treatment. Secondary outcome: Endpoints at 6 and 12 weeks were clinical response (defined as a reduction of 1.5 points on the Simple Clinical Colitis Activity Index (SCCAI), a validated disease activity index tool in ulcerative colitis), clinical remission (defined as a SCCAI of ≤2), endoscopic response, change in median (Inflammatory Bowel Disease Questionnaire [IBDQ]) score from baseline to shortly after treatment (week 6), and adverse events. Inclusion criteria: enteric infection, use of biologics within 8 weeks or	Donors were healthy partners, relatives, or volunteers. Working in healthcare: Not stated Donor demographics: >18 yrs Donor screening: Questionnaire - Dutch Red Cross Questionnaire addressing risk factors for potential transmissible diseases used for screening of blood donors in The Netherlands. Travel and antibiotic exclusion period: Excluded as donor if antibiotics within 8 weeks. Screening blood tests: CMV (IgG + IgM), EBV (IgG + IgM), hepatitis A (total antibody), hepatitis B (HBsAg), hepatitis C (hepatitis C virus antibody), HIV (1+2 antibodies/antigen), HTLV (I + II antibodies), <i>Entamoeba</i> (antibodies against <i>Entamoeba histolytica</i>), <i>Strongyloides</i> (<i>Strongyloides</i> ELISA). Screening stools: Multiplex PCR containing probes against enteral viruses (<i>rotavirus, norovirus, enterovirus parechovirus, sapovirus, adenovirus 40/41/52, astrovirus</i>), FT + TFT II: PCR op <i>Giardia, SSYC,</i> <i>Clostridium</i> toxin	Amount of stool per transplant / administered to patients: 120g Diluent used to prepare: Normal saline Diluent used to store if frozen: not stated Preparation methods: Not anaerobic Time from preparation to transplant (fresh): not stated Time period for storage (frozen): not stated Route administered and frequency: Upper GI: Nasoduodenal route. 2 infusions three weeks apart. Nil lower GI or capsule Bowel purgative: Macrogol before both infusions PPI: Not described Antimotility: Not described Prokinetics: Not described	Donor faeces arm: Remission rates: 30% (n=7/23) Clincial response rates: 47.8% $(n=11/23)$ at 12 weeks. Quality of Life Assessment: IBDQ only calculated based on responders vs nonresponders. Autologous faeces arm: Remission rates: 20% (n=5/25), $(p=0.51)$. Clincial response rates: 52% (n=13/25) at 12 weeks.	Minor GI adverse events: 78.3% (n=18/23) of donor stool and 64% (n=16/25) of autologous stool experienced side effects post FMT: transient borborygmus, diarrhoea, vomiting, fever. Minor non-GI adverse events: None. Serious adverse events: x4 overall (small bowel perforation – secondary to Crohn's), CMV infection, abdominal pain, cervical carcinoma. Deaths: Nil.
--	---	--	--	--	--

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	methotrexate within 4 weeks Concomitant medications: stable doses of thiopurines, mesalamine, or corticosteroids 10 mg/day for the 8 weeks before inclusion. Total follow-up period: 12 weeks. Cochrane Collaboration risk of bias assessment: low risk of bias.	ential. Co			
23 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46		104 https://mc.manuscripte	Chiefe Ch	Dry	

Paramsothy et al, Lancet, 2017	Intervention: FMT. Number of patients: 41. Female: male 19: 22. Age (median, (range)): 35.6 (27.8- 48.9) years.Comparator: Placebo-isotonic saline with added colourant odourant and glycerol 	Donors were between 3-7 unrelated donors. Working in healthcare: No. Donor demographics: Not described. Donor screening: Questionnaire asked regarding: • Known HIV, hepatitis B or hepatitis C infection • Known exposure to HIV or viral hepatitis within the previous 12 months • High risk sexual behavior (e.g. sexual contact with anyone with HIV/AIDS or viral hepatitis, men who have sex with men, sex for drugs or money) • Use of illicit drugs • Tattoo or body piercing within the preceding 6 months • Incarceration or history of incarceration • Known current communicable disease (e.g. upper respiratory tract infection) • Risk factors for variant Creutzfeldt- Jakob disease • Travel within last 2 weeks to areas of the world where diarrhoeal illnesses are endemic or risk of traveler's diarrhea is high • History of or current inflammatory bowel disease (IBD) • History of or current irritable	Amount of stool per transplant / administered to patients: 37.5g of blended stool to isotonic saline; volume of each infusion was 150ml. Diluent used to prepare: isotonic saline with 10% glycerol cryoprecipitant. Diluent used to store if frozen: -80°C with glycerol cryoprotectant (concentration 10%). Preparation methods: Donors had to provide faeces within 4 hours of a bowel movement, which was inspected visually for suitability (formed stool, no blood or mucous). Donor stool homogenised for a given batch on each day in a biosafety cabinet in isotonic saline then filtered. Placebo infusions comprised isotonic saline; brown food colourant, odourant, and glycerol cryoprotectant (concentration 10%) was added to all study infusions (investigational and placebo). The volume of each infusion was 150 mL. Infusions were stored at -80°C until dispensation to patients at fortnightly study visits for home freezer storage at -20°C before daily administration. Time from preparation to transplant (fresh): Not described.	Donor FMT arm: Remission rates: 275 (n=11/41). Clincial response rates: 54% (n=22/41). Quality of Life Assessment: Not described. Placebo arm: Remission rates: 8% (n=3/40) (p=0.021). Clincial response rates: 23% (n=9/40) (p=0.04). Quality of Life Assessment: Not described.	FMT arm: Minor GI adverse events: abdominal pain x12 (29%), colitis x10 (24%), flatulance x10 (24%), bloating x8 (20%), nausea x2 (5%), elevated ALT x2 (5%), vomiting x2 (5%), enterocolitis x1 (2%), diarrhoea x1 (2%), reflux x1 (2%), haemorrhoids x1 (2%), elective surgical procedure x1 (2%). Minor non-GI adverse events: None. Serious adverse events: x2 (5%) - x1 clinical deterioration and colectomy, x1 needed intravenous intravenous steroids. Deaths: Nil. Placebo arm: Minor GI adverse events: abdominal pain x11 (28%), colitis x9 (23%), flatulance x8 (20%), bloating x11 (28%), nausea x5 (13%), vomiting x1 (3%), enterocolitis x3 (8%), anal fissure x1 (3%), faecal incontinence x1
--------------------------------------	---	---	--	--	--

Page 274 of 454

2	response (defined as a Mayo	bowel syndrome (IBS), chronic	Time period for storage (frozen): Not	 (3%), elevated ALT x2
3	endoscopy subscore of 1 or less,	constipation, chronic diarrhea or	described.	(5%).
4	with a reduction of at least 1 point	other intrinsic gastrointestinal		(373).
5	from baseline); steroid-free	illness / condition	Route administered and frequency:	Minor non-GI adverse
5	endoscopic remission (defined as a	History of or current	Upper GI: 0; lower GI: 5 enemas per	events: None.
7	Mayo endoscopy subscore of 0);	gastrointestinal malignancy or	week following colonosopic delivery	
8	quality of life (assessed with the	known polyposis or strong family	-5 days on, two days off for 8 weeks	Serious adverse events:
9	IBDQ); and safety (assessed with the	history of colorectal cancer	(40 enemas per patient); capsule: 0.	x1 (3%) - admitted to
10	adverse events).	History of major gastrointestinal		hospital (no details why).
11	daverse eventsj.	surgery (e.g. gastric bypass, partial	Bowel purgative: Yes, but no details	
12	Inclusion criteria: 1. 18-75 years; 2.	colectomy)h	bower purgative. res, but no details	Deaths: Nil.
13	UC for >3 months; 3. UC of any	Antimicrobials (antibiotics,	PPI: Not described	
14	extent except isolated proctitis	antivirals, antifungals), probiotics or	FFI. NOT described	
15	<5cm; 4. currently active mild-	proton pump inhibitors (PPIs) within	Antimotility: Not described	
16	moderate UC as mesured by a	the preceding 3 months	Antimotility. Not described	
17	Mayo score of 4-10, endoscopy	Major immunosuppressive	Prokinetics: Not described	
18	score must be greater or equal to 1	medications (e.g. calcineurin	Prokinetics. Not described	
19	and a physician global assessment	inhibitors, biological agents,	1	
20	score of less than or equal to 2; 5.	exogenous glucocorticoids)		
21	Written consent.	exogenous giucocoi licolus		
22	Written consent.	Systemic anti-neoplastic agents Household members with active GI	Review	
23	Concomitant medications: Drugs	infection Systemic autoimmunity		
24	permitted as long as the dose was	Infection systemic autoinfinuity	10	
25	stable preceding enrolment: oral 5-	(e.g. multiple sclerosis, connective tissue disease)		
26		tissue disease)		
27	aminosalicylates (stable dose for 4	· Atopic disease (e.g. moderate -		
28	weeks); thiopurines and	severe asthma, eosinophilic		
29	methotrexate (on medication for	disorders of the gastrointestinal		
30	≥90 days and dose stable for 4	tract)		
31	weeks); and oral prednisolone	• Metabolic syndrome, obesity (BMI		
32	(dose ≤20mg daily and stable for 2	>30) or moderate to severe under-		
33	weeks). During the study, patients	nutrition / malnutrition	1	
34	remained on the same dose of 5-	• Chronic pain syndromes (e.g.		
35	aminosalicylate, thiopurine, and	chronic fatigue syndrome,		
36	methotrexate. For oral	fibromyalgia) or neurologic /		
37	prednisolone, patients received a	neurodevelopmental		
38	mandatory taper of up to 2.5 mg	disorders		
39	per week so that patients would be	 History of malignant illness or 		
40	steroid-free by week 8.	ongoing oncologic therapy		

l					
3 4 5 6 7 8 9 20 21 22 23 24 25 26 27 28 29	Cochrane Collaboration risk of bias assessment: low risk of bias.	Travel and antibiotic exclusion period: Excluded if travel within last 2 weeks to areas where diarrheal illnesses are endemic or risk of travelers diarrhea is high. Screening blood tests: Complete blood count, electrolytes, urea and creatinine, LFTS, ESR, CRP, HIV-1 and -2, hepatitis A IgM, hepatitis B SAg, hepatitis B core antibody (IgM and IgG) and surface antibody, hepatitis c antibody, rapid plasma reagin and/or fluorescent treponemal antibody-absorbed, HTLV-1 and HTLV-2. Screening stools: <i>C difficile</i> PCR, faecal MC&S with routine bacterial culture for enteric pathiogens, <i>Giardia</i> antigen, <i>Cryptosporidium</i> antigen, faecal ova/cysts/parasites including <i>Blastocystitis hominis</i> and <i>Dientamoeba fragilis</i> , and Norovirus.	Review		
30 31 32 33		<u></u>	(2012	
3 4 5					
5					
6 7					
8					
8 9					
0					
1		407			
2		107			
12					

Page 276 of 454

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Costello et al, Journal of Crohn's and Colitis (abstract), 20 (abstract), 21 2017 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37	 Intervention: Donor FMT. Number of patients: 38. Female: male: Not stated. Age (mean/median): Not stated. Comparator: Control - autologous FMT in saline. Number of patients: 35. Female: male: Not stated. Age (mean/median): Not stated. Primary outcome: Steroid-free remission of UC, as defined by total Mayo of 2 or less with an endoscopic Mayo score of 1 or less at week 8. Secondary outcome: Clinical response (at least 3 point reduction in Mayo score), clinical remission (i.e. SCCAI of 2 or less), endoscopic remission (Mayo 1 or less), and safety. Inclusion criteria: UC - Mayo 3-10 with endoscopic subscore at least 2. Concomitant medications: Stable dose of immunomodulator, 5-ASA, biological, tapering prednisolone. Cochrane Collaboration risk of bias assessment: uncertain risk of bias. 	Donors were healthy volunteers. Working in healthcare: Not clear. Donor demographics: Not described. Donor screening: Questionnaire – yes but no details described. Travel and antibiotic exclusion period: Not described. Screening blood tests: Yes but not described . Screening stool tests: Yes but not described.	Amount of stool per transplant / administered to patients: 50g of stool for first FMT, 25g of stool in subsequent enemas. Diluent used to prepare: 65% saline. Diluent used to store if frozen: Yes - frozen with 10% glycerol. Preparation methods: Anaerobic prep, donor stool pooled from 3-4 donors. Time from preparation to transplant (fresh): N/A. Time period for storage (frozen): Not stated. Route administered and frequency: Upper GI: nil; lower GI: FMT via colonoscopy on day 0, followed by 2 enemas on day 7 (38); capsule: nil Bowel purgative: PEG before colonoscopy but not enema PPI: Not described Antimotility: Not described Prokinetics: Not described	Donor FMT arm: Remission rates: 32% ($n=12/38$) in steroid-free remission at week 8. Clincial response rates: 55% ($n=21/38$). Quality of Life Assessment: Not described. Autologous FMT arm: Remission rates: 9% . ($n=3/35$) in steroid-free remission at week 8 ($p<0.01$). Clincial response rates: 20% ($n=7/35$) ($p<0.01$). Quality of Life Assessment: Not described.	Donor FMT arm: Minor GI adverse events: Nil. Minor non-GI adverse events: Nil. Serious adverse events: Worsening colitis in x2 patients Deaths: Nil. Control - autologous FMT in saline arm. Minor GI adverse events: Nil. Minor non-GI adverse events: None. Serious adverse events: Worsening colitis in x2 placebo patients. x1 patient requiring colectomy, x1 pneumonia. Deaths: Nil.
--	--	--	--	---	---

Gut

Intervention: Donor FMT. Number of patients: 55. Female: male: 36: 19. Age (median, (range)): 44 (33-54) years.Comparator: Control - autologous FMT . Number of patients: 28. Female: male: 19: 9. Age (median (range)): 45 (34-57) years.Johnsen et al, Lancet Gastroenterology and Hepatology, 2017Johnsen et al, Lancet Concet Gastroenterology and Hepatology, 2017Johnsen et al, Lancet Concet Gastroenterology and Hepatology, 2017Johnsen et al, Lancet Concet Concet Concet Age (median (range)): 45 (34-57) years.Johnsen et al, Lancet Gastroenterology and Hepatology, 2017Johnsen et al, Lancet Concet than 75 points assessed by IBS-SSS at 3 months after FMT.Inclusion criteria: 18-75 yrs of age, IBS with diarrhoea or mixed IBS according to Rome III criteria. Exclusion criteria: participants with severe cardiac disease, pulmonary disease, or kidney failure, non-IBS type abdominal pain, immunodeficiency or on immunomodulating agents.Cochrane Collaboration risk of bias assessment: low risk of bias	 Donors were two volunteers screened at start and at 7 months post donation. Working in healthcare: Not stated. Donor demographics: Not described. Donor screening: Questionnaire - new tattoos or piercings in the past 3 months; high-risk sexual behaviour; former imprisonment; or history of any of the following conditions: chronic diarrhoea, constipation, inflammatory bowel disease, IBS, colorectal polyps or cancer, immunosuppression, obesity, metabolic syndrome, atopic skin disease, or chronic fatigue. Travel and antibiotic exclusion period: Excluded if antibiotics within past three months. Screening blood tests: Glycated haemoglobin; and serology for HIV, <i>Treponema pallidum</i>, and hepatitis A, B, and C. Screening stool tests: <i>Salmonella</i> spp, <i>Shigella</i> spp, <i>Campylobacter</i> spp, <i>Yersinia</i> spp, and toxin-producing <i>C difficile</i>; faecal tests for <i>Helicobacter pylori</i> antigen, 	 Amount of stool per transplant / administered to patients: 50 to 80g of stool in 50mls. Diluent used to prepare: 200ml isotonic saline and 50mls of 85% glycerol. Diluent used to store if frozen: glycerol, only for autologous transplants. Preparation methods: Aerobic, stool from both donors was mixed together. Time from preparation to transplant (fresh): 7 hours. Time period for storage (frozen): 2-4 weeks. Route administered and frequency: upper GI: none; lower GI: single infusion of FMT via colonscopy; nil capsule. Bowel purgative: Picoprep. PPI: Not described. Antimotility: Loperamide 8mg 2 hours before. Prokinetics: Not described. 	Donor FMT arm: Remission rates: 66% (n=36/55) . Quality of Life Assessment: Not described. Autologous FMT arm: Remission rates: 43% (n=12/28) (p=0.49). Quality of Life Assessment: Not described.	FMT arm: Minor GI adverse even Self limiting intermitted abdominal pain x1, self limiting nausea and vertigo x1. Minor non-GI adverse events: Nil. Serious adverse events Nil. Deaths: Nil. Placebo arm: Minor GI adverse even Self limiting intermitted abdominal pain x2. Minor non-GI adverse events: Nil. Serious adverse events Nil. Deaths: Nil. Deaths: Nil.
---	---	---	---	---

1	
2	viruses (norovirus, rotavirus,
3	
4	Sapovirus, adenovirus),
5	and faecal calprotectin.
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	Onridential: For Review
28	
29	
30	
31	
32	Ch Only
33	
34	
35	
36	
37	
38	
39	
40	
41	110
42	110
43	https://mc.manuscriptcentral.com/gut
44	https://fic.manuscriptcentral.com/gut
45	
46	
-10	

	Intervention: Donor FMT. Number of patients: 10. Female: male: 0: 10. Age (mean+/-standard deviation): 64.5 +/- 5.1 years. Aetiology (HCV / alcohol / HCV+alcohol / NAFLD / others): 2/4/2/2/0. Comparator: Standard of care (lactulose/ rifaximin). Number of patients: 10.	Single donor only - identified based on highest relative abundances of <i>Lachnospiraceae</i> and <i>Ruminococcaceae</i> (16S rRNA gene sequencing analysis) among a universal stool donor bank (OpenBiome). Working in healthcare: Not stated. Donor demographics: Not described	Amount of stool per transplant / administered to patients: 37.5g of stool. Diluent used to prepare: 90mls glycerol saline buffer in total. Diluent used to store if frozen: glycerol. Preparation methods: Aerobic.	FMT arm: Patients with SAEs at day 150: 20% ($n = 2/10$) ($p=0.02$). Total SAEs at day 150: 20% ($n = 2/10$) ($p=0.01$). Patients with altered mental status by day 150: 0% ($n = 0/10$) ($p=0.03$).	FMT arm: Serious adverse events: x1 hospitalisation for acute kidney injury, and
	Female: male: 0: 10. Age (mean+/-standard deviation):	Donor screening: Based on OpenBiome screening. 178-point	Time from preparation to transplant (fresh): N/A - frozen.	Total HE episodes at day 150: 0% (n =0/10) (p=0.03).	1 was due to chest pain (all within 5 months post FMT).
	62.9 +/- 9.8 years. Aetiology (HCV / alcohol / HCV+alcohol / NAFLD / others): 1/5/2/1/1.	clinical assessment for infectious and microbiome-mediated diseases and 30 stool pathogen and serological tests before and after	Time period for storage (frozen): not stated.	Stroop OffTime+OnTime change (day 0 and day 20); positive indicates	Deaths: Nil.
Bajaj <i>et al,</i> <i>Hepatology,</i> 2017	Primary outcome: Proportion of participants with FMT-related serious adverse events (SAEs) at day 150, a composite endpoint of	the stool is collected. Screening blood tests: HIV-1/-2 status, hepatitis A/B/C, <i>Treponema</i> <i>pallidum</i> ,	Route administered and frequency: Upper GI: non; lower GI: Single infusion of FMT via enema. Bowel purgative: Picoprep.	improvement: 29.1 +/- 27.9 (p=0.04) (N.B. Stroop OffTime+OnTime is a validated tool for objectively assessing for	Standard of care arm: Serious adverse events: x11 in total. x9 events linked to liver-related complications, of which
	death, hospitalisations, emergency room visits or transmissible infections, as defined by the FDA.	LFT, Complete Blood Count (CBC) (Includes differentials and platelets), HTLV-I/II antibody, with Reflex to	PPI: Not described.	hepatic encephalopathy using a smartphone app).	x4 needed hospitalisation. x1 patient developed pneumonia and x1
	Secondary outcomes: Changes in cognitive function at day 20,	Confirmatory Assay. Screening stool tests: <i>Clostridium</i>	Antimotility: Loperamide 8mg 2 hrs before.	PHES score change (day 0 and day 20); negative indicates improvement -	developed gastroenteritis.
	cirrhosis severity (MELD score, albumin), changes in liver function	<i>difficile</i> Toxin B and PCR, <i>Cyclospora</i> and <i>Isospora</i> Examination, ova, cysts	Prokinetics: None.	3.1+/-2.1 (<i>p</i> =0.01).	Deaths: Nil.
	and white blood cell (WBC) count, development of all adverse events (AEs), and changes in microbiota	and parasites with <i>Giardia</i> Antigen EIA, <i>Salmonella/ Shigella/</i> <i>Campylobacter</i> Culture, Shiga Toxin	Others: Lactulose and rifaximin were continued for all patients throughout the trial. A 5-day broad-spectrum	MELD score change (day 0 and day 35): 0.1+/-2.0 (p=0.78).	
	composition and function in the FMT arm compared to standard of	EIA with Reflex to <i>E. coli</i> O157 Culture and <i>Vibrio</i> Culture,	coverage regimen was used (metronidazole 500 mg orally three	Standard of care arm:	
	care arm.	Cryptosporidium Antigen EIA, Helicobacter pylori Antigen EIA,	times daily, ciprofloxacin 500 mg orally twice-daily, and amoxicillin	Patients with SAEs at day 150: 80% (<i>n</i> =8/10).	

Gut

3 out 4 out 5 (HE) 6 (HE) 7 doc 8 requivalence 9 Excl 10 Excl 11 on of 12 anti 13 non 14 rifax 15 anti 16 med 17 test 18 thos 19 and 20 con 21 22	usion criteria: >/:18 yrs patients with cirrhosis and urrent hepatic encephalopathy) defined as at last two cumented overt HE episodes uiring therapy. lusion criteria: MELD score >17, oral or intravenous imicrobial agents besides habsorbable ximin, allergies to pretreatment ibiotics, immunosuppressive dications, positive C. difficile t, pregnancy, active infection, se with active alcohol abuse, d unable to provide informed usent	Stool Norovirus EIA, Stool Rotavirus Antigen Detection, Adenovirus Antigen Detection, Gastroenteritis EIA, Vancomycin-resistant Enterococcus Culture, <i>Microsporidia</i> Exam.	500 mg orally three times daily). All antibiotics were discontinued at least 12 hours before FMT. This regime was not used in patients randomised to standard of care arm.	Total SAEs at day 150: 11. Patients with altered mental status day 150: 50% (<i>n</i> =5/10). Total HE eps day 150: 6 Stroop OffTime+OnTime change (day 0 and day 20): - 43.5 +/- 95.7. PHES score change (day 0 and day 20): 0.0 +/- 3.1. MELD score change (day 0 and day 35): 0.2 +/- 2.7. N.B. no significant difference in serum albumin, AST, ALT, WBC or haemoglobin counts between the two groups.
24 25 26	essment. Iow risk of blas		Rev:	haemoglobin counts
27 28 29 30			eh,	
31 32 33 34				うん

Tian <i>et al,</i> <i>PLoS ONE,</i> 2017	Intervention: Donor FMT (one for six days in a row).Number of patients: 30. Female: male 19: 11. Age (mean+/-SD): 53.1 +/- 10.2 years.Comparator: Standard of care (education, behavioural strategies, oral laxaives; expressively told to 	 One universal donor used throughout (24 year old healthy university student). Working in healthcare: No. Donor demographics: As above. Donor screening: Similar to FDA blood screening. Screening blood tests: Full blood count, chemistry and iron profile, hepatitis A, B and C, HIV-1 and-2, CMV, EBV, HSV, VZV, and <i>Treponema pallidum</i>. Screening stool tests: <i>Yersinia spp</i>, <i>Salmonella spp, Shigella spp</i>, <i>Campylobacter jejuni, C difficile</i> toxin, helminths, ova, parasites, and <i>Helicobacter pylori</i>. 	 Amount of stool per transplant / administered to patients: 100g of stool. Diluent used to prepare: Either 500mls normal saline, or normal saline amended with glycerol to final concentration of 10%. Diluent used to store if frozen: Glycerol. Preparation methods: Not stated. Time from preparation to transplant (fresh): 2 hours. Time period for storage (frozen): 1-4 weeks. Route administered and frequency: Upper GI: all via nasojejunal tube (originally placed endoscopically); lower GI: nil. Bowel purgative: Not described. PPI: Not described. Antimotility: Not described. Prokinetics: None. 	Donor FMT arm Meeting primary outcome: 37% (n=11/30) (p=0.04). Meeting second outcomes: At least one more CSBM per week: $53\% (n=16/30)$ (p=0.009). Number of CSBMs per week: $3.2+/-1.4$. Stool consistency score: 3.9+/-1.3. Colonic transit time (hours): 58.5+/-9.8. Wexner constipation score: 8.6+/-1.5. Quality of Life Assessment: Not described. Autologous FMT arm: Meeting primary outcome: 13% (n=4/30) Meeting second outcomes: At least one more CSBM per week: $20\% (n=6/30)$. Number of CSBMs per week: $2.1+/-1.2$. Stool consistency score: 2.4+/-1.1.	FMT arm: 50 in total (1 x sedation contraindications, x22 endoscopy-related respiratory difficulty, x12 nausea, x5 abdominal pain, x4 diarrhoea, x4 flatulence, x2 transient fever). Placebo arm: x4 in total (x0 sedation contraindications, x0 endoscopy-related respiratory difficulty, x0 nausea, x3 abdominal pain, x0 diarrhoea, x1 flatulence, x0 transient fever).
--	--	---	--	---	---

Gut

Page 282 of 454

1					
2 3	documented overt HE episodes			Colonic transit time (hours):	
4	requiring therapy.			73.6+/-8.7.	
5 6	Exclusion criteria: At least 18 years,			Wexner constipation score:	
7	BMI of 18-25 kg/m ² , and slow			12.7+/-2.5.	
8	transit constipation defined as colonic transit time of >48hr, and			Quality of Life Assessment:	
9 10	symptoms unresponsive to dietary			Not described.	
11	modification, enemas or				
12 13	biofeedback in the previous six months.				
13					
15	Cochrane Collaboration risk of bias assessment: low risk of bias.				
16 17	assessment: low risk of blas.				
18					
19 20					
20 21					
22		U	5		
23 24			R		
25					
26 27		ential. Fo	Vi		
28			Children (
29 30					
31					
32					
33 34					
35					
36 37					
38					
39					
40 41					
42		114			
43 44		https://mc.manuscripte	central.com/gut		
44					


Vrieze et al, Gastroenterology, 2012	Intervention: Donor FMT Number of patients: 9. Female: male 0: 9. Age (mean+/-SD): 47 +/- 4 years.Comparator: Autologous FMT. Number of patients: 9. Female: male 0: 9. Age (mean+/-SD): 53 +/- 3 years.Primary outcome: Effect of 	Lean healthy Caucasian males (body mass index < 23 kg/m ² . Working in healthcare: Not stated. Donor demographics: As above. Donor screening: Questionnaires regarding diet and bowel habits, travel history, comorbidity including (family history of) diabetes mellitus, and lack of medication use. Screening blood tests: Human immunodeficiency virus; human T-lymphotropic virus; hepatitis A, B, and C; cytomegalovirus; Epstein–Barr virus; <i>Strongyloides</i> ; and amoebiasis. Screening stool tests: Presence of parasites (eg, <i>Blastocystis hominis</i> or <i>Dientamoeba fragilis</i>), <i>Clostridium difficile</i> , or other pathogenic bacteria (<i>Shigella</i> , <i>Campylobacter</i> , <i>Yersinia</i> , <i>Salmonella</i>)	Amount of stool per transplant / administered to patients: Not stated. Diluent used to prepare: 500mls of normal saline. Diluent used to store if frozen: N/A. Preparation methods: Faeces was covered with sterile saline (500 ml 0.9% NaCl) to reduce exposure to oxygen, transferred to a blender, and mixed for 10 minutes. The homogenized solution then was filtered twice through a clean metal sieve. Time from preparation to transplant (fresh): Same day. Time period for storage (frozen): N/A. Route administered and frequency: Upper GI: all via nasoduodenal tube (originally placed endoscopically); lower GI: nil. Bowel purgative: PEG solution. PPI: Not described. Antimotility: Not described. Prokinetics: None.	Donor FMT arm: Median rate of glucose disappearance, Rd: from 26.2 to 45.3 μ mol/kg/min; p<0.05). Autologous FMT arm: Median rate of glucose disappearance, Rd: from 18.9 to 19.5 μ mol/kg/min). Quality of Life Assessment: Not described. Secondary outcomes: No change in the total numbers of fecal bacteria (allogenic, from 10.8 +/- 0.2 to 11.0 +/- 0.4 vs autologous, from 11.6 +/- 0.6 to 11.3 +/- 0.4 log ₁₀ bacteria/g faeces, non significant [NS]). Fecal short-chain fatty acids decreased after allogenic gut microbiota infusion (median acetate from 49.5 to 37.6; p <0.05; butyrate, from 14.1 to 8.9; p < 0.05; and propionate, from 18.2 to 16.3 mmol/kg feces; NS).	No adverse events
--	--	---	---	--	-------------------

Gut

Page 284 of 454

Kootte et al, <i>Cell</i> <i>Metabolism</i> , 2017	Intervention: Donor FMT Number of patients: 26. Female: male 0: 26. Age (mean): 54 years. Comparator: Autologous FMT. Number of patients: 12. Female: male 0: 12. Age (mean): 54 years. Primary outcome: Change in intestinal microbiota composition upon FMT in relation to insulin sensitivity. Secondary outcomes: Post-prandial lipid, glucose excursions and plasma metabolites Inclusion criteria: All adult (age 21- 69 years) Caucasian males, who had obesity (body mass index (BMI) > 30 kg/m ²), fulfilled the National Cholesterol Education Program (NCEP)-criteria for metabolic syndrome, were treatment-naive and who where otherwise healthy. Exclusion criteria: History of recent weight loss, cardiovascular event, cholecystectomy and the use of any medication known to influence gut microbial composition in the last three months (including proton pump inhibitors, antibiotics and pre-/pro-/synbiotics) or treatments targeting metabolic diseases.	Lean healthy Caucasian males (body mass index < 25 kg/m ² . Working in healthcare: Not stated. Donor demographics: As above. Donor screening: Questionnaires regarding diet and bowel habits, travel history, comorbidity including (family history of) diabetes mellitus, and lack of medication use. Screening blood tests: Human immunodeficiency virus; human T-lymphotropic virus; hepatitis A, B, and C; cytomegalovirus; Epstein–Barr virus; <i>Strongyloides</i> ; lues and amoebiasis Screening stool tests: Pathogenic parasites (e.g., <i>Blastocystis hominis,</i> <i>dientamoeba fragilis, giardia</i> <i>lamblia</i>), bacteria (<i>Shigella,</i> <i>Campylobacter, Yersinia,</i> <i>Salmonella,</i> enteropathogenic <i>E. coli</i> and <i>Clostridium difficile</i>) or viruses (noro-, rota-, astro-, adeno (40/41/52)-, entero-, parecho- and sapovirus).	Amount of stool per transplant / administered to patients: Not stated. Diluent used to prepare: 500mls ofnormal saline. Diluent used to store if frozen: N/A. Preparation methods: Faeces was covered with sterile saline (500 ml 0.9% NaCl) to reduce exposure to oxygen, transferred to a blender, and mixed for 10 minutes. The homogenized solution then was filtered twice through a clean metal sieve. Time from preparation to transplant (fresh): Same day. Time period for storage (frozen): N/A. Route administered and frequency: Upper GI: Single infusion all via nasoduodenal tube (originally placed endoscopically). A subgroup of patients receiving donor FMT had a second infusion; lower GI: nil. Bowel purgative: PEG solution. PPI: Not described. Antimotility: Not described. Prokinetics: None.	Donor FMT arm: improved peripheral insulin sensitivity at week 6 (from 25.8 to 28.8 μ mol/kg/min, , p < 0.05. This change was no longer significant at week 18 (including those that had a second infusion). Autologous FMT arm: FMT had no effect at week 6 (from 22.5 to 20.8 μ mol/kg/min, NS) Quality of Life Assessment: Not described. Secondary outcomes: No significant changes in fecal butyrate levels (butyrate from 13 to 20 mmol/g faeces, $p = 0.096$). Fecal acetate levels, however, were significantly increased from 62 to 85] mmol/g feces ($p < 0.05$) after allogenic FMT, whereas fecal proprionate was borderline signifi- cantly altered (from 23 to 28 mmol/g faeces, $p = 0.062$).	No adverse events
--	--	---	--	---	-------------------

Page 285 of 454



Appendix D. Excluded clinical studies

D.1. *Clostridium difficile* infection:

1 2

3

4 5

6 7

D.1.1. Studies excluded at Sift 2 by working group:

8	-	
9	Paper:	Grounds for exclusion:
10 11 12 13 14 15	Allegretti JR, Allegretti AS, Phelps E, et al. Asymptomatic <i>Clostridium difficile</i> carriage rate post- fecal microbiota transplant is low: a prospective clinical and stool assessment. <i>Clin Microbiol Infect</i> 2017; doi: 10.1016/j.cmi.2017.10.022	Prospective case series of FMT for CDI, but insufficient patient data to fully populate data table (study primarily designed to evaluate <i>C.</i> <i>difficile</i> carriage post-FMT).
16 17 18 19 20 21 22	Aroniadis OC, Brandt LJ, Greenberg A, <i>et al.</i> Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated <i>Clostridium difficile</i> infection: a multicenter experience. <i>J Clin</i> <i>Gastroenterol</i> 2016;50(5):398-402.	Case series of FMT for CDI, but insufficient patient data to fully populate data table.
23 24 25 26 27	Cammarota G, Ianiro G, Masucci L, <i>et al.</i> OC.12.9 Fecal microbiota transplantation for recurrent <i>C. difficile</i> infection: a 2-year experience from a European referral centre. <i>Dig Liver Dis</i> 2016;48 S2:e118.	Case series of FMT for CDI, but abstract only.
28 29 30 31 32 33 34	Dutta SK, Girortra M, Garg S, <i>et al.</i> Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent <i>Clostridium difficile</i> infection. <i>Clin Gastroenterol Hepatol</i> 2014;12(9):1572-1576.	Prospective case series of FMT for CDI, but heterogenous primary endpoint (combination of clinical symptoms and <i>C difficile</i> toxin, but assessed between 1-3 months after FMT).
35 36 37 38 39	Ganc AJ, Ganc RL, Reimao SM, <i>et al.</i> Fecal microbiota transplant by push enteroscopy to treat diarrhea caused by <i>Clostridium difficile. Einstein</i> 2015;13(2):338-339.	Case series of FMT for CDI, but insufficient patient data to fully populate data table.
40 41 42 43 44	Ganc A, Ganc R, Frisoli Jr A, <i>et al.</i> Fecal transplantation – an original per-oral endoscopic technique with a pediatric colonoscope. <i>J Gastroenterol Hepatol</i> 2013;28 S3:115	Case series of FMT for CDI, but abstract only.
45 46 47 48 49	Jorup-Ronstrom C, Hakanson A, Sandell S, <i>et al.</i> Fecal transplant against relapsing <i>Clostridium difficile</i> -associated diarrhea in 32 patients. <i>Scand J Gastroenterol</i> 2012;47(5):548-552.	Case series of 'FMT' for CDI, but bacteriotherapy rather than true FMT.
50 51 52 53 54 55 56 57	Kao D, Roach B, Beck P, <i>et al.</i> A dual center, randomized trial comparing colonoscopy and oral capsule delivered fecal microbiota transplantation in the treatment of recurrent <i>Clostridium difficile</i> infection: preliminary results. <i>Am J Gastroenterol</i> 2015;110:S553.	Abstract of RCT of capsulised vs colonoscopic FMT for CDI, but same trial/ data set reported in more developed stage at later date ⁴⁸ , so this abstract excluded.
57 58 59 60	Mah XJ, Paramsothy R, Lo-Cao E, et al. Faecal microbiota transplant (FMT) for recurrent and life	Case series of FMT for CDI, but abstract only.

1

2 threatening Clostridium difficile infection. J 3 Gastroenterol Hepatol 2016;31:167-168. 4 5 Mandali A, Ward A, Tauxe W, et al. Fecal transplant is Case series of FMT for CDI, but 6 as effective and safe in immunocompromised as noninsufficient patient data to fully 7 immunocompromised patients for populate data table. Clostridium 8 *difficile. Int J Colorectal Dis* 2016;31(5):1059-1060. 9 10 Oprita R, Bratu M, Oprita B, et al. Fecal transplantation Prospective case series of FMT for 11 the new, inexpensive, safe, and rapidly effective CDI or UC, but insufficient patient 12 approach in the treatment of gastrointestinal tract data to fully populate data table. 13 disease. J Med Life 2016;9(2):160-162. 14 15 Ott SJ, Waetzig GH, Rehman A, et al. Efficacy of sterile Case series of 'FMT' for CDI, but 16 fecal filtrate transfer for treating patients with only five patients. Furthermore, 17 Clostridium difficile infection. sterile faecal filtrate rather than Gastroenterology 18 19 2017;152(4):799-811. true FMT. 20 Orenstein R, Dubberke E, Hardi R, et al. Safety and Prospective case series of FMT for 21 durability of RBX2660 (microbiota suspension) for CDI, but using 'microbiota 22 recurrent *Clostridium difficile* infection: results of the suspension' derived from stool 23 PUNCH CD study. Clin Infect Dis 2016;62(5):596-602. rather than conventional FMT. 24 25 Ray A, Jones C, Shannon B, et al. Does the donor Abstract of RCT of treatment for 26 matter? Results from PUNCH CD 2: a randomized CDI, but 'microbiota suspension' 27 controlled trial of a microbiota-based drug for rather than true FMT. 28 recurrent Clostridium difficile infection. Am J Gastro 29 30 2016;111:S65-S66. 31 Ray A, Smith R, Breaux J. Fecal microbiota Case series of FMT for CDI, but 32 transplantation for Clostridium difficile infection: the heterogenous primary end point. 33 Ochsner experience. Ochsner Journal 2014;14(4):538-34 35 544. 36 Rupali P, Mittal C, Deol A, et al. Fecal microbiota Case series of FMT for CDI, but 37 transplantation for *Clostridium difficile* infection in abstract only. 38 immunocompromised hosts: one easy strategy, one 39 40 giant success. Transplantation 2014;98:687-688. 41 Russell GH, Kaplan JL, Youngster I, et al. Case series of FMT for CDI, but all Fecal 42 transplant for recurrent Clostridium difficile infection children, and presented as 43 in children with and without inflammatory bowel separate cases rather than as 44 45 disease. J Pediatric Gastroenterol Nut 2014;58(5):588group of 10 recipients. 46 592. 47 Tauxe WM, Haydek JP, Rebolledo PA, et al. Fecal Case series of FMT for CDI, but 48 microbiota transplant for Clostridium difficile infection 49 heterogenous primary end point. 50 in older adults. Ther Adv Gastroenterol 2016;9(3):273-51 281. 52 True E, Tsoraides S, Wang H, et al. Predictors of failure Case series of FMT for CDI, but 53 microbiota therapy with fecal 54 for recurrent abstract only. 55 *Clostridium difficile* colitis. Dis Colon Rectum 56 2014;57(5):e99-e100. 57 Tvede M, Tinggaard M, Helms M. Case series of 'FMT' for CDI, but Rectal 58 59 bacteriotherapy for recurrent Clostridium difficilebacteriotherapy rather than true 60 associated diarrhoea: results from a case series of 55 FMT.

Gut

D.1.2. Abstracts not fulfilling selection criteria:

1 2

3

9 10 11

12

13

14

Borody TJ, Wettstein A, Nowak A, Finlayson S, Leis S. Fecal microbiota transplantation (FMT) eradicates clostridium difficile infection (CDI) in inflammatory bowel disease (IBD). United Eur Gastroenterol J. 2013;1)(PG-A57):A57.

Gut

D.N. S, Seril DN, Shen B. Clostridium difficile infection in patients with ileal pouches. Am J Gastroenterol. B.
 Shen, Department of Gastroenterology/Hepatology-A31, Digestive Disease Institute, Cleveland Clinic
 Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, United States. E-mail: shenb@ccf.org: Nature
 Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom); 2014;109(7):941–7.

Ganc AJ, Ganc RL. Fecal microbiota transplantation, by means of push enteroscopy. A novel endoscopic
 technique, for the treatment of chronic diarrhea associated with clostridium difficile-a pilot study.
 Gastrointest Endosc. 2014;1)(PG-AB380-AB381):AB380-AB381.

Garg S, Fricke WF, Girotra M, Dutta A, Von Rosenvinge EC, Dutta S. Recurrent clostridium difficile infection:
 A longitudinal study of alterations in fecal microbiome in patients-donor pairs before and after fecal
 microbiota therapy. Gastroenterology. 2013;1)(PG-S184-S185):S184–5.

Garg S, Fricke WF, Girotra M, Von Rosenvinge EC, Dutta A, Dutta SK. Emerging role of fecal microbiota therapy in the treatment of recurrent clostridium difficile infection in children. Gastroenterology. 2013;1)(PG-S45):S45.

Garg S, Song Y, Han MAT, Girotra M, Fricke WF, Dutta S. Post-infectious irritable bowel syndrome in patients
 undergoing fecal microbiota transplantation for recurrent clostridium difficile colitis. Gastroenterology.
 2014;1)(PG-S83-S84):S83–4.

Girotra M, Bartlett J, Koerner K, Dutta S. Combined jejunal and colonic fecal bacteriotherapy in patients with recurrent clostridium difficile infection (RCDI). Am J Gastroenterol. 2011;106(PG-S162-S163):S162–3.

Girotra M, Dutta A, Koerner K, Bodner B, Dutta SK. Recurrent clostridium difficile infection (RCDI) in geriatric
 patients: A long-term follow up of simultaneous jejunal and colonic administration of fecal bacteriotherapy
 (FT). Gastroenterology. 2012;1)(PG-S130):S130.

Goyal A, Chu A, Calabro K, Firek B, Bush B, Morowitz M. Safety and efficacy of fecal microbiota transplant in
 children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016;63(PG-S212):S212.

Goyal A, Kufen A, Jackson Z, Morowitz M. A study of fecal microbiota transplantation in pediatric patients
 with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:S74.

Graham D, Attumi T, Opekun A, Metcalf G, Muzny D, Hyde E, et al. Triple bacteroides fecal replacement
 therapy for relapsing clostridium difficile diarrhea (fecal transplantation sans feces). Am J Gastroenterol.
 2013;108(PG-S170):S170.

Page 289 of 454

Gut

- Greenberg A, Aroniadis O, Shelton C, Brandt L. Long-term follow-up study of fecal microbiota transplantation (FMT) for inflammatory bowel disease (IBD). Am J Gastroenterol. 2013;108(PG-S540):S540. Greenwald D, Patel T, Barto A. Fecal microbiota transplant for treatment of refractory C. Difficile colitis: Long-term follow-up of 58 patients. Am J Gastroenterol. 2014;109(PG-S679):S679. Greig J, Swope LK, Calvin H. Shaking up clostidium difficile infections: Implementation of a fecal microbiota transplant program. Am J Infect Control. 2014;1)(PG-S4-S5):S4-5. Grzesiowski P, Hermann A, Dubaniewicz A, Kasprzyk J, Pawlik D, Zak-Pulawska Z. Effectiveness of FMT in recurrent Clostridium difficile infection. Antimicrob Resist Infect Control Conf 3rd Int Conf Prev Infect Control ICPIC. 2015;4(no pagination PG-). Gupta S, He SM, Noordhof C, Allen-Vercoe E, Petrof EO. Minimalist defined gut microbial ecosystem demonstrates protection against clostridium difficile toxin-mediated effects in vitro via toxin degradation. Gastroenterology. 2016;1)(PG-S544):S544. Haran M, Tsang T, Kupfer Y, Tessler S. Intravenous immunoglobulins in severe clostridium difficile colitis. Chest Conf CHEST. 2011;140(4 MEETING ABSTRACT PG-). Gastroenterol. 2016;9(2 PG-229-239):229–39. Harrison MJ, Burke D, Fleming C, McCarthy M, Shortt C, O'Callaghan G, et al. Clostridium difficile in adult cystic fibrosis (CF): Prevalence, ribotyping and toxigenic capability. A prospective study. J Cyst Fibrosis Conf 36th Eur Cyst Fibros Conf Lisbon Port Conf Start. 12(pp S6 PG-). Holvoet T, Boelens J, Joossens M, Raes J, De Vos M, De Looze D. Fecal microbiota transplantation in irritable bowel syndrome with bloating: Results from a prospective pilot study. Gastroenterology. 2015;1)(PG-S963-S964):S963-4. Holzwanger EA, Kaufman D, Foley A, Pellish R. Fecal microbiota transplantation via colonoscope: A single-center experience. Am J Gastroenterol. 2016;111(PG-S1232):S1232. Hourigan S, Ann Chen L, Grigoryan Z, Laroche G, Weidner M, Sears CL, et al. Microbiome changes associated with sustained eradication of clostridium difficile after fecal microbiota transplantation in children with and without inflammatory bowel disease. Gastroenterology. 2015;1)(PG-S45):S45. Hubble L, Joshua S, Glover PH, Trivedi A, Pfanner TP. Colonoscopic vs. Upper endoscopic placement of fecal microbiota transplant for recurrent clostridium difficile infection: A retrospective review. Gastroenterology. 2015;1)(PG-S728):S728. Ihara S, Hirata Y, Serizawa T, Suzuki N, Kinoshita H, Nakagawa H, et al. Transforming growth factor-beta signaling on dendritic cells regulates bacterial communities and gut homeostasis. Gastroenterology. 2014;1)(PG-S-113):S-113. Ihunnah C, Khoruts A, Fischer M, Afzali A, Aroniadis O, Barto A, et al. Fecal microbiota transplantation (FMT) for treatment of clostridium difficile infection (CDI) in immunocompromised patients ACG governors award for excellence in clinical research. Am J Gastroenterol. 2013;108(PG-S179-S180):S179-80.
- ⁵⁹ Ishikawa D, Osada T, Haga K, Kodani T, Shibuya T, Watanabe S. Combination therapy of fresh faecal microbial
 ⁶⁰ transplantation and antibiotics for ulcerative colitis. J Crohn's Colitis. 2016;10(PG-S335-S336):S335–6.

Jain A, Parian AM, Dudley-Brown S, Lazarev M. Fecal microbiota transplantation is safe and effective for treatment of recurrent clostridium difficile infection in inflammatory bowel disease patients. Gastroenterology. 2015;1)(PG-S869):S869. Jamot S, Kelly CR, Shah S. Won the battle, lost the war: Crohn's flare after fecal microbiota transplant (FMT) for recurrent C. Difficile infection. Am J Gastroenterol. 2016;111(PG-S833-S834):S833-4. Kassam Z, Hundal R, Marshall JK, Lee CH. Fecal transplantation via retention enema is effective for recurrent or refractory clostridium difficile-associated diarrhea. Gastroenterology. 2010;1)(PG-S207-S208):S207-8. Kellermayer R, Hollister EB, Nagy-Szakal D, Ihekweazu FD, Haynes A, Pitashny M, et al. Special considerations for fecal microbiota transplantation in pediatric recurrent clostridium difficile infection. Gastroenterology. 2015;1)(PG-S961-S962):S961-2. Khanna S, Kashyap P, Rainey J, Loftus E, Pardi D. Outcomes from fecal microbiota transplantation in adults with C. difficile infection and inflammatory bowel disease. Am J Gastroenterol. 2013;108(PG-S508):S508. Khanna S, Weatherly R, Kammer P, Pardi D. Management and outcomes of patients with failed fecal microbiota transplantation for recurrent clostridium difficile infection. Am J Gastroenterol. 2015;110(PG-S580):S580. Khanna S, Weatherly RM, Kammer PP, Loftus E V, Pardi DS. Long-term follow-up after fecal microbiota transplantation for C. Difficile infection in inflammatory bowel disease patients. Gastroenterology. 2015;1)(PG-S726):S726. Khoruts A, Hamilton MJ, Weingarden A, Sadowsky MJ. Treatment of C. difficile by fecal transplantation. Gastrointest Endosc. 2012;1)(PG-AB329):AB329. Khoruts A, Rank KM, Viskocil K, Newman KM. Diagnostic value of colonoscopy in patients receiving fecal microbiota transplantation in treatment of refractory clostridium difficile infection. Gastroenterology. 2015;1)(PG-S729):S729. Kukkadapu T, Chintalapally R, Daram S. Clostridium difficile infection in adult patients with acute myeloid leukemia: Incidence, recurrence, and outcomes. Am J Gastroenterol. 2015;110(PG-S590):S590. Kump PK, Grochenig HP, Spindelbock W, Hoffmann CM, Gorkiewicz G, Wenzl H, et al. Preliminary clinical results of repeatedly fecal microbiota transplantation (FMT) in chronic active ulcerative colitis. United Eur Gastroenterol J. 2013;1)(PG-A57):A57. Kump PK, Wurm P, Grochenig HP, Reiter L, Hoffmann KM, Spindelboeck W, et al. Impact of antibiotic treatment before faecal microbiota transplantation (FMT) in chronic active ulcerative colitis. United Eur Gastroenterol J. 2015;1)(PG-A437):A437. LaBarbera F, Jackson W, Surace L. FMT in our ASC: Successful fecal microbiota transplantation for recurrent clostridium difficile infections in an ambulatory surgical center. Am J Gastroenterol. 2015;110(PG-S559-S560):S559-60.

Gut

⁵⁹ Lan N, Stocchi L, Remzi FH, Shen B. Fecal microbiota transplantation for recurrent clostridium difficile ⁶⁰ infection in patients with ileal pouches. Gastroenterology. 2016;1)(PG-S542):S542. Page 291 of 454

Gut

Landy J, Al-Hassi HO, Mann ER, Peake ST, McLaughlin SD, Ciclitira PJ, et al. A prospective controlled pilot study of fecal microbiota transplantation for chronic refractory pouchitis. Gastroenterology. 2013;1)(PG-S897):S897. Landy J, Omar H, Ronde E, Mann E, Peake S, McLaughlin S, et al. A prospective controlled pilot study of faecal microbiota transplantation for chronic refractory pouchitis. J Crohn's Colitis. 2013;7:S247–8. Licht E, Maltz C. The potential role of lactulose in the prevention of clostridium difficile diarrhea. Am J Gastroenterol. 2012;107(PG-S203-S204):S203-4. Lin E, Jaworski A, Furnari V, Wong C, Bull M, Chapman B, et al. Twelve week storage trial of microbial viability in lyophilized and frozen fecal microbiota preparations. Gastroenterology. 2015;1)(PG-S962):S962. Long Miao C, Mowery A, Khara H, Shellenberger M, Komar M. C. difficile enteritis after total proctocolectomy successfully treated with fecal transplant. Am J Gastroenterol. 2014;109(PG-S442):S442. Mandalia A, Ward A, Kraft CS, Dhere TA. Outcomes for route and immunocompromised status do not significantly differ in fecal microbiota transplant for recurrent clostridium difficile. Gastroenterology. 2014;1)(PG-S252-S253):S252-3. Martin D, Munoz R, Yoder K, Allegretti JR, Smith M, Kassam Z. Assessing the landscape of fecal microbiota transplantation programs for recurrent clostridium difficile infection: A survey of existing practices among healthcare centers using an international public stool bank. Gastroenterology. 2016;1)(PG-S238):S238. Mehta SR, Kelly CR, Kao D, Dimitry J, Martin T, Allegretti JR, et al. Inpatient status, severe clostridium difficile infection and immunocompromised state predict failure despite multiple fecal microbiota transplants: A multicenter study. Gastroenterology. 2016;1)(PG-S745-S746):S745-6. Meighani A, Ramesh M, Salgia R. Successful outcomes of fecal microbiota transplantation in patients with chronic liver disease. Hepatology. 2016;63 (1 Supplement 1)(PG-1016A-1017A):1016A-1017A. Mellow M, Kanatzar A, Brandt L, Aroniadis O, Kelly C, Park T, et al. Longterm follow-up of colonoscopic Fecal Microbiota Transplant (FMT) for recurrent C. difficile infection (RCDI). Am J Gastroenterol. 2011;106(PG-S149-S150):S149-50. Mellow M, Kanatzar A. Colonoscopic fecal bacteriotherapy in the treatment of recurrent clostridium difficile infection-results and follow-up. Am J Gastroenterol. 2010;105(PG-S135):S135. Mellow M, Kohli V, Jalil S, Jabbour N. Persistent clostridium difficile infection in a patient with decompensated liver disease: "double transplant" saves a life! Am J Gastroenterol. 2012;107(PG-S461):S461. Mendelson AH, Rifkin S, Shay J, Razvi MA, Lee LA. Gastroenterology. 2017;152(5 Supplement 1):S949-S950. Mikamo H. Treatment for Clostridium difficile infections. Int J Antimicrob Agents. 2013;42(PG-S16):S16. Miller CB, Dellon E, Isaacs K, Gangarosa L. Fecal bacteriotherapy via colonoscopy as rescue therapy for refractory and recurrent clostridium difficile - Associated diarrhea. Am J Gastroenterol. 2010;105(PG-S323):S323.

Mintz M, Monzur F, Chowdhury T, Rowehl L, Grewal S, Li E, et al. Comparing fecal microbial transplant outcomes in patients with recurrent clostridium difficile or ulcerative colitis. Inflamm Bowel Dis. 2016;22(PG-S31):S31.

Misra B, Ramesh M, Sobcinski MK. Evaluation of health-related quality of life in patients treated with RBX2660 (Microbiota Suspension) for Recurrent C. Difficile Infection. Am J Gastroenterol. 2014;109(PG-S188):S188.

Mitchell SW, Jaworski A, Bull M, Wong C, Furnari V, Chapman B, et al. Lyophilized fecal microbiota transplantation and cryoprotectants for viable bacteria preservation. Gastroenterology. 2016;1)(PG-S542-S543):S542–3.

Mittal C, John A, Hart BR, Miller N, Meighani A, Ramesh M. Fecal microbiota transplantation for recurrent
 and/or refractory clostridium difficile infection: A large retrospective study of failure rates, predictors of
 failure and outcomes. Gastroenterology. 2015;1)(PG-S723-S724):S723-4.

Monzur F, Mintz M, Tian X, Grewal S, Khair S, Rowehl L, et al. Microbiome analysis and fecal microbiota transplant outcomes in clostridium difficile and ulcerative colitis patients. Am J Gastroenterol. 2016;111(PG-S321):S321.

Newton D, Hewlett A. Fecal biotherapy as treatment for recurrent clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2013;108(PG-S178):S178.

Niccum BA, Stein DJ, Wang P, Cohn SM, Hays RA. Zinc deficiency: A possible contributor to long-term FMT
 failure in recurrent clostridium difficile infection. Am J Gastroenterol. 2016;111(PG-S92):S92.

Norin E. Experience with cultivated microbiota transplant: ongoing treatment of Clostridium difficile patients
 in Sweden. Microb Ecol Heal Dis. 2015;26(PG-27638):27638.

O'Brien K, Osman M, Eysenbach L, Stoltzner Z, Day R, Norgaard KS, et al. Clinical efficacy of fecal microbiota
 transplantation for recurrent clostridium difficile infection from an international public stool bank: Results
 from a 1,406 patient multi-center cohort. Gastroenterology. 2016;1)(PG-S539-S540):S539-40.

O'Brien K, Petimar J, Ling K, Omas Gurry T, Ladha A, Day R, et al. Nutritional composition of stool donors'
 diets relative to that of the U.S. population: Results from 44 donors from an international stool bank for fecal
 microbiota transplantation. Am J Gastroenterol. 2016;111(PG-S447-S448):S447–8.

Olefson SH, Jackson M, Kelly C. Clostridium difficile: The spectrum of diagnoses in patients referred for fecal
 microbiota transplant. Gastroenterology. 2015;1)(PG-S727):S727.

Oprita R, Kostov A, Musat F. Clostridium difficile-associated diarrhea, a new challenge. Eur J Intern Med.
 2013;24(PG-e73):e73.

Ordway S, Harris N, Wong R. Skinning the cat twice: Refractory CDI in an solid organ transplant patient requiring 2 fecal microbiota transplants. Am J Gastroenterol. 2015;110(PG-S171):S171.

Osman M, Dubois N, Gangireddy V, Amaratunga K, Allegretti JR, Kassam Z. The great mimic: Food-borne
 illness masquerading as an infectious adverse event following fecal microbiota transplantation. Am J
 Gastroenterol. 2016;111(PG-S592):S592.

Page 293 of 454

Gut

Osman M, Khoiri A, Stoltzner Z, Koelsch E, O'Brien K, Ling K, et al. Clinical effectiveness and safety of fecal microbiota transplantation in children for clostridium difficile infection: Results from 9 pediatric centers in the United States 2016 ACG presidential poster award. Am J Gastroenterol. 2016;111(PG-S452):S452. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology. 2016;17(PG-17):17. Paramsothy S, Borody T, Lin E, Finlayson S, Walsh A, Samuel D, et al. Obstacles to donor recruitment for faecal microbiota transplantation: Experiences from the focus study. Am J Gastroenterol. 2014;109(PG-S188):S188. Paramsothy S, Borody T, Lin E, Finlayson S, Walsh A, Samuel D, et al. Obstacles to donor recruitment for faecal microbiota transplantation-Experiences from the FOCUS study. J Gastroenterol Hepatol. 2014;29(PG-135):135. Parekh R, Ramesh MS, Tang J. Lymphocytic colitis in patients with recurrent clostridium difficile colitis: Case series. Am J Gastroenterol. 2016;111(PG-S1308):S1308. Park L, Tzimas D, Price J, Mone A, Hirsh J, Poles M, et al. Perceptions of fecal microbiota transplantation: Factors that predict acceptance: A preliminary analysis. Am J Gastroenterol. 2014;109(PG-S206):S206. Patel LN, Schairer J, Shen B. Fecal transplantation therapy for Clostridium difficile-associated pouchitis. Int J Colorectal Dis. 2014;29(2 PG-263-264):263-4. Patel LN, Schairer J, Shen B. Fecal transplantation therapy for Clostridium difficile-associated pouchitis. Int J Colorectal Dis. 2014;29(2 PG-263-264):263-4. Patel P, Goyal A. Comparative analysis of the efficacy of fecal transplantation in pediatric inflammatory bowel disease patients with and without clostridium difficile infection. Inflamm Bowel Dis. 2016;22(PG-S68-S69):S68-9. Patel P, Goyal A. Comparative analysis of the efficacy of fecal transplantation in pediatric inflammatory bowel disease patients with and without clostridium difficile infection. Inflamm Bowel Dis. 2016;22(PG-S68-S69):S68-9. Patel S, Kelly C, Colombel JF, Atreja A. Comparative cost analysis of fecal microbiota transplant and antibiotic treatment for recurrent clostridium difficile infection. Am J Gastroenterol. 2013;108(PG-S169-S170):S169-70. Patel S, Kelly C, Colombel JF, Atreja A. Comparative cost analysis of fecal microbiota transplant and antibiotic treatment for recurrent clostridium difficile infection. Am J Gastroenterol. 2013;108(PG-S169-S170):S169-70. Patel SS, Grinspan A, Colombel JF, Atreja A. Cost effectiveness analysis of fecal microbiota transplant and antibiotic treatment for recurrent clostridium difficile infection. Gastroenterology. 2014;1)(PG-S190-S191):S190-1.

Patel SS, Grinspan A, Colombel JF, Atreja A. Cost effectiveness analysis of fecal microbiota transplant and antibiotic treatment for recurrent clostridium difficile infection. Gastroenterology. 2014;1)(PG-S190-S191):S190-1. Pinn D, Aroniadis O, Brandt L. Follow-up study of fecal microbiota transplantation (FMT) for the treatment of refractory irritable bowel syndrome (IBS). Am J Gastroenterol. 2013;108(PG-S563):S563. Potakamuri L, Turnbough L, Maheshwari A, Kantsevoy S, Ofosu A, Thuluvath P, et al. Effectiveness of fecal microbiota transplantation for the treatment of recurrent clostridium difficile infection: Community hospital experience. Am J Gastroenterol. 2013;108(PG-S175):S175. Pyo-Twist A, Brumbaugh D, Fidanza SJ, Montero C, Dolan S, Hughes S, et al. Preliminary outcomes of a registered nurse driven fecal microbiota transplantation (FMT) procedure to treat clostridium difficile (c.diff) infection in pediatrics. J Pediatr Gastroenterol Nutr. 2016;63(PG-S154):S154. Quraishi MN, McCune V, Iqbal TH, Pathmakanthan S, Struthers JK, Moran E, et al. Faecal microbiota transplantation via nasogastric route for the treatment of recurrent and antibiotic refractory Clostridum Difficile infection: The UK experience. J Crohn's Colitis. 2015;9(PG-S323-S324):S323-4. Quraishi MN, McCune VL, Igbal T, Pathmakanthan S, Struthers JK, Moran E, et al. Faecal microbiota transplantation via nasogastric route for the treatment of recurrent and antibiotic refractory clostridum difficile infection: The UK experience. Gastroenterology. 2015;1)(PG-S641-S642):S641–2. Quraishi MN, Segal J, Mullish B, McCune V, Hawkey P, Colville A, et al. National survey of practice of faecal microbiota transplantation for clostridium difficile infection in the United Kingdom. Gut. 2016;65(PG-A23-A24):A23-4. Quraishi N, McMillan M, Widlak M, Nell L, Quraishi K, Pathmakanthan S, et al. Patient perception towards faecal microbiota transplantation for treatment of inflammatory bowel disease. United Eur Gastroenterol J. 2014;1)(PG-A383):A383. Quraishi N, McMillan M, Widlak M, Nell L, Quraishi K, Pathmakanthan S, et al. Patient perception towards faecal microbiota transplantation for treatment of Inflammatory Bowel Disease. J Crohn's Colitis. 2015;9(PG-S252):S252. Ramesh M, Misra B, Ray A, Smith R, Sobcinski MK. RBX2660 (Microbiota Suspension) for Recurrent C. Difficile infection: 60-day interim analysis of the PUNCH CD phase 2 safety study. Am J Gastroenterol. 2014;109(PG-S188):S188. Ray A, Hardi R, Ramesh M, Sobcinski MK. Enema administration of RBX2660 (microbiota suspension) for Recurrent C. difficile infection: Lessons learned from the PUNCH CD Study. Am J Gastroenterol. 2014;109(PG-S192-S193):S192-3. Razik R, Osman M, Lieberman A, Dubois N, Allegretti JR, Smith M, et al. Characterizing patients who fail fecal microbiota transplantation for clostridium difficile infection: Results from a 135-patient, multi-center, non-responder cohort. Am J Gastroenterol. 2016;111(PG-S66):S66.

Page 295 of 454

1 2

3

4 5

6 7

8

9

Rezk AN, Stewart D, West S, Miao C, Khara HS, Komar M. Outcomes, safety and predictors of failure of fecal microbiota transplantation for refractory clostridium difficile infection. Am J Gastroenterol. 2016;111(PG-S82-S83):S82–3.

Roediger R, Grinspan A. Safety and efficacy of fecal microbiota transplantation for clostridium difficile in a cohort of patients with a severe infection and/or IBD. Am J Gastroenterol. 2016;111(PG-S446):S446.

Sadowsky MJ, Weingarden A, Khoruts A, Gonzalez A, Vazquez-Baeza Y, Weiss S, et al. Short and long term
 changes in bacterial composition following fecal microbiota transplantation for CDI visualized in movie
 format. Gastroenterology. 2014;1)(PG-S-838):S-838.

Sbahi H, Di Palma JA. Faecal microbiota transplantation: applications and limitations in treating
 gastrointestinal disorders. BMJ Open Gastroenterol. 2016;3(1 PG-e000087):e000087.

Scaldaferri F, Pecere S, Bruno G, Ianiro G, Laterza L, Gerardi V, et al. An Open-label, pilot study to assess
 feasibility and safety of fecal microbiota transplantation in patients with mild-moderate ulcerative colitis:
 Preliminary results. J Crohn's Colitis. 2015;9(PG-S278):S278.

Scaldaferri F, Pecere S, Bruno G, Ianiro G, Laterza L, Gerardi V, et al. An open-label, pilot study to assess
 feasibility and safety of fecal microbiota transplantation in patients with mild-moderate ulcerative colitis:
 Preliminary results. Gastroenterology. 2015;1)(PG-S870):S870.

- Scaldaferri F, Pecere S, Lopetuso LR, Ianiro G, Laterza L, Schiavoni E, et al. An open-label, pilot study to assess
 feasibility and safety of fecal microbiota transplantation in patients with mild-moderate ulcerative colitis:
 Preliminary results. United Eur Gastroenterol J. 2015;1)(PG-A257):A257.
- Shah R, Robinson L, Herrera HR, Swaroop PP. Human probiotic infusion (HPI) in ulcerative colitis-'patient's
 perceptions and predictors of efficacy'. Gastroenterology. 2012;1)(PG-S253):S253.

Shogbesan O, Poudel D, Jehangir A, Fadahunsi O, Shogbesan G, Donato A. Fecal microbiota transplantation
 for clostridium difficile infections in immunocompromised patients: A systematic review. Am J Gastroenterol.
 2016;111(PG-S79):S79.

⁴²Singh T, Yu S, Gangireddy V, Rao S. Diarrhea after fecal microbiota transplantation and usefulness of commercial stool donor for C. difficile infection. Am J Gastroenterol. 2015;110(PG-S589-S590):S589–90.

Staley C, Kelly CR, Brandt LJ, Khoruts A, Sadowsky MJ. Characterization of fecal microbiota in response to
 heterologous versus autologous (placebo) fecal microbial transplantation: Results from a dual-center,
 randomized, placebo-controlled trial. Gastroenterology. 2016;1)(PG-S542):S542.

Swanson S, Herman M, Vindigni S, Broussard E. Application of a predictive model for early failure of FMT
 (fecal microbiota transplant). Am J Gastroenterol. 2016;111(PG-S82):S82.

Tafesh Z, O'Neil S, Crawford Jr C V. Fecal microbiota transfer as rescue therapy: Is there a role in severe C. difficile infection? Am J Gastroenterol. 2015;110(PG-S185):S185.

Tariq R, Weatherly RM, Kammer PP, Pardi D, Khanna S. Experience and outcomes from a specialized
 clostridium difficile clinical practice. Gastroenterology. 2016;1)(PG-S746-S747):S746–7.

Gut

Van Beurden YH, De Groot PF, Van Nood E, Nieuwdorp M, Keller JJ, Goorhuis A. Complications and long term follow-up of fecal microbiota transplantation for treatment of recurrent clostridium difficile infection. Gastroenterology. 2016;1)(PG-S544):S544.

Vermeire S, Joossens M, Verbeke K, Hildebrand F, Machiels K, Van den Broeck K, et al. Pilot Study on the Safety and Efficacy of Faecal Microbiota Transplantation in Refractory Crohn's Disease. Gastroenterology. 2012;142(5):S-360.

Vitek P, Zela O, Mikoviny Kajzrlikova I, Kuchar J, Chalupa J. Age is the main risk factor of mortality among patients with clostridium difficile infection. United Eur Gastroenterol J. 2014;1)(PG-A543):A543.

Wang PT, Fashandi AZ, Martin AN, Hays RA. Comparing fecal microbiota transplantation to total abdominal
 colectomy and loop ileostomy in severe and complicated clostridium difficile infections. Am J Gastroenterol.
 2016;111(PG-S94-S95):S94–5.

Wang PT, Schall SE, Doran AE, Tuskey AG, Hays RA. Healthy pregnancy in a newly diagnosed crohn's patient
 treated with fecal microbiota transplant for recurrent clostridium difficile infections. Am J Gastroenterol.
 2016;111(PG-S595-S596):S595–6.

Wang Y, Shen B. Fecal microbiota transplantation in refractory clostridium difficile pouchitis. Inflamm Bowel Dis. 2016;22(PG-S11-S12):S11–2.

Watson JB, Habr F, Kelly C. First reported complication of fecal microbiota transplant: Ulcerative colitis flare
 after FMT for relapsing clostridium difficile infection. Gastroenterology. 2012;1)(PG-S540):S540.

Weingarden A, Hamilton MJ, Sadowsky MJ, Khoruts A. Changes in bacterial composition following fecal microbiota transplantation for severe clostridium difficie infection. Gastroenterology. 2013;1)(PG-S829):S829.

Wieczorek T, Macholz M, Bethge A, Neumann F, Schreiter K, Lindner M, et al. Fecal microbiome therapy in relapsing clostridium difficile infection-long-term results. Int J Infect Dis. 2016;45(PG-347):347.

Wilcox GM. Early experience with a Fecal Bacteriotherapy (FB) program for recurrent and c-difficile infection
 (CDI). Gastroenterology. 2011;1)(PG-S361):S361.

Zhou E, Kumar V, Mansoor MS, Feuerstadt P. Pseudomembranes are infrequently seen in patients
 undergoing fecal microbiota transplant (FMT) for recurrent C. Difficile infection (CDI). Am J Gastroenterol.
 2016;111(PG-S68):S68.

Zhu J, Roach B, Kao D. Successful eradication of recurrent clostridium difficile infection (rCDI) of small bowel
 with frozen encapsulated fecal microbiota transplantation (FMT) in a patient with crohn's disease and
 ileostomy. Can J Gastroenterol Hepatol Conf. 2016; (pagination PG-)

D.1.3. Case series not fulfilling selection criteria

1 2

3

4

5 6 7

8

9

10 11 12

13

14 15

19

28

40

57 58

⁵⁹ Alhmoud T, Gavin M. An unusual complication after a fecal microbiota transplant via colonoscopy. Am J
 ⁶⁰ Gastroenterol. 2014;109(PG-S424):S424.

Gut

- Allegretti JR, Day R, Kassam Z, Smith M. Empiric treatment of suspected recurrent clostridium difficile infection with vancomycin may interfere with evaluation for fecal microbiota transplantation. Am J Gastroenterol. 2016;111(PG-S87):S87. Allegretti JR, Hamilton MJ, Korzenik JR, Chan WW. Factors associated with C. Difficile negative gastrointestinal symptoms after intestinal microbiome restoration. Gastroenterology. 2015;1)(PG-S643):S643. Allegretti JR, Korzenik JR, Hamilton MJ. Intestinal microbiome restoration for recurrent clostridium difficile infection in patients with concurrent inflammatory bowel disease. Gastroenterology. 2015;1)(PG-S869):S869. Allegretti JR, Phelps E, Xu H, Kassam Z, Fischer M. Redefining cure in clostridium difficile infection: Clinical assessment 4 weeks after fecal microbiota transplantation is predictive of standard 8-week cure endpoint. Am J Gastroenterol. 2016;111(PG-S56):S56. Allegretti JR, Storm M, Smith M, Kelly CR, Kearney S, Perrotta A, et al. Strain-level analysis of microbial engraftment associated with resolution of recurrent clostridium difficile following fecal microbiota transplantation. Gastroenterology. 2016;1)(PG-S540-S541):S540–1. Anand R, Sinha A, Sivaraman A, Hasan S, Garg S, Dutta S. Quality of life index in patients with recurrent clostridium difficile colitis following fecal microbiota transplantation: Long-term outcome. Am J Gastroenterol. 2015;110(PG-S568):S568. Andrews J, Costello S. The emerging role of faecal microbiota transplantation. Med Today. 2014;15(7 PG-62-64):62-4. Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 2013;108(10 PG-1620-1630):1620-30. Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after faecal microbiota transplantation. J Crohn's
- Arkkila P, Mattila E, Anttila VJ. [Fecal transfusion as treatment of Clostridium difficile infection]. [Finnish]. Duodecim. 2013;129(16 PG-1671-1679):1671-9.
- Arkkila P, Mattila E, Anttila VJ. [Fecal transfusion as treatment of Clostridium difficile infection]. Duodecim. 2013;129(16 PG-1671-9):1671-9.
- Asonuma K, Kuroki Y, Ino S, Hanamura S, Takano Y, Yamamura E, et al. Severe refractory Clostridium difficile infection with good response to fecal microbiota transplantation: A case report. [Japanese]. J Japanese Soc Gastroenterol. 2016;113(1 PG-55-62):55-62.
- Atkins KA, Kao D. Potential cost savings associated with timely fecal microbiota transplantation (FMT) for recurrent clostridium difficile infection (RCDI). Gastroenterology. 2014;1)(PG-S-252):S-252.

Colitis. 2013;7(PG-S291):S291.

Balzola F, Cullen G, Hoentjen F, Ho GT, Russell R. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. Inflamm Bowel Dis Monit. 2013;13(4 PG-167):167.

1 2

3

4 5

6 7

8

9

10 11

22

35

47

52

Gut

Bansal S, Serban R, Kemal N, Casey K, Dunnigan K, Kurchin A. Fecal microbiota transplant for recurrent clostridium difficile infection at a teaching hospital in upstate New York: Our experience. Am J Gastroenterol. 2013;108(PG-S383-S384):S383–4.

Bartlett M, Alsafadi A. The outcomes of using fresh parental stool versus frozen anonymous-donor stool in
 pediatric fecal microbiota transplant. J Pediatr Gastroenterol Nutr. 2016;63(PG-S314):S314.

Borody TJ, Mitchell SW, Wong C, Jaworski A. Encapsulated lyophilized fecal microbiota therapy for the treatment of clostridium difficile infection. Am J Gastroenterol. 2016;111(PG-S409):S409.

Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy.
 J Clin Gastroenterol. 2003;37(1):42–7.

Brandt L, Aroniadis O. Long-term follow-up study of fecal microbiota transplantation (FMT) for ulcerative
 colitis (UC). Am J Gastroenterol. 2012;107(PG-S657):S657.

Buers M, Quatrara B, Niccum B, Vance S, Hays RA. All-cause hospital admissions decreased after fecal microbiota transplantation for recurrent clostridium difficile infection. Am J Gastroenterol. 2016;111(PG-S91-S92):S91–2.

Burns LJ, Dubois N, Smith MB, Mendolia GM, Burgess J, Edelstein C, et al. Donor recruitment and eligibility
 for fecal microbiota transplantation: Results from an international public stool bank. Gastroenterology.
 2015;1)(PG-S96-S97):S96–7.

Cammarota G, Ianiro G, Gasbarrini A, Masucci L, Sanguinetti M. Faecal transplantation for Clostridium
 difficile infection. Three cases treated in Italy. Dig Liver Dis. 2014;46(5 PG-475):475.

Cheng YW, Xu H, Rogers N, Sagi S, Bohm M, Fischer M. Sequential fecal microbiota transplant protocol: A
 promising alternative to colectomy in severe and severe/complicated clostridium difficile. Am J
 Gastroenterol. 2016;111(PG-S59-S60):S59–60.

Cherem JH, Ulloa IH. Home fecal transplantation in elderly women. Gac Med Mex. 2014;150(1 PG-106-107):106–7.

Chetan M, Benjamin H, Ajin J, Alireza M, Nichole M, Mayur R. Fecal transplant for recurrent and/or refractory
 clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(PG S72):S72.

Costello S, La Brooy J, Tucker E, Holloway R, Schoeman M, Andrews JM. Establishment of a fecal microbiota
 transplant service for the treatment of recurrent Clostridium difficile colitis in the Australian public hospital
 setting. J Gastroenterol Hepatol. 2014;29(PG-134):134.

Damman C, Brittnacher M, Hayden H, Radey M, Hager K, Miller S, et al. Single colonoscopically administered
 fecal microbiota transplant for ulcerative colitis-a pilot study to determine therapeutic benefit and graft
 stability. Gastroenterology. 2014;1)(PG-S-460):S-460.

Page 299 of 454

Gut

2 3 4 5 6	Dimitry J, Keshteli A, Kao D. Independent predictors of failure of fecal microbiota transplantation (FMT) for recurrent or refractory clostridium difficile infection. Can J Gastroenterol Hepatol Conf. 2016;(pagination PG-).
7 8 9	Dimitry J, Keshteli AH, Kao D. Su1746 Predictors of Failure of Fecal Microbiota Transplantation (FMT) in the Management of Recurrent Clostridium difficile Infection. Gastroenterology. 2016 Apr;150(4):S543.
10 11 12 13	Doran A, Vance S, Warren C, Kolling G, Chaplain A, Archbald-Pannone L, et al. Microscopic colitis in recurrent C. difficile infection may resolve spontaneously after fmt. Am J Gastroenterol. 2015;110(PG-S584):S584.
14 15 16 17 18	El-Halabi M, Cheng YW, Rogers N, Sagi S, Bohm M, Xu H, et al. Changes in mortality, colectomy, and length of hospital stay after implementation of inpatient fecal microbiota transplantation program for severe clostridium difficile infection. Am J Gastroenterol. 2016;111(PG-S67):S67.
19 20 21	Elliott R. Stool transplant for recurrent clostridium difficile infection using designated screened donors in a community hospital. Am J Gastroenterol. 2016;111(PG-S71):S71.
22 23 24 25 26	Elliott RJ, Njenga M, Ladha A, Warren K, Blackler D, Stoltzner Z, et al. Stool processing speed and storage duration do not impact clinical effectiveness of fecal microbiota transplantation across 1,924 clostridium difficile infection patients. Am J Gastroenterol. 2016;111(PG-S57):S57.
27 28 29 30 31	Emanuelsson F, Claesson BEB, Ljungström L, Tvede M, Ung K-A. Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: A retrospective evaluation of 31 patients. Scand J Infect Dis. 2014 Feb 20;46(2):89–97.
32 33 34 35 36	Falconer S, Moss E, Andermann T, Systrom H, Mahabamunuge J, Hohmann E, et al. Fecal microbiota transplant is a potentially safe and effective treatment for clostridium difficile infection in hematopoietic stem cell recipients. Biol Blood Marrow Transplant. 2016;1)(PG-S53-S54):S53–4.
37 38 39 40 41	Fischer M, Bittar M, Papa E, Kassam Z, Smith M. Can you cause IBD with fecal transplantation? 31-patient case series of fecal transplantation using stool from a donor who later developed Crohn's disease. Am J Gastroenterol. 2016;111(PG-S294-S295):S294–5.
42 43 44 45 46	Fischer M, Cook G, Rogers N, Sipe B, Vuppalanchi R. Rescue therapy with fecal microbiota transplantation in hospitalized patients with severe and severe-complicated clostridium difficile infection. Am J Gastroenterol. 2014;109(PG-S195):S195.
47 48 49 50 51	Fischer M, Kelly C, Kao D, Kuchipudi A, Jafri SM, Blumenkehl M, et al. Outcomes of fecal microbiota transplantation for C. Difficile infection in patients with inflammatory bowel disease. Am J Gastroenterol. 2014;109(PG-S487):S487.
52 53 54 55	Fischer M, Mehta S, Martin T, Cook G, Phelps E, Sipe B, et al. Predictors of failure after fecal microbiota transplantation (FMT) for the therapy of clostridium difficile infection (CDI). Am J Gastroenterol. 2015;110(PG-S582):S582.
56 57 58 59	Fischer M, Phelps E, Bolla R, Storm M, Allegretti JR. Long-term risk of clostridium difficile infection recurrence with or without antibiotic exposure following successful fecal microbiota transplant. Gastroenterology. 2016;1)(PG-S23):S23.

60

Fischer M, Rex DK, Cook GK. Fecal microbiota transplantation for recurrent clostridium difficle in patients with prolonged immunosuppression. United Eur Gastroenterol J. 2013;1)(PG-A380):A380.

Frank J, Hogenauer C, Grochenig HP, Hoffmann KM, Reicht G, Wenzl HH, et al. Safety of fecal microbiota transplantation in patients with chronic colitis and immunosuppressive treatement. J Crohn's Colitis. 2015;9(PG-S245-S246):S245–6.

Freeman AE, Roberts SC, Chey WD, Kao JY, Rao K. New onset functional gi disorders following fecal
 microbiota transplant for recurrent clostridium difficile infection-prevalence and risk factors.
 Gastroenterology. 2016;1)(PG-S495):S495.

Gallegos-Orozco JF, Paskvan-Gawryletz CD, Gurudu SR, Orenstein R. Successful colonoscopic fecal transplant
 for severe acute Clostridium difficile pseudomembranous colitis. Rev Gastroenterol Mex. 2012;77(1 PG-40 2):40–2.

Gupta A, Khanna S. Ipilimumab-associated colitis or refractory Clostridium difficile infection? BMJ Case Rep.
 2015;2015 (no pagination)(A1084 PG-).

Gweon TG, Kim J, Lim CH, Park JM, Lee DG, Lee IS, et al. Fecal Microbiota Transplantation Using Upper
 Gastrointestinal Tract for the Treatment of Refractory or Severe Complicated Clostridium difficile Infection
 in Elderly Patients in Poor Medical Condition: The First Study in an Asian Country. Gastroenterol Res Pract.
 2016;2016 (no pagination)(2687605 PG-).

³⁰ Gweon TG, Lee KJ, Kang D, Park SS, Kim KH, Seong H, et al. A case of toxic megacolon caused by Clostridium
 ³¹ difficile infection and treated with fecal microbiota transplantation. Gut Liver. 2015;9(2 PG-247-250):247–
 ³³ 50.

³⁵ Gweon TG, Lee KJ, Kang DH, Park SS, Kim KH, Seong HJ, et al. A case of toxic megacolon caused by clostridium
 ³⁶ difficile infection and treated with fecal microbiota transplantation. Gut Liver. 2015;9(2 PG-247-50):247–50.

Hourigan SK, Chen LA, Grigoryan Z, Laroche G, Weidner M, Sears CL, et al. Microbiome changes associated
 with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children
 with and without inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42(6 PG-741-752):741–52.

IrreGaertner W, Madoff R, Mellgren A, Kwaan M, Melton G. Impact of postoperative clostridium difficile
 infection after colon and rectal operations. Color Dis. 2014;16(PG-145):145.

Karolewska-Bochenek K, Lazowska-Przeorek I, Banaszkiewicz A, Gawronska A, Kotowska M, Dziekiewicz M,
 et al. Fecal microbiota transplantation for CMV infection in pediatric patients with IBD. J Pediatr
 Gastroenterol Nutr. 2016;62(PG-147):147.

Karolewska-Bochenek K, Lazowska-Przeorek I, Grzesiowski P, Banaszkiewicz A, Albrecht P, Gawronska A, et
 al. Fecal microbiota transplantation in refractory pediatric UC - Preliminary data. J Crohn's Colitis. 2015;9(PG S294):S294.

Kelly C, De Leon L. Successful treatment of recurrent clostridium difficile infection with donor stool
 administered at colonoscopy: A case series. Am J Gastroenterol. 2010;105(PG-S135):S135.

59 60

1 2

3

4 5 6

7

8

9

23

29

34

Page 301 of 454

1 2

3

4

5 6 7

8

9

22

29

34

Gut

Kump PK, Gröchenig H-P, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis. 2013;19(10):2155–65.

Laszlo M, Ciobanu L, Andreica V, Pascu O. Fecal transplantation indications in ulcerative colitis. Preliminary study. Clujul Med. 2016;89(2 PG-224-8):224–8.

Le L, El-Nachef N. Fecal microbiota transplantation in solid organ transplant and hematopoietic stem cell
 transplant patients with recurrent or refractory clostridium difficile infection: A case series. Am J
 Gastroenterol. 2016;111(PG-S615):S615.

Link A, Lachmund T, Schulz C, Weigt J, Malfertheiner P. Endoscopic peroral jejunal fecal microbiota
 transplantation. Dig Liver Dis. 2016;48(11 PG-1336-1339):1336–9.

Lofland D, Josephat F, Partin S. Fecal transplant for recurrent Clostridium difficile infection. Clin Lab Sci.
 2013;26(3 PG-131-135):131-5.

Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, et al. Stool substitute transplant therapy
 for the eradication of Clostridium difficile infection: "RePOOPulating" the gut. Microbiome. 2013 Jan;1(1):3.

Pierog A, Mencin A, Reilly NR. Fecal microbiota transplantation in children with recurrent clostridium difficile
 infection. Pediatr Infect Dis J. 2014;33(11 PG-1198-1200):1198–200.

Ponte A, Pinho R, Mota M, Silva J, Vieira N, Oliveira R, et al. Initial experience with fecal microbiota transplantation in Clostridium difficile infection - transplant protocol and preliminary results. Rev Esp Enfermedades Dig. 2015;107(7 PG-402-407):402–7.

Ray A, Jones C. Does the donor matter? Donor vs patient effects in the outcome of a next-generation
 microbiota-based drug trial for recurrent Clostridium difficile infection. Future Microbiol. 2016;11(PG-611-6):611–6.

Rebello D, Yen E, Lio P, Kelly CR. Unexpected benefits: Hair growth in two alopecia patients after fecal
 microbiota transplant. Am J Gastroenterol. 2016;111(PG-S623-S624):S623–4.

Satokari R, Mattila E, Kainulainen V, Arkkila PE. Simple faecal preparation and efficacy of frozen inoculum in
 faecal microbiota transplantation for recurrent Clostridium difficile infection - an observational cohort study.
 Aliment Pharmacol Ther. 2015;41(1):46–53.

Schulz-Stubner S, Textor Z, Anetseder M. Fecal Microbiota Therapy as Rescue Therapy for Life-Threatening
 Clostridium difficile Infection in the Critically III: A Small Case Series. Infect Control Hosp Epidemiol. 2016;37(9
 PG-1129-1131):1129–31.

Silverman MS, Davis I, Pillai DR. Success of Self-Administered Home Fecal Transplantation for Chronic
 Clostridium difficile Infection. Clin Gastroenterol Hepatol. 2010;8(5 PG-471-473):471–3.

Veling N. A novel approach in the treatment of clostridium difficile: A case study. J Spinal Cord Med. 2014;37
 (4)(PG-441-442):441-2.

59 60

47

Vigvari S, Nemes Z, Vincze A, Solt J, Sipos D, Feiszt Z, et al. Faecal microbiota transplantation in Clostridium difficile infections. Infect Dis (Auckl). 2015;47(2 PG-114-116):114–6.

Gut

Webb BJ, Brunner A, Ford CD, Gazdik MA, Petersen FB, Hoda D. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2016;18(4 PG-628-633):628–33.

Weidner M, Hourigan S, Ling K, O'Brien K, Oliva-Hemker M. Fecal microbiota transplantation using banked donor stool is effective in the treatment of recurrent clostridium difficile infection in children. J Pediatr Gastroenterol Nutr. 2016;63(PG-S143-S144):S143–4.

D.1.4. Case reports

Abeyesundere RL. A ward outbreak of Clostridium difficile enterocolitis. J Infect. 1982;5(3 PG-277-282):277–82.

Adamski JK, Jaschke BB, Uusitalo-Seppala RS, Moilanen KVJ, Pehkonen AV, Weigl W. Routine Treatment-Resistant Clostridium difficile Infection during Recovery from Myxedema. Case Reports in Gastroenterology. 2017:740-6.

Agrawal M, Aroniadis OC, Brandt LJ, Kelly C, Freeman S, Surawicz C, et al. A long-term follow-up study of the
 efficacy and safety of fecal microbiota transplant (FMT) for Recurrent/Severe/Complicated C. Difficile
 Infection (CDI) in the elderly. Gastroenterology. 2014;1)(PG-S42-S43):S42–3.

Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. Both oral metronidazole and oral vancomycin
 promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium
 difficile-associated disease. Antimicrob Agents Chemother. 2008;52(7 PG-2403-2406):2403–6.

Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis. 2015;2 (1) (no
 pagination)(ofv004 PG-).

Alonso CD, Kamboj M. Clostridium difficile Infection (CDI) in solid organ and hematopoietic stem cell
 transplant recipients. Curr Infect Dis Rep. 2014;16 (8) (no pagination)(414 PG-).

Alrabaa S, Noel PR, Wills T. Clostridium difficile infection: What you need to know. Consultant. 2013;53(6
 PG-389-395):389–95.

Alsakka M, Sharabash N, Alktaifi A, Salih M, German M. Successful fecal microbiota transplantation (FMT)
 for recurrent clostridium difficile infection (CDI) after subtotal colectomy. Am J Gastroenterol. 2013;108(PG S365-S366):S365–6.

Anand R, Song Y, Sinha A, Hasan S, Sivaraman A, Garg S, et al. Effect of aging on the fecal microbiome in healthy donors for fecal microbiota transplant. Gastroenterology. 2015;1)(PG-S719):S719.

Andrews R, Gavin M. Post-infectious IBS following recurrent/ relapsing C. difficile associated diarrhea
 (CDAD). J Investig Med. 2016;64 (1)(PG-244):244.

Page 303 of 454

1

6

7

8

Gut

- Ang P, Cheong WK, Khoo KS. Pseudomembranous colitis in a patient treated with paclitaxel for carcinoma of
 the breast: A case report. Ann Acad Med Singapore. 2000;29(1 PG-132-134):132–4.
 - Aratari A, Cammarota G, Papi C. Fecal microbiota transplantation for recurrent C. difficile infection in a patient with chronic refractory ulcerative colitis. J Crohns Colitis. 2015;9(4 PG-367):367.
- Asonuma K, Kuroki Y, Ino S, Hanamura S, Takano Y, Yamamura E, et al. Severe refractory Clostridium difficile
 infection with good response to fecal microbiota transplantation: a case report. Nippon Shokakibyo Gakkai
 Zasshi Japanese J Gastroenterol. 2016;113(1 PG-55-62):55–62.
- Bamba S, Nishida A, Imaeda H, Inatomi O, Sasaki M, Sugimoto M, et al. Successful treatment by fecal
 microbiota transplantation for Japanese patients with refractory Clostridium difficile infection: A prospective
 case series. Journal of Microbiology, Immunology and Infection. 2017.
- Bartosz C, Marino D, DeCross A. A highly illustrative case report detailing the profound subjective and
 objective response of severe pseudomembranous colitis (from clostridium difficile) to fecal transplant. Am J
 Gastroenterol. 2016;111(PG-S620):S620.
- Bartosz C, Marino D, DeCross A. A highly illustrative case report detailing the profound subjective and
 objective response of severe pseudomembranous colitis (from clostridium difficile) to fecal transplant. Am J
 Gastroenterol. 2016;111(PG-S620):S620.
- Berro ZZ, Hamdan RH, Dandache IH, Saab MN, Karnib HH, Younes MH. Fecal microbiota transplantation for
 severe clostridium difficile infection after left ventricular assist device implantation: A case control study and
 concise review on the local and regional therapies. BMC Infect Dis. 2016;16 (1) (no pagination)(234 PG-).
- Binkovitz LA, Allen E, Bloom D, Long F, Hammond S, Buonomo C, et al. Atypical presentation of Clostridium
 difficile colitis in patients with cystic fibrosis. Am J Roentgenol. 1999;172(2 PG-517-521):517–21.
- Brechmann T, Swol J, Knop-Hammad V, Willert J, Aach M, Cruciger O, et al. Complicated fecal microbiota
 transplantation in a tetraplegic patient with severe Clostridium difficile infection. World J Gastroenterol.
 2015;21(12 PG-3736-3740):3736–40.
- Broecker F, Klumpp J, Schuppler M, Russo G, Biedermann L, Hombach M, et al. Long-term changes of bacterial and viral compositions in the intestine of a recovered Clostridium difficile patient after fecal microbiota transplantation. Cold Spring Harb Mol Case Stud. 2016;2(1 PG-a000448):a000448.
- ⁴⁷Broecker F, Kube M, Klumpp J, Schuppler M, Biedermann L, Hecht J, et al. Analysis of the intestinal ⁴⁸microbiome of a recovered clostridium difficile patient after fecal transplantation. Digestion. 2013;88(4 PG-⁵⁰243-251):243–51.
- Cammarota G, Ianiro G, Masucci L, Pecere S, Bibbo S, Scaldaferri F, et al. Fecal microbiota transplantation for
 recurrent C. difficile infection: A 2-year experience from a European referral centre. United Eur Gastroenterol
 J. 2015;1)(PG-A131):A131.
- Chang B, Rezaie A. Post-fecal microbiota transplantation (FMT) constipation and abdominal distention due
 to methane-predominant bacterial overgrowth contracted from the donor. Am J Gastroenterol.
 2016;111(PG-S807-S808):S807-8.

Chao HC, Yu WL. Treatment failure of fecal microbiota transplant for pseudomembranous colitis due to coexistent cytomegalovirus colitis. J Microbiol Immunol Infect. 2016;49(4 PG-617-618):617–8.

Cho S, Spencer E, Hirten R, Grinspan A, Dubinsky M. High recurrence rate after fecal microbiota transplant for recurrent clostridium difficile infection in pediatric inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2017;65 (Supplement 2):S279-S80.

Chu A, Michail S. Pediatric recurrent c difficile infections-a sign of undiagnosed gi disease. Journal of Pediatric
 Gastroenterology and Nutrition. 2017;65 (Supplement 2):S70.

Colleen K, Hassan Z, Stacy K. New diagnosis of crohn's colitis 6 weeks after fecal microbiota transplantation
 (FMT). Inflamm Bowel Dis. 2014;20(PG-S21):S21.

Collins DC. Pseudomembranous enterocolitis. Further observations on the value of donor fecal enemata as
 an adjunct in the treatment of pseudomembranous enterocolitis. Am J Proctol. 1960;2(PG-389-91):389–91.

Costello SP, Chung A, Andrews JM, Fraser RJ. Fecal microbiota transplant for clostridium difficile colitis induced toxic megacolon. Am J Gastroenterol. 2015;110(5 PG-775-777):775–7.

Davidovics ZH, Vance K, Etienne N, Hyams JS. Fecal Transplantation Successfully Treats Recurrent D-Lactic
 Acidosis in a Child With Short Bowel Syndrome. Jpen J Parenter Enter Nutr. 2015;29(PG-29):29.

De Castro CG, Ganc AJ, Ganc RL, Petrolli MS, Hamerschlack N. Fecal microbiota transplant after
 hematopoietic SCT: Report of a successful case. Bone Marrow Transplant. 2015;50(1 PG-145):145.

Diamond C, McNeilly T. Faecal microbiota transplantation for clostridium difficile - a local perspective. Ulster Medical Journal. 2017;86(2):108-10.

³⁵ Didesch MM, Averill A, Oh-Park M. Peripheral Neuropathy After Fecal Microbiota Transplantation for ³⁶ Clostridium difficile Infection: A Case Report. PM R. 2016;8(8 PG-813-816):813–6.

Didesch MM, Averill A, Oh-Park M. Peripheral neuropathy after fecal transplantation for clostridium difficile
 infection: A case report. PM R. 2014;1)(PG-S237-S238):S237–8.

⁴² Duke PS, Fardy J. Recurrent Clostridium difficile infection treated with home fecal transplantation: A case ⁴³ report. J Med Case Rep. 2014;8 (1) (no pagination)(393 PG-).

Dumitru IM, Dumitru E, Resul G, Curtali L, Paris S, Rugina S. Concomitant CMV and Clostridium difficile colitis
 in an immunocompetent patient treated with Ganciclovir and fecal transplantation. J Gastrointest Liver Dis.
 2014;23(2 PG-221-222):221–2.

Duplessis CA, You D, Johnson M, Speziale A. Efficacious outcome employing fecal bacteriotherapy in severe
 Crohn's colitis complicated by refractory Clostridium difficile infection. Infection. 2012;40(4 PG-469 472):469–72.

Ehlermann P, Dosch AO, Katus HA. Donor fecal transfer for recurrent Clostridium difficile-associated diarrhea
 in heart transplantation. J Hear Lung Transplant. 2014;33(5 PG-551-553):551–3.

58 59 60

1 2

3

4 5 6

7

8

9

16

Page 305 of 454

1 2

3

4 5

6 7

8

9

17

22

29

34

46

53

Enriquez R, Borras-Blasco J, Sirvent AE, Padilla S, Navarro-Ruiz A, Solavera J, et al. Imipenem-induced Clostridium difficile diarrhea in a patient with chronic renal failure. Saudi J Kidney Dis Transpl. 2011;22(3 PG-541-543):541–3.

Espinoza R, Quera R, Meyer L, Rivera D. [Fecal microbiota transplantation: first case report in Chile and review]. Rev Chil Infectol. 2014;31(4 PG-477-82):477–82.

Floe A, Leutscher P. [Recurrent Clostridium difficile infection treated with faecal microbiota transplantation].
 Ugeskr Laeger. 2014;176(4 PG-17):17.

Freeman S, Mao E, Shah S, Kelly C. A case of recurrent clostridium difficile enteritis treated with fecal microbiota transplant. Am J Gastroenterol. 2014;109(PG-S328):S328.

Garcia-Fernandez S, Morosini MI, Cobo M, Foruny JR, Lopez-Sanroman A, Cobo J, et al. Gut eradication of VIM-1 producing ST9 Klebsiella oxytoca after fecal microbiota transplantation for diarrhea caused by a Clostridium difficile hypervirulent R027 strain. Diagn Microbiol Infect Dis. 2016;86(4 PG-470-471):470–1.

Garg S, Walia R, Girotra M, Gjikopulli A, Mirza Y, Cuffari C, et al. A novel treatment for recurrent clostridium
 difficile infection in a 20-month-old. Am J Gastroenterol. 2012;107(PG-S556):S556.

Gathe JC, Diejomaoh EM, Mayberry CC, Clemmons JB. Fecal Transplantation for Clostridium Difficile - "all Stool May Not Be Created Equal." J Int Assoc Provid AIDS Care. 2016;15(2 PG-107-108):107–8.

Goeser F, Schlabe S, Ruiner CE, Kramer L, Strassburg CP, Spengler U. Non-invasive fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient presenting with hypertensive disorder post interventionem. Z Gastroenterol. 2016;54(10 PG-1143-1146):1143–6.

Gundling F, Tiller M, Agha A, Schepp W, Iesalnieks I. Successful autologous fecal transplantation for chronic
 diversion colitis. Tech Coloproctol. 2015;19(1 PG-51-52):51–2.

Jang MO, An JH, Jung SI, Park KH. Refractory Clostridium difficile Infection Cured With Fecal Microbiota Transplantation in Vancomycin-Resistant Enterococcus Colonized Patient. Intest Res. 2015;13(1 PG-80-4):80–4.

Kakkar E, Othman M. Fecal transplant in recurrent clostridium difficile enteritis. Journal of General Internal
 Medicine. 2017;32 (2 Supplement 1):S499.

Kao D, Madsen K. Fecal microbiota transplantation (FMT) in the treatment of inflammatory bowel disease
 (IBD): A case report acg/astrazeneca clinical vignette award. Am J Gastroenterol. 2013;108:S415–6.

Karlsson KA. Faecal transplantation for the treatment of recurrent clostridium difficile associated diarrhoea.
 South African Gastroenterol Rev. 2012;10(2 PG-19):19.

Kelly CR, Olefson S, Jackson M. A challenging case of diarrhea after fecal microbiota transplant. Am J
 Gastroenterol. 2015;110(PG-S156-S157):S156–7.

Kim JE, Gweon TG, Yeo CD, Cho YS, Kim GJ, Kim JY, et al. A case of Clostridium difficile infection complicated
 by acute respiratory distress syndrome treated with fecal microbiota transplantation. World J Gastroenterol.
 2014;20(35 PG-12687-12690):12687–90.

Gut

Kleger A, Schnell J, Essig A, Wagner M, Bommer M, Seufferlein T, et al. Fecal transplant in refractory Clostridium difficile colitis. Dtsch Arztebl Int. 2013;110(7 PG-108-15):108–15.

Konturek P, Haziri D, Helfritzsch H, Hess T, Heymann S, Harsch I. Successful Therapy of Severe Pseudomembranous Clostridium difficile Colitis using Combination of Fecal Microbiota Therapy and Fidaxomicin. Med Princ Pract. 2016;15(PG-).

Kurtz M, Morgan M. Concomitant Clostridium difficile colitis and cytomegalovirus colitis in an immunocompetent elderly female. BMJ Case Rep. 2012;(no pagination)(1379 PG-).

Laster J, Sultan M, Mattar M. Fecal microbiota transplantation in refractory clostridium difficile infection in children: Case report and review of the literature. Am J Gastroenterol. 2015;110(PG-S399):S399.

Lingala S. Fecal microbiota transplantation in critically ill patient with severe clostridium difficile colitis. Gastroenterology. 2014;1)(PG-S-251):S-251.

Loke P, Heine RG, McWilliam V, Cameron DJ, Tang ML, Allen KJ. Fecal microbial transplantation in a pediatric case of recurrent Clostridium difficile infection and specific antibody deficiency. Pediatr Allergy Immunol. 2016;27(8 PG-872-874):872–4.

Loke P, Heine RG, McWilliam V, Cameron DJS, Tang MLK, Allen KJ. Fecal microbial transplantation in a pediatric case of recurrent Clostridium difficile infection and specific antibody deficiency. Pediatr Allergy Immunol. 2016;27(8 PG-872-874):872–4.

Mandalia A, Kraft CS, Dhere T. Diverticulitis after fecal microbiota transplant for C. difficile infection. Am J Gastroenterol. 2014;109(12 PG-1956-1957):1956–7.

Marcos LA, Gersh A, Blanchard K, Foil S, Mallini B, Farrell SE, et al. Fecal transplantation to treat initial severe
 Clostridium difficile infection with sepsis. J Miss State Med Assoc. 2015;56(2 PG-38-40):38–40.

Matsushita M, Watanabe O, Nakamura M, Yamamura T, Funasaka K, Ohno E, et al. Two cases of fecal
 microbiota transplantation in patients with recurrent clostridium difficile infection. J Gastroenterol Hepatol.
 2016;31(PG-217):217.

Midani D, Criner G, Clauss H, Smith MS, Ehrlich AC. Fecal microbiota transplant as a bridge to organ
 transplant: An alternative indication for treatment of C. Difficile in a critically ill patient. Am J Gastroenterol.
 2016;111(PG-S616):S616.

Million M, Hocquart M, Seghboyan JM, Griffiths K, Halfon P, Lagier JC, et al. Faecal microbiota transplantation
 as salvage therapy for fulminant Clostridium difficile infections. Int J Antimicrob Agents. 2015;46(2 PG-227 228):227–8.

Mohamed A, Hogan N, Moloney M. Faecal transplant in the management of Crohn's colitis with persistent
 clostridium difficile infection: A case report. Ir J Med Sci. 2015;184 (6 Supplement 1)(PG-S236):S236.

Morales SJ, Medvedev S, Lee A, Mattar M. A case of successful treatment of refractory clostridium difficile
 colitis with fecal microbiota transplantation in a critically ill patient. Am J Gastroenterol. 2015;110(PG S146):S146.

Page 307 of 454

Gut

Navalkele BD, Lerner SA. Intravenous tigecycline facilitates cure of severe Clostridium difficile infection (CDI) after failure of standard therapy: A case report and literature review of tigecycline use in CDI. Open Forum Infect Dis. 2016;3 (2) (no pagination)(ofw094 PG-).

Neelakanta A, Moudgal V, Upadhyay N, Valenstein P, Gunaratnam NT. Title: Successful treatment of refractory clostridium difficile infection(CDI) with intestinal microbiota transplant (IMT) in two patients with inflammatory bowel disease (IBD) and its effects on IBD. Gastroenterology. 2012;1)(PG-S395):S395.

Neemann K, Eichele DD, Smith PW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis. 2012;14(6 PG-E161-5):E161-5.

Neemann K, Eichele DDD, Smith PPW, Bociek R, Akhtari M, Freifeld A. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis. 2012;14(6 PG-E161-E165):E161-5.

Oppfeldt AM, Dahlerup JF, Christensen LA, Hvas CL. Faecal microbiota transplantation for recurring Clostridium difficile infection in a patient with Crohn's disease and ileorectal anastomosis. BMJ Case Rep. 2016;(PG-).

Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol. 2000;95(11 PG-3283-3285):3283-5.

Pitts K, Shah N, Uppal D, Hays RA. Fecal microbiota transplantation in a patient with liver cirrhosis: Changing the intestinal microbiota in a high-risk group. Am J Gastroenterol. 2015;110(PG-S358):S358.

Popa D, Laszlo M, Ciobanu L, Ucenic E, Mihalache M, Pascu O. Self-Administered home series fecal "minitransplants" for recurrent Clostridium difficile infection on a rectal remnant. J Gastrointest Liver Dis. 2015;24(4 PG-531-533):531-3.

Porr CI. Uncontrolled asthma - Case presentation. Allergy Eur J Allergy Clin Immunol. 2014;69(PG-585):585.

Porter RJ, Fogg C. Faecal microbiota transplantation for Clostridium difficile infection in the United Kingdom. Clin Microbiol Infect. 2015 Jun;21(6):578-82.

Porter RJ. Pulsed faecal microbiota transplantation for recalcitrant recurrent Clostridium difficile infection. Clin Microbiol Infect. 2015;21(3 PG-e23-e24):e23-4.

Quera R, Espinoza R, Estay C, Rivera D. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection. J Crohn's Colitis. 2014;8(3 PG-252-253):252-3.

Raghunathan VM, Sheng I, Lim SH. Intestinal dysbiosis and allogeneic hematopoietic progenitor cell transplantation. J Transl Med. 2016;14 (1) (no pagination)(335 PG-).

Rahman O, Faroog H, Mahmood SB, Khalid MB, Kapoor R, Wack M. Clostridium difficile enteritis and proctitis: Novel multimodality treatment regimen postcolectomy. Crit Care Med. 2016;44 (12 Supplement 1)(PG-520):520.

Ramay FH, Amoroso A, Von Rosenvinge EC, Saharia K. Fecal microbiota transplantation for treatment of severe, recurrent, and refractory clostridium difficile infection in a severely immunocompromised patient. Infect Dis Clin Pract. 2016;24(4 PG-237-240):237–40.

1 2

3

4 5

6 7

8

9

10 11

23

34

52

Robin C, Paul M, Nebbad B, Beckerich F, Lepeule R, Ait Ammar N, et al. Fecal microbiota transplantation after allogeneic HSCT for curing recurrent Clostridium difficile infection: Why using the stem cell donor again? Bone Marrow Transplant. 2016;51(PG-S199-S200):S199–200.

Russell G, Kaplan J, Ferraro M, Michelow IC. Fecal bacteriotherapy for relapsing Clostridium difficile infection
 in a child: A proposed treatment protocol. Pediatrics. 2010;126(1 PG-e239-e242):e239-42.

Saeedi BJ, Morison DG, Kraft CS, Dhere T. Fecal Microbiota Transplant for Clostridium difficile Infection in a
 Pregnant Patient. Obstet Gynecol. 2017;129(3):507-9.

Satokari R, Fuentes S, Mattila E, Jalanka J, de Vos WM, Arkkila P. Fecal transplantation treatment of
 antibiotic-induced, noninfectious colitis and long-term microbiota follow-up. Case Rep Med. 2014;2014(PG 913867):913867.

Satokari R, Fuentes S, Mattila E, Jalanka J, De Vos WM, Arkkila P. Fecal transplantation treatment of
 antibiotic-induced. Case Rep Med. 2014;2014 (no pagination)(913867 PG-).

Schunemann M, Oette M. Fecal microbiota transplantation for Clostridium difficile-associated colitis in a
 severely immunocompromized critically ill AIDS patient: A case report. Aids. 2014;28(5 PG-798-799):798–9.

Seth AK, Rawal P, Bagga R, Jain P. Successful colonoscopic fecal microbiota transplantation for active ulcerative colitis: First report from India. Indian J Gastroenterol. 2016;35(5 PG-393-395):393–5.

Seth AK, Rawal P, Bagga R. Successful stool transplantation for severe ulcerative colitis: First report from
 India. Indian J Gastroenterol. 2015;1)(PG-A21-A22):A21-2.

Shin JY, Ko EJ, Lee SH, Shin JB, Kim SI, Kwon KS, et al. Refractory pseudomembranous colitis that was treated
 successfully with colonoscopic fecal microbial transplantation. Intest Res. 2016;14(1 PG-83-8):83–8.

Singh P, Udeh B, Dalton J, Udeh C, Hata J. Cost-effectiveness of 6 treatments for primary clostridium difficile
 infection in an ICU population. Crit Care Med. 2014;1)(PG-A1474):A1474.

Singh S, Jing E, Stollman N. Self-Limited Sepsis Syndrome Following Fecal Microbiota Therapy for Refractory
 C. difficile Infection. Dig Dis Sci. 2016;61(9 PG-2488-2491):2488–91.

Smith S. Intestinal microbiota transplantation: A case of Crohn's colitis with superimposed Clostridium difficile infection. West Indian Med J. 2013;62(7 PG-675-677):675–7.

Sonpal N, Datta S, Mammen A, Haber G. The stool strikes back: Fecal transplantation for the treatment of
 clostridium difficile infection. Am J Gastroenterol. 2015;110(PG-S159):S159.

Soota K, Telfah M, Ramesh N, Pereira M, Lingutla D. Treatment of recurrent clostridium difficile infection
 with combined jejunal and colonic fecal microbiota transplant. Am J Gastroenterol. 2013;108(PG S398):S398.

Page 309 of 454

Gut

1	
2 3 4	Stanley E, McNamara D. "Non-Resolving C. difficile infection cured by transplant." Ir J Med Sci. 2015;1)(PG-S342):S342.
5 6 7 8	Stein D, Rizvi S, Modiri AN, Fang T, Naik AS. Two case reports of toxic megacolon from clostridium difficile infection successfully treated with fecal microbiota therapy. Gastroenterology. 2015;1)(PG-S645):S645.
9 10 11 12 13	Stollman N, Smith M, Giovanelli A, Mendolia G, Burns L, Didyk E, et al. Frozen encapsulated stool in recurrent clostridium difficile: Exploring the role of pills in the treatment hierarchy of fecal microbiota transplant nonresponders. Am J Gastroenterol. 2015;110(4 PG-600-601):600–1.
14 15	Stollman N, Surawicz C. Fecal transplant for Clostridium difficile. Arch Intern Med. 2012;172(10 PG-825):825.
16 17 18 19 20	Stripling J, Kumar R, Baddley JW, Nellore A, Dixon P, Howard D, et al. Loss of vancomycin-resistant enterococcus fecal dominance in an organ transplant patient with Clostridium difficile colitis after fecal microbiota transplant. Open Forum Infect Dis. 2015;2 (2) (no pagination)(ofv078 PG-).
21 22 23 24	Stysly B, Kukkadapu T, Singh E. Clostridium difficile in ulcerative colitis complicated by underlying aplastic anemia. Am J Gastroenterol. 2014;109(PG-S443):S443.
25 26 27	Sun W, Arunachalam A, Siddique S, Zandman D. Multi-organism bacteremia after fecal microbiota transplantation for relapsing clostridium difficile infection. Am J Gastroenterol. 2014;109(PG-S420):S420.
28 29 30 31	Syed R, Rahim U, Humphrey F, Ray A. Fecal microbiota transplant for severe complicated clostridium difficile infection via a loop ileostomy: A novel administration route. Am J Gastroenterol. 2015;110(PG-S142):S142.
32 33 34 35	Tafesh Z, O'Neil S, Crawford Jr C V. Frozen universal stool for fecal microbiota transfer (FMT) in recurrent C. difficile infection. Am J Gastroenterol. 2015;110(PG-S588):S588.
36 37 38	Tanaka T, Kato H, Fujimoto T. Successful fecal microbiota transplantation as an initial therapy for Clostridium difficile infection on an outpatient basis. Intern Med. 2016;55(8 PG-999-1000):999–1000.
39 40 41 42	Tariq R, Smyrk T, Pardi DS, Tremaine WJ, Khanna S. New-onset microscopic colitis in an ulcerative colitis patient after fecal microbiota transplantation. Am J Gastroenterol. 2016;111(5 PG-751-752):751–2.
43 44 45 46	Tian H, Ding C, Gong J, Wei Y, McFarland L V, Li N. Freeze-dried, capsulized fecal microbiota transplantation for relapsing clostridium difficile infection. J Clin Gastroenterol. 2015;49(6 PG-537-538):537–8.
47 48 49 50	Trubiano JA, Gardiner B, Kwong JC, Ward P, Testro AG, Charles PG. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol. 2013;25(2 PG-255-7):255–7.
51 52 53 54 55	Trubiano JA, Gardiner B, Kwong JC, Ward P, Testro AG, Charles PGP. Faecal microbiota transplantation for severe clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol. 2013;25(2 PG-255-257):255–7.
56 57 58 59 60	Trubiano JA, George A, Barnett J, Siwan M, Heriot A, Prince HM, et al. A different kind of "allogeneic transplant": Successful fecal microbiota transplant for recurrent and refractory Clostridium difficile infection in a patient with relapsed aggressive B-cell lymphoma. Leuk Lymphoma. 2015;56(2 PG-512-514):512–4.

Walia R, Garg S, Song Y, Girotra M, Cuffari C, Fricke WF, et al. Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome. J Pediatr Gastroenterol Nutr. 2014;59(5 PG-565-570):565-70.

Wang J, Xiao Y, Lin K, Song F, Ge T, Zhang T. Pediatric severe pseudomembranous enteritis treated with fecal microbiota transplantation in a 13-month-old infant. Biomed Reports. 2015;3(2 PG-173-175):173–5.

Wang PT, Fashandi AZ, Hays RA. Comparison of laparascopic loop ileostomy and fecal microbiota transplantation in a patient with two episodes of severe and complicated clostridium difficile infection: A case report. Am J Gastroenterol. 2016;111(PG-S624):S624.

Wonderlick JS, D'Agostino R. Fecal microbiota transplantation via fluoroscopy-guided nasojejunal catheter placement: indications, technique, and the role of radiology. Abdom Radiol. 2016;41(10 PG-2020-2025):2020-5.

You D, Johnson M, Duplessis C, Speziale A. Successful Use of Fecal Bacteriotherapy in Severe Crohn's Colitis and Refractory Clostridium difficile Infection. Am J Gastroenterol. 2011;106(PG-S315):S315.

You DM, Franzos MA, Holman RP. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med. 2008;148(8 PG-632-633):632-3.

Youssef MA, Gavin M. Fecal microbiota transplant: A case report in an immunosuppressed patient with crohn's disease and recurrent clostridium difficile infection. Gastroenterology. 2013;1)(PG-S626):S626.

Yu S, Abdelkarim A, Nawras A, Hinch BT, Mbaso C, Valavoor S, et al. Fecal transplant for treatment of toxic megacolon associated with clostridium difficile colitis in a patient with duchenne muscular dystrophy. Am J Ther. 2016;23(2 PG-e609-e613):e609-13.

Zainah H, Silverman A. Fecal Bacteriotherapy: A Case Report in an Immunosuppressed Patient with Ulcerative Colitis and Recurrent Clostridium difficile Infection. Case Reports Infect Dis. 2012;2012(PG-810943):810943.

D.1.5. Non-English language:

Chinese Li N, Tian H, Ma C, Ding C, Ge X, Gu L, Zhang X, Yang B, Hua Y, Zhu Y, Zhou Y. Efficacy analysis of fecal microbiota transplantation in the treatment of 406 cases with gastrointestinal disorders [Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2017;20(1):40-46.

Chinese Wang Y, Yang B, Ye Y, Li Z, Kang W. Therapeutic effects and the possible mechanism of fecal transplantation on rats with Clostridium difficile-associated pseudomembranous colitis. [Chinese]. Chinese J Microbiol Immunol. 2015;35(8 PG-582-586):582-6.

Chinese Yang Y, Wang Z. Advances in study on fecal microbiota transplantation. [Chinese]. Chinese J Gastroenterol. 2014;19(1 PG-1-5):1–5.

Czech Polak P, Freibergerova M, Husa P, Jurankova J, Svacinka R, Mikesova L, et al. Fecal bacteriotherapy for the treatment of recurrent Clostridium difficile colitis used in the Clinic of Infectious Diseases of the

Gut

Page 311 of 454

1

28

Gut

- 2 University Hospital Brno in 2010-2014 - a prospective study. [Czech]. Epidemiol Mikrobiol Imunol Cas Spol 3 pro Epidemiol a Mikrobiol Ces Lek Spol JE. 2015; Purkyne. 64(4 PG-232-235): 232-5. 4 5 6 Czech Polak P, Freibergerova M, Husa P, Jurankova J, Svacinka R, Mikesova L, et al. [Fecal bacteriotherapy 7 for the treatment of recurrent Clostridium difficile colitis used in the Clinic of Infectious Diseases of the 8 University Hospital Brno in 2010-2014 - a prospective study]. Epidemiol Mikrobiol Imunol. 2015;64(4 PG-9 232-5):232-5. 10 11 12 Czech Polak P, Freibergerova M, Jurankova J, Kocourkova H, Mikesova L, Svacinka R, et al. First experiences 13 with faecal bacteriotherapy in the treatment of relapsing pseudomembranous colitis due to Clostridium 14 difficile. [Czech]. Klin Mikrobiol Infekc Lek. 2011;17(6 PG-214-217):214–7. 15 16 17 Czech Polak P, Husa P, Freibergerova M. Colitis due to Clostridium difficile in broader context. [Czech]. Interni 18 Med pro Praxi. 2014;16(6 PG-241-244):241-4. 19 20 Dutch Holvoet T, Van De Wiele T, Boelens J, Raes J, Hindryckx P, De Vos M, et al. Fecal transplantation: 21 Overview of the indications. [Dutch]. Tijdschr Geneeskd. 2014;70(6 PG-289-297):289-97. 22 23
- Dutch Nieuwdorp M, Van Nood E, Speelman P, Van Heukelem HA, Jansen JM, Visser CE, et al. Treatment of
 recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces. [Dutch]. Ned Tijdschr
 Geneeskd. 2008;152(35 PG-1927-1932):1927–32.
- Dutch Nood E, Keller JJ, Kuijper EJ, Speelman P. New treatment options for infections with. [Dutch]. Ned
 Tijdschr Geneeskd. 2014;158(3 PG-).
- Dutch Terveer EM, van Beurden YH, Kuijper EJ, Keller JJ. [Fecal microbiota transplantation, a novel therapy
 for recurrent Clostridium difficile infection]. Ned Tijdschr Tandheelkd. 2016;123(9 PG-406-9):406–9.
- Dutch van Nood E, Keller JJ, Kuijper EJ, Speelman P. [New treatment options for infections with Clostridium difficile]. [Dutch]. Ned Tijdschr Geneeskd. 2013;157(48 PG-A6580):A6580.
- Finnish Harkonen N. [Reccurent pseudomembranous colitis treated with the donor feces]. Duodecim.
 1996;112(19 PG-1803-4):1803-4.
- French Giger A, Barberini L, Bruchez P, Castioni J, Claude F, Rochat MC, et al. General internal medicine in
 hospital practice: The year 2013 put into perspective by residents. [French]. Rev Med Suisse. 2014;10(414
 PG-164-170):164–70.
- French Kohn M, Robin C, Beckerich F, Cordonnier C. Clostridium difficile infections and blood disease: What
 should I know? Infections a Clostridium difficile et hemopathies: que faut-il savoir?. [French]. Hematologie.
 2015;21(1 PG-18-27):18–27.
- French Lagier JC, Raoult D. [Fecal microbiota transplantation: indications and perspectives]. M S-Medecine
 Sci. 2016;32(11 PG-991-997):991–7.
- French Lagier JC. Faecal microbiota transplantation: From practice to legislation before considering
 industrialization. Clin Microbiol Infect. 2014;20(11 PG-1112-1118):1112–8.
- 59 60

47

biological drug, not a tissue. Ann Pharm Fr. 2014;72(4 PG-217-220):217-20. French Megerlin F, Fouassier E. [Faecal microbiota transplantation in France: what applicable law?]. Ann Pharm Fr. 2014;72(5 PG-363-74):363-74. French Megerlin F, Fouassier E. Faecal microbiota transplantation in France: What applicable law?. [French]. Ann Pharm Fr. 2014;72(5 PG-363-374):363-74. French Rozier P, Fraisse T, Lauda M, Priner M, Forestier E, Paccalin M. Clostridium difficile in geriatrics. [French]. Cah l'Annee Gerontol. 2014;6(3 PG-107-113):107-13. French Rozier P, Fraisse T, Lauda M, Priner M, Forestier E, Paccalin M. Clostridium difficile in geriatrics. [French]. Cah l'Annee Gerontol. 2014;6(3 PG-107-113):107-13. French Seksik P. Clostridium difficileassociated colitis. [French]. Hepato-Gastro Oncol Dig. 2016;23(8 PG-775-784):775-84. French Sokol H, Galperine T, Kapel N, Bourlioux P, Seksik P, Barbut F, et al. Fecal microbiota transplantation for treatment of relapsing clostridium difficile infection: Guidelines for clinical practice. [French]. Hepato-Gastro Oncol Dig. 2015;22(4 PG-278-290):278-90. French Surawicz CM, Alexander J. Treatment of refractory and recurrent Clostridium difficile infection. Nat Rev Gastroenterol Hepatol. 2011;19(PG-). French Surawicz CM. [The microbiota and infectious diarrhea]. [French]. Gastroenterol Clin Biol. 2010;34 Suppl 1(PG-S29-36):S29-36. French Surawicz CM. [The microbiota and infectious diarrhea]. Gastroenterol Clin Biol. 2010;34 Suppl 1(PG-S29-36):S29-36. French Surawicz CM. Clostridium difficile infection: risk factors, diagnosis and management. Curr Treat Options Gastroenterol. 2015;13(1 PG-121-9):121-9. French Terrier MCZ, Frossard JL, Simonet ML. Recurrent Clostridium difficile infections : The importance of the intestinal microbiota. [French]. Rev Med Suisse. 2013;9(402 PG-1898-1904):1898-904. French Tissot F, Maillard MH. Clostridium difficile infections: Update on new European recommandations. [French]. Rev Med Suisse. 2014;10(427 PG-913-919):913-9. French Voide C, Asner S, Giulieri S, Cavassini M, Merz L, Tissot F, et al. Infectious diseases. [French]. Rev Med Suisse. 2014;10(412-413-61-65):61-5. French Werner CC. Fecal transplantation in the treatment of Clostridium difficile infections. [French]. Rev Med Suisse. 2013;9(373 PG-388-389):388-9. German eufferlein T, Kleger A, Nitschmann S. [Recurrent Clostridium difficile infection. Treatment with duodenal infusion of donor feces]. Internist. 2014;55(4 PG-455-9):455-9.

French Megerlin F, Fouassier E, Lopert R, Bourlioux P. Faecal microbiota transplantation: A sui generis

Page 313 of 454

Gut

1 2	German Hagel S, Stallmach A, Vehreschild M, Angeli W, Bachmann O, Gross M, et al. Fecal microbiota
3 4 5 6 7	transplant in patients with recurrent Clostridium difficile infection - A retrospective multicenter observational study from the MicroTrans registry. [German]. Dtsch Arztebl Int. 2016;113(35-36-583–589):583–9.
8 9 10 11	German Hibbeler B. Clostridium difficile: Fecal bacteriotherapy as an option. Dtsch Arztebl Int. 2016;113(5 PG-A185):A185.
12 13 14	German Liebhardt E, Seufferlein T, Wagner M. Fecal microbiota transplantation for Clostridium difficile infection. [German]. Arzneimitteltherapie. 2016;34(9 PG-285-291):285–91.
15 16 17 18	<i>German</i> Lubbert C, Weis S. [Drug therapy of infectious diarrhea: part 1: acute diarrhea]. Internist. 2013;54(11 PG-1383-92):1383–92.
19 20 21 22	<i>German</i> Lubbert C, Weis S. Drug therapy of infectious diarrhea: Part 1: Acute diarrhea. [German]. Internist. 2013;54(11 PG-1383-1392):1383–92.
23 24 25	<i>German</i> Lubbert C. Fecal microbiota transplantation (FMT): Indications for treatment and future perspectives. [German]. Diabetologe. 2016;12(6 PG-409-419):409–19.
26 27 28 29	German Menzel J. Fecal transplantation for refractory chronic Clostridium difficile infection. [German]. Gastroenterologe. 2013;8(4 PG-336-337):336–7.
30 31 32	German Ramsauer B, Konig C, Sabelhaus T, Ockenga J, Otte JM. Fecal microbiota transplantation in relapsing clostridium difficile colitis. [German]. MMW-Fortschritte der Medizin. 2016;158(PG-17-20):17–20.
 33 34 35 36 37 38 39 40 41 42 	German Rohrenbach J, Matthess A, Maier R, Von Bunau R. Treatment of children with E. coli strain Nissle 1917. Results of a prospective data collection with 668 patients. [German]. Padiatr Prax. 2009;73(4 PG-645-652):645–52.
	German Rohrenbach J, Matthess A, Maier R, Von Bunau R. Treatment of children with E. coli strain Nissle 1917. Results of a prospective data collection with 668 patients. [German]. Padiatr Prax. 2009;73(4 PG-645-652):645–52.
43 44 45 46	German Rosien U, Hagel S, Gotz M. Stool transplant for recurrent Clostridium difficile infection. [German]. Gastroenterologe. 2015;10(2 PG-122-126):122–6.
47 48 49	German Rosien U, Hagel S, Gotz M. Stool transplant for recurrent Clostridium difficile infection. [German]. Gastroenterologe. 2015;10(2 PG-122-126):122–6.
50 51 52 53	German Salzberger B, Rauscher C. [The microbiome of the gut in critically ill patients]. Med Klin Intensivmed Notfmed. 2015;110(7 PG-521-5):521–5.
54 55 56	German Salzberger B, Rauscher C. The microbiome of the gut in critically ill patients. [German]. Medizinische Klin - Intensivmed und Notfallmedizin. 2015;110(7 PG-521-525):521–5.
57 58 59 60	German Schmelz R, Hampe J. [Fecal microbiota transplantation: when and for whom?]. Dtsch Medizinische Wochenschrift. 2014;139(23 PG-1237-9):1237–9.

German Schmitz F. Fecal transplantation is highly effective in the treatment of recurrent Clostridium difficile infection. [German]. Gastroenterologe. 2013;8(1 PG-54-55):54-5. German Seufferlein T, Kleger A, Nitschmann S. Recurrent Clostridium difficile infection. Treatment with duodenal infusion of donor feces. [German]. Internist. 2014;55(4 PG-455-459):455-9. German Stallmach A. [Clostridium difficile infection : What is currently available for treatment?]. Internist. 2016;57(12 PG-1182-1190):1182-90. German Stallmach A. Clostridium difficile infection: What is currently available for treatment?. [German]. Internist. 2016;57(12 PG-1182-1190):1182-90. German Storr M, Starostzik C. [Stool transplantation: also an option for irritable bowel syndrome?]. MMW Fortschr Med. 2014;156(12 PG-16):16. German Storr M. [Donor stool now available in capsules]. MMW Fortschr Med. 2015;157 Suppl 1(PG-32):32. German Trautmann M. Fecal transplantation in Clostridium difficile colitis: New studies about a long-known therapeutic option. [German]. Krankenhauspharmazie. 2013;34(8 PG-414-415):414–5. German U R, S H, M G. Erratum to: Stool transplant for recurrent Clostridium difficile infection [Gastroenterologe, (2015), DOI:10.1007/s11377-014-0962-8]. [German]. Gastroenterologe. 2015;10(2 PG-110):110. German von Muller L. [New aspects on Clostridium difficile infection]. Dtsch Medizinische Wochenschrift. 2016;141(16 PG-1144-7):1144-7. German Von Muller L. New aspects on Clostridium difficile infection. [German]. Dtsch Medizinische Wochenschrift. 2016;141(16 PG-1144-1147):1144-7. German Weis S, John E, Lippmann N, Mossner J, Lubbert C. [Clostridium difficile infection (CDI) in the course of time - an issue only for the internist?]. Zentralbl Chir. 2014;139(4 PG-460-8):460-8. German Zoller V, Laguna AL, Prazeres Da Costa O, Buch T, Goke B, Storr M. [Fecal microbiota transfer (FMT) in a patient with refractory irritable bowel syndrome]. Dtsch Medizinische Wochenschrift. 2015;140(16 PG-1232-6):1232-6. German Zoller V, Laguna AL, Prazeres Da Costa O, Buch T, Goke B, Storr M. Fecal microbiota transfer (FMT) in a patient with refractory irritable bowel syndrome. [German]. Dtsch Medizinische Wochenschrift. 2015;140(16 PG-1232-1236):1232-6. Greek Mentis AFA, Gypas F, Mentis AF. Human enteric microbiome: Its role in health and disease. [Greek]. Arch Hell Med. 2013;30(3 PG-272-288):272-88. Hebrew Israeli E, Shoenfeld Y. [Harnessing nature for treating infectious and autoimmune diseases: good and bad bacteria]. [Hebrew]. Harefuah. 2013;152(4 PG-188-189, 249):188–189,249. Hebrew Israeli E, Shoenfeld Y. [Harnessing nature for treating infectious and autoimmune diseases: good and bad bacteria]. Harefuah. 2013;152(4 PG-188-9, 249):188-189,249.

Gut

1

6

7

8 9 Gut

Hebrew Maharshak N. [Use of fecal microbial transplantations for disease states in Israel]. Harefuah.
 2015;154(3 PG-152-4, 213):152–154,213.

Hebrew Maharshak N. Use of fecal microbial transplantations for disease states in Israel. [Hebrew]. Harefuah. 2015;154(3 PG-152-4, 213):152–154,213.

Hungarian Kovacs G. [To the Editors, regarding feces transplantation]. [Hungarian]. Orv Hetil. 2013;154(11
 PG-434-435):434–5.

Hungarian Kovacs G. [To the Editors, regarding feces transplantation]. Orv Hetil. 2013;154(11 PG-434-5):434–5.

Hungarian Nagy GG, Varvolgyi C, Balogh Z, Orosi P, Paragh G. [Detailed methodological recommendations
 for the treatment of Clostridium difficile-associated diarrhea with faecal transplantation]. Orv Hetil.
 2013;154(1 PG-10-9):10–9.

Hungarian Nagy GG, Varvolgyi C, Balogh Z, Orosi P, Paragh G. Detailed methodological recommendations for
 the treatment of Clostridium diffi cile-associated diarrhea with faecal transplantation. [Hungarian]. Orv Hetil.
 2013;154(1 PG-10-19):10–9.

Hungarian Nagy GG, Varvolgyi C, Paragh G. [Successful treatment of life-threatening, treatment resistant
 Clostridium difficile infection associated pseudomembranous colitis with faecal transplantation]. Orv Hetil.
 2012;153(52 PG-2077-83):2077–83.

Hungarian Szabolcs V, Zsuzsanna N, Aron V, Jen S, David S, Zsofia F, et al. Experience with fecal microbiota
 transplantation in the treatment of clostridium difficile infection. [Hungarian]. Orv Hetil. 2014;155(44 PG 1758-1762):1758–62.

Hungarian Vigvari S, Nemes Z, Vincze A, Solt J, Sipos D, Feiszt Z, et al. [Experience with fecal transplantation
 in the treatment of Clostridium difficile infection]. Orv Hetil. 2014;155(44 PG-1758-62):1758–62.

HungarianNagy GG, Varvolgyi C, Paragh G. [Successful treatment of life-threatening, treatment resistant
 Clostridium difficile infection associated pseudomembranous colitis with faecal transplantation].
 [Hungarian]. Orv Hetil. 2012;153(52 PG-2077-2083):2077–83.

Italian Russello G, Brovarone F, Bardaro M, Carretto E. Treating Clostridium difficile infection with faecal
 transplantation: Donor microbiological testing. Infez Med. 2014;22(1 PG-5-10):5–10.

Japanese akamur I, Kunihiro M, Kato H. Bacteremia due to Clostridium difficile. [Japanese]. Kansenshogaku
 zasshi. 2004;The Journal of the Japanese Association for Infectious Diseases. 78(12 PG-1026-1030):1026–30.

Japanese Nakamur I, Kunihiro M, Kato H. [Bacteremia due to Clostridium difficile]. Kansenshogaku Zasshi - J
 Japanese Assoc Infect Dis. 2004;78(12 PG-1026-30):1026–30.

Japenese Ohkusa T, Koido S. [Gut Microbiota and Internal Diseases: Update Information. Topics: II. Fecal microbiota transplantation and its clinical application]. Nippon Naika Gakkai Zasshi - J Japanese Soc Intern Med. 2015;104(1 PG-42-7):42–7.

59 60

PG-1973-81):1973-81. Japense Suzuki K, Kitahora T, Yokota A. Clinical studies of acute hemorrhagic colitis associated with antibiotic therapy. 3. Fecal bacterial flora and fecal short chain fatty acids. [Japanese]. IRYO - Japanese J Natl Med Serv. 1984;38(6 PG-570-576+543-544):570-576+543. Korean Kim SW. [Treatment of refractory or recurrent Clostridium difficile infection]. Korean J Gastroenterol Sohwagi Hakhoe Chi. 2012;60(2 PG-71-8):71-8. Korean Kim SW. [Treatment of refractory or recurrent Clostridium difficile infection]. [Korean]. Korean J Gastroenterol. 2012;60(2 PG-71-78):71-8. Korean Ko JS. [The intestinal microbiota and human disease]. [Korean]. Korean J Gastroenterol. 2013;62(2 PG-85-91):85-91. Korean Ko JS. [The intestinal microbiota and human disease]. Korean J Gastroenterol Sohwagi Hakhoe Chi. 2013;62(2 PG-85-91):85-91. Norwegian Lund-Tonnesen S, Berstad A, Schreiner A, Midtvedt T. [Clostridium difficile-associated diarrhea treated with homologous feces]. Tidsskr Den Nor Laegeforening. 1998;118(7 PG-1027-30):1027-30. Norwegian Lund-Tonnesen S, Berstad A, Schreiner A, Midtvedt T. Clostridium difficile-associated diarrhoea treated with homologous faeces. [Norwegian]. Tidsskr Den Nor Laegeforening. 1998;118(7 PG-1027-1030):1027-30. Polish Malopolska M, Fol M. [Intestinal microbiota transplantation for the treatment of Clostridium difficile infection]. Med Dosw Mikrobiol. 2015;67(3-4-207-19):207-19. Polish Malopolska M, Fol M. Intestinal microbiota transplantation for the treatment of Clostridium difficile infection. [Polish]. Med Dosw Mikrobiol. 2015;67(3-4-207–219):207–19. Polish Piekarska M, Wandalowicz AD, Miigoc H. [Clostridium difficile infection--diagnostics, prevention and treatment]. Pol Merkur Lek. 2014;36(214 PG-278-82):278-82. Polish Piekarska M, Wandalowicz AD, Miigoc H. [Clostridium difficile infection--diagnostics, prevention and treatment]. [Polish]. Pol Merkur Lekarski. 2014;36(214 PG-278-282):278-82. Polish Rebizak E, Sierant K, Labuzek K, Okopien B. [Fecal transplantation the future therapy?]. Pol Merkur Lek. 2015;39(230 PG-73-6):73-6. Serbian Suljagic V, Djordjevic D, Lazic S, Mijovic B. [Epidemiological characteristics of nosocomial diarrhea caused by Clostridium difficile in a tertiary level hospital in Serbia]. Srp Arh Celok Lek. 2013;141(7-8-482-9):482-9. Serbian Suljagic V, Djordjevic D, Lazic S, Mijovic B. Epidemiological characteristics of nosocomial diarrhea caused by Clostridium difficile in a tertiary level hospital in Serbia. [Serbian]. Srp Arh Celok Lek. 2013;141(7-8-482-489):482-9.

Japenese Osada T, Ishikawa D, Watanabe S. [Fecal microbiota transplantation therapy for patients with

gastrointestinal tract diseases]. Nippon Shokakibyo Gakkai Zasshi - Japanese J Gastroenterol. 2015;112(11

Page 317 of 454

Slovakian Sturdik I, Hlavaty T, Payer J. [Fecal microbiota transplantation]. Vnitr Lek. 2016;62(2 PG-147-51):147-51. Slovakian Sturdik I, Hlavaty T, Payer J. Fecal microbiota transplantation. [Slovak]. Vnitr Lek. 2016;62(2 PG-147-151):147-51. Spanish Garcia-Garcia-de-Paredes A, Rodriguez-de-Santiago E, Aguilera-Castro L, Ferre-Aracil C, Lopez-Sanroman A. Fecal microbiota transplantation. [Spanish]. Gastroenterol Hepatol. 2015;38(3 PG-123-134):123-34. Spanish Halabe Cherem J, Hoyo Ulloa I. [Successful home-made fecal transplant for an elderly woman]. Gac Med Mex. 2014;150(1 PG-106-7):106-7. Spanish Hernandez-Rocha C, Pidal P, Ajenjo MC, Quera R, Quintanilla M, Lubascher J, et al. [Chilean consensus of prevention, diagnosis and treatment of Clostridium difficile-associated diarrhea]. Rev Chil Infectol. 2016;33(1 PG-98-118):98-118. Spanish Montejano Sanchez R. Duodenal infusion of donor feces for recurrent Clostridium difficile. [Spanish]. Rev Clin Esp. 2013;213(4 PG-213):213. Spanish Moscoso F, Simian D, Rivera D, Acuna G, Quera R. [Fecal microbiota transplantation in recurrent Clostridium difficile infection. Report of one case]. Rev Med Chil. 2015;143(4 PG-531-5):531–5. Spanish Moscoso F, Simian D, Rivera D, Acuna G, Quera R. Fecal microbiota transplantation in recurrent Clostridium difficile infection. Report of one case. [Spanish]. Rev Med Chil. 2015;143(4 PG-531-535):531–5. Spanish Munez E, Ramos A, Banos I, Cuervas-Mons V. [Fecal transplantation for the treatment of relapsing diarrhea associated with Clostridium difficile infection in a liver transplantation patient]. Med Clin (Barc). 2016;146(1 PG-e3-4):e3-4. Spanish Pareja-Sierra T. [Diarrhea associated with Clostridium difficile in the elderly: new perspectives]. Rev Esp Geriatr Gerontol. 2014;49(4 PG-188-93):188–93. Spanish Pareja-Sierra T. Diarrhea associated with Clostridium difficile in the elderly: New perspectives. [Spanish]. Rev Esp Geriatr Gerontol. 2014;49(4 PG-188-193):188–93. Spanish: Munez E, Ramos A, Banos I, Cuervas-Mons V. Fecal transplantation for the treatment of relapsing diarrhea associated with Clostridium difficile infection in a liver transplantation patient. [Spanish]. Med Clin (Barc). 2016;146(1 PG-e3-e4):e3-4. Swiss Giger A, Barberini L, Bruchez P, Castioni J, Claude F, Cosma Rochat M, et al. [General internal medicine in hospital practice: the year 2013 put into perspective by residents]. Rev Med Suisse. 2014;10(414 PG-164, 166-70):164,166-170. D.1.6. Basic sciences:

Basic scilhekweazu F, Fofanova T, Nagy-Szakal D, Hulten K, Queliza K, Opekun A, et al. Complex and defined bacteriotherapy can inhibit acute colitis in mice. J Pediatr Gastroenterol Nutr. 2016;63(PG-S277-S278):S277–8.

Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol. 2010;44(8 PG-551-561):551–61.

Gu S, Chen Y, Zhang X, Lu H, Lv T, Shen P, et al. Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population. Microbes Infect. 2016;18(1 PG-30-38):30–8.

Halpin AL, de Man TJ, Kraft CS, Perry KA, Chan AW, Lieu S, et al. Intestinal microbiome disruption in patients
 in a long-term acute care hospital: A case for development of microbiome disruption indices to improve
 infection prevention. Am J Infect Control. 2016;44(7 PG-830-6):830–6.

Halpin AL, de Man TJB, Kraft CS, Perry KA, Chan AW, Lieu S, et al. Intestinal microbiome disruption in patients
 in a long-term acute care hospital: A case for development of microbiome disruption indices to improve
 infection prevention. Am J Infect Control. 2016;44(7 PG-830-836):830–6.

Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. High-throughput DNA sequence analysis
 reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria.
 Gut Microbes. 2013;4(2):125–35.

Hecker MT, Obrenovich ME, Cadnum JL, Jencson AL, Jain AK, Ho E, et al. Fecal microbiota transplantation by
 freeze-dried oral capsules for recurrent clostridium difficile infection. Open Forum Infect Dis. 2016;3 (2) (no
 pagination)(ofw091 PG-).

Hevia A, Delgado S, Margolles A, Sanchez B. Application of density gradient for the isolation of the fecal
 microbial stool component and the potential use thereof. Sci Rep. 2015;5(PG-16807):16807.

Jalanka J, Mattila E, Jouhten H, Hartman J, de Vos WM, Arkkila P, et al. Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection. BMC Med. 2016;14 (1) (no pagination)(155 PG-).

Khanna S, Montassier E, Patel R, Kammer PP, Knights D, Pardi D, et al. Gut microbiome signatures at the time
 of primary clostridium difficile infection predict recurrence. Gastroenterology. 2016;1)(PG-S23):S23.

Khanna S, Montassier E, Schmidt B, Lynch D, Bernard C, Lekatz H, et al. Gut microbiota changes as predictors
 of treatment failure in primary clostridium difficile infection. Am J Gastroenterol. 2015;110(PG-S578):S578.

Khanna S, Vazquez-Baeza Y, Gonzalez A, Weiss S, Schmidt B, Muniz-Pedrogo D, et al. Changes in microbial
 ecology after fecal microbiota transplantation for recurrent C. Difficile infection depends on underlying
 inflammatory bowel disease. Am J Gastroenterol. 2016;111(PG-S75):S75.

Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome
 after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol.
 2010;44(5):354–60.

58 59

53

59 60

1 2

3

4 5

6 7

8

9 10

11 12

13

23

Gut

- Kumar R, Maynard CL, Eipers P, Goldsmith KT, Ptacek T, Grubbs JA, et al. Colonization potential to reconstitute a microbe community in patients detected early after fecal microbe transplant for recurrent C. difficile. BMC Microbiol. 2016;16 (1) (no pagination)(5 PG-).
- Kumar V, Zhou E, Mansoor MS, Feuerstadt P. Treatment of initial recurrence of C. Difficile infection (CDI) with vancomycin may not prevent eventual need for fecal microbial transplantation (FMT). Am J Gastroenterol. 2016;111(PG-S93):S93.
- Landy J, Walker AW, Li J V, Al-Hassi HO, Ronde E, English NR, et al. Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis. Sci Rep. England; 2015;5:12955.
- Li SS, Zhu A, Benes V, Costea PI, Hercog R, Hildebrand F, et al. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science (80-). 2016;352(6285 PG-586-589):586-9.
- Lichtman JS, Ferreyra JA, Ng KM, Smits SA, Sonnenburg JL, Elias JE. Host-Microbiota Interactions in the Pathogenesis of Antibiotic-Associated Diseases. Cell Rep. 2016;14(5 PG-1049-1061):1049-61.
- Likotrafiti E, Manderson KS, Fava F, Tuohy KM, Gibson GR, Rastall RA. Molecular identification and anti-pathogenic activities of putative probiotic bacteria isolated from faeces of healthy elderly individuals. Microb Ecol Health Dis. 2004;16(2-3-105-112):105-12.
- Lofgren ET, Moehring RW, Anderson DJ, Weber DJ, Fefferman NH. A mathematical model to evaluate the routine use of fecal microbiota transplantation to prevent incident and recurrent clostridium difficile infection. Infect Control Hosp Epidemiol. 2014;35(1 PG-18-27):18-27.
- Low DE, Shahinas D, Silverman M, Sittler T, Chiu C, Kim P, et al. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16s rRNA gene deep sequencing. MBio. 2012;3(5 PG-).
- Luna R, Pitashny M, Runge J, Shang Y, Hollister E, Nagy-Szakal D, et al. Microbiome characterization as a diagnostic tool in fecal microbiome transplantation. J Mol Diagnostics. 2013;15 (6)(PG-874-875):874–5.
- Millan B, Hotte N, Mathieu O, Burguiere P, Tompkins TA, Kao D, et al. Effects of fecal microbial transplantation on the gut resistome in patients with recurrent clostridium difficile infection. Gastroenterology. 2015;1)(PG-S120):S120.
- Millan B, Park H, Hotte N, Fedorak R, Kao D, Madsen K. Antibiotics and bowel preparation enhance the ability of fecal microbial transplantation to reshape the gut microbiota in IL-10^{-/-} mice. Can J Gastroenterol Hepatol Conf. 2016; (pagination PG-).
- Millan B, Park H, Hotte N, Mathieu O, Burguiere P, Tompkins TA, et al. Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients with Recurrent Clostridium difficile Infection. Clin Infect Dis. 2016;62(12 PG-1479-1486):1479-86.
- Moelling K, Broecker F. Fecal microbiota transplantation to fight Clostridium difficile infections and other intestinal diseases. Bacteriophage. 2016;18(PG-).

Murdoch DA, Gibbs S, Price CGA, Easmon S, Franklin J, Lister TA, et al. Effect of ceftazidime and gentamicin on the oropharyngeal and faecal flora of patients with haematological malignancies. J Antimicrob Chemother. 1990;26(3 PG-419-428):419-28.

Nord CE, Kager L, Philipson A, Stiernstedt G. Impact of imipenem/cilastatin therapy on faecal flora. Eur J Clin Microbiol. 1984;3(5 PG-475-477):475-7.

Peer X, An G. Agent-based model of fecal microbial transplant effect on bile acid metabolism on suppressing clostridium difficile infection: An example of agent-based modeling of intestinal bacterial infection. J Pharmacokinet Pharmacodyn. 2014;41(5 PG-493-507):493-507.

Schenck LP, Hirota S, Armstrong G, MacDonald J, Beck P. Investigating the effect of antibiotics on gut microbiota components and subsequent Clostridium difficile infection. FASEB Journal Conf Exp Biol. 2014;28(1 SUPPL. 1 PG-).

Schenck LP, Hirota SA, Armstrong GD, MacDonald JA, Beck PL. Elucidating intestinal microbiota components that play a protective or deleterious role during clostridium difficile infections. Gastroenterology. 2013;1)(PG-S185):S185.

Seekatz AM, Aas J, Gessert CE, Rubin TA, Saman DM, Bakken JS, et al. Recovery of the gut microbiome following fecal microbiota transplantation. MBio. 2014;5(3):e00893-14.

Seekatz AM, Rao K, Santhosh K, Young VB. Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. Genome Med. 2016;8 (1) (no pagination)(47 PG-).

Seekatz AM, Theriot CM, Molloy CT, Wozniak KL, Bergin IL, Young VB. Fecal microbiota transplantation eliminates Clostridium difficile in a murine model of relapsing disease. Infect Immun. 2015;83(10 PG-3838-3846):3838-46.

Shanahan F. Separating the microbiome from the hyperbolome. Genome Med. 2015;7 (1) (no pagination)(17 PG-).

Shankar V, Hamilton MJ, Khoruts A, Kilburn A, Unno T, Paliy O, et al. Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome. 2014;2 (1) (no pagination)(13 PG-).

Soma G, Inagawa H. Methods to Prevent or Treat Refractory Diseases by Focusing on Intestinal Microbes Using LPS and Macrophages. Anticancer Res. 2015;35(8 PG-4393-6):4393–6.

Song Y, Garg S, Girotra M, Maddox C, Von Rosenvinge EC, Dutta A, et al. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One. 2013;8 (11) (no pagination)(e81330 PG-).

Song Y, Garg S, Girotra M, Maddox C, Von Rosenvinge EC. Correction: Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection (PLoS ONE (2013) 8, 11 (e81330) DOI: 10.1371/journal.pone.0081330). PLoS One. 2014;9 (7) (no pagination)(e104471 PG-).

Spinler JK, Brown A, Ross CL, Boonma P, Conner ME, Savidge TC. Administration of probiotic kefir to mice with Clostridium difficile infection exacerbates disease. Anaerobe. 2016;40(PG-54-7):54-7.

Page 321 of 454

1 2

3

4 5 6

7

8

9

34

39

40 41

46 47 48

49

Tian Z, Liu J, Liao M, Li W, Zou J, Han X, et al. Beneficial Effects of Fecal Microbiota Transplantation on Ulcerative Colitis in Mice. Dig Dis Sci. 2016;61(8 PG-2262-2271):2262–71.

Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, et al. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(4 PG-387-94):387–94.

 Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, et al. Donor Species Richness Determines
 Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. J Crohn's Colitis. 2016;10(4 PG-387-394):387–94.

Villafuerte-Galvez JA, Patel IJ, Xu H, Yang X, Chen X, Kelly CP. Elevated serum IL-27 concentrations predict
 adverse outcomes in clostridium difficile associated diarrhea. Gastroenterology. 2014;1)(PG-S253 S254):S253–4.

Weingarden A, Gonzalez A, Vazquez-Baeza Y, Weiss S, Humphry G, Berg-Lyons D, et al. Dynamic changes in
 short- and long-term bacterial composition following fecal microbiota transplantation for recurrent
 Clostridium difficile infection. Microbiome. 2015;3 (1) (no pagination)(10 PG-).

Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, et al. Microbiota transplantation restores normal
 fecal bile acid composition in recurrent Clostridium difficile infection. AJP Gastrointest Liver Physiol. 2014
 Feb 15;306(4):G310–9.

Weingarden AR, Chen C, Zhang N, Graiziger CT, Dosa PI, Steer CJ, et al. Ursodeoxycholic acid inhibits clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J Clin Gastroenterol. 2016;50(8 PG-624-630):624–30.

Weingarden AR, Dosa PI, DeWinter E, Steer CJ, Shaughnessy MK, Johnson JR, et al. Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control Clostridium difficile germination and growth. PLoS One. 2016;11 (1) (no pagination)(e0147210 PG-).

Weingarden AR, Hamilton MJ, Sadowsky MJ, Khoruts A. Resolution of severe clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol. 2013;47(8 PG-735-737):735–7.

D.1.7. Narrative reviews

Actis GC. The gut microbiome. Inflamm Allergy - Drug Targets. 2014;13(4 PG-217-223):217–23.

Adamu BO, Lawley TD. Bacteriotherapy for the treatment of intestinal dysbiosis caused by Clostridium difficile infection. Curr Opin Microbiol. 2013;16(5 PG-596-601):596–601.

Agito MD, Atreja A, Rizk MK. Fecal microbiota transplantation for recurrent C difficile infection: Ready for prime time? Cleve Clin J Med. 2013;80(2 PG-101-108):101–8.

Allegretti JR, Hamilton MJ, J.R. A, M.J. H, Allegretti JR, Hamilton MJ. Restoring the gut microbiome for the
 treatment of inflammatory bowel diseases. World J Gastroenterol. M. J. Hamilton, Division of

Gut

Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. J Vis Exp. MyJoVE Corporation; 2014 Dec;(94). Allegretti JR, Phelps E, Xu H, Kassam Z, Fischer M. Redefining cure in clostridium difficile infection: Clinical assessment 4 weeks after fecal microbiota transplantation is predictive of standard 8-week cure endpoint. Am J Gastroenterol. 2016;111(PG-S56):S56. Allen-Vercoe E, Petrof EO. Artificial stool transplantation: Progress towards a safer, more effective and acceptable alternative. Expert Rev Gastroenterol Hepatol. 2013;7(4 PG-291-293):291-3. Allen-Vercoe E, Reid G, Viner N, Gloor GB, Hota S, Kim P, et al. A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics. Can J Gastroenterol. 2012;26(7 PG-457-462):457–62. Almeida R, Gerbaba T, Petrof EO. Recurrent Clostridium difficile infection and the microbiome. J Gastroenterol. 2016;51(1 PG-1-10):1-10. Amirtha T. MICROBIOME RESEARCH. Banking on stool despite an uncertain future. Science (80-). 2016;352(6291 PG-1261-2):1261-2. Anand R, Girotra M, Garg S, Dutta S. Safety and efficacy of fecal microbiota transplantation (FMT) for recurrent clostridium difficile infection (RCDI) in septuagenarians, octogenarians, and nonegenarians: A single-center experience. Am J Gastroenterol. 2014;109(PG-S195):S195. Anderson JL, Edney RJ, Whelan K. Systematic review: Faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36(6 PG-503-516):503-16. Anonymous. Donor faeces for recurrent Clostridium difficile diarrhoea? BMJ. 2013;346 (no pagination)(f376 PG-). Anonymous. Faecal microbiota transplantation. Drug Ther Bull. 2014;52(12 PG-141-144):141–4. Anonymous. Faecal microbiota transplantation. Drug Ther Bull. 2014;52(12 PG-141-144):141–4. Anonymous. Fecal microbiota therapy for Clostridium difficile infection: A health technology assessment. Ont Health Technol Assess Ser. 2016;16(17 PG-). Anonymous. Fecal microbiota transplantation for treating recurrent Clostridium difficile infection. OR Manager. 2012;28(8 PG-15-18):15-8. Anonymous. Fecal microbiota transplantation for treating recurrent Clostridium difficile infection. Manag Care. 2013;22(6 PG-18-19):18-9. Anonymous. Fecal microbiota transplantation for treatment of recurrent C. difficile infection. Clin Privil White Pap. 2013;(246 PG-1-15):1-15.

Gastroenterology, Brigham and Women's Hospital and Harvard Medical School, 75 Francis St, Boston, MA

02115, United States. E-mail: mjhamilton@partners.org: WJG Press; 2014;20(13):3468-74.

Page 323 of 454

Anonymous. Fecal microbiota transplantation: Where is it leading? Gastroenterol Hepatol. 2014;10(5 PG-307-309):307-9. Anonymous. Fecal microbiota transplantation: Where is it leading? Gastroenterol Hepatol. 2014;10(5 PG-307-309):307-9. Anonymous. Infection: FMT: a safe treatment for Clostridium difficile infection in immunocompromised patients. Nat Rev Gastroenterol Hepatol. 2014;1(PG-). Anonymous. More on faecal microbiota transplantation. Drug Ther Bull. 2015;53(7 PG-76-77):76–7. Anonymous. More on faecal microbiota transplantation. Drug Ther Bull. 2015;53(7 PG-76-77):76–7. Anonymous. Novel therapy for C. difficile infections. Infusions of donated feces may help those with recurrent infections. Harv Health Lett. 2011;36(12 PG-7):7. Anonymous. Probiotics are beneficial in Clostridium difficile infection: Healthy microbiota by probiotics or fecal transplantation prevent diarrhea. [Dutch]. Pharm Weekbl Wet Platf. 2014;149(10 PG-). Anonymous. Solving a C.difficile problem. If antibiotics fail, a stool transplant can help cure a severe infection. Johns Hopkins Med Lett Health After 50. 2014;25(13 PG-3):3. Anonymous. Solving a C.difficile problem. If antibiotics fail, a stool transplant can help cure a severe infection. Johns Hopkins Med Lett Health After 50. 2014;25(13 PG-3):3. Anonymous. Therapy: FMT effective in patients with severe and/or complicated CDI. Nat Rev Gastroenterol Hepatol. 2015;21(PG-). Anonymous. Therapy: FMT effective in patients with severe and/or complicated CDI. Nat Rev Gastroenterol Hepatol. 2015;21(PG-). Anonymous. Treat Clostridium difficile infection based on its severity and number of previous episodes. Drugs Ther Perspect. 2012;28(2 PG-10-13):10-3. Antonopoulos DA, Chang EB. Transplanting a microbial organ: The good, the bad, and the unknown. MBio. 2016;7 (3) (no pagination)(e00572-16 PG-). Apostolescu C, Moroti R, Molagic V, Gheorghite V, Telepan D, Popoiu M, et al. Gut microbiota and its complex role. The experience of the national institute for infectious diseases Prof. Dr. Matei Bals in fecal bacteriotherapy for Clostridium difficile infection. BMC Infect Dis Conf 9th Ed Sci Days Natl Inst Infect Dis "Prof Dr Matei Bals" Rom Conf Start. 2013;13(no pagination PG-). Aroniadis OC, Brandt LJ, Greenberg A, Borody TJ, Kelly C, Mellow M, et al. Long-term follow-up study of fecal microbiota transplantation (FMT) for severe or complicated clostridium difficile infection (CDI). Gastroenterology. 2013;1)(PG-S185):S185. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013;29(1):79-84.

2013;29(1):79-84. Aroniadis OC, Brandt LJ. Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease. Gastroenterol Hepatol. 2014;10(4 PG-230-237):230-7. Austin M, Mellow M, Tierney WM. Fecal microbiota transplantation in the treatment of clostridium difficile infections. Am J Med. 2014;127(6 PG-479-483):479-83. Avery L, Hasan M. Fecal bacteriotherapy for clostridium difficile infections - its time has come. Clin Microbiol Newsl. 2013;35(15 PG-119-124):119-24. Badger VO, Ledeboer NA, Graham MB, Edmiston CE. Clostridium difficile: Epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. J Parenter Enter Nutr. 2012;36(6 PG-645-662):645-62. Bafeta A, Yavchitz A, Riveros C, Batista R, Ravaud P. Methods and Reporting Studies Assessing Fecal Microbiota Transplantation: A Systematic Review. Ann Intern Med. 2017;167(1):34-9. Bagdasarian, N.; Rao, K.; Malani, P. N. Diagnosis and treatment of clostridium difficile in adults: A systematic review. Journal of the American Medical Association 27 Jan 2015;313(4):398-408 Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe. 2009;15(6):285–9. Bakken JS. Feces transplantation for recurrent Clostridium difficile infection: US experience and recommendations. Microb Ecol Heal Dis. 2015;26(PG-27657):27657. Bakken JS. Staggered and tapered antibiotic withdrawal with administration of kefir for recurrent Clostridium difficile infection. Clin Infect Dis. 2014;59(6 PG-858-861):858–61. Balzola F, Cullen G, Ho GT, Russell R. Fecal microbiota transplantation: Indication, methods, evidence and further directions: Commentary. Inflamm Bowel Dis Monit. 2014;14(2 PG-56-57):56–7. Barbut F, Collignon A, Butel MJ, Bourlioux P. [Fecal microbiota transplantation: review]. Ann Pharm Fr. 2015;73(1 PG-13-21):13-21. Barbut F, Collignon A, Butel MJ, Bourlioux P. Fecal microbiota transplantation: Review. [French]. Ann Pharm Fr. 2015;73(1 PG-13-21):13-21. Barbut F, Guery B, Eckert C. How to treat Clostridium difficile infections in 2014?. [French]. Reanimation. 2014;23(3 PG-284-297):284-97. Barbut F. Alleviating the burden of CDI: Current and emerging treatment options. Int J Antimicrob Agents. 2013;42(PG-S11):S11. Barnes D, Park KT. Donor Considerations in Fecal Microbiota Transplantation. Current Gastroenterology Reports. 2017;19 (3) (no pagination)(10).

Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol.

Page 325 of 454

- Baron TH, Kozarek RA. Fecal microbiota transplant: We know its history, but can we predict its future? Mayo Clin Proc. 2013;88(8 PG-782-785):782-5. Bartnicka A, Szachta P, Galecka M. Faecal microbiota transplant - prospects and safety. Pomeranian J life Sci. 2015;61(3 PG-282-286):282-6. Batista R, Kapel N, Megerlin F, Chaumeil JC, Barbut F, Bourlioux P, et al. [Fecal microbiota transplantation in recurrent Clostridium difficile infections. Framework and pharmaceutical preparation aspects]. Ann Pharm Fr. 2015;73(5 PG-323-31):323-31. Batista R, Kapel N, Megerlin F, Chaumeil JC, Barbut F, Bourlioux P, et al. Fecal microbiota transplantation in recurrent Clostridium difficile infections. Framework and pharmaceutical preparation aspects. [French]. Ann Pharm Fr. 2015;73(5 PG-323-331):323-31. Bauer MP, van Dissel JT. Alternative strategies for Clostridium difficile infection. Int J Antimicrob Agents. 2009;33(SUPPL. 1 PG-S51-S56):S51-6. Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of the literature. J Hosp Infect. 2016 Feb;92(2):117-27. Benes J, Husa P, Nyc O, Polivkova S. [Diagnosis and therapy of Clostridium difficile infection: Czech national guidelines]. Klin Mikrobiol Infekc Lek. 2014;20(2 PG-56-66):56–66. Benes J, Husa P, Nyc O, Polivkova S. Diagnosis and therapy of Clostridium difficile infection: Czech national guidelines. [Croatian]. Klin Mikrobiol Infekc Lek. 2014;20(2 PG-56-66):56–66. Benes J, Husa P, Nyc O. [Recommendations for diagnosis and therapy of colitis caused by Clostridium difficile]. Klin Mikrobiol Infekc Lek. 2012;18(5 PG-160-7):160-7. Benes J, Husa P, Nyc O. [Recommendations for diagnosis and therapy of colitis caused by Clostridium difficile]. [Czech]. Klin Mikrobiol Infekc Lek. 2012;18(5 PG-160-167):160-7. Berg AM, Farraye FA. Duodenal infusion of stool is more effective than vancomycin in patients with recurrent Clostridium difficile. Evid Based Med. 2013;18(6 PG-220-221):220-1. Berg D, Clemente JC, Colombel JF. Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome? Expert Rev Gastroenterol Hepatol. 2015;9(6 PG-781-795):781–95. Biehl L. Fecal microbiota transfer. Transfusion Medicine and Hemotherapy. 2017;44 (Supplement 1):22. Biltaji E, Varier R, Smith K, Roberts M, Lafleur J, Nelson RE. Cost-effectiveness analysis of treatment strategies for initial clostridium difficile infection. Value Heal. 2014;17 (3)(PG-A38):A38. Blackburn LM, Bales A, Caldwell M, Cordell L, Hamilton S, Kreider H. Fecal microbiota transplantation in patients with cancer undergoing treatment. Clin J Oncol Nurs. 2015;19(1 PG-111-4):111-4.
- Bloukh SI. Clostridium difficile infection: An overview of the disease and its pathogenesis, diagnosis, treatment, prevention and management. Res J Pharm Biol Chem Sci. 2013;4(4 PG-1219-1232):1219–32.

Bojanova DP, Bordenstein SR. Fecal Transplants: What Is Being Transferred? PLoS Biol. 2016;14 (7) (no pagination)(e1002503 PG-). Bookstaver PB, Ahmed Y, Millisor VE, Siddiqui W, Albrecht H. Clostridium difficile: case report and concise review of fecal microbiota transplantation. J S C Med Assoc. 2013;109(2 PG-62-66):62–6. Borgia G, Maraolo AE, Foggia M, Buonomo AR, Gentile I. Fecal microbiota transplantation for Clostridium difficile infection: Back to the future. Expert Opin Biol Ther. 2015;15(7 PG-1001-1014):1001-14. Borody T, Fischer M, Mitchell S, Campbell J. Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead. Expert Rev Gastroenterol Hepatol. 2015;9(11 PG-1379-1391):1379–91. Borody T, Torres M, Campbell J, Leis S, Nowak A. Reversal of inflammatory bowel disease (IBD) with recurrent faecal microbiota transplants (FMT). Am J Gastroenterol. 2011;106(PG-S366):S366. Borody T, Wettstein A, Campbell J, Leis S, Torres M, Finlayson S, et al. Fecal microbiota transplantation in ulcerative colitis: Review of 24 years experience. Am J Gastroenterol. 2012;107(PG-S665):S665. Borody TJ, Brandt LJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: A new standard treatment option for Clostridium difficile infection. Expert Rev Anti Infect Ther. 2013;11(5 PG-447-449):447-9. Borody TJ, Brandt LJ, Paramsothy S. Therapeutic faecal microbiota transplantation: Current status and future developments. Curr Opin Gastroenterol. 2014;30(1 PG-97-105):97–105. Borody TJ, Brandt LJ, Paramsothy S. Therapeutic faecal microbiota transplantation: Current status and future developments. Curr Opin Gastroenterol. 2013;19(PG-). Borody TJ, Campbell J. Fecal microbiota transplantation: Current status and future directions. Expert Rev Gastroenterol Hepatol. 2011;5(6 PG-653-655):653–5. Borody TJ, Campbell J. Fecal Microbiota Transplantation. Techniques, Applications, and Issues. Gastroenterol Clin North Am. 2012;41(4):781–803. Borody TJ, Campbell J. Fecal Microbiota Transplantation. Techniques, Applications, and Issues. Gastroenterol Clin North Am. 2012;41(4):781–803. Borody TJ, Connelly N, Mitchell SW. Fecal microbiota transplantation in gastrointestinal diseases: What practicing physicians should know. Pol Arch Med Wewn. 2015;125(11 PG-852-858):852-8. Borody TJ, Finlayson S, Paramsothy S. Is Crohn's disease ready for fecal Microbiota transplantation? J Clin Gastroenterol. 2014;48(7 PG-582-583):582-3. Borody TJ, Finlayson S. Fecal microbiota transplantation for Clostridium difficile infection: A surgeon's perspective. Semin Colon Rectal Surg. 2014;25(3 PG-163-166):163-6. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2012;9(2 PG-88-96):88-96.

Gut

Page 327 of 454

1 2 Gut

2 3 4 5	Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2011;20(PG-).
5 6 7 8	Borody TJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: Indications, methods, evidence, and future directions. Curr Gastroenterol Rep. 2013;15(8):1–7.
o 9 10 11	Borody TJ, Peattie D, Kapur A. Could fecal microbiota transplantation cure all Clostridium difficile infections? Future Microbiol. 2014;9(1 PG-1-3):1–3.
12 13 14	Borody TJ, Peattie D, Mitchell SW. Fecal microbiota transplantation: Expanding horizons for Clostridium
15 16 17	difficile infections and beyond. Antibiotics. 2015;4(3 PG-254-266):254–66. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with
18 19 20	human motions. J Clin Gastroenterol. 2004;38(6):475–83.
21 22 23	Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol. 2004;38(6):475–83.
24 25 26	Bourlioux P, workgroup of the French Academy of P. Faecal microbiota transplantation: Key points to consider. Ann Pharm Fr. 2015;73(3 PG-163-8):163–8.
27 28 29 30	Bourlioux P. Faecal microbiota transplantation: Key points to consider. Ann Pharm Fr. 2015;73(3 PG-163-168):163–8.
31 32 33 34	Bowman KA, Broussard EK, Surawicz CM. Fecal microbiota transplantation: Current clinical efficacy and future prospects. Clin Exp Gastroenterol. 2015;8(PG-285-291):285–91.
35 36 37	Boyle ML, Ruth-Sahd LA, Zhou Z. Fecal microbiota transplant to treat recurrent Clostridium difficile infections. Crit Care Nurse. 2015;35(2 PG-51-64; quiz 65):51–64; quiz 65.
38 39 40 41	Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: Techniques, indications, and outcomes. Gastrointest Endosc. 2013;78(2 PG-240-249):240–9.
42 43 44	Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: "First-line" treatment for severe clostridium difficile infection? J Clin Gastroenterol. 2011;45(8 PG-655-657):655–7.
45 46 47 48	Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent Clostridium difficile infection. J Clin Gastroenterol. 2011;45(SUPPL. 3 PG-S159-S167):S159–67.
49 50 51 52	Brandt LJ. Fecal microbiota transplant Respice, Adspice, Prospice. J Clin Gastroenterol. 2015;49(PG-S65-S68):S65–8.
53 54 55	Brandt LJ. Fecal transplantation for the treatment of Clostridium difficile infection. Gastroenterol Hepatol. 2012;8(3 PG-191-194):191–4.
56 57 58	Brandt LJ. FMT: First step in a long journey. Am J Gastroenterol. 2013;108(8 PG-1367-1368):1367–8.
59 60	Brezina J, Bajer L, Spicak J, Draatich P. Faecal microbial transplantation in inflammatory bowel disease. [Czech]. Gastroenterol a Hepatol. 2016;70(1 PG-51-56):51–6.

2016;25(1 PG-76-84):76-84. Broecker F, Klumpp J, Moelling K. Long-term microbiota and virome in a Zurich patient after fecal transplantation against Clostridium difficile infection. Ann New York Acad Sci. 2016; (PG-). Brown WR. Fecal microbiota transplantation in treating Clostridium difficile infection. J Dig Dis. 2014;15(8 PG-405-408):405-8. Burke KE, Lamont JT. Fecal transplantation for recurrent clostridium difficile infection in older adults: A review. J Am Geriatr Soc. 2013;61(8 PG-1394-1398):1394-8. Burton, H. E.; Mitchell, S. A.; Watt, M. The cost effectiveness of treatments for clostridium difficile infection: A systematic review. Value in Health May 2016;19 (3)():A218 Cammarota G, Ianiro G, Bibbo S, Gasbarrini A. Fecal microbiota transplantation a new old kid on the block for the management of gut microbiota-related disease. J Clin Gastroenterol. 2014;48(PG-S80-S84):S80-4. Cammarota G, Ianiro G, Bibbo S, Gasbarrini A. Gut microbiota modulation: probiotics, antibiotics or fecal microbiota transplantation? Intern Emerg Med. 2014;9(4 PG-365-373):365-73. Cammarota, G.; Ianiro, G.; Gasbarrini, A. Fecal microbiota transplantation for the treatment of clostridium difficile infection: A systematic reviewJournal of Clinical Gastroenterology September 2014;48(8):693-702 Cammarota G, Ianiro G, Tilg H, Rajilic-Stojanovic M, Kump P, Satokari R, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569-80. Carlucci C, Petrof EO, Allen-Vercoe E. Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity. EBioMedicine. 2016;13(PG-37-45):37-45. Carstensen JW, Hansen AK. [Faecal transplantation as a treatment for Clostridium difficile infection, ulcerative colitis and the metabolic syndrome]. Ugeskr Laeger. 2014;176(4 PG-17):17. Chapman, B. C.; Moore, H. B.; Overbey, D. M.; Morton, A. P.; Harnke, B.; Gerich, M. E.; Vogel, J. D. Fecal microbiota transplant in patients with Clostridium difficile infection: A systematic review Journal of Trauma and Acute Care Surgery 01 Oct 2016;81(4):756-764 Chen B, Avinashi V, Dobson S. Fecal microbiota transplantation for recurrent Clostridium difficile infection in children. Journal of Infection. 2017;74:S120-S7. Choi HH, Cho YS. Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives. Clin Endosc. 2016;49(3 PG-257-65):257-65. Clostridium difficile Infection in Older Adults: Systematic Review of Efforts to Reduce Occurrence and Improve Outcomes Cohen NA, Ami RB, Guzner-Gur H, Santo ME, Halpern Z, Maharshak N. Fecal microbiota transplantation for Clostridium difficile-associated diarrhea. Isr Med Assoc J. 2015;17(8 PG-510-514):510-4.

Bridges E, McNeill M, Munro N. Research in Review: Driving Critical Care Practice Change. Am J Crit Care.

Page 329 of 454

1	
2 3 4 5	Cohen NA, Ben Ami R, Guzner-Gur H, Santo ME, Halpern Z, Maharshak N. Fecal Microbiota Transplantation for Clostridium difficile-Associated Diarrhea. Isr Med Assoc J Imaj. 2015;17(8 PG-510-4):510–4.
6 7	Colonoscopic fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infectionresults and follow-up
8 9 10 11 12	Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: A review and pooled analysis .Consensus report: faecal microbiota transfer - clinical applications and procedures Consultant Pharmacist Jan 01 2017;32(1):24-41
13	
14 15 16 17 18	Cramer JP. [Infusion of donor feces in recurrent Clostridium difficile infection? - Infusion of donor feces: Promising intervention with several question marks]. Dtsch Medizinische Wochenschrift. 2013;138(12 PG- 566):566.
19 20 21 22 23	Cramer JP. Infusion of donor feces in recurrent Clostridium difficile infection? - Infusion of donor feces: Promising intervention with several question marks. [German]. Dtsch Medizinische Wochenschrift. 2013;138(12 PG-566):566.
24 25 26 27 28	Crow JR, Davis SL, Chaykosky DM, Smith TT, Smith JM. Probiotics and fecal microbiota transplant for primary and secondary prevention of clostridium difficile infection. Pharmacotherapy. 2015;35(11 PG-1016-1025):1016–25.
29 30 31	Crum-Cianflone NF, Sullivan E, Ballon-Landa G. Fecal microbiota transplantation and successful resolution of multidrug-resistant-organism colonization. J Clin Microbiol. 2015;53(6 PG-1986-1989):1986–9.
32 33 34 35	Cui BT, Wang M, Ji GZ, Fan ZN, Zhang FM. Fecal microbiota transplantation: From the 4 th century to 2013. [Chinese]. World Chinese J Dig. 2013;21(30 PG-3222-3229):3222–9.
36 37 38	Dai C, Jiang M, Sun MJ. Fecal microbiota transplantation for treatment of clostridium difficile infection. J Clin Gastroenterol. 2015;49(2 PG-171-172):171–2.
39 40 41 42	Dai T, Tang T. [Research progress of fecal microbiota transplantation]. Zhonghua Weichang Waike Zazhi. 2015;18(7 PG-733-7):733–7.
43 44 45 46	Dai T, Tang T. Research progress of fecal microbiota transplantation. [Chinese]. Zhonghua Wei Chang Wai Ke Za Zhi. 2015;18(7 PG-733-737):733–7.
40 47 48 49	Dakhoul, L.; Parikh, K.; Berkelhammer, C. Fecal microbiota transplant in treatment of clostridium difficile colitis-pooled data analysis and a systematic review Gastroenterology April 2015;1)():S404
50 51 52 53	Daloiso V, Minacori R, Refolo P, Sacchini D, Craxi L, Gasbarrini A, et al. Ethical aspects of fecal microbiota transplantation (fmt). Eur Rev Med Pharmacol Sci. 2015;19(17 PG-3173-3180):3173–80.
54 55 56	Damman CJ, Miller SI, Surawicz CM, Zisman TL. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol. 2012;107(10):1452–9.
57 58 59 60	Davidovics ZH, Hyams JS. Fecal transplantation: Re-discovering the value of stool. Curr Opin Pediatr. 2013;25(5 PG-618-623):618–23.

Davidovics ZH, Sylvester FA. Medical stool: The future of treatment for inflammatory bowel disease? J Pediatr Gastroenterol Nutr. 2013;56(6 PG-583):583.

De Vos WM. Fame and future of faecal transplantations - developing next-generation therapies with synthetic microbiomes. Microb Biotechnol. 2013;6(4 PG-316-325):316-25.

Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection. Clin Microbiol Infect. 2014 Mar;20(s2):1-26.

Debast, S. B.; Bauer, M. P.; Kuijper, E. J.; Allerberger, F.; Bouza, E.; Coia, J. E.; Cornely, O. A.; Fitzpatrick, F.; Guery, B.; Wilcox, M.; Nathwani, D.; Noren, T.; Olesen, B.; Rakoczi, E.; Welte, T.; Widmer, A. F. European society of clinical microbiology and infectious diseases: Update of the treatment guidance document for Clostridium difficile infection Clinical Microbiology and Infection 2014;20(S2):1-26

Di Bella S, Drapeau C, Garcia-Almodovar E, Petrosillo N. Fecal microbiota transplantation: the state of the art. Infect Dis Rep. 2013;5(2 PG-e13):e13.

Di Bella S, Gouliouris T, Petrosillo N. Fecal microbiota transplantation (FMT) for Clostridium difficile infection: Focus on immunocompromised patients. J Infect Chemother. 2015;21(4 PG-230-237):230-7.

Dickinson B, Surawicz CM. Infectious Diarrhea: An Overview. Curr Gastroenterol Rep. 2014;16(8 PG-).

Dickson I. Therapy: Sterile faecal transfer for C. difficile infection. Nat Rev Gastroenterol Hepatol. 2017;14(1 PG-4):4.

Dickson I. Therapy: Sterile faecal transfer for C. difficile infection. Nat Rev Gastroenterol Hepatol. 2016;14(PG-).

Dodin, M.; Katz, D. E.. Faecal microbiota transplantation for Clostridium difficile infection. International Journal of Clinical Practice March 2014;68(3):363-368

Dougherty T, Taneja S, Borum ML. More than just clostridium difficile infection: The potential role of fecal microbiota transplantation in patients with inflammatory bowel disease. Am J Gastroenterol. 2016;111(PG-S833):S833.

Drekonja, D.; Reich, J.; Gezahegn, S.; Greer, N.; Shaukat, A.; MacDonald, R.; Rutks, I.; Wilt, T. J. Fecal microbiota transplantation for clostridium difficile infection a systematic review Annals of Internal Medicine 05 May 2015;162(9):630-638

Edelstein CA, Kassam Z, Daw J, Smith MB, Kelly CR. The regulation of fecal microbiota for transplantation: An international perspective for policy and public health. Clin Res Regul Aff. Taylor & Francis; 2015 Jul;32(3):99-107.

Edmond MB. The Power of Poop: Fecal Microbiota Transplantation for Clostridium Difficile Infection. Trans Am Clin Climatol Assoc. 2016;127(PG-71-80):71-80.

El-Matary W, Simpson R, Ricketts-Burns N. Fecal microbiota transplantation: Are we opening a can of worms? Gastroenterology. 2012;143(2 PG-e19):e19.

Page 331 of 454

1

2 3 4 5	El-Matary W. Fecal microbiota transplantation: Long-term safety issues. Am J Gastroenterol. 2013;108(9 PG-1537-1538):1537–8.
6 7 8	Elopre L, Rodriguez M. Fecal microbiota therapy for recurrent Clostridium difficile infection in HIV-infected persons. Ann Intern Med. 2013;158(10 PG-779-780):779–80.
9 10 11 12	Esposito S, Umbrello G, Castellazzi L, Principi N. Treatment of Clostridium difficile infection in pediatric patients. Expert Rev Gastroenterol Hepatol. 2015;9(6 PG-747-755):747–55.
13 14 15 16	Ettinger G, Burton JP, Reid G. If microbial ecosystem therapy can change your life, what's the problem? BioEssays. 2013;35(6 PG-508-512):508–12.
17 18 19	Evrensel A, Ceylan ME. Fecal microbiota transplantation and its usage in neuropsychiatric disorders. Clin Psychopharmacol Neurosci. 2016;14(3 PG-231-237):231–7.
20 21 22 23	Faecal microbiota transplantation in recurrent Clostridium difficile infection: Recommendations from the French Group of Faecal microbiota Transplantation. Dig Liver Dis. W.B. Saunders; 2016 Mar;48(3):242–7.
24 25 26	Famularo G, Trinchieri V, De Simone C. Fecal bacteriotherapy or probiotics for the treatment of intestinal diseases? Am J Gastroenterol. 2001;96(7 PG-2262-4):2262–4.
27 28 29 30	Rossen NG, MacDonald JK, de Vries EM, et al. Fecal microbiota transplantation as novel therapy in gastroenterology: a systematic review
31 32 33 34	Fecal microbiota transplantation via nasogastric tube for recurrent clostridium difficile infection in pediatric patients
35 36 37 38	Ferre Aracil C, Aguilera Castro L, Rodriguez de Santiago E, Garcia Garcia de Paredes A, Lopez San Roman A. Fecal microbiota transplantation - something more than merely a therapeutic curiosity. Rev Esp Enfermedades Dig. 2015;107(PG-19):19.
39 40 41 42 43	Ferre-Aracil C, Aguilera-Castro L, Rodriguez-de-Santiago E, Garcia-Garcia-de-Paredes A, Lopez-Sanroman A. Fecal microbiota transplantation - something more than merely a therapeutic curiosity. Rev Esp Enfermedades Dig. 2015;107(7 PG-399-401):399–401.
44 45 46 47	Floch MH. Editorial: Fecal bacteriotherapy, fecal transplant, and the microbiome. J Clin Gastroenterol. 2010;44(8 PG-529-530):529–30.
48 49 50	Floch MH. Fecal bacteriotherapy, fecal transplant, and the microbiome. J Clin Gastroenterol. 2010;44(8 PG-529-30):529–30.
51 52 53 54	Floch MH. The power of poop: Probiotics and fecal microbial transplant. J Clin Gastroenterol. 2012;46(8 PG-625-626):625–6.
55 56 57 58 59 60	Fredericks. Sages clinical guidelines for Faecal Microbiota Transplantation (FMT). South African Gastroenterol Rev. 2015;13(3 PG-27):27.

Friedman-Moraco RJ, Mehta AK, Lyon GM, Kraft CS. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant. 2014;14(2 PG-477-480):477–80.

1 2

3

4 5

6 7

8

9 10

11 12

13

17

35

47

58

Fu N, Wong T. Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Curr Infect Dis Rep. 2016;18 (6) (no pagination)(19 PG-).

Fuentes S, de Vos WM. How to Manipulate the Microbiota: Fecal Microbiota Transplantation. Adv Exp Med Biol. 2016;902(PG-143-53):143–53.

Fuentes S, De Vos WM. How to manipulate the microbiota: Fecal microbiota transplantation. E-mail: barbara.b.bertram@gsk.com: Springer New York LLC; 2016;(902 PG-143-153):143–53.

Fuessl HS. Fecal microbiota transplantation helps in Clostridium difficile colitis: Commentary. [German].
 MMW-Fortschritte der Medizin. 2012;154(17 PG-38):38.

Fumery M, Corcos O, Kapel N, Stefanescu C, Thomas M, Joly F. Interest and techniques of fecal
 transplantation. [French, English]. J des Anti-Infectieux. 2013;15(4 PG-187-192):187–92.

Furuya-Kanamori L, Doi SAR, Paterson DL, Helms SK, Yakob L, McKenzie SJ, et al. Upper Versus Lower
 Gastrointestinal Delivery for Transplantation of Fecal Microbiota in Recurrent or Refractory Clostridium
 difficile Infection: A Collaborative Analysis of Individual Patient Data From 14 Studies. J Clin Gastroenterol.
 2016;11(PG-).

Gallo A, Passaro G, Gasbarrini A, Landolfi R, Montalto M. Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. World J Gastroenterol. 2016;22(32 PG-7186-7202):7186– 202.

Garcia-Garcia-de-Paredes A, Rodriguez-de-Santiago E, Aguilera-Castro L, Ferre-Aracil C, Lopez-Sanroman A.
 [Fecal microbiota transplantation]. Gastroenterol Hepatol. 2015;38(3 PG-123-34):123–34.

Gens KD, Elshaboury RH, Holt JS. Fecal microbiota transplantation and emerging treatments for Clostridium
 difficile infection. J Pharm Pract. 2013;26(5 PG-498-505):498–505.

Gianotti RJ, Moss AC. The Use and Efficacy of Fecal Microbiota Transplantation for Refractory Clostridium difficile in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(11 PG-2704-2710):2704– 10.

Giordani A, Bove V, Cianchi D. Nursing skills for management of fecal microbiota transplantation in pediatric
 patient with clostridium difficile infection. Transpl Int. 2015;28(PG-427):427.

Goldberg EJ, Bhalodia S, Jacob S, Patel H, Trinh K V, Varghese B, et al. Clostridium difficile infection: A brief
 update on emerging therapies. Am J Heal Pharm. 2015;72(12 PG-1007-1012):1007–12.

Goldenberg SD. Faecal microbiota transplantation for recurrent Clostridium difficile infection and beyond: Risks and regulation. J Hosp Infect. 2016;92(2 PG-115-116):115–6.

⁵⁹ Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal ⁶⁰ bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53(10):994–1002. Page 333 of 454

1

2 3 4 5	Grady NG, Petrof EO, Claud EC. Microbial therapeutic interventions. Semin Fetal Neonatal Med. 2016;21(6 PG-418-423):418–23.
6 7 8	Granitto MH, Norton CK. Fecal microbiota transplantation in recurrent C. difficile infection. Nurs Crit Care. 2016;11(1 PG-25-30):25–30.
9 10 11 12	Grinspan AM, Kelly CR. Fecal Microbiota Transplantation for Ulcerative Colitis: Not Just Yet. Gastroenterology. 2015 Jul;149(1):15–8.
13 14 15 16	Groen AK, Nieuwdorp M. An evaluation of the therapeutic potential of fecal microbiota transplantation to treat infectious and metabolic diseases. EMBO Mol Med. 2017;9(1 PG-1-3):1–3.
17 18 19	Gross M, Meyer C. [Stool transplantation for relapsing Cl. difficile colitis]. Z Gastroenterol. 2013;51(12 PG-1441-3):1441–3.
20 21 22 23	Gross M, Meyer C. Stool transplantation for relapsing cldifficile colitis. [German]. Z Gastroenterol. 2013;51(12 PG-1441-1443):1441–3.
24 25 26	Guo WT, Dong LN, Wang JP, Liu P. New advances in clinical application of fecal microbiota transplantation. [Chinese]. World Chinese J Dig. 2014;22(30 PG-4593-4598):4593–8.
27 28 29 30	Guo WT, Wang JP, Liu P, Dong LN. New advances in clinical application of fecal microbiota transplantation. J Dig Dis. 2014;15(PG-118-119):118–9.
31 32 33 34 35	Guo, B.; Harstall, C.; Louie, T.; Veldhuyzen van Zanten, S.; Dieleman, L. A. Systematic review: faecal transplantation for the treatment of <i>Clostridium difficile</i> -associated disease. Aliment Pharmacol Ther 2012;35(8):865-875.
36 37 38 39	Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: In perspective. Therap Adv Gastroenterol. 2016;9(2 PG-229-239):229–39.
 40 41 42 43 44 45 	Gutierrez-Delgado, E. M.; Garza-Gonzalez, E.; Martinez-Vazquez, M. A.; Gonzalez-Gonzalez, J. A.; Maldonado-Garza, H. J.; Mendoza-Olazaran, S.; Hernandez-Balboa, C. L.; Camacho-Ortiz, A. Fecal transplant for Clostridium difficile infection relapses using "pooled" frozen feces from non-related donors Acta Gastro-Enterologica Belgica 01 Jun 2016;79(2):268-270
46 47 48 49	Hammad TA, Khan MA, Srour K, Abdelfattah T, Alastal Y, Lee WM, et al. Efficacy and safety of oral, capsulized, frozen fecal microbiota transplantation for recurrent clostridium difficile infection. A systematic review and meta-analysis. Gastroenterology. 2017;152 (5 Supplement 1):S346.
50 51 52 53	Han S, Shannahan S, Pellish R. Fecal microbiota transplant: Treatment options for clostridium difficile infection in the intensive care unit. J Intensive Care Med. 2016;31(9 PG-577-586):577–86.
54 55 56 57	Hashash JG, Binion DG. Managing Clostridium difficile in Inflammatory Bowel Disease (IBD). Curr Gastroenterol Rep. 2014;16 (7) (no pagination)(393 PG-).
57 58 59 60	Health Quality, Ontario Fecal Microbiota Therapy for Clostridium difficile Infection: A Health Technology Assessment

difficile infection in patients with cancer. Expert Rev Antiinfective Ther. 2016;14(11 PG-1077-1085):1077-85. Hebbard AIT, Slavin MA, Reed C, Teh BW, Thursky KA, Trubiano JA, et al. The epidemiology of Clostridium difficile infection in patients with cancer. Expert Rev Anti Infect Ther. 2016;14(11 PG-1077-1085):1077–85. Holmes E, Wijeyesekera A, Taylor-Robinson SD, Nicholson JK. The promise of metabolic phenotyping in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol. 2015;12(8 PG-458-471):458-71. Honda H, Dubberke ER. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Infect Dis. 2014;27(4 PG-336-341):336-41. Honda H, Dubberke ER. The changing epidemiology of Clostridium difficile infection. Curr Opin Gastroenterol. 2014;30(1):54-62. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol. 2009;15(13 PG-1554-1580):1554-80. Hourigan SK, Oliva-Hemker M. Fecal microbiota transplantation in children: A brief review. Pediatr Res. 2016;80(1 PG-2-6):2-6. Hryckowian AJ, Pruss KM, Sonnenburg JL. The emerging metabolic view of Clostridium difficile pathogenesis. Curr Opin Microbiol. 2017;35(PG-42-47):42-7. Hryckowian AJ, Pruss KM, Sonnenburg JL. The emerging metabolic view of Clostridium difficile pathogenesis. Curr Opin Microbiol. 2016;35(PG-42-47):42-7. Hudson LE, Anderson SE, Corbett AH, Lamb TJ. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev. 2017;30(1):191-231. Hudson LE, Anderson SE, Corbett AH, Lamb TJ. Gleaning insights from fecal microbiota transplantation and probiotic studies for the rational design of combination microbial therapies. Clin Microbiol Rev. 2017;30(1 PG-191-231):191-231. Huebner ES, Surawicz CM. Treatment of recurrent Clostridium difficile diarrhea. Gastroenterol Hepatol. 2006;2(3 PG-203-208):203-8. Hur KY, Lee MS. Gut microbiota and metabolic disorders. Diabetes Metab J. 2015;39(3 PG-198-203):198-203. Hussack G, Tanha J. An update on antibody-based immunotherapies for Clostridium difficile infection. Clin Exp Gastroenterol. 2016;9(PG-209-224):209-24. i, Y. T.; Cai, H. F.; Wang, Z. H.; Xu, J.; Fang, J. Y. Ianiro G, Bibbò S, Gasbarrini A, Cammarota G. Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives. Curr Drug Targets. 2014 Jul 31;15(8):762–70.

Hebbard AI, Slavin MA, Reed C, Teh BW, Thursky KA, Trubiano JA, et al. The epidemiology of Clostridium

Page 335 of 454

- Ianiro G, Bibbò S, Scaldaferri F, Gasbarrini A, Cammarota G. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore). 2014;93(19):e97. Ianiro G, Bibbò S, Scaldaferri F, Gasbarrini A, Cammarota G. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore). 2014;93(19):e97. Ianiro G, Bibbò S, Scaldaferri F, Gasbarrini A, Cammarota G. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore). 2014;93(19):e97. Ince MN, Blazar BR, Edmond MB, Tricot G, Wannemuehler MJ. Understanding Luminal Microorganisms and Their Potential Effectiveness in Treating Intestinal Inflammation. Inflamm Bowel Dis. 2016;22(1 PG-194-201):194-201. Infection December 2012;40(6):643-648 Infection February 2014;42(1):43-59 IV EC, Iii EC, Johnson DA. Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J Gastrointest Pharmacol Ther. 2014;5(1 PG-1-26):1-26. Jarrad AM, Karoli T, Blaskovich MA, Lyras D, Cooper MA. Clostridium difficile drug pipeline: challenges in discovery and development of new agents. J Med Chem. 2015;58(13 PG-5164-85):5164-85. Jarrad AM, Karoli T, Blaskovich MAT, Lyras D, Cooper MA. Clostridium difficile Drug Pipeline: Challenges in Discovery and Development of New Agents. J Med Chem. 2015;58(13 PG-5164-5185):5164-85. Jaworski A, Borody TJ, Leis S, Gadalla S, Dawson V. Treatment of first-time clostridium difficile infection with fecal microbiota transplantation. Am J Gastroenterol. 2015;110(PG-S587):S587. Jaworski A, Mitchell SW, Wong C, Chapman B, Bull M, Gadalla S, et al. FMT; how do alternate formats compare? Am J Gastroenterol. 2016;111(PG-S438):S438. Jaworski A, Mitchell SW, Wong C, Gadalla S, Borody TJ. Patient with relapsing C. difficile successfully treated with lyophilised encapsulated faecal microbiota transplant product. J Gastroenterol Hepatol. 2016;31(PG-161):161. Jehangir A, Bennett K, Fareedy SB, Rettew A, Shaikh B, Qureshi A, et al. Recurrent C. difficile in a Patient with IgG Deficiency. Case Rep Gastrointest Med. 2015;2015(PG-356293):356293.
- Jeon YD, Hong N, Kim JH, Park SH, Kim SB, Song IJ, et al. Fecal Transplantation using a Nasoenteric Tube
 during an Initial Episode of Severe Clostridium difficile Infection. Infect Chemother. 2016;48(1 PG-31-5):31–
 5.
- Jeon YD, Hong N, Kim JH, Park SH, Song IJ, Ann HW, et al. Fecal transplantation using a nasoenteric tube
 during an initial episode of severe clostridium difficile infection. Infect Chemother. 2016;48(1 PG-31-35):31–
 5.
- Jia N. A Misleading Reference for Fecal Microbiota Transplant. Am J Gastroenterol. 2015;110(12 PG 1731):1731.

Jiang ZD, Ajami N, Lasco T, Petrosino J, Hochman F, Ankoma-Sey V, et al. Fresh, frozen, or lyophilized fecal microbiota transplantation (FMT) for multiple recurrent C. Difficile Infection (CDI). Am J Gastroenterol. 2014;109(PG-S213):S213.

Jiang ZD, Dupont H, Ajami N, Lasco T, Ke S, Petrosino J, et al. Donor species richness determines fecal microbiota transplantation success in patients with recurrent clostridium difficile infection. Gastroenterology. 2016;1)(PG-S895):S895.

Jiang ZD, DuPont H, Ke S. A mouse model of clostridium difficile infection (CDI) suitable for study of human
 fecal microbiota transplantation (FMT). Am J Gastroenterol. 2015;110(PG-S577):S577.

Jiang ZD, Hoang LN, Lasco TM, Garey KW, DuPont HL. Physician attitudes toward the use of fecal
 transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin Infect Dis. 2013;56(7
 PG-1059-1060):1059–60.

Johnson S. Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes. J
 Infect. 2009;58(6 PG-403-410):403–10.

Jones JD, Murphy DW. Rescue fecal microbiota transplantation in refractory severe and complicated clostridium difficile infection using frozen stool specimens. Gastroenterology. 2015;1)(PG-S641):S641.

Jones L, Jones C. Does the donor matter? Donor vs. patient effects in the outcome of next-generation fecal
 transplant for recurrent clostridium difficile infection. Gastroenterology. 2015;1)(PG-S328-S329):S328–9.

Joseph J, Singhal S, Patel GM, Anand S. Clostridium difficile colitis: Review of the therapeutic approach. Am J Ther. 2014;21(5 PG-385-394):385–94.

Joseph J, Singhal S, Patel GM, Anand S. Clostridium difficile colitis: Review of the therapeutic approach. Am
 J Ther. 2012;17(PG-).

Journal of Digestive Diseases September 2016;17():43

1 2

3

4 5

6 7

8

9

10 11

23

34

47

58

Journal of Gastroenterology and Hepatology (Australia) November 2016;31():155

Journal of Pediatric Gastroenterology and Nutrition 13 Jan 2015;60(1):23-26

Jung Lee W, Lattimer LD, Stephen S, Borum ML, Doman DB. Fecal Microbiota Transplantation: A Review of
 Emerging Indications Beyond Relapsing Clostridium difficile Toxin Colitis. Gastroenterol Hepatol (N Y).
 2015;11(1 PG-24-32):24–32.

Kahn SA, Goeppinger SR, Rubin DT. Fecal microbiota transplantation: an interest in IBD? Nestle Nutr Inst
 Workshop Ser. 2014;79(PG-101-114):101–14.

Kahn SA, Goeppinger SR, Rubin DT. Fecal microbiota transplantation: A new therapy for IBD? Proceeding
 with caution. Inflamm Bowel Dis Monit. 2013;13(4 PG-127-134):127–34.

Kahn SA, Young S, Rubin DT. Colonoscopic fecal microbiota transplant for recurrent clostridium difficile infection in a child. Am J Gastroenterol. 2012;107(12 PG-1930-1931):1930–1.

Kaiser AM, Hogen R, Bordeianou L, Alavi K, Wise PE, Sudan R, et al. Clostridium Difficile Infection from a
 Surgical Perspective. J Gastrointest Surg. 2015;19(7 PG-1363-77):1363–77.

Page 337 of 454

- Kang DJ, Hylemon PB, Bajaj JS. Fecal transplant to mitigate hyperammonemia and hepatic encephalopathy in animal models. Ann Hepatol. 2015;14(5 PG-762-763):762-3. Kapel N, Thomas M, Corcos O, Mayeur C, Barbot-Trystram L, Bouhnik Y, et al. Practical implementation of faecal transplantation. Clin Microbiol Infect. 2014;20(11 PG-1098-1105):1098-105. Karadsheh Z, Sule S. Fecal transplantation for the treatment of recurrent Clostridium difficile infection. N Am J Med Sci. 2013;5(6 PG-339-343):339-43. Kassam Z, Blackler D, Osman M, Dubois N, Ling K, Burns L, et al. Novel safety features in fecal microbiota transplantation for recurrent clostridium difficile infection: Quality assurance and adverse events workflow. Am J Gastroenterol. 2015;110(PG-S589):S589. Kassam Z, Lee CH, Hunt RH. Review of the emerging treatment of clostridium difficile infection with fecal microbiota transplantation and insights into future challenges. Clin Lab Med. 2014;34(4 PG-787-798):787-98. Kassam, Z.; Lee, C. H.; Yuan, Y.; Hunt, R. H. Fecal microbiota transplantation for clostridium difficile infection: Systematic review and meta-analysis American Journal of Gastroenterology April 2013;108(4):500-508 Kee VR. Clostridium difficile infection in older adults: A review and update on its management. Am J Geriatr Pharmacother. 2012;10(1 PG-14-24):14-24. Keller JJ, Kuijper EJ. Treatment of recurrent and severe clostridium difficile infection. 4139 El Camino Way, P.O. Box 10139, Palo Alto CA 94306, United States: Annual Reviews Inc.; 2015;(66 PG-373-386):373-86. Keller JJ, Kuijper EJ. Treatment of recurrent and severe Clostridium difficile infection. Annu Rev Med. 2015;66(PG-373-86):373-86. Keller PM, Weber MH. Rational therapy of Clostridium difficile infections. Visz Gastrointest Med Surg. 2014;30(5 PG-304-309):304-9. Kellermayer R. Prospects and challenges for intestinal microbiome therapy in pediatric gastrointestinal disorders. World J Gastrointest Pathophysiol. 2013;4(4 PG-91-3):91–3. Kelly CP. Fecal microbiota transplantation - An old therapy comes of age. N Engl J Med. 2013;368(5 PG-474-475):474-5. Kelly CP. Fecal microbiota transplantation--an old therapy comes of age. N Engl J Med. 2013;368(5 PG-474-5):474–5. Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, et al. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology. Elsevier; 2015 Nov 19;149(1):223-37. Kelly P. Infectious diarrhoea. Med (United Kingdom). 2015;43(5 PG-253-258):253-8. Kerman DH. Endoscopic Delivery of Fecal Biotherapy in Inflammatory Bowel Disease. Gastrointest Endosc
- ⁶⁰ Clin N Am. 2016;26(4 PG-707-717):707–17.

Khan, M. A.; Sofi, A. A.; Ahmad, U.; Alaradi, O.; Khan, A. R.; Hammad, T.; Pratt, J.; Sodeman, T.; Sodeman, W.; Kamal, S.; Nawras, A. Efficacy and safety of, and patient satisfaction with, colonoscopic-administered fecal microbiota transplantation in relapsing and refractory community- and hospital-acquired Clostridium difficile infection Canadian Journal of Gastroenterology and Hepatology 01 Sep 2014;28(8):434-438 Khanna S, Pardi DS. Clostridium difficile infection: Management strategies for a difficult disease. Therap Adv Gastroenterol. 2014;7(2 PG-72-86):72-86. Khanna S, Pardi DS. Clostridium difficile infection: New insights into management. Mayo Clin Proc. 2012;87(11 PG-1106-1117):1106-17. Khanna S, Tosh PK. A clinician's primer on the role of the microbiome in human health and disease. Mayo Clin Proc. 2014;89(1 PG-107-14):107-14. Khanna, S.; Pardi, D. S.; Kelly, C. R.; Kraft, C. S.; Dhere, T.; Henn, M. R.; Lombardo, M. J.; Vulic, M.; Ohsumi, T.; Winkler, J.; Pindar, C.; McGovern, B. H.; Pomerantz, R. J.; Aunins, J. G.; Cook, D. N.; Hohmann, E. L. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection Journal of Infectious Diseases 15 Jul 2016;214(2):173-181 Khoruts A, Sadowsky MJ, Hamilton MJ. Development of Fecal Microbiota Transplantation Suitable for Mainstream Medicine. Clin Gastroenterol Hepatol. 2015;13(2 PG-246-250):246-50. Khoruts A, Sadowsky MJ. Therapeutic transplantation of the distal gut microbiota. Mucosal Immunol. 2011;4(1 PG-4-7):4-7. Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol. 2016 Jun;13(9):508–16. Khoruts A, Weingarden AR. Emergence of fecal microbiota transplantation as an approach to repair disrupted microbial gut ecology. Immunol Lett. 2014;162(2 Pt A PG-77-81):77-81. Khoruts A. Faecal Microbiota transplantation in 2013: Developing human gut Microbiota as a class of therapeutics. Nat Rev Gastroenterol Hepatol. 2014;11(2 PG-79-80):79-80. Khoruts A. Fecal microbiota transplantation-early steps on a long journey ahead. Gut Microbes. 2017;8(3):199-204. Kim S, Lee Y, Kim SH. Safety and effectiveness of fecal microbiota transplantation: A systematic review. [Korean]. Journal of the Korean Medical Association. 2017;60(9):761-8. Kim YG, Jang BI. Current advances related to Clostridium difficile infection. Indian J Med Res. 2015;141(2 PG-172-174):172-4.

Martins FS. Fecal Microbiota Transplantation for Ulcerative Colitis: FoMenTing Change? Dig Dis Sci. 2016;61(8 PG-2154-2155):2154-5.

Knight CL, Surawicz CM. Clostridium difficile Infection. Med Clin North Am. 2013;97(4 PG-523-536):523–36.

Page 339 of 454

Gut

Kociolek LK, Gerding DN. Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat Rev Gastroenterol Hepatol. 2016;13(3 PG-150-160):150-60. Koenigsknecht MJ, Young VB. Faecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection: Current promise and future needs. Curr Opin Gastroenterol. 2013;29(6 PG-628-632):628-32. Konig J, Brummer RJ. Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome. Benef Microbes. 2014;5(3 PG-247-261):247-61. Konig J, Siebenhaar A, Hogenauer C, Arkkila P, Nieuwdorp M, Noren T, et al. Consensus report: faecal microbiota transfer - clinical applications and procedures. Aliment Pharmacol Ther. 2017;45(2):222-39. Konturek PC, Haziri D, Brzozowski T, Hess T, Heyman S, Kwiecien S, et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases. J Physiol Pharmacol. 2015;66(4 PG-483-491):483-91. Konturek PC, Hess T. Stool transplantation - Gut bacteria as a novel therapeutic option. MMW-Fortschritte der Medizin. 2015;157(3 PG-61-63):61-3. Korman TM. Diagnosis and Management of Clostridium difficile Infection. Semin Respir Crit Care Med. 2015;36(1 PG-31-43):31-43. Kump PK, Krause R, Allerberger F, Hogenauer C. Faecal microbiota transplantation--the Austrian approach. Clin Microbiol Infect. 2014;20(11 PG-1106-11):1106-11. Kump PK, Krause R, Allerberger F, Hogenauer C. Faecal microbiota transplantation-the Austrian approach. Clin Microbiol Infect. 2014;20(11 PG-1106-1111):1106-11. Lagier JC. Gut microbiota and Clostridium difficile infections. Hum Microbiome J. 2016;2(PG-10-14):10-4. Landy J, Al-Hassi HO, McLaughlin SD, Walker AW, Ciclitira PJ, Nicholls RJ, et al. Review article: Faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther. 2011;34(4 PG-409-415):409-15. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. BioMed Central; 2016 Apr 13;8(1):39. Lankelma JM, Nieuwdorp M, de Vos WM, Wiersinga WJ. The gut microbiota in internal medicine: Implications for health and disease. Neth J Med. 2015;73(2 PG-61-68):61-8. Le Monnier A, Zahar JR, Barbut F. Update on clostridium difficile infections. Med Mal Infect. 2014;44(8 PG-354-365):354-65. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16 PG-1539-1548):1539–48.

Lemon KP, Armitage GC, Relman DA, Fischbach MA. Microbiota-targeted therapies: An ecological perspective. Sci Transl Med. 2012;4 (137) (no pagination)(137rv5 PG-). Leszczyszyn JJ, Radomski M, Leszczyszyn AM. Intestinal microbiota transplant - Current state of knowledge. Reumatologia. 2016;54(1 PG-24-28):24-8. Lewis SS, Anderson DJ. Treatment of Clostridium difficile infection: Recent trial results. Clin Investig (Lond). 2013;3(9 PG-875-886):875-86. Liubakka A, Vaughn BP. Clostridium difficile Infection and Fecal Microbiota Transplant. AACN Adv Crit Care. 2016;27(3 PG-324-337):324-37. Lo Vecchio A, Cohen MB. Fecal microbiota transplantation for Clostridium difficile infection: Benefits and barriers. Curr Opin Gastroenterol. 2014;30(1 PG-47-53):47-53. Lo Vecchio A, Zacur GM. Clostridium difficile infection: An update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol. 2012;28(1 PG-1-9):1-9. Lopez J, Grinspa A. Fecal microbiota transplantation for inflammatory bowel disease. Gastroenterol Hepatol. 2016;12(6 PG-374-379):374-9. Lubbert C, John E, von Muller L. Clostridium difficile infection: guideline-based diagnosis and treatment. Dtsch Arztebl Int. 2014;111(43 PG-723-731):723-31. Lubbert C. Antimicrobial therapy of acute diarrhoea: A clinical review. Expert Rev Anti Infect Ther. 2016;14(2 PG-193-206):193-206. Malikowski T, Khanna S, Pardi DS. Fecal microbiota transplantation for gastrointestinal disorders. Curr Opin Gastroenterol. 2017;33(1 PG-8-13):8–13. Malnick S, Melzer E. Human microbiome: From the bathroom to the bedside. World J Gastrointest Pathophysiol. 2015;6(3 PG-79-85):79-85. Manges AR, Steiner TS, Wright AJ. Fecal microbiota transplantation for the intestinal decolonization of extensively antimicrobial-resistant opportunistic pathogens: a review. Infect Dis (Auckl). 2016;48(8 PG-587-92):587-92. Marra F, Ng K. Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection. Drugs. 2015;75(10 PG-1095-1118):1095-118. Martin J, Mawer D, Wilcox MH. Clostridium difficile: Biological therapies. Curr Opin Infect Dis. 2013;26(5 PG-454-460):454-60. Martin J, Wilcox M. New and emerging therapies for Clostridium difficile infection. Curr Opin Infect Dis. 2016 Dec;29(6):546-54. Mathur H, Rea MC, Cotter PD, Paul Ross R, Hill C. The potential for emerging therapeutic options for Clostridium difficile infection. Gut Microbes. 2015;5(6 PG-696-710):696-710.

Gut

Page 341 of 454

1	
2 3 4	Mathur H, Rea MC, Cotter PD, Ross RP, Hill C. The potential for emerging therapeutic options for Clostridium difficile infection. Gut Microbes. 2014;5(6 PG-696-710):696–710.
5	
6 7 8	Matsuoka K, Mizuno S, Hayashi A, Hisamatsu T, Naganuma M, Kanai T. Fecal microbiota transplantation for gastrointestinal diseases. Keio J Med. 2014;63(4 PG-69-74):69–74.
9 10	Mattner J, Schmidt F, Siegmund B. Faecal microbiota transplantation-A clinical view. Int J Med Microbiol.
11 12	2016;306(5 PG-310-315):310–5.
13 14 15 16	McCune VL, Struthers JK, Hawkey PM. Faecal transplantation for the treatment of Clostridium difficile infection: A review. Int J Antimicrob Agents. 2014;43(3 PG-201-206):201–6.
17 18 19	Merenstein D, El-Nachef N, Lynch S V. Fecal microbial therapy: Promises and pitfalls. J Pediatr Gastroenterol Nutr. 2014;59(2 PG-157-161):157–61.
20 21 22	Mergenhagen KA, Wojciechowski AL, Paladino JA. A review of the economics of treating Clostridium difficile infection. Pharmacoeconomics. 2014;32(7 PG-639-650):639–50.
23 24 25	Mizusawa M, Doron S, Gorbach S. Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options. Drugs and Aging. 2015;32(8 PG-639-647):639–47.
26 27	
28 29 30	Moayyedi P, Marshall J, Yuan Y, Hunt R. Canadian Association of Gastroenterology position statement: Fecal microbiota transplant therapy. Can J Gastroenterol Hepatol. 2014;28(2 PG-66-68):66–8.
31 32 33	Moayyedi P. Fecal transplantation: Any real hope for inflammatory bowel disease? Curr Opin Gastroenterol. 2016;32(4 PG-282-286):282–6.
34 35 36 37	Monsour Jr. HP, Quigley EM. The Microbiome: What Will the Future Hold? Semin Liver Dis. 2016;36(4 PG- 354-359):354–9.
38 39 40 41	Monsour HP, Quigley EMM. The Microbiome: What Will the Future Hold? Semin Liver Dis. 2016;36(4 PG-354-359):354–9.
42 43 44	Moore T, Rodriguez A, Bakken JS. Fecal microbiota transplantation: A practical update for the infectious disease specialist. Clin Infect Dis. 2014;58(4 PG-541-545):541–5.
45 46 47 48	Mosby D, Lopresto BI, Bacon A, Levy S. Systematic review: Fecal microbiota transplantation in the treatment of pediatric gastrointestinal diseases. Inflamm Bowel Dis. 2016;22(PG-S73):S73.
49 50 51 52 53	Moayyedi P, Yuan Y, Baharith H, Ford AC. Faecal microbiota transplantation for Clostridium difficile -associated diarrhoea: a systematic review of randomised controlled trials. Med J Aust. 2017;207(4):166-72.
54 55 56	Mulcahy-O'Grady H, Workentine ML. The challenge and potential of metagenomics in the clinic. Front Immunol. 2016;7 (FEB) (no pagination)(29 PG-).
57 58 59 60	Mullish BH, Marchesi JR, Thursz MR, Williams HR. Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection. Qjm. 2015;108(5 PG-355-9):355–9.

transplantation as a therapeutic strategy in Clostridium difficile infection. Qjm. 2015;108(5 PG-355-359):355–9<mark>.</mark> Mullish BH, McDonald JAK, Pechlivanis A, Rees DN, Williams HRT, Marchesi JR, et al. Understanding the efficacy of faecal microbiota transplantation in clostridium difficile infection: Re-Establishment of gut microbiota with the ability to degrade bile? Gut. 2016;65(PG-A184):A184. Mullish BH, Williams HR. Obstacles to establishing an NHS faecal transplant programme. BMJ. 2015;351(PG-h6043):h6043. Mullish BH, Williams HRT. Obstacles to establishing an NHS faecal transplant programme. BMJ. 2015;351 (no pagination)(3496 PG-). Myers F. Beyond mainstream: making the case for fecal bacteriotherapy. Nursing (Lond). 2011;41(12 PG-50-53):50-3. Navarro F, Liu Y, Rhoads JM. Can probiotics benefit children with autism spectrum disorders? World J Gastroenterol. 2016;22(46 PG-10093-10102):10093-102. Nicholson MR, Osgood CL, Acra SA, Edwards KM. Clostridium difficile infection in the pediatric transplant patient. Pediatr Transplantation. 2015;(PG-). Nitzan O, Elias M, Chazan B, Raz R, Saliba W. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. World J Gastroenterol. China; 2013;19(43):7577–85. Obi O, Hampton D, Anderson T, Leung P, Abdul MKM, Chandra G, et al. Fecal microbiota transplant for treatment of resistant C. Difficile infection using a standardized protocol: A community hospital experience. Am J Gastroenterol. 2014;109(PG-S629):S629. Ofosu A. Clostridium difficile infection: A review of current and emerging therapies. Ann Gastroenterol. 2016;29(2 PG-147-154):147-54. Orenstein R, Griesbach CL, Dibaise JK. Moving fecal microbiota transplantation into the mainstream. Nutr Clin Pract. 2013;28(5 PG-589-598):589–98. P. K, Kump P, Hogenauer C. Any Future for Fecal Microbiota Transplantation as Treatment Strategy for Inflammatory Bowel Diseases?. Dig Dis. Switzerland: S. Karger AG; 2016;34(1 Supplement 1):74–81. Paasche S. Fecal microbiota transplantation: An innovative approach to treating Clostridium difficile disease. J Am Acad Physician Assist. 2013;26(8 PG-46-49):46–9. Pacheco SM, Johnson S. Important clinical advances in the understanding of Clostridium difficile infection. Curr Opin Gastroenterol. 2013;29(1 PG-42-48):42-8. Padua D, Pothoulakis C. Novel approaches to treating Clostridium difficile-associated colitis. Expert Rev Gastroenterol Hepatol. 2016;10(2 PG-193-204):193-204.

Mullish BH, Marchesi JR, Thursz MR, Williams HRT. Microbiome manipulation with faecal microbiome

Page 343 of 454

1 2

3

4 5 6

7

8 9

17 18 19

35

Pant C, Sferra TJ, Deshpande A, Minocha A. Clinical approach to severe Clostridium difficile infection: Update for the hospital practitioner. Eur J Intern Med. 2011;22(6 PG-561-568):561–8.

Pathak R, Enuh HA, Patel A, Wickremesinghe P. Treatment of relapsing clostridium difficile infection using fecal microbiota transplantation. Clin Exp Gastroenterol. 2014;7(1 PG-).

Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology.
 2014;146(6 PG-1573-1582):1573-82.

Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, et al. Systematic review with meta-analysis:
 the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium
 difficile infection. Aliment Pharmacol Ther. 2017;46(5):479-93.

Rabe SM. Treatment of recurrent Clostridium difficile infection with fecal transplantation. Gastroenterol
 Nurs. 2014;37(2 PG-156-63; quiz 164-5):156–63; quiz 164.

Raghunath V, Levy M, Koo K, Foo H, Borody TJ, Wong J. Recurrent clostridium difficile infection in a renal
 transplant recipient successfully treated with fecal microbiota transplantation. Nephrology. 2014;19(PG 98):98.

Rao K, Higgins PD. Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients
 with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(7 PG-1744-54):1744–54.

Rao K, Higgins PDR. Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients
 with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(7 PG-1744-1754):1744–54.

Rao K, Safdar N. Fecal microbiota transplantation for the treatment of Clostridium difficile infection. J Hosp
 Med. 2016;11(1 PG-56-61):56–61.

Rao K, Young VB, Aronoff DM. Fecal microbiota therapy: Ready for prime time? Infect Control Hosp
 Epidemiol. 2014;35(1 PG-28-30):28–30.

Rao K, Young VB. Fecal Microbiota Transplantation for the Management of Clostridium difficile Infection.
 Infect Dis Clin North Am. 2015;29(1 PG-109-122):109–22.

Rao K, Young VB, Malani PN. Capsules for Fecal Microbiota Transplantation in Recurrent Clostridium difficile
 Infection: The New Way Forward or a Tough Pill to Swallow? Jama. 2017;318(20):1979-80.

Raoult D. Faecal transplantation and infectious diseases practitioners. Clin Microbiol Infect. 2014;20(11 PG 1097):1097.

Raoult D. The return of microbes. Clin Microbiol Infect. 2016;22(10 PG-822-823):822–3.

Ray K. Infection : Microbiota reconstitution for resistance to Clostridium difficile infection-fight fire with fire?
 Nat Rev Gastroenterol Hepatol. 2015;12(1 PG-4):4.

59 60

Ray K. Infection: microbiota reconstitution for resistance to Clostridium difficile infection--fight fire with fire? Nat Rev Gastroenterol Hepatol. 2015;12(1 PG-4):4.

Rineh A, Kelso MJ, Vatansever F, Tegos GP, Hamblin MR. Clostridium difficile infection: Molecular pathogenesis and novel therapeutics. Expert Rev Anti Infect Ther. 2014;12(1 PG-131-150):131-50.

Rodriguez C, Taminiau B, Van Broeck J, Delmee M, Daube G. Clostridium difficile infection and intestinal microbiota interactions. Microb Pathog. 2015;89(PG-201-209):201-9.

Rogers GB, Bruce KD. Challenges and opportunities for faecal microbiota transplantation therapy. Epidemiol Infect. 2013;141(11 PG-2235-2242):2235-42.

Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol. 2012;5(6):403-20.

Rubin DT, Kirsner JB. Fecal microbiota transplantation for the treatment of inflammatory bowel disease. Gastroenterol Hepatol. 2015;11(9 PG-618-620):618-20.

Rubin DT. Curbing our enthusiasm for fecal transplantation in ulcerative colitis. Am J Gastroenterol. 2013;108(10 PG-1631-1633):1631-3.

Rubin TA, Gessert CE, Aas J. Stool transplantation for older patients with clostridium difficile infection. J Am Geriatr Soc. 2009;57(12 PG-2386-2387):2386-7.

Russell RK, Protheroe A, Roughton M, Croft N, Murphy MS, Spray C, et al. Inpatient paediatric UC care in the UK in 2011 is characterised by increasing rates of rescue therapy and stool cultures but low use of pucai scores. Gut. 2012;61(PG-A22):A22.

Sageer M, Barto A. Recurrent Clostridium difficile infection: The scope of the problem and management decisions. Semin Colon Rectal Surg. 2014;25(3 PG-158-162):158-62.

Salman S, Vardatsikos G, Avard D, Palmour N, Dewar K, Zawati MH. FMT Happens: Regulating Fecal Microbiota Therapy in Canada; What You Need to Know. World Med Heal Policy. 2016;8(1 PG-95-106):95-106.

Sampath K, Levy LC, Gardner TB. Fecal transplantation: Beyond the aesthetic. Gastroenterology. 2013;145(5 PG-1151-1153):1151-3.

Satokari R, Mattila E, Kainulainen V, Arkkila PE. Editorial: a simple faecal preparation for faecal microbiota transplantation--authors' reply. Aliment Pharmacol Ther. 2015;41(3 PG-321):321.

Satokari R, Mattila E, Kainulainen V, Arkkila PE. Editorial: A simple faecal preparation for faecal microbiota transplantation - Authors' reply. Aliment Pharmacol Ther. 2015;41(3 PG-321):321.

Scaldaferri F, Pecere S, Petito V, Zambrano D, Fiore L, Lopetuso LR, et al. Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises from a First Meta-Analysis. Transplant Proc. 2016;48(2 PG-402-407):402-7.

Page 345 of 454

1	
2 3 4	Schenck LP, Beck PL, MacDonald JA. Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection. World J Gastrointest Pathophysiol. 2015;6(4 PG-169-80):169–80.
5 6 7 8	Scott KP, Antoine JM, Midtvedt T, van Hemert S. Manipulating the gut microbiota to maintain health and treat disease. Microb Ecol Heal Dis. 2015;26(PG-25877):25877.
9 10	Shin JH, Chaves-Olarte E, Warren CA. Clostridium difficile Infection. Microbiol Spectr. 2016;4(3 PG-).
11 12 13	Siebenhaar A, Rosien U. Fecal microbiome transfer. Internist Prax. 2016;56(2 PG-269-277):269–77.
14 15 16 17	Singh B, Qin N, Reid G. Microbiome regulation of autoimmune, gut and liver associated diseases. Inflamm Allergy - Drug Targets. 2015;14(2 PG-84-93):84–93.
17 18 19 20	Singh N, Suskind D, Wahbeh G. Fecal bacteriotherapy in a 6 year old patient with ulcerative colitis and clostridium difficile. Inflamm Bowel Dis. 2012;18(PG-S69):S69.
21 22 23 24 25	Singh R, Nieuwdorp M, ten Berge IJ, Bemelman FJ, Geerlings SE. The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection. Clin Microbiol Infect. 2014;20(11 PG-1119-25):1119–25.
26 27 28 29 30	Singh R, Nieuwdorp M, ten Berge IJM, Bemelman FJ, Geerlings SE. The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection. Clin Microbiol Infect. 2014;20(11 PG-1119-1125):1119–25.
31 32 33	Sirisinha S. The potential impact of gut microbiota on your health: Current status and future challenges. Asian Pacific J Allergy Immunol. 2016;34(4 PG-249-264):249–64.
34 35 36 37	Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145(5):946–53.
38 39 40	Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Prim. 2016;2(PG-1-20):1–20.
41 42 43 44	Steinert A, Radulovic K, Niess J. Gastro-intestinal tract: The leading role of mucosal immunity. Swiss Med Wkly. 2016;146(PG-w14293):w14293.
45 46 47 48 49	Stuntz M, Des Vignes F. Treating Clostridium difficile infections: Should fecal microbiota transplantation be reclassified from investigational drug to human tissue? Contemp Clin Trials Commun. 2015;1(PG-39-41):39–41.
50 51 52 53	Surawicz CM. Fecal microbiota transplantation: What we know and what we need to know. Ann Intern Med. 2015;162(9 PG-662-663):662–3.
54 55 56	Suwantarat N, Bobak DA. Fecal bacteriotherapy for recurrent clostridium difficile infection: What's old is new again? Curr Infect Dis Rep. 2013;15(2 PG-101-103):101–3.
57 58 59 60	Tamma PD, Sandora TJ. Clostridium difficile infection in children: Current state and unanswered questions. J Pediatric Infect Dis Soc. 2012;1(3 PG-230-243):230–43.

Tang G, Yin W, Liu W. Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: A meta-analysis? Diagnostic Microbiology and Infectious Disease. 2017;88(4):322-9.

1 2

3

4

5 6 7

8

9

17

34

46

53

Tariq R, Khanna S. Clostridium difficile infection: Updates in management. Indian J Gastroenterol. 2016;(PG-1-8):1–8.

Taur Y, Pamer EG. Harnessing microbiota to kill a pathogen: Fixing the microbiota to treat Clostridium difficile
 infections. Nat Med. 2014;20(3 PG-246-247):246–7.

Taur Y, Pamer EG. The intestinal microbiota and susceptibility to infection in immunocompromised patients.
 Curr Opin Infect Dis. 2013;26(4 PG-332-337):332–7.

Thomas L V, Suzuki K, Zhao J. Probiotics: a proactive approach to health. A symposium report. Br J Nutr.
 2015;114 Suppl 1(PG-S1-15):S1-15.

Too early to determine whether fecal microbiota transplant has therapeutic promise for ulcerative colitis?
 Journal of Pediatric Gastroenterology and Nutrition. G.H. Russell, Division of Gastroenterology and Nutrition,
 Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, United States: Lippincott Williams and
 Wilkins; 2015. p. 3.

Tran MC, Claros MC, Goldstein EJ. Therapy of Clostridium difficile infection: perspectives on a changing
 paradigm. Expert Opin Pharmacother. 2013;14(17 PG-2375-86):2375–86.

Tran MCN, Claros MC, Goldstein EJC. Therapy of Clostridium difficile infection: Perspectives on a changing
 paradigm. Expert Opin Pharmacother. 2013;14(17 PG-2375-2386):2375–86.

Treating Clostridium difficile Infection With Fecal Microbiota Transplantation. Clin Gastroenterol Hepatol.
 W.B. Saunders; 2011 Dec;9(12):1044–9.

Trifan A, Stoica O, Stanciu C, Cojocariu C, Singeap AM, Girleanu I, et al. Clostridium difficile infection in patients with liver disease: a review. Eur J Clin Microbiol Infect Dis. 2015;34(12 PG-2313-2324):2313–24.

Trubiano JA, Cheng AC, Korman TM, Roder C, Campbell A, May ML, et al. Australasian Society of Infectious
 Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in
 Australia and New Zealand. Intern Med J. 2016;46(4 PG-479-93):479–93.

Turner JD. Evaluation of clostridium difficile treatment with fecal microbiota transplantation. Am J Trop Med
 Hyg. 2013;1)(PG-217):217.

Unal CM, Steinert M. Novel therapeutic strategies for Clostridium difficile infections. Expert Opin Ther
 Targets. 2016;20(3 PG-269-285):269–85.

Vaishnavi C. Fecal microbiota transplantation for management of Clostridium difficile infection. Indian J
 Gastroenterol. 2014;33(4 PG-301-307):301–7.

Van Dissel JT. Alternative strategies for Clostridium difficile infection. Antonie van Leeuwenhoek, Int J Gen
 Mol Microbiol. 2009;95(PG-41):41.

Page 347 of 454

1

35

41

53

- van Nispen tot Pannerden CM, Verbon A, Kuipers EJ. Recurrent Clostridium difficile infection: what are the
 treatment options? Drugs. 2011;71(7 PG-853-68):853–68.
 Van Nispen Tot Pannerden CMF, Verbon A, Kuipers EJ. Recurrent clostridium difficile infection: What are the
 treatment options? Drugs. 2011;71(7 PG-853-868):853–68.
- van Nood E, Speelman P, Kuijper EJ, Keller JJ. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? Euro Surveill. 2009;14(34 PG-).
- Van Nood E, Speelman P, Nieuwdorp M, Keller J. Fecal microbiota transplantation: Facts and controversies.
 Curr Opin Gastroenterol. 2014;30(1 PG-34-39):34–9.
- Vandenplas Y, Pierard D, De Greef E. Fecal Microbiota Transplantation: Just a Fancy Trend? J Pediatr
 Gastroenterol Nutr. 2015;61(1 PG-4-7):4–7.
- Vemuri RC, Gundamaraju R, Shinde T, Eri R. Therapeutic interventions for gut dysbiosis and related disorders
 in the elderly: antibiotics, probiotics or faecal microbiota transplantation? Benef Microbes. 2016;(PG-1 15):1–15.
- Venuto C, Butler M, Ashley ED, Brown J. Alternative therapies for Clostridium difficile infections.
 Pharmacother J Hum Pharmacol Drug Ther. 2010;30(12 PG-1266-78):1266–78.
- Venuto C, Butler M, Dodds Ashley E, Brown J. Alternative therapies for Clostridium difficile infections.
 Pharmacotherapy. 2010;30(12 PG-1266-1278):1266–78.
- Verbeke KA, Boesmans L, Boets E. Modulating the microbiota in inflammatory bowel diseases: prebiotics,
 probiotics or faecal transplantation?. Proc Nutr Soc. England; 2014;73(4):490–7.
- Verspohl E. Therapy of Clostridium difficile-associated diarrhea. Fecal microbiota transplants: History and
 clinical trials. Med Monatsschr Pharm. 2016;39(12 PG-539-542):539–42.
- Vestal R. Fecal Microbiota Transplant. Hosp Med Clin. 2016;5(1 PG-58-70):58–70.
- Vincent C, Manges AR. Antimicrobial use, human gut microbiota and Clostridium difficile colonization and
 infection. Antibiotics. 2015;4(3 PG-230-253):230–53.
- Vincent Y, Manji A, Gregory-Miller K, Lee C. A review of management of Clostridium difficile infection:
 Primary and recurrence. Antibiotics. 2015;4(4 PG-411-423):411–23.
- Vindigni SM, Broussard EK, Surawicz CM. Alteration of the intestinal microbiome: Fecal microbiota transplant
 and probiotics for Clostridium difficile and beyond. Expert Rev Gastroenterol Hepatol. 2013;7(7 PG-615 628):615–28.
- Vindigni SM, Surawicz CM. The gut microbiome: A clinically significant player in transplantation? Expert Rev
 Clin Immunol. 2015;11(7 PG-781-783):781–3.
- von Ameln-Mayerhofer A. [Clostridium difficile infection an update]. Med Monatsschr Pharm. 2015;38(6
 PG-211-8; quiz 219-20):211–8; quiz 219.

Vyas D, L'Esperance H E, Vyas A. Stool therapy may become a preferred treatment of recurrent Clostridium difficile? World J Gastroenterol. 2013;19(29 PG-4635-7):4635-7.

Gut

Vyas D, L'Esperance HE, Vyas A. Stool therapy may become a preferred treatment of recurrent Clostridium difficile? World J Gastroenterol. 2013;19(29 PG-4635-4637):4635-7.

Walia R, Kunde S, Mahajan L. Fecal microbiota transplantation in the treatment of refractory Clostridium difficile infection in children: An update. Curr Opin Pediatr. 2014;26(5 PG-573-578):573-8.

Walker AW, Lawley TD. Therapeutic modulation of intestinal dysbiosis. Pharmacol Res. 2013;69(1 PG-75-86):75-86.

Walsh CJ, Guinane CM, O'Toole PW, Cotter PD. Beneficial modulation of the gut microbiota. FEBS Lett. 2014;588(22 PG-4120-4130):4120-30.

Waltz P, Zuckerbraun B. Novel therapies for severe Clostridium difficile colitis. Curr Opin Crit Care. 2016;22(2 PG-167-73):167-73.

Wang AY, Popov J, Pai N. Fecal microbial transplant for the treatment of pediatric inflammatory bowel disease. World J Gastroenterol. 2016;22(47 PG-10304-10315):10304-15.

Wang SN, Cao HL, Wang BM. Systematic review: Adverse events of fecal microbiota transplantation. J Dig Dis. 2016;17(PG-59):59.

Wang ZK, Yang YS, Chen Y, Yuan J, Sun G, Peng LH. Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease. World J Gastroenterol. 2014;20(40 PG-14805-14820):14805-20.

Weissman JS, Coyle W. Stool transplants: Ready for prime time? Curr Gastroenterol Rep. 2012;14(4 PG-313-316):313-6.

West CE, Renz H, Jenmalm MC, Kozyrskyj AL, Allen KJ, Vuillermin P, et al. The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies. J Allergy Clin Immunol. 2015;135(1 PG-3-13; quiz 14):3–13; quiz 14.

West CE, Renz H, Jenmalm MC, Kozyrskyj AL, Allen KJ, Vuillermin P, et al. The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies. J Allergy Clin Immunol. 2015;135(1 PG-3-13):3–13.

Wiedel N, Gilbert J, Baloun B, Nelson C. Clostridium difficile Associated Diarrhea. S D Med. 2016;69(3 PG-124-127):124-7.

Wischmeyer PE, McDonald D, Knight R. Role of the microbiome, probiotics, and "dysbiosis therapy" in critical illness. Curr Opin Crit Care. 2016;22(4 PG-347-53):347–53.

Wise J. Frozen faecal matter works as well as fresh for transplantation in C difficile patients. BMJ. 2016;352(PG-i138):i138.

Woodworth MH, Carpentieri C, Sitchenko KL, Kraft CS. Challenges in fecal donor selection and screening for Page 349 of 454

1

1 2 3	fecal microbiota transplantation: A review. Gut Microbes. 2017;8(3):225-37.
4 5 6 7 8	Woodworth MH, Neish EM, Miller NS, Dhere T, Burd EM, Carpentieri C, et al. Laboratory Testing of Donors and Stool Samples for Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. J Clin Microbiol. 2017;55(4):1002-10.
9 10 11 12 13	Woodworth MH, Neish EM, Miller NS, Dhere T, Burd EM, Carpentieri C, et al. Laboratory Testing of Donors and Stool for Fecal Microbiota Transplantation for Recurrent C. difficile Infection. J Clin Microbiol. 2017;11(PG-11):11.
14 15 16 17	Xu MQ, Cao HL, Wang WQ, Wang S, Cao XC, Yan F, et al. Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol. 2015;21(1 PG-102-111):102–11.
18 19 20	Yang X, Wu M. Fecal microbiota transplantation and inflammatory bowel disease. [Chinese]. Chinese J Gastroenterol. 2016;21(8 PG-491-493):491–3.
21 22 23 24	Ye L. Fecal microbiota transplantation: A potential therapy for inflammatory bowel disease? J Dig Dis. 2015;16(PG-81):81.
25 26 27	Young VB. Therapeutic manipulation of the microbiota: past, present, and considerations for the future. Clin Microbiol Infect. 2016;22(11 PG-905-909):905–9.
28 29 30 31	Youngster I, Gerding DN. Editorial: Making Fecal Microbiota Transplantation Easier to Swallow: Freeze-Dried Preparation for Recurrent Clostridium difficile Infections. Am J Gastroenterol. 2017;112(6):948-50.
32 33	Youngster I. Fecal micobiota transplants - The clinical perspective. Int J Infect Dis. 2016;45(PG-37):37.
34 35 36 37	Yuille S, Mackay WG, Morrison DJ, Tedford MC. Optimising gut colonisation resistance against Clostridium difficile infection. Eur J Clin Microbiol Infect Dis. 2015;34(11 PG-2161-2166):2161–6.
38 39 40 41	Zagaria MAE. Fecal transplantation for recurrent clostridium difficile infection. US. 2014;Pharmacist. 39(12 PG-20-22):20–2.
42 43 44 45 46	Zainah H, Hassan M, Shiekh-Sroujieh L, Hassan S, Alangaden G, Ramesh M. Intestinal Microbiota Transplantation, a Simple and Effective Treatment for Severe and Refractory Clostridium Difficile Infection. Dig Dis Sci. 2015 Jan 23;60(1):181–5.
40 47 48 49	Zalig S, Rupnik M. Clostridium difficile infection and gut microbiota. Semin Colon Rectal Surg. 2014;25(3 PG-124-127):124–7.
50 51 52 53	Zanella Terrier MC, Frossard JL, Simonet ML. [Recurrent Clostridium difficile infections: the importance of the intestinal microbiota]. Rev Med Suisse. 2013;9(402 PG-1898, 1900-4):1898,1900-1904.
54 55 56 57 58	Zanella Terrier MC, Simonet ML, Bichard P, Frossard JL. Recurrent Clostridium difficile infections: The importance of the intestinal microbiota. World J Gastroenterol. 2014;20(23 PG-7416-7423):7416–23.
59 60	D.1.8. Commentary/ editorials/ opinion:

Infect Dis. 2012;55(12 PG-1659-1660):1659-60. Glauser W. Risk and rewards of fecal transplants. CMAJ. 2011;183(5 PG-541-542):541–2. Goyal H, Singla U. Infectious diseases society of america or american college of gastroenterology guidelines for treatment of clostridium difficile infection: Which one to follow? Am J Med. 2015;128(4 PG-). Hecht GA, Blaser MJ, Gordon J, Kaplan LM, Knight R, Laine L, et al. What is the value of a food and drug administration investigational new drug application for fecal microbiota transplantation to treat clostridium difficile infection? Clin Gastroenterol Hepatol. 2014;12(2 PG-289-291):289-91. Hellemans R, Naegels S, Holvoet J. Fecal transplantation for recurrent Clostridium difficile colitis, an underused treatment modality. Acta Gastroenterol Belg. 2009;72(2 PG-269-270):269-70. Heuer AH. Fecal transplantation with side effect: Bearer of hope for Clostridium difficile patients is still insufficiently researched. Dtsch Apotheker Zeitung. 2016;156(46 PG-). Johnson S, Gerding DN. Fecal Fixation: Fecal Microbiota Transplantation for Clostridium difficile Infection. Clin Infect Dis. 2016;9(PG-09):9. Karakan T. Fecal microbiota transplant in immunocompromised patients: Encouraging results in a vulnarable population. Turkish J Gastroenterol. 2014;25(3 PG-346):346. Keller JJ, Van Nood E, Speelman P, Kuijper EJ. Application of feces transplantation for treatment of relapsing Clostridium difficile infection. Antonie van Leeuwenhoek, Int J Gen Mol Microbiol. 2009;95(PG-40-41):40-1. Kellermayer R. Burdening questions about clostridium difficile in pediatric inflammatory bowel diseases. J Pediatr Gastroenterol Nutr. 2015;60(4 PG-421-422):421–2. Kelly CR. Editorial: A simple faecal preparation protocol for faecal microbiota transplantation. Aliment Pharmacol Ther. 2015;41(3 PG-320):320. Kuperman AA, Koren O. The era of fecal microbiota transplantation. Isr Med Assoc J. 2015;17(8 PG-515-516):515-6. Laffin M, Millan B, Madsen KL. Fecal microbial transplantation as a therapeutic option in patients colonized with antibiotic resistant organisms. Gut Microbes. 2017;(PG-0):0. Louie T, Adams PC. Nature's therapy for recurrent Clostridium difficile diarrhea. Can J Gastroenterol. 2008;22(5 PG-455-456):455-6. Lynch S V. Fecal microbiota transplantation for recurrent clostridium difficile infection in pediatric patients: Encouragement wrapped in caution. J Pediatr Gastroenterol Nutr. 2015;60(1 PG-1-3):1–3. Malani PN, Rao K. Expanded evidence for frozen fecal microbiota transplantation for clostridium difficileinfection a fresh take. JAMA - J Am Med Assoc. 2016;315(2 PG-137-138):137-8.

Brandt LJ. Editorial commentary: Fecal microbiota transplantation: Patient and physician attitudes. Clin

Page 351 of 454

1 2

2 3 4 5	Mardani M. Intestinal microbiota transplantation for recurrent Clostridium difficile infection. Iran J Clin Infect Dis. 2011;6(3 PG-103):103.
6 7 8	Marsh JW, Curry SR. Therapeutic approaches for clostridium difficile infections. Curr Protoc Microbiol. 2013;(SUPPL.30) (no pagination)(9A.3 PG-).
9 10 11 12	Mayor S. Donor faecal transplantation is highly curative in recurrent C difficile infection, trial finds. BMJ. 2016;354 (no pagination)(i4638 PG-).
13 14 15 16	McFarland L V. The role of compassion in the practice of evidence-based medicine. Am J Gastroenterol. 2012;107(5 PG-768-769):768–9.
17 18 19	McKinney M. Despite "eww" factor fecal transplants gain ground against C. diff. Mod Healthc. 2013;43(4 PG-12-13):12–3.
20 21 22 23	McKinney M. FDA slaps regs on fecal transplants. Increased steps for C. diff treatment draw mixed reactions from providers. Mod Healthc. 2013;43(21 PG-10):10.
24 25	Nieuwdorp M. Faecal microbiota transplantation. Br J Surg. 2014;101(8 PG-887-8):887–8.
26 27 28 29	Olson DC, Scobey MW. The Challenge of Clostridium difficile Infection. N C Med J. 2016;77(3 PG-206-10):206–10.
30 31 32 33	Owens C, Broussard E, Surawicz C. Fecal microbiota transplantation and donor standardization. Trends Microbiol. 2013;21(9 PG-443-445):443–5.
34 35 36 37	Pakyz AL, Moczygemba LR, Vanderwielen LM, Edmond MB. Fecal microbiota transplantation for recurrent Clostridium difficile infection: The patient experience. Am J Infect Control. 2016;44(5 Supplement PG-554-559):554–9.
38 39 40 41	Pamer EG. Fecal microbiota transplantation: Effectiveness, complexities, and lingering concerns. Mucosal Immunol. 2014;7(2 PG-210-214):210–4.
42 43 44 45 46	Patel K V, Digby-Bell JL, Goel RM, Henry N, Sanderson JD, Irving PM, et al. Faecal microbiota transplantation: Implementing a new treatment for recurrent/refractory clostridium difficile infection using banked stool in a tertiary UK centre. Gut. 2015;64(PG-A23):A23.
47 48	Patel K, Spector TD. Estimating the risks of faecal transplants. J Hosp Infect. 2016;92(2 PG-128-129):128–9.
49 50 51 52	Rutecki GW. An "aesthetically unappealing" transplant: Fecal microbiota. Consultant. 2013;53(5 PG-338):338.
53 54 55	Sachs RE, Edelstein CA. Ensuring the safe and effective FDA regulation of fecal microbiota transplantation. J Law Biosci. 2015;2(2 PG-396-415):396–415.
56 57 58 59 60	Senior K. Faecal transplantation for recurrent C difficile diarrhoea. Lancet Infect Dis. 2013;13(3 PG-200-201):200–1.

Sokol H. Toward Rational Donor Selection in Faecal Microbiota Transplantation for IBD. J Crohns Colitis. 2016;10(4 PG-375-6):375–6.

D.1.9. Letters

1 2

3

9 10

11 12

13 14

15

16 17 18

19

20

24 25

26

27 28

35

42

47

Anonymous. Fecal Transplant for Clostridium difficile-Reply. Arch Intern Med. 2012;172(10 PG-825-6):825– 6.

Green MR, Acharya UH, Yeager AM. Is fidaxomicin the drug of choice for treating clostridium difficile -Associated diarrhea in patients with cancer? J Clin Oncol. 2013;31(34 PG-4376-4378):4376–8.

Gundacker ND, Morrow CD, Rodriguez M. Letter: a simple out-patient faecal microbiota transplant technique. Aliment Pharmacol Ther. 2016;44(1 PG-101):101.

Gutman J, Kurchin A. Split donation fecal microbiota transplantation. Am J Gastroenterol. 2013;108(10 PG 1659-1660):1659–60.

Ho N, Prasad V. Clostridium difficile diarrhea and fecal transplantation. J Clin Gastroenterol. 2011;45(8 PG-742-743):742–3.

Ho N, Prasad V. Lacking the incentive to cure? Recurring clostridium difficile diarrhea and our reluctance to
 use fecal transplantation. J Clin Gastroenterol. 2011;45(4 PG-379-380):379–80.

Hodes RM. Fecal flora reconstitution for amyotrophic lateral sclerosis. J Clin Gastroenterol. 2013;47(7 PG-655):655.

Hogenauer C, Kump PK, Krause R. Tempered enthusiasm for fecal transplantation? Clin Infect Dis. 2014;59(9
 PG-1348-1349):1348–9.

laniro G, Gasbarrini A, Cammarota G. Letter: Faecal microbiota transplantation - Not a one-size-fits-all
 approach. Aliment Pharmacol Ther. 2014;40(1 PG-119):119.

Jouhten H, Mattila E, Arkkila P, Satokari R. Reduction of Antibiotic Resistance Genes in Intestinal Microbiota
 of Patients With Recurrent Clostridium difficile Infection After Fecal Microbiota Transplantation. Clin Infect
 Dis. 2016;63(5 PG-710-711):710–1.

Kassam Z, Lee CH, Yuan Y, Hunt RH. Navigating long-term safety in fecal microbiota transplantation. Am J
 Gastroenterol. 2013;108(9):1538.

Konstantinov SR, Peppelenbosch MP. Fecal microbiota transfer may increase irritable bowel syndrome and
 inflammatory bowel diseases-associated bacteria. Gastroenterology. 2013;144(4 PG-e19-e20):e19–20.

 Malnick SD, Oppenheim A, Melzer E. Immune Thrombocytopenia Caused by Fecal Microbial Transplantation
 in a Patient With Severe Recurrent Clostridium difficile Infection. J Clin Gastroenterol. 2015;49(10 PG-888-9):888–9.

Page 353 of 454

1

2 3 4 5 6	Malnick SDH, Oppenheim A, Melzer E. Immune thrombocytopenia caused by fecal microbial transplantation in a patient with severe recurrent clostridium difficile infection. J Clin Gastroenterol. 2015;49(10 PG-888-889):888–9.
7 8	Martin L. Modified fecal transplantation. J Clin Gastroenterol. 2011;45(8 PG-742):742.
9 10 11 12	Matuchansky C. Fecal microbiota transplantation: the case of immunocompromised patients. Am J Med. 2015;128(3 PG-e21):e21.
13 14 15 16	Mawer DP, Wilcox MH. Clarifying the management of Clostridium difficile infection. BMJ. 2015;351(PG-h6130):h6130.
17 18 19 20 21	Mittal C, Miller N, Meighani A, Hart BR, John A, Ramesh M. Fecal microbiota transplant for recurrent Clostridium difficile infection after peripheral autologous stem cell transplant for diffuse large B-cell lymphoma. Bone Marrow Transplant. 2015;50(7 PG-1010):1010.
22 23 24 25	Pecere S, Sabatelli M, Fantoni M, Ianiro G, Gasbarrini A, Cammarota G. Letter: Faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;42(8 PG-1030):1030.
26 27 28 29 30	Schwartz M, Gluck M, Koon S. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol. 2013;108(8 PG-1367):1367.
31 32 33 34	Sha S, Wu K. Letter: Faecal microbiota transplantation - Not a one-size-fits-all approach; Authors' reply. Aliment Pharmacol Ther. 2014;40(1 PG-119-120):119–20.
35 36 37 38	Sohn KM, Cheon S, Kim YS. Can Fecal Microbiota Transplantation (FMT) Eradicate Fecal Colonization with Vancomycin-Resistant Enterococci (VRE)? Infect Control Hosp Epidemiol. 2016;37(12 PG-1519-1521):1519–21.
39 40 41 42	Solari PR, Fairchild PG, Noa LJ, Wallace MR. Tempered enthusiasm for fecal transplant. Clin Infect Dis. 2014;59(2 PG-319):319.
43 44 45	Solari PR, Wallace MR. Reply to Krause et al. Clin Infect Dis. 2014;59(9 PG-1349):1349.
46 47 48	Spector T, Knight R. Authors' reply to Mawer and Wilcox and Mullish and Williams. BMJ. 2015;351(PG-h6132):h6132.
49 50 51	Spector T, Knight R. Faecal transplants. BMJ. 2015;351 (no pagination)(h5149 PG-).
52 53 54 55	Tacke D, Wisplinghoff H, Kretzschmar A, Farowski F, Koehler P, Herweg J, et al. First implementation of frozen, capsulized faecal microbiota transplantation for recurrent Clostridium difficile infection into clinical practice in Europe. Clin Microbiol Infect. 2015;21(11 PG-e82-e84):e82–4.
56 57 58 59 60	Tacke D, Wisplinghoff H, Kretzschmar A, Farowski F, Koehler P, Herweg J, et al. First implementation of frozen, capsulized faecal microbiota transplantation for recurrent Clostridium difficile infection into clinical practice in Europe. Clin Microbiol Infect. 2015;21(11 PG-e82-4):e82-4.

Wang XJ, Kraft CS, Dhere T. Use of standard donors in fecal microbiotal transplants. South Med J. 2015;108(1 PG-68-69):68–9.

Gut

Youngster I, Hohmann EL. Fecal microbiota transplantation for Clostridium difficile infection--reply. JAMA. 2015;313(7 PG-726):726.

D.1.10.Not relevant, miscellaneous

1 2

3

4 5 6

7

14

15

16

17 18

19

20 21

34 35

36

37

38 39

52

60

A.M. B, C.P. K, Berg AM, Kelly CP, Farraye FA. Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis. A.M. Berg, Section of Gastroenterology, Boston Medical Center, 85 East Concord St., Suite 7720, Boston, MA 02118-2338, United States. E-mail: adam.berg@bmc.org: Lippincott Williams and Wilkins (530 Walnut Street, P O Box 327, Philadelphia PA 19106-3621, United States); 2013;19(1):194–204.

Ahir HB, Marcella S, Jiang Y, Mayes A, Burnett H, Rajpura J. Systematic literature review of economic evaluations and healthcare resource utilisation studies in the treatment of clostridium difficile infection. Value in Health. 2017;20 (9):A791

Allegretti J, Eysenbach LM, El-Nachef N, Fischer M, Kelly C, Kassam Z. The Current Landscape and Lessons
 from Fecal Microbiota Transplantation for Inflammatory Bowel Disease: Past, Present, and Future.
 Inflammatory Bowel Diseases. 2017;23(10):1710-7.

Allegretti JR, Bry L, Gerber G, Clish C, Korzenik JR. Investigation of dysbiosis and bile salt composition associated with c. Difficile infection. Am J Gastroenterol. 2015;110(PG-S573-S574):S573–4.

Allegretti JR, Kao DH, Sitko J, Fischer M, Kassam Z. Prevalence of early antibiotic use post-fecal microbiota transplantation and corresponding risk of FMT failure. Gastroenterology. 2017;152 (5 Supplement 1):S342-S3.

Allegretti JR, Kassam Z, Chan WW. Small Intestinal Bacterial Overgrowth: Should Screening Be Included in
 the Pre-fecal Microbiota Transplantation Evaluation? Digestive Diseases and Sciences. 2017:1-5.

Allegretti JR, Kassam Z, Smith M, Korzenik JR, Chan WW. Irregular bowel movements following fecal microbiota transplantation (FMT) are associated with pre-existing irritable bowel syndrome but not FMTrelated factors. Gastroenterology. 2016;1)(PG-S742):S742.

Alonso CD, Braun DA, Patel I, Akbari M, Oh DJ, Jun T, et al. A multicenter, retrospective, case-cohort study of
 the epidemiology and risk factors for Clostridium difficile infection among cord blood transplant recipients.
 Transpl Infect Dis. 2017;19 (4) (no pagination)(e12728).

American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. American Journal of Gastroenterology. L.J. Brandt, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, United States. E-mail: Ibrandt@montefiore.org: Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom); 2013. p. 177–85.

Anand R, Song Y, Garg S, Girotra M, Sinha A, Sivaraman A, et al. Effect of Aging on the Composition of Fecal

Page 355 of 454

1	
2 3 4	Microbiota in Donors for FMT and Its Impact on Clinical Outcomes. Dig Dis Sci. 2017;62(4):1002-8.
4 5 6 7	Andermann TM, Rezvani A, Bhatt AS. Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation. Curr Hematol Malig Rep. 2016;11(1 PG-19-28):19–28.
8 9 10	Anonymous. ALS Untangled No. 21: Fecal transplants. Amyotroph Lateral Scler Front Degener. 2013;14(5-6-482–485):482–5.
11 12 13 14	Anonymous. AMMI Canada-CACMID 2012 Annual Conference Abstracts. Can J Infect Dis Med Microbiol Conf AMMI Canada CACMID. 2012;23(no pagination PG-).
15 16 17 18 19	Anonymous. Erratum: Oral, capsulized frozen fecal microbiota transplantation for relapsing clostridium difficile infection (JAMA - Journal of the American Medical Association (2014) 312:17 (1772-1778) DOI: 10.1001/jama.2014.13875). JAMA - J Am Med Assoc. 2015;313(7 PG-729):729.
20 21 22 23	Anonymous. Faecal microbiota transplantation for ulcerative colitis. Drug and Therapeutics Bulletin. 2017;55(5):51.
24 25 26 27 28	Arkkila P, Hillamaa A, Jalanka J, Mattila E, Anttila V, Satokari R. Long-term safety and effect on gastrointestinal symptoms of fecal microbiota transplantation. United European Gastroenterology Journal. 2017;5 (5 Supplement 1):A757.
29 30 31	Armstrong MJ, Pathmakanthan S, Iqbal TH. Fecal microbiota transplantation for Clostridium difficile infection. JAMA - J Am Med Assoc. 2015;313(7 PG-725-726):725–6.
32 33 34 35 36	Assar S, Nakhle A, Lazar M. Eat your heart out: Right heart collapse from bowel obstruction. American Journal of Respiratory and Critical Care Medicine Conference: American Thoracic Society International Conference, ATS. 2017;195(no pagination).
37 38 39	Bagdasarian N, Rao K, Malani PN. Changing Epidemiology and Control of Clostridium difficile in Older Adults. Curr Transl Geriatr Gerontol Reports. 2013;2(3 PG-143-150):143–50.
40 41 42 43	Bajaj JS, Fagan A, Sikaroodi M, White MB, Sterling RK, Gilles H, et al. Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. Liver Transplantation. 2017;23(7):907-14.
44 45 46 47	Barketi-Klai A, Hoys S, Lambert-Bordes S, Collignon A, Kansau I. Role of fibronectin-binding protein A in Clostridium difficile intestinal colonization. J Med Microbiol. 2011;60(8 PG-1155-1161):1155–61.
48 49 50 51 52	Barnes D, Park KT, Smith M, Kassam Z. Feasibility of a competitively selected universal donor fecal microbiota transplantation protocol and characterization of post-transplant microbiota modification. J Pediatr Gastroenterol Nutr. 2016;63(PG-S142-S143):S142–3.
53 54 55	Barnes DM, Park KT, Kassam Z, Smith MB. Optimizing fecal microbiota transplant: An innovative method to competitively select a universal donor. Am J Gastroenterol. 2015;110(PG-S985):S985.
56 57 58 59 60	Baro E, Galperine T, Denies F, Lannoy D, Lenne X, Odou P, et al. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France. PLoS ONE. 2017;12(1):e0170258.

Bashan A, Gibson TE, Friedman J, Carey VJ, Weiss ST, Hohmann EL, et al. Universality of human microbial dynamics. Nature. 2016;534(7606 PG-259-262):259–62.

1 2

3

4 5 6

7

8

9 10

11 12

13 14

15

16 17

29

41

46

52

56

Battaglioli E, Hale V, Chen J, Jeraldo P, Rekdal VM, Huq L, et al. Prophylactic fecal microbial transplant restores clostridium difficile colonization resistance in a dysbiotic subset of diarrhea associated human microbial communities modeled in germ free mice. Gastroenterology. 2017;152 (5 Supplement 1):S348.

Baty V, Mougin B. What about public perception of antibiotics in the era of the fecal microbiota transplantation? between the devil and the deep blue sea. Am J Gastroenterol. 2013;108(9 PG-1540):1540.

Baumgart DC. [The human microbiome]. Dtsch Medizinische Wochenschrift. 2015;140(19 PG-1451-6):1451– 6.

 Baumgart DC. The human microbiome. [German]. Dtsch Medizinische Wochenschrift. 2015;149(19 PG-1451-1456):1451–6.

Baxter M, Ahmad T, Colville A, Sheridan R. Fatal aspiration pneumonia as a complication of fecal microbiota
 transplant. Clin Infect Dis. 2015;61(1 PG-136-137):136–7.

Bella CJ, Coulson S, Vitetta L. Is co-prescribing a multi-strain probiotic the solution for treating and preventing
 proton pump inhibitor (PPIs) induced Clostridium difficile associated diarrhoea (CDAD) while maintaining
 evidence based pharmacotherapy? Adv Integr Med. 2014;1(1 PG-52-54):52–4.

Benes J, Polivkova S. [Antibiotic treatment of clostridial colitis]. Epidemiol Mikrobiol Imunol. 2016;65(1 PG 15-24):15–24.

Beus A. Recurrent Clostridium difficile infections: Significance and treatment. Infektoloski Glas. 2011;31(3
 PG-155-161):155–61.

Bhanvadia A, Zhu R, Amarnani A, Yang J, Smith M, Grossman EB, et al. Gut microbiota profiling in patients with clostridium difficile infections at urban safety net hospitals: A comparison to the human microbiome project. Gastroenterology. 2016;1)(PG-S895-S896):S895–6.

Bi Z, Lu Y, Weigarden AR, Yao D, Wang L, Khoruts A, et al. Identification of p-cresol sulfate and secondary bile
 salts in human urine as sensitive biomarkers of fecal microbiota transplantation in R-CDI patients. FASEB
 Journal Conference: Experimental Biology. 2017;31(1 Supplement 1).

Biedermann L, Rogler G. Clostridium difficile colitis. [German]. Gastroenterologe. 2014;9(4 PG-350 359):350–9.

50 51 Biedermann L, Rogler G. Clostridium difficile infection. [German]. Gastroenterologe. 2017;12(3):237-52.

Biedermann L, Rogler G. The intestinal microbiota: its role in health and disease. Eur J Pediatr. 2015;174(2
 PG-151-167):151–67.

⁵⁷Bilal M, Khehra R, Strahotin C, Mitre R. Long-term follow-up of fecal microbiota transplantation for treatment
 ⁵⁸of recurrent clostridium difficile infection in a dual solid organ transplant recipient. Case Rep Gastroenterol.
 ⁶⁰2015;9(PG-156-159):156–9.

Page 357 of 454

1 2

3

4 5 6

7

8 9

17

29

34

39

Gut

Blosser R. Probiotic infusion during colonoscopy is an effective therapeutic alternative for refractory or recurrent C. Difficile colitis. Am J Gastroenterol. 2013;108(PG-S181):S181.

Breaux JL, Ray A, Michael S. Characteristics of patients undergoing fecal microbiota transplantation for clostridium difficile infection: One institution's story. Gastroenterology. 2017;152 (5 Supplement 1):S633.

Broecker F, Klumpp J, Moelling K. Long-term microbiota and virome in a Zurich patient after fecal transplantation against Clostridium difficile infection. E-mail: subscrip@blackwellpub.com: Blackwell Publishing Inc.; 2016;(1372 1 PG-29-41):29–41.

Broecker F, Russo G, Klumpp J, Moelling K. Stable core virome despite variable microbiome after fecal transfer. Gut Microbes. 2016;(PG-1-7):1–7.

Broecker F, Russo G, Klumpp J, Moelling K. Stable core virome despite variable microbiome after fecal
 transfer. Gut Microbes. 2017;8(3):214-20.

Brumboiu MI, Poolay Mootien C, Petrus DI, Tzaneva V, Manole FI. The host defense mechanisms and diarrhea
with Clostridium difficile: Who are the patients? Eur J Clin Invest. 2015;45(PG-55):55.

Bruminhent J, Cawcutt KA, Thongprayoon C, Petterson TM, Kremers WK, Razonable RR. Epidemiology, risk
 factors, and outcome of Clostridium difficile infection in heart and heart-lung transplant recipients. Clinical
 Transplantation. 2017;31 (6) (no pagination)(e12968).

Budree S, Elliott RJ, Rao S, Njenga M, Ladha A, Allegretti JR, et al. Donor stool processing time: The effect on the intestinal microbiome and clinical outcomes of fecal microbiota transplantation in clostridium difficile infection. Gastroenterology. 2017;152 (5 Supplement 1):S1006.

³⁵Budree S, Panchal P, Tu E, Kahn S, Kassam Z, Osman M. Access and effectiveness of fecal microbiome transplantation for recurrent clostridium difficile infection in the United States pediatric population: A universal stool bank experience. Journal of Pediatric Gastroenterology and Nutrition. 2017;64:68-9.

Budree S, Rao S, Allegretti JR, Fischer M, Kelly CR, Smith M, et al. The association of donor stool consistency
 by bristol stool scale on microbial profile and clinical outcomes of fecal microbiota transplantation in
 clostridium difficile infection. Gastroenterology. 2017;152 (5 Supplement 1):S630.

Budree S, Tu E, Leith T, Allegretti JR, Rao S, Day R, et al. The association of stool donor diet on microbial
 profile and clinical outcomes of fecal microbiota transplantation in clostridium difficile infection.
 Gastroenterology. 2017;152 (5 Supplement 1):S630-S1.

Budree S, Wong WF, Tu E, Rao S, Allegretti JR, Fischer M, et al. Do specific bacteria drive clinical cure in fecal
 microbiota transplantation for clostridium difficile infection?: Clinical, microbial and metabolomic
 characterization of universal FMT donors. Gastroenterology. 2017;152 (5 Supplement 1):S349.

Bush BR, Rogers MB, Firek B, Kufen A, Jackson Z, Morowitz M, et al. Dynamic changes in the intestinal
 microbiota following fecal microbiota transplantation for refractory inflammatory bowel disease in children.
 Gastroenterology. 2016;1)(PG-S541):S541.

⁵⁹ C. B, G.B. G, M. R, E. A-V, E.O. P, Brace C, et al. Microbial composition analysis of Clostridium difficile infections in an ulcerative colitis patient treated with multiple fecal microbiota transplantations. J Crohns

Colitis. Netherlands: Brace,Chantalle. Dept. Medicine, GI Diseases Research Unit, Queen's University, Kingston, ON, Canada. Electronic address: chantalle.brace@queensu.ca.; 2014;8(9):1133–7.

1 2

3

4 5 6

7

8 9

10

11 12

17

24

29

34

52

Callejas-Diaz A, Gea-Banacloche JC. Clostridium difficile: Deleterious impact on hematopoietic stem cell transplantation. Curr Hematol Malig Rep. 2014;9(1 PG-85-90):85–90.

Cammarota G, Ianiro G, Magalini S, Gasbarrini A, Gui D. Decrease in surgery for clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med. 2015;163(6 PG-487-488):487–8.

Cammarota G, Pecere S, Ianiro G, Masucci L, Curro D. Principles of DNA-Based Gut Microbiota Assessment
 and Therapeutic Efficacy of Fecal Microbiota Transplantation in Gastrointestinal Diseases. Dig Dis. 2016;34(3
 PG-279-285):279–85.

Carlet J. The gut is the epicentre of antibiotic resistance. Antimicrob Resist Infect Control. 2012;1 (no
 pagination)(39 PG-).

Cattaneo C. Gram-positive infections: New and old pathogens in haematological patient. Haematologica.
 2015;100(PG-191-193):191–3.

Chehoud C, Dryga A, Hwang Y, Nagy-Szakal D, Hollister EB, Luna RA, et al. Transfer of viral communities
 between human individuals during fecal microbiota transplantation. MBio. 2016;7 (2) (no
 pagination)(e00322-16 PG-).

Chen LA, Hourigan S, Radin A, Weidner M, Oliva-Hemker MM, Sears C, et al. Bile acid composition changes
 over 6 months following fecal microbiota transplantation in children with recurrent C. Difficile infections
 2016 ACG presidential poster award. Am J Gastroenterol. 2016;111(PG-S453-S454):S453–4.

Chintalapally R, Kukkadapu T, Parikh S, Mangaonkar AA, Boppidi HR, Kota V, et al. Clostridium difficile infection in adult patients with acute myeloid leukemia: Incidence, recurrence, and outcomes. J Clin Oncol Conf. 2015;33(15 SUPPL. 1 PG-).

Chitnavis M V, Hays RA. Acute-on-chronic neutropenic fever as a complication following fecal microbiota
 transplantation (FMT) in a patient with shwachman-diamond syndrome. Am J Gastroenterol. 2015;110(PG S492):S492.

Cho J, Sampathkumar P, Seville MT, Kashyap P. Detecting outcomes from clostridium difficile screening on
 admission in patients admitted to a bone marrow transplant unit. Gastroenterology. 2017;152 (5
 Supplement 1):S345.

Chu ND, Smith MB, Perrotta AR, Kassam Z, Alm EJ. Profiling Living Bacteria Informs Preparation of Fecal Microbiota Transplantations. PLoS ONE. 2017;12(1):e0170922.

⁵³ Chuong KH, O'Doherty KC, Secko DM. Media Discourse on the Social Acceptability of Fecal Transplants. Qual
 ⁵⁴ Health Res. 2015;25(10 PG-1359-71):1359–71.

Cicerone C, Bruno G, Lamonaca L, D'Abramo A, Oliva A, Zingaropoli MA, et al. Fecal microbiota
 transplantation via enema for recurrent clostridium difficile infection modulates the inflammatory host
 response and restores intestinal dysbiosis. Digestive and Liver Disease. 2017;49 (Supplement 2):e102.

Page 359 of 454

1

6 7

8

9

17

25

26

27 28 Gut

Cicerone C, Bruno G, Lamonaca L, Trancassini M, Corazziari ES. Fecal microbiota transplantation for recurrent
 clostridium difficile infection: Transplant protocol by retention enema and preliminary results. Digestive and
 Liver Disease. 2017;49 (Supplement 2):e175.

Claassen E. Healthy microbiota by probiotics or fecal transplantation prevent diarrhea: Probiotics are beneficial in case of Clostridium difficile infection. [Dutch]. Pharm Weekbl. 2014;149(10 PG-16-17):16–7.

Claes IJJ, Vargas Garcia CE, Lebeer S. Novel opportunities for the exploitation of host-microbiome
 interactions in the intestine. Curr Opin Biotechnol. 2015;32(PG-28-34):28–34.

Cocanour CS. Best strategies in recurrent or persistent Clostridium difficile infection. Surg Infect (Larchmt).
 2011;12(3 PG-235-239):235-9.

Cohen NA, Maharshak N. Novel Indications for Fecal Microbial Transplantation: Update and Review of the
 Literature. Dig Dis Sci. 2017;62(5):1131-45.

Collins SM, Kassam Z, Bercik P. The adoptive transfer of behavioral phenotype via the intestinal microbiota:
 Experimental evidence and clinical implications. Curr Opin Microbiol. 2013;16(3 PG-240-245):240–5.

Comito D, Cascio A, Romano C. Microbiota biodiversity in inflammatory bowel disease. Ital J Pediatr. 2014;40 (1) (no pagination)(32 PG-).

Costello SP, Tucker EC, La Brooy J, Schoeman MN, Andrews JM. Establishing a fecal microbiota transplant
 service for the treatment of clostridium difficile infection. Clin Infect Dis. 2016;62(7 PG-908-914):908–14.

Costello SP, Van Der Poorten D, Andrews JM. Fecal microbiota transplantation for recurrent Clostridium
 difficile infection: When regulatory affairs do not keep pace with evidence-based medicine. Journal of
 Gastroenterology and Hepatology (Australia). 2017;32:156-7.

Costello SP, Waters O, Bryant RV, Katsikeros R, Makanyanga J, Schoeman M, et al. Short duration, low
 intensity, pooled fecal microbiota transplantation induces remission in patients with mildmoderately active
 ulcerative colitis: A randomised controlled trial. Gastroenterology. 2017;152 (5 Supplement 1):S198-S9.

Crabtree S, Gupta J. Knowledge and attitudes towards faecal bacteriotherapy on ITU. Intensive Care Med.
 2014;1)(PG-S106):S106.

Culligan EP, Sleator RD. Advances in the microbiome: Applications to clostridium difficile infection. J Clin
 Med. 2016;5 (9) (no pagination)(83 PG-).

⁴⁹₅₀ Curry SR. Clostridium difficile. Clin Lab Med. 2017;37(2):341-69.

Davidovics ZH, Vance K, Etienne N, Hyams JS. Fecal Transplantation Successfully Treats Recurrent D-Lactic
 Acidosis in a Child with Short Bowel Syndrome. Journal of Parenteral and Enteral Nutrition. 2017;41(5):896 7.

de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M. Fecal microbiota transplantation in metabolic
 syndrome: History, present and future. Gut Microbes. 2017;8(3):253-67.

59 60

De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11(8 PG-1036-1038):1036-8. De Santis S, Cavalcanti E, Mastronardi M, Jirillo E, Chieppa M. Nutritional keys for intestinal barrier modulation. Front Immunol. 2015;6 (DEC) (no pagination)(612 PG-). del Campo-Moreno R, Alarcon-Cavero T, D'Auria G, Delgado-Palacio S, Ferrer-Martinez M. Enfermedades Infecciosas y Microbiologia Clinica. 2017;06. Dennis M, Salpeter MJ, Hota S. Low awareness but positive attitudes toward fecal transplantation in ontario physicians. Can J Infect Dis Med Microbiol. 2015;26(1 PG-30-32):30-2. Dinh A, Bouchand F, Le Monnier A. [Current treatment and epidemiology of Clostridium difficile infections]. Rev Med Interne. 2015;36(9 PG-596-602):596-602. Dinh A, Bouchand F, Le Monnier A. Current treatment and epidemiology of Clostridium difficile infections. [French]. Rev Med Interne. 2015;36(9 PG-596-602):596-602. Donnelly SC. Elements: In this month's issue. Qjm. 2015;108(5 PG-351-351):351. Dore J, Multon MC, Behier JM, participants of Giens Xxxii RTN. The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect? Therapie. 2017;72(1):21-38. Downs IA, Brandt LJ, Oneto C, Feuerstadt P, Aroniadis OC. Perceptions of fecal microbiota transplantation for diarrhea predominant irritable bowel syndrome. Am J Gastroenterol. 2016;111(PG-S1250-S1251):S1250-1. Drekonja DM. Clostridium difficile infection: Current, forgotten and emerging treatment options. J Comp Eff Res. 2014;3(5 PG-547-557):547-57. Dryden G. Use of serum-derived bovine immunoglobulin/protein isolate (SBI) to manage refractory ulcerative colitis symptoms and avoid surgery. Am J Gastroenterol. 2014;109(PG-S440):S440. Dunwoody R, Steel A, Landy J, Simmonds N. Clostridium difficile and cystic fibrosis: Management strategies and the role of faecal transplantation. Paediatric Respiratory Reviews. 2017. DuPont HL. Diagnosis and management of clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11(10 PG-1216-1223):1216-23. Ebigbo A, Messmann H. [Challenges of Clostridium difficile infection]. Med Klin Intensivmed Notfmed. 2013;108(8 PG-624-7):624-7. Ebigbo A, Messmann H. Challenges of Clostridium difficile infection. [German, English]. Medizinische Klin -Intensivmed und Notfallmedizin. 2013;108(8 PG-624-627):624-7. El Feghaly RE, Bangar H, Haslam DB. The molecular basis of Clostridium difficile disease and host response. Curr Opin Gastroenterol. 2015;31(1 PG-24-29):24-9.

Page 361 of 454

Gut

El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in clostridium difficile infection. Clin Infect Dis. 2013;56(12 PG-1713-1721):1713-21. El-Nachef N, Piceno YM, Kassam Z, Zydek M, Ablaza AJ, Leith T, et al. Fecal microbiota transplantation is safe and effective in chronic pouchitis patients. Gastroenterology. 2017;152 (5 Supplement 1):S1009. Elias J, Lichtman J, Sonnenburg J. Quantifying dynamic host-microbiota signatures of antibiotic-associated GI infection: What can the host proteome tell us? FASEB Journal Conf Exp Biol. 2015;29(1 Meeting Abstracts PG-). Fang Y, Chen J, Yu J, Luo Y, Lou J. The preliminary investigation of fecal microbiota transplantation for pediatric recurrent chronic bowel disease and literary review. J Pediatr Gastroenterol Nutr. 2016;62(PG-233-234):233-4. Farrell JJ, Martin D, Bogner A, Thompson S V, Taylor AM, Swanson KS, et al. Evolving composition of the human intestinal microbiota following fecal transplantation. Gastroenterology. 2016;1)(PG-S430):S430. Fasullo MJ, Al-Azzawi Y, Abergel J. Microscopic colitis after fecal microbiota transplant. ACG Case Reports Journal. 2017;4 (15) (no pagination)(e87). Fenner I, Lensing C, Katz A, Petersen H. Clostridium difficile - Diagnosis by culture or PCR? Int J Med Microbiol. 2009;299(PG-43):43. Ferm S, Varadi N, Fisher C, Gutkin E. Serum-derived bovine immunoglobulin as novel adjunct in complicated clostridium difficile colitis treatment. ACG Case Reports Journal. 2017;4 (10) (no pagination)(e64). Fischer M, Kao DH, Phelps EL, Smith JD, Roach B, Kassam Z, et al. Should we recommend anti-clostridium difficile antibiotic or probiotic prophylaxis?: Risk of clostridium difficile infection with systemic antimicrobial therapy following successful fecal microbiota transplant. Gastroenterology. 2017;152 (5 Supplement 1):S1005. Fischer M, Kelly CR, Phelps EL, Wang E, Roach B, Smith JD, et al. Quality of bowel preparation does not affect outcome of fecal microbiota transplantation for the therapy clostridium difficile infection. Gastroenterology. 2017;152 (5 Supplement 1):S1004-S5. Fischer M, Khan M, Phelps EL, Safdar N, Misch EA, Kaur N, et al. Fecal microbiota transplantation is safe and effective for the treatment of clostridium difficile infection in solid organ transplant recipients. Gastroenterology. 2017;152 (5 Supplement 1):S1005. Fischer M, Phelps E, Cook G, Sipe B, Rex DK, Xu H. Clostridium difficile pcr testing post fecal microbiota transplantation (FMT) predicts success. Am J Gastroenterol. 2015;110(PG-S580):S580. Fischer M, Rex DK, Sipe BW. Letter: faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent Clostridium difficile infection--authors' reply. Aliment Pharmacol Ther. 2015;42(8 PG-1031):1031. Fischer M, Rex DK, Sipe BW. Letter: Faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent Clostridium difficile infection - Authors' reply. Aliment Pharmacol Ther. 2015;42(8 PG-1031):1031.

1):S1004. Fischer M, Torbeck M, Cook G, Mazur S, Phelps E, Sipe B, et al. Weight change after fecal microbiota transplantation (FMT) is not associated with donor body mass index (BMI). Am J Gastroenterol. 2015;110(PG-S585):S585. Flamaing J. Treatment of Clostridium difficileassociated diarrhoea: Guidelines. [Dutch]. Tijdschr Geneeskd. 2015;71(23 PG-1592-1595):1592-5. Floch MH, Walker WA, Madsen K, Sanders ME, Macfarlane GT, Flint HJ, et al. Recommendations for probiotic use - 2011 update. J Clin Gastroenterol. 2011;45(SUPPL. 3 PG-S168-S171):S168-71. Founas A, Wakade Z, Ramachanran P, Ghodoussi A, Tocco J, Moore J, et al. Small bowel obstruction successfully treated with lubiprostone. Am J Gastroenterol. 2015;110(PG-S404):S404. Freedberg DE, Abrams JA. Recent therapeutic advances in gastroenterology and hepatology. Adv Ther. 2013;30(10 PG-855-857):855-7. Freedberg DE, Toussaint NC, Ratner AJ, Whittier S, Wang TC, Wang H, et al. Proton pump inhibitors alter specific taxa in the human fecal microbiome: Results of a crossover trial. Gastroenterology. 2015;1)(PG-S619):S619. Friedman-Korn T, Livovsky DM, Maharshak N, Aviv Cohen N, Paz K, Bar-Gil Shitrit A, et al. Fecal Transplantation for Treatment of Clostridium Difficile Infection in Elderly and Debilitated Patients. Digestive Diseases and Sciences. 2017:1-6. Fuentes S, van Nood E, Tims S, Heikamp-de Jong I, ter Braak CJ, Keller JJ, et al. Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME J. 2014;8(8 PG-1621-1633):1621-33. Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol. 2016;22(22 PG-6817-6819):6817-9. Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol. 2015;21(22 PG-6817-6819):6817-9. Galperine T, Sokol H, Guery B. Fecal microbiota transplantation: Do we need harmonization? Clin Infect Dis. 2017;64(9):1292. Gasbarrini G, Bonvicini F, Gramenzi A. Probiotics history. J Clin Gastroenterol. 2016;50(PG-S116-S119):S116-9. Gedgaudas R, Urba M, Petkevicius V, Jonaitis L, Kiudelis G, Kupcinskas L, et al. First case series of fecal microbiota transplantation for recurrent clostridium difficile infection in baltic countries. United European Gastroenterology Journal. 2017;5 (5 Supplement 1):A313.

Gut

Fischer M, Sipe B, Torbeck M, Xu H, Kassam Z, Allegretti JR. Does fecal microbiota transplantation from an

obese donor lead to weight gain? A case series of 70 recipients. Gastroenterology. 2017;152 (5 Supplement

Gianotti RJ, Moss AC. Fecal microbiota transplantation: From clostridium difficile to inflammatory bowel

1

Gut

2 3	disease. Gastroenterology and Hepatology. 2017;13(4):209-13.
4 5 6 7 8	Gibson D, Kendrick S, Simpson E, Costello D, Davis R, Szetela A, et al. Implementation of xenon ultraviolet-C disinfection robot to reduce hospital acquired infections in hematopoietic stem cell transplant population. Biology of Blood and Marrow Transplantation. 2017;23 (3 Supplement 1):S367.
9 10 11 12	Gollwitzer ES, Marsland BJ. Microbiota abnormalities in inflammatory airway diseases - Potential for therapy. Pharmacol Ther. 2014;141(1 PG-32-39):32–9.
13 14 15 16	Gomollon F. [Developments in the treatment of inflammatory bowel disease: 2014 overview]. Gastroenterol Hepatol. 2014;37 Suppl 3(PG-14-21):14–21.
17 18 19	Gomollon F. Developments in the treatment of inflammatory bowel disease: 2014 overview. [Spanish]. Gastroenterol Hepatol. 2014;37(S3 PG-14-21):14–21.
20 21 22 23	Gorkiewicz G, Wurm P, Hogenauer C, Spindelbock W. Life-threatening antibiotic-associated enterocolitis and severe dysbiosis in critically ill intensive care unit patients. Virchows Arch. 2015;1)(PG-S37):S37.
24 25 26	Gotz VP, Rand KH. Medical management of antimicrobial-associated diarrhea and colitis. Pharmacother J Hum Pharmacol Drug Ther. 1982;2(2 PG-100-9):100–9.
27 28 29 30 31	Goudarzi M, Seyedjavadi SS, Goudarzi H, Mehdizadeh Aghdam E, Nazeri S. Clostridium difficile Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options. Scientifica (Cairo). 2014;2014(PG- 916826):916826.
32 33 34 35 36	Goyal A, Yeh A, Siebold L, Calabro K, Firek B, Bush BR, et al. Clinical efficacy and microbiome findings following fecal microbiota transplant in children with refractory inflammatory bowel disease. Gastroenterology. 2017;152 (5 Supplement 1):S959.
37 38 39	Graness N, Swidsinski A, Schusser GF. Equine fecal microbiota in association with systemic use of antimicrobial drugs in horses with acute colitis. Equine Veterinary Education. 2017;29:16.
40 41 42 43	Greathouse KL, Harris CC, Bultman SJ. Dysfunctional families: Clostridium scindens and secondary bile acids inhibit the growth of clostridium difficile. Cell Metab. 2015;21(1 PG-9-10):9–10.
44 45 46	Groschel DH. Clostridium difficile infection. Crit Rev Clin Lab Sci. 1996;33(3 PG-203-45):203–45.
40 47 48	Groschel DHM. Clostridium difficile infection. Crit Rev Clin Lab Sci. 1996;33(3 PG-203-245):203–45.
49 50 51 52	Habib I, Huq N, Muddana V. Standardized openbiome product as a treatment for clostridium difficile infections: A single center experience. Gastroenterology. 2017;152 (5 Supplement 1):S951.
53 54 55 56	Han S, Lee K, Lee KA, Paik H, Lee J, Kim M, et al. Importance of acquisition of carbapenemase (KPC)-producing enterobacteriaceae in solid organ transplant recipients: A single-center experience. American Journal of Transplantation. 2017;17:327.
57 58 59 60	He Z, Zhang F. Principle, Protocol and Risk Management of Chinese Fecal Microbiota Bank. [Chinese]. Chinese Journal of Gastroenterology. 2017;22(4):193-8.

Hecht GA, Orenstein R, Dubberke ER, Lee C, Khanna S. Lack of association with patient demographics and outcomes in punch CD 2, a randomized controlled trial of RBX2660, a microbiota-based drug for recurrent clostridium difficile infection. Gastroenterology. 2017;152 (5 Supplement 1):S951-S2. Hecker MT, Ho E, Donskey CJ. Fear of Failure: Engaging Patients in Antimicrobial Stewardship after Fecal Transplantation for Recurrent Clostridium difficile Infection. Infect Control Hosp Epidemiol. 2017;38(1 PG-127-129):127-9. Hell M, Bernhofer C, Stalzer P, Kern JM, Claassen E. Probiotics in Clostridium difficile infection: Reviewing the need for a multistrain probiotic. Benef Microbes. 2013;4(1 PG-39-51):39–51. Hove H, Tvede M, Mortensen PB. Antibiotic-associated diarrhoea, Clostridium difficile, and short-chain fatty acids. Scand J Gastroenterol. 1996;31(7 PG-688-693):688-93. Hrebinko K, Zuckerbraun BS. Clostridium difficile: What the surgeon needs to know. Seminars in Colon and Rectal Surgery. 2017. Iacob T, TaTulescu DF, Dumitrascu DL. Therapy of the postinfectious irritable bowel syndrome: An update. Clujul Medical. 2017;90(2):133-8. Ianiro G, Masucci L, Simonelli C, Sanguinetti M, Gasbarrini A, Cammarota G. Single-infusion fecal microbiota transplantation is not effective in treating severe clostridium difficile infection. United European Gastroenterology Journal. 2017;5 (5 Supplement 1):A155 iations across the United States: A 10-year nationwide analysis. Gastrointestinal Endoscopy. 2017;85 (5 Supplement 1):AB246-AB7. Jackson M, Olefson S, MacHan JT, Kelly CR. A high rate of alternative diagnoses in patients referred for presumed clostridium difficile infection. J Clin Gastroenterol. 2016;50(9 PG-742-746):742-6. Jansen JW. Fecal microbiota transplant vs oral vancomycin taper: Important undiscussed limitations. Clin Infect Dis. 2017;64(9):1292-3. Jiang ZD, Alexander A, Ke S, Valilis EM, Hu S, Li B, et al. Stability and efficacy of frozen and lyophilized fecal microbiota transplant (FMT) product in a mouse model of Clostridium difficile infection (CDI). Anaerobe. 2017;48:110-4. Joseph OD, Thompson SV, Bogner A, Martin D, Farrell JJ, Swanson KS, et al. Longitudinal study of the human gastrointestinal microbiota following fecal microbiota transplant (FMT) for clostridium difficile infections. FASEB Journal Conference: Experimental Biology. 2017;31(1 Supplement 1). Joshi NM, Goodhand J, Alazawi W, Das S, Wilks M, Rampton D. Predicting treatment failure in C. difficile infection: A prospective observational cohort study. Gut. 2016;65(PG-A209):A209.

Gut

Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother. 2007;51(8 PG-2883-7):2883-7.

Gut

- Jump RLP, Donskey CJ. Clostridium difficile in the Long-Term Care Facility: Prevention and Management Topical Collection on Infectious Diseases in the Elderly. Curr Geriatr Reports. 2015;4(1 PG-60-69):60-9.
- Jump RLP, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: A potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother. 2007;51(8 PG-2883-2887):2883-7.
- Juszczuk K, Grudlewska K, Mikucka A, Gospodarek E. Fecal microbiota transplantation - methods of treatment of recurrent Clostridium difficile infections and other diseases. Postepy Hig Med Dosw (Online). 2017;71(0):220-6.
- Kao PC, Han QJ, Liu S, Li XJ, Inman KS, Chia N. Letter to the editor: The surge of type 2 diabetes mellitus in China - An international alert: Physical exercise and low-caloric diet may reduce the risks of type 2 diabetes mellitus and dementia. Ann Clin Lab Sci. 2016;46(1 PG-114-118):114-8.
- Karakan T. Fecal microbiota transplantation for treating recurrent hepatic encephalopathy: Ready for clinical application? Turk J Gastroenterol. 2017;28(5):425-6.
- Kashani A, Shih DQ. Fecal microbiota transplantation is highly effective for treatment of clostridium difficile infection in patiants with inflammatory bowel disease; a meta-analysis. Gastroenterology. 2017;152 (5 Supplement 1):S988.
- Kassam Z, Fridman S, Burgess J, Fischer M, Amaratunga K, Edelstein C, et al. The cost-effectiveness of competing strategies for managing multiply recurrent clostridium difficile infection: Examining the impact of universal stool banks and encapsulated fecal microbiota transplantation. Am J Gastroenterol. 2015;110(PG-S933-S934):S933-4.
- Kassam Z, Lieberman A, Munoz R, Edelstein C, Osman M, Smith M, et al. The impact of stool banks on access to fecal microbiota transplantation for recurrent clostridium difficile infection in the United States: A geospatial analysis. Am J Gastroenterol. 2016;111(PG-S410):S410.
- Kassam Z, Mendolia G, Vo E, Boughari S, Njenga M, Warren K, et al. Microbial emulsion matrices: A novel method to produce stable, orally available capsules for fecal microbiota transplantation to treat clostridium difficile. Am J Gastroenterol. 2015;110(PG-S568-S569):S568-9.
- Kato K, Sekizuka T, Sugiyama T, Ishii Y, Kuroda M, Ohkusa T. Characterization of gut microbiome associated with improvement of ulcerative colitis after antibiotic combination therapy using fecal metagenomic analysis. United European Gastroenterology Journal. 2017;5 (5 Supplement 1):A264-A5.
- Kazerouni A, Burgess J, Burns LJ, Wein LM. Optimal screening and donor management in a public stool bank. Microbiome. 2015;3(PG-75):75.
- Kellermayer R, Balderas M, Nagy-Szakal D, Luna RA, Ihekweazu F, Queliza K, et al. Microbiome and metabolome responses to fecal microbiota transplantation for recurrent clostridium difficile infection in pediatric patients. Gastroenterology. 2017;152 (5 Supplement 1):S152.
- Kelly C, De Leon L, Kerstetter D, Okpara N. Barriers to greater utilization of fecal bacteriotherapy for chronic clostridium difficile infection. Am J Gastroenterol. 2010;105(PG-S135-S136):S135-6.

Kelly CR, Kunde SS, Khoruts A. Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies. Clin Gastroenterol Hepatol. 2014;12(2 PG-283-288):283–8.

1 2

3

4 5 6

7

8 9

33

46

51

57

Kercsak A, Sullivan E, Sikand H. Implementation and outcomes of fecal microbiota transplantation in a four hospital system. Pharmacotherapy. 2015;35 (11)(PG-e274):e274.

Khanna S, Hecht GA, Dubberke ER, Orenstein R, Lee C, Gerding DN. Alterations in microbial diversity are associated with treatment success with RBX2660, a microbiota-based drug for the prevention of recurrent clostridium difficile infection: Results from punch CD 2, a randomized doubleblind placebo-controlled trial. Gastroenterology. 2017;152 (5 Supplement 1):S46-S7.

Khanna S, Shin A, Kelly CP. Management of Clostridium difficile Infection in Inflammatory Bowel Disease:
 Expert Review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol
 Hepatol. 2017;15(2):166-74.

Khanna S, Vazquez-Baeza Y, Gonzalez A, Weiss S, Schmidt B, Muniz-Pedrogo DA, et al. Changes in microbial
 ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying
 inflammatory bowel disease. Microbiome. 2017;5(1):55.

Khoruts A, Staley C, Vaughn BP, Graiziger C, Sadowsky MJ. Treatment of urinary tract infections without
 affecting the gut microbiota in patients with recurrent clostridium difficile infection. Gastroenterology.
 2016;1)(PG-S689):S689.

Konijeti G, Sauk J, Shrime M, Ananthakrishnan A. Cost-effectiveness of competing strategies for recurrent
 clostridium difficile infection acg/astrazeneca fellow award. Am J Gastroenterol. 2013;108(PG-S473):S473.

Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing strategies
 for management of recurrent clostridium difficile infection: A decision analysis. Clin Infect Dis. 2014;58(11
 PG-1507-1514):1507–14.

Konturek PC, Dieterich W, Neurath M, Zopf Y. Successful therapy of clostridium difficile infection with fecal
 microbiota transplantation. Gastroenterology. 2017;152 (5 Supplement 1):S341.

Kroner PT, Jirapinyo P, Abougergi MS, Thompson CC. Clostridium difficile regional and divisional incidence
 variations across the United States: a 10-year nationwide analysis. Gastrointestinal Endoscopy. 2017. (5
 Supplement):AB246-AB247.

Kucher MA, Goloschapov OV, Moiseev IS, Afanasyev BV. Fecal microbiota transplantation as a method to
 treat complications after hematopoietic stem cell transplantation. Cellular Therapy and Transplantation.
 2017;6(1):20-9.

Kump PK, Krause R, Steininger C, Grochenig HP, Moschen A, Madl C, et al. [Recommendations for the use of
 faecal microbiota transplantation "stool transplantation": consensus of the Austrian Society of
 Gastroenterology and Hepatology (OGGH) in cooperation with the Austrian Society of Infectious Diseases
 and Tropical Medicine]. Z Gastroenterol. 2014;52(12 PG-1485-92):1485–92.

Laffin M, Millan B, Madsen KL. Fecal microbial transplantation as a therapeutic option in patients colonized
 with antibiotic resistant organisms. Gut Microbes. 2017;8(3):221-4.

Page 367 of 454

Gut

2 3 4 5	Lagier JC, Aubry C, Delord M, Michelet P, Tissot-Dupont H, Million M, et al. From Expert Protocols to Standardized Management of Infectious Diseases. Clin Infect Dis. 2017;65:S12-S9.
6 7 8	Landy J, Perry-woodford ZL, Clark SK, Hart A. Patients' perspectives of faecal transplantation for pouchitis. J Crohn's Colitis. 2012;6(PG-S143):S143.
9 10 11 12 13	Lapointe-Shaw L, Tran KL, Coyte PC, Hancock-Howard RL, Powis J, Poutanen SM, et al. Cost-effectiveness analysis of six strategies to treat recurrent clostridium difficile infection. PLoS One. 2016;11 (2) (no pagination)(e0149521 PG-).
14 15 16 17 18	Leber A, Hontecillas R, Abedi V, Tubau-Juni N, Zoccoli-Rodriguez V, Stewart C, et al. Modeling new immunoregulatory therapeutics as antimicrobial alternatives for treating Clostridium difficile infection. Artif Intell Med. 2017;78:1-13.
19 20 21 22 23	Leber A, Viladomiu M, Hontecillas R, Abedi V, Philipson C, Hoops S, et al. Systems modeling of interactions between mucosal immunity and the gut microbiome during Clostridium difficile infection. PLoS One. 2015;10 (7) (no pagination)(e0134849 PG-).
24 25 26 27	Lee C, Kim PT, Smith E. Outcome of fecal microbiota transplantation for recurrent clostridium difficile infection on quality of life. Gastroenterology. 2017;152 (5 Supplement 1):S949.
27 28 29 30 31	Lee JC, Lee HY, Kim TK, Kim MS, Park YM, Kim J, et al. Obesogenic diet-induced gut barrier dysfunction and pathobiont expansion aggravate experimental colitis. PLoS ONE. 2017;12(11):e0187515.
32 33	Lee STM, Kahn SA, Delmont TO, Shaiber A, Esen OC, Hubert NA, et al. Tracking microbial colonization in
34	fecal microbiota transplantation experiments via genome-resolved metagenomics. Microbiome.
35 36 37 38	2017;5(1):50.
39 40 41	Leigh DA, Simmons K. Effect of clindamycin and lincomycin therapy on faecal flora. J Clin Pathol. 1978;31(5 PG-439-443):439–43.
42 43 44 45	Lenhart A, Mittal C, Zierle-Ghosh A, Alangaden G. Is colonization with non-toxigenic clostridium difficile organism protective against toxigenic strains? Gastroenterology. 2015;1)(PG-S725):S725.
46 47 48	Lewis BB, Pamer EG. Microbiota-Based Therapies for Clostridium difficile and Antibiotic-Resistant Enteric Infections. Annual Review of Microbiology. 2017;71:157-78.
49 50 51 52	Lichtenstein GR. Fecal microbiota transplantation: An update. Gastroenterology and Hepatology. 2017;13(4):203.
53 54 55 56 57	Lubbert C, Mutters R. [Gastrointestinal infections]. Internist (Berl). 2017;58(2):149-69. Lubbert C, Salzberger B, Mossner J. Fecal microbiota transplantation. [German]. Internist (Berl). 2017;58(5):456-68.

Luo Y, Yang N, Roediger R, Ungaro RC, Grinspan A. Outcomes of fecal microbiota transplantation for clostridium difficile infections in inflammatory bowel disease patients. Gastroenterology. 2017;152 (5 Supplement 1):S342.

Luong Nguyen LB, Osman M, Chiang AL, Edelstein C, Fischer M, Ananthakrishnan AN, et al. The cost-effectiveness of competing strategies for treating severe-complicated clostridium difficile infection: Comparing fecal microbiota transplantation with standard colectomy. Gastroenterology. 2016;1)(PG-S543):S543. Ma GK, Brensinger CM, Wu Q, Lewis JD. Increasing Incidence of Multiply Recurrent Clostridium difficile Infection in the United States: A Cohort Study. Ann Intern Med. 2017;167(3):152-8. Ma GK, Brensinger CM, Wu Q, Lewis JD. Rising incidence of multiply-recurrent clostridium difficile infection in the United States. Gastroenterology. 2017;152 (5 Supplement 1):S340-S1 Makkawi S, Metz L. Case report: Fecal microbiota transplantation associated with 10 years of disease stability in a patient with secondary progressive multiple sclerosis. Multiple Sclerosis Journal. 2017;23 (3 Supplement 1):517. Manthey CF, Eckmann L, Fuhrmann V. Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin? Expert Rev Clin Pharmacol. 2017;10(11):1239-50. Marshall LL, Peasah S, Stevens GA. Clostridium difficile Infection in Older Adults: Systematic Review of Efforts to Reduce Occurrence and Improve Outcomes. Consult Pharm. 2017;32(1):24-41. Massachi S, Hay JW. Cost-effectiveness of various clostridium difficile infection (CDI) treatments in patients with recurrent infections. Value Heal. 2014;17 (3)(PG-A273-A274):A273-4. May T, Mackie RI, Fahey Jr GC, Cremin JC, Garleb KA. Effect of fiber source on short-chain fatty acid production and on the growth and toxin production by clostridium difficile. Scand J Gastroenterol. 1994;29(10 PG-916-922):916-22. Meinke KW, Hamedani F, Wu S, Balla A, Guzman G. Prototheca zopfii associated diverticulitis in an immunosuppressed host, a case presentation and literature review. Human Pathology: Case Reports. 2017;10:43-5. Merlo G, Graves N, Brain D, Connelly LB. Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia. J Gastroenterol Hepatol. 2016;31(12 PG-1927-1932):1927-32. Merlo G, Graves N, Connelly L. Economic evaluation of fecal microbiota transplantation for the treatment of recurrent clostridium difficile infection in Australia. Value Heal. 2015;18 (7)(PG-A628):A628. Mertz L. Omics tech, gut-on-a-chip, and bacterial engineering: New approaches for treating inflammatory bowel diseases. IEEE Pulse. 2016;7(5 PG-9-12):9-12. Metan G, Ture Z, Kaynar L, Berk E, Gursoy S, Alp E, et al. Tigecycline for the treatment of Clostridium difficile infection refractory to metronidazole in haematopoietic stem cell transplant recipients. J Chemother. 2015;27(6 PG-354-7):354-7. Millan B, Laffin M, Madsen K. Fecal Microbiota Transplantation: Beyond Clostridium difficile. Current Infectious Disease Reports. 2017;19 (9) (no pagination)(31).

Page 369 of 454

Gut

Mitchell DK, Van R, Mason EH, Norris DM, Pickering LK. Prospective study of toxigenic Clostridium difficile in children given amoxicillin/clavulanate for otitis media. Pediatr Infect Dis J. 1996;15(6 PG-514-519):514-9. Mitchell I, Shropshire K, Ruel J. Clostridium difficile infection and fecal bacteriotherapy. Gastroenterol Nurs. 2013;36(1 PG-42-50):42-50. Mitchell SW, DeZoysa P, Leis S, Jayewardene AF, Maistry P, Gadalla S, et al. Adverse effects of liquid vs. encapsulated lyophilized fullspectrum microbiota for the treatment of clostridium difficile infection. Gastroenterology. 2017;152 (5 Supplement 1):S346-S7. Mittal C, Hassan S, Abrencillo R, Bajjoka I, Abouljoud M, Patel A, et al. Changing trends of clostridium difficile associated diarrhea (CDAD) in liver transplant recipients (LTR) over 15 years. Transplantation. 2012;94(PG-549):549. Monaghan T, Negm O, MacKenzie B, Hamed M, Shone C, Humphreys DP, et al. High prevalence of subclass-specific binding and neutralising antibodies against clostridium difficile toxins in adult cystic fibrosis sera: Possible mode of protection against symptomatic clostridium difficile infection. Gastroenterology. 2017;152 (5 Supplement 1):S344. Moossavi S, Bishehsari F, Ansari R, Vahedi H, Nasseri-Moghaddam S, Merat S, et al. Minimum requirements for reporting fecal microbiota transplant trial. Middle East J Dig Dis. 2015;7(3 PG-177-180):177-80. Morgan D. New antibiotics: What do we need? Int J Infect Dis. 2016;45(PG-51):51. Moss EL, Falconer SB, Tkachenko E, Wang M, Systrom H, Mahabamunuge J, et al. Long-term taxonomic and functional divergence from donor bacterial strains following fecal microbiota transplantation in immunocompromised patients. PLoS ONE. 2017;12(8):e0182585. Muenyi V, Kerman DH. Changes in the body mass index (BMI) of patients treated with fecal microbiota transplant (FMT) for recurrent C. difficile infection. Gastroenterology. 2017;152 (5 Supplement 1):S820-S1. Mullish BH, McDonald JA, Kao DH, Allegretti JR, Petrof EO, Pechlivanis A, et al. Understanding the mechanisms of efficacy of fecal microbiota transplantation in the treatment of clostridium difficile infection: The potential role of bilemetabolising enzymes. Gastroenterology. 2017;152 (5 Supplement 1):S47. Mullish BH, McDonald JAK, Thursz MR, Marchesi JR. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017;66(4):1354-5. Mussatto CC, Wang J, Koon HW. Orally active cathelicidin mimic ceragenin CSA13 modulates clostridium difficile-associated colitis in mice via a modification of intestinal microbiome. Gastroenterology. 2017;152 (5 Supplement 1):S347-S8. Nanayakkara D, Nanda N. Clostridium difficile infection in solid organ transplant recipients. Current Opinion in Organ Transplantation. 2017;22(4):314-9. Narula N, Kassam Z, Yuan Y, Colombel JF, Ponsioen C, Reinisch W, et al. Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. Inflammatory Bowel Diseases. 2017;23(10):1702-9. https://mc.manuscriptcentral.com/gut

Newman KM, Rank K, Vaughn BP, Khoruts A. Treatment of recurrent clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease. Gastroenterology. 2017;152 (5 Supplement 1):S343.

Ng SCC, Wong SH, Lui RN, Cheung K, Ching JYL, Tang W, et al. Vancomycin followed by fecal microbiota transplantation versus vancomycin for initial clostridium difficile infection: An open-label randomised controlled trial. United European Gastroenterology Journal. 2017;5 (5 Supplement 1):A314.

Niccum BA, Stein DJ, Behm BW, Hays RA. Zinc deficiency predicts fecal microbiota transplant failure in recurrent clostridium difficile infection. Gastroenterology. 2017;152 (5 Supplement 1):S347.

Nicholson M, Alexander E, Bartlett M, Becker P, Davidovics Z, Doby E, et al. Young faculty clinical investigator
 award fecal microbiota transplantation in pediatric clostridium difficile infection, a multi-center study.
 Journal of Pediatric Gastroenterology and Nutrition. 2017;65 (Supplement 2):S219-S20.

Nozu R, Inoue T, Sato K, Hayashimoto N. Safety evaluation of fecal microbiota transplantation materials for
 Clostridium difficile infection in common marmosets. Experimental Animals. 2017;66:S68.

Ong GK, Reidy TJ, Huk MD, Lane FR. Clostridium difficile colitis: A clinical review. Am J Surg. 2017;213(3):565-71.

Oreiro MB, De La Guia AL, Nieto JB, De Paz R, Baltasar P, Hernandez D, et al. Fecal calprotectin in allogeneic
 stem cell trasplantation as surrogate marker of gastrointestinal graft versus host disease. Blood Conf 52nd
 Annu Meet Am Soc Hematol ASH. 2010;116(21 PG-). Pestana L, Pardi D, Khanna S. Incidental colonoscopy
 findings during fecal microbiota transplantation for C. Difficile infection. Gastroenterology. 2016;1)(PG-S747 S748):S747–8.

Pamer EG. Microbiota-mediated defense against intestinal infection. Annals of Hematology. 2017;96:S43 S4.

Panchal P, Budree S, Tu E, Kahn SA, Allegretti JR, Fischer M, et al. Pediatric access to fecal microbiota
 transplantation for recurrent clostridium difficile infection in the United States and the impact of stool banks:
 A geospatial analysis. Gastroenterology. 2017;152 (5 Supplement 1):S849-S50.

Paramsothy S, Borody TJ, Lin E, Finlayson S, Walsh AJ, Samuel D, et al. Donor Recruitment for Fecal
 Microbiota Transplantation. Inflamm Bowel Dis. 2015;21(7 PG-1600-6):1600–6.

Paramsothy S, Borody TJ, Lin E, Finlayson S, Walsh AJ, Samuel D, et al. Donor recruitment for fecal microbiota
 transplantation. Inflamm Bowel Dis. 2015;21(7 PG-1600-1606):1600–6.

Paramsothy S, Walsh A, Borody T, Samuel D, Van Den Bogaerde J, Leong R, et al. Gastroenterologist
 perceptions of faecal microbiota transplantation. J Gastroenterol Hepatol. 2015;30(PG-21):21.

Paramsothy S, Walsh AJ, Borody T, Samuel D, Van Den Bogaerde J, Leong RWL, et al. Gastroenterologist
 perceptions of faecal microbiota transplantation. World J Gastroenterol. 2015;21(38 PG-10907 10914):10907–14.

Page 371 of 454

Gut

- Paramsothy S, Walsh AJ, Borody T, Samuel D, van den Bogaerde J, Leong RW, et al. Gastroenterologist perceptions of faecal microbiota transplantation. World J Gastroenterol. 2015;21(38 PG-10907-14):10907-14. Park HK, Millan B, Hotte N, Kao DH, Madsen K. Altered phage diversity and increased growth rate of escherichia coli are associated with fecal transplantation failure in patients with clostridium difficile infection. Gastroenterology. 2017;152 (5 Supplement 1):S191. Park L, Mone A, Price JC, Tzimas D, Hirsh J, Poles MA, et al. Perceptions of fecal microbiota transplantation for Clostridium difficile infection: Factors that predict acceptance. Ann Gastroenterol. 2017;30(1 PG-83-88):83-8. Pechine S, Janoir C, Collignon A. Emerging monoclonal antibodies against Clostridium difficile infection. Expert Opin Biol Ther. 2017;17(4):415-27. Perez E, Lee CH, Petrof EO. A Practical Method for Preparation of Fecal Microbiota Transplantation. Methods Mol Biol. 2016;1476(PG-259-67):259-67. Perez E, Lee CH, Petrof EO. A practical method for preparation of fecal microbiota transplantation. E-mail: humana@humanapr.com: Humana Press Inc.; 2016;(1476 PG-259-267):259-67. Piceno YM, El-Nachef N, Kassam Z, Smith M, Fadrosh D, Lynch K, et al. Fecal microbiota transplantation differentially influences the gut microbiota of clostridium difficile infection and ileal pouch anal anastomosis patients. Gastroenterology. 2017;152 (5 Supplement 1):S1006. Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? Neurogastroenterol Motil. 2015;27(1 PG-19-29):19–29. Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. Am J Gastroenterol. 2014;109(11 PG-1831-1832):1831–2. Plant BJ. Clostridium Difficile and other gut infections in patients with pulmonary disease, including in cystic fibrosis. Pediatr Pulmonol. 2015;50(PG-113-115):113-5. Prayitno N, Akhavan P, Khan M, Willey BM, Hota S, Sales V, et al. Determination of the optimal storage duration and conditions for faecal transplantation (FTX) samples. Can J Infect Dis Med Microbiol. 2012;23(PG-3B):3B. Prior AR, Kevans D, McDowell L, Cudmore S, Fitzpatrick F. Treatment of Clostridium difficile infection: A national survey of clinician recommendations and the use of faecal microbiota transplantation. J Hosp Infect. 2016;14(PG-). Prior AR, Kevans D, McDowell L, Cudmore S, Fitzpatrick F. Treatment of Clostridium difficile infection: a national survey of clinician recommendations and the use of faecal microbiota transplantation. J Hosp Infect. 2017;95(4):438-41.
- Quraishi MN, Segal J, Mullish B, McCune VL, Hawkey P, Colville A, et al. National survey of practice of faecal
 microbiota transplantation for Clostridium difficile infection in the UK. Journal of Hospital Infection. 2016.

Quraishi MN, Segal J, Mullish B, McCune VL, Hawkey P, Colville A, et al. National survey of practice of faecal microbiota transplantation for Clostridium difficile infection in the UK. J Hosp Infect. 2017;95(4):444-5.

Gut

Ray A, Jones CR, Shannon B, Carter S. Donors are universal in the fight against clostridium difficile: Results from two trials investigating the safety and efficacy of RBX2660, a microbiota-based drug. Gastroenterology. 2017;152 (5 Supplement 1):S950.

Ren RR, Sun G, Yang YS, Peng LH, Wang SF, Shi XH, et al. Chinese physicians' perceptions of fecal microbiota Transplantation. World J Gastroenterol. 2016;22(19 PG-4757-4765):4757–65.

Rice LB. The complex dynamics of antimicrobial activity in the human gastrointestinal tract. Trans Am Clin Climatol Assoc. 2013;124(PG-123-132):123–32.

Richardson C, Kim P, Lee C, Bersenas A, Weese JS. Comparison of Clostridium difficile isolates from individuals with recurrent and single episode of infection. Anaerobe. 2015;33(PG-105-108):105–8.

Saffouri G, Khanna S, Pardi D. Outcomes from rectal vancomycin therapy in patients with severe-complicated
 clostridium difficile infection. Am J Gastroenterol. 2013;108(PG-S175):S175.

Saffouri G, Pardi D, Kashyap P, Khanna S. Body mass index changes after fecal microbiota transplant for recurrent clostridium difficile infection. Am J Gastroenterol. 2016;111(PG-S103):S103.

Sammons JS, Gerber JS, Tamma PD, Sandora TJ, Beekmann SE, Polgreen PM, et al. Diagnosis and
 management of Clostridium difficile infection by pediatric infectious diseases physicians. J Pediatric Infect
 Dis Soc. 2014;3(1 PG-43-48):43–8.

Samuel BP, Crumb TL, Duba MM. What nurses need to know about fecal microbiota transplantation: education, assessment, and care for children and young adults. J Pediatr Nurs. 2014;29(4 PG-354-361):354– 61.

Schvartz B, Leveque N. Asymptomatic carriage of gastro-intestinal pathogens in renaltransplant recipients :
 Epidemiology and risk factors. Nephrol Dial Transplant. 2015;30(PG-iii356-iii357):iii356-iii357.

Sears P, Crook DW, Louie TJ, Miller MA, Weiss K. Fidaxomicin attains high fecal concentrations with minimal
 plasma concentrations following oral administration in patients with clostridium difficile infection. Clin Infect
 Dis. 2012;55(SUPPL.2 PG-S116-S120):S116–20.

Seril DN, Shen B. Clostridium difficile infection in the postcolectomy patient. Inflamm Bowel Dis. United
 States; 2014;20(12):2450–69.

Shaughnessy MK, Bobr A, Kuskowski MA, Johnston BD, Sadowsky MJ, Khoruts A, et al. Environmental
 Contamination in Households of Patients with Recurrent Clostridium difficile Infection. Appl Environ
 Microbiol. 2016;82(9 PG-2686-92):2686–92.

Sheehan D, Brown J, Flemer B, Zulquernain SA, Gahan CG, Joyce S, et al. Mechansims underpinning successful
 faecal microbiota transplantation (FMT) for recurrent clostridium difficile infection. Gastroenterology.
 2017;152 (5 Supplement 1):S47-S8.

60 c

Shen NT, Gold SL, Schneider Y, Cohen-Mekelburg SA, Maw AM, Crawford CV. Probiotic sepsis in patients with

Page 373 of 454
1
2
3 inflammatory bowel disease; Is it some

inflammatory bowel disease; Is it something to worry about? Gastroenterology. 2017;152 (5 Supplement 1):S817.

Gut

Sidhu M, van der Poorten D. The gut microbiome. Aust Fam Physician. 2017;46(4):206-11.

Simmerlein R, Basta A, Gosch M. [Clostridium difficile infections in geriatric patients]. Z Gerontol Geriatr. 2016;49(8 PG-743-761):743–61.

Simojoki ST, Kirjavainen V, Rahiala J, Kanerva J. Surveillance cultures in pediatric allogeneic hematopoietic
 stem cell transplantation. Pediatr Transplant. 2014;18(1 PG-87-93):87–93.

5 Smith AD, Zhang IT, Schubert AM, Giordano NP, Hastie JE, Cowley SC, et al. MAIT cells: Shaping the 7 microbiome, contributing to Clostridium difficile infection. Journal of Immunology Conference: 104th 7 Annual Meeting of the American Association of Immunologists, AAI. 2017;198(1 Supplement 1).

Smith JD, Roach B, Silva M, Louie T, Xu H, Kao DH. Donor body mass index (BMI) does not impact recipient
 BMI following fecal microbiota transplantation for recurrent clostridium difficile infection. Gastroenterology.
 2017;152 (5 Supplement 1):S1007.

Smith MB, Kassam Z, Burgess J, Perrotta AR, Burns LJ, Mendolia GM, et al. The international public stool bank: A scalable model for standardized screening and processing of donor stool for fecal microbiota transplantation. Gastroenterology. 2015;1)(PG-S211):S211.

³⁰ Smith MB, Kelly C, Alm EJ. Policy: How to regulate faecal transplants. Nature. 2014;506(7488):290–1.

Sofi A, Georgescu C, Sodeman T, Nawras A. Physician outlook towards fecal microbiota transplantation in the treatment of recurrent clostridium difficile infection. Gastroenterology. 2013;1)(PG-S241):S241.

Sofi A, Nawras A, Sodeman T, Garborg K, Silverman A. Fecal bacteriotherapy works for clostridium difficile infection - A meta-analysis. Am J Gastroenterol. 2011;106(PG-S161):S161.

Sofi AA, Georgescu C, Sodeman T, Nawras A. Physician outlook toward fecal microbiota transplantation in the treatment of Clostridium difficile infection. Am J Gastroenterol. 2013;108(10 PG-1661-1662):1661–2.

Sofi AA, Silverman AL, Khuder S, Garborg K, Westerink JM, Nawras A. Relationship of symptom duration and
 fecal bacteriotherapy in Clostridium difficile infection-pooled data analysis and a systematic review. Scand J
 Gastroenterol. 2013;48(3 PG-266-73):266–73.

Solbach P, Dersch P, Bachmann O. Individualized treatment strategies for Clostridium difficile infections.
 [German]. Internist (Berl). 2017;58(7):675-81.

Song Y, Garg S, Girotra M, Maddox C, von Rosenvinge EC, Dutta A, et al. Microbiota dynamics in patients
 treated with fecal microbiota transplantation for recurrent Clostridium difficile infection.[Erratum appears
 in PLoS One. 2014;9(7):e104471]. PLoS ONE [Electronic Resour. 2013;8(11 PG-e81330):e81330.

Spalinger M, Gottier C, Hering L, Lang S, Rogler G, Scharl MM. Co-housing DSS treated mice with healthy
 mice results in faster normalization of the intestinal microbiota and promotes recovery. Gastroenterology.
 2017;152 (5 Supplement 1):S987.

Spiceland CM, Saffouri G, Pardi D, Khanna S. Outcomes of fidaxomicin treatment of clostridium difficile infection. Gastroenterology. 2016;1)(PG-S744):S744. Srinivasan I, Tang SJ, Sones JQ. Fecal microbial transplantation. Gastrointestinal Endoscopy. 2017;85(5):1107-8.

Staley C, Hamilton MJ, Vaughn BP, Graiziger C, Newman KM, Kabage A, et al. Successful resolution of recurrent clostridium difficile infection using freeze-dried, encapsulated fecal microbiota. Gastroenterology. 2017;152 (5 Supplement 1):S343-S4.

Staley C, Kelly CR, Brandt LJ, Khoruts A, Sadowsky MJ. Complete microbiota engraftment is not essential for recovery from recurrent Clostridium difficile infection following fecal microbiota transplantation. MBio. 2016;7 (6) (no pagination)(e01965-16 PG-).

Staley C, Khoruts A, Sadowsky MJ. Contemporary Applications of Fecal Microbiota Transplantation to Treat Intestinal Diseases in Humans. Archives of Medical Research. 2017.

Staley C, Vaughn BP, Graiziger CT, Sadowsky MJ, Khoruts A. Gut-sparing treatment of urinary tract infection in patients at high risk of Clostridium difficile infection. J Antimicrob Chemother. 2016;20(PG-20):20.

Staley C, Vaughn BP, Graiziger CT, Sadowsky MJ, Khoruts A. Gut-sparing treatment of urinary tract infection in patients at high risk of Clostridium difficile infection. J Antimicrob Chemother. 2017;72(2):522-8.

Staley C, Vaughn BP, Graiziger CT, Singroy S, Hamilton MJ, Yao D, et al. Community dynamics drive punctuated engraftment of the fecal microbiome following transplantation using freeze-dried, encapsulated fecal microbiota. Gut Microbes. 2017;8(3):276-88.

Steevens CD, Roto D, DeCross AJ. Obese stool donors in fecal microbiota transplantation: Not associated with recipient weight gain! Gastroenterology. 2017;152 (5 Supplement 1):S1007-S8.

Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–98; guiz 499.

Tan M, Smitasin N, Ong D, Lee AJ, Jureen R, Tambyah P, et al. Bacteraemia following faecal microbiota transplantation for recurrent clostridium difficile infection in an immunosuppressed patient. Antimicrobial Resistance and Infection Control Conference: International Conference on Prevention and Infection Control, ICPIC. 2017;6(Supplement 3).

Tariq R, Khanna S. Clostridium difficile infection: Updates in management. Indian J Gastroenterol. 2017;36(1):3-10.

Tariq R, Pardi DS, Weatherly RM, Kammer PP, Khanna S. Outcomes and management of patients with failed fecal microbiota transplantation for recurrent clostridium difficile infection. Gastroenterology. 2017;152 (5 Supplement 1):S346.

Tarig R, Weatherly R, Kammer P, Pardi D, Khanna S. Donor screening experience for fecal microbiota transplantation for patients with recurrent C. Difficile infection. Am J Gastroenterol. 2016;111(PG-S458):S458.

Page 375 of 454

Gut

- Tariq R, Weatherly R, Kammer P, Pardi DS, Khanna S. Donor Screening Experience for Fecal Microbiota Transplantation in Patients With Recurrent C. difficile Infection. J Clin Gastroenterol. 2016;14(PG-). Tariq R, Weatherly RM, Kammer PP, Walker RC, Razonable RR, Pardi DS, et al. Improved urinary tract infections with fecal microbiota transplantation for recurrent clostridium difficile infection. Gastroenterology. 2017;152 (5 Supplement 1):S815. Taur Y, Jeng RR, Perales MA, Littmann ER, Morjaria S, Ling L, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014;124(7 PG-1174-1182):1174-82. Tauxe WM, Dhere T, Ward A, Racsa LD, Varkey JB, Kraft CS. Fecal microbiota transplant protocol for Clostridium Difficile infection. Lab Med. 2015;46(1 PG-e19-e23):e19-23. Taylor KN, McHale MT, Saenz CC, Plaxe SC. Diagnosis and treatment of Clostridium difficile (C. diff) colitis: Review of the literature and a perspective in gynecologic oncology. Gynecol Oncol. 2016;23(PG-). Taylor KN, McHale MT, Saenz CC, Plaxe SC. Diagnosis and treatment of Clostridium difficile (C. diff) colitis: Review of the literature and a perspective in gynecologic oncology. Gynecol Oncol. 2017;144(2):428-37. Thaiss CA, Elinav E. The remedy within: will the microbiome fulfill its therapeutic promise? Journal of Molecular Medicine. 2017;95(10):1021-7. Tissot F, Maillard MH. [Clostridium difficile infections: update on new European recommendations]. Rev Med Suisse. 2014;10(427 PG-913-6, 918-9):913-916,918. To KB, Napolitano LM. Clostridium difficile infection: Update on diagnosis, epidemiology, and treatment strategies. Surg Infect (Larchmt). 2014;15(5 PG-490-502):490-502. Trinh SA, Echenique IA, Penugonda S, Angarone MP. Optimal strategies for the diagnosis of community-onset diarrhea in solid organ transplant recipients: Less is more. Transpl Infect Dis. 2017;19 (2) (no pagination)(e12673). Tschudin-Sutter S, Widmer AF, Perl TM. Clostridium difficile: Novel insights on an incessantly challenging disease. Curr Opin Infect Dis. 2012;25(4 PG-405-411):405–11. Ulmer L, Verma A, Brock J, Iyer R. Fecal microbiota transplant for C. difficile colitis from thawed frozen stool and "real world" experience in a community hospital over two years. Gastroenterology. 2017;152 (5 Supplement 1):S341. Van den Abbeele P, Verstraete W, El Aidy S, Geirnaert A, Van de Wiele T. Prebiotics, faecal transplants and microbial network units to stimulate biodiversity of the human gut microbiome. Microb Biotechnol. 2013;6(4 PG-335-340):335-40.
- Varier RU, Biltaji E, Smith KJ, Roberts MS, Jensen MK, LaFleur J, et al. Cost-effectiveness analysis of treatment
 strategies for initial Clostridium difficile infection. Clin Microbiol Infect. 2014;20(12 PG-1343-1351):1343–51.

Varier RU, Biltaji E, Smith KJ, Roberts MS, Jensen MK, LaFleur J, et al. Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Infect Control Hosp Epidemiol. 2015;36(4 PG-438-444):438-44.

Varier RU, Biltaji E, Smith KJ, Roberts MS, Kyle Jensen M, LaFleur J, et al. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol. 2015;36(4 PG-438-444):438-44.

Varier RU, Biltaji EO, Smith KJ, Roberts MS, LaFleur J, Nelson RE. Cost-effectiveness analysis of fecal microbiota transplantation versus vancomycin for recurrent clostridium difficile infection. Gastroenterology. 2014;1)(PG-S250-S251):S250-1.

Vaughn B, Kahn S, Rubin D, Moss A. Donor stool preparation for fecal transplantation in patients with IBD: Regulatory and financial aspects. Inflamm Bowel Dis. 2013;19(PG-S88):S88.

Vemuri RC, Gundamaraju R, Shinde T, Eri R. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: Antibiotics, probiotics or faecal microbiota transplantation? Beneficial Microbes. 2017;8(2):179-92.

Verna EC, Macesic N, Annavajhala M, Giddins M, Stump S, Brown RS, et al. Dynamic adaptations of intestinal microbiota after liver transplantation. Hepatology. 2017;66 (Supplement 1):116A.

Vestermark CA, Singla MB, Rodriguez B, Armbruster SP. Salmonella-associated clostridium difficile infection presenting as new onset ascites. Am J Gastroenterol. 2016;111(PG-S617):S617.

Vyas D, Aekka A, Vyas A. Fecal transplant policy and legislation. World J Gastroenterol. 2015;21(1 PG-6-11):6–11.

Waye A, Atkins K, Kao D. Cost averted with timely fecal microbiota transplantation in the management of recurrent clostridium difficile infection in Alberta, Canada. J Clin Gastroenterol. 2016;50(9 PG-747-753):747-53.

Weil AA, Hohmann EL. Fecal microbiota transplant: Benefits and risks. Open Forum Infect Dis. 2015;2 (1) (no pagination)(ofv005 PG-).

Weingarden AR, Vaughn BP. Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. Gut Microbes. 2017;8(3):238-52.

Wilson D, Rahni D, Kelly C. Safety outcomes after fecal microbiota transplantation (FMT) For C. Difficile Infection (CDI). Am J Gastroenterol. 2014;109(PG-S207):S207.

Wilson M, Ritz N, Singh S, Lin HC. Successful fecal microbiota transplant depends on the gut microbial community of the recipient to be already perturbed. Gastroenterology. 2017;152 (5 Supplement 1):S1039.

Wolf-Meyer MJ. Normal, Regular and Standard: Scaling the Body through Fecal Microbial Transplants. Med Anthropol Q. 2016;30(PG-30):30.

Wolf-Meyer MJ. Normal, Regular, and Standard: Scaling the Body through Fecal Microbial Transplants. Med Anthropol Q. 2017;31(3):297-314.

Med. 2017;45(6):e600-e6.

Gut

Wurm P, Spindelboeck W, Krause R, Plank J, Fuchs G, Bashir M, et al. Antibiotic-Associated Apoptotic

Enterocolitis in the Absence of a Defined Pathogen: The Role of Intestinal Microbiota Depletion. Crit Care

Xi D, Michail S. Fecal microbiota transplantation in children does not significantly alter body mass index. Gastroenterology. 2017;152 (5 Supplement 1):S648. Yakob L, Riley T V, Paterson DL, Marquess J, Clements AC. Assessing control bundles for Clostridium difficile: a review and mathematical model. Emerg Microbes Infect. 2014;3(6 PG-e43):e43. Yakob L, Riley T V, Paterson DL, Marguess J, Clements ACA. Assessing control bundles for Clostridium difficile: A review and mathematical model. Emerg Microbes Infect. 2014;3 (no pagination)(e43 PG-). Yamazaki Y, Kawarai S, Morita H, Kikusui T, Iriki A. Faecal transplantation for the treatment of Clostridium difficile infection in a marmoset. BMC Vet Res. 2017;13(1):150. Yang Z, Wang X, Bu C. Fecal microbiota transplant for Crohn's disease: A prospective, randomized study in chinese population. United European Gastroenterology Journal. 2017;5 (5 Supplement 1):A112-A3. Yeh A, Morowitz MJ. Probiotics and fecal microbiota transplantation in surgical disorders. Seminars in Colon and Rectal Surgery. 2017. Young VB. Treatment With Fecal Microbiota Transplantation: The Need for Complete Methodological Reporting for Clinical Trials. Ann Intern Med. 2017;167(1):61-2. Zeitz J, Bissig M, Barthel C, Biedermann L, Scharl S, Pohl D, et al. Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease? Eur J Gastroenterol Hepatol. 2016;22(PG-). Zeitz J, Bissig M, Barthel C, Biedermann L, Scharl S, Pohl D, et al. Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease? Eur J Gastroenterol Hepatol. 2017;29(3):322-30. Zellmer C, De Wolfe TJ, Van Hoof S, Blakney R, Safdar N. Patient Perspectives on Fecal Microbiota Transplantation for Clostridium Difficile Infection. Infect Dis Ther. 2016;5(2 PG-155-164):155–64. Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation. Am J Gastroenterol. 2012;107(11 PG-1755):1755. Zhu YL, Guo XH, Zhang LF, Qin YM. A case of fecal microbiota transplantation for treatment of ulcerative colitis. [Chinese]. World Chinese Journal of Digestology. 2017;25(14):1321-6. Zhu YM, Li L. New recognition of gut microbiota and related diseases. [Chinese]. World Chinese Journal of Digestology. 2017;25(23):2095-101. Zipursky JS, Sidorsky TI, Freedman C a., Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis. 2012;55(12):1652-8. https://mc.manuscriptcentral.com/gut

Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection. Can J Gastroenterol Hepatol. 2014;28(6 PG-319-324):319-24.

Gut

Zowall H, Brewer C, Deutsch A. A model of clostridium difficile infection: Dynamic transmission between hospitals, long-term care facilities and communities. Value Heal. 2014;17 (3)(PG-A280-A281):A280–1.

Zowall H, Brewer C, Deutsch A. Cost-effectiveness of fecal microbiota transplant in treating clostridium difficile infection in Canada. Value Heal. 2014;17 (7)(PG-A676):A676.

Zowall H, Brewer C, Deutsch A. Projected cost savings of introducing fecal microbiota transplant treatment for clostridium difficile infection in Canada. Value Heal. 2015;18 (3)(PG-A238):A238.

Zucca M, Scutera S, Savoia D. Novel avenues for Clostridium difficile infection drug discovery. Expert Opin Drug Discov. 2013;8(4 PG-459-477):459-77.

Zuo T, Wong SH, Lam K, Lui R, Cheung K, Tang W, et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut. 2017;15.

D.2. Non-CDI indications:D.2.1. Abstracts not fulfilling selection criteria:

Bajaj JS, Kassam Z, Fagan A, Gavis E, Liu EJ, Kheradman R, et al. Fecal microbiota transplant using a precision medicine approach is safe, associated with lower hospitalization risk and improved cognitive function in recurrent hepatic encephalopathy. Gastroenterology. 2017;152 (5 Supplement 1):S906.

El-Nachef N, Piceno YM, Kassam Z, Zydek M, Ablaza AJ, Leith T, et al. Fecal microbiota transplantation is safe and effective in chronic pouchitis patients. Gastroenterology. 2017;152 (5 Supplement 1):S1009.

Hefazi M, Patnaik MM, Hogan WJ, Litzow MR, Pardi DS, Khanna S. Safety and efficacy of fecal microbiota transplantation for recurrent clostridium infection in patients with hematologic malignancies. Blood Conference: 58th Annual Meeting of the American Society of Hematology, ASH. 2016;128(22).

Ianiro G, Masucci L, Valerio L, Nagel D, D'Aversa F, Poto R, et al. Fecal microbiota transplantation for recurrent C. Difficile infection: Analysis of factors associated with the need for multiple fecal infusions. United European Gastroenterology Journal. 2016;4 (5 Supplement 1):A96-A7.

Karakan T, Ibis M, Cindoruk M, Sargin ZG, Alizadeh N. Faecal microbiota transplantation as a rescue therapy for steroid-dependent and/or nonresponsive patients with ulcerative colitis: A pilot study. Journal of Crohn's and Colitis. 2016;10:S425-S6.

Masaoka T, Yamane T, Mizuno S, Mori K, Hirata K, Matsushita M, et al. Safety and efficacy of fecal microbiota transplantation on functional bowel disorders-a pilot study. Neurogastroenterology and Motility. 2016;28 (Supplement 1):96.

Paramsothy S, Kaakoush N, Kamm MA, Faith J, Clemente J, Walsh A, et al. Faecal microbiota transplantation (FMT) in ulcerative colitis (UC) is associated with specific bacterial changes: Stool and colonic mucosa 16s microbiota analysis from the randomised controlled focus study. United European Gastroenterology Journal.

1 2

3 4 5

6

7

8 9

15

16 17

23 24

25

26

27 28

33

38

43 44

49

2016;4 (5 Supplement 1):A30-A1.

Paramsothy S, Kamm M, Walsh A, Van Den Bogaerde J, Samuel D, Leong R, et al. Multi-donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: A randomised placebocontrolled trial. Journal of Crohn's and Colitis. 2016;10:S14.

Paramsothy S, Kamm MA, Walsh AJ, Van Den Bogaerde J, Samuel D, Leong RWL, et al. Multi donor intense
 faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: A randomised
 placebocontrolled trial and microbiota analysis. Journal of Gastroenterology and Hepatology (Australia).
 2016;31:143.

Rossen N, Fuentes S, Van Der Spek M, Tijssen J, Hartman J, Duflou A, et al. Faecal microbiota transplantation in Ulcerative Colitis: A randomised controlled trial. Journal of Crohn's and Colitis. 2015;9:S2.

D.2.2. Case series not fulfilling selection criteria:

Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: Safety, feasibility, and efficacy trial results. Journal of Gastroenterology and Hepatology (Australia). 2015;30(1):51-8.

Cui B, Li P, Xu L, Zhao Y, Wang H, Peng Z, et al. Step-up fecal microbiota transplantation strategy: A pilot
 study for steroid-dependent ulcerative colitis. Journal of Translational Medicine. 2015;13 (1) (no
 pagination)(298).

Davido B, Batista R, Michelon H, Lepainteur M, Bouchand F, Lepeule R, et al. Is faecal microbiota transplantation an option to eradicate highly drug-resistant enteric bacteria carriage? Journal of Hospital Infection. 2017;95(4):433-7.

Fang YH, Chen J, Yu JD, Luo YY, Lou JG. The preliminary investigation of faecal microbiota transplantation for
 paediatric recurrent chronic bowel diseases and literature review. Hong Kong Journal of Paediatrics.
 2017;22(4):199-203.

Grewal CS, Sood A, Mehta V, Mahajan R. Role of fecal microbiota transplantation in steroid dependant ulcerative colitis: A prospective observational study. Indian Journal of Gastroenterology. 2016;35 (1 Supplement):A39.

Grewal CS, Sood A, Mehta V, Sood N, Midha V, Mahajan R, et al. Role of fecal microbiota transplantation in
 patients with steroid dependant ulcerative colitis. American Journal of Gastroenterology. 2016;111:S1252 S3.

Ishikawa D, Osada T, Haga K, Kodani T, Shibuya T, Watanabe S. Combination therapy of fresh faecal microbial
 transplantation and antibiotics for ulcerative colitis. Journal of Crohn's and Colitis. 2016;10:S335-S6.

Jacob V, Crawford C, Cohen-Mekelburg S, Viladomiu M, Putzel GG, Schneider Y, et al. Single Delivery of High Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity
 in Active Ulcerative Colitis. Inflammatory Bowel Diseases. 2017;23(6):903-11.

Karakan T, Ibis M, Gok Sargn Z. Faecal microbiota transplantation (FMT) as a rescue therapy for steroiddependent and/or nonresponsive patients with ulcerative colitis (UC): A pilot study. United European Gastroenterology Journal. 2016;4 (5 Supplement 1):A268.

Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H, et al. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. Journal of Pediatric Gastroenterology and Nutrition. 2013;56(6):597-601.

Midha V, Singh A, Grewal CS, Mahajan R, Mehta V, Sood A. Efficacy and safety of fecal microbiota therapy in
 ulcerative colitis: Early experience. Journal of Gastroenterology and Hepatology. 2017;32 (Supplement
 3):150-1.

Nishida A, Imaeda H, Ohno M, Inatomi O, Bamba S, Sugimoto M, et al. Efficacy and safety of single fecal
 microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis. Journal of
 Gastroenterology. 2017;52(4):476-82.

Suskind DL, Singh N, Nielson H, Wahbeh G. Fecal microbial transplant via nasogastric tube for active pediatric
 ulcerative colitis. Journal of Pediatric Gastroenterology and Nutrition. 2015;60(1):27-9.

Uygun A, Ozturk K, Demirci H, Oger C, Avci IY, Turker T, et al. Fecal microbiota transplantation is a rescue
 treatment modality for refractory ulcerative colitis. Medicine (United States). 2017;96 (16) (no
 pagination)(e6479).

Wei Y, Gong J, Zhu W, Tian H, Ding C, Gu L, et al. Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora. BMC Microbiology. 2016;16(1):1-9.

Wei Y, Zhu W, Gong J, Guo D, Gu L, Li N, et al. Fecal microbiota transplantation improves the quality of life in patients with inflammatory bowel disease. Gastroenterology Research and Practice. 2015;2015 (no pagination)(517597).

D.2.3. Narrative reviews:

1 2 3

4 5

6

7 8

9

10 11

12

22

26

41 42

43 44 45

46 47

48

49 50 51

52

53 54 55

56

Biehl L. Fecal microbiota transfer. Transfusion Medicine and Hemotherapy. 2017;44 (Supplement 1):22.

Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: Toying with human motions. Journal of Clinical Gastroenterology. 2004;38(6):475-83.

Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. Journal of Crohn's and Colitis. 2014;8(12):1569-81.

D.2.4. Miscellaneous, not relevant:

Aarbiou J, Leeming DJ, Cruwys S, Gudmann NS, Brockbank S, Young A, et al. A comparison of compounds
 with claimed anti-fibrotic activity in a novel human fibroblast to myofibroblast transition assay using IPF
 derived patient material. American Journal of Respiratory and Critical Care Medicine Conference: American
 Thoracic Society International Conference, ATS. 2017;195(no pagination).

Page 381 of 454

- - Abbas SH, Abdulridha MK, Najeb AA. Potential benefit of curcumin adjuvant therapy to the standard Helicobacter pylori eradication therapy in patients with peptic ulcer disease. Asian Journal of Pharmaceutical and Clinical Research. 2017;10(5):313-7.
 - Adachi JA, DuPont HL. Rifaximin: A novel nonabsorbed rifamycin for gastrointestinal disorders. Clinical Infectious Diseases. 2006;42(4):541-7.
 - Adam B, Koldehoff M, Ditschkowski M, Gromke T, Hlinka M, Trenschel R, et al. Endoscopic and Histological Findings Are Predicted by Fecal Calprotectin in Acute Intestinal Graft-Versus-Host-Disease. Digestive Diseases and Sciences. 2016;61(7):2019-26.
 - Agachan F, Pfeifer J, Joo JS, Nogueras JJ, Weiss EG, Wexner SD. Results of perineal procedures for the
 treatment of rectal prolapse. American Surgeon. 1997;63(1):9-12.
 - Ahmed AR, Watanabe H, Aoki J, Shinozaki T, Takagishi K. Schwannoma of the extremities: The role of PET in preoperative planning. European Journal of Nuclear Medicine. 2001;28(10):1541-51.
 - Al-Bayati I, Saadi M, Elhanafi S, McCallum RW. Effectiveness of Bulking Agent (Solesta) Therapy in Fecal Incontinence in Patients Refractory to Conventional Therapies. American Journal of the Medical Sciences. 2017.
 - Almeida AG, Mesquita Gabriel H, Coutinho CA, Sargento L, David C, Oliveira J, et al. Myocardial perfusion and angioplasty. Comparison of myocardial contrast echocardiography and scintigraphy. [Portuguese, English]. Revista Portuguesa de Cardiologia. 2002;21(7-8):859-68.
 - Amini M, Khedmat H, Yari F. Eradication rate of Helicobacter pylori in dyspeptic patients. Medical Science Monitor. 2005;11(4):CR193-CR5.
 - Amini-Bavil-Olyaee S, Trautwein C, Tacke F. Hepatitis E vaccine: Current status and future prospects. Future Virology. 2009;4(2):143-54.
 - Andersen ML, Fallentin E, Lauridsen CA, Kjaer MS, Clemmesen O, Larsen FS, et al. Evaluation of blood perfusion in liver cirrhosis by dynamic contrast enhanced computed tomography. Hepatology. 2017;66 (Supplement 1):343A.
 - Anonymous. Abstracts of the 10th Congress of ECCO. Journal of Crohn's and Colitis Conference: 10th Congress of the European Crohn's and Colitis Organisation, ECCO. 2015;9(no pagination).
 - ⁵⁰ Arguedas MR, Fallon MB. Hepatitis A. Current Treatment Options in Gastroenterology. 2004;7(6):443-50.
 - Arnow PM, Carandang GC, Zabner R, Irwin ME. Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Clinical Infectious Diseases. 1996;22(6):997-1003.
 - Asari SO, Nakajima T, Kojima K, Miyauchi A, Saitou JI, Saga Y, et al. FMT-PET analysis in gene therapy for
 AADC deficiency. Clinical Neurology. 2016;56:S268.

Ashraf W, Park F, Lof J, Quigley EM. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther. 1995;9(6):639-47.

Badin RA, Binley K, Van Camp N, Jan C, Gourlay J, Stewart H, et al. Advancing a state of the art gene therapy for parkinson's disease. Molecular Therapy. 2015;23:S79-S80.

Bajaj JS, Kassam Z, Fagan A, Gavis EA, John B, Fuchs M, et al. Fecal microbiota transplantation from a rationally selected donor is safe in patients with recurrent hepatic encephalopathy: Preliminary data from a randomized trial. Hepatology. 2016;64 (1 Supplement 1):717A.

Bajaj JS, Sikaroodi M, White M, Fagan A, Gilles HC, Heuman DM, et al. Liver transplant significantly improves gut microbial dysbiosis and microbial diversity in cirrhotic patients. Hepatology. 2016;64 (1 Supplement 1):492A-3A.

Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, et al. Thalidomide for inflammatory bowel disease: Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia). 2002;17(2):135-9.

Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol. 2002;17(2):135-9.

Barnes D, Park KT, Smith M, Kassam Z. Feasibility of a competitively selected universal donor fecal microbiota transplantation protocol and characterization of post-transplant microbiota modification. Journal of Pediatric Gastroenterology and Nutrition. 2016;63:S142-S3.

Basu PP, Krishnaswamy N, Korapati R, Tammisetti S, Shah NJ, Hampole H, et al. A new ultra short regimen with dexlansoprazole, moxifloxacin, amoxicillin, nitazoxanide, and doxycycline (DeMAND) in eradication of Helicobacter pylori: An open-label randomized clinical trial. International Journal of Infectious Diseases. 2010;14:S52.

Beecher B, Glassner P, Malchau H, Kwon YM. A concise minimum eight year follow-up of proximally porous-coated tapered titanium femoral stem in primary total hip arthroplasty. International Orthopaedics. 2012;36(8):1561-5.

Belin A, Prost PL, Mercadier G, Grollier G, Lablanche JM. Comparative study of verapamil LI 120 mg 3 times a day and verapamil LP 120 mg twice a day in stable exertional angina. A multicentre study. [French]. Annales de Cardiologie et d'Angeiologie. 1995;44(7):365-71.

Belin A, Prost PL, Mercadier G, Grollier G, Lablanche JM. [Comparative study of verapamil LI 120 mg 3 times a day and verapamil LP 120 mg twice a day in stable exertion-induced angina. A multicenter study]. Ann Cardiol Angeiol (Paris). 1995;44(7):365-71.

Berg KJ, Lundby B, Reinton V, Nordal KP, Rootwelt K, Smith HJ. Gadodiamide in renal transplant patients: Effects on renal function and usefulness as a glomerular filtration rate marker. Nephron. 1996;72(2):212-7.

Bharucha AE. Outcome Measures for Fecal Incontinence: Anorectal Structure and Function. Gastroenterology. 2004;126(1):S90-S8.

Gut

Bhatnagar S, Bahl R, Sharma PK, Kumar GT, Saxena SK, Bhan MK. Zinc with oral rehydration therapy reduces stool output and duration of diarrhea in hospitalized children: A randomized controlled trial. Journal of Pediatric Gastroenterology and Nutrition. 2004;38(1):34-40.

Bosi A, Fanci R, Pecile P, Guidi S, Saccardi R, Vannucchi AM, et al. Aztreonam versus colistin-neomycin for selective decontamination of the digestive tract in patients undergoing bone marrow transplantation: a randomized study. J Chemother. 1992;4(1):30-4.

Bowden R, Murali K, Lambert K, Smyth M, Lonergan M. Chronic use of sodium polystyrene sulfonate (resonium) enables wider implementation of renin-angiotensinaldosterone inhibition in chronic kidney disease patients. Nephrology. 2017;22:67.

Boyle BJ, Long WB, Balistreri WF, Widzer SJ, Huang N. Effect of cimetidine and pancreatic enzymes on serum
 and fecal bile acids and fat absorption in cystic fibrosis. Gastroenterology. 1980;78(5 Pt 1):950-3.

Brenner D, Hiergeist A, Adis C, Gessner A, Ludolph A, Weishaupt J. The fecal microbiome ALS patients.
 Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2017;18 (Supplement 2):198.

Brittnacher MJ, Heltshe SL, Hayden HS, Radey MC, Weiss EJ, Damman CJ, et al. GUTSS: An Alignment-Free Sequence Comparison Method for Use in Human Intestinal Microbiome and Fecal Microbiota Transplantation Analysis. PLoS ONE [Electronic Resource]. 2016;11(7):e0158897.

Burigo T, Fagundes RLM, Trindade EBSDM, Vasconcelos HCFF. Bifidogenic effect of fructooligosaccharides in the intestinal flora of patients with hematological neoplasia. [Portuguese]. Revista de Nutricao. 2007;20(5):491-7.

Butcher KS, Parsons M, MacGregor L, Barber PA, Chalk J, Bladin C, et al. Refining the perfusion-diffusion mismatch hypothesis. Stroke. 2005;36(6):1153-9.

³⁹ Butcher KS, Parsons M, MacGregor L, Barber PA, Chalk J, Bladin C, et al. Refining the perfusion-diffusion ⁴⁰ mismatch hypothesis. Stroke. 2005;36(6):1153-9.

Byrne TA, Persinger RL, Young LS, Ziegler TR, Wilmore DW. A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet. Annals of Surgery. 1995;222(3):243-54; discussion 54-5.

Cai CJ, Li MR, Yi SH, Wang GS, Lu MQ, Chen GH. [Application of somatostatin combined with oral vancomycin
 in the treatment of intestinal obstruction after liver transplantation]. Zhonghua Wei Chang Wai Ke Za Zhi.
 2008;11(4):335-8.

Canullo L, Quaranta A, Teles RP. The microbiota associated with implants restored with platform switching:
 A preliminary report. Journal of Periodontology. 2010;81(3):403-11.

Cao Z, Li Z, Liu Y, Mo R, Ren P, Chen L, et al. The role of bacterial infection (BI) in decompensated cirrhosis
 patients with or without acute-on-chronic liver failure (ACLF). Hepatology International. 2017;11 (1
 Supplement 1):S527-S8.

Carter NJ, Keating GM. Micafungin: A review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients. Pediatric Drugs. 2009;11(4):271-91.

Carter R, Hemingway D, Cooke TG, Pickard R, Poon FW, McKillop JA, et al. A prospective study of six methods for detection of hepatic colorectal metastases. Ann R Coll Surg Engl. 1996;78(1):27-30.

Cataldo PA, O'Brien S, Osler T. Transanal endoscopic microsurgery: A prospective evaluation of functional results. Diseases of the Colon and Rectum. 2005;48(7):1366-71.

Cello JP, Grendell JH, Basuk P, Simon D, Weiss L, Wittner M, et al. Effect of octreotide on refractory AIDSassociated diarrhea. A prospective, multicenter clinical trial. Annals of Internal Medicine. 1991;115(9):705-10.

Ceran N, Mert D, Kocdogan FY, Erdem I, Adalati R, Ozyurek S, et al. A randomized comparative study of singledose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. Journal of Infection and Chemotherapy. 2010;16(6):424-30.

Chakrabarti S, Collingham KE, Stevens RH, Pillay D, Fegan CD, Milligan DW. Isolation of viruses from stools in stem cell transplant recipients: A prospective surveillance study. Bone Marrow Transplantation. 2000;25(3):277-82.

Cheetham M, Brazzelli M, Norton C, Glazener CM. Drug treatment for faecal incontinence in adults. Cochrane
 database of systematic reviews (Online). 2003(3):CD002116.

Chen YL, Cui XH, Li JL. A transposition of iliopsoas in replacement of pelvic floor for incontinence of urination
 and/or defecation in children. [Chinese]. Zhonghua wai ke za zhi [Chinese journal of surgery].
 1994;32(12):724-6.

Chiaravalloti ND, Tulsky DS, Glosser G. Validation of the WMS-III Facial Memory subtest with the Graduate
 Hospital Facial Memory Test in a sample of right and left anterior temporal lobectomy patients. J Clin Exp
 Neuropsychol. 2004;26(4):484-97.

Cho CS, Dayton MT, Thompson JS, Koltun WA, Heise CP, Harms BA. Proctocolectomy-ileal pouch-anal anastomosis for ulcerative colitis after liver transplantation for primary sclerosing cholangitis: A multiinstitutional analysis. Journal of Gastrointestinal Surgery. 2008;12(7):1221-6.

Cho WS, Chae C. Expression of nitric oxide synthase 2 and cyclooxygenase-2 in swine experimentally infected
 with Actinobacillus pleuropneumoniae. Vet Pathol. 2004;41(6):666-72.

⁵⁰ Chouinard LE, Schoeller DA, Watras AC, Clark RR, Close RN, Buchholz AC. Bioelectrical impedance vs. four-⁵¹ compartment model to assess body fat change in overweight adults. Obesity. 2007;15(1):85-92.

Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, et al. Safety and tolerability of
 putaminal AADC gene therapy for Parkinson disease. Neurology. 2009;73(20):1662-9.

Cichowski SB, Dunivan GC, Rogers RG, Murrietta AM, Komesu YM. Standard compared with mnemonic
 counseling for fecal incontinence: A randomized controlled trial. Obstetrics and Gynecology.
 2015;125(5):1063-70.

Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, et al. Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma. 2012;53(5):901-6.

Clerici C, Setchell KD, O'Connell N, Gentili G, Rusticali G, Aversa F, et al. Effect of ursodeoxycholic acid on hypertransaminasaemia and bile acid composition in patients undergoing bone marrow transplantation--a double-blind randomized control study. Italian Journal of Gastroenterology. 1996;28(4):191-8.

Clerici C, Setchelli KDR, O'Connell N, Gentili G, Rusticali G, Aversa F, et al. Effect of ursodeoxycholic acid on
 hypertransaminasaemia and bile acid composition in patients undergoing bone marrow transplantation - A
 double-blind randomized control study. Italian Journal of Gastroenterology. 1996;28(4):191-8.

⁸ Cocchiara G, Calderone F, Luna E, Virzi C, Agrusa A, Romano G, et al. Endoscopic treatment of colorectal
 polyps in a digestive endoscopy outpatient department. [Italian]. Chirurgia italiana. 2004;56(5):669-73.

Cohen HS, Kimball KT. Usefulness of some current balance tests for identifying individuals with disequilibrium due to vestibular impairments. Journal of Vestibular Research: Equilibrium and Orientation. 2008;18(5-6):295-303.

Collins MG, Teo E, Cole SR, Chan CY, McDonald SP, Russ GR, et al. Screening for colorectal cancer and advanced colorectal neoplasia in kidney transplant recipients: cross sectional prevalence and diagnostic accuracy study of faecal immunochemical testing for haemoglobin and colonoscopy. Bmj. 2012;345:e4657.

2 Congilosi SM. The artificial anal sphincter. Perspectives in Colon and Rectal Surgery. 2000;13(1):41-51.

Copelan EA, Bechtel TP, Klein JP, Klein JL, Tutschka P, Kapoor N, et al. Controlled trial of orally administered
 immunoglobulin following bone marrow transplantation. Bone Marrow Transplantation. 1994;13(1):87-91.

Corpetti G, Rosignoli MT, Dionisio P. Comparative bioavailability study of two oral formulations of ibuprofen.
 Arzneimittel-Forschung/Drug Research. 1998;48(4):392-5.

Cox GJ, Matsui SM, Lo RS, Hinds M, Bowden RA, Hackman RC, et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology. 1994;107(5):1398-407.

⁴⁵ Cranen K, Groothuis-Oudshoorn CG, Vollenbroek-Hutten MM, M.J IJ. Toward Patient-Centered
 ⁴⁶ Telerehabilitation Design: Understanding Chronic Pain Patients' Preferences for Web-Based Exercise
 ⁴⁸ Telerehabilitation Using a Discrete Choice Experiment. Journal of medical Internet research. 2017;19(1):e26.

Cranen K, Groothuis-Oudshoorn CG, Vollenbroek-Hutten MM, MJ IJ. Toward Patient-Centered
 Telerehabilitation Design: Understanding Chronic Pain Patients' Preferences for Web-Based Exercise
 Telerehabilitation Using a Discrete Choice Experiment. Journal of Medical Internet Research. 2017;19(1):e26.

55 Culbert P, Gillett H, Ferguson A. Highly effective oral therapy (polyethylene glycol/electrolyte solution) for 56 faecal impaction and severe constipation. Clinical Drug Investigation. 1998;16(5):355-60.

Culbert P, Gillett H, Ferguson A. Highly effective new oral therapy for faecal impaction. British Journal of General Practice. 1998;48(434):1599-600. Culkin DJ, Ramsey CE. Urethrorectal fistula: Transanal, transsphincteric approach with locally based pedicle interposition flaps. Journal of Urology. 2003;169(6):2181-3.

1 2 3

4 5

6 7

8

9 10 11

12

13

14 15

16 17

18

19

24

25

26 27

32

50

55

Curran MP. Bimatoprost: A review of its use in open-angle glaucoma and ocular hypertension. Drugs and Aging. 2009;26(12):1049-71.

Damman CJ, Brittnacher MJ, Westerhoff M, Hayden HS, Radey M, Hager KR, et al. Low level engraftment and improvement following a single colonoscopic administration of fecal microbiota to patients with ulcerative colitis. PLoS ONE. 2015;10 (8) (no pagination)(e0133925).

Davis SC, Yadav JS, Barrow SD, Robertson BK. Gut microbiome diversity influenced more by the Westernized dietary regime than the body mass index as assessed using effect size statistic. MicrobiologyOpen. 2017;6 (4) (no pagination)(e00476).

De Caro G, Gaiani F, Duranti S, Fugazza A, Madia C, Milani C, et al. The role of bifidobacteria in ulcerative
 colitis: Preliminary results. American Journal of Gastroenterology. 2016;111:S325-S6.

de Castro CG, Jr., Ganc AJ, Ganc RL, Petrolli MS, Hamerschlack N. Fecal microbiota transplant after hematopoietic SCT: report of a successful case. Bone Marrow Transplantation. 2015;50(1):145.

De Groot PF, Kahn MT, Backhed F, Nieuwdorp M. Faecal microbiota transfer from donors post bariatric
 surgery does not improve insulin sensitivity in metabolic syndrome subjects. Diabetologia. 2016;59 (1
 Supplement 1):S172-S3.

DeJesus OT. Positron-labeled DOPA analogs to image dopamine terminals. Drug Development Research.
 2003;59(2):249-60.

Demetriades D, Murray JA, Chan L, Ordonez C, Bowley D, Nagy KK, et al. Penetrating colon injuries requiring
 resection: Diversion or primary anastomosis? An AAST prospective multicenter study. Journal of Trauma Injury, Infection and Critical Care. 2001;50(5):765-75.

Demetriades D, Murray JA, Chan LS, Ordonez C, Bowley D, Nagy KK, et al. Handsewn versus stapled
 anastomosis in penetrating colon injuries requiring resection: a multicenter study. J Trauma. 2002;52(1):117 21.

Demetriades D, Murray JA, Chan LS, Ordonez C, Bowley D, Nagy KK, et al. Handsewn versus stapled
 anastomosis in penetrating colon injuries requiring resection: A multicenter study. Journal of Trauma - Injury,
 Infection and Critical Care. 2002;52(1):117-21.

⁵¹ Depauw S, Bosch G, Hesta M, Whitehouse-Tedd K, Hendriks WH, Kaandorp J, et al. Fermentation of animal ⁵² components in strict carnivores: A comparative study with cheetah fecal inoculum. Journal of Animal ⁵⁴ Science. 2012;90(8):2540-8.

Dessinioti C. Managing adverse reactions to HPI. Journal of the European Academy of Dermatology and
 Venereology. 2017;31:16.

59 60 Dhillon S. Argatroban: A review of its use in the management of heparin-induced thrombocytopenia.

218

https://mc.manuscriptcentral.com/gut

Gut

Page 387 of 454

1

Gut

2 3	Am
4 5 6 7 8	Di ulti 199
9 10 11 12	Di ulti
13 14 15 16 17 18	Dill cor Soc 201
19 20 21 22 23	Din clin of (
24 25 26 27 28	Din clin Gas
20 29 30 31 32 33	Do Fee Me
34 35 36 37 38	Doi Saf kai
39 40 41 42 43	Doi Saf 201
44 45 46 47	Dol div 23.
48 49 50 51 52	Do ^v for S1.
53 54 55 56	Du for
57 58	Du

- American Journal of Cardiovascular Drugs. 2009;9(4):261-82.
- Di Giulio G, Lupo L, Tirelli A, Vinci R, Rotondo A, Angelelli G. Blood flow assessment with Doppler color ultrasonography in primary and secondary tumors of the liver. [Italian]. La Radiologia medica. 1997;93(3):225-9.
- Di Giulio G, Lupo L, Tirelli A, Vinci R, Rotondo A, Angelelli G. [Blood flow assessment with Doppler color ultrasonography in primary and secondary tumors of the liver]. Radiol Med (Torino). 1997;93(3):225-9.
- Dillon MT, Tubbs RS, Adunka MC, King ER, Hillman TA, Adunka OF, et al. Round window stimulation for
 conductive and mixed hearing loss. Otology & neurotology: official publication of the American Otological
 Society, American Neurotology Society [and] European Academy of Otology and Neurotology.
 2014;35(9):1601-8.
- Ding T, Telesco S, Monast C, Brodmerkel C, Yatsunenko T, Das A, et al. The gut microbiome differentiates clinical phenotypes in moderate to severe crohn's disease: Results from the certifi study. Canadian Journal of Gastroenterology and Hepatology Conference. 2016(pagination).
- Ding T, Telesco S, Monast CS, Brodmerkel C, Yatsunenko T, Das A, et al. The gut microbiome differentiates
 clinical phenotypes in moderate to severe crohn's disease: Results from the CERTIFI study. United European
 Gastroenterology Journal. 2015;1):A133-A4.
- Doering TM, Reaburn PR, Borges NR, Cox GR, Jenkins DG. The Effect of Higher Than Recommended Protein
 Feedings Post-Exercise on Recovery Following Downhill Running in Masters Triathletes. Int J Sport Nutr Exerc
 Metab. 2017;27(1):76-82.
- ³⁴Doi K, Kanzaki S, Kumakawa K, Usami S, Iwasaki S, Yamanaka N, et al. Evaluation of the Effectiveness and ³⁵Safety in a Multi-center Clinical Trial of VIBRANT SOUNDBRIDGE in Japan. [Japanese]. Nihon Jibiinkoka Gakkai ³⁷kaiho. 2015;118(12):1449-58.
- ³⁹ Doi K, Kanzaki S, Kumakawa K, Usami S, Iwasaki S, Yamanaka N, et al. [Evaluation of the Effectiveness and ⁴⁰ Safety in a Multi-center Clinical Trial of VIBRANT SOUNDBRIDGE in Japan]. Nippon Jibiinkoka Gakkai Kaiho. ⁴¹ 2015;118(12):1449-58.
- Doki N, Suyama M, Sasajima S, Ota J, Igarashi A, Mimura I, et al. Clinical impact of pre-transplant gut microbial
 diversity on outcomes of allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2017;96(9):1517 23.
- Downs IA, Brandt LJ, Oneto C, Feuerstadt P, Aroniadis OC. Perceptions of fecal microbiota transplantation for diarrhea predominant irritable bowel syndrome. American Journal of Gastroenterology. 2016;111:S1250-S1.
- Duman N, Utkutan S, Ozkan H, Ozdogan S. Are the stool characteristics of preterm infants affected by infant formulas? The Turkish journal of pediatrics. 2000;42(2):138-44.
- Dummer R, Migden M. Long-term effects of sonidegib on tumor burden: 30-month results from the phase 2 randomized bolt trial. Annals of Oncology. 2017;28 (Supplement 5):v436.

Dutheil F, Lac G, Courteix D, Dore E, Chapier R, Roszyk L, et al. Treatment of Metabolic syndrome by combination of physical activity and diet needs an optimal protein intake: A randomized controlled trial. Nutrition Journal. 2012;11 (1) (no pagination)(72). Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008;70(21):1980-3. Edenfield AL, Amundsen CL, Wu JM, Levin PJ, Siddiqui NY. Posterior tibial nerve stimulation for the treatment of fecal incontinence: A systematic review. Female Pelvic Medicine and Reconstructive Surgery. 2013;19:S29. Eguchi S, Takatsuki M, Hidaka M, Soyama A, Ichikawa T, Kanematsu T. Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: A prospective randomized study. American Journal of Surgery. 2011;201(4):498-502. Ehrenpreis ED, Chang D, Eichenwald E. Pharmacotherapy for fecal incontinence: A review. Diseases of the Colon and Rectum. 2007;50(5):641-9. El-Nachef N, Kassam Z, Piceno YM, Ablaza AJ, Zydek M, Elliott RJ, et al. Does rifaximin prior to fecal microbiota transplantation improve clinical outcomes compared to microbiome restoration alone in ulcerative colitis? A cohort study evaluating the impact of non-absorbable antibiotic pretreatment. Gastroenterology. 2017;152 (5 Supplement 1):S1008-S9. El-Nachef N, Piceno YM, Kassam Z, Ablaza AJ, Zydek M, Fadrosh D, et al. The role of fecal microbiota transplantation in ulcerative colitis and crohn's disease: Results from a parallel inflammatory bowel disease cohort study. Gastroenterology. 2017;152 (5 Supplement 1):S1008. Enck P, Daublin G, Lubke HJ, Strohmeyer G. Long-term efficacy of biofeedback training for fecal incontinence. Dis Colon Rectum. 1994;37(10):997-1001. Enck P, Daublin G, Lubke HJ, Strohmeyer G, Stein BL, Gordon PH. Long-term efficacy of biofeedback training for fecal incontinence. Diseases of the Colon and Rectum. 1994;37(10):997-1001. Espigado I, Aguilar-Guisado M, Martin-Pena A, Gudiol C, Falantes J, Vazquez L, et al. Discontinuing antibacterial therapy after apyrexia and clinical stability regardless of neutrophil count in febril neutropenia is safe and reduces exposition to antibiotics (howlong randomized trial). Haematologica. 2017;102:330-1. Evans RC, Shim Wong V, Morris AI, Rhodes JM. Treatment of corticosteroid-resistant ulcerative colitis with heparin - A report of 16 cases. Alimentary Pharmacology and Therapeutics. 1997;11(6):1037-40. Evans S, Daly A, Davies P, Macdonald A. Fibre content of enteral feeds for the older child. Journal of Human Nutrition and Dietetics. 2009;22(5):414-21. Fachner J, Gold C, Erkkila J. Music therapy modulates fronto-temporal activity in rest-EEG in depressed clients. Brain Topogr. 2013;26(2):338-54. Ferrara G, Sancin L, Bibalo C, Tommasini A, Taddio A, Pastore S. Faecal calprotectin as screening tool to identify inflammatory bowel disease among juvenile idiopathic patients: Results from a monocentric Italian study. Pediatric Rheumatology. 2017;15:118.

Gut

Ferrecchia CE, Hobbs TR. A technique for orally administered fecal bacteriotherapy to treat chronic diarrhea in rhesus macaques (macaca mulatta). Journal of the American Association for Laboratory Animal Science. 2012;51 (5):655.

Ferrecchia CE, Hobbs TR. Efficacy of oral fecal bacteriotherapy in rhesus macaques (Macaca mulatta) with chronic diarrhea. Comp Med. 2013;63(1):71-5.

Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: What has changed over the past 10 years? British Journal of Haematology. 2007;136(4):521-38.

Fineberg SE, Rathbun MJ, Hufferd S, Fineberg NS, Spradlin CT, Galloway JA, et al. Immunologic aspects of human proinsulin therapy. Diabetes. 1988;37(3):276-80.

Fishpool SJ, Amato-Watkins A, Hayhurst C. Free middle turbinate mucosal graft reconstruction after primary endoscopic endonasal pituitary surgery. Eur Arch Otorhinolaryngol. 2017;274(2):837-44.

Fong SS, Guo X, Cheng YT, Liu KP, Tsang WW, Yam TT, et al. A Novel Balance Training Program for Children With Developmental Coordination Disorder: A Randomized Controlled Trial. Medicine. 2016;95(16):e3492.

Fong SS, Guo X, Liu KP, Ki WY, Louie LH, Chung RC, et al. Task-Specific Balance Training Improves the Sensory
 Organisation of Balance Control in Children with Developmental Coordination Disorder: A Randomised
 Controlled Trial. Scientific reports. 2016;6:20945.

Fong SSM, Guo X, Cheng YTY, Liu KPY, Tsang WWN, Yam TTT, et al. A novel balance training program for children with developmental coordination disorder a randomized controlled trial. Medicine (United States). 2016;95 (16) (no pagination)(e3492).

Ford CD, Reilly W, Wood J, Classen DC, Burke JP. Oral antimicrobial prophylaxis in bone marrow transplant recipients: Randomized trial of ciprofloxacin versus ciprofloxacin-vancomycin. Antimicrobial Agents and Chemotherapy. 1998;42(6):1402-5.

Franscini LC, Vazquez-Montes M, Buclin T, Perera R, Dunand M, Grouzmann E, et al. Pediatric reference intervals for plasma free and total metanephrines established with a parametric approach: relevance to the diagnosis of neuroblastoma. Pediatr Blood Cancer. 2015;62(4):587-93.

Freedman SF, Holgado S, Enyedi LB, Toth CA. Management of ocular torsion and diplopia after macular translocation for age-related macular degeneration: Prospective clinical study. American Journal of Ophthalmology. 2003;136(4):640-8.

Fritsch C, Lang K, Bolsen K, Lehmann P, Ruzicka T. Congenital erythropoietic porphyria. Skin Pharmacology and Applied Skin Physiology. 1998;11(6):347-57.

Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. Expert Opinion on Biological Therapy. 2008;8(9):1417-23.

Garcia-Plaza A, Arenas JI, Belda O, Diago A, Dominguez A, Fernandez C, et al. [A multicenter clinical trial. Zinc
 acexamate versus famotidine in the treatment of acute duodenal ulcer. Study Group of Zinc acexamate (new

UP doses)]. Revista Espanola de Enfermedades Digestivas. 1996;88(11):757-62.

Garcia-Plaza A, Arenas JI, Belda O, Diago A, Dominguez A, Fernandez C, et al. A multicentric trial of zinc acexamate versus famotidine in the treatment of acute duodenal ulcer. [Spanish]. Revista Espanola de Enfermedades Digestivas. 1996;88(11):757-62.

Gut

Gaughran F, Stahl D, Ismail K, Atakan Z, Lally J, Gardner-Sood P, et al. Improving physical health and reducing substance use in psychosis - randomised control trial (IMPACT RCT): Study protocol for a cluster randomised controlled trial. BMC Psychiatry. 2013;13 (no pagination)(263).

Gaughran F, Stahl D, Ismail K, Atakan Z, Lally J, Gardner-Sood P, et al. Improving physical health and reducing substance use in psychosis--randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial. BMC Psychiatry. 2013;13:263.

Gebhard DJ, Price J, Kennedy CE, Akcan-Arikan A. Staging of cardiorenal syndrome for outcome prediction in
 pediatric acute decompensated heart failure. Intensive Care Medicine Experimental Conference: 29th
 Annual Congress of the European Society of Intensive Care Medicine, ESICM. 2016;4(no pagination).

Gelisken F, Voelker M, Schwabe R, Besch D, Aisenbrey S, Szurman P, et al. Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefe's Archive for Clinical and Experimental Ophthalmology. 2007;245(8):1085-95.

Geller RB, Gilmore CE, Dix SP, Lin LS, Topping DL, Davidson TG, et al. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. American Journal of Hematology. 1995;50(3):167-72.

Girgis NI, Butler T, Frenck RW, Sultan Y, Brown FM, Tribble D, et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrobial Agents and Chemotherapy. 1999;43(6):1441-4.

Giuliano M, Pantosti A, Gentile G, Venditti M, Arcese W, Martino P. Effects on oral and intestinal microfloras
 of norfloxacin and pefloxacin for selective decontamination in bone marrow transplant patients. Antimicrob
 Agents Chemother. 1989;33(10):1709-13.

Goel A, Aggarwal R. Prevention of hepatitis E: Another step forward. Future Microbiology. 2011;6(1):23-7.

Goel H, Szczepanczyk K, Bindal P, Shukla P, Tendler B, Latif S. Pituitary germinoma in adult man masquerading
 as pituitary apoplexy: Perils of delayed diagnosis. Endocrine Reviews Conference: 99th Annual Meeting of
 the Endocrine Society, ENDO. 2017;38(3 Supplement 1).

Gomollon F. Treatment of inflammatory bowel diseases. [Spanish]. Gastroenterologia y Hepatologia. 24 2015;38:13-9.

Gosselin KB, Feldman HA, Sonis AL, Bechard LJ, Kellogg MD, Gura K, et al. Serum citrulline as a biomarker of
 gastrointestinal function during hematopoietic cell transplantation in children. Journal of Pediatric
 Gastroenterology and Nutrition. 2014;58(6):709-14.

Page 391 of 454

1 2

3

4 5

6 7

8

9

27

38

Goyal A, Chu A, Calabro K, Firek B, Bush B, Morowitz M. Safety and efficacy of fecal microbiota transplant in children with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition. 2016;63:S212.

Goyal A, Kufen A, Jackson Z, Morowitz M. A study of fecal microbiota transplantation in pediatric patients with inflammatory bowel disease. Inflammatory Bowel Diseases. 2016;22:S74.

Grandjean P, Acker M, Madoff R, Williams NS, Woloszko J, Kantor C. Dynamic myoplasty: Surgical transfer
 and stimulation of skeletal muscle for functional substitution or enhancement. Journal of Rehabilitation
 Research and Development. 1996;33(2):133-44.

Gregory CR, Gourley IM, Cain GR, Patz JD, Imondi KA, Martin JA. Mizoribine serum levels associated with
 enterotoxicity in the dog. Transplantation. 1991;51(4):877-81.

Gruss HJ. Macrogol 3350: Treatment of choice in severe cases of chronic constipation and faecal impactation.
 [German]. Coloproctology. 1998;20(4):161-7.

Gu L, Ding C, Tian H, Yang B, Zhang X, Hua Y, et al. Serial frozen fecal microbiota transplantation in the treatment of chronic intestinal pseudo-obstruction: A preliminary study. Journal of Neurogastroenterology and Motility. 2017;23(2):289-97.

Guay DRP. Drug forecast - The peptide deformylase inhibitors as antibacterial agents. Therapeutics and
 Clinical Risk Management. 2007;3(4):513-25.

Guiot HF, Biemond J, Klasen E, Gratama JW, Kramps JA, Zwaan FE. Protein loss during acute graft-versus host disease: diagnostic and clinical significance. European journal of haematology. 1987;38(2):187-96.

Hadengue A, Spahr L. From bench to bedside: Is the road trickier in alcoholic liver disease? Alcoholism:
 Clinical and Experimental Research. 2010;34:53A.

Hahn S, Kim Y, Garner P. Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children: Systematic review. British Medical Journal. 2001;323(7304):81-5.

Hakkinen K, Pakarinen A, Hannonen P, Hakkinen A, Airaksinen O, Valkeinen H, et al. Effects of strength
training on muscle strength, cross-sectional area, maximal electromyographic activity, and serum hormones
in premenopausal women with fibromyalgia. Journal of Rheumatology. 2002;29(6):1287-95.

Halibasic E, Fuerst E, Heiden D, Japtok L, Diesner SC, Hillebrand P, et al. Significantly reduced plasma levels
 of the bioactive sphingolipid S1P in lung transplanted cystic fibrosis patients are associated with
 gastrointestinal symptoms. Allergy: European Journal of Allergy and Clinical Immunology. 2017;72:195.

Hansson J, Hauschild A, Kunstfeld R, Jacques Grob J, Dreno B, Mortier L, et al. Vismodegib (VISMO), a
 hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in
 1215 patients (pts). Journal of Clinical Oncology Conference. 2016;34(no pagination).

Hasper D, Schefold JC, Baumgart DC. Management of severe abdominal infections. Recent Patents on Anti Infective Drug Discovery. 2009;4(1):57-65.

Transplantation. 2010;14(4):520-8. Hellinger WC, Yao JD, Alvarez S, Blair JE, Cawley JJ, Paya CV, et al. A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation. Transplantation. 2002;73(12):1904-9. Hemingway DM, Cooke TG, Warren H, Bessent RG, McKillop JH, McArdle CS. Dynamic hepatic scintigraphy in colorectal cancer. Nucl Med Commun. 1995;16(10):867-9. Hendrickson R, Ryan J, Dandridge L, Andrews W, Daniel J, Fischer R, et al. Conservative management of pneumatosis intestinalis after pediatric liver transplantation. American Journal of Transplantation. 2017;17:605. Herms F, Haudebourg L, Bagot M, Dutriaux C, Grob JJ, Guillot B, et al. Follow-up of patients with complete remission of locally advanced basal cell carcinoma treated with vismodegib after treatment discontinuation: A retrospective multicentric French study. Journal of Clinical Oncology Conference. 2017;35(15 Supplement 1). Hickman C, Wells D, Gwinnett D, Wilkinson T, Christiansen S, Oliana O, et al. Euploid rate sensitivity to laboratory culture environment: A blind, prospective, randomised, sibling study. Human Reproduction. 2016;31:i216-i8. Ho KS, Ho YH. Controlled, randomized trial of island flap anoplasty for treatment of trans-sphincteric fistula-in-ano: Early results. Techniques in Coloproctology. 2005;9(2):166-8. Holger Johnsen P, Mazzawi T, El-Salhy M, Hausken T, Goll R, Valle PC. Effect of faecal microbiota transplantation on the enteroendocrine cells of the colon in patients with Irritable Bowel Syndrome (IBS): Double blinded-placebo controlled study. Neurogastroenterology and Motility. 2017;29:71. Holster S, Brummer RJ, Repsilber D, Konig J. Fecal microbiota transplantation in irritable bowel syndrome and a randomized placebo-controlled trial. Gastroenterology. 2017;152 (5 Supplement 1):S101-S2. Holvoet T, Boelens J, Joossens M, Raes J, De Vos M, De Looze D. Fecal microbiota transplantation in irritable bowel syndrome with bloating: Results from a prospective pilot study. Gastroenterology. 2015;1):S963-S4. Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int. 2006;70(7):1305-11. Horrocks E, Bremner SA, Stevens N, Norton C, Eldridge S, Knowles CH. Double blind randomised controlled trial of Percutaneous Tibial Nerve Stimulation (PTNS) VS. sham electrical stimulation in the treatment of faecal incontinence. Gastroenterology. 2015;1):S177. Horrocks E, Bremner SA, Stevens N, Norton C, O'Connell PR, Eldridge S, et al. Double blind randomised controlled trial of percutaneous tibial nerve stimulation for the treatment of faecal incontinence in adults. Gut. 2015;64:A4.

Haveman LM, De Jager W, Van Loon AM, Claas ECJ, Prakken BJ, Bierings M. Different cytokine signatures in

children with localized and invasive adenovirus infection after stem cell transplantation. Pediatric

Page 393 of 454

Gut

- Hoverstad T, Carlstedt-Duke B, Lingaas E, Norin E, Saxerholt H, Steinbakk M, et al. Influence of oral intake of seven different antibiotics on faecal short-chain fatty acid excretion in healthy subjects. Scandinavian Journal of Gastroenterology. 1986;21(8):997-1003. Hsu YF, Huang YZ, Lin YY, Tang CW, Liao KK, Lee PL, et al. Intermittent theta burst stimulation over ipsilesional primary motor cortex of subacute ischemic stroke patients: A pilot study. Brain Stimulation. 2013;6(2):166-74. Hu XY, Zhang Y, Chen G, Zhong S, Fan XJ. A prospective cohort study on the influence of high doses of herbs for clearing heat and resolving stasis on survival rates in patients with hepatitis B-related acute-on-chronic liver failure. Journal of Chinese Integrative Medicine. 2012;10(2):176-85. Huang W, Wan X. Update of critical care medicine 2013. [Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014;26(1):3-10. Huang Z, Huang Y, Peng K, Li X, Cheng X, Zhao R, et al. The mutation of interleukin-10/interleukin-10 receptors and clinical characterization of Chinese children with very early onset inflammatory bowel disease: A survery of Chinese very early onset inflammatory bowel disease study group. Journal of Pediatric Gastroenterology and Nutrition. 2016;63:S376. Hudson CO, Karp DR, Pratt T, Northington GM. Anticholinergic therapy and fecal incontinence symptoms in patients with dual incontinence: A pilot study. Female Pelvic Medicine and Reconstructive Surgery. 2016;22 (5 Supplement 1):S108. Huijgens PC, Simoons-Smit AM, Van Loenen AC, Prooy E, Van Tinteren H, Ossenkoppele GJ, et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. Journal of Clinical Pathology. 1999;52(5):376-80. Husain M, Khan RN, Rehmani B, Haris H. Omental patch technique for the ileal perforation secondary to typhoid fever. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association. 2011;17(3):208-11. Ibanez-Cervantes G, Bello-Lopez JM, Fernandez-Sanchez V, Dominguez-Mendoza CA, Acevedo-Alfaro LI. Prevalence of bacterial contamination in platelet concentrates at the National Center of Blood Transfusion (Mexico). Transfusion Clinique et Biologique. 2017;24(2):56-61. Inoue T, Koyama K, Oriuchi N, Alyafei S, Yuan Z, Suzuki H, et al. Detection of malignant tumors: Whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG - Preliminary study. Radiology. 2001;220(1):54-62. Inoue T, Koyama K, Oriuchi N, Alyafei S, Yuan Z, Suzuki H, et al. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study. Radiology. 2001;220(1):54-62. Inoue T, Shibasaki T, Oriuchi N, Aoyagi K, Tomiyoshi K, Amano S, et al. 18F alpha-methyl tyrosine PET studies in patients with brain tumors. Journal of Nuclear Medicine. 1999;40(3):399-405.
- Inoue T, Shibasaki T, Oriuchi N, Aoyagi K, Tomiyoshi K, Amano S, et al. ¹⁸F alpha-methyl tyrosine PET studies in patients with brain tumors. Journal of Nuclear Medicine. 1999;40(3):399-405.

Ishihara S, Kaji T, Kawamura A, Rumi MA, Sato H, Okuyama T, et al. Diagnostic accuracy of a new non-invasive enzyme immunoassay for detecting Helicobacter pylori in stools after eradication therapy. Aliment Pharmacol Ther. 2000;14(5):611-4.

1 2

3

4 5

6 7

8

9

10 11 12

13

14 15

16 17

18

22

27

32

50

54

Shikawa D, Sasaki T, Osada T, Kuwahara-Arai K, Haga K, Shibuya T, et al. Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis. Inflammatory Bowel Diseases. 2017;23(1):116-25.

Ivanyi JL, Plander M, Szendrei T, Toth C. Prevention and treatment of invasive fungal infections in patients with hematological malignancies-results from a single hematological centre. Haematologica. 2016;101:765.

Jaafari A, Boukhriss B, Selmi K, Bencheikh M, Boussabah E, Benyoussef S. [Echocardiography under perfusion with dobutamine. Experience of Tunisian cardiologic service. About 70 cases]. Tunis Med. 2004;82(4):373-6.

Jalanka J, Salonen A, Salojarvi J, Ritari J, Immonen O, Marciani L, et al. Effects of bowel cleansing on the intestinal microbiota. Gut. 2015;64(10):1562-8.

Jaworski A, Mitchell SW, Wong C, Gadalla S, Borody TJ. Patient with relapsing C. difficile successfully treated
 with lyophilised encapsulated faecal microbiota transplant product. Journal of Gastroenterology and
 Hepatology (Australia). 2016;31:161.

Jian Z, Hatib F, Pinsky M. Prevalence of hypotension and prediction of hypotension in intensive care unit.
 Critical Care Conference: 37th International Symposium on Intensive Care and Emergency Medicine Belgium.
 2017;21(1 Supplement 1).

Johnsen PH, Hilpusch F, Cavanagh JP, Sande Leikanger I, Kolstad C, Valle PC, et al. Fecal transplantation in
 Irritable Bowel Syndrome (IBS): An RCT. Neurogastroenterology and Motility. 2017;29:135.

Jolly S, Lobo A. Neuraxial analgesia in the laboring parturient with arnold-chiari type i malformation-relief of
 pain in unchartered terrain? Regional Anesthesia and Pain Medicine Conference: 41st Annual Regional
 Anesthesiology and Acute Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain
 Medicine, ASRA. 2016;41(5).

Jones C, Shannon B. Placebo responders in a randomised controlled trial of rbx2660 for recurrent c. difficile
 infection: Predictive value of 16 s rRNA microbiome analysis. United European Gastroenterology Journal.
 2016;4 (5 Supplement 1):A652.

Jones MP, Talley NJ, Nuyts G, Dubois D. Lack of objective evidence of efficacy of laxatives in chronic constipation. Digestive Diseases and Sciences. 2002;47(10):2222-30.

Joshi NM, Goodhand J, Alazawi W, Das S, Wilks M, Rampton D. Predicting treatment failure in C. difficile infection: A prospective observational cohort study. Gut. 2016;65:A209.

Journois D, Safran D, Castelain MH, Chanu D, Drevillon C, Barrier G. [Comparison of the antithrombotic effects of heparin, enoxaparin and prostacycline in continuous hemofiltration]. Ann Fr Anesth Reanim. 1990;9(4):331-7.

59 60 Joyce MR, Hull TL. Endoanal Advancement Flaps in the Management of Complex Anorectal Fistulas. Seminars

Gut

1 2 3	in Colon and Rectal Surgery. 2009;20(1):24-31.
4 5 6 7	Jung K, Kang BK, Kim JY, Shin KS, Lee CS, Song DS. Effects of epidermal growth factor on atrophic enteritis in piglets induced by experimental porcine epidemic diarrhoea virus. Vet J. 2008;177(2):231-5.
8 9 10 11 12	Kaido T, Shimamura T, Sugawara Y, Sadamori H, Shirabe K, Yamamoto M, et al. Multicentre, randomised, placebocontrolled trial of extract of Japanese herbal medicine Daikenchuto to prevent bowel dysfunction after adult liver transplantation (DKB 14 Study). BMJ Open. 2015;5 (9) (no pagination)(e008356).
13 14 15 16 17	Kaido T, Shimamura T, Sugawara Y, Sadamori H, Shirabe K, Yamamoto M, et al. Multicentre, randomised, placebo-controlled trial of extract of Japanese herbal medicine Daikenchuto to prevent bowel dysfunction after adult liver transplantation (DKB 14 Study). BMJ Open. 2015;5(9):e008356.
18 19 20	Kajbafzadeh A. The dream of functional organ engineering and preclinical transplantation. Iranian Journal of Biotechnology. 2017;ISSUE):43-5.
21 22 23 24	Kajbafzadeh AM. Tissue engineering in pediatric urology reconstruction. International Journal of Urology. 2012;19:250.
25 26 27 28	Kakihana K, Fujioka Y, Suda W, Najima Y, Kuwata G, Sasajima S, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood. 2016;128(16):2083-8.
29 30 31 32 33	Kallarackal GU, Ansari EA, Amos N, Martin JC, Lane C, Camilleri JP. A comparative study to assess the clinical use of Fluorescein Meniscus Time (FMT) with Tear Break up Time (TBUT) and Schirmer's tests (ST) in the diagnosis of dry eyes. Eye. 2002;16(5):594-600.
34 35 36 37	Kanauchi O, Suga T, Tochihara M, Hibi T, Naganuma M, Homma T, et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: First report of a multicenter open control trial. Journal of Gastroenterology. 2002;37(SUPPL. 14):67-72.
38 39 40 41 42	Kang DW, Adams JB, Gregory AC, Borody T, Chittick L, Fasano A, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: An open-label study. Microbiome. 2017;5 (1) (no pagination)(10).
43 44 45 46	Kang SB, Lee TG. Muscle regeneration: Research for the treatment of fecal incontinence. [Korean]. Journal of the Korean Society of Coloproctology. 2010;26(1):1-7.
47 48 49 50 51	Kao SS, Wu DC, Tsay FWT, Tsai KW, Hsu PI. A randomized controlled study comparing 14-day reverse hybrid and bismuth quadruple therapies for helicobacter pylori infection and impacts on clarithromycin resistance of gut microbiota. Gastroenterology. 2017;152 (5 Supplement 1):S183.
52 53 54 55 56	Kato K, Sekizuka T, Sugiyama T, Ishii Y, Kuroda M, Ohkusa T. Characterization of gut microbiome associated with improvement of ulcerative colitis after antibiotic combination therapy using fecal metagenomic analysis. United European Gastroenterology Journal. 2017;5 (5 Supplement 1):A264-A5.
57 58 59 60	Kaufmann S, Horger T, Oelker A, Kloth C, Nikolaou K, Schulze M, et al. Characterization of hepatocellular carcinoma (HCC) lesions using a novel CT-based volume perfusion (VPCT) technique. European Journal of Radiology. 2015;84(6):1029-35.

Kawecki D, Chmura A, Pacholczyk M, Lagiewska B, Adadynski L, Wasiak D, et al. Bacterial infections in the early period after liver transplantation: Etiological agents and their susceptibility. Medical Science Monitor. 2009;15(12):CR628-CR37. Keshaw H, Foong KS, Forbes A, Day RM. Perianal fistulae in Crohn's disease: Current and future approaches to treatment. Inflammatory Bowel Diseases. 2010;16(5):870-80. Khoruts A. Implementation of colorectal cancer guidelines. Pediatric Pulmonology. 2016;51:184. Kim CH, Oh Y, Han K, Seo HW, Kim D, Kang I, et al. Expression of secreted mucins (MUC2, MUC5AC, MUC5B, and MUC6) and membrane-bound mucin (MUC4) in the lungs of pigs experimentally infected with Actinobacillus pleuropneumoniae. Res Vet Sci. 2012;92(3):486-91. Kirk KF, Kousgaard SJ, Nielsen HL, Nielsen H, Thorlacius-Ussing O. Faecal transplant for the treatment of chronic pouchitis-A randomised, placebo-controlled, clinical trial. Colorectal Disease. 2017;19 (Supplement 2):143. Kisiel JB, Taylor WR, Allawi H, Yab TC, Simonson JA, Devens ME, et al. Detection of colorectal cancer and polyps in patients with inflammatory bowel disease by novel methylated stool DNA markers. Gastroenterology. 2014;1):S440-S1. Knowles CH, Horrocks EJ, Bremner SA, Stevens N, Norton C, O'Connell PR, et al. Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDENT): A double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial. The Lancet. 2015;386(10004):1640-8. Knowles CH, Horrocks EJ, Bremner SA, Stevens N, Norton C, O'Connell PR, et al. Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDENT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial. Lancet. 2015;386(10004):1640-8. Ko CY, Tong J, Lehman RE, Shelton AA, Schrock TR, Welton ML. Biofeedback is effective therapy for fecal incontinence and constipation. Arch Surg. 1997;132(8):829-33; discussion 33-4. Komura T, Miura K, Shirasaka T, Ohnuma S, Shimada M, Kajiwara T, et al. Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects. International Journal of Clinical Oncology. 2015;20(1):117-25. Komura T, Ohnuma S, Miura K, Shirasaka T, Kajiwara T, Kudoh K, et al. Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: A shorter drug-free interval leads to more efficient antitumor effects. Cancer Research Conference: 105th Annual Meeting of the American Association for Cancer Research, AACR. 2014;74(19 SUPPL. 1).

Gut

Kovatcheva-Datchary P, Nilsson A, Akrami R, Lee YS, De Vadder F, Arora T, et al. Dietary Fiber-Induced
 Improvement in Glucose Metabolism Is Associated with Increased Abundance of Prevotella. Cell
 Metabolism. 2015;22(6):971-82.

2	
3	Kova
4 5	Koyaı assoc
6	Annu
7	Annu
8	Kram
9 10	enter
11	enter
12	Kram
13	coli s
14 15	Zeitso
16	
17	Kram
18	coli s
19 20	Gastr
20	
22	Kuma
23	Soun
24 25	2015;
25 26	
27	Kuma
28	Soun
29 30	2015;
30 31	
32	Kuma
33	recor
34 25	diffici
35 36	
37	Kushi
38	2012;
39	
40 41	Lacim
41	incon
43	
44	Lad Y
45 46	Parki
40 47	
48	Ladas
49	in chi
50 51	2016;
51 52	
53	Lame
54	in ulc
55 56	
56 57	Lang
58	haplo
50	a nro

Koyama D, Murata M, Hanajiri R, Okuno S, Kamoshita S, Julamanee J, et al. REG3A polymorphism is associated with the incidence of extensive chronic Gvhd after allogeneic BMT. Blood Conference: 58th Annual Meeting of the American Society of Hematology, ASH. 2016;128(22).

Kramer P, Peters B, Schubert S, Photiadis J, Berger F, Ovroutski S. Treatment strategies for protein-losing enteropathy in Fontan patients. Cardiology in the Young. 2016;26:S54.

Krammer HJ, Kamper H, Von Bunau R, Zieseniss E, Stange C, Schlieger F, et al. Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): Results of a prospective study of the records of 3807 patients. [German]. Zeitschrift fur Gastroenterologie. 2006;44(8):651-6.

Krammer HJ, Kamper H, von Bunau R, Zieseniss E, Stange C, Schlieger F, et al. [Probiotic drug therapy with E.
 coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients]. Zeitschrift fur
 Gastroenterologie. 2006;44(8):651-6.

Kumakawa K, Kanzaki S, Usami S, Iwasaki S, Yamanaka N, Doi K, et al. Multicenter Clinical Study of Vibrant Soundbridge in Japan: Analysis of Subjective Questionnaires. [Japanese]. Nihon Jibiinkoka Gakkai kaiho. 2015;118(11):1309-18.

Kumakawa K, Kanzaki S, Usami S, Iwasaki S, Yamanaka N, Doi K, et al. [Multicenter Clinical Study of Vibrant
 Soundbridge in Japan: Analysis of Subjective Questionnaires]. Nippon Jibiinkoka Gakkai Kaiho.
 2015;118(11):1309-18.

Kumar R, Maynard CL, Eipers P, Goldsmith KT, Ptacek T, Grubbs JA, et al. Colonization potential to reconstitute a microbe community in patients detected early after fecal microbe transplant for recurrent C. difficile. BMC Microbiology. 2016;16:5.

Kushnir J, Sadeh A. Assessment of brief interventions for nighttime fears in preschool children. Eur J Pediatr.
 2012;171(1):67-75.

Lacima G, Pera M, Amador A, Escaramis G, Pique JM. Long-term results of biofeedback treatment for faecal incontinence: A comparative study with untreated controls. Colorectal Disease. 2010;12(8):742-9.

Lad Y, Badin RA, Binley K, Van Camp N, Jan C, Gourlay J, et al. OXB-102: An enhanced gene therapy for Parkinson's disease. Human Gene Therapy. 2015;26 (10):A82.

Ladas EJ, Bhatia M, Chen L, Sandler E, Petrovic A, Berman DM, et al. The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation. Bone Marrow Transplantation. 2016;51(2):262-6.

Lamere B, Wendt ER, Kanwar B, Lynch SV. Investigating the microbiome in a phase 1B study of andecaliximab
 in ulcerative colitis. United European Gastroenterology Journal. 2017;5 (5 Supplement 1):A263.

Lang PJ, Schlegel PG, Meisel R, Schulz AS, Greil J, Bader P, et al. TCR-alpha/beta and CD19 depleted
 haploidentical stem cell transplantation following reduced intensity conditioning in children: First results of
 a prospective multicenter phase I/II clinical trial. Blood Conference: 58th Annual Meeting of the American
 Society of Hematology, ASH. 2016;128(22).

Lee K, Byun B, Kim B, Lim I, Choi C, Youn S, et al. Microdose study for amino acid imaging using D-¹⁸F]FMT PET in human brains. European Journal of Nuclear Medicine and Molecular Imaging. 2017;44 (2 Supplement 1):S527.

Lee KC, Byun BH, Kim BI, Lim I, Choi CW, Youn SM, et al. A phase 0 study for amino acid imaging using D-[¹⁸F]FMT PET in human brains. Journal of Labelled Compounds and Radiopharmaceuticals. 2017;60:S182.

Lee SH, Carey S, Dubey R, Matz R. Intervention program in college instrumental musicians, with kinematics analysis of cello and flute playing: a combined program of yogic breathing and muscle strengthening-flexibility exercises. Med Probl Perform Art. 2012;27(2):85-94.

Lenisa L, Espin-Basany E, Rusconi A, Mascheroni L, Escoll-Rufino J, Lozoya-Trujillo R, et al. Anal fistula plug is a valid alternative option for the treatment of complex anal fistula in the long term. International Journal of Colorectal Disease. 2010;25(12):1487-93.

³ Leong L, Choo J, Serisier D, Rogers G. Long-term erythromycin therapy affects microbiota composition and antibiotic resistance gene prevalence in the oropharynx of bronchiectasis patients. Respirology. 2015;20:29.

Leung LY, Lim HK, Abell MW, Zimmerman JJ. Pharmacokinetics and metabolic disposition of sirolimus in
 healthy male volunteers after a single oral dose. Ther Drug Monit. 2006;28(1):51-61.

Leuschner U, Guldutuna S, Imhof M, Hubner K, Benjaminov A, Leuschner M. Effects of ursodeoxycholic acid
 after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. Journal of Hepatology.
 1994;21(4):624-33.

Lewis JD, Reinisch W, Bressler B, Parikh A, Yang H, Rosario M, et al. Faecal calprotectin reductions in patients
 achieving mucosal healing with vedolizumab induction therapy in GEMINI 1. Journal of Crohn's and Colitis.
 2016;10:S206-S8.

Lim TY, Pavlidis P, Pirani T, Gulati S, Samaan M, Chung-Faye G, et al. Vedolizumab in primary and autoimmune sclerosing cholangitis associated inflammatory bowel disease pre and post liver transplantation: A case series. Gut. 2016;65:A89.

⁵Lin E, Jaworski A, Furnari V, Wong C, Bull M, Chapman B, et al. Twelve week storage trial of microbial viability in lyophilized and frozen fecal microbiota preparations. Gastroenterology. 2015;1):S962.

Lin WY, Wang SJ, Yeh SH. Hepatic perfusion index in evaluating treatment effect of transcatheter hepatic artery embolization in patients with hepatocellular carcinoma. Neoplasma. 1995;42(2):89-92.

Lista F, Redondo C, Meilan E, Garcia-Tello A, Ramon de Fata F, Angulo JC. Efficacy and safety of fosfomycintrometamol in the prophylaxis for transrectal prostate biopsy. Prospective randomized comparison with ciprofloxacin. Actas urologicas espanolas. 2014;38(6):391-6.

Lorenz F, Marklund S, Werner M, Palmqvist R, Wahlin BE, Wahlin A. Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation. Scientific reports. 2015;5:7920.

Luber RP, Kariyawasam VC, Dawson LP, Munari SC, Gibson PR, Sparrow MP, et al. Combination therapy with infliximab and a thiopurine vs. infliximab monotherapy in Crohn's disease. Journal of Gastroenterology and Hepatology (Australia). 2016;31:141-2.

Luke M, Ziemssen F, Bartz-Schmidt KU, Gelisken F. Quality of life in a prospective, randomised pilot-trial of
 photodynamic therapy versus full macular translocation in treatment of neovascular age-related macular
 degeneration - A report of 1 year result. Graefe's Archive for Clinical and Experimental Ophthalmology.
 2007;245(12):1831-6.

Luke M, Ziemssen F, Bartz-Schmidt KU, Gelisken F. Quality of life in a prospective, randomised pilot-trial of
 photodynamic therapy versus full macular translocation in treatment of neovascular age-related macular
 degeneration--a report of 1 year results. Graefes Arch Clin Exp Ophthalmol. 2007;245(12):1831-6.

Luke M, Ziemssen F, Voker M, Altpeter E, Beutel J, Besch D, et al. Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefe's Archive for Clinical and Experimental Ophthalmology. 2009;247(6):745-54.

Luke M, Ziemssen F, Volker M, Altpeter E, Beutel J, Besch D, et al. Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol. 2009;247(6):745-54.

Madoff RD. Surgical Treatment Options for Fecal Incontinence. Gastroenterology. 2004;126(1):S48-S54.

Mady FM, Abou-Taleb AE, Khaled KA, Yamasaki K, Iohara D, Taguchi K, et al. Evaluation of carboxymethylbeta-cyclodextrin with acid function: Improvement of chemical stability, oral bioavailability and bitter taste of famotidine. International Journal of Pharmaceutics. 2010;397(1-2):1-8.

Makhlough A, Fakheri H, Hojati S, Hosseini V, Bari Z. A comparison between hybrid therapy and standard triple therapy for Helicobacter pylori eradication in patients with uremia: A randomized clinical trial. Middle East Journal of Digestive Diseases. 2016;8(1):39-43.

Mann PA, McNicholas PM, Chau AS, Patel R, Mendrick C, Ullmann AJ, et al. Impact of antifungal prophylaxis
 on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother.
 2009;53(12):5026-34.

Mansour-Ghanaei F, Shafaghi A, Fallah M. The effect of metronidazole in treating human fascioliasis. Medical
 Science Monitor. 2003;9(10):PI127-PI30.

Mariotti G, Quaranta A, Merli M, Paterno Holtzman L, Piemontese M. Chronic periodontitis and cardiovascular disease: A controlled clinical trial. European Journal of Inflammation. 2013;11(2):459-67.

Marquez HP, Karalli A, Haubenreisser H, Mathew RP, Alkadhi H, Brismar TB, et al. Computed tomography
 perfusion imaging for monitoring transarterial chemoembolization of hepatocellular carcinoma. European
 Journal of Radiology. 2017;91:160-7.

organisms are common in fecal surveillance cultures and do not predict bacteremia but correlate with poorer outcomes in patients undergoing allogeneic stem cell transplants. Blood Conference: 58th Annual Meeting of the American Society of Hematology, ASH. 2016;128(22). Maughan J, Parkin A, Smith AH, Barker MC, Robinson PJ, Finan P, et al. Hepatic perfusion index: a multicentre trial. Nucl Med Commun. 1992;13(3):161-7. Mazique DC. Anchors away: Anchoring bias, confirmation bias, and pulmonary emboli. Journal of General Internal Medicine. 2017;32 (2 Supplement 1):S447. McLauchlin J, Amar CFL, Pedraza-Diaz S, Mieli-Vergani G, Hadzic N, Davies EG. Polymerase chain reaction-based diagnosis of infection with Cryptosporidium in children with primary immunodeficiencies. Pediatric Infectious Disease Journal. 2003;22(4):329-34. McNeil SA, Malani PN, Chenoweth CE, Fontana RJ, Magee JC, Punch JD, et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clinical Infectious Diseases. 2006;42(2):195-203. Metafuni E, Giammarco S, De Ritis D, Rossi M, Bacigalupo A, Sica S, et al. Comparison between serum and fecal calprotectin as marker of graft-versus-host disease. Haematologica. 2016;101:868-9. Michot F, Lefebure B, Bridoux V, Gourcerol G, Kianifard B, Leroi AM, et al. Artificial anal sphincter for severe fecal incontinence implanted by a transvaginal approach: Experience with 32 patients treated at one institution. Diseases of the Colon and Rectum. 2010;53(8):1155-60. Mielcarek M, Furlong T, Storer BE, Green ML, Carpenter PA, McDonald GB, et al. Efficacy and safety of lower-dose glucocorticoids for initial treatment of acute graft-versus-host disease: A randomized controlled trial. Blood Conference: 55th Annual Meeting of the American Society of Hematology, ASH. 2013;122(21). Migden M. Sonidegib's duration of response: Results from the pivotal phase 2 BOLT study over 30 months in patients with locally advanced basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology. 2017;31:39. Miyazaki K, Collins DJ, Walker-Samuel S, Taylor JN, Padhani AR, Leach MO, et al. Quantitative mapping of hepatic perfusion index using MR imaging: A potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. European Radiology. 2008;18(7):1414-21. Mizukami K, Sonoda A, Okimoto T, Kodama M, Murakami K. An open-label prospective randomized multicentre study of daily granulocyte and monocyte adsorptive apheresis as compared with intensive treatment in patients with active ulcerative colitis. Journal of Crohn's and Colitis. 2015;9:S352. Modiba MCM, Koto Z, Lowan TA, Magano S, Segal I, Esser J, et al. Distal splenorenal shunt for non-cirrhotic variceal bleeding in black South Africans. South African Journal of Surgery. 1994;32(3):87-90. Moen MD, McKeage K, Plosker GL, Siddiqui MAA. Imatinib: A review of its use in chronic myeloid leukaemia. Drugs. 2007;67(2):299-320.

Mathews V, Srivastava A, George B, Korula A, Perumalla S, Abubacker FN, et al. Multi-drug resistant

Gut

Molina JM, Tourneur M, Sarfati C, Chevret S, De Gouvello A, Gobert JG, et al. Fumagillin treatment of intestinal microsporidiosis. New England Journal of Medicine. 2002;346(25):1963-9.
Molina JM, Tourneur M, Sarfati C, Chevret S, de Gouvello A, Gobert JG, et al. Fumagillin treatment of intestinal microsporidiosis. New England Journal of Medicine. 2002;346(25):1963-9.
Moller A, Iwasaki K, Kawamura A, Teramura Y, Shiraga T, Hata T, et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos. 1999;27(6):633-6.
Montebugnoli L, Venturi M, Cervellati F, Servidio D, Vocale C, Pagan F, et al. Peri-Implant Response and Microflora in Organ Transplant Patients 1 Year after Prosthetic Loading: A Prospective Controlled Study. Clinical implant dentistry and related research. 2015;17(5):972-82.
Mortimer K, Brown A, Feary J, Jagger C, Lewis S, Antoniak M, et al. Dose-ranging study for trials of therapeutic infection with necator Americanus in humans. American Journal of Tropical Medicine and Hygiene. 2006;75(5):914-20.

Muller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q<inf>10</inf> supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neuroscience Letters. 2003;341(3):201-4.

Muller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neuroscience Letters. 2003;341(3):201-4.

Muraji T, Nishijima E, Higashimoto Y, Tsugawa C. Biliary atresia: current management and outcome. The Tohoku journal of experimental medicine. 1997;181(1):155-60.

Muramatsu SI. A phase i study of aromatic l-amino acid decarboxylase gene therapy for parkinson7s disease. Journal of Gene Medicine. 2014;16 (7-8):218.

Muramatsu SI. In vivo imaging in cell and gene therapy for parkinson's disease. Journal of Gene Medicine. 2014;16 (7-8):214.

⁴ Muramatsu SI, Fujimoto KI, Kato S, Asari S, Mizukami H, Ikeguchi K, et al. Aadc gene therapy for parkinson's ⁵ disease: Four years of follow-up. Journal of Gene Medicine. 2014;16 (7-8):220.

Muramatsu SI, Fujimoto KI, Kato S, Mizukami H, Asari S, Ikeguchi K, et al. A phase i study of aromatic l-amino
 acid decarboxylase gene therapy for parkinson's disease. Molecular Therapy. 2010;18(9):1731-5.

Naeini AE, Sharifi M, Shahidi S, Taheri S, Seirafian S, Taheri D, et al. Intestinal fungal and parasitic infections
 in kidney transplant recipients: a multi-center study. Saudi journal of kidney diseases and transplantation:
 an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2012;23(4):677-83.

Nagappan V, Deresinski S. Posaconazole: A broad-spectrum triazole antifungal agent. Clinical Infectious
 Diseases. 2007;45(12):1610-7.

Nagel R, Cuttell L, Stensvold CR, Mills PC, Bielefeldt-Ohmann H, Traub RJ. Blastocystis subtypes in

symptomatic and asymptomatic family members and pets and response to therapy. Internal Medicine Journal. 2012;42(11):1187-95.

Gut

Nahmias C, Wahl L, Chirakal R, Firnau G, Garnett ES. A probe for intracerebral aromatic amino-acid decarboxylase activity: Distribution and kinetics of [¹⁸F]6-fluoro-L-m-tyrosine in the human brain. Movement Disorders. 1995;10(3):298-304.

Nordgaard I, Hove H, Clausen MR, Mortensen PB. Colonic production of butyrate in patients with previous colonic cancer during long-term treatment with dietary fibre (Plantago ovata seeds). Scandinavian Journal of Gastroenterology. 1996;31(10):1011-20.

Norton C, Chelvanayagam S, Wilson-Barnett J, Redfern S, Kamm MA. Randomized Controlled Trial of Biofeedback for Fecal Incontinence. Gastroenterology. 2003;125(5):1320-9.

Obradovic V, Artiko V, Radevic B, Dapcevic B, Petrovic N. Single injection hepatic radionuclide angiography and hepatobiliary scintigraphy in the evaluation of liver transplant function. Nucl Med Rev Cent East Eur. 2004;7(1):21-5.

O'Connell MJ, Schutt AJ, Moertel CG, Rubin J, Hahn RG, Scott M. A randomized clinical trial of combination chemotherapy in advanced colorectal cancer. American journal of clinical oncology. 1987;10(4):320-4.

Ogholikhan S, Franciscovich A, Mogul D. PoopMD, a mobile application to screen for biliary atresia, accurately identifies Acholic Stools in the Field. Hepatology. 2016;64 (1 Supplement 1):152A.

Oh Y, Ha Y, Han K, Seo HW, Kang I, Park C, et al. Expression of Leucocyte Function-associated Antigen-1 and Intercellular Adhesion Molecule-1 in the Lungs of Pigs Infected with Actinobacillus pleuropneumoniae. Journal of Comparative Pathology. 2013;148(2-3):259-65.

Orlowska E, Czubkowski P, Motyl I, Klewicka E, Libudzisz Z, Socha P. The clinical effect and changes of microflora under probiotic supplementation in children with biliary atresia-a randomized controlled trial. United European Gastroenterology Journal. 2015;1):A349.

Orr DW, Myint H, Murphy R. Probiotic supplementation after Very Low Calorie Diet does not aid improvement of the metabolic syndrome or maintenance of weight loss post Liver Transplant. A randomised double-blind placebo controlled trial. Hepatology. 2016;64 (1 Supplement 1):113A-4A.

Ortiz M, Schnabel K, Teut M, Rotter G, Binting S, Cree M, et al. Complementary and integrative medicine in nursing homes-results of a prospective, exploratory, comparative, two-armed cohort study from the residents' perspective. BMC Complementary and Alternative Medicine Conference: World Congress Integrative Medicine and Health. 2017;17(Supplement 1).

Orvain C, Moles-Moreau MP, Francois S, Mercier M, Moal F, Hamel JF, et al. Miconazole mucoadhesive buccal tablet in high-dose therapy with autologous stem cell transplantation (HDT/ASCT)-induced mucositis. Supportive Care in Cancer. 2015;23(2):359-64.

Palaoro LG, Araujo VP, Matos SL, Alves CLGF, Brito VN, Cunha FS, et al. Effects of long term testosterone administration and gonadectomy on gonadotropin secretion in female to male transsexuals. Endocrine Reviews Conference: 97th Annual Meeting and Expo of the Endocrine Society, ENDO. 2015;36(no

pagination).

Pallotta N, Rubinetto MP, Zaccaro C, Gizzi G, Villani V, Barbara L. Calcium polycarbophil in clinical practice. Treatment of constipation. [Italian]. Minerva Gastroenterologica e Dietologica. 1993;39(4):175-8.

Pallotta N, Rubinetto MP, Zaccaro C, Gizzi G, Villani V, Barbara L. [Calcium polycarbophil in clinical practice. The therapy of constipation]. Minerva Gastroenterologica e Dietologica. 1993;39(4):175-8.

Palou J, Angulo JC, Ramon De Fata F, Garcia-Tello A, Gonzalez-Enguita C, Boada A, et al. Randomized comparative study for the assessment of a new therapeutic schedule of fosfomycin trometamol in postmenopausal women with uncomplicated lower urinary tract infection. [Spanish]. Actas Urologicas Espanolas. 2013;37(3):147-55.

Palou J, Angulo JC, Ramon de Fata F, Garcia-Tello A, Gonzalez-Enguita C, Boada A, et al. [Randomized comparative study for the assessment of a new therapeutic schedule of fosfomycin trometamol in postmenopausal women with uncomplicated lower urinary tract infection]. Actas Urologicas Espanolas. 2013;37(3):147-55.

Paramsothy S, Borody T, Lin E, Finlayson S, Walsh A, Samuel D, et al. Obstacles to donor recruitment for faecal microbiota transplantation: Experiences from the focus study. American Journal of Gastroenterology. 2014;109:S188.

Paramsothy S, Borody T, Lin E, Finlayson S, Walsh A, Samuel D, et al. Obstacles to donor recruitment for faecal microbiota transplantation-Experiences from the FOCUS study. Journal of Gastroenterology and Hepatology (Australia). 2014;29:135.

Paramsothy S, Borody TJ, Lin E, Finlayson S, Walsh AJ, Samuel D, et al. Donor Recruitment for Fecal Microbiota Transplantation. Inflammatory Bowel Diseases. 2015;21(7):1600-6.

Paramsothy S, Kaakoush NO, Kamm MA, Faith JJ, Clemente JC, Walsh AJ, et al. Faecal microbiota transplantation (FMT) in ulcerative colitis is associated with specific bacterial changes: Stool and colonic mucosa 16S microbiota analysis from the randomised controlled FOCUS study. Journal of Gastroenterology and Hepatology (Australia). 2016;31:125-6.

Park EJ, Kang J, Baik SH. Treatment of Faecal incontinence using allogeneic-adipose-derived mesenchymal stem cells: A study protocol for a pilot randomised controlled trial. BMJ Open. 2016;6 (2) (no pagination)(e010450).

Parnetti L. Clinical pharmacokinetics of drugs for Alzheimer's disease. Clinical Pharmacokinetics. 1995;29(2):110-29.

Paul D, Gokarn AG, Bhat V, Bonda A, Zanwar S, Mathew L, et al. Impact of surveillance stool culture guided selection of antibiotics in allogeneic hematopoietic stem cell transplant patients. Blood Conference: 58th Annual Meeting of the American Society of Hematology, ASH. 2016;128(22).

Pawlowska J, Klewicka E, Czubkowski P, Motyl I, Jankowska I, Libudzisz Z, et al. Effect of Lactobacillus casei DN-114001 Application on the Activity of Fecal Enzymes in Children After Liver Transplantation. Transplantation Proceedings. 2007;39(10):3219-21.

Peng Z, Xiang J, He Z, Zhang T, Xu L, Cui B, et al. Colonic transendoscopic enteral tubing: A novel way of transplanting fecal microbiota. Endoscopy International Open. 2016;4(6):E610-E3.

1 2 3

4 5

6 7

8

9 10 11

12

13

14 15

39

44

49

54

Gut

Perlick DA, Miklowitz DJ, Lopez N, Chou J, Kalvin C, Adzhiashvili V, et al. Family-focused treatment for caregivers of patients with bipolar disorder. Bipolar Disord. 2010;12(6):627-37.

Persson GR, Samuelsson E, Lindahl C, Renvert S. Mechanical non-surgical treatment of peri-implantitis: A single-blinded randomized longitudinal clinical study. II. Microbiological results. Journal of Clinical Periodontology. 2010;37(6):563-73.

Pertile G, Claes C. Macular translocation with 360 degree retinotomy for management of age-related
 macular degeneration with subfoveal choroidal neovascularization. American Journal of Ophthalmology.
 2002;134(4):560-5.

Pfundstein J, Roghmann MC, Schwalbe RS, Qaiyumi SQ, McCarter Jr RJ, Keay S, et al. A randomized trial of
 surgical antimicrobial prophylaxis with and without vancomycin in organ transplant patients. Clinical
 Transplantation. 1999;13(3):245-52.

Pfundstein J, Roghmann MC, Schwalbe RS, Qaiyumi SQ, McCarter RJ, Jr., Keay S, et al. A randomized trial of
 surgical antimicrobial prophylaxis with and without vancomycin in organ transplant patients. Clinical
 Transplantation. 1999;13(3):245-52.

Philips CA, Shasthry SM, Pande A, Jamwal KD, Chandel SS, Kumar G, et al. Fecal microbiota transplantation
 (FMT) improves outcome and survival in steroid ineligible severe alcoholic hepatitis-A randomized control
 trial (NCT 02458079). Hepatology. 2016;64 (1 Supplement 1):706A.

Philips CA, Shasthry SM, Pande A, Jamwal KD, Khillan V, Hussain MS, et al. Outcomes of fecal microbiota
 transplantation in steroid ineligible severe alcoholic hepatitis-Arandomized control trial (NCT02458079).
 Indian Journal of Gastroenterology. 2016;35 (1 Supplement):A68-A9.

Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral
 fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia.
 Multicentre Study Group. Journal of Antimicrobial Chemotherapy. 1993;31(6):973-84.

Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G, Tanzer J, et al. Randomized comparison
 of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of
 neutropenia. Journal of Antimicrobial Chemotherapy. 1993;31(6):973-84.

Pipkin KM, Hagey JV, Rayburn MC, Chigerwe M. A randomized clinical trial evaluating metabolism of colostral
 and plasma derived immunoglobulin G in Jersey bull calves. Journal of veterinary internal medicine /
 American College of Veterinary Internal Medicine. 2015;29(3):961-6.

Price CE, Cox S, Rode H. The use of diverting colostomies in paediatric peri-anal burns: Experience in 45
 patients. South African Journal of Surgery. 2013;51(3):102-5.

Pulungsih SP, Punjabi NH, Rafli K, Rifajati A, Kumala S, Simanjuntak CH, et al. Standard WHO-ORS versus
 reduced-osmolarity ORS in the management of cholera patients. Journal of Health, Population and Nutrition.

3 4 5

6

7

8 9

16

21

39

43

56

2006;24(1):107-12.

Qian C, Decot V, Wang Y, Cai HL, Venard V, Jeulin H, et al. Adoptive immunotherapy of refractory systemic adenovirus infections after allogeneic umbilical cord blood (UCB) or peripheral blood stem cell transplantation. Bone Marrow Transplantation. 2015;50:S120.

Queenan KM, Stewart ML, Smith KN, Thomas W, Fulcher RG, Slavin JL. Concentrated oat beta-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial. Nutrition Journal. 2007;6 (no pagination)(6).

¹⁴ 15 Quirke P. Simplicity and complexity-improving outcomes in bowel cancer. Journal of Pathology. 2013;231:S6.

Quraishi N, McMillan M, Widlak M, Nell L, Quraishi K, Pathmakanthan S, et al. Patient perception towards
 faecal microbiota transplantation for treatment of inflammatory bowel disease. United European
 Gastroenterology Journal. 2014;1):A383.

Quraishi N, McMillan M, Widlak M, Nell L, Quraishi K, Pathmakanthan S, et al. Patient perception towards
 faecal microbiota transplantation for treatment of Inflammatory Bowel Disease. Journal of Crohn's and
 Colitis. 2015;9:S252.

Rams TE, Degener JE, van Winkelhoff AJ. Antibiotic resistance in human peri-implantitis microbiota. Clinical
 oral implants research. 2014;25(1):82-90.

Ranganathan N, Friedman EA, Tam P, Rao V, Ranganathan P, Dheer R. Probiotic dietary supplementation in
 patients with stage 3 and 4 chronic kidney disease: A 6-month pilot scale trial in Canada. Current Medical
 Research and Opinion. 2009;25(8):1919-30.

Rathmann N, Kara K, Budjan J, Henzler T, Smakic A, Schoenberg SO, et al. Parenchymal liver blood volume
 and dynamic volume perfusion CT measurements of hepatocellular carcinoma in patients undergoing
 transarterial chemoembolization. Anticancer Research. 2017;37(10):5681-5.

Ratto C, Buntzen S, Aigner F, Altomare DF, Heydari A, Donisi L, et al. Multicentre observational study of the
 Gatekeeper for faecal incontinence. The British journal of surgery. 2016;103(3):290-9.

Rayes A, Morrow AL, Payton LR, Lake KE, Lane A, Davies SM. A Genetic Modifier of the Gut Microbiome
 Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell
 Transplantation. Biol Blood Marrow Transplant. 2016;22(3):418-22.

Rebello D, Yen E, Lio P, Kelly CR. Unexpected benefits: Hair growth in two alopecia patients after fecal
 microbiota transplant. American Journal of Gastroenterology. 2016;111:S623-S4.

Reinhardt K, Foell D, Vogl T, Mezger M, Wittkowski H, Fend F, et al. Monocyte-induced development of Th17
 cells and the release of S100 proteins are involved in the pathogenesis of graft-versus-host disease. J
 Immunol. 2014;193(7):3355-65.

Reinshagen M, Stallmach A. Multidonor intensive faecal microbiota transplantation for active ulcerative
 colitis: A randomised placebo-controlled trial. [German]. Zeitschrift fur Gastroenterologie. 2017;55(8):779 80.

Reintgen D, Pendas S, Jakub J, Swor G, Giuliano R, Bauer J, et al. National trials involving lymphatic mapping for melanoma: The multicenter selective lymphadenectomy trial, the SunBelt melanoma trial, and the Florida melanoma trial. Seminars in Oncology. 2004;31(3):363-73.

Renvert S, Lindahl C, Renvert H, Persson GR. Clinical and microbiological analysis of subjects treated with Branemark or AstraTech implants: A 7-year follow-up study. Clinical Oral Implants Research. 2008;19(4):342-7.

Riko K, Pichora-Fuller MK, Alberti PW. Clinical evaluation of a two-channel amplitude compression hearing aid. Laryngoscope. 1986;96(11):1226-30.

Riley DK, Pavia AT, Beatty PG, Denton D, Carroll KC. Surveillance cultures in bone marrow transplant recipients: Worthwhile or wasteful? Bone Marrow Transplantation. 1995;15(3):469-73.

Robaeys G, Cassiman D, Verslype C, Monbaliu D, Aerts R, Pirenne J, et al. Successful Conversion From
 Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium (Myfortic) in Liver Transplant Patients
 With Gastrointestinal Side Effects. Transplantation Proceedings. 2009;41(2):610-3.

Rodrigues JFV, Rayo J, Vicente J, Carolino E, Figueiredo S, Vieira L. Influence of the geometry and positioning
 of the regions of interest in the transplanted renogram. European Journal of Nuclear Medicine and Molecular
 Imaging. 2017;44 (2 Supplement 1):S896-S7.

Rohrenbach J, Matthess A, Maier R, Von Bunau R. Treatment of children with E. coli strain Nissle 1917.
 Results of a prospective data collection with 668 patients. [German]. Padiatrische Praxis. 2009;73(4):645-52.

Romaniszyn M, Rozwadowska N, Malcher A, Kolanowski T, Walega P, Kurpisz M. Implantation of autologous
 muscle-derived stem cells in treatment of fecal incontinence: results of an experimental pilot study.
 Techniques in Coloproctology. 2015;19(11):685-96.

Romano G, Cocchiara G, Calderone F, Luna E, Virzi C, Agrusa A, et al. [Endoscopic treatment of colorectal polyps in a digestive endoscopy outpatient department]. Chirurgia Italiana. 2004;56(5):669-73.

Rongen MJ, Adang EM, van der Hoop AG, Baeten CG. One-step vs two-step procedure in dynamic
 graciloplasty. Colorectal Disease. 2001;3(1):51-7.

Rongen MJGM, Adang EMM, Gerritsen van der Hoop A, Baeten CGMI. One step vs two-step procedure in
 dynamic graciloplasty. Colorectal Disease. 2001;3(1):51-7.

Rossen N, Bart A, Verhaar N, Van Nood E, Kootte R, De Groot P, et al. Low prevalence of blastocystis SP in
 active ulcerative colitis patients. Gastroenterology. 2014;1):S-371.

Rossen N, Bart A, Verhaar N, Van Nood E, Kootte R, De Groot P, et al. Low prevalence of Blastocystis sp. In
 active ulcerative colitis patients. Journal of Crohn's and Colitis. 2014;8:S349.

Roth B, Birkhauser FD, Zehnder P, Burkhard FC, Thalmann GN, Studer UE. Readaptation of the peritoneum
 following extended pelvic lymphadenectomy and cystectomy has a significant beneficial impact on early

238

1 2 3

4 5

6

7 8

9

10 11

12 13

14

15 16 17

18

19

38

49

Page 407 of 454

1

22

44

49

Gut

- postoperative recovery and complications: Results of a prospective randomized trial. European Urology.
 2011;59(2):204-10.
 Bump IA Arndt R Arnold A Bendick C Dichtelmuller H Franke M et al Treatment of diarrhoea in human
- Rump JA, Arndt R, Arnold A, Bendick C, Dichtelmuller H, Franke M, et al. Treatment of diarrhoea in human
 immunodeficiency virus-infected patients with immunoglobulins from bovine colostrum. Clin Investig.
 1992;70(7):588-94.
- Runde V, Ross S, Trenschel R, Lagemann E, Basu O, Renzing-Kohler K, et al. Adenoviral infection after
 allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a
 prospective multi center surveillance study. Bone Marrow Transplantation. 2001;28(1):51-7.
- Rzepecki P, Barzal J, Oborska S. Blood and marrow transplantation and nutritional support. Supportive Care
 in Cancer. 2010;18(SUPPL. 2):S57-S65.
- Sabharwal S, Abraham JM, Grand R, Mascarenhas M. "ins and outs" of constipation and DIOS. Pediatric
 Pulmonology. 2016;51:147.
- Samy E, Wu Y, Higginbotham G, Grenningloh R, Xu D. The alphav integrin inhibitor abituzumab inhibits
 myofibroblast differentiation. Arthritis and Rheumatology Conference: American College of
 Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP.
 2017;69(Supplement 10).
- Santini B, Antonelli M, Battistini A, Bertasi S, Collura M, Esposito I, et al. Comparison of two enteric coated
 microsphere preparations in the treatment of pancreatic exocrine insufficiency caused by cystic fibrosis.
 Digestive and Liver Disease. 2000;32(5):406-11.
- Santos JL, Carvalho E, Bezerra JA. Advances in biliary atresia: From patient care to research. Brazilian Journal
 of Medical and Biological Research. 2010;43(6):522-7.
- Santosham M, Burns BA, Reid R, Letson GW, Duncan B, Powlesland JA, et al. Glycine-based oral rehydration
 solution: reassessment of safety and efficacy. Journal of Pediatrics. 1986;109(5):795-801.
- Sanz Y, Santacruz A, Gauffin P. Gut microbiota in obesity and metabolic disorders. Proceedings of the
 Nutrition Society. 2010;69(3):434-41.
- Sarveazad A, Newstead GL, Mirzaei R, Joghataei MT, Bakhtiari M, Babahajian A, et al. A new method for
 treating fecal incontinence by implanting stem cells derived from human adipose tissue: preliminary findings
 of a randomized double-blind clinical trial. Stem Cell Research and Therapy. 2017;8 (1) (no pagination)(40).
- Sasaki M, Shimozato A, Ogasawara N, Funaki Y, Ebi M, Hijikata Y, et al. Transglucosidase improves the bowel
 movements in type 2 diabetes mellitus patients: A randomized double-blind, placebo-controlled study.
 Gastroenterology. 2017;152 (5 Supplement 1):S1012-S3.
- Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy.
 Trends in Pharmacological Sciences. 2009;30(6):303-12.
- Schneider HJ, Pickel J, Stalla GK. Typical female 2nd-4th finger length (2D:4D) ratios in male-to-female
 transsexuals-possible implications for prenatal androgen exposure. Psychoneuroendocrinology.

2006;31(2):265-9.

Seekatz AM, Aas J, Gessert CE, Rubin TA, Saman DM, Bakken JS, et al. Recovery of the gut microbiome following fecal microbiota transplantation. mBio. 2014;5(3):e00893-14.

Seo Y, Hawkins R, Christine C, Larson P, Bankiewicz K. In vivo quantitative PET/MR imaging of gene expression in Parkinson's Disease. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI. 2015;56(no pagination).

Shah K, Jacobs A, Breakefield XO, Weissleder R. Molecular imaging of gene therapy for cancer. Gene Therapy. 2004;11(15):1175-87.

Shimoyama T, Sawaya M, Ishiguro A, Hanabata N, Yoshimura T, Fukuda S. Applicability of a rapid stool antigen test, using monoclonal antibody to catalase, for the management of Helicobacter pylori infection. Journal of Gastroenterology. 2011;46(4):487-91.

Shiogai T, Koshimura M, Uebo C, Makino M, Mizuno T, Nakajima K. Acetazolamide vasoreactivity in persistent vegetative state and vascular dementia evaluated by transcranial harmonic perfusion imaging and Doppler sonography. Acta neurochirurgica. 2003; Supplement. 87:63-9.

Shiogai T, Morisaka A, Takayasu N, Yoshikawa K, Mizuno T, Nakagawa M, et al. Quantitative evaluation of cerebrovascular reactivity in brain tissue by a refill kinetic method of transcranial ultrasonic perfusion imaging: a comparison with Doppler sonography. Acta neurochirurgica. 2005; Supplement. 95:183-90.

Shukla A. Those spots on his penis: It is bannayan riley ruvalcaba syndrome!! Pediatric Dermatology. 2017;34:S141-S2.

Sidhu SS, Goyal O, Kishore H, Sidhu S. New paradigms in management of alcoholic hepatitis: a review. Hepatology International. 2017:1-13.

Simonetti F, Fortunato S, Rousseau M, Tascini C, Menichetti F, Stefanelli A, et al. Oral gentamicin therapy for carbapenem-resistent klebsiella pneumoniae infections in hematologic patients: A single center experience. Haematologica. 2016;101:485.

Siproudhis L, Morcet J, Laine F. Elastomer implants in faecal incontinence: A blind, randomized placebo-controlled study. Alimentary Pharmacology and Therapeutics. 2007;25(9):1125-32.

Smith RC, Lindenmayer JP, Hu Q, Kelly E, Viviano TF, Cornwell J, et al. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: A randomized five month study. Schizophrenia Research. 2010;120(1-3):204-9.

Smith SD, Jackson RJ, Hannakan CJ, Wadowsky RM, Tzakis AG, Rowe MI. Selective decontamination in pediatric liver transplants. A randomized prospective study. Transplantation. 1993;55(6):1306-9.

Somsouk M, Vujkovic-Cvijin I, Pao M, Hunt P, McCune M. Safety of fecal microbial transplantation during treated hiv infection. American Journal of Gastroenterology. 2015;110:S578-S9.

Spence C, Verleden S, Einarsson G, Yserbyt J, Lee AJ, Van Herck A, et al. Impact of azithromycin on the post-

Gut

Gut

•	
2 3	lung transplant microbiota. Thorax. 2017;72 (Supplement 3):A15.
4 5 6 7 8	Staikuniene N, Valantinas J, Pukalskas A, Simoliuniene R, Karciauskaite D. The effect of synbiotic and prokinetic on intestinal permeability, endotoxemia and childpugh score in patients with liver cirrhosis: A prospective cohort study. United European Gastroenterology Journal. 2016;4 (5 Supplement 1):A536-A7.
9 10 11 12 13	Staley C, Kelly CR, Brandt LJ, Khoruts A, Sadowsky MJ. Characterization of fecal microbiota in response to heterologous versus autologous (placebo) fecal microbial transplantation: Results from a dualcenter, randomized, placebo-controlled trial. Gastroenterology. 2016;1):S542.
14 15 16 17	Stockfleth E. Sonidegib tolerability across 30-months: Results from the phase 2 randomized BOLT trial. Journal of Investigative Dermatology. 2017;137 (10 Supplement 2):S285.
18 19 20 21	Stockfleth E. Sonidegib duration of response across 30 months: Results from the randomized phase 2 BOLT trial. Journal of Investigative Dermatology. 2017;137 (10 Supplement 2):S284.
22 23 24 25 26	Stojkovic M, Stojkovic M, Artiko V, Zuvela M, Lekic N, Petrovic M, et al. Is identification of malignant lesions of the liver and of hemangiomas possible by Doppler ultrasonography and radionuclide angiography? Hellenic J Nucl Med. 2011;14(1):38-42.
27 28 29 30	Storey RF, Bliden KP, Ecob R, Karunakaran A, Butler K, Wei C, et al. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb Haemost. 2011;9(9):1730-7.
31 32 33 34	Stratigos AJ. Update on systemic treatment of basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology. 2017;31:16.
35 36 37 38	Strik AS, Brandse JF, Koelink P, Wildenberg M, De Vries A, Van Den Brink G, et al. Underestimation of fecal loss of infliximab due to proteolysis. Gastroenterology. 2017;152 (5 Supplement 1):S388-S9.
39 40 41	Subramaniam K, Watthayalage R, Neeman T, Pavli P. Is anti-TNF therapeutic drug monitoring of value in IBD patients in clinical remission? Journal of Gastroenterology and Hepatology (Australia). 2016;31:149.
42 43 44 45	Subramanian S, Huq S, Yatsunenko T, Haque R, Mahfuz M, Alam MA, et al. Persistent gut microbiota immaturity in malnourished Bangladeshi children. Nature. 2014;510(7505):417-21.
46 47 48 49	Sudan D. Small bowel transplantation: Current status and new developments in allograft monitoring. Current Opinion in Organ Transplantation. 2005;10(2):124-7.
50 51 52 53	Sulkowski JP, Nacion KM, Deans KJ, Minneci PC, Levitt MA, Mousa HM, et al. Sacral nerve stimulation: a promising therapy for fecal and urinary incontinence and constipation in children. J Pediatr Surg. 2015;50(10):1644-7.
54 55 56 57 58	Sunshine A, Mulhern SA, Olson N, Elkind A, Almas M, Sikes C. Comparative sensitivity of stopwatch methodology and conventional pain assessment measures for detecting early response to triptans in migraine: Results of a randomized, open-label pilot study. Clinical Therapeutics. 2006;28(8):1107-15.
59 60	Suskind DL, Brittnacher MJ, Wahbeh G, Shaffer ML, Hayden HS, Qin X, et al. Fecal microbial transplant effect

on clinical outcomes and fecal microbiome in active Crohn's disease. Inflammatory Bowel Diseases. 2015;21(3):556-63.

1 2

3

4 5 6

7

8

9 10 11

15

28

39

44

49

Suzuki H, Watanabe H, Shinozaki T, Yanagawa T, Suzuki R, Takagishi K. Positron emission tomography imaging of musculoskeletal tumors in the shoulder girdle. Journal of Shoulder and Elbow Surgery. 2004;13(6):635-47.

Suzuki R, Watanabe H, Yanagawa T, Sato J, Shinozaki T, Suzuki H, et al. PET evaluation of fatty tumors in the
 extremity: possibility of using the standardized uptake value (SUV) to differentiate benign tumors from
 liposarcoma. Ann Nucl Med. 2005;19(8):661-70.

Sylvester FA, Turner D, Draghi A, 2nd, Uuosoe K, McLernon R, Koproske K, et al. Fecal osteoprotegerin may
 guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. Inflammatory
 Bowel Diseases. 2011;17(8):1726-30.

Tamandl D, Waneck F, Sieghart W, Unterhumer S, Kolblinger C, Baltzer P, et al. Early response evaluation
 using CT-perfusion one day after transarterial chemoembolization for HCC predicts treatment response and
 long-term disease control. European Journal of Radiology. 2017;90:73-80.

Tan JJY, Chan M, Tjandra JJ. Evolving therapy for fecal incontinence. Diseases of the Colon and Rectum.
 2007;50(11):1950-67.

Tanpowpong P, Prachasitthisak N, Treepongkaruna S, Lertudomphonwanit C, Boonsathorn S,
 Angkathunyakul N, et al. Stool cytomegalovirus polymerase chain reaction for the diagnosis of
 cytomegalovirus causing gastrointestinal disease in immunocompromised children. Journal of Pediatric
 Gastroenterology and Nutrition. 2016;63:S13.

Thin NN, Taylor SJ, Bremner SA, Emmanuel AV, Hounsome N, Williams NS, et al. Randomized clinical trial of
 sacral versus percutaneous tibial nerve stimulation in patients with faecal incontinence. The British journal
 of surgery. 2015;102(4):349-58.

Thin NN, Taylor SJ, Bremner SA, Emmanuel AV, Hounsome N, Williams NS, et al. Randomized clinical trial of sacral versus percutaneous tibial nerve stimulation in patients with faecal incontinence. Br J Surg. 2015;102(4):349-58.

Tischer S, Schultze-Florey R, Heim A, Picksak G, Mynarek M, Sauer M, et al. Monitoring of adenovirus-specific
 T cells after HSCT in children: Equal detection of hexon and penton-specific T cells. Transfusion Medicine and
 Hemotherapy. 2016;43:62.

⁵⁰ Tjellstrom A, Luetje CM, Hough JV, Arthur B, Hertzmann P, Katz B, et al. Acute human trial of the floating ⁵¹ mass transducer. Ear Nose Throat J. 1997;76(4):204-6.

Tornatore L, Acton G, Adams N, Campbell EA, Kelly J, Szydlo RM, et al. Cancer-selective targeting of the NF kappab survival pathway in multiple myeloma with the GADD45beta/MKK7 inhibitor, DTP3. Blood. 2015;126
 (23):868.

Totman JJ, O'Gorman R L, Kane PA, Karani JB. Comparison of the hepatic perfusion index measured with gadolinium-enhanced volumetric MRI in controls and in patients with colorectal cancer. Br J Radiol.

2005;78(926):105-9.

Tsai F, Coyle WJ. The microbiome and obesity: Is obesity linked to our gut flora? Current Gastroenterology Reports. 2009;11(4):307-13.

Tsunashima D, Kawamura A, Murakami M, Sawamoto T, Undre N, Brown M, et al. Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover study. Clinical Therapeutics. 2014;36(5):748-59.

Tsunashima D, Kawamura A, Murakami M, Sawamoto T, Undre N, Brown M, et al. Assessment of tacrolimus absorption from the human intestinal tract: Open-label, randomized, 4-way crossover study. Clinical Therapeutics. 2014;36(5):748-59.

Turki AT, Basu O, Ditschkowski M, Trenschel R, Beelen DW, Steckel NK. Ileostomy as feasible treatment option for patients with severe refractory graft versus host disease of the gastrointestinal tract after allogeneic stem cell transplantation. Oncology Research and Treatment. 2016;39:167.

Valkeinen H, Hakkinen K, Pakarinen A, Hannonen P, Hakkinen A, Airaksinen O, et al. Muscle hypertrophy, strength development, and serum hormones during strength training in elderly women with fibromyalgia. Scandinavian Journal of Rheumatology. 2005;34(4):309-14.

Van Beurden YH, Budding AE, Terveer EM, Keller JJ, Kuijper EJ, Vandenbroucke-Grauls CMJE, et al. Fecal microbiota transplantation for patients with post-infectious or antibiotic-induced irritable bowel syndrome: Results from a prospective pilot study. United European Gastroenterology Journal. 2017;5 (5 Supplement 1):A566.

van Kraaij MG, Dekker AW, Verdonck LF, van Loon AM, Vinje J, Koopmans MP, et al. Infectious gastro-enteritis: an uncommon cause of diarrhoea in adult allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplantation. 2000;26(3):299-303.

Varsano I, Eidlitz-Marcus T, Nussinovitch M, Elian I. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. Journal of Pediatrics. 1991;118(41):627-32.

Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik J, et al. Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease. Inflammatory Bowel Diseases. 2016;22(9):2182-90.

Vlaspolder F, de Zeeuw G, Rozenberg-Arska M, Egyedi P, Verhoef J. The influence of flucloxacillin and amoxicillin with clavulanic acid on the aerobic flora of the alimentary tract. Infection. 1987;15(4):241-4.

Vrieze A, Holleman F, Serlie MJ, Ackermans MT, Dallinga-Thie GM, Groen AK, et al. Metabolic effects of transplanting gut microbiota from lean donors to subjects with metabolic syndrome. Diabetologia. 2010;53:S44.

Vrieze A, Out C, Fuentes S, Jonker L, Reuling I, Kootte RS, et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. Journal of Hepatology. 2014;60(4):824-31.

Wagner B. Azathioprine and allopurinol-a deadly combination. Pharmacotherapy. 2016;36 (12):e293.

Wahl LM, Chen JJ, Thompson M, Chirakal R, Nahmias C. The time course of metabolites in human plasma after 6-[¹⁸F]fluoro-L-m-tyrosine administration. European Journal of Nuclear Medicine. 1999;26(11):1407-12. Wang B, Feng Q, Ye X, Zeng S. The experience and technique in laparoscopic portoenterostomy for biliary atresia. J Laparoendosc Adv Surg Tech A. 2014;24(5):350-3. Wasserman EI, Hidalgo M, Hornedo J, Cortes-Funes H. Octreotide (SMS 201-995) for hematopoietic supportdependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: Dose finding study and evaluation of efficacy. Bone Marrow Transplantation. 1997;20(9):711-4. Watanabe H, Inoue T, Shinozaki T, Yanagawa T, Ahmed AR, Tomiyoshi K, et al. PET imaging of musculoskeletel tumours with fluorine-18 alpha-methyltyrosine: Comparison with fluorine-18 fluorodeoxyglucose PET. European Journal of Nuclear Medicine. 2000;27(10):1509-17. Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone: A review of its use in type 2 diabetes mellitus. Drugs. 2006;66(1):85-109. Weber E, Doppelmayr M. Kinesthetic motor imagery training modulates frontal midline theta during imagination of a dart throw. International Journal of Psychophysiology. 2016;110:137-45. Wei Y, Gong J, Zhu W, Guo D, Gu L, Li N, et al. Fecal microbiota transplantation restores dysbiosis in patients with methicillin resistant Staphylococcus aureus enterocolitis. BMC infectious diseases. 2015;15:265. Wilk CM, Weber I, Rachmuhl C, Seidl K, Burgel AH, Muller AMS, et al. Prevalence and eradication of colonizing staphylococcus aureus in patients undergoing allogeneic hematopoietic cell transplantation. Blood Conference: 58th Annual Meeting of the American Society of Hematology, ASH. 2016;128(22). Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Manneras-Holm L, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850-8. Xi D, Michail S. Fecal microbiota transplantation in children does not significantly alter body mass index. Journal of Pediatric Gastroenterology and Nutrition. 2017;65 (Supplement 2):S73-S4. Yahyaoui R, Esteva I, Haro-Mora JJ, Almaraz MC, Morcillo S, Rojo-Martinez G, et al. Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. J Clin Endocrinol Metab. 2008;93(6):2230-3. Yang Z, Wang X, Bu C. Fecal microbiota transplant for Crohn's disease: A prospective, randomized study in chinese population. United European Gastroenterology Journal. 2017;5 (5 Supplement 1):A112-A3. Yao Q, Huang Q, Cao Y, Qian P, Chen H. Porcine interferon-gamma protects swine from foot-and-mouth disease virus (FMDV). Vet Immunol Immunopathol. 2008;122(3-4):309-11. Ye X, Van JN, Munoz FM, Revell PA, Kozinetz CA, Krance RA, et al. Noroviruses as a Cause of Diarrhea in Immunocompromised Pediatric Hematopoietic Stem Cell and Solid Organ Transplant Recipients. American

Gut

1 2	
2 3 4	Journal of Transplantation. 2015;15(7):1874-81.
5 6 7	Young VB. Treatment with fecal microbiota transplantation: The need for complete methodological reporting for clinical trials. Annals of Internal Medicine. 2017;167(1):61-2.
8 9 10 11 12	Yu C, Benhammou JN, Goyal D, Oh D, Wang L, Jacobs J, et al. High protein dietary intervention improves body mass index (BMI) and reduces the NAFLD fibrosis score (NFS) in veterans with obesity. American Journal of Gastroenterology. 2016;111:S349.
13 14 15 16 17	Zaza G, Dalla Gassa A, Granata S, Felis G, Lupo A. Impact of the maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus-versus a standard tacrolimus-based regimen. Nephrology Dialysis Transplantation. 2017;32 (Supplement 3):iii408.
18 19 20 21	Zhang C, Yin A, Li H, Wang R, Wu G, Shen J, et al. Dietary Modulation of Gut Microbiota Contributes to Alleviation of Both Genetic and Simple Obesity in Children. EBioMedicine. 2015;2(8):968-84.
22 23 24	Zhang C, Yin A, Li H, Wang R, Wu G, Shen J, et al. Dietary Modulation of Gut Microbiota Contributes to Alleviation of Both Genetic and Simple Obesity in Children. EBioMedicine. 2015;2(8):968-84.
25 26 27 28	Zhang FM, Wang HG, Wang M, Cui BT, Fan ZN, Ji GZ. Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn's disease. World Journal of Gastroenterology. 2013;19(41):7213-6.
29 30 31	Zhang T, Xiang J, Cui B, He Z, Li P, Chen H, et al. Cost-effectiveness analysis of fecal microbiota transplantation for inflammatory bowel disease. Oncotarget. 2017;8(51):88894-903.
32 33 34 35 36 27	Zheng Y, Lee J, Masand A, Dadhania D, Thangamani M, Suthanthiran M. Tacrolimus precision medicine: Antibiotics increase intra-patient variability in tacrolimus trough concentrations in kidney transplant recipients. American Journal of Transplantation. 2016;16:776.
37 38 39 40	Zhu J, Zhang F, Zhou J, Li H. Assessment of therapeutic response in Crohn's disease using quantitative dynamic contrast enhanced MRI (DCE-MRI) parameters. Medicine. 2017;96(32).
41 42 43 44 45 46 47	Ziemssen F, Luke M, Bartz-Schmidt KU, Gelisken F. Time-dependent effects on contrast sensitivity, near and distance acuity: Difference in functional parameters? (Prospective, randomized pilot trial of photodynamic therapy versus full macular translocation). Graefe's Archive for Clinical and Experimental Ophthalmology. 2008;246(5):653-9.
48 49 50 51 52	
53 54 55	
56 57 58 59	
60	

Appendix E. Peer review

Healthcare Infection Society

Gut

Consultation – The use of faecal microbiota transplant as treatment for recurrent or refractory *Clostridium difficile* infection and other potential indications:

joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.

Closing date: 5pm on 18 January 2018			
Organisation	Royal College of General Practitioners		
Title (e.g. Dr, Mr, Ms, Prof)	Drs		
Name	Clinical Adviser: Kevin Barrett Medical Director: Matthew Hoghton		
Job title or role	As above		
Address and post code	30 Euston square, London, Nw1 2FB		
Telephone number	0203 188 7688		
Email address	clinicaladvisers@rcgp.org.uk		
Please note: comments will o	nly be accepted electronically on this proforma.		

Please provide comments on the draft guideline on the form below, putting each new comment in a new row. When feeding back, please note the section you are commenting on (for example, section 1 Introduction and line number). If your comment relates to the guideline as a whole then please put 'general'. Add extra rows if required.

Section	Comments	Working group response
A	This is an important consultation of an important treatment for recurrent or refractory CDI. The recommendations are sensible and will help produce a universal service to patients across the UK.	Thank you for your comment.
В	Hudson et al doi: 10.1128/CMR.00049-16Clin. Microbiol. Rev. January 2017 vol. 30 no. 1 191-2311 January 2017 review suggests that faecal microbiotca transplant in the United States is used not only in refractory or recurrent Clostridium Difficile (CDI) but also in initial CDI and Ulcerative colitis	We cannot find mention of FMT use as treatment for initial CDI in this review. Updated searches have identified a small RCT evaluating the use of FMT as treatment for first CDI (Camacho-Ortiz <i>et al,</i> 2017), and this is now evaluated by the working group within the guideline (Section 8.1.1.3). All published RCTs evaluating the use of the FMT as treatment for ulcerative colitis have been reviewed by the working group within the guideline (Section 8.6.2).
C	There is a lack of GP representation on the working group (5.6) and this is reflected in the consultation with a lack of a suggested referral pathway for community based patients	We agree that the implications of this guideline for primary care were not well-described, and we have strengthened this within the guideline. In particular, we have more strongly highlighted the responsibility of microbiology staff in clinical laboratories to liaise proactively with primary care teams regarding the possibility of FMT when recurrent positive stool samples are received from the community on a particular patient (Section 8.7.1).
D	There has also been a reported case of the development of obesity following FMT from an overweight donor but this has not been substantiated in other studies. The BMI restriction on donors (8.3.2) may restrict donors.	The recruitment of suitable donors is relatively restrictive by necessity since FMT is an unlicensed and poorly-studied medicinal product. There is a growing literature base demonstrating an association between a high or low BMI and perturbation of the structure and/or function of the gut microbiota and subclinical chronic inflammation. The implications of this for the safety and efficacy of FMT are not well-defined. The suggested BMI range does not make it prohibitively difficult to find suitable donors. As such, the working group believes that their existing recommendation is reasonable.

Section	Comments	Working group response
E	It would be useful to have a standard UK pre and post questionnaire for patients to standardise recording (8.1.2.3)	We agree that the introduction of standardised questionnaires would have clear potential advantages for clinical care and/ or research. We now discuss this further in Section 10 , 'further research'.
F	It may useful to consider measuring the micriobiol strains of donors to monitor the impact of combinations of specific microbial strains to understand the undefined nature of faecal preparations	We agree of the importance of this, and this is now discussed in more detail in Section 10 , 'further research'.
G	The lack of universal definitions of cures (8.1.2.4) is likely to hamper future studies	We agree with this comment. Section 10 , 'further research' has been amended accordingly. Furthermore, we expect that the attention generated by this guideline will highlight this inadequacy.
Η	With the introduction of the clinical term SNOMECT across primary care in 2018 and secondary care in 2020 it is important to record faecal microbiota transplant so that long term sequaelae can be measured and patients can be potentially contacted in the future.	We agree that there should be specific procedure codes for FMT (according to route of administration), so that this can be accurately recorded in the patient's medical record. This would also lay the foundation for a future HRG code and tariff for the procedure which is not currently funded by CCGs. Members of the working group are in discussion with NHS England about this.
Closing date	Please forward this electronically by 5pm on January 2018 at the very latest to <u>co</u> Healthcare Infection Se	nsultations@his.org.uk
Consultation	Healthcare Infection So n – The use of faecal microbiota transplant as treatment for recurrent or re	nsultations@his.org.uk ociety fractory <i>Clostridium difficile</i> infection and other potential
Consultation	Healthcare Infection So	nsultations@his.org.uk ociety fractory <i>Clostridium difficile</i> infection and other potential
Consultation	Healthcare Infection So n – The use of faecal microbiota transplant as treatment for recurrent or re	nsultations@his.org.uk ociety fractory <i>Clostridium difficile</i> infection and other potential

Organisation	NHS Highland
Title (e.g. Dr, Mr, Ms, Prof)	Dr
Name	Alex Cochrane
Job title or role	Consultant Microbiology and Infectious Diseases
Address and post code	Raigmore Hospital, Perth Road, Inverness IV2 3UJ
Telephone number	01463 704000
Email address	Alexandra.cochrane@nhs.net

Please provide comments on the draft guideline on the form below, putting each new comment in a new row. When feeding back, please note the section you are commenting on (for example, section 1 Introduction and line number). If your comment relates to the guideline as a whole then please put 'general'. Add extra rows if required.

Section	Comments	Working group response
8.1.1.1	I dont think you should limit FMT for first recurrence to those with specific risk factors. If clinicians wish to use FMT rather than fidaxomicin for the first recurrence on cost effectiveness grounds then that is reasonable. Suggest that you recommend FMT may be offered for the first or second or subsequent recurrences.	poorly-studied long term sequelae, the working group considered that it should generally be reserved for patients

Section	Comments	Working group response
	C	recurrence) to offer FMT after the second episode. Cost effectiveness analysis was outside the remit of the working group.
8.1.1.3 (ii)	I disagree that patients should have previously been treated with extended/pulsed vancomicin or fidaxomicin before being offered FMT. You dont present any evidence to show that these antibiotic treatment is superior to FMT. Where FMT is the preferred treatment for the first recurrence it is quite likely that the patient will not have had a prolonged or tapered course, and this should not be a barrier to giving FMT which as you say is highly efficacious.	or bezlotoxumab, and only one study comparing a vancomycin taper to FMT (Hota <i>et al</i> , 2017). The safety profile of these medications is well-established from large randomised controlled trials, whilst randomised studie
8.1.1.3 (iii)	You dont cite any evidence that fidaxomicin or bezlotoxumab have better cure rates than FMT. My practice has been not to use fidaxomicin in life threatening C. difficile due to lack of evidence of efficacy in this setting, though I may be out of date with this.	Pre-planned subgroup analysis of patients with severe CDI in a randomised trial demonstrated a significantly lower

Gut

Page 419 of 454

Section	Comments	Working group response
	6	the balance of safety and potential risks, consideration should be given to using antimicrobial/ antitoxin therapy associated with reduced CDI recurrence prior to considering the use of FMT.
5.1.1 (iii)	Is there adequate published material or experience to ensure th safety of loperamide? It is usually avoided in C. difficile disease due To increased risk of complications.	
ising date: Please for	ward this electronically by 5pm on January 2018 at the very latest to <u>o</u>	onsultations@his.org.uk
	Healthcare Infection	Society
		10.
onsultation – The use	of faecal microbiota transplant as treatment for recurrent or	efractory <i>Clostridium difficile</i> infection and other potential in
int British Society o	f Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.
int British Society o	FGastroenterology (BSG) and Healthcare Infection Society (HIS Closing date: 5pm on Jar	
Organisation	Closing date: 5pm on Jar NHS Lothian	
Organisation itle (e.g. Dr, Mr, Ms, F	Closing date: 5pm on Jar NHS Lothian	
int British Society o Drganisation Title (e.g. Dr, Mr, Ms, F Name	Closing date: 5pm on Jar NHS Lothian rof) Dr	

	04		
-		nt in a new row. When feeding back, please note the section you are es to the guideline as a whole then please put 'general'. Add extra row	
Please note: comments v	vill only be accepted electronically on this proforma.		
Email address	ewan.olson@luht.scot.nhs.uk		
Telephone number	0131 2326048		
	10ha		
	Edinburgh EH16 4SA		
	51 Little France Crescent		
Address and post code	Royal Infirmary of Edinburgh		
Job title or role	Consultant Microbiologist		

Gut

8.3.4.	Laboratory Screening of donors	Whilst vancomycin-resistant Enterococci (VRE) carriage is
		relatively common in the community (probably related to
	"Whilst vancomycin-resistant Enterococci (VRE) carriage is relatively	food consumption) (Endtz et al, 1997), community strains of
	common in the community, they are of low pathogenicity, and	VRE are genetically distinct from (and generally of much lower
	screening for them was not felt to be justified."	pathogenicity than) those found nosocomially (Willems <i>et al,</i>
		2005); as such, the working group felt that routine screening
	VRE can cause life threatening infections that are difficult to treat.	was not justified. However, the working group acknowledged
	Any patient who is VRE positive requires isolation in a sideroom with	that the potential infection risk from VRE (and MRSA) would
	ensuite facilities.	vary regionally dependent upon local prevalence and
		pathogenicity, and as such recommended that a risk
	I would suggest that donors should be screened for VRE before	assessment was performed to assess whether screening for
	accepting stool for donation. If there is a shortage of donor patients	these organisms should be considered.

Section	Comments	Working group response
	should be offered VRE positive donations only with informed consent.	
Closing date: Please t	forward this electronically by 5pm on January 2018 at the very latest to <u>co</u>	nsultations@his.org.uk
	Healthcare Infection Se	ociety
Consultation – The	use of faecal microbiota transplant as treatment for recurrent or re	fractory Clostridium difficile infection and other potential indication
joint British Society	of Gastroenterology (BSG) and Healthcare Infection Society (HIS)	guidelines.
	<u> </u>	<u>~</u>
Organisation	On behalf of European Study Group for C. <i>dificile</i> (ESGCD), a Medical Center (drs. E. Terveer, drs. E. Boeije-Koppenol, pro	f. Hein Verspaget, dr. Y van Beurden, drs. R Ooijevaar, dr.

Josbert Keller) and Department of Infectious Diseases, University of Koln (dr. Mar		University of Koln (dr. Maria Vehreschild).
Title (e.g. Dr, Mr, Ms, Prof)	Prof. Dr.	0
Name	Ed Kuijper	W O
Job title or role	Head of Experimental Bacteriology	
Address and post code	LUMC, Albinusdreef2, 2333 ZA, Leiden	
Telephone number	31-71-5263574	

Email address

e.j.kuijper@lumc.nl

https://mc.manuscriptcentral.com/gut

Please note: comments will only be accepted electronically on this proforma.

Closing date: 5pm on January 2018

Gut

Please provide comments on the draft guideline on the form below, putting each new comment in a new row. When feeding back, please note the section you are commenting on (for example, section 1 Introduction and line number). If your comment relates to the guideline as a whole then please put 'general'. Add extra rows if required.

Section	Comments	Working group response
general	The literature was searched until April 2017, but please use the recently published document of E.M Terveer et al. entitled "How to: Establish and run a stool bank" and published in Clin Microbiol Infect. 2017 Dec;23(12):924-930. This document has considerable overlap with the proposed guideline, but also shows some important unresolved issues.	updated, to January 2018.
Lay summary, line 3	Capsules may also be prepared by use of non-freeze dried microbiota. Also, the possibility of using frozen products in general may be mentioned in this sentence.	
8.1.1.1	The authors are correct that CDI due to Type 07 responds less to FMT compared with CDI due to other PCR ribotypes. We register all infections by PCR ribotype to obtain more insights in successes and failures associated with strain characteristics and think that this is relevant for future recommendations, such as repeated FMT treatments for specific PCR ribotypes.	
recommendation	"FMT should be offered to patients with recurrent CDI who have had at least two recurrences, or those who have had one recurrence and have risk factors for further episodes, including severe CDI (strong)." Please elucidate how this risk assessment can be performed.	

Section	Comments	Working group response
8.1.1.2	Refractory CDI is also considered as an indication for FMT. Can the authors please provide a recommendation on the number of FMTs that should be used? Are patients on Intensive Care Units with refractory CDI also eligible? in 8.2.1 IC admission can be considered as a contraindication, but there are sufficient publications supporting to apply it for patients with severe CDI at ICU.	contraindications to receiving FMT, and noted that certain
		As stated in Section 8.1.1.2 , there are a relatively small numbe of cases reported in the reviewed literature of refractory CDI As such, the working group are unable to give recommendations that patients with refractory CDI receiving FMT should be managed in any particular way differently to those with recurrent CDI.
8.1.1.3	Antibiotic treatment of rCDI. Though the literature search was until April 2017, please mention the recent trials of tapered doses of vancomycin and fidaxomicin (PMID 29273269, PMID: 28591789; PMID 29255732).	We agree that these trials are all relevant, and have updated the guideline accordingly.
	Recommendation II is less clear. How have the authors interpreted the literature that a tapered dosage of vancomycin before FMT increases the success rate of FMT? Are these studies also available for fidaxomicin?	There are no studies comparing FMT to fidaxomicin o bezlotoxumab, and only one study comparing a vancomycin taper to FMT (Hota <i>et al</i> , 2017). The safety profile of these medications is well-established from large randomised controlled trials, whilst randomised studies involving FMT have tended to be smaller, and have more variable patient follow up. Furthermore, FMT remains (in the UK) an unlicensed medicine. As such, on the balance of safety, the working group agreed that antimicrobial/ antitioxin therapy associated with reduced CDI recurrence should be considered prior to FMT Reflecting the uncertainties in this area within the reviewed literature, the relevant recommendation is 'conditional' rather than 'strong'.

Section	Comments	Working group response
	Recommendation iii is difficult to understand; do the authors recommend to treat severe and complicated CDI not with vancomycin, but with fidaxomicin or vanco+bezlo? If a recurrence occurs, then followed by a FMT?	The wording of this recommendation has been amended, along with expansion of the explanatory text of Section 8.1.1.4 .
	A recommendation for FMT treatment in severe (refractory), complicated CDI is missing (e.g. multiple sequential FMTs); should this also be accompanied with anti-CDI antibiotics? See review v. Beurden, Ther Advances in Gast, 2017 and Fischer, Ali Pharm Ther 2015	As stated in Section 8.1.1.2 , there are a relatively small number of cases reported in the reviewed literature of refractory CDI. As such, the working group are unable to give recommendations that patients with refractory CDI receiving FMT should be managed in any particular way differently to those with recurrent CDI.
8.1.2.1	We suggest to differentiate between "non-responding" and "late failure". The latter can be defined as a relapse of CDI after an initial response to FMT. For instance, use of antibiotics in the first month after FMT may provoke a new episode of CDI. This new episode doesn't need a FMT and can be treated with conventional anti-CDI treatment, preferably microbiota sparing such as fidaxomicin.	We agree that this distinction is useful, and have amended the guideline accordingly.
8.1.2.2	Should a psychological questionnaire routinely be taken from recipients (before and after FMT) and from donors (regularly)? A tenweek follow-up is too short to recognize long term side-effects of FMT.	The working group did not consider that this was a priority.
8.1.2.3	We consider swallowing disorders a contraindication for upper GI delivery; death of a patient due to aspiration pneumonia with upper GI delivery has been described (PMID: 29026601); this patient had a swallowing disorder following oropharyngeal radiation after surgical removal of a maxillary carcinoma.	We note that this patient received a very large volume (500ml) of nasoduodenal FMT. This guideline recommends a much lower maximum volume with the specific aim of minimising this problem. Nevertheless, we agree that this is an important consideration, and have amended Section 8.1.2.3 and Section 8.5.2.2 accordingly.
8.2.1	What is the advice of the committee for coeliac patients with recurrent CDI?	The working group did not have any specific advice regarding patients with coeliac disease.
8.2.2	FMT in immunocompromised patients: we think that the presence of neutropenia ($<0.5 \times 10^9$ /L) can be considered as a contraindiction for FMT, especially if hematological patients are treated with	The working group have recommended that FMT is offered 'with caution' to immunosuppressed patients, reflecting the careful individualised assessment required for each patient.

Gut

Comments	Working group response
selective gut decontamination to prevent translocation and infections with aerobe Gram-negatives. Second, should donors and immunocompromised recipients be matched for the EBV and CMV status to prevent a herpesvirus infection?	We agree with the comment regarding matching donors and immunosuppressed recipients for EBV and CMV status, and have updated Section 8.2.2 and Section 8.3.4 accordingly.
The effect of FMT on the IBD status for IBD patients with rCDI is under discussion. Is it possible that FMT will result in cure of CDI but an exacerbation of IBD. Should we differentiate UC from CD? Ref 71 suggests that IBD can worsen. The recommendation "strong" is debatable. Is the IBD group not a better candidate for vancomycin tapering, fidaxomicin (tapering) or bezlotoxumab before FMT is given?	We agree that there is evidence that FMT to treat CDI in patients with IBD may be associated with a flare of IBD activity (Qazi <i>et al,</i> 2017); we have updated the recommendation accordingly.
Age and BMI of the donor. We agree with the BMI of the donor but have some difficulties with the age, We consider an age above 50 as a contraindication, based on the risks to develop colon carcinoma and metabolic (diabetes) diseases. Additionally, older people seems to have a less stable gut microbiota.	and microbial diversity were similar in donors > 60 years compared to younger donors, and donations from older donors
Donor screening history. Donors should also undergo a long term follow-up to recognize microbiota related diseases, including colon malignancies, autoimmune diseases, metabolic diseases and psychiatric illnesses.	We agree with the principle of this statement, and allude to this in Section 8.7.7.
Please consider to add to the recommendation/evidence: Potential donors should be extensively screened by a questionnaire and a personal interview concerning risk factors for transmissible diseases and factors influencing the intestinal microbiota	We agree with this suggestion, and have amended Section 8.3.3 accordingly.
Screening of the donor. Table 4. The Dutch guideline advises screening donors for multi-drug resistant bacteria (MDR), including VRE, MRSA, CPE and ESBL-producing Gram-negatives, and quinolone/aminoglycoside resistant Enterobacteriaceae. Most of the patients with rCDI have much comorbidity and are frequently	The working group reviewed their recommendation regarding screening for multi-drug resistant bacteria, and Section 8.3.4 has been updated accordingly. We agree with the principle of a 'window period'/ quarantine
	 selective gut decontamination to prevent translocation and infections with aerobe Gram-negatives. Second, should donors and immunocompromised recipients be matched for the EBV and CMV status to prevent a herpesvirus infection? The effect of FMT on the IBD status for IBD patients with rCDI is under discussion. Is it possible that FMT will result in cure of CDI but an exacerbation of IBD. Should we differentiate UC from CD? Ref 71 suggests that IBD can worsen. The recommendation "strong" is debatable. Is the IBD group not a better candidate for vancomycin tapering, fidaxomicin (tapering) or bezlotoxumab before FMT is given? Age and BMI of the donor. We agree with the BMI of the donor but have some difficulties with the age, We consider an age above 50 as a contraindication, based on the risks to develop colon carcinoma and metabolic (diabetes) diseases. Additionally, older people seems to have a less stable gut microbiota. Donor screening history. Donors should also undergo a long term follow-up to recognize microbiota related diseases, including colon malignancies, autoimmune diseases, metabolic diseases and psychiatric illnesses. Please consider to add to the recommendation/evidence: Potential donors should be extensively screened by a questionnaire and a personal interview concerning risk factors for transmissible diseases and factors influencing the intestinal microbiota Screening of the donor. Table 4. The Dutch guideline advises screening donors for multi-drug resistant bacteria (MDR), including VRE, MRSA, CPE and ESBL-producing Gram-negatives, and quinolone/aminoglycoside resistant Enterobacteriaceae. Most of the

Section	Comments	Working group response
	UTI. Infections with MDR are more difficult to treat, mostly with intravenously administered antibiotics. If these patients become colonized with MDR they should be nursed with specific infection control precautions. We also apply a "window period"; donors stools samples are stored in quarantine for 2 months and only become available after a negative second screening.	
	We additionally screen for: Yersinia enterocolitica, Yersinia pseudotuberculosis, Plesiomonas shigelloides, shiga toxin producing <i>E. coli</i> (not only 0157 E.coli), Astrovirus, Sapovirus, Adenovirus, Enterovirus, Parechovirus, Hepatitis E, Entamoeba histolytica, <i>Microsporidium</i> species, <i>Blastocystis hominis, Dientamoeba fragilis</i> , and Strongyloides (if a travel history to Middle and South America, Africa, or Asia is present).	The working group agreed that recommendations should be made to test for Shiga toxin-producing <i>Escherichia coli</i> , hepatitis E IgM, <i>Entamoeba histolytica</i> serology and <i>Strongyloides stercoralis</i> IgG (Table 3). However, the working group consensus was that screening with the other tests suggested is not justified.
	We advise to include carriership of <i>E. histolytica</i> and Strongyloides to the mandatory screening, because of the serious infections that occur in immunocompromised patients. We have detected unexpectedly a donor carrying <i>E. histolyica</i> (Terveer, CMI, 2017).	Pelie
8.4.1	Recommendation i. Please elucidate how donors should deliver their stools. We favour the use of specific device systems to prevent contamination with environmental microorganisms. Recommendation ii. Processing within 6 hours is proven effective, consider changing 'conditional' to 'strong' recommendation Recommendation iii. A meta-analysis concludes that lless than 50 gram of feces is related to a 4-fold increase in recurrence rates. The recommendation status should be changed to 'strong'.	 i. We think that the text as it stands gives sufficient information about best practice in this area. ii. We agree with this suggestion, and have amended Section 8.4.1 accordingly. iii. We agree with this suggestion, and have amended Section 8.4.1 accordingly.

Gut

Page 427 of 454

Section	Comments	Working group response
8.4.2	An important advantage of frozen FMT is the possibility to use a "window period" of, for example, two months. When donors are screened after this window period, the results determine if the stored FMTs can be used.	We have cross-referenced Section 8.4.2 to Section 8.3.5 , where the concept of a window period/ quarantine is discussed in more detail.
8.4.3	We think that there is not enough evidence to state that feces suspensions can only be used up to six months from preparation. There is no sufficient data that show a decreased efficacy with feces suspensions stored over 6 months. Additionally, multiple stool banks set the expiration date at 1 year after storage.	A trend towards decrease in the viability of certain gut bacterial groups was noted when faecal aliquots were frozen in 10% glycerol for six months (Costello <i>et al, Alimentary Pharm & Ther</i> , 2015), and as such, the working group agreed that six months was the acceptable limit for freezing of an FMT in glycerol. This rationale is now within the text.
	Good practice point: Thawing overnight in a 4C refrigerator is also a good and much used alternative.	None of the working group had sufficient experience with this means of thawing FMT, and as such were unable to make this good practice point.
8.5.1.1.	It is not clear, why the administration of a bowel lavage in upper GI administration, of PPI, of loperamide and of metroclopramide are recommended. There is no evidence to support their use, and all of them are drugs with known side effects. The only reason why they are used is that the first RCT used them. However, the RCT did not assess their importance, and there are many case series showing that FMT has a high success rate even without their use.	All of these interventions have a clear biological or practical rationale for their use. Significant side effects in association with a single dose of these medications are generally rare, and their use has not been associated with adverse outcomes in FMT studies. Our recommendations for their use are only conditional. As such, the working group uphold their recommendations.
8.5.2.1.	Not all capsules necessarily contain lyophylized microbiota, frozen preparations have also been shown to be effective.	We agree with this comment, and have updated the guideline accordingly.
8.5.2.2	Are there studies indicating that 50 ml for upper gastrointestinal have comparable efficacy as 250 ml? If not, this should be more pronounced mentioned, also in the research session. We use at least 50 gram suspended in 200 ml and a slow infusion of 10cc/min.	As described in the text, the working group considered that mass of stool was a more important consideration than volume of diluent. They also noted that as low as 25ml of FMT has been demonstrated to be effective as upper GI FMT (Aas <i>et al, Clin Infect Dis,</i> 2003). However, the working group revised their decision, and now recommend 100ml as the threshold volume for upper GI FMT administration.

Section	Comments	Working group response
8.5.2.4.	The recommendation not to use capsules seems rather strong. It is unlikely that concerning transmission of infection, the risk would differ in any way from other ways of administration. Also, no safety concerns based on endoscopic complications can possibly arise. We would therefore not pronounce a recommendation against use.	We agree with this statement. Of note, whilst the Kao <i>et al</i> , 2017 study (RCT of capsulised vs colonoscopic FMT) was not published at the time of initial searches, it has been identified by updated searches and has now been reviewed by the working group. As such, the guideline has been updated accordingly.
8.6	Consider to add that specific donor microbiota may have better outcomes (e.g. donor B in Moayyedi, gastroenterology, 2015) FMT for other conditions than rCDI. Why have the authors not included the role of FMT to eradicate MDR from the intestinal tract?	Reference to Donor B in this paper has been added to Section 8.6.2.2. In keeping with NICE methodology, for the consideration of FMT as treatment for non-CDI conditions, only RCTs could be considered. The working group are aware of case studies and case series using FMT to attempt gut decolonisation of multidrug resistant microorganisms. Members of the working party have themselves contributed to the literature in this field. But no RCTs currently exist.
8.6.3.	Consider adding: characterisation of specific CU patient population that would potentially benefit from FMT. "However, recommendations for clinical use for this indication cannot be made until there is clearer evidence of the most appropriate CU patient characteristics , methodology for its preparation, route of delivery, and intensity of administration of FMT"	We agree with this comment, and have updated the guideline accordingly.
8.7.2 and 8.7.4	FMT is considered as a medicinal product under supervision of MHRA and licensing should follow the GMP guidelines. The activities should be performed in a dedicated containment level 2 laboratory with personal protective equipment and a quality assessment system. Does this indicate that FMTs should be prepared under GMP conditions at the Pharmacy Department and not within the Medical Microbiology? Or is this statement too strong?	No. MHRA guidance does not specify where the manufacture should take place. This could be pharmacy, the microbiology laboratory, or another place.
8.7.6	Please consider to add that aliquots of donor FMT materials (and original feces samples) used for patients treatment should be stored,	We agree, and we have updated Sections 6.3 and 8.7.6 accordingly.

Section	Comments	Working group response
	enabling to use these samples when adverse effects after FMT developed. This should also been included in 6.3 (auditing).	
Table 4	PCRs are more sensitive than conventional microscopy and antigen tests for parasites. Second, can the authors please specify the parasites? There is some debate on the significance of Blastocystes spp. and Dientamoeba spp. Why is only E. coli 157 excluded and not other STEC pathogens?	Table 4 has been updated to specify Shiga toxin-producing <i>Escherichia coli</i> screening by PCR. The working group did not consider that specific screening for <i>Blastocystis spp</i> or <i>Dientamoeba spp</i> was justified.
Propose to add: Eligibility of patients for FMT	At the NDFB, all requests by the treating physician are evaluated by at least two clinical members of our feces bank board to determine the eligibility of the patient. It is required that patients have a laboratory documented episode of recurrent CDI following at least one course of adequate CDI antibiotic therapy. Recurrent CDI is defined as the re-appearance of diarrhoea (\geq 3 unformed stools per 24 hours for two consecutive days; or \geq 8 unformed stools per 48 hours) within eight weeks after cessation of antibiotic therapy in combination with a positive diagnostic test for <i>C. difficile</i> . We strongly recommend a two-stage testing algorithm, as recently advised by the <i>C. difficile</i> working group/ESCMID (ESGCD). Using this algorithm, we reject approximately 20% of all requests for FMT. We would like to add our experience that of 79 candidate patients for FMT, only 75% were considered as suitable candidates for FMT treatment; most rejected requests were patients with underlying IBD who concomitantly carried <i>C. difficile</i> .	
Need for antimicrobial stewardship after FMT (also for 8.5.1.3)	After FMT, we advise that an infectious disease specialist or medical microbiologists should be involved for antibiotic treatment (or prophylaxis) of the patient during the first month after FMT, since 50% of our registered failures were patients who received antibiotics within one month after FMT. Interestingly, all patients responded to conventional anti-CDI treatment and did not need a second FMT. It can be considered to use microbiota sparing fidaxomicin after FMT.	

	Healthcare Infection Society
	ecal microbiota transplant as treatment for recurrent or refractory <i>Clostridium difficile</i> infection and other potential indications: roenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Closing date: 5pm on January 2018
Organisation	OpenBiome
Title (e.g. Dr, Mr, Ms, Prof)	Dr
Name	Majdi Osman
Job title or role	Clinical Program Director, OpenBiome; Visiting Assistant Professor, Harvard Medical School
Address and post code	200 Inner Belt Road, Somerville, MA 02143
Telephone number	+1 (617) 575-2201
Email address	majdi@openbiome.org
Please note: comments will c	nly be accepted electronically on this proforma.

Gut

Page 431 of 454

Section	Comments
<i>Clostridium difficile</i> infection	"FMT should be offered to patients with recurrent CDI who I had at least two recurrences, or those who have had one recurre and have risk factors for further episodes, including severe (strong)." We agree however for full clarity we would recommend re-wor to: "FMT should be offered to patients with recurrent CDI who I had at least two recurrences, or those who have had one recurre
	and have risk factors for further episodes, including severe severe-complicated CDI (strong)." "FMT should be considered in cases of refractory CDI (condition
Clostridium difficile infection:	We agree.
	 i. FMT for recurrent CDI should only be considered of failure of antimicrobial anti-C. difficile therapy which been administered for a minimum of 10 days (condition ii. Recipients of FMT as treatment for recurrent CDI she have previously been treated with extended/ purvancomycin and/or fidaxomicin (conditional). iii. For those with severe or complicated CDI, which appea be associated with reduced cure rates, consideration she given to offering patients treatment with medicat which are associated with reduced risk of recurrence fidaxomicin and bezlotoxumab), before offering (conditional).
	We suggest rewording point <i>iii</i> , that recommends fidaxomici bezlotoxumab should be offered to patients with severe
1	263

263 https://mc.manuscriptcentral.com/gut Working group response

We agree with this statement, and have updated the

Pre-planned subgroup analysis of patients with severe CDI in

a randomised trial demonstrated a significantly lower

recurrence rate when treated with fidaxomicin (13.0%,

n=12/92) than when treated with vancomycin (26.6%,

n=29/209) (Louie et al, 2011); this finding was replicated in

another randomised controlled trial, with 8.3% (n=4/48) and

32.6% (*n*=14/43) experiencing a recurrence respectively

(Cornely et al, 2012). In a further randomised trial,

bezlotoxumab (together with standard of care antibiotics)

was shown to reduce recurrence of severe CDI compared to standard of care antibiotics alone (10.9% (n=6/55) vs 20%

The working group noted that there are no studies comparing

FMT to fidaxomicin or bezlotoxumab, and only one study

(*n*=13/65) respectively) (Wilcox *et al*, 2017).

guideline accordingly.

Thank you for this comment.

Section	Comments	Working group response
	complicated CDI before FMT. There is little evidence on the role of bezlotoxumab and fidaxomicin in severe or severe-complicated CDI. Although the evidence base is similarly lacking for FMT in severe or severe-complicated disease, there is a growing body of evidence from trials, multiple case series and reports indicating the potential for FMT in this population.	comparing a vancomycin taper to FMT (Hota <i>et al</i> , 2017). The working group agreed that in the absence of this evidence, on the balance of safety and potential risks, consideration should be given to using antimicrobial/ antitoxin therapy associated with reduced CDI recurrence prior to considering the use of FMT.
	Bezlotuxumab: The performance of bezlotuxumab has not been evaluated in a severe or severe-complicated population. Results from MODIFY I and II suggest a modest 10% improvement in rates of sustained cure with bezlotoxumab. Importantly, only 15.6% were severe CDI. Based on the modest gains in efficacy and the few severe/severe-complicated patients in the MODIFY trials, we feel that further evidence is required before proposing bezlotuxumab be offered ahead of FMT in this patient population.	
	In comparison, across similar patient populations FMT has demonstrated in several randomized controlled trials reduced risk of recurrence. Based on the available evidence we therefore feel that the statement that bezlotuximab is "associated with reduced risk of recurrence" compared to FMT is not supported by the evidence.	review
	Fidaxomicin: Similarly, there is a dearth of evidence on the role of fidaxomicin in the severe CDI population. We agree that it has demonstrated superior efficacy compared to vancomycin in the general CDI population. In an RCT comparing extended-pulsed fidaxomicin versus vancomycin for CDI, Guery et al (2017) observed increased recurrence in severe CDI compared to non-severe CDI with an odds ratio 0.57 (95% CI 0.36–0.91) p=0.019. We therefore recommend that fidaxomixin should be offered to patients with	review only

Page 433 of 454

Section	Comments	Working group response
	 performance of fidaxomicin would be better than FMT. We acknowledge that access to fidaxomicin is likely to be more timely in settings where FMT is not readily available. The role of FMT in severe CDI: In their recent review, Van Beurden et al (2017) reviewed the literature on FMT in severe CDI and found 23 reports (12 case reports; 11 case series) about FMT as treatment for severe or complicated CDI. The patients described (n=200) all had severe or complicated CDI, did not respond to conventional CDI antibiotic treatment and received FMT as last resort treatment. In all studies, patients were treated with (sequential) FMT, whether or not followed by additional antibiotic CDI treatment, appears to be a promising curative treatment option in patients with severe and complicated CDI who do not respond sufficiently to conventional antibiotic treatment. FMT has been proposed by Fischer et al (2015) as an option utilizing an endoscopic response-guided approach, which may be particularly useful in non-surgical candidates. In an open-label cohort study (n = 17), FMT was delivered by colonoscopy. If pseudomembranes were identified, patients reinitiated oral vancomycin 24 hour after FMT and continued for 5 days. A repeat FMT by colonoscopy was given on day 7. If pseudomembranes were absent during any colonoscopy, no further therapy was initiated. The results were promising with a combined clinical cure rate of 88%. In conclusion, we agree that there is a lack of evidence available to make a strong recommendation on the role of FMT in severe CDI. However, there is insufficient evidence to suggest that fidaxomicin 	Review Only

https://mc.manuscriptcentral.com/gut

Page 434 of 454

Section	Comments	Working group response
	or bezlotuximab would be superior to FMT in this population. On the	
	contrary, the growing pool of experience in using FMT in severe and	
	severe-complicated CDI patients demonstrates that it appears to be	
	generally safe and effective (quality of evidence: 3).	
	We would therefore suggest re-wording point iii to:	
	iii. For those with severe or complicated CDI, which appears to be	
	associated with reduced cure rates, consideration should be given	
	to offering patients treatment with medications which are	
	associated with reduced risk of recurrence (e.g. fidaxomicin or	
	bezlotuxumab), or offering FMT (conditional).	
	Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota	
	transplantation plus selected use of vancomycin for severe-	~
	complicated Clostridium difficile infection: description of a protocol	
	with high success rate. Aliment Pharmacol Ther. 2015;42(4):470-476. doi:10.1111/apt.13290.	
	uol.10.1111/apt.15290.	
	Van Beurden YH, Nieuwdorp M, van de Berg PJEJ, Mulder CJJ,	
	Goorhuis A. Current challenges in the treatment of severe	
	Clostridium difficile infection: early treatment potential of fecal	
	microbiota transplantation. Therapeutic Advances in	
	Gastroenterology. 2017;10(4):373-381.	
	doi:10.1177/1756283X17690480.	
-	Further FMT should be offered after initial FMT failure (strong).	Thank you for this comment.
MT failure:	We agree	
3.1.2.2. General	We agree. All FMT recipients should routinely receive follow-up. Given the	Thank you for this comment. In light of other comments fro
		the working group and stakeholders, this follow-up period ha
post-FMT:	clinicians should follow-up FMT recipients for long enough to fully	
	266	1
	https://mc.manuscriptcentra	

Page 435 of 454

		Working group response
	establish efficacy/ adverse events, and at least ten weeks in total (strong).	
3.1.2.3. Management of he FMT recipient:	 We agree. <i>i.</i> Immediate management after endoscopic administration of FMT should be as per endoscopy unit protocol (strong). <i>ii.</i> Patients should be warned about short term adverse events, in particular the possibility of self-limiting GI symptoms. They should be advised that serious adverse events are rare (strong). <i>iii.</i> After enteral tube administration, patients may have the tube removed and oral water given from 30 minutes post- administration (strong). 	Thank you for this comment.
	We agree.	
3.1.2.4. Definition of	A decision regarding cure/remission from CDI should be recorded	Thank you for this comment.
cure post-FMT for CDI:	during follow-up. However, this has no uniformly-agreed definition,	To
	and should be decided on a case-by-case basis (strong).	
	We agree.	
	Treatment failure/recurrence should be defined on a case-by-case	We agree on the use of ESCMID guidelines in CDI testing, an
reatment failure post- MT for CDI:	basis. Routine testing for C. difficile toxin after FMT is not recommended, but is appropriate to consider in the case of persistent CDI symptoms/suspected relapse (strong). When testing is to be performed, we would recommend clinicians follow the 2016 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for CDI testing, which state that no single commercial test can be used as a stand-alone test for diagnosing CDI, and recommend a 2-step approach (highly sensitive with reflex to highly specific test). These guidelines recommend performing an initial test with a high negative predicative value;	refer to these clearly in Section 8.1.1.1 . However, Section 8.1.2.5 specifically refers to diagnosing failure post-FMT for CDI rather than initial diagnosis of CDI, and no good uniform definition exists for this. We think that the guidance given, the define treatment failure on a case-by-case basis, is the most fair summary of the current literature on this topic.
	267	

Section	Comments	Working group response
	therefore, if negative, no further testing needs to be done. Specifically, they suggest glutamate dehydrogenase (GDH) EIA or NAAT/PCR testing. Our recommendation is GDH EIA as it is less expensive and has a slightly superior NPV at higher CDI prevalence compared with NAAT/PCR (98 vs 96 at hypothetical CDI prevalence of 50%), and an NPV of 100% at lower CDI prevalence. The second test should be a test with a high positive predictive value, such as EIA for toxin A/B. Obtaining CDI testing at each suspected CDI recurrence and working with institutional laboratories to use an appropriate testing algorithm is a key component to ensuring appropriate patient selection for FMT.	
	As currently worded, the recommendations risk encouraging over testing in a context where patients may develop post-infectious IBS.	
	This concept is highlighted by evidence suggesting that up to 25% of	
	patients referred to an FMT center for "C difficile infection" were	
	found to have an alternative diagnosis, with younger patients being	
	more likely to have a non-CDI diagnosis (Jackson 2016).	· C
	Jackson M, Olefson S, Machan JT, Kelly CR. A high rate of alternative diagnoses in patients referred for presumed clostridium difficile infection. J Clin Gastroenterol. 2016 Oct;50(9):742-6.	evien.
8.2.1. General approach	FMT should be offered with caution in patients with	The working group thought it important to emphasise the
	decompensated chronic liver disease and should be avoided in	'good practice point' that in patients with true anaphylaxis,
FMT:	those with anaphylactic food allergy (strong).	the risks of FMT administration were likely to outweigh the
		benefits. As such, this suggestion has not been incorporated.
	The authors may want to consider the approach recommended by Allegretti et al (2017). In patients with a severe food allergy, a potential option for FMT could be from a patient identified donor living with the patient (e.g. spouse) who avoids the same allergens.	
	200	

Gut

Section	Comments	Working group response
	Allegretti JR, Kassam Z, Osman M, Budree S, Fischer M, Kelly CR. The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection. Gastrointest Endosc [Internet]. 2017 Jul 26; Available from: http://dx.doi.org/10.1016/j.gie.2017.05.036	
8.2.2. Immunosuppression and FMT:	FMT should be offered with caution to immunosuppressed patients, in whom FMT appears efficacious without significant additional adverse effects (strong). We agree.	
8.2.3. Other co- morbidities and FMT:		
8.3.1. General approach to donor selection:	Related or unrelated donors should both be considered acceptable. However, where possible, FMT is best sourced from a centralised stool bank, from a healthy unrelated donor (conditional). We agree.	Thank you for this comment.
-	People should only be considered as potential FMT donors if they are ≥ 18 and ≤ 60 years old, and have a BMI of < 30 kg/m ² (conditional).	Thank you for this comment.
8.3.3. General approach to the donor screening assessment:	 We agree. A donor-screening history/ questionnaire is mandatory (Table 2) (strong). 1. Receipt of antimicrobials within the past three months. 	
	269	·

Page 438 of 454

Section	Comments	Working group response
	 Known prior exposure to HIV and/ or viral hepatitis, and known previous or latent tuberculosis. Risk factors for blood-borne viruses - including high risk sexual behaviours, use of illicit drugs, any tattoo/ body piercing/ needlestick injury/ blood transfusion/ acupuncture, all within previous six months. Receipt of a live attenuated virus within the past six months. Underlying gastrointestinal conditions (e.g. history of IBD, IBS, chronic diarrhoea, chronic constipation, coeliac disease, bowel resection or bariatric surgery). Family history of any significant gastrointestinal conditions (e.g. family history of IBD, or colorectal cancer). History of atopy (e.g. asthma, eosinophilic disorders). Any systemic autoimmune conditions. Any metabolic conditions, including diabetes and obesity. Any neurological or psychiatric conditions, or known risk of prion disease. History of any malignancy. Taking particular regular medications, or such medications within the past three months, i.e. antimicrobials, proton pump inhibitors, immunosuppression, chemotherapy History of receiving growth hormone, insulin from cows, or clotting factor concentrates. History of receiving an experimental medicine or vaccine within the past six months. 	Reviewony

Gut

Page 439 of 454

44 45 46

Section	Comments	Working group response
8.3.4. Laboratory	Blood and stool screening of donors is mandatory (Tables 2 and 3)	We agree with the comment regarding matching donors
screening of potentia	(strong).	immunosuppressed recipients for EBV and CMV status
donors:	Table 3: Recommended blood screening for stool donors:Pathogen screening:	have updated Section 8.2.2 and Section 8.3.4 according
	Hepatitis A IgM	The working group did not think that screening for adence
	• Hepatitis B (HBsAg and HBcAb)	was justified.
	Hepatitis C antibody	
	Hepatitis E IgM	Whilst vancomycin-resistant Enterococci (VRE) carria
	• HIV -1 and -2 antibodies	relatively common in the community (probably relate
	HTLV-1 and -2 antibodies	food consumption) (Endtz et al, 1997), the form of VRE i
	Treponema pallidum antibodies (TPHA, VDRL)	community is genetically distinct from that f
	Epstein-Barr virus IgM	nosocomially, with much lower pathogenicity in comm forms (Willems <i>et al</i> , 2005). As such, the working g
	Cytomegalovirus IgM	strongly opined that routine screening was not just
	Strongyloides stercoralis IgG	However, it was acknowledged that the potential infe
	Entamoeba histolytica serology	risk from VRE (and MRSA) would vary regionally depending
		local prevalence and pathogenicity, and as such a local
	General/ metabolic screening:	assessment has been recommended to decide wh
	• Full blood count with differential.	screening for these organisms should be considered.
	Creatinine and electrolytes	
	• Liver enzymes (including albumin, bilirubin,	
	aminotransferases, gamma-glutamyltransferase and	
	alkaline phosphatase).	
	C-reactive protein	on l
	Table 4: Recommended stool screening for stool donors:	
	Clostridium difficile PCR	
	• Campylobacter, Salmonella, and Shigella by standard stool	
	culture and/ or PCR	
	• Escherichia coli 0157 H7 by culture and/or PCR	
	271	
	https://mc.manuscriptcentra	al.com/gut

	Working group response
 Multi-drug resistant bacteria, specifically carbapenemase-producing Enterobacteriaceae. Stool ova, cysts and parasite analysis, including for Microsporidia. Faecal antigen for Cryptosporidium and Giardia. Acid fast stain for Cyclospora and Isospora. Helicobacter pylori faecal antigen. Norovirus and Rotavirus PCR. We recommend: CMV and EBV: Given the high rates of carriage for both EBV and CMV in a healthy, adult population, excluding EBV or CMV positive donors would make it prohibitively difficult to identify suitable donors to provide access to care (Bate et al). Moreover, excluding EBV or CMV positive candidates is not expected to provide a significant benefit to the majority of the patients that would be served by a centralized stool bank, who are not severely immunocompromised. Given the need to ensure a reliable supply of material for the vast majority of rCDI patients while protecting severely immunocompromised patients, until now OpenBiome has chosen not to test for EBV and CMV. Instead, we treat material as presumptively CMV and EBV positive and discourage use in severely immunocompromised patients who are seronegative for CMV or EBV. We are sensitive to the fact that this leaves clinicians with an additional challenge for managing these already difficult cases (severely immunocompromised rCDI patients). Should FMT be 	Review Only

Gut

Page 441 of 454

Section	Comments	Working group response
	 patient at risk of CMV or EBV infection either: 1) CMV and EBV testing of the recipient to confirm positive serology, in which case FMT may be considered after extensive discussion of the risks, benefits, and alternatives in the informed consent process; or 2) the use of a directed donor with matching serology. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010;50:1439–1447. Adenovirus: We recommend including adenovirus on stool in addition to norovirus and rotavirus. Vancomycin resistant enterococcus (VRE): VRE should be specifically mentioned in "Multi-drug resistant bacteria". VRE is a leading cause for donor exclusion despite prospective donors having no known risk factors for colonization. 	
	Further final screening should take place prior to collection of a stool sample for processing into FMT (strong). We agree.	Thank you for this comment. In light of this and othe comments, the recommendation on repeat screening habeen strengthended.
8.4.1. General	Recommendation:	Thank you for this comment.
principles of FMT preparation:	(strong). ii. Donor stool should be processed within 6 hours of defecation (conditional).	
	iii. Both aerobically and anaerobically prepared FMT treatments should be considered suitable when preparing FMT for the treatment of recurrent CDI (strong).	

https://mc.manuscriptcentral.com/gut

Page 442 of 454

Section	Comments	Working group response
	 iv. Sterile 0.9% saline should be considered as an appropriate diluent for FMT production, and cryoprotectant such as glycerol should be added for frozen FMT (strong). v. Consider ≥50g of stool for use in FMT preparation (conditional). Good practice points: i. Stool should be mixed 1:5 with diluent to make the initial faecal emulsion (conditional). ii. Homogenisation and filtration of FMT should be undertaken in a closed disposable system (conditional). We agree. 	
8.4.2. Fresh vs frozen FMT:	The use of banked frozen FMT material should be considered preferable to fresh preparations for CDI (strong). We agree.	Thank you for this comment.
8.4.3. Use of frozen FMT:	-	"en
8.5.1. Use of specific medications in the period around FMT administration:	Recommendation:	Thank you for this comment.

Page 443 of 454

Section	Comments	Working group response
8.5.1.1. General principles of FMT administration:	 ii. For upper GI FMT administration, a proton pump inhibitor should be considered, e.g. the evening before and morning of delivery (conditional). iii. Loperamide (or other anti-motility drugs) should be considered following lower GI FMT delivery (conditional). Good practice point: Prokinetics (such as metoclopramide) should be considered prior to FMT via the upper GI route (conditional). ii. Best practice for prevention of further transmission of CDI should be applied throughout when administering FMT to patients with CDI (nursing with enteric precautions, sporicidal treatment of endoscope, etc). 	
	We agree.	
8.5.1.2. Additional antibiotics pre-FMT:	Consider further antimicrobial treatment for CDI for at least 72 hours prior to FMT (conditional). We agree.	Thank you for this comment.
8.5.1.3. Washout	To minimise any deleterious effect of antimicrobials on the FMT	Thank you for this comment.
period between	material, there should be a minimum washout period of 24 hours between the last dose of antibiotic and treatment with FMT (strong). We agree.	NON/
8.5.2.2. Upper	Recommendation:	Thank you for this comment. In light of further discussion by
gastrointestinal tract administration of FMT:		the working group, the maximum volume of FMT recommended by upper GI administration is now 100ml.

Page 444 of 454

Section	Comments	Working group response
	nasoduodenal, or nasojejunal tube, or alternatively via upper GI endoscopy. Administration via a permanent feeding tube is also appropriate (strong). Good practice point: It is recommended that no more than 50ml of FMT is administered to the upper GI tract (conditional). We agree.	
8.5.2.3. Lower gastrointestinal tract administration of FMT:	 Recommendation: i. Colonoscopic administration of FMT as treatment for recurrent or refractory CDI should be used where appropriate (strong). ii. Where colonoscopic administration is employed, consider preferential delivery to the caecum or terminal ileum, as this appears to give the highest efficacy rate (conditional). 	
	We recommend rewording point <i>iii</i> . Although there is limited data, flexible sigmoidoscopy may be the preferred route of delivery where colonoscopic delivery is not possible. Several experts have advised less invasive modalities such sigmoidoscopy in high risk patients (Brandt 2013; Kelly 2014). This may provide a more effective method for delivering material as proximally as possible and improving retention. We therefore recommend re-wording point <i>iii</i> to:	Ch Ch
	FMT via enema should be used as a lower GI option when colonoscopic or flexible sigmoidoscopy delivery is not possible (strong).	

Page 445 of 454

Section	Comments	Working group response
8.5.2.4. Capsulised FMT:	 Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: Techniques, indications, and outcomes. Gastrointest Endosc. 2013 Aug;78(2):240-9. Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. Fecal microbiota transplant for treatment of clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014 Jul;109(7):1065-71. <i>Capsulised FMT holds promise as a treatment option for recurrent CDI, but further evidence regarding its safety and efficacy is awaited, and it should not be considered for use at present (conditional).</i> There is a growing body of evidence on encapsulated FMT and the delivery modality presents a potential option in circumstances where it may be inappropriate, contraindicated, or contrary to patient preferences to deliver material via traditional routes of administration for CDI. In terms of patient perceptions, Zipursky and colleagues report that more aesthetically appealing FMT formulations, such as capsules, would both eliminate potential barriers to treatment and reduce the necessity for healthcare resources and procedure time for clinicians. Capsule administration is approximately 20 minutes (range 10-30 minute) (Allegretti, unpublished data). Although the optimal dose is still under investigation (as with other FMT delivery modalities), there have been several studies that have shown equivalent efficacy rates. Youngster and colleagues reported 	2017 study was not published at the time of initial searches it has been identified by updated searches and has now beer reviewed by the working group. The guideline has beer updated accordingly.

Page 446 of 454

Section	Comments	Working group response
	of stool per capsule in which they dosed 15 capsules on 2 consecutive days. They reported a 70% cure rate after an initial dose in a cohort of 140 patients. Those that failed to achieve cure were re-treated, bringing the cumulative cure rate up to 90%.	
	Similarly, Hirsch and colleagues demonstrated a clinical cure rate of 68% in the 19 participants, using capsules containing purified, concentrated, and cryopreserved fecal bacteria and this increased to 89% with retreatment.	
	Allegretti and colleagues conducted the first dose-finding study for FMT capsules (0.75 grams of stool per capsule with upper GI release) assessing 30 capsules once (low dose) versus 30 capsules on 2 consecutive days (high dose). Efficacy rates between the groups were similar on initial dose (70%) and there were no adverse events reported.	
	Lastly the largest randomized control trial to date of FMT used encapsulated FMT with good safety and efficacy outcomes equivalent to colonoscopy FMT. In Kao et al's non-inferiority randomized clinical trial (cited in the guidelines) that included 116 adults with rCDI, the proportion without recurrence over 12 weeks was 96.2% after a single treatment in a group treated with oral capsules and in a group treated via colonoscopy. Given this 1+ level	
	of evidence, in addition to multiple smaller studies of encapsulated FMT, we feel that there is a good body of evidence to support the short-term safety of encapsulated FMT. We agree that further evidence is needed on optimal dosing and formulation, however this applies to all delivery modalities.	

Page 447 of 454

Section	Comments	Working group response
	We agree that capsule availability is very limited in the UK at present however this shouldn't preclude guidelines recommending this as a potential FMT delivery option.	
	We therefore recommend rewording the 8.5.2.4 to:	
	Capsulised FMT holds promise as a treatment option for recurrent CDI and should be offered to patients as a potential treatment modality. Capsule preparations should follow a standard protocol. Further evidence regarding its optimal dosing and formulation is needed (conditional).	
	Allegretti J*, Fischer M*, Papa E, Elliot R, Klank M, Mendolia G, et al. Fecal microbiota transplantation delivered via oral capsules achieves microbial engraftment similar to traditional delivery modalities: Safety, efficacy and engraftment results from a multi-center cluster randomized dose-finding study. Digestive Disease Week 2016.	
	Hirsch BE, Saraiya N, Poeth K, Schwartz RM, Epstein ME, Honig G. Effectiveness of fecal- derived microbiota transfer using orally administered capsules for recurrent clostridium difficile infection. BMC Infect Dis. 2015 Apr 17;15:191,015-0930-z.	
	Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing clostridium difficile infection. JAMA. 2014 Nov 5;312(17):1772-8.	
	Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation	

Section	Comments	Working group response
	in the treatment of recurrent clostridium difficile infection. Clin Infect Dis. 2012 Dec;55(12):1652-8.	
effectiveness of faecal	FMT is not currently recommended as treatment for inflammatory bowel disease. There is insufficient evidence to recommend FMT for any other gastrointestinal or non-gastrointestinal disease (strong). We agree.	Thank you for this comment.
8.7. Basic requirements for implementing a FMT service	<i>The development of FMT centres should be encouraged (strong).</i> We agree.	Thank you for this comment.
8.7.5. FMT manufacturing:	Ensure traceability of supply (strong). We agree.	Thank you for this comment.
FMT in patients with IBD	We recommend emphasizing the importance of counselling patients with IBD on the risk of flare or worsening IBD activity post-FMT.	We agree with this comment, and have updated Section 8.2.3. accordingly.
FMT in paediatric populations	A recommendation on paediatric FMT should be include. The evidence base is limited but safety and efficacy appears comparable to adult FMT. Patients and caregivers should be counselled on the unknown long-term risks of FMT. Recommendation: <i>i. FMT should be offered to paediatric patients with recurrent CDI.</i> <i>ii. Paediatric patients and caregivers should be counselled on the</i> <i>unknown short and long-term risks of FMT.</i>	FMT in the paediatric setting is outside of the remit of thi
Closing date: Please forw	ard this electronically by 5pm on January 2018 at the very latest to <u>co</u>	onsultations@his.org.uk
	280	
	https://mc.manuscriptcentra	il.com/gut

Supplementary Material 3 for Gut

The use of faecal microbiota transplant as treatment for recurrent or refractory *Clostridium difficile* infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.

Supplementary Material 3: Basic requirements for implementing a FMT service:

1. Basic requirements for implementing a FMT service:

1.1. General considerations:

Although it is possible to prepare and administer FMT on an individual patient basis in a single hospital, the regulatory requirements are more readily fulfilled by a specialist centre approach for the production of a safe FMT product. This particularly applies to record keeping and staff expertise in quality control and production. Recent European consensus advice suggests that FMT should be administered in a referral centre¹, however an alternative approach which limits the need for patient transfer is to undertake controlled production in a large centre and transport treatment to the patient, a supply model which has been well established in the USA (OpenBiome)² and has also been successfully replicated in the UK in a large centre in Birmingham, which has supplied FMT to nine NHS Trusts across three regions³. This service design only requires that a responsible clinician is capable of administering the FMT safely at the satellite clinical site. It also eliminates the need for patient transfer between clinical sites, which in the case of severe CDI may not be practical.

The working group encouraged the use of frozen FMT material supplied from a carefully controlled production site. This allows donor screening more closely to meet regulatory requirements, ensuring that the window period between donor testing and FMT production is maintained to a minimum. The costs of donor screening are substantially reduced using this supply model, as a single donor can provide multiple FMT donations under a single screening period.

The working group also noted that given the novelty of FMT, awareness of this as a potential treatment option for recurrent or refractory CDI may be low amongst certain groups of clinicians. For instance, clinicians working in primary care, or those whose practice is not located near to an FMT centre, are likely to have less knowledge about the potential suitability of FMT for patients with CDI, or be unaware of referral pathways. As such, there is a responsibility for FMT centres to raise awareness and educate as wide a range of clinicians as possible about the potential role for FMT.

Supplementary Material 3 for Gut

Furthermore, microbiology staff processing stool samples for *C difficile* assays from the community should proactively liaise with primary care teams where recurrent positive tests are received from a single patient to raise awareness and suggest the option of FMT.

Similarly, given the expectation that FMT and/ or other 'microbiome therapeutics' are likely to play an increasing role within medicine over future years, there is also an expectation for FMT centres to not only educate about the potential role for FMT, but also to train relevant healthcare professionals in the practicalities of delivering an FMT service, to enable longer-term ongoing provision of services. This is likely to be most of relevance to specialty trainee and consultant physicians specialising in gastroenterology, infectious diseases and/ or medical microbiology, but potentially to other healthcare professionals too, including infection prevention and control nurses, infectious diseases pharmacists, etc.

Recommendations:

i. The development of FMT centres should be encouraged (GRADE of evidence: very low; strength of recommendation: strong).

ii. We suggest that FMT centres should work to raise awareness about FMT as a treatment option amongst clinicians caring for patients with CDI, and provide training to relevant healthcare professionals on the practicalities of delivering an FMT service (GRADE of evidence: very low; strength of recommendation: weak).

1.2. Legal aspects and clinical governance:

In the United Kingdom, FMT is now considered a medicinal product based on the definitions of purpose and efficacy, in The Medicines Directive 2001/83 and The Human Medicines Regulations⁴. As the competent authority for medicines regulation, the Medicines and Healthcare products Regulatory Agency (MHRA) has indicated that the approach to regulation will be proportionate, depending on factors such as supply being within or outside a legal entity and FMT production scale. Specifically:

- When FMT is supplied on prescription on a named patient basis, then supply under a pharmacy exemption may be used subject to ensuring proper governance and traceability⁴.
- If production scale reaches an 'industrial' level, defined 'by virtue of the batch sizes, the extent of processing and/ or whether potential use includes supply between legal entities'⁴, the route to regulation is via adherence to HMR and formal Manufacturer's 'Specials' (MS) license.

 Gut

Supplementary Material 3 for Gut

• If a supply is to a clinical trial, then an MIA (IMP) manufacturing license is required (further information on license applications⁵ and specials⁶ is available online).

Centres establishing an FMT service should undertake steps to ensure practice meets the required compliance levels and seek guidance from the MHRA. If pharmacy exemption is applied, there should be justifiable processes in place to ensure traceability, health and safety, governance and to prevent cross-contamination. FMT is regulated as a medicine, rather than a tissue, but no products have been licensed following an assessment against the criteria of safety, quality and efficacy, for there is a possible risk that donor screening protocols will not be sufficiently considered, a step which is critical to the quality of the product and therefore safety of the patient⁷. To mitigate this, it is advisable that donor screening protocols are under regularly review and risk assessment, and to ensure that consideration is also given to the Guide to Quality and Safety Assurance for Human Tissues and Cells for Patient Treatment, particularly Annex B related to donor testing⁸. When formal licencing is sought, this is overseen by a Production Manager and Quality Control Manager if under an MS, or by a Qualified Person if under an MIA (IMP). Both should follow the Good Manufacturing Practice (GMP) guidelines, found within The Orange Guide Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2017⁹, or at: https://ec.europa.eu/health/documents/eudralex/vol-4 en .

The working group noted that outside the UK, the legal and regulatory framework relating to FMT was highly variable between different countries. They agreed that FMT should only be administered after appropriate approval from the competent body of each country.

Recommendation:

In the UK, FMT must be manufactured in accordance with MHRA guidance for human medicines regulation. When FMT is supplied on a named patient basis, within a single organisation, a pharmacy exemption may be used, subject to ensuring proper governance and traceability. All centres that are processing and distributing FMT should seek guidance from the MHRA and where necessary obtain appropriate licenses prior to establishing an FMT service. This is a legal requirement. In countries other than the UK, FMT should only be manufactured following appropriate approval from the national authority of that country (GRADE of evidence: very low; strength of recommendation: strong). Gut

Supplementary Material 3 for Gut

1.3. Multidisciplinary teams:

To promote safe and high quality FMT supply, it is strongly recommended that providers adopt a multidisciplinary team approach. The choice of the team required is subject to the scale of production, but should involve as a minimum a clinical gastroenterologist, microbiologist/infectious diseases clinician, state-registered experienced healthcare scientist and pharmacist. Governance and quality expertise will be required, which may be provided by consultation. If FMT production is to be under a 'specials' licence, the team should be expanded to include a Qualified Person, Quality Manager and Production Manager, all with GMP training.

Recommendation:

We recommend that a multidisciplinary team should be formed to deliver FMT services (GRADE of evidence: very low; strength of recommendation: strong).

1.4. Infrastructure:

Dedicated laboratory facilities for FMT production are recommended to ensure that the process adheres to Health and Safety requirements, to reduce the risk of cross-contamination, and to facilitate standardisation of the production process. In some studies, FMT has been prepared in a clinical environment¹⁰; however, this may not be advisable because of the risks of cross-contamination. The manipulation of human stool should be conducted in a Containment Level 2 laboratory according to current Health and Safety guidance (Health and Safety at Work Act 1974, COSHH Control of Substances Hazardous to Health Regulations, 2002), and at least within a microbiological safety cabinet which provides user protection (Class I) or, ideally, user and product protection (Class II). To meet the requirements of GMP, this facility should be sole use or be risk assessed for multipurpose use with adequate separation of different activities. The working group recommend that the facility complies with the new GMP production facility classification of 'clean not sterile'. The use of personal protective equipment - such as laboratory coat, gloves and face mask - is also recommended to prevent production contamination. It is essential to risk assess the process and develop control measures to reduce microbial ingress into the facility and monitor the microbiological cleanliness of the production suite. FMT preparation under a 'specials' licence should ensure that the production process is integrated into a Quality Management System, to safeguard production and maintain the minimum criteria for audit, monitoring, standard operating procedures, document control, training, facilities, equipment and storage. With regard to storage, it is essential that the freezer system has real-time temperature monitoring which provides notification outside pre-set limits.

Recommendation:

We recommend utilisation of suitable laboratory facilities and infrastructure for FMT production (GRADE of evidence: very low; strength of recommendation: strong).

1.5. **FMT** manufacturing:

It is strongly recommended to employ a batch numbering system to track FMT preparations from production to use. It should be possible from records to identify an individual FMT aliquot, trace it to a specific donation, and identify all other FMT aliquots prepared from the same donation. It must also be clear which FMT aliquots patients have received, which should be verifiable from the donor to the patient and vice-versa. It is therefore strongly recommended that a treatment directory be maintained documenting all production and use of FMT, and that an unambiguous record is created in the patients' clinical notes to identify the specific FMT batch number. Further to this, it is also recommended that treatment directories also record clinical outcome, such as that developed in the USA¹¹ and Germany¹² to standardise and improve future clinical practice.

Recommendation:

We recommend ensuring the traceability of supply (GRADE of evidence: very low; strength of recommendation: strong).

1.6. FMT production quality control:

Safety and clinical governance is a central responsibility for FMT centres, particularly in light of the absence of phase III licensing trials for FMT, which would normally be required for a novel medicinal product. Reporting and investigating adverse events and reactions contributes to knowledge of the FMT safety profile, while also identifying previously unknown safety issues. Governance structures and processes must be in place to monitor, notify and investigate all FMT-related adverse events or reactions locally, and FMT users are encouraged to use the MHRA Yellow Card Scheme for formal notification. FMT supply should be suspended if serious adverse events or reactions occur which are directly attributable to FMT, and there should be a clear documented pathway to achieve this. To facilitate a 'look-back exercise' if required, it is advisable to store documentation and reference samples, both product-based and donor/ patient-based. Specifically, retention of production documentation should be for at least five years after the use of the batch; retention of reference FMT

Page 454 of 454

Supplementary Material 3 for Gut

samples (and stool samples from donors and recipients) should be for at least one year after the last use. Retention of excipient samples should be for at least one year after expiry of the excipient.

Recommendation:

We recommend monitoring, notification and investigation of all adverse events and reactions related to FMT (GRADE of evidence: very low; strength of recommendation: strong).

1.7. Donor screening governance:

The testing requirements for donor screening have been discussed previously; however, it is worth noting here the pertinent clinical governance issues which should be addressed. Donor anonymity should be maintained at all times. The laboratory undertaking testing of donor samples should be competent for such activity, demonstrable by accreditation with the United Kingdom Accreditation Service (UKAS). The results of donor testing should remain confidential. There should be appropriate standard operating procedures to ensure that the outcome of donor screening is built into a robust FMT batch release process. To ensure unbiased autonomy during donor screening, it is suggested that a clinician independent to the FMT production team is responsible for ratifying FMT donors prior to donation. Finally, the duration of donor follow-up should be considered and extend beyond the period of active donation to capture acute and chronic health changes.

Recommendation:

We recommend ensuring the clinical governance of donor screening (GRADE of evidence: very low; strength of recommendation: strong).

2. <u>References:</u>

- Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. *Gut*. 2017;66(4):569-580. doi:10.1136/gutjnl-2016-313017.
- 2. Home OpenBiome. http://www.openbiome.org/home/. Accessed October 19, 2017.
- 3. Quraishi MN, Segal J, Mullish B, et al. National survey of practice of faecal microbiota

Gut

Supplementary Material 3 for Gut

transplantation for Clostridium difficile infection in the UK. *J Hosp Infect*. 2016. doi:10.1016/j.jhin.2016.10.023.

- Faecal Microbiota Transplantation (FMT) MHRA's position.
 http://www.bsg.org.uk/images/stories/docs/clinical/guidance/fmt_mhra_position_june2015.
 pdf. Accessed October 3, 2017.
- Medicines and Healthcare products Regulatory Agency. Apply for manufacturer or wholesaler of medicines licences - GOV.UK. https://www.gov.uk/guidance/apply-for-manufacturer-orwholesaler-of-medicines-licences#apply-for-a-manufacturerimporter-licence. Accessed February 15, 2018.
- Medicines and Healthcare products Regulatory Agency. Supply unlicensed medicinal products (specials) - GOV.UK. https://www.gov.uk/government/publications/supply-unlicensedmedicinal-products-specials. Accessed February 15, 2018.
- Edelstein CA, Kassam Z, Daw J, Smith MB, Kelly CR. The regulation of fecal microbiota for transplantation: An international perspective for policy and public health. *Clin Res Regul Aff*. 2015;32(3):99-107. doi:10.3109/10601333.2015.1046602.
- Human Tissue Authority Guide to Quality and Safety Assurance for Human Tissues and Cells for Patient Treatment. 2010. https://www.hta.gov.uk/sites/default/files/Annex_-_Guide_to_Quality_and_Safety_Assurance_for_Tissues_and_Cells_for_Patient_Treatment.pd f. Accessed October 9, 2017.
- 9. Great Britain. Medicines and Healthcare products Regulatory Agency. *Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2017.*
- 10. Allegretti JR, Korzenik JR, Hamilton MJ. Fecal microbiota transplantation via colonoscopy for recurrent C. difficile Infection. *J Vis Exp*. 2014;(94). doi:10.3791/52154.
- Kelly CR, Kim AM, Laine L, Wu GD. The AGA's Fecal Microbiota Transplantation National Registry: An Important Step Toward Understanding Risks and Benefits of Microbiota Therapeutics. *Gastroenterology*. 2017;152(4):681-684. doi:10.1053/j.gastro.2017.01.028.
- Vehreschild M. MicroTrans A Multicenter Registry of Fecal Microbiota Transplantation (MicroTrans). doi:10.1016/j.cmi.2015.06.027.